<?xml version="1.0" encoding="UTF-8"?>
<documents>
<document id="DBMI.pac1" origId="pac1">
	<sentence id="DBMI.pac1.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Established Drug Interactions\n\nClinical recommendations based on the results of drug interaction studies are listed in Table 5."/>
	<sentence id="DBMI.pac1.s1" origId="s1" text="Pharmacokinetic results of drug interaction studies are shown in Tables 9 to 12 [see Contraindications (4.1 and 4.2) and Clinical Pharmacology (12.3)]."/>
	<sentence id="DBMI.pac1.s2" origId="s2" text="Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].">
		<entity charOffset="367-377" id="DBMI.pac1.s2.e0" origId="s2.e0" text="tenofovir " type="Active ingredient"/>
		<entity charOffset="318-329" id="DBMI.pac1.s2.e1" origId="s2.e1" text="didanosine " type="Active ingredient"/>
		<pair e1="DBMI.pac1.s2.e0" e2="DBMI.pac1.s2.e1" id="DBMI.pac1.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="didanosine " precipitant="tenofovir "/>
		<pair e1="DBMI.pac1.s2.e1" e2="DBMI.pac1.s2.e0" id="DBMI.pac1.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac1.s3" origId="s3" text="Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy."/>
	<sentence id="DBMI.pac1.s4" origId="s4" text="Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response."/>
	<sentence id="DBMI.pac1.s5" origId="s5" text="Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)]."/>
	<sentence id="DBMI.pac1.s6" origId="s6" text="Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily."/>
	<sentence id="DBMI.pac1.s7" origId="s7" text="7.2 Predicted Drug Interactions\n\nPredicted drug interactions with didanosine delayed-release are listed in Table 6."/>
	<sentencespan id="DBMI.pac1.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Established Drug Interactions\n\nClinical recommendations based on the results of drug interaction studies are listed in Table 5. Pharmacokinetic results of drug interaction studies are shown in Tables 9 to 12 [see Contraindications (4.1 and 4.2) and Clinical Pharmacology (12.3)]. Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].">
		<entity charOffset="367-377" id="DBMI.pac1.sp0.e0" origId="sp0.e0" text="tenofovir " type="Active ingredient"/>
		<entity charOffset="318-329" id="DBMI.pac1.sp0.e1" origId="sp0.e1" text="didanosine " type="Active ingredient"/>
		<pair e1="DBMI.pac1.sp0.e0" e2="DBMI.pac1.sp0.e1" id="DBMI.pac1.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="didanosine " precipitant="tenofovir "/>
		<pair e1="DBMI.pac1.sp0.e1" e2="DBMI.pac1.sp0.e0" id="DBMI.pac1.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac1.sp1" origId="sp1" text="Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy. Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response. Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)]."/>
	<sentencespan id="DBMI.pac1.sp2" origId="sp2" text="Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily. 7.2 Predicted Drug Interactions\n\nPredicted drug interactions with didanosine delayed-release are listed in Table 6."/>
</document>

<document id="DBMI.pac100" origId="pac100">
	<sentence id="DBMI.pac100.s0" origId="s0" text="Drugs demonstrated to be inducers of CYP3A\n\n Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam. ">
		<entity charOffset="45-59" id="DBMI.pac100.s0.e0" origId="s0.e0" text="Carbamazepine " type="Active ingredient"/>
		<entity charOffset="138-149" id="DBMI.pac100.s0.e1" origId="s0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac100.s0.e0" e2="DBMI.pac100.s0.e1" id="DBMI.pac100.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="alprazolam " precipitant="Carbamazepine "/>
		<pair e1="DBMI.pac100.s0.e1" e2="DBMI.pac100.s0.e0" id="DBMI.pac100.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac100.sp0" origId="sp0" text="Drugs demonstrated to be inducers of CYP3A\n\n Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam. ">
		<entity charOffset="45-59" id="DBMI.pac100.sp0.e0" origId="sp0.e0" text="Carbamazepine " type="Active ingredient"/>
		<entity charOffset="138-149" id="DBMI.pac100.sp0.e1" origId="sp0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac100.sp0.e0" e2="DBMI.pac100.sp0.e1" id="DBMI.pac100.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="alprazolam " precipitant="Carbamazepine "/>
		<pair e1="DBMI.pac100.sp0.e1" e2="DBMI.pac100.sp0.e0" id="DBMI.pac100.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac102" origId="pac102">
	<sentence id="DBMI.pac102.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nThe effects of metoclopramide on gastrointestinal motility can impact the absorption of other drugs."/>
	<sentence id="DBMI.pac102.s1" origId="s1" text="The known drug-drug interactions are listed below."/>
	<sentence id="DBMI.pac102.s2" origId="s2" text="7.1 Anticholinergic and Narcotic Analgesic Drugs\n\nThe effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics."/>
	<sentence id="DBMI.pac102.s3" origId="s3" text="Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers."/>
	<sentence id="DBMI.pac102.s4" origId="s4" text="7.2 Monoamine Oxidase Inhibitors\n\nMetoclopramide has been shown to release catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients taking monoamine oxidase (MAO) inhibitors."/>
	<sentence id="DBMI.pac102.s5" origId="s5" text="7.3 Drug Absorption\n\nAbsorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).">
		<entity charOffset="802-817" id="DBMI.pac102.s5.e0" origId="s5.e0" text="metoclopramide " type="Active ingredient"/>
		<entity charOffset="824-832" id="DBMI.pac102.s5.e1" origId="s5.e1" text="digoxin " type="Active ingredient"/>
		<entity charOffset="962-971" id="DBMI.pac102.s5.e2" origId="s5.e2" text="levodopa " type="Active ingredient"/>
		<entity charOffset="972-980" id="DBMI.pac102.s5.e3" origId="s5.e3" text="ethanol " type="Active ingredient"/>
		<entity charOffset="981-994" id="DBMI.pac102.s5.e4" origId="s5.e4" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="948-961" id="DBMI.pac102.s5.e5" origId="s5.e5" text="tetracycline " type="Active ingredient"/>
		<entity charOffset="933-947" id="DBMI.pac102.s5.e6" origId="s5.e6" text="acetaminophen " type="Active ingredient"/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="levodopa " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethanol " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p4" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tetracycline " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="acetaminophen " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac102.s6" origId="s6" text="7.4 Insulin\n\nBecause the action of metoclopramide will hasten the movement of food to the intestines and therefore the rate of absorption, insulin dosage or timing of dosage may require adjustment."/>
	<sentence id="DBMI.pac102.s7" origId="s7" text="Increasing movement of food to the intestines may lead to absorption of less glucose from a meal, hence less glucose in the circulation for a particular dose of administered insulin to act upon, resulting in hypoglycemia."/>
	<sentence id="DBMI.pac102.s8" origId="s8" text="7.5 Antidepressants, Antipsychotics, and Neuroleptics\n\nConcomitant use of metoclopramide should be avoided in patients taking antidepressants, antipsychotics, and/or neuroleptics that have been associated with  extrapyramidal reactions such as tardive dyskinesia or Neuroleptic Malignant Syndrome (NMS) that have occurred in association with metoclopramide [see Warnings and Precautions (5.2), (5.3) and Adverse Reactions (6.2)]. "/>
	<sentencespan id="DBMI.pac102.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nThe effects of metoclopramide on gastrointestinal motility can impact the absorption of other drugs. The known drug-drug interactions are listed below. 7.1 Anticholinergic and Narcotic Analgesic Drugs\n\nThe effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics."/>
	<sentencespan id="DBMI.pac102.sp1" origId="sp1" text="Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 7.2 Monoamine Oxidase Inhibitors\n\nMetoclopramide has been shown to release catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients taking monoamine oxidase (MAO) inhibitors. 7.3 Drug Absorption\n\nAbsorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).">
		<entity charOffset="802-817" id="DBMI.pac102.sp1.e0" origId="sp1.e0" text="metoclopramide " type="Active ingredient"/>
		<entity charOffset="824-832" id="DBMI.pac102.sp1.e1" origId="sp1.e1" text="digoxin " type="Active ingredient"/>
		<entity charOffset="962-971" id="DBMI.pac102.sp1.e2" origId="sp1.e2" text="levodopa " type="Active ingredient"/>
		<entity charOffset="972-980" id="DBMI.pac102.sp1.e3" origId="sp1.e3" text="ethanol " type="Active ingredient"/>
		<entity charOffset="981-994" id="DBMI.pac102.sp1.e4" origId="sp1.e4" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="948-961" id="DBMI.pac102.sp1.e5" origId="sp1.e5" text="tetracycline " type="Active ingredient"/>
		<entity charOffset="933-947" id="DBMI.pac102.sp1.e6" origId="sp1.e6" text="acetaminophen " type="Active ingredient"/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="levodopa " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethanol " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p4" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tetracycline " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="acetaminophen " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac102.sp2" origId="sp2" text="7.4 Insulin\n\nBecause the action of metoclopramide will hasten the movement of food to the intestines and therefore the rate of absorption, insulin dosage or timing of dosage may require adjustment. Increasing movement of food to the intestines may lead to absorption of less glucose from a meal, hence less glucose in the circulation for a particular dose of administered insulin to act upon, resulting in hypoglycemia. 7.5 Antidepressants, Antipsychotics, and Neuroleptics\n\nConcomitant use of metoclopramide should be avoided in patients taking antidepressants, antipsychotics, and/or neuroleptics that have been associated with  extrapyramidal reactions such as tardive dyskinesia or Neuroleptic Malignant Syndrome (NMS) that have occurred in association with metoclopramide [see Warnings and Precautions (5.2), (5.3) and Adverse Reactions (6.2)]. "/>
</document>

<document id="DBMI.pac104" origId="pac104">
	<sentence id="DBMI.pac104.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A\n\nConivaptan is a sensitive substrate of CYP3A."/>
	<sentence id="DBMI.pac104.s1" origId="s1" text="The effect of ketoconazole, a potent CYP3A inhibitor, on the pharmacokinetics of intravenous conivaptan has not been evaluated."/>
	<sentence id="DBMI.pac104.s2" origId="s2" text="Coadministration of oral conivaptan hydrochloride 10 mg with ketoconazole 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of conivaptan, respectively [see Contraindications (4.2)].">
		<entity charOffset="267-280" id="DBMI.pac104.s2.e0" origId="s2.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="231-242" id="DBMI.pac104.s2.e1" origId="s2.e1" text="conivaptan " type="Active ingredient"/>
		<pair e1="DBMI.pac104.s2.e0" e2="DBMI.pac104.s2.e1" id="DBMI.pac104.s2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="conivaptan " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac104.s2.e1" e2="DBMI.pac104.s2.e0" id="DBMI.pac104.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s3" origId="s3" text="Conivaptan is a potent mechanism-based inhibitor of CYP3A."/>
	<sentence id="DBMI.pac104.s4" origId="s4" text="The effect of conivaptan on the pharmacokinetics of co-administered CYP3A substrates has been evaluated with the coadministration of conivaptan with midazolam, simvastatin, and amlodipine."/>
	<sentence id="DBMI.pac104.s5" origId="s5" text="VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively.">
		<entity charOffset="648-657" id="DBMI.pac104.s5.e0" origId="s5.e0" text="VAPRISOL " type="Drug product"/>
		<entity charOffset="771-781" id="DBMI.pac104.s5.e1" origId="s5.e1" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac104.s5.e0" e2="DBMI.pac104.s5.e1" id="DBMI.pac104.s5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="VAPRISOL "/>
		<pair e1="DBMI.pac104.s5.e1" e2="DBMI.pac104.s5.e0" id="DBMI.pac104.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s6" origId="s6" text="VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin.">
		<entity charOffset="796-805" id="DBMI.pac104.s6.e0" origId="s6.e0" text="VAPRISOL " type="Drug product"/>
		<entity charOffset="859-871" id="DBMI.pac104.s6.e1" origId="s6.e1" text="simvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac104.s6.e0" e2="DBMI.pac104.s6.e1" id="DBMI.pac104.s6.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="simvastatin " precipitant="VAPRISOL "/>
		<pair e1="DBMI.pac104.s6.e1" e2="DBMI.pac104.s6.e0" id="DBMI.pac104.s6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s7" origId="s7" text="Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].">
		<entity charOffset="877-888" id="DBMI.pac104.s7.e0" origId="s7.e0" text="conivaptan " type="Active ingredient"/>
		<entity charOffset="978-989" id="DBMI.pac104.s7.e1" origId="s7.e1" text="amlodipine " type="Active ingredient"/>
		<pair e1="DBMI.pac104.s7.e0" e2="DBMI.pac104.s7.e1" id="DBMI.pac104.s7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="amlodipine " precipitant="conivaptan "/>
		<pair e1="DBMI.pac104.s7.e1" e2="DBMI.pac104.s7.e0" id="DBMI.pac104.s7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s8" origId="s8" text="7.2 Digoxin\n\nCoadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].">
		<entity charOffset="1125-1136" id="DBMI.pac104.s8.e0" origId="s8.e0" text="conivaptan " type="Active ingredient"/>
		<entity charOffset="1078-1086" id="DBMI.pac104.s8.e1" origId="s8.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac104.s8.e0" e2="DBMI.pac104.s8.e1" id="DBMI.pac104.s8.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="conivaptan "/>
		<pair e1="DBMI.pac104.s8.e1" e2="DBMI.pac104.s8.e0" id="DBMI.pac104.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s9" origId="s9" text="7.3 Warfarin\n\nVAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.">
		<entity charOffset="1333-1342" id="DBMI.pac104.s9.e0" origId="s9.e0" text="VAPRISOL " type="Drug product"/>
		<entity charOffset="1406-1415" id="DBMI.pac104.s9.e1" origId="s9.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac104.s9.e0" e2="DBMI.pac104.s9.e1" id="DBMI.pac104.s9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="warfarin " precipitant="VAPRISOL "/>
		<pair e1="DBMI.pac104.s9.e1" e2="DBMI.pac104.s9.e0" id="DBMI.pac104.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s10" origId="s10" text="The corresponding prothrombin time and international normalized ratio values were unchanged."/>
	<sentence id="DBMI.pac104.s11" origId="s11" text="7.4 Captopril and Furosemide\n\nThe pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.">
		<entity charOffset="1802-1812" id="DBMI.pac104.s11.e0" origId="s11.e0" text="captopril " type="Active ingredient"/>
		<entity charOffset="1727-1738" id="DBMI.pac104.s11.e1" origId="s11.e1" text="conivaptan " type="Active ingredient"/>
		<entity charOffset="1821-1832" id="DBMI.pac104.s11.e2" origId="s11.e2" text="furosemide " type="Active ingredient"/>
		<pair e1="DBMI.pac104.s11.e0" e2="DBMI.pac104.s11.e1" id="DBMI.pac104.s11.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="conivaptan " precipitant="captopril "/>
		<pair e1="DBMI.pac104.s11.e0" e2="DBMI.pac104.s11.e2" id="DBMI.pac104.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.s11.e1" e2="DBMI.pac104.s11.e0" id="DBMI.pac104.s11.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.s11.e1" e2="DBMI.pac104.s11.e2" id="DBMI.pac104.s11.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.s11.e2" e2="DBMI.pac104.s11.e0" id="DBMI.pac104.s11.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.s11.e2" e2="DBMI.pac104.s11.e1" id="DBMI.pac104.s11.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="conivaptan " precipitant="furosemide "/>
	</sentence>
	<sentencespan id="DBMI.pac104.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A\n\nConivaptan is a sensitive substrate of CYP3A. The effect of ketoconazole, a potent CYP3A inhibitor, on the pharmacokinetics of intravenous conivaptan has not been evaluated. Coadministration of oral conivaptan hydrochloride 10 mg with ketoconazole 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of conivaptan, respectively [see Contraindications (4.2)].">
		<entity charOffset="267-280" id="DBMI.pac104.sp0.e0" origId="sp0.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="231-242" id="DBMI.pac104.sp0.e1" origId="sp0.e1" text="conivaptan " type="Active ingredient"/>
		<pair e1="DBMI.pac104.sp0.e0" e2="DBMI.pac104.sp0.e1" id="DBMI.pac104.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="conivaptan " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac104.sp0.e1" e2="DBMI.pac104.sp0.e0" id="DBMI.pac104.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac104.sp1" origId="sp1" text="Conivaptan is a potent mechanism-based inhibitor of CYP3A. The effect of conivaptan on the pharmacokinetics of co-administered CYP3A substrates has been evaluated with the coadministration of conivaptan with midazolam, simvastatin, and amlodipine. VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively.">
		<entity charOffset="648-657" id="DBMI.pac104.sp1.e0" origId="sp1.e0" text="VAPRISOL " type="Drug product"/>
		<entity charOffset="771-781" id="DBMI.pac104.sp1.e1" origId="sp1.e1" text="midazolam " type="Active ingredient"/>
		<entity charOffset="859-871" id="DBMI.pac104.sp1.e2" origId="sp1.e2" text="simvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac104.sp1.e0" e2="DBMI.pac104.sp1.e1" id="DBMI.pac104.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="VAPRISOL "/>
		<pair e1="DBMI.pac104.sp1.e0" e2="DBMI.pac104.sp1.e2" id="DBMI.pac104.sp1.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="simvastatin " precipitant="VAPRISOL "/>
		<pair e1="DBMI.pac104.sp1.e1" e2="DBMI.pac104.sp1.e0" id="DBMI.pac104.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp1.e1" e2="DBMI.pac104.sp1.e2" id="DBMI.pac104.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp1.e2" e2="DBMI.pac104.sp1.e0" id="DBMI.pac104.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp1.e2" e2="DBMI.pac104.sp1.e1" id="DBMI.pac104.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac104.sp2" origId="sp2" text="VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin. Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)]. 7.2 Digoxin\n\nCoadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].">
		<entity charOffset="1125-1136" id="DBMI.pac104.sp2.e0" origId="sp2.e0" text="conivaptan " type="Active ingredient"/>
		<entity charOffset="1078-1086" id="DBMI.pac104.sp2.e1" origId="sp2.e1" text="digoxin " type="Active ingredient"/>
		<entity charOffset="796-805" id="DBMI.pac104.sp2.e2" origId="sp2.e2" text="VAPRISOL " type="Drug product"/>
		<entity charOffset="859-871" id="DBMI.pac104.sp2.e3" origId="sp2.e3" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="978-989" id="DBMI.pac104.sp2.e4" origId="sp2.e4" text="amlodipine " type="Active ingredient"/>
		<pair e1="DBMI.pac104.sp2.e0" e2="DBMI.pac104.sp2.e1" id="DBMI.pac104.sp2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="conivaptan "/>
		<pair e1="DBMI.pac104.sp2.e0" e2="DBMI.pac104.sp2.e2" id="DBMI.pac104.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e0" e2="DBMI.pac104.sp2.e3" id="DBMI.pac104.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e0" e2="DBMI.pac104.sp2.e4" id="DBMI.pac104.sp2.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="amlodipine " precipitant="conivaptan "/>
		<pair e1="DBMI.pac104.sp2.e1" e2="DBMI.pac104.sp2.e0" id="DBMI.pac104.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e1" e2="DBMI.pac104.sp2.e2" id="DBMI.pac104.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e1" e2="DBMI.pac104.sp2.e3" id="DBMI.pac104.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e1" e2="DBMI.pac104.sp2.e4" id="DBMI.pac104.sp2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e2" e2="DBMI.pac104.sp2.e0" id="DBMI.pac104.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e2" e2="DBMI.pac104.sp2.e1" id="DBMI.pac104.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e2" e2="DBMI.pac104.sp2.e3" id="DBMI.pac104.sp2.p10" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="simvastatin " precipitant="VAPRISOL "/>
		<pair e1="DBMI.pac104.sp2.e2" e2="DBMI.pac104.sp2.e4" id="DBMI.pac104.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e3" e2="DBMI.pac104.sp2.e0" id="DBMI.pac104.sp2.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e3" e2="DBMI.pac104.sp2.e1" id="DBMI.pac104.sp2.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e3" e2="DBMI.pac104.sp2.e2" id="DBMI.pac104.sp2.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e3" e2="DBMI.pac104.sp2.e4" id="DBMI.pac104.sp2.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e4" e2="DBMI.pac104.sp2.e0" id="DBMI.pac104.sp2.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e4" e2="DBMI.pac104.sp2.e1" id="DBMI.pac104.sp2.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e4" e2="DBMI.pac104.sp2.e2" id="DBMI.pac104.sp2.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e4" e2="DBMI.pac104.sp2.e3" id="DBMI.pac104.sp2.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac104.sp3" origId="sp3" text="7.3 Warfarin\n\nVAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively. The corresponding prothrombin time and international normalized ratio values were unchanged. 7.4 Captopril and Furosemide\n\nThe pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.">
		<entity charOffset="1333-1342" id="DBMI.pac104.sp3.e0" origId="sp3.e0" text="VAPRISOL " type="Drug product"/>
		<entity charOffset="1406-1415" id="DBMI.pac104.sp3.e1" origId="sp3.e1" text="warfarin " type="Active ingredient"/>
		<entity charOffset="1802-1812" id="DBMI.pac104.sp3.e2" origId="sp3.e2" text="captopril " type="Active ingredient"/>
		<entity charOffset="1727-1738" id="DBMI.pac104.sp3.e3" origId="sp3.e3" text="conivaptan " type="Active ingredient"/>
		<entity charOffset="1821-1832" id="DBMI.pac104.sp3.e4" origId="sp3.e4" text="furosemide " type="Active ingredient"/>
		<pair e1="DBMI.pac104.sp3.e0" e2="DBMI.pac104.sp3.e1" id="DBMI.pac104.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="warfarin " precipitant="VAPRISOL "/>
		<pair e1="DBMI.pac104.sp3.e0" e2="DBMI.pac104.sp3.e2" id="DBMI.pac104.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e0" e2="DBMI.pac104.sp3.e3" id="DBMI.pac104.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e0" e2="DBMI.pac104.sp3.e4" id="DBMI.pac104.sp3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e1" e2="DBMI.pac104.sp3.e0" id="DBMI.pac104.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e1" e2="DBMI.pac104.sp3.e2" id="DBMI.pac104.sp3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e1" e2="DBMI.pac104.sp3.e3" id="DBMI.pac104.sp3.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e1" e2="DBMI.pac104.sp3.e4" id="DBMI.pac104.sp3.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e2" e2="DBMI.pac104.sp3.e0" id="DBMI.pac104.sp3.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e2" e2="DBMI.pac104.sp3.e1" id="DBMI.pac104.sp3.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e2" e2="DBMI.pac104.sp3.e3" id="DBMI.pac104.sp3.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="conivaptan " precipitant="captopril "/>
		<pair e1="DBMI.pac104.sp3.e2" e2="DBMI.pac104.sp3.e4" id="DBMI.pac104.sp3.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e3" e2="DBMI.pac104.sp3.e0" id="DBMI.pac104.sp3.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e3" e2="DBMI.pac104.sp3.e1" id="DBMI.pac104.sp3.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e3" e2="DBMI.pac104.sp3.e2" id="DBMI.pac104.sp3.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e3" e2="DBMI.pac104.sp3.e4" id="DBMI.pac104.sp3.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e4" e2="DBMI.pac104.sp3.e0" id="DBMI.pac104.sp3.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e4" e2="DBMI.pac104.sp3.e1" id="DBMI.pac104.sp3.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e4" e2="DBMI.pac104.sp3.e2" id="DBMI.pac104.sp3.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e4" e2="DBMI.pac104.sp3.e3" id="DBMI.pac104.sp3.p19" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="conivaptan " precipitant="furosemide "/>
	</sentencespan>
</document>

<document id="DBMI.pac106" origId="pac106">
	<sentence id="DBMI.pac106.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Catecholamine Depleting Drugs\n\nCatecholamine depleting drugs (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents."/>
	<sentence id="DBMI.pac106.s1" origId="s1" text="Observe patients treated with TOPROL-XL plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension."/>
	<sentence id="DBMI.pac106.s2" origId="s2" text="7.2 CYP2D6 Inhibitors\n\nDrugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration.">
		<entity charOffset="444-454" id="DBMI.pac106.s2.e0" origId="s2.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="518-529" id="DBMI.pac106.s2.e1" origId="s2.e1" text="metoprolol " type="Active ingredient"/>
		<entity charOffset="455-466" id="DBMI.pac106.s2.e2" origId="s2.e2" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="467-478" id="DBMI.pac106.s2.e3" origId="s2.e3" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="483-495" id="DBMI.pac106.s2.e4" origId="s2.e4" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac106.s2.e0" e2="DBMI.pac106.s2.e1" id="DBMI.pac106.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="quinidine "/>
		<pair e1="DBMI.pac106.s2.e0" e2="DBMI.pac106.s2.e2" id="DBMI.pac106.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e0" e2="DBMI.pac106.s2.e3" id="DBMI.pac106.s2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e0" e2="DBMI.pac106.s2.e4" id="DBMI.pac106.s2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e1" e2="DBMI.pac106.s2.e0" id="DBMI.pac106.s2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e1" e2="DBMI.pac106.s2.e2" id="DBMI.pac106.s2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e1" e2="DBMI.pac106.s2.e3" id="DBMI.pac106.s2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e1" e2="DBMI.pac106.s2.e4" id="DBMI.pac106.s2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e2" e2="DBMI.pac106.s2.e0" id="DBMI.pac106.s2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e2" e2="DBMI.pac106.s2.e1" id="DBMI.pac106.s2.p9" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac106.s2.e2" e2="DBMI.pac106.s2.e3" id="DBMI.pac106.s2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e2" e2="DBMI.pac106.s2.e4" id="DBMI.pac106.s2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e3" e2="DBMI.pac106.s2.e0" id="DBMI.pac106.s2.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e3" e2="DBMI.pac106.s2.e1" id="DBMI.pac106.s2.p13" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="paroxetine "/>
		<pair e1="DBMI.pac106.s2.e3" e2="DBMI.pac106.s2.e2" id="DBMI.pac106.s2.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e3" e2="DBMI.pac106.s2.e4" id="DBMI.pac106.s2.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e4" e2="DBMI.pac106.s2.e0" id="DBMI.pac106.s2.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e4" e2="DBMI.pac106.s2.e1" id="DBMI.pac106.s2.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="propafenone "/>
		<pair e1="DBMI.pac106.s2.e4" e2="DBMI.pac106.s2.e2" id="DBMI.pac106.s2.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e4" e2="DBMI.pac106.s2.e3" id="DBMI.pac106.s2.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac106.s3" origId="s3" text="In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life.">
		<entity charOffset="629-639" id="DBMI.pac106.s3.e0" origId="s3.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="668-679" id="DBMI.pac106.s3.e1" origId="s3.e1" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac106.s3.e0" e2="DBMI.pac106.s3.e1" id="DBMI.pac106.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="quinidine "/>
		<pair e1="DBMI.pac106.s3.e1" e2="DBMI.pac106.s3.e0" id="DBMI.pac106.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac106.s4" origId="s4" text="In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d.with immediate-release metoprolol 50 mg t.i.d.resulted in two- to five-fold increases in the steady-state concentration of metoprolol.">
		<entity charOffset="844-856" id="DBMI.pac106.s4.e0" origId="s4.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="893-904" id="DBMI.pac106.s4.e1" origId="s4.e1" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac106.s4.e0" e2="DBMI.pac106.s4.e1" id="DBMI.pac106.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="propafenone "/>
		<pair e1="DBMI.pac106.s4.e1" e2="DBMI.pac106.s4.e0" id="DBMI.pac106.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac106.s5" origId="s5" text="These increases in plasma concentration would decrease the cardioselectivity of metoprolol."/>
	<sentence id="DBMI.pac106.s6" origId="s6" text="7.3 Digitalis, Clonidine, and Calcium Channel Blockers\n\nDigitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate."/>
	<sentence id="DBMI.pac106.s7" origId="s7" text="Concomitant use with beta blockers can increase the risk of bradycardia."/>
	<sentence id="DBMI.pac106.s8" origId="s8" text="If clonidine and a beta blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine."/>
	<sentence id="DBMI.pac106.s9" origId="s9" text="If replacing clonidine by beta-blocker therapy, delay the introduction of beta-blockers for several days after clonidine administration has stopped [see Warnings and Precautions(5.11)]. "/>
	<sentencespan id="DBMI.pac106.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Catecholamine Depleting Drugs\n\nCatecholamine depleting drugs (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with TOPROL-XL plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7.2 CYP2D6 Inhibitors\n\nDrugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration.">
		<entity charOffset="444-454" id="DBMI.pac106.sp0.e0" origId="sp0.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="518-529" id="DBMI.pac106.sp0.e1" origId="sp0.e1" text="metoprolol " type="Active ingredient"/>
		<entity charOffset="455-466" id="DBMI.pac106.sp0.e2" origId="sp0.e2" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="467-478" id="DBMI.pac106.sp0.e3" origId="sp0.e3" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="483-495" id="DBMI.pac106.sp0.e4" origId="sp0.e4" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac106.sp0.e0" e2="DBMI.pac106.sp0.e1" id="DBMI.pac106.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="quinidine "/>
		<pair e1="DBMI.pac106.sp0.e0" e2="DBMI.pac106.sp0.e2" id="DBMI.pac106.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e0" e2="DBMI.pac106.sp0.e3" id="DBMI.pac106.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e0" e2="DBMI.pac106.sp0.e4" id="DBMI.pac106.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e1" e2="DBMI.pac106.sp0.e0" id="DBMI.pac106.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e1" e2="DBMI.pac106.sp0.e2" id="DBMI.pac106.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e1" e2="DBMI.pac106.sp0.e3" id="DBMI.pac106.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e1" e2="DBMI.pac106.sp0.e4" id="DBMI.pac106.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e2" e2="DBMI.pac106.sp0.e0" id="DBMI.pac106.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e2" e2="DBMI.pac106.sp0.e1" id="DBMI.pac106.sp0.p9" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac106.sp0.e2" e2="DBMI.pac106.sp0.e3" id="DBMI.pac106.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e2" e2="DBMI.pac106.sp0.e4" id="DBMI.pac106.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e3" e2="DBMI.pac106.sp0.e0" id="DBMI.pac106.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e3" e2="DBMI.pac106.sp0.e1" id="DBMI.pac106.sp0.p13" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="paroxetine "/>
		<pair e1="DBMI.pac106.sp0.e3" e2="DBMI.pac106.sp0.e2" id="DBMI.pac106.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e3" e2="DBMI.pac106.sp0.e4" id="DBMI.pac106.sp0.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e4" e2="DBMI.pac106.sp0.e0" id="DBMI.pac106.sp0.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e4" e2="DBMI.pac106.sp0.e1" id="DBMI.pac106.sp0.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="propafenone "/>
		<pair e1="DBMI.pac106.sp0.e4" e2="DBMI.pac106.sp0.e2" id="DBMI.pac106.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e4" e2="DBMI.pac106.sp0.e3" id="DBMI.pac106.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac106.sp1" origId="sp1" text="In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life. In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d.with immediate-release metoprolol 50 mg t.i.d.resulted in two- to five-fold increases in the steady-state concentration of metoprolol. These increases in plasma concentration would decrease the cardioselectivity of metoprolol.">
		<entity charOffset="629-639" id="DBMI.pac106.sp1.e0" origId="sp1.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="668-679" id="DBMI.pac106.sp1.e1" origId="sp1.e1" text="metoprolol " type="Active ingredient"/>
		<entity charOffset="844-856" id="DBMI.pac106.sp1.e2" origId="sp1.e2" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac106.sp1.e0" e2="DBMI.pac106.sp1.e1" id="DBMI.pac106.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="quinidine "/>
		<pair e1="DBMI.pac106.sp1.e0" e2="DBMI.pac106.sp1.e2" id="DBMI.pac106.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp1.e1" e2="DBMI.pac106.sp1.e0" id="DBMI.pac106.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp1.e1" e2="DBMI.pac106.sp1.e2" id="DBMI.pac106.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp1.e2" e2="DBMI.pac106.sp1.e0" id="DBMI.pac106.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp1.e2" e2="DBMI.pac106.sp1.e1" id="DBMI.pac106.sp1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="propafenone "/>
	</sentencespan>
	<sentencespan id="DBMI.pac106.sp2" origId="sp2" text="7.3 Digitalis, Clonidine, and Calcium Channel Blockers\n\nDigitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. Concomitant use with beta blockers can increase the risk of bradycardia. If clonidine and a beta blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine."/>
	<sentencespan id="DBMI.pac106.sp3" origId="sp3" text="If replacing clonidine by beta-blocker therapy, delay the introduction of beta-blockers for several days after clonidine administration has stopped [see Warnings and Precautions(5.11)]. "/>
</document>

<document id="DBMI.pac108" origId="pac108">
	<sentence id="DBMI.pac108.s0" origId="s0" text="Quinidine:  Quinidine is a substrate of CYP3A and has been shown to inhibit CYP3A in vitro."/>
	<sentence id="DBMI.pac108.s1" origId="s1" text="Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.">
		<entity charOffset="130-140" id="DBMI.pac108.s1.e0" origId="s1.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="168-179" id="DBMI.pac108.s1.e1" origId="s1.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac108.s1.e0" e2="DBMI.pac108.s1.e1" id="DBMI.pac108.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="quinidine "/>
		<pair e1="DBMI.pac108.s1.e1" e2="DBMI.pac108.s1.e0" id="DBMI.pac108.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac108.s2" origId="s2" text="The heart rate in the initial interval after drug administration was increased by up to 17.9 beats/minute."/>
	<sentence id="DBMI.pac108.s3" origId="s3" text="The exposure to quinidine was not importantly changed in the presence of nifedipine.">
		<entity charOffset="476-487" id="DBMI.pac108.s3.e0" origId="s3.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="419-429" id="DBMI.pac108.s3.e1" origId="s3.e1" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac108.s3.e0" e2="DBMI.pac108.s3.e1" id="DBMI.pac108.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="quinidine " precipitant="nifedipine "/>
		<pair e1="DBMI.pac108.s3.e1" e2="DBMI.pac108.s3.e0" id="DBMI.pac108.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac108.s4" origId="s4" text="Monitoring of heart rate and adjustment of the nifedipine dose, if necessary, are recommended when quinidine is added to a treatment with nifedipine."/>
	<sentencespan id="DBMI.pac108.sp0" origId="sp0" text="Quinidine:  Quinidine is a substrate of CYP3A and has been shown to inhibit CYP3A in vitro. Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively. The heart rate in the initial interval after drug administration was increased by up to 17.9 beats/minute.">
		<entity charOffset="130-140" id="DBMI.pac108.sp0.e0" origId="sp0.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="168-179" id="DBMI.pac108.sp0.e1" origId="sp0.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac108.sp0.e0" e2="DBMI.pac108.sp0.e1" id="DBMI.pac108.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="quinidine "/>
		<pair e1="DBMI.pac108.sp0.e1" e2="DBMI.pac108.sp0.e0" id="DBMI.pac108.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac108.sp1" origId="sp1" text="The exposure to quinidine was not importantly changed in the presence of nifedipine. Monitoring of heart rate and adjustment of the nifedipine dose, if necessary, are recommended when quinidine is added to a treatment with nifedipine.">
		<entity charOffset="476-487" id="DBMI.pac108.sp1.e0" origId="sp1.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="419-429" id="DBMI.pac108.sp1.e1" origId="sp1.e1" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac108.sp1.e0" e2="DBMI.pac108.sp1.e1" id="DBMI.pac108.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="quinidine " precipitant="nifedipine "/>
		<pair e1="DBMI.pac108.sp1.e1" e2="DBMI.pac108.sp1.e0" id="DBMI.pac108.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac109" origId="pac109">
	<sentence id="DBMI.pac109.s0" origId="s0" text="Diltiazem:  Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d.diltiazem p.o.increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively.">
		<entity charOffset="74-84" id="DBMI.pac109.s0.e0" origId="s0.e0" text="diltiazem " type="Active ingredient"/>
		<entity charOffset="235-246" id="DBMI.pac109.s0.e1" origId="s0.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac109.s0.e0" e2="DBMI.pac109.s0.e1" id="DBMI.pac109.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="diltiazem "/>
		<pair e1="DBMI.pac109.s0.e1" e2="DBMI.pac109.s0.e0" id="DBMI.pac109.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac109.s1" origId="s1" text="The corresponding Cmax values of nifedipine increased by factors of 2.0 and 1.7, respectively."/>
	<sentence id="DBMI.pac109.s2" origId="s2" text="Caution should be exercised when coadministering diltiazem and nifedipine and a reduction of the dose of nifedipine should be considered."/>
	<sentencespan id="DBMI.pac109.sp0" origId="sp0" text="Diltiazem:  Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d.diltiazem p.o.increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively. The corresponding Cmax values of nifedipine increased by factors of 2.0 and 1.7, respectively. Caution should be exercised when coadministering diltiazem and nifedipine and a reduction of the dose of nifedipine should be considered.">
		<entity charOffset="74-84" id="DBMI.pac109.sp0.e0" origId="sp0.e0" text="diltiazem " type="Active ingredient"/>
		<entity charOffset="235-246" id="DBMI.pac109.sp0.e1" origId="sp0.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac109.sp0.e0" e2="DBMI.pac109.sp0.e1" id="DBMI.pac109.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="diltiazem "/>
		<pair e1="DBMI.pac109.sp0.e1" e2="DBMI.pac109.sp0.e0" id="DBMI.pac109.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac11" origId="pac11">
	<sentence id="DBMI.pac11.s0" origId="s0" text="In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group.">
		<entity charOffset="83-94" id="DBMI.pac11.s0.e0" origId="s0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="161-172" id="DBMI.pac11.s0.e1" origId="s0.e1" text="sertraline " type="Active ingredient"/>
		<pair e1="DBMI.pac11.s0.e0" e2="DBMI.pac11.s0.e1" id="DBMI.pac11.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sertraline " precipitant="cimetidine "/>
		<pair e1="DBMI.pac11.s0.e1" e2="DBMI.pac11.s0.e0" id="DBMI.pac11.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac11.s1" origId="s1" text="The clinical significance of these changes is unknown."/>
	<sentencespan id="DBMI.pac11.sp0" origId="sp0" text="In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group. The clinical significance of these changes is unknown.">
		<entity charOffset="83-94" id="DBMI.pac11.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="161-172" id="DBMI.pac11.sp0.e1" origId="sp0.e1" text="sertraline " type="Active ingredient"/>
		<pair e1="DBMI.pac11.sp0.e0" e2="DBMI.pac11.sp0.e1" id="DBMI.pac11.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sertraline " precipitant="cimetidine "/>
		<pair e1="DBMI.pac11.sp0.e1" e2="DBMI.pac11.sp0.e0" id="DBMI.pac11.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac110" origId="pac110">
	<sentence id="DBMI.pac110.s0" origId="s0" text="Irbesartan: In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites by nifedipine."/>
	<sentence id="DBMI.pac110.s1" origId="s1" text="However, in clinical studies, concomitant nifedipine had no effect on irbesartan pharmacokinetics.">
		<entity charOffset="166-177" id="DBMI.pac110.s1.e0" origId="s1.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="194-205" id="DBMI.pac110.s1.e1" origId="s1.e1" text="irbesartan " type="Active ingredient"/>
		<pair e1="DBMI.pac110.s1.e0" e2="DBMI.pac110.s1.e1" id="DBMI.pac110.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac110.s1.e1" e2="DBMI.pac110.s1.e0" id="DBMI.pac110.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac110.sp0" origId="sp0" text="Irbesartan: In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites by nifedipine. However, in clinical studies, concomitant nifedipine had no effect on irbesartan pharmacokinetics.">
		<entity charOffset="166-177" id="DBMI.pac110.sp0.e0" origId="sp0.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="194-205" id="DBMI.pac110.sp0.e1" origId="sp0.e1" text="irbesartan " type="Active ingredient"/>
		<pair e1="DBMI.pac110.sp0.e0" e2="DBMI.pac110.sp0.e1" id="DBMI.pac110.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac110.sp0.e1" e2="DBMI.pac110.sp0.e0" id="DBMI.pac110.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac111" origId="pac111">
	<sentence id="DBMI.pac111.s0" origId="s0" text="Doxazosin:  Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d.alone or combined with 20 mg nifedipine ER b.i.d."/>
	<sentence id="DBMI.pac111.s1" origId="s1" text="Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively.">
		<entity charOffset="202-213" id="DBMI.pac111.s1.e0" origId="s1.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="255-265" id="DBMI.pac111.s1.e1" origId="s1.e1" text="doxazosin " type="Active ingredient"/>
		<pair e1="DBMI.pac111.s1.e0" e2="DBMI.pac111.s1.e1" id="DBMI.pac111.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="doxazosin " precipitant="nifedipine "/>
		<pair e1="DBMI.pac111.s1.e1" e2="DBMI.pac111.s1.e0" id="DBMI.pac111.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac111.s2" origId="s2" text="In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively.">
		<entity charOffset="357-367" id="DBMI.pac111.s2.e0" origId="s2.e0" text="doxazosin " type="Active ingredient"/>
		<entity charOffset="384-395" id="DBMI.pac111.s2.e1" origId="s2.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac111.s2.e0" e2="DBMI.pac111.s2.e1" id="DBMI.pac111.s2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="doxazosin "/>
		<pair e1="DBMI.pac111.s2.e1" e2="DBMI.pac111.s2.e0" id="DBMI.pac111.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac111.s3" origId="s3" text="Compared to nifedipine monotherapy, blood pressure was lower in the presence of doxazosin."/>
	<sentence id="DBMI.pac111.s4" origId="s4" text="Blood pressure should be monitored when doxazosin is coadministered with nifedipine and dose reduction of nifedipine considered."/>
	<sentencespan id="DBMI.pac111.sp0" origId="sp0" text="Doxazosin:  Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d.alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively. In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively.">
		<entity charOffset="202-213" id="DBMI.pac111.sp0.e0" origId="sp0.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="255-265" id="DBMI.pac111.sp0.e1" origId="sp0.e1" text="doxazosin " type="Active ingredient"/>
		<pair e1="DBMI.pac111.sp0.e0" e2="DBMI.pac111.sp0.e1" id="DBMI.pac111.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="doxazosin " precipitant="nifedipine "/>
		<pair e1="DBMI.pac111.sp0.e1" e2="DBMI.pac111.sp0.e0" id="DBMI.pac111.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="doxazosin "/>
	</sentencespan>
	<sentencespan id="DBMI.pac111.sp1" origId="sp1" text="Compared to nifedipine monotherapy, blood pressure was lower in the presence of doxazosin. Blood pressure should be monitored when doxazosin is coadministered with nifedipine and dose reduction of nifedipine considered."/>
</document>

<document id="DBMI.pac113" origId="pac113">
	<sentence id="DBMI.pac113.s0" origId="s0" text="Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine."/>
	<sentence id="DBMI.pac113.s1" origId="s1" text="Two studies investigated the impact of coadministered cimetidine on blood pressure in hypertensive subjects on nifedipine."/>
	<sentence id="DBMI.pac113.s2" origId="s2" text="In normotensive subjects receiving single doses of 10 mg or multiple doses of up to 20 mg nifedipine t.i.d.alone or together with cimetidine up to 1000 mg/day, the AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence of cimetidine.">
		<entity charOffset="417-428" id="DBMI.pac113.s2.e0" origId="s2.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="465-476" id="DBMI.pac113.s2.e1" origId="s2.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac113.s2.e0" e2="DBMI.pac113.s2.e1" id="DBMI.pac113.s2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac113.s2.e1" e2="DBMI.pac113.s2.e0" id="DBMI.pac113.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac113.s3" origId="s3" text="The Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02.">
		<entity charOffset="624-635" id="DBMI.pac113.s3.e0" origId="s3.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="594-605" id="DBMI.pac113.s3.e1" origId="s3.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac113.s3.e0" e2="DBMI.pac113.s3.e1" id="DBMI.pac113.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac113.s3.e1" e2="DBMI.pac113.s3.e0" id="DBMI.pac113.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac113.s4" origId="s4" text="The increase in exposure to nifedipine by cimetidine was accompanied by relevant changes in blood pressure or heart rate in normotensive subjects."/>
	<sentence id="DBMI.pac113.s5" origId="s5" text="Hypertensive subjects receiving 10 mg q.d.nifedipine alone or in combination with cimetidine 1000 mg q.d.also experienced relevant changes in blood pressure when cimetidine was added to nifedipine."/>
	<sentence id="DBMI.pac113.s6" origId="s6" text="The interaction between cimetidine and nifedipine is of clinical relevance and blood pressure should be monitored and a reduction of the dose of nifedipine considered."/>
	<sentencespan id="DBMI.pac113.sp0" origId="sp0" text="Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine. Two studies investigated the impact of coadministered cimetidine on blood pressure in hypertensive subjects on nifedipine. In normotensive subjects receiving single doses of 10 mg or multiple doses of up to 20 mg nifedipine t.i.d.alone or together with cimetidine up to 1000 mg/day, the AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence of cimetidine.">
		<entity charOffset="417-428" id="DBMI.pac113.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="465-476" id="DBMI.pac113.sp0.e1" origId="sp0.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac113.sp0.e0" e2="DBMI.pac113.sp0.e1" id="DBMI.pac113.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac113.sp0.e1" e2="DBMI.pac113.sp0.e0" id="DBMI.pac113.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac113.sp1" origId="sp1" text="The Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02. The increase in exposure to nifedipine by cimetidine was accompanied by relevant changes in blood pressure or heart rate in normotensive subjects. Hypertensive subjects receiving 10 mg q.d.nifedipine alone or in combination with cimetidine 1000 mg q.d.also experienced relevant changes in blood pressure when cimetidine was added to nifedipine.">
		<entity charOffset="624-635" id="DBMI.pac113.sp1.e0" origId="sp1.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="594-605" id="DBMI.pac113.sp1.e1" origId="sp1.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac113.sp1.e0" e2="DBMI.pac113.sp1.e1" id="DBMI.pac113.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac113.sp1.e1" e2="DBMI.pac113.sp1.e0" id="DBMI.pac113.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac113.sp2" origId="sp2" text="The interaction between cimetidine and nifedipine is of clinical relevance and blood pressure should be monitored and a reduction of the dose of nifedipine considered."/>
</document>

<document id="DBMI.pac114" origId="pac114">
	<sentence id="DBMI.pac114.s0" origId="s0" text="Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine."/>
	<sentence id="DBMI.pac114.s1" origId="s1" text="Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy.">
		<entity charOffset="198-211" id="DBMI.pac114.s1.e0" origId="s1.e0" text="quinupristin " type="Active ingredient"/>
		<entity charOffset="228-239" id="DBMI.pac114.s1.e1" origId="s1.e1" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="211-224" id="DBMI.pac114.s1.e2" origId="s1.e2" text="dalfopristin " type="Active ingredient"/>
		<pair e1="DBMI.pac114.s1.e0" e2="DBMI.pac114.s1.e1" id="DBMI.pac114.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="quinupristin "/>
		<pair e1="DBMI.pac114.s1.e0" e2="DBMI.pac114.s1.e2" id="DBMI.pac114.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.s1.e1" e2="DBMI.pac114.s1.e0" id="DBMI.pac114.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.s1.e1" e2="DBMI.pac114.s1.e2" id="DBMI.pac114.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.s1.e2" e2="DBMI.pac114.s1.e0" id="DBMI.pac114.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.s1.e2" e2="DBMI.pac114.s1.e1" id="DBMI.pac114.s1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="dalfopristin "/>
	</sentence>
	<sentence id="DBMI.pac114.s2" origId="s2" text="Upon coadministration of quinupristin/dalfopristin with nifedipine, blood pressure should be monitored and a reduction of the dose of nifedipine considered."/>
	<sentencespan id="DBMI.pac114.sp0" origId="sp0" text="Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine. Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy. Upon coadministration of quinupristin/dalfopristin with nifedipine, blood pressure should be monitored and a reduction of the dose of nifedipine considered.">
		<entity charOffset="198-211" id="DBMI.pac114.sp0.e0" origId="sp0.e0" text="quinupristin " type="Active ingredient"/>
		<entity charOffset="228-239" id="DBMI.pac114.sp0.e1" origId="sp0.e1" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="211-224" id="DBMI.pac114.sp0.e2" origId="sp0.e2" text="dalfopristin " type="Active ingredient"/>
		<pair e1="DBMI.pac114.sp0.e0" e2="DBMI.pac114.sp0.e1" id="DBMI.pac114.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="quinupristin "/>
		<pair e1="DBMI.pac114.sp0.e0" e2="DBMI.pac114.sp0.e2" id="DBMI.pac114.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.sp0.e1" e2="DBMI.pac114.sp0.e0" id="DBMI.pac114.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.sp0.e1" e2="DBMI.pac114.sp0.e2" id="DBMI.pac114.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.sp0.e2" e2="DBMI.pac114.sp0.e0" id="DBMI.pac114.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.sp0.e2" e2="DBMI.pac114.sp0.e1" id="DBMI.pac114.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="dalfopristin "/>
	</sentencespan>
</document>

<document id="DBMI.pac115" origId="pac115">
	<sentence id="DBMI.pac115.s0" origId="s0" text="Phenytoin: Nifedipine is metabolized by CYP3A4."/>
	<sentence id="DBMI.pac115.s1" origId="s1" text="Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%.">
		<entity charOffset="136-146" id="DBMI.pac115.s1.e0" origId="s1.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="68-79" id="DBMI.pac115.s1.e1" origId="s1.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac115.s1.e0" e2="DBMI.pac115.s1.e1" id="DBMI.pac115.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac115.s1.e1" e2="DBMI.pac115.s1.e0" id="DBMI.pac115.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac115.s2" origId="s2" text="When using nifedipine with phenytoin, the clinical response to nifedipine should be monitored and its dose adjusted if necessary."/>
	<sentencespan id="DBMI.pac115.sp0" origId="sp0" text="Phenytoin: Nifedipine is metabolized by CYP3A4. Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%. When using nifedipine with phenytoin, the clinical response to nifedipine should be monitored and its dose adjusted if necessary.">
		<entity charOffset="136-146" id="DBMI.pac115.sp0.e0" origId="sp0.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="68-79" id="DBMI.pac115.sp0.e1" origId="sp0.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac115.sp0.e0" e2="DBMI.pac115.sp0.e1" id="DBMI.pac115.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac115.sp0.e1" e2="DBMI.pac115.sp0.e0" id="DBMI.pac115.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac116" origId="pac116">
	<sentence id="DBMI.pac116.s0" origId="s0" text="Rosiglitazone:  Coadministration of rosiglitazone (4 mg b.i.d.)was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.">
		<entity charOffset="36-50" id="DBMI.pac116.s0.e0" origId="s0.e0" text="rosiglitazone " type="Active ingredient"/>
		<entity charOffset="139-150" id="DBMI.pac116.s0.e1" origId="s0.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac116.s0.e0" e2="DBMI.pac116.s0.e1" id="DBMI.pac116.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine " precipitant="rosiglitazone "/>
		<pair e1="DBMI.pac116.s0.e1" e2="DBMI.pac116.s0.e0" id="DBMI.pac116.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac116.sp0" origId="sp0" text="Rosiglitazone:  Coadministration of rosiglitazone (4 mg b.i.d.)was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.">
		<entity charOffset="36-50" id="DBMI.pac116.sp0.e0" origId="sp0.e0" text="rosiglitazone " type="Active ingredient"/>
		<entity charOffset="139-150" id="DBMI.pac116.sp0.e1" origId="sp0.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac116.sp0.e0" e2="DBMI.pac116.sp0.e1" id="DBMI.pac116.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine " precipitant="rosiglitazone "/>
		<pair e1="DBMI.pac116.sp0.e1" e2="DBMI.pac116.sp0.e0" id="DBMI.pac116.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac118" origId="pac118">
	<sentence id="DBMI.pac118.s0" origId="s0" text="Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.">
		<entity charOffset="30-39" id="DBMI.pac118.s0.e0" origId="s0.e0" text="Synercid " type="Drug product"/>
		<entity charOffset="282-293" id="DBMI.pac118.s0.e1" origId="s0.e1" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="297-307" id="DBMI.pac118.s0.e2" origId="s0.e2" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac118.s0.e0" e2="DBMI.pac118.s0.e1" id="DBMI.pac118.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="Synercid "/>
		<pair e1="DBMI.pac118.s0.e0" e2="DBMI.pac118.s0.e2" id="DBMI.pac118.s0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="Synercid "/>
		<pair e1="DBMI.pac118.s0.e1" e2="DBMI.pac118.s0.e0" id="DBMI.pac118.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.s0.e1" e2="DBMI.pac118.s0.e2" id="DBMI.pac118.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.s0.e2" e2="DBMI.pac118.s0.e0" id="DBMI.pac118.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.s0.e2" e2="DBMI.pac118.s0.e1" id="DBMI.pac118.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac118.s1" origId="s1" text="The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively."/>
	<sentencespan id="DBMI.pac118.sp0" origId="sp0" text="Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.">
		<entity charOffset="30-39" id="DBMI.pac118.sp0.e0" origId="sp0.e0" text="Synercid " type="Drug product"/>
		<entity charOffset="282-293" id="DBMI.pac118.sp0.e1" origId="sp0.e1" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="297-307" id="DBMI.pac118.sp0.e2" origId="sp0.e2" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac118.sp0.e0" e2="DBMI.pac118.sp0.e1" id="DBMI.pac118.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="Synercid "/>
		<pair e1="DBMI.pac118.sp0.e0" e2="DBMI.pac118.sp0.e2" id="DBMI.pac118.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="Synercid "/>
		<pair e1="DBMI.pac118.sp0.e1" e2="DBMI.pac118.sp0.e0" id="DBMI.pac118.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.sp0.e1" e2="DBMI.pac118.sp0.e2" id="DBMI.pac118.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.sp0.e2" e2="DBMI.pac118.sp0.e0" id="DBMI.pac118.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.sp0.e2" e2="DBMI.pac118.sp0.e1" id="DBMI.pac118.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac12" origId="pac12">
	<sentence id="DBMI.pac12.s0" origId="s0" text="In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03).">
		<entity charOffset="123-134" id="DBMI.pac12.s0.e0" origId="s0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="230-239" id="DBMI.pac12.s0.e1" origId="s0.e1" text="diazepam " type="Active ingredient"/>
		<pair e1="DBMI.pac12.s0.e0" e2="DBMI.pac12.s0.e1" id="DBMI.pac12.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="diazepam " precipitant="sertraline "/>
		<pair e1="DBMI.pac12.s0.e1" e2="DBMI.pac12.s0.e0" id="DBMI.pac12.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac12.s1" origId="s1" text="There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p &lt; 0.03).">
		<entity charOffset="419-430" id="DBMI.pac12.s1.e0" origId="s1.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="394-412" id="DBMI.pac12.s1.e1" origId="s1.e1" text="desmethyldiazepam " type="Metabolite"/>
		<pair e1="DBMI.pac12.s1.e0" e2="DBMI.pac12.s1.e1" id="DBMI.pac12.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desmethyldiazepam " precipitant="sertraline "/>
		<pair e1="DBMI.pac12.s1.e1" e2="DBMI.pac12.s1.e0" id="DBMI.pac12.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac12.s2" origId="s2" text="The clinical significance of these changes is unknown."/>
	<sentencespan id="DBMI.pac12.sp0" origId="sp0" text="In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03). There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p &lt; 0.03). The clinical significance of these changes is unknown.">
		<entity charOffset="123-134" id="DBMI.pac12.sp0.e0" origId="sp0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="230-239" id="DBMI.pac12.sp0.e1" origId="sp0.e1" text="diazepam " type="Active ingredient"/>
		<entity charOffset="394-412" id="DBMI.pac12.sp0.e2" origId="sp0.e2" text="desmethyldiazepam " type="Metabolite"/>
		<pair e1="DBMI.pac12.sp0.e0" e2="DBMI.pac12.sp0.e1" id="DBMI.pac12.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="diazepam " precipitant="sertraline "/>
		<pair e1="DBMI.pac12.sp0.e0" e2="DBMI.pac12.sp0.e2" id="DBMI.pac12.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desmethyldiazepam " precipitant="sertraline "/>
		<pair e1="DBMI.pac12.sp0.e1" e2="DBMI.pac12.sp0.e0" id="DBMI.pac12.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac12.sp0.e1" e2="DBMI.pac12.sp0.e2" id="DBMI.pac12.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac12.sp0.e2" e2="DBMI.pac12.sp0.e0" id="DBMI.pac12.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac12.sp0.e2" e2="DBMI.pac12.sp0.e1" id="DBMI.pac12.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac122" origId="pac122">
	<sentence id="DBMI.pac122.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP2C8 Inhibitors and Inducers\n\nAn inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone.">
		<entity charOffset="170-179" id="DBMI.pac122.s0.e0" origId="s0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="204-218" id="DBMI.pac122.s0.e1" origId="s0.e1" text="rosiglitazone " type="Active ingredient"/>
		<entity charOffset="87-99" id="DBMI.pac122.s0.e2" origId="s0.e2" text="gemfibrozil " type="Active ingredient"/>
		<pair e1="DBMI.pac122.s0.e0" e2="DBMI.pac122.s0.e1" id="DBMI.pac122.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="rosiglitazone " precipitant="rifampin "/>
		<pair e1="DBMI.pac122.s0.e0" e2="DBMI.pac122.s0.e2" id="DBMI.pac122.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.s0.e1" e2="DBMI.pac122.s0.e0" id="DBMI.pac122.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.s0.e1" e2="DBMI.pac122.s0.e2" id="DBMI.pac122.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.s0.e2" e2="DBMI.pac122.s0.e0" id="DBMI.pac122.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.s0.e2" e2="DBMI.pac122.s0.e1" id="DBMI.pac122.s0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="rosiglitazone " precipitant="gemfibrozil "/>
	</sentence>
	<sentence id="DBMI.pac122.s1" origId="s1" text="Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response."/>
	<sentence id="DBMI.pac122.s2" origId="s2" text="[See Clinical Pharmacology (12.4).]"/>
	<sentencespan id="DBMI.pac122.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP2C8 Inhibitors and Inducers\n\nAn inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response. [See Clinical Pharmacology (12.4).]">
		<entity charOffset="170-179" id="DBMI.pac122.sp0.e0" origId="sp0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="204-218" id="DBMI.pac122.sp0.e1" origId="sp0.e1" text="rosiglitazone " type="Active ingredient"/>
		<entity charOffset="87-99" id="DBMI.pac122.sp0.e2" origId="sp0.e2" text="gemfibrozil " type="Active ingredient"/>
		<pair e1="DBMI.pac122.sp0.e0" e2="DBMI.pac122.sp0.e1" id="DBMI.pac122.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="rosiglitazone " precipitant="rifampin "/>
		<pair e1="DBMI.pac122.sp0.e0" e2="DBMI.pac122.sp0.e2" id="DBMI.pac122.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.sp0.e1" e2="DBMI.pac122.sp0.e0" id="DBMI.pac122.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.sp0.e1" e2="DBMI.pac122.sp0.e2" id="DBMI.pac122.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.sp0.e2" e2="DBMI.pac122.sp0.e0" id="DBMI.pac122.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.sp0.e2" e2="DBMI.pac122.sp0.e1" id="DBMI.pac122.sp0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="rosiglitazone " precipitant="gemfibrozil "/>
	</sentencespan>
</document>

<document id="DBMI.pac123" origId="pac123">
	<sentence id="DBMI.pac123.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nRosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity."/>
	<sentence id="DBMI.pac123.s1" origId="s1" text="Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPAR)."/>
	<sentence id="DBMI.pac123.s2" origId="s2" text="In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver."/>
	<sentence id="DBMI.pac123.s3" origId="s3" text="Activation of PPAR nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization."/>
	<sentence id="DBMI.pac123.s4" origId="s4" text="In addition, PPAR-responsive genes also participate in the regulation of fatty acid metabolism."/>
	<sentence id="DBMI.pac123.s5" origId="s5" text="Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes."/>
	<sentence id="DBMI.pac123.s6" origId="s6" text="The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues."/>
	<sentence id="DBMI.pac123.s7" origId="s7" text="Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat."/>
	<sentence id="DBMI.pac123.s8" origId="s8" text="In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulins action in the liver, muscle, and adipose tissues."/>
	<sentence id="DBMI.pac123.s9" origId="s9" text="Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis."/>
	<sentence id="DBMI.pac123.s10" origId="s10" text="The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue."/>
	<sentence id="DBMI.pac123.s11" origId="s11" text="Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance."/>
	<sentence id="DBMI.pac123.s12" origId="s12" text="12.2 Pharmacodynamics\n\nPatients with lipid abnormalities were not excluded from clinical trials of AVANDIA."/>
	<sentence id="DBMI.pac123.s13" origId="s13" text="In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids."/>
	<sentence id="DBMI.pac123.s14" origId="s14" text="These changes were statistically significantly different from placebo or glyburide controls (Table 7)."/>
	<sentence id="DBMI.pac123.s15" origId="s15" text="Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials."/>
	<sentence id="DBMI.pac123.s16" origId="s16" text="In contrast, HDL continued to rise over time."/>
	<sentence id="DBMI.pac123.s17" origId="s17" text="As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time."/>
	<sentence id="DBMI.pac123.s18" origId="s18" text="Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids."/>
	<sentence id="DBMI.pac123.s19" origId="s19" text="At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily."/>
	<sentence id="DBMI.pac123.s20" origId="s20" text="The corresponding values for glyburide were 3.2, 3.1, and 2.9."/>
	<sentence id="DBMI.pac123.s21" origId="s21" text="The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant."/>
	<sentence id="DBMI.pac123.s22" origId="s22" text="The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy."/>
	<sentence id="DBMI.pac123.s23" origId="s23" text="The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls."/>
	<sentence id="DBMI.pac123.s24" origId="s24" text="12.3 Pharmacokinetics\n\nMaximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8)."/>
	<sentence id="DBMI.pac123.s25" origId="s25" text="The elimination half-life is 3 to 4 hours and is independent of dose."/>
	<sentence id="DBMI.pac123.s26" origId="s26" text="Absorption\n\nThe absolute bioavailability of rosiglitazone is 99%."/>
	<sentence id="DBMI.pac123.s27" origId="s27" text="Peak plasma concentrations are observed about 1 hour after dosing."/>
	<sentence id="DBMI.pac123.s28" origId="s28" text="Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours)."/>
	<sentence id="DBMI.pac123.s29" origId="s29" text="These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food."/>
	<sentence id="DBMI.pac123.s30" origId="s30" text="Distribution\n\nThe mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis."/>
	<sentence id="DBMI.pac123.s31" origId="s31" text="Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin."/>
	<sentence id="DBMI.pac123.s32" origId="s32" text="Metabolism\n\nRosiglitazone is extensively metabolized with no unchanged drug excreted in the urine."/>
	<sentence id="DBMI.pac123.s33" origId="s33" text="The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid."/>
	<sentence id="DBMI.pac123.s34" origId="s34" text="All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone."/>
	<sentence id="DBMI.pac123.s35" origId="s35" text="In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway."/>
	<sentence id="DBMI.pac123.s36" origId="s36" text="Excretion\n\nFollowing oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively."/>
	<sentence id="DBMI.pac123.s37" origId="s37" text="The plasma half-life of [14C]related material ranged from 103 to 158 hours."/>
	<sentence id="DBMI.pac123.s38" origId="s38" text="Population Pharmacokinetics in Patients With Type 2 Diabetes\n\nPopulation pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption."/>
	<sentence id="DBMI.pac123.s39" origId="s39" text="Both oral clearance (CL/F) and oral steady-state volume of distribution (Vss/F) were shown to increase with increases in body weight."/>
	<sentence id="DBMI.pac123.s40" origId="s40" text="Over the weight range observed in these analyses (50 to 150 kg), the range of predicted CL/F and Vss/F values varied by &lt;1.7-fold and &lt;2.3-fold, respectively."/>
	<sentence id="DBMI.pac123.s41" origId="s41" text="Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients."/>
	<sentence id="DBMI.pac123.s42" origId="s42" text="Special Populations\n\nGeriatric\n\nResults of the population pharmacokinetic analysis (n = 716 &lt;65 years; n = 331 65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone."/>
	<sentence id="DBMI.pac123.s43" origId="s43" text="Gender\n\nResults of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642)."/>
	<sentence id="DBMI.pac123.s44" origId="s44" text="As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females."/>
	<sentence id="DBMI.pac123.s45" origId="s45" text="In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response."/>
	<sentence id="DBMI.pac123.s46" origId="s46" text="In monotherapy studies, a greater therapeutic response was observed in females; however, in more obese patients, gender differences were less evident."/>
	<sentence id="DBMI.pac123.s47" origId="s47" text="For a given body mass index (BMI), females tend to have a greater fat mass than males."/>
	<sentence id="DBMI.pac123.s48" origId="s48" text="Since the molecular target PPAR is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to AVANDIA in females."/>
	<sentence id="DBMI.pac123.s49" origId="s49" text="Since therapy should be individualized, no dose adjustments are necessary based on gender alone."/>
	<sentence id="DBMI.pac123.s50" origId="s50" text="Hepatic Impairment\n\nUnbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects."/>
	<sentence id="DBMI.pac123.s51" origId="s51" text="As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively."/>
	<sentence id="DBMI.pac123.s52" origId="s52" text="Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects."/>
	<sentence id="DBMI.pac123.s53" origId="s53" text="Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT &gt;2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)]."/>
	<sentence id="DBMI.pac123.s54" origId="s54" text="Pediatric\n\nPharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg)."/>
	<sentence id="DBMI.pac123.s55" origId="s55" text="Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively."/>
	<sentence id="DBMI.pac123.s56" origId="s56" text="These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis."/>
	<sentence id="DBMI.pac123.s57" origId="s57" text="Renal Impairment\n\nThere are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function."/>
	<sentence id="DBMI.pac123.s58" origId="s58" text="No dosage adjustment is therefore required in such patients receiving AVANDIA."/>
	<sentence id="DBMI.pac123.s59" origId="s59" text="Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients."/>
	<sentence id="DBMI.pac123.s60" origId="s60" text="Race\n\nResults of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone."/>
	<sentence id="DBMI.pac123.s61" origId="s61" text="12.4 Drug-Drug Interactions\n\nDrugs That Inhibit, Induce, or are Metabolized by Cytochrome P450\n\nIn vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations."/>
	<sentence id="DBMI.pac123.s62" origId="s62" text="In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9."/>
	<sentence id="DBMI.pac123.s63" origId="s63" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.">
		<entity charOffset="9050-9058" id="DBMI.pac123.s63.e0" origId="s63.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="9152-9163" id="DBMI.pac123.s63.e1" origId="s63.e1" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="9210-9224" id="DBMI.pac123.s63.e2" origId="s63.e2" text="norethindrone " type="Active ingredient"/>
		<entity charOffset="9188-9206" id="DBMI.pac123.s63.e3" origId="s63.e3" text="ethinyl estradiol " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s63.e0" e2="DBMI.pac123.s63.e1" id="DBMI.pac123.s63.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s63.e0" e2="DBMI.pac123.s63.e1" id="DBMI.pac123.s63.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s63.e0" e2="DBMI.pac123.s63.e2" id="DBMI.pac123.s63.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="norethindrone " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s63.e0" e2="DBMI.pac123.s63.e3" id="DBMI.pac123.s63.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s63.e1" e2="DBMI.pac123.s63.e0" id="DBMI.pac123.s63.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e1" e2="DBMI.pac123.s63.e2" id="DBMI.pac123.s63.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e1" e2="DBMI.pac123.s63.e3" id="DBMI.pac123.s63.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e2" e2="DBMI.pac123.s63.e0" id="DBMI.pac123.s63.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e2" e2="DBMI.pac123.s63.e1" id="DBMI.pac123.s63.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e2" e2="DBMI.pac123.s63.e3" id="DBMI.pac123.s63.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e3" e2="DBMI.pac123.s63.e0" id="DBMI.pac123.s63.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e3" e2="DBMI.pac123.s63.e1" id="DBMI.pac123.s63.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e3" e2="DBMI.pac123.s63.e2" id="DBMI.pac123.s63.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s64" origId="s64" text="Gemfibrozil\n\nConcomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.">
		<entity charOffset="9317-9329" id="DBMI.pac123.s64.e0" origId="s64.e0" text="gemfibrozil " type="Active ingredient"/>
		<entity charOffset="9379-9393" id="DBMI.pac123.s64.e1" origId="s64.e1" text="rosiglitazone " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s64.e0" e2="DBMI.pac123.s64.e1" id="DBMI.pac123.s64.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="rosiglitazone " precipitant="gemfibrozil "/>
		<pair e1="DBMI.pac123.s64.e1" e2="DBMI.pac123.s64.e0" id="DBMI.pac123.s64.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s65" origId="s65" text="Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)]."/>
	<sentence id="DBMI.pac123.s66" origId="s66" text="Rifampin\n\nRifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4\n\nGlyburide\n\nAVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.">
		<entity charOffset="9731-9740" id="DBMI.pac123.s66.e0" origId="s66.e0" text="Rifampin " type="Active ingredient"/>
		<entity charOffset="9833-9847" id="DBMI.pac123.s66.e1" origId="s66.e1" text="rosiglitazone " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s66.e0" e2="DBMI.pac123.s66.e1" id="DBMI.pac123.s66.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="rosiglitazone " precipitant="Rifampin "/>
		<pair e1="DBMI.pac123.s66.e1" e2="DBMI.pac123.s66.e0" id="DBMI.pac123.s66.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s67" origId="s67" text="Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.">
		<entity charOffset="10201-10209" id="DBMI.pac123.s67.e0" origId="s67.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="10295-10305" id="DBMI.pac123.s67.e1" origId="s67.e1" text="glyburide " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s67.e0" e2="DBMI.pac123.s67.e1" id="DBMI.pac123.s67.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="glyburide " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s67.e1" e2="DBMI.pac123.s67.e0" id="DBMI.pac123.s67.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s68" origId="s68" text="In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA."/>
	<sentence id="DBMI.pac123.s69" origId="s69" text="Glimepiride\n\nSingle oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.">
		<entity charOffset="10434-10442" id="DBMI.pac123.s69.e0" origId="s69.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="10362-10372" id="DBMI.pac123.s69.e1" origId="s69.e1" text="glyburide " type="Active ingredient"/>
		<entity charOffset="10478-10490" id="DBMI.pac123.s69.e2" origId="s69.e2" text="glimepiride " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s69.e0" e2="DBMI.pac123.s69.e1" id="DBMI.pac123.s69.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="glyburide " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s69.e0" e2="DBMI.pac123.s69.e2" id="DBMI.pac123.s69.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s69.e1" e2="DBMI.pac123.s69.e0" id="DBMI.pac123.s69.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s69.e1" e2="DBMI.pac123.s69.e2" id="DBMI.pac123.s69.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s69.e2" e2="DBMI.pac123.s69.e0" id="DBMI.pac123.s69.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA " precipitant="glimepiride "/>
		<pair e1="DBMI.pac123.s69.e2" e2="DBMI.pac123.s69.e1" id="DBMI.pac123.s69.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s70" origId="s70" text="No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.">
		<entity charOffset="10706-10714" id="DBMI.pac123.s70.e0" origId="s70.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="10645-10657" id="DBMI.pac123.s70.e1" origId="s70.e1" text="glimepiride " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s70.e0" e2="DBMI.pac123.s70.e1" id="DBMI.pac123.s70.p0" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="glimepiride " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s70.e1" e2="DBMI.pac123.s70.e0" id="DBMI.pac123.s70.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s71" origId="s71" text="Metformin\n\nConcurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.">
		<entity charOffset="10811-10819" id="DBMI.pac123.s71.e0" origId="s71.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="10842-10852" id="DBMI.pac123.s71.e1" origId="s71.e1" text="metformin " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s71.e0" e2="DBMI.pac123.s71.e1" id="DBMI.pac123.s71.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="metformin " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s71.e1" e2="DBMI.pac123.s71.e0" id="DBMI.pac123.s71.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA " precipitant="metformin "/>
	</sentence>
	<sentence id="DBMI.pac123.s72" origId="s72" text="Acarbose\n\nCoadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.">
		<entity charOffset="11026-11035" id="DBMI.pac123.s72.e0" origId="s72.e0" text="acarbose " type="Active ingredient"/>
		<entity charOffset="11178-11186" id="DBMI.pac123.s72.e1" origId="s72.e1" text="AVANDIA " type="Drug product"/>
		<pair e1="DBMI.pac123.s72.e0" e2="DBMI.pac123.s72.e1" id="DBMI.pac123.s72.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA " precipitant="acarbose "/>
		<pair e1="DBMI.pac123.s72.e1" e2="DBMI.pac123.s72.e0" id="DBMI.pac123.s72.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s73" origId="s73" text="Digoxin\n\nRepeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.">
		<entity charOffset="11219-11227" id="DBMI.pac123.s73.e0" origId="s73.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="11308-11316" id="DBMI.pac123.s73.e1" origId="s73.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s73.e0" e2="DBMI.pac123.s73.e1" id="DBMI.pac123.s73.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s73.e1" e2="DBMI.pac123.s73.e0" id="DBMI.pac123.s73.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s74" origId="s74" text="Warfarin\n\nRepeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.">
		<entity charOffset="11391-11399" id="DBMI.pac123.s74.e0" origId="s74.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="11473-11482" id="DBMI.pac123.s74.e1" origId="s74.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s74.e0" e2="DBMI.pac123.s74.e1" id="DBMI.pac123.s74.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.s74.e1" e2="DBMI.pac123.s74.e0" id="DBMI.pac123.s74.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s75" origId="s75" text="Ethanol\n\nA single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA."/>
	<sentence id="DBMI.pac123.s76" origId="s76" text="Ranitidine\n\nPretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.">
		<entity charOffset="11699-11710" id="DBMI.pac123.s76.e0" origId="s76.e0" text="ranitidine " type="Active ingredient"/>
		<entity charOffset="11823-11837" id="DBMI.pac123.s76.e1" origId="s76.e1" text="rosiglitazone " type="Active ingredient"/>
		<pair e1="DBMI.pac123.s76.e0" e2="DBMI.pac123.s76.e1" id="DBMI.pac123.s76.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="rosiglitazone " precipitant="ranitidine "/>
		<pair e1="DBMI.pac123.s76.e1" e2="DBMI.pac123.s76.e0" id="DBMI.pac123.s76.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s77" origId="s77" text="These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.\n"/>
	<sentencespan id="DBMI.pac123.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nRosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPAR). In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver."/>
	<sentencespan id="DBMI.pac123.sp1" origId="sp1" text="Activation of PPAR nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPAR-responsive genes also participate in the regulation of fatty acid metabolism. Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes."/>
	<sentencespan id="DBMI.pac123.sp2" origId="sp2" text="The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues. Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat. In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulins action in the liver, muscle, and adipose tissues."/>
	<sentencespan id="DBMI.pac123.sp3" origId="sp3" text="Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis. The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue. Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance."/>
	<sentencespan id="DBMI.pac123.sp4" origId="sp4" text="12.2 Pharmacodynamics\n\nPatients with lipid abnormalities were not excluded from clinical trials of AVANDIA. In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids. These changes were statistically significantly different from placebo or glyburide controls (Table 7)."/>
	<sentencespan id="DBMI.pac123.sp5" origId="sp5" text="Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time."/>
	<sentencespan id="DBMI.pac123.sp6" origId="sp6" text="Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids. At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily. The corresponding values for glyburide were 3.2, 3.1, and 2.9."/>
	<sentencespan id="DBMI.pac123.sp7" origId="sp7" text="The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant. The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy. The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls."/>
	<sentencespan id="DBMI.pac123.sp8" origId="sp8" text="12.3 Pharmacokinetics\n\nMaximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8). The elimination half-life is 3 to 4 hours and is independent of dose. Absorption\n\nThe absolute bioavailability of rosiglitazone is 99%."/>
	<sentencespan id="DBMI.pac123.sp9" origId="sp9" text="Peak plasma concentrations are observed about 1 hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours). These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food."/>
	<sentencespan id="DBMI.pac123.sp10" origId="sp10" text="Distribution\n\nThe mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis. Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin. Metabolism\n\nRosiglitazone is extensively metabolized with no unchanged drug excreted in the urine."/>
	<sentencespan id="DBMI.pac123.sp11" origId="sp11" text="The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid. All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone. In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway."/>
	<sentencespan id="DBMI.pac123.sp12" origId="sp12" text="Excretion\n\nFollowing oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively. The plasma half-life of [14C]related material ranged from 103 to 158 hours. Population Pharmacokinetics in Patients With Type 2 Diabetes\n\nPopulation pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption."/>
	<sentencespan id="DBMI.pac123.sp13" origId="sp13" text="Both oral clearance (CL/F) and oral steady-state volume of distribution (Vss/F) were shown to increase with increases in body weight. Over the weight range observed in these analyses (50 to 150 kg), the range of predicted CL/F and Vss/F values varied by &lt;1.7-fold and &lt;2.3-fold, respectively. Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients."/>
	<sentencespan id="DBMI.pac123.sp14" origId="sp14" text="Special Populations\n\nGeriatric\n\nResults of the population pharmacokinetic analysis (n = 716 &lt;65 years; n = 331 65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone. Gender\n\nResults of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642). As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females."/>
	<sentencespan id="DBMI.pac123.sp15" origId="sp15" text="In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response. In monotherapy studies, a greater therapeutic response was observed in females; however, in more obese patients, gender differences were less evident. For a given body mass index (BMI), females tend to have a greater fat mass than males."/>
	<sentencespan id="DBMI.pac123.sp16" origId="sp16" text="Since the molecular target PPAR is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to AVANDIA in females. Since therapy should be individualized, no dose adjustments are necessary based on gender alone. Hepatic Impairment\n\nUnbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects."/>
	<sentencespan id="DBMI.pac123.sp17" origId="sp17" text="As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively. Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects. Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT &gt;2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)]."/>
	<sentencespan id="DBMI.pac123.sp18" origId="sp18" text="Pediatric\n\nPharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg). Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively. These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis."/>
	<sentencespan id="DBMI.pac123.sp19" origId="sp19" text="Renal Impairment\n\nThere are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function. No dosage adjustment is therefore required in such patients receiving AVANDIA. Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients."/>
	<sentencespan id="DBMI.pac123.sp20" origId="sp20" text="Race\n\nResults of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone. 12.4 Drug-Drug Interactions\n\nDrugs That Inhibit, Induce, or are Metabolized by Cytochrome P450\n\nIn vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations. In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9."/>
	<sentencespan id="DBMI.pac123.sp21" origId="sp21" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4. Gemfibrozil\n\nConcomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].">
		<entity charOffset="9050-9058" id="DBMI.pac123.sp21.e0" origId="sp21.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="9152-9163" id="DBMI.pac123.sp21.e1" origId="sp21.e1" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="9210-9224" id="DBMI.pac123.sp21.e2" origId="sp21.e2" text="norethindrone " type="Active ingredient"/>
		<entity charOffset="9188-9206" id="DBMI.pac123.sp21.e3" origId="sp21.e3" text="ethinyl estradiol " type="Active ingredient"/>
		<entity charOffset="9317-9329" id="DBMI.pac123.sp21.e4" origId="sp21.e4" text="gemfibrozil " type="Active ingredient"/>
		<entity charOffset="9379-9393" id="DBMI.pac123.sp21.e5" origId="sp21.e5" text="rosiglitazone " type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="norethindrone " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p25" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="rosiglitazone " precipitant="gemfibrozil "/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac123.sp22" origId="sp22" text="Rifampin\n\nRifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4\n\nGlyburide\n\nAVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy. Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%. In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.">
		<entity charOffset="10201-10209" id="DBMI.pac123.sp22.e0" origId="sp22.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="10295-10305" id="DBMI.pac123.sp22.e1" origId="sp22.e1" text="glyburide " type="Active ingredient"/>
		<entity charOffset="9731-9740" id="DBMI.pac123.sp22.e2" origId="sp22.e2" text="Rifampin " type="Active ingredient"/>
		<entity charOffset="9833-9847" id="DBMI.pac123.sp22.e3" origId="sp22.e3" text="rosiglitazone " type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp22.e0" e2="DBMI.pac123.sp22.e1" id="DBMI.pac123.sp22.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="glyburide " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp22.e0" e2="DBMI.pac123.sp22.e1" id="DBMI.pac123.sp22.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="glyburide " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp22.e0" e2="DBMI.pac123.sp22.e2" id="DBMI.pac123.sp22.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e0" e2="DBMI.pac123.sp22.e3" id="DBMI.pac123.sp22.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e1" e2="DBMI.pac123.sp22.e0" id="DBMI.pac123.sp22.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e1" e2="DBMI.pac123.sp22.e2" id="DBMI.pac123.sp22.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e1" e2="DBMI.pac123.sp22.e3" id="DBMI.pac123.sp22.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e2" e2="DBMI.pac123.sp22.e0" id="DBMI.pac123.sp22.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e2" e2="DBMI.pac123.sp22.e1" id="DBMI.pac123.sp22.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e2" e2="DBMI.pac123.sp22.e3" id="DBMI.pac123.sp22.p9" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="rosiglitazone " precipitant="Rifampin "/>
		<pair e1="DBMI.pac123.sp22.e3" e2="DBMI.pac123.sp22.e0" id="DBMI.pac123.sp22.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e3" e2="DBMI.pac123.sp22.e1" id="DBMI.pac123.sp22.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e3" e2="DBMI.pac123.sp22.e2" id="DBMI.pac123.sp22.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac123.sp23" origId="sp23" text="Glimepiride\n\nSingle oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA. No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects. Metformin\n\nConcurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.">
		<entity charOffset="10434-10442" id="DBMI.pac123.sp23.e0" origId="sp23.e0" text="AVANDIA " type="Drug product"/>
		<entity charOffset="10362-10372" id="DBMI.pac123.sp23.e1" origId="sp23.e1" text="glyburide " type="Active ingredient"/>
		<entity charOffset="10478-10490" id="DBMI.pac123.sp23.e2" origId="sp23.e2" text="glimepiride " type="Active ingredient"/>
		<entity charOffset="10842-10852" id="DBMI.pac123.sp23.e3" origId="sp23.e3" text="metformin " type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp23.e0" e2="DBMI.pac123.sp23.e1" id="DBMI.pac123.sp23.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="glyburide " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp23.e0" e2="DBMI.pac123.sp23.e2" id="DBMI.pac123.sp23.p1" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="glimepiride " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp23.e0" e2="DBMI.pac123.sp23.e3" id="DBMI.pac123.sp23.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="metformin " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp23.e1" e2="DBMI.pac123.sp23.e0" id="DBMI.pac123.sp23.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp23.e1" e2="DBMI.pac123.sp23.e2" id="DBMI.pac123.sp23.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp23.e1" e2="DBMI.pac123.sp23.e3" id="DBMI.pac123.sp23.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp23.e2" e2="DBMI.pac123.sp23.e0" id="DBMI.pac123.sp23.p6" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA " precipitant="glimepiride "/>
		<pair e1="DBMI.pac123.sp23.e2" e2="DBMI.pac123.sp23.e1" id="DBMI.pac123.sp23.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp23.e2" e2="DBMI.pac123.sp23.e3" id="DBMI.pac123.sp23.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp23.e3" e2="DBMI.pac123.sp23.e0" id="DBMI.pac123.sp23.p9" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA " precipitant="metformin "/>
		<pair e1="DBMI.pac123.sp23.e3" e2="DBMI.pac123.sp23.e1" id="DBMI.pac123.sp23.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp23.e3" e2="DBMI.pac123.sp23.e2" id="DBMI.pac123.sp23.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac123.sp24" origId="sp24" text="Acarbose\n\nCoadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA. Digoxin\n\nRepeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers. Warfarin\n\nRepeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.">
		<entity charOffset="11026-11035" id="DBMI.pac123.sp24.e0" origId="sp24.e0" text="acarbose " type="Active ingredient"/>
		<entity charOffset="11178-11186" id="DBMI.pac123.sp24.e1" origId="sp24.e1" text="AVANDIA " type="Drug product"/>
		<entity charOffset="11308-11316" id="DBMI.pac123.sp24.e2" origId="sp24.e2" text="digoxin " type="Active ingredient"/>
		<entity charOffset="11473-11482" id="DBMI.pac123.sp24.e3" origId="sp24.e3" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp24.e0" e2="DBMI.pac123.sp24.e1" id="DBMI.pac123.sp24.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA " precipitant="acarbose "/>
		<pair e1="DBMI.pac123.sp24.e0" e2="DBMI.pac123.sp24.e2" id="DBMI.pac123.sp24.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e0" e2="DBMI.pac123.sp24.e3" id="DBMI.pac123.sp24.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e1" e2="DBMI.pac123.sp24.e0" id="DBMI.pac123.sp24.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e1" e2="DBMI.pac123.sp24.e2" id="DBMI.pac123.sp24.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp24.e1" e2="DBMI.pac123.sp24.e3" id="DBMI.pac123.sp24.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="AVANDIA "/>
		<pair e1="DBMI.pac123.sp24.e2" e2="DBMI.pac123.sp24.e0" id="DBMI.pac123.sp24.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e2" e2="DBMI.pac123.sp24.e1" id="DBMI.pac123.sp24.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e2" e2="DBMI.pac123.sp24.e3" id="DBMI.pac123.sp24.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e3" e2="DBMI.pac123.sp24.e0" id="DBMI.pac123.sp24.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e3" e2="DBMI.pac123.sp24.e1" id="DBMI.pac123.sp24.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e3" e2="DBMI.pac123.sp24.e2" id="DBMI.pac123.sp24.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac123.sp25" origId="sp25" text="Ethanol\n\nA single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA. Ranitidine\n\nPretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers. These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.\n">
		<entity charOffset="11699-11710" id="DBMI.pac123.sp25.e0" origId="sp25.e0" text="ranitidine " type="Active ingredient"/>
		<entity charOffset="11823-11837" id="DBMI.pac123.sp25.e1" origId="sp25.e1" text="rosiglitazone " type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp25.e0" e2="DBMI.pac123.sp25.e1" id="DBMI.pac123.sp25.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="rosiglitazone " precipitant="ranitidine "/>
		<pair e1="DBMI.pac123.sp25.e1" e2="DBMI.pac123.sp25.e0" id="DBMI.pac123.sp25.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac124" origId="pac124">
	<sentence id="DBMI.pac124.s0" origId="s0" text="The AUC of propafenone is increased by more than 200% by co-administration of propranolol.">
		<entity charOffset="78-90" id="DBMI.pac124.s0.e0" origId="s0.e0" text="propranolol " type="Active ingredient"/>
		<entity charOffset="11-23" id="DBMI.pac124.s0.e1" origId="s0.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac124.s0.e0" e2="DBMI.pac124.s0.e1" id="DBMI.pac124.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="propranolol "/>
		<pair e1="DBMI.pac124.s0.e1" e2="DBMI.pac124.s0.e0" id="DBMI.pac124.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac124.sp0" origId="sp0" text="The AUC of propafenone is increased by more than 200% by co-administration of propranolol.">
		<entity charOffset="78-90" id="DBMI.pac124.sp0.e0" origId="sp0.e0" text="propranolol " type="Active ingredient"/>
		<entity charOffset="11-23" id="DBMI.pac124.sp0.e1" origId="sp0.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac124.sp0.e0" e2="DBMI.pac124.sp0.e1" id="DBMI.pac124.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="propranolol "/>
		<pair e1="DBMI.pac124.sp0.e1" e2="DBMI.pac124.sp0.e0" id="DBMI.pac124.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac125" origId="pac125">
	<sentence id="DBMI.pac125.s0" origId="s0" text="The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.">
		<entity charOffset="65-75" id="DBMI.pac125.s0.e0" origId="s0.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="18-30" id="DBMI.pac125.s0.e1" origId="s0.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac125.s0.e0" e2="DBMI.pac125.s0.e1" id="DBMI.pac125.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol " precipitant="quinidine "/>
		<pair e1="DBMI.pac125.s0.e1" e2="DBMI.pac125.s0.e0" id="DBMI.pac125.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac125.sp0" origId="sp0" text="The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.">
		<entity charOffset="65-75" id="DBMI.pac125.sp0.e0" origId="sp0.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="18-30" id="DBMI.pac125.sp0.e1" origId="sp0.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac125.sp0.e0" e2="DBMI.pac125.sp0.e1" id="DBMI.pac125.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol " precipitant="quinidine "/>
		<pair e1="DBMI.pac125.sp0.e1" e2="DBMI.pac125.sp0.e0" id="DBMI.pac125.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac126" origId="pac126">
	<sentence id="DBMI.pac126.s0" origId="s0" text="The mean Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.">
		<entity charOffset="104-116" id="DBMI.pac126.s0.e0" origId="s0.e0" text="propranolol " type="Active ingredient"/>
		<entity charOffset="25-36" id="DBMI.pac126.s0.e1" origId="s0.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac126.s0.e0" e2="DBMI.pac126.s0.e1" id="DBMI.pac126.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="propranolol "/>
		<pair e1="DBMI.pac126.s0.e1" e2="DBMI.pac126.s0.e0" id="DBMI.pac126.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac126.sp0" origId="sp0" text="The mean Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.">
		<entity charOffset="104-116" id="DBMI.pac126.sp0.e0" origId="sp0.e0" text="propranolol " type="Active ingredient"/>
		<entity charOffset="25-36" id="DBMI.pac126.sp0.e1" origId="sp0.e1" text="nifedipine " type="Active ingredient"/>
		<pair e1="DBMI.pac126.sp0.e0" e2="DBMI.pac126.sp0.e1" id="DBMI.pac126.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine " precipitant="propranolol "/>
		<pair e1="DBMI.pac126.sp0.e1" e2="DBMI.pac126.sp0.e0" id="DBMI.pac126.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac127" origId="pac127">
	<sentence id="DBMI.pac127.s0" origId="s0" text="Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.">
		<entity charOffset="0-12" id="DBMI.pac127.s0.e0" origId="s0.e0" text="Propranolol " type="Active ingredient"/>
		<entity charOffset="52-62" id="DBMI.pac127.s0.e1" origId="s0.e1" text="verapamil " type="Active ingredient"/>
		<entity charOffset="66-79" id="DBMI.pac127.s0.e2" origId="s0.e2" text="norverapamil " type="Metabolite"/>
		<pair e1="DBMI.pac127.s0.e0" e2="DBMI.pac127.s0.e1" id="DBMI.pac127.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="verapamil " precipitant="Propranolol "/>
		<pair e1="DBMI.pac127.s0.e0" e2="DBMI.pac127.s0.e2" id="DBMI.pac127.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="norverapamil " precipitant="Propranolol "/>
		<pair e1="DBMI.pac127.s0.e1" e2="DBMI.pac127.s0.e0" id="DBMI.pac127.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.s0.e1" e2="DBMI.pac127.s0.e2" id="DBMI.pac127.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.s0.e2" e2="DBMI.pac127.s0.e0" id="DBMI.pac127.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.s0.e2" e2="DBMI.pac127.s0.e1" id="DBMI.pac127.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac127.s1" origId="s1" text="Verapamil does not affect the pharmacokinetics of propranolol.">
		<entity charOffset="80-90" id="DBMI.pac127.s1.e0" origId="s1.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="130-142" id="DBMI.pac127.s1.e1" origId="s1.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac127.s1.e0" e2="DBMI.pac127.s1.e1" id="DBMI.pac127.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="Verapamil "/>
		<pair e1="DBMI.pac127.s1.e1" e2="DBMI.pac127.s1.e0" id="DBMI.pac127.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac127.sp0" origId="sp0" text="Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol.">
		<entity charOffset="0-12" id="DBMI.pac127.sp0.e0" origId="sp0.e0" text="Propranolol " type="Active ingredient"/>
		<entity charOffset="52-62" id="DBMI.pac127.sp0.e1" origId="sp0.e1" text="verapamil " type="Active ingredient"/>
		<entity charOffset="66-79" id="DBMI.pac127.sp0.e2" origId="sp0.e2" text="norverapamil " type="Metabolite"/>
		<entity charOffset="80-90" id="DBMI.pac127.sp0.e3" origId="sp0.e3" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="130-142" id="DBMI.pac127.sp0.e4" origId="sp0.e4" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac127.sp0.e0" e2="DBMI.pac127.sp0.e1" id="DBMI.pac127.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="verapamil " precipitant="Propranolol "/>
		<pair e1="DBMI.pac127.sp0.e0" e2="DBMI.pac127.sp0.e2" id="DBMI.pac127.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="norverapamil " precipitant="Propranolol "/>
		<pair e1="DBMI.pac127.sp0.e0" e2="DBMI.pac127.sp0.e3" id="DBMI.pac127.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e0" e2="DBMI.pac127.sp0.e4" id="DBMI.pac127.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e1" e2="DBMI.pac127.sp0.e0" id="DBMI.pac127.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e1" e2="DBMI.pac127.sp0.e2" id="DBMI.pac127.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e1" e2="DBMI.pac127.sp0.e3" id="DBMI.pac127.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e1" e2="DBMI.pac127.sp0.e4" id="DBMI.pac127.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e2" e2="DBMI.pac127.sp0.e0" id="DBMI.pac127.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e2" e2="DBMI.pac127.sp0.e1" id="DBMI.pac127.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e2" e2="DBMI.pac127.sp0.e3" id="DBMI.pac127.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e2" e2="DBMI.pac127.sp0.e4" id="DBMI.pac127.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e3" e2="DBMI.pac127.sp0.e0" id="DBMI.pac127.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e3" e2="DBMI.pac127.sp0.e1" id="DBMI.pac127.sp0.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e3" e2="DBMI.pac127.sp0.e2" id="DBMI.pac127.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e3" e2="DBMI.pac127.sp0.e4" id="DBMI.pac127.sp0.p15" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="Verapamil "/>
		<pair e1="DBMI.pac127.sp0.e4" e2="DBMI.pac127.sp0.e0" id="DBMI.pac127.sp0.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e4" e2="DBMI.pac127.sp0.e1" id="DBMI.pac127.sp0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e4" e2="DBMI.pac127.sp0.e2" id="DBMI.pac127.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e4" e2="DBMI.pac127.sp0.e3" id="DBMI.pac127.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac128" origId="pac128">
	<sentence id="DBMI.pac128.s0" origId="s0" text="Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.">
		<entity charOffset="0-12" id="DBMI.pac128.s0.e0" origId="s0.e0" text="Propranolol " type="Active ingredient"/>
		<entity charOffset="42-51" id="DBMI.pac128.s0.e1" origId="s0.e1" text="diazepam " type="Active ingredient"/>
		<pair e1="DBMI.pac128.s0.e0" e2="DBMI.pac128.s0.e1" id="DBMI.pac128.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="Propranolol "/>
		<pair e1="DBMI.pac128.s0.e1" e2="DBMI.pac128.s0.e0" id="DBMI.pac128.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac128.s1" origId="s1" text="Diazepam does not alter the pharmacokinetics of propranolol.">
		<entity charOffset="123-132" id="DBMI.pac128.s1.e0" origId="s1.e0" text="Diazepam " type="Active ingredient"/>
		<entity charOffset="171-183" id="DBMI.pac128.s1.e1" origId="s1.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac128.s1.e0" e2="DBMI.pac128.s1.e1" id="DBMI.pac128.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="Diazepam "/>
		<pair e1="DBMI.pac128.s1.e1" e2="DBMI.pac128.s1.e0" id="DBMI.pac128.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac128.sp0" origId="sp0" text="Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol.">
		<entity charOffset="0-12" id="DBMI.pac128.sp0.e0" origId="sp0.e0" text="Propranolol " type="Active ingredient"/>
		<entity charOffset="42-51" id="DBMI.pac128.sp0.e1" origId="sp0.e1" text="diazepam " type="Active ingredient"/>
		<entity charOffset="123-132" id="DBMI.pac128.sp0.e2" origId="sp0.e2" text="Diazepam " type="Active ingredient"/>
		<entity charOffset="171-183" id="DBMI.pac128.sp0.e3" origId="sp0.e3" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac128.sp0.e0" e2="DBMI.pac128.sp0.e1" id="DBMI.pac128.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="Propranolol "/>
		<pair e1="DBMI.pac128.sp0.e0" e2="DBMI.pac128.sp0.e2" id="DBMI.pac128.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e0" e2="DBMI.pac128.sp0.e3" id="DBMI.pac128.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e1" e2="DBMI.pac128.sp0.e0" id="DBMI.pac128.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e1" e2="DBMI.pac128.sp0.e2" id="DBMI.pac128.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e1" e2="DBMI.pac128.sp0.e3" id="DBMI.pac128.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e2" e2="DBMI.pac128.sp0.e0" id="DBMI.pac128.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e2" e2="DBMI.pac128.sp0.e1" id="DBMI.pac128.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e2" e2="DBMI.pac128.sp0.e3" id="DBMI.pac128.sp0.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="Diazepam "/>
		<pair e1="DBMI.pac128.sp0.e3" e2="DBMI.pac128.sp0.e0" id="DBMI.pac128.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e3" e2="DBMI.pac128.sp0.e1" id="DBMI.pac128.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e3" e2="DBMI.pac128.sp0.e2" id="DBMI.pac128.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac129" origId="pac129">
	<sentence id="DBMI.pac129.s0" origId="s0" text="Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively.">
		<entity charOffset="38-49" id="DBMI.pac129.s0.e0" origId="s0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="21-33" id="DBMI.pac129.s0.e1" origId="s0.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac129.s0.e0" e2="DBMI.pac129.s0.e1" id="DBMI.pac129.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="cimetidine "/>
		<pair e1="DBMI.pac129.s0.e1" e2="DBMI.pac129.s0.e0" id="DBMI.pac129.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac129.s1" origId="s1" text="Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.">
		<entity charOffset="171-190" id="DBMI.pac129.s1.e0" origId="s1.e0" text="aluminum hydroxide " type="Active ingredient"/>
		<entity charOffset="232-244" id="DBMI.pac129.s1.e1" origId="s1.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac129.s1.e0" e2="DBMI.pac129.s1.e1" id="DBMI.pac129.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol " precipitant="aluminum hydroxide "/>
		<pair e1="DBMI.pac129.s1.e1" e2="DBMI.pac129.s1.e0" id="DBMI.pac129.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac129.sp0" origId="sp0" text="Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively. Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.">
		<entity charOffset="171-190" id="DBMI.pac129.sp0.e0" origId="sp0.e0" text="aluminum hydroxide " type="Active ingredient"/>
		<entity charOffset="232-244" id="DBMI.pac129.sp0.e1" origId="sp0.e1" text="propranolol " type="Active ingredient"/>
		<entity charOffset="38-49" id="DBMI.pac129.sp0.e2" origId="sp0.e2" text="cimetidine " type="Active ingredient"/>
		<pair e1="DBMI.pac129.sp0.e0" e2="DBMI.pac129.sp0.e1" id="DBMI.pac129.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol " precipitant="aluminum hydroxide "/>
		<pair e1="DBMI.pac129.sp0.e0" e2="DBMI.pac129.sp0.e2" id="DBMI.pac129.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac129.sp0.e1" e2="DBMI.pac129.sp0.e0" id="DBMI.pac129.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac129.sp0.e1" e2="DBMI.pac129.sp0.e2" id="DBMI.pac129.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac129.sp0.e2" e2="DBMI.pac129.sp0.e0" id="DBMI.pac129.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac129.sp0.e2" e2="DBMI.pac129.sp0.e1" id="DBMI.pac129.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="cimetidine "/>
	</sentencespan>
</document>

<document id="DBMI.pac13" origId="pac13">
	<sentence id="DBMI.pac13.s0" origId="s0" text="In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium.">
		<entity charOffset="87-98" id="DBMI.pac13.s0.e0" origId="s0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="139-147" id="DBMI.pac13.s0.e1" origId="s0.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac13.s0.e0" e2="DBMI.pac13.s0.e1" id="DBMI.pac13.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="sertraline "/>
		<pair e1="DBMI.pac13.s0.e1" e2="DBMI.pac13.s0.e0" id="DBMI.pac13.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac13.sp0" origId="sp0" text="In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium.">
		<entity charOffset="87-98" id="DBMI.pac13.sp0.e0" origId="sp0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="139-147" id="DBMI.pac13.sp0.e1" origId="sp0.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac13.sp0.e0" e2="DBMI.pac13.sp0.e1" id="DBMI.pac13.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="sertraline "/>
		<pair e1="DBMI.pac13.sp0.e1" e2="DBMI.pac13.sp0.e0" id="DBMI.pac13.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac130" origId="pac130">
	<sentence id="DBMI.pac130.s0" origId="s0" text="Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolols pharmacokinetics.">
		<entity charOffset="21-36" id="DBMI.pac130.s0.e0" origId="s0.e0" text="metoclopramide " type="Active ingredient"/>
		<entity charOffset="57-69" id="DBMI.pac130.s0.e1" origId="s0.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac130.s0.e0" e2="DBMI.pac130.s0.e1" id="DBMI.pac130.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac130.s0.e1" e2="DBMI.pac130.s0.e0" id="DBMI.pac130.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac130.sp0" origId="sp0" text="Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolols pharmacokinetics.">
		<entity charOffset="21-36" id="DBMI.pac130.sp0.e0" origId="sp0.e0" text="metoclopramide " type="Active ingredient"/>
		<entity charOffset="57-69" id="DBMI.pac130.sp0.e1" origId="sp0.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac130.sp0.e0" e2="DBMI.pac130.sp0.e1" id="DBMI.pac130.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="metoclopramide "/>
		<pair e1="DBMI.pac130.sp0.e1" e2="DBMI.pac130.sp0.e0" id="DBMI.pac130.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac131" origId="pac131">
	<sentence id="DBMI.pac131.s0" origId="s0" text="Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.">
		<entity charOffset="21-36" id="DBMI.pac131.s0.e0" origId="s0.e0" text="cholestyramine " type="Active ingredient"/>
		<entity charOffset="55-67" id="DBMI.pac131.s0.e1" origId="s0.e1" text="propranolol " type="Active ingredient"/>
		<entity charOffset="39-50" id="DBMI.pac131.s0.e2" origId="s0.e2" text="colestipol " type="Active ingredient"/>
		<pair e1="DBMI.pac131.s0.e0" e2="DBMI.pac131.s0.e1" id="DBMI.pac131.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="cholestyramine "/>
		<pair e1="DBMI.pac131.s0.e0" e2="DBMI.pac131.s0.e2" id="DBMI.pac131.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.s0.e1" e2="DBMI.pac131.s0.e0" id="DBMI.pac131.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.s0.e1" e2="DBMI.pac131.s0.e2" id="DBMI.pac131.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.s0.e2" e2="DBMI.pac131.s0.e0" id="DBMI.pac131.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.s0.e2" e2="DBMI.pac131.s0.e1" id="DBMI.pac131.s0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="colestipol "/>
	</sentence>
	<sentencespan id="DBMI.pac131.sp0" origId="sp0" text="Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.">
		<entity charOffset="21-36" id="DBMI.pac131.sp0.e0" origId="sp0.e0" text="cholestyramine " type="Active ingredient"/>
		<entity charOffset="55-67" id="DBMI.pac131.sp0.e1" origId="sp0.e1" text="propranolol " type="Active ingredient"/>
		<entity charOffset="39-50" id="DBMI.pac131.sp0.e2" origId="sp0.e2" text="colestipol " type="Active ingredient"/>
		<pair e1="DBMI.pac131.sp0.e0" e2="DBMI.pac131.sp0.e1" id="DBMI.pac131.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="cholestyramine "/>
		<pair e1="DBMI.pac131.sp0.e0" e2="DBMI.pac131.sp0.e2" id="DBMI.pac131.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.sp0.e1" e2="DBMI.pac131.sp0.e0" id="DBMI.pac131.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.sp0.e1" e2="DBMI.pac131.sp0.e2" id="DBMI.pac131.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.sp0.e2" e2="DBMI.pac131.sp0.e0" id="DBMI.pac131.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.sp0.e2" e2="DBMI.pac131.sp0.e1" id="DBMI.pac131.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="colestipol "/>
	</sentencespan>
</document>

<document id="DBMI.pac132" origId="pac132">
	<sentence id="DBMI.pac132.s0" origId="s0" text="Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.">
		<entity charOffset="21-33" id="DBMI.pac132.s0.e0" origId="s0.e0" text="propranolol " type="Active ingredient"/>
		<entity charOffset="38-49" id="DBMI.pac132.s0.e1" origId="s0.e1" text="lovastatin " type="Active ingredient"/>
		<entity charOffset="52-64" id="DBMI.pac132.s0.e2" origId="s0.e2" text="pravastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac132.s0.e0" e2="DBMI.pac132.s0.e1" id="DBMI.pac132.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="lovastatin " precipitant="propranolol "/>
		<pair e1="DBMI.pac132.s0.e0" e2="DBMI.pac132.s0.e2" id="DBMI.pac132.s0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pravastatin " precipitant="propranolol "/>
		<pair e1="DBMI.pac132.s0.e1" e2="DBMI.pac132.s0.e0" id="DBMI.pac132.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.s0.e1" e2="DBMI.pac132.s0.e2" id="DBMI.pac132.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.s0.e2" e2="DBMI.pac132.s0.e0" id="DBMI.pac132.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.s0.e2" e2="DBMI.pac132.s0.e1" id="DBMI.pac132.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac132.s1" origId="s1" text="Propranolol did not have an effect on the pharmacokinetics of fluvastatin.">
		<entity charOffset="145-157" id="DBMI.pac132.s1.e0" origId="s1.e0" text="Propranolol " type="Active ingredient"/>
		<entity charOffset="207-219" id="DBMI.pac132.s1.e1" origId="s1.e1" text="fluvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac132.s1.e0" e2="DBMI.pac132.s1.e1" id="DBMI.pac132.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin " precipitant="Propranolol "/>
		<pair e1="DBMI.pac132.s1.e1" e2="DBMI.pac132.s1.e0" id="DBMI.pac132.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac132.sp0" origId="sp0" text="Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Propranolol did not have an effect on the pharmacokinetics of fluvastatin.">
		<entity charOffset="145-157" id="DBMI.pac132.sp0.e0" origId="sp0.e0" text="Propranolol " type="Active ingredient"/>
		<entity charOffset="207-219" id="DBMI.pac132.sp0.e1" origId="sp0.e1" text="fluvastatin " type="Active ingredient"/>
		<entity charOffset="21-33" id="DBMI.pac132.sp0.e2" origId="sp0.e2" text="propranolol " type="Active ingredient"/>
		<entity charOffset="38-49" id="DBMI.pac132.sp0.e3" origId="sp0.e3" text="lovastatin " type="Active ingredient"/>
		<entity charOffset="52-64" id="DBMI.pac132.sp0.e4" origId="sp0.e4" text="pravastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac132.sp0.e0" e2="DBMI.pac132.sp0.e1" id="DBMI.pac132.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin " precipitant="Propranolol "/>
		<pair e1="DBMI.pac132.sp0.e0" e2="DBMI.pac132.sp0.e2" id="DBMI.pac132.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e0" e2="DBMI.pac132.sp0.e3" id="DBMI.pac132.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e0" e2="DBMI.pac132.sp0.e4" id="DBMI.pac132.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e1" e2="DBMI.pac132.sp0.e0" id="DBMI.pac132.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e1" e2="DBMI.pac132.sp0.e2" id="DBMI.pac132.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e1" e2="DBMI.pac132.sp0.e3" id="DBMI.pac132.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e1" e2="DBMI.pac132.sp0.e4" id="DBMI.pac132.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e2" e2="DBMI.pac132.sp0.e0" id="DBMI.pac132.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e2" e2="DBMI.pac132.sp0.e1" id="DBMI.pac132.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e2" e2="DBMI.pac132.sp0.e3" id="DBMI.pac132.sp0.p10" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="lovastatin " precipitant="propranolol "/>
		<pair e1="DBMI.pac132.sp0.e2" e2="DBMI.pac132.sp0.e4" id="DBMI.pac132.sp0.p11" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pravastatin " precipitant="propranolol "/>
		<pair e1="DBMI.pac132.sp0.e3" e2="DBMI.pac132.sp0.e0" id="DBMI.pac132.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e3" e2="DBMI.pac132.sp0.e1" id="DBMI.pac132.sp0.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e3" e2="DBMI.pac132.sp0.e2" id="DBMI.pac132.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e3" e2="DBMI.pac132.sp0.e4" id="DBMI.pac132.sp0.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e4" e2="DBMI.pac132.sp0.e0" id="DBMI.pac132.sp0.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e4" e2="DBMI.pac132.sp0.e1" id="DBMI.pac132.sp0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e4" e2="DBMI.pac132.sp0.e2" id="DBMI.pac132.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e4" e2="DBMI.pac132.sp0.e3" id="DBMI.pac132.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac133" origId="pac133">
	<sentence id="DBMI.pac133.s0" origId="s0" text="Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.">
		<entity charOffset="33-45" id="DBMI.pac133.s0.e0" origId="s0.e0" text="propranolol " type="Active ingredient"/>
		<entity charOffset="112-125" id="DBMI.pac133.s0.e1" origId="s0.e1" text="thioridazine " type="Active ingredient"/>
		<entity charOffset="211-224" id="DBMI.pac133.s0.e2" origId="s0.e2" text="mesoridazine " type="Metabolite"/>
		<pair e1="DBMI.pac133.s0.e0" e2="DBMI.pac133.s0.e1" id="DBMI.pac133.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="thioridazine " precipitant="propranolol "/>
		<pair e1="DBMI.pac133.s0.e0" e2="DBMI.pac133.s0.e2" id="DBMI.pac133.s0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mesoridazine " precipitant="propranolol "/>
		<pair e1="DBMI.pac133.s0.e1" e2="DBMI.pac133.s0.e0" id="DBMI.pac133.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac133.s0.e1" e2="DBMI.pac133.s0.e2" id="DBMI.pac133.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac133.s0.e2" e2="DBMI.pac133.s0.e0" id="DBMI.pac133.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac133.s0.e2" e2="DBMI.pac133.s0.e1" id="DBMI.pac133.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac133.sp0" origId="sp0" text="Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.">
		<entity charOffset="33-45" id="DBMI.pac133.sp0.e0" origId="sp0.e0" text="propranolol " type="Active ingredient"/>
		<entity charOffset="112-125" id="DBMI.pac133.sp0.e1" origId="sp0.e1" text="thioridazine " type="Active ingredient"/>
		<entity charOffset="211-224" id="DBMI.pac133.sp0.e2" origId="sp0.e2" text="mesoridazine " type="Metabolite"/>
		<pair e1="DBMI.pac133.sp0.e0" e2="DBMI.pac133.sp0.e1" id="DBMI.pac133.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="thioridazine " precipitant="propranolol "/>
		<pair e1="DBMI.pac133.sp0.e0" e2="DBMI.pac133.sp0.e2" id="DBMI.pac133.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mesoridazine " precipitant="propranolol "/>
		<pair e1="DBMI.pac133.sp0.e1" e2="DBMI.pac133.sp0.e0" id="DBMI.pac133.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac133.sp0.e1" e2="DBMI.pac133.sp0.e2" id="DBMI.pac133.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac133.sp0.e2" e2="DBMI.pac133.sp0.e0" id="DBMI.pac133.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac133.sp0.e2" e2="DBMI.pac133.sp0.e1" id="DBMI.pac133.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac134" origId="pac134">
	<sentence id="DBMI.pac134.s0" origId="s0" text="Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level.">
		<entity charOffset="21-36" id="DBMI.pac134.s0.e0" origId="s0.e0" text="chlorpromazine " type="Active ingredient"/>
		<entity charOffset="41-53" id="DBMI.pac134.s0.e1" origId="s0.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac134.s0.e0" e2="DBMI.pac134.s0.e1" id="DBMI.pac134.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="chlorpromazine "/>
		<pair e1="DBMI.pac134.s0.e1" e2="DBMI.pac134.s0.e0" id="DBMI.pac134.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac134.sp0" origId="sp0" text="Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level.">
		<entity charOffset="21-36" id="DBMI.pac134.sp0.e0" origId="sp0.e0" text="chlorpromazine " type="Active ingredient"/>
		<entity charOffset="41-53" id="DBMI.pac134.sp0.e1" origId="sp0.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac134.sp0.e0" e2="DBMI.pac134.sp0.e1" id="DBMI.pac134.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="chlorpromazine "/>
		<pair e1="DBMI.pac134.sp0.e1" e2="DBMI.pac134.sp0.e0" id="DBMI.pac134.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac136" origId="pac136">
	<sentence id="DBMI.pac136.s0" origId="s0" text="In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.">
		<entity charOffset="194-204" id="DBMI.pac136.s0.e0" origId="s0.e0" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="117-127" id="DBMI.pac136.s0.e1" origId="s0.e1" text="trazodone " type="Active ingredient"/>
		<entity charOffset="209-219" id="DBMI.pac136.s0.e2" origId="s0.e2" text="indinavir " type="Active ingredient"/>
		<pair e1="DBMI.pac136.s0.e0" e2="DBMI.pac136.s0.e1" id="DBMI.pac136.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="trazodone " precipitant="ritonavir "/>
		<pair e1="DBMI.pac136.s0.e0" e2="DBMI.pac136.s0.e2" id="DBMI.pac136.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.s0.e1" e2="DBMI.pac136.s0.e0" id="DBMI.pac136.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.s0.e1" e2="DBMI.pac136.s0.e2" id="DBMI.pac136.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.s0.e2" e2="DBMI.pac136.s0.e0" id="DBMI.pac136.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.s0.e2" e2="DBMI.pac136.s0.e1" id="DBMI.pac136.s0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="trazodone " precipitant="indinavir "/>
	</sentence>
	<sentence id="DBMI.pac136.s1" origId="s1" text="The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects.">
		<entity charOffset="263-273" id="DBMI.pac136.s1.e0" origId="s1.e0" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="347-357" id="DBMI.pac136.s1.e1" origId="s1.e1" text="trazodone " type="Active ingredient"/>
		<pair e1="DBMI.pac136.s1.e0" e2="DBMI.pac136.s1.e1" id="DBMI.pac136.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="trazodone " precipitant="ritonavir "/>
		<pair e1="DBMI.pac136.s1.e1" e2="DBMI.pac136.s1.e0" id="DBMI.pac136.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac136.s2" origId="s2" text="The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%."/>
	<sentence id="DBMI.pac136.s3" origId="s3" text="Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were coadministered."/>
	<sentencespan id="DBMI.pac136.sp0" origId="sp0" text="In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir. The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%.">
		<entity charOffset="194-204" id="DBMI.pac136.sp0.e0" origId="sp0.e0" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="117-127" id="DBMI.pac136.sp0.e1" origId="sp0.e1" text="trazodone " type="Active ingredient"/>
		<entity charOffset="209-219" id="DBMI.pac136.sp0.e2" origId="sp0.e2" text="indinavir " type="Active ingredient"/>
		<pair e1="DBMI.pac136.sp0.e0" e2="DBMI.pac136.sp0.e1" id="DBMI.pac136.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="trazodone " precipitant="ritonavir "/>
		<pair e1="DBMI.pac136.sp0.e0" e2="DBMI.pac136.sp0.e1" id="DBMI.pac136.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="trazodone " precipitant="ritonavir "/>
		<pair e1="DBMI.pac136.sp0.e0" e2="DBMI.pac136.sp0.e2" id="DBMI.pac136.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.sp0.e1" e2="DBMI.pac136.sp0.e0" id="DBMI.pac136.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.sp0.e1" e2="DBMI.pac136.sp0.e2" id="DBMI.pac136.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.sp0.e2" e2="DBMI.pac136.sp0.e0" id="DBMI.pac136.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.sp0.e2" e2="DBMI.pac136.sp0.e1" id="DBMI.pac136.sp0.p6" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="trazodone " precipitant="indinavir "/>
	</sentencespan>
	<sentencespan id="DBMI.pac136.sp1" origId="sp1" text="Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were coadministered."/>
</document>

<document id="DBMI.pac137" origId="pac137">
	<sentence id="DBMI.pac137.s0" origId="s0" text="Carbamazepine induces CYP3A4."/>
	<sentence id="DBMI.pac137.s1" origId="s1" text="Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.">
		<entity charOffset="124-138" id="DBMI.pac137.s1.e0" origId="s1.e0" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="171-181" id="DBMI.pac137.s1.e1" origId="s1.e1" text="trazodone " type="Active ingredient"/>
		<entity charOffset="193-198" id="DBMI.pac137.s1.e2" origId="s1.e2" text="mCPP " type="Metabolite"/>
		<pair e1="DBMI.pac137.s1.e0" e2="DBMI.pac137.s1.e1" id="DBMI.pac137.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="trazodone " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac137.s1.e0" e2="DBMI.pac137.s1.e2" id="DBMI.pac137.s1.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mCPP " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac137.s1.e1" e2="DBMI.pac137.s1.e0" id="DBMI.pac137.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.s1.e1" e2="DBMI.pac137.s1.e2" id="DBMI.pac137.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.s1.e2" e2="DBMI.pac137.s1.e0" id="DBMI.pac137.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.s1.e2" e2="DBMI.pac137.s1.e1" id="DBMI.pac137.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac137.sp0" origId="sp0" text="Carbamazepine induces CYP3A4. Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.">
		<entity charOffset="124-138" id="DBMI.pac137.sp0.e0" origId="sp0.e0" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="171-181" id="DBMI.pac137.sp0.e1" origId="sp0.e1" text="trazodone " type="Active ingredient"/>
		<entity charOffset="193-198" id="DBMI.pac137.sp0.e2" origId="sp0.e2" text="mCPP " type="Metabolite"/>
		<pair e1="DBMI.pac137.sp0.e0" e2="DBMI.pac137.sp0.e1" id="DBMI.pac137.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="trazodone " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac137.sp0.e0" e2="DBMI.pac137.sp0.e2" id="DBMI.pac137.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mCPP " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac137.sp0.e1" e2="DBMI.pac137.sp0.e0" id="DBMI.pac137.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.sp0.e1" e2="DBMI.pac137.sp0.e2" id="DBMI.pac137.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.sp0.e2" e2="DBMI.pac137.sp0.e0" id="DBMI.pac137.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.sp0.e2" e2="DBMI.pac137.sp0.e1" id="DBMI.pac137.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac139" origId="pac139">
	<sentence id="DBMI.pac139.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Antacids\n\nFexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids."/>
	<sentence id="DBMI.pac139.s1" origId="s1" text="In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2  60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox1) decreased fexofenadine AUC by 41% and Cmax by 43%.">
		<entity charOffset="273-282" id="DBMI.pac139.s1.e0" origId="s1.e0" text="aluminum " type="Active ingredient"/>
		<entity charOffset="202-215" id="DBMI.pac139.s1.e1" origId="s1.e1" text="fexofenadine " type="Active ingredient"/>
		<entity charOffset="286-296" id="DBMI.pac139.s1.e2" origId="s1.e2" text="magnesium " type="Active ingredient"/>
		<pair e1="DBMI.pac139.s1.e0" e2="DBMI.pac139.s1.e1" id="DBMI.pac139.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fexofenadine " precipitant="aluminum "/>
		<pair e1="DBMI.pac139.s1.e0" e2="DBMI.pac139.s1.e2" id="DBMI.pac139.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s1.e1" e2="DBMI.pac139.s1.e0" id="DBMI.pac139.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s1.e1" e2="DBMI.pac139.s1.e2" id="DBMI.pac139.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s1.e2" e2="DBMI.pac139.s1.e0" id="DBMI.pac139.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s1.e2" e2="DBMI.pac139.s1.e1" id="DBMI.pac139.s1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fexofenadine " precipitant="magnesium "/>
	</sentence>
	<sentence id="DBMI.pac139.s2" origId="s2" text="1 Maalox is a registered trademark of Novartis Consumer Healthcare."/>
	<sentence id="DBMI.pac139.s3" origId="s3" text="7.2 Erythromycin and Ketoconazole\n\nFexofenadine has been shown to exhibit minimal (ca."/>
	<sentence id="DBMI.pac139.s4" origId="s4" text="5%) metabolism."/>
	<sentence id="DBMI.pac139.s5" origId="s5" text="However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.">
		<entity charOffset="619-632" id="DBMI.pac139.s5.e0" origId="s5.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="690-703" id="DBMI.pac139.s5.e1" origId="s5.e1" text="fexofenadine " type="Active ingredient"/>
		<entity charOffset="635-648" id="DBMI.pac139.s5.e2" origId="s5.e2" text="erythromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac139.s5.e0" e2="DBMI.pac139.s5.e1" id="DBMI.pac139.s5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac139.s5.e0" e2="DBMI.pac139.s5.e2" id="DBMI.pac139.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s5.e1" e2="DBMI.pac139.s5.e0" id="DBMI.pac139.s5.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s5.e1" e2="DBMI.pac139.s5.e2" id="DBMI.pac139.s5.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s5.e2" e2="DBMI.pac139.s5.e0" id="DBMI.pac139.s5.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s5.e2" e2="DBMI.pac139.s5.e1" id="DBMI.pac139.s5.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="erythromycin "/>
		<pair e1="DBMI.pac139.s5.e2" e2="DBMI.pac139.s5.e1" id="DBMI.pac139.s5.p6" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="erythromycin "/>
	</sentence>
	<sentence id="DBMI.pac139.s6" origId="s6" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.">
		<entity charOffset="730-743" id="DBMI.pac139.s6.e0" origId="s6.e0" text="Fexofenadine " type="Active ingredient"/>
		<entity charOffset="791-804" id="DBMI.pac139.s6.e1" origId="s6.e1" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="807-820" id="DBMI.pac139.s6.e2" origId="s6.e2" text="ketoconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac139.s6.e0" e2="DBMI.pac139.s6.e1" id="DBMI.pac139.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="Fexofenadine "/>
		<pair e1="DBMI.pac139.s6.e0" e2="DBMI.pac139.s6.e2" id="DBMI.pac139.s6.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ketoconazole " precipitant="Fexofenadine "/>
		<pair e1="DBMI.pac139.s6.e1" e2="DBMI.pac139.s6.e0" id="DBMI.pac139.s6.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s6.e1" e2="DBMI.pac139.s6.e2" id="DBMI.pac139.s6.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s6.e2" e2="DBMI.pac139.s6.e0" id="DBMI.pac139.s6.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s6.e2" e2="DBMI.pac139.s6.e1" id="DBMI.pac139.s6.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac139.s7" origId="s7" text="In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study)."/>
	<sentence id="DBMI.pac139.s8" origId="s8" text="No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole."/>
	<sentence id="DBMI.pac139.s9" origId="s9" text="The findings of these studies are summarized in the following table:\n\nThe changes in plasma levels were within the range of plasma levels achieved in adequate and well controlled clinical trials."/>
	<sentence id="DBMI.pac139.s10" origId="s10" text="The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models."/>
	<sentence id="DBMI.pac139.s11" origId="s11" text="These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.">
		<entity charOffset="1638-1651" id="DBMI.pac139.s11.e0" origId="s11.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="1693-1706" id="DBMI.pac139.s11.e1" origId="s11.e1" text="fexofenadine " type="Active ingredient"/>
		<entity charOffset="1654-1667" id="DBMI.pac139.s11.e2" origId="s11.e2" text="erythromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac139.s11.e0" e2="DBMI.pac139.s11.e1" id="DBMI.pac139.s11.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac139.s11.e0" e2="DBMI.pac139.s11.e2" id="DBMI.pac139.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s11.e1" e2="DBMI.pac139.s11.e0" id="DBMI.pac139.s11.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s11.e1" e2="DBMI.pac139.s11.e2" id="DBMI.pac139.s11.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s11.e2" e2="DBMI.pac139.s11.e0" id="DBMI.pac139.s11.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s11.e2" e2="DBMI.pac139.s11.e1" id="DBMI.pac139.s11.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="erythromycin "/>
	</sentence>
	<sentence id="DBMI.pac139.s12" origId="s12" text="This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein."/>
	<sentence id="DBMI.pac139.s13" origId="s13" text="In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion."/>
	<sentence id="DBMI.pac139.s14" origId="s14" text="7.3 Fruit Juices\n\nFruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine."/>
	<sentence id="DBMI.pac139.s15" origId="s15" text="This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis."/>
	<sentence id="DBMI.pac139.s16" origId="s16" text="The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water."/>
	<sentence id="DBMI.pac139.s17" origId="s17" text="Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice."/>
	<sentence id="DBMI.pac139.s18" origId="s18" text="The clinical significance of these observations is unknown."/>
	<sentence id="DBMI.pac139.s19" origId="s19" text="In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%."/>
	<sentence id="DBMI.pac139.s20" origId="s20" text="Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)]."/>
	<sentencespan id="DBMI.pac139.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Antacids\n\nFexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids. In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2  60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox1) decreased fexofenadine AUC by 41% and Cmax by 43%. 1 Maalox is a registered trademark of Novartis Consumer Healthcare.">
		<entity charOffset="273-282" id="DBMI.pac139.sp0.e0" origId="sp0.e0" text="aluminum " type="Active ingredient"/>
		<entity charOffset="202-215" id="DBMI.pac139.sp0.e1" origId="sp0.e1" text="fexofenadine " type="Active ingredient"/>
		<entity charOffset="286-296" id="DBMI.pac139.sp0.e2" origId="sp0.e2" text="magnesium " type="Active ingredient"/>
		<pair e1="DBMI.pac139.sp0.e0" e2="DBMI.pac139.sp0.e1" id="DBMI.pac139.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fexofenadine " precipitant="aluminum "/>
		<pair e1="DBMI.pac139.sp0.e0" e2="DBMI.pac139.sp0.e2" id="DBMI.pac139.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp0.e1" e2="DBMI.pac139.sp0.e0" id="DBMI.pac139.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp0.e1" e2="DBMI.pac139.sp0.e2" id="DBMI.pac139.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp0.e2" e2="DBMI.pac139.sp0.e0" id="DBMI.pac139.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp0.e2" e2="DBMI.pac139.sp0.e1" id="DBMI.pac139.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fexofenadine " precipitant="magnesium "/>
	</sentencespan>
	<sentencespan id="DBMI.pac139.sp1" origId="sp1" text="7.2 Erythromycin and Ketoconazole\n\nFexofenadine has been shown to exhibit minimal (ca. 5%) metabolism. However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.">
		<entity charOffset="619-632" id="DBMI.pac139.sp1.e0" origId="sp1.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="690-703" id="DBMI.pac139.sp1.e1" origId="sp1.e1" text="fexofenadine " type="Active ingredient"/>
		<entity charOffset="635-648" id="DBMI.pac139.sp1.e2" origId="sp1.e2" text="erythromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac139.sp1.e0" e2="DBMI.pac139.sp1.e1" id="DBMI.pac139.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac139.sp1.e0" e2="DBMI.pac139.sp1.e2" id="DBMI.pac139.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp1.e1" e2="DBMI.pac139.sp1.e0" id="DBMI.pac139.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp1.e1" e2="DBMI.pac139.sp1.e2" id="DBMI.pac139.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp1.e2" e2="DBMI.pac139.sp1.e0" id="DBMI.pac139.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp1.e2" e2="DBMI.pac139.sp1.e1" id="DBMI.pac139.sp1.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="erythromycin "/>
		<pair e1="DBMI.pac139.sp1.e2" e2="DBMI.pac139.sp1.e1" id="DBMI.pac139.sp1.p6" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="erythromycin "/>
	</sentencespan>
	<sentencespan id="DBMI.pac139.sp2" origId="sp2" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study). No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.">
		<entity charOffset="730-743" id="DBMI.pac139.sp2.e0" origId="sp2.e0" text="Fexofenadine " type="Active ingredient"/>
		<entity charOffset="791-804" id="DBMI.pac139.sp2.e1" origId="sp2.e1" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="807-820" id="DBMI.pac139.sp2.e2" origId="sp2.e2" text="ketoconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac139.sp2.e0" e2="DBMI.pac139.sp2.e1" id="DBMI.pac139.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="Fexofenadine "/>
		<pair e1="DBMI.pac139.sp2.e0" e2="DBMI.pac139.sp2.e2" id="DBMI.pac139.sp2.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ketoconazole " precipitant="Fexofenadine "/>
		<pair e1="DBMI.pac139.sp2.e1" e2="DBMI.pac139.sp2.e0" id="DBMI.pac139.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp2.e1" e2="DBMI.pac139.sp2.e2" id="DBMI.pac139.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp2.e2" e2="DBMI.pac139.sp2.e0" id="DBMI.pac139.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp2.e2" e2="DBMI.pac139.sp2.e1" id="DBMI.pac139.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac139.sp3" origId="sp3" text="The findings of these studies are summarized in the following table:\n\nThe changes in plasma levels were within the range of plasma levels achieved in adequate and well controlled clinical trials. The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models. These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.">
		<entity charOffset="1638-1651" id="DBMI.pac139.sp3.e0" origId="sp3.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="1693-1706" id="DBMI.pac139.sp3.e1" origId="sp3.e1" text="fexofenadine " type="Active ingredient"/>
		<entity charOffset="1654-1667" id="DBMI.pac139.sp3.e2" origId="sp3.e2" text="erythromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac139.sp3.e0" e2="DBMI.pac139.sp3.e1" id="DBMI.pac139.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac139.sp3.e0" e2="DBMI.pac139.sp3.e2" id="DBMI.pac139.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp3.e1" e2="DBMI.pac139.sp3.e0" id="DBMI.pac139.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp3.e1" e2="DBMI.pac139.sp3.e2" id="DBMI.pac139.sp3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp3.e2" e2="DBMI.pac139.sp3.e0" id="DBMI.pac139.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp3.e2" e2="DBMI.pac139.sp3.e1" id="DBMI.pac139.sp3.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine " precipitant="erythromycin "/>
	</sentencespan>
	<sentencespan id="DBMI.pac139.sp4" origId="sp4" text="This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion. 7.3 Fruit Juices\n\nFruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine."/>
	<sentencespan id="DBMI.pac139.sp5" origId="sp5" text="This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis. The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water. Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice."/>
	<sentencespan id="DBMI.pac139.sp6" origId="sp6" text="The clinical significance of these observations is unknown. In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%. Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)]."/>
</document>

<document id="DBMI.pac14" origId="pac14">
	<sentence id="DBMI.pac14.s0" origId="s0" text="In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.)co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%, but was not associated with any changes in EKG.">
		<entity charOffset="66-77" id="DBMI.pac14.s0.e0" origId="s0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="49-58" id="DBMI.pac14.s0.e1" origId="s0.e1" text="pimozide " type="Active ingredient"/>
		<pair e1="DBMI.pac14.s0.e0" e2="DBMI.pac14.s0.e1" id="DBMI.pac14.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pimozide " precipitant="sertraline "/>
		<pair e1="DBMI.pac14.s0.e1" e2="DBMI.pac14.s0.e0" id="DBMI.pac14.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac14.s1" origId="s1" text="Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known."/>
	<sentence id="DBMI.pac14.s2" origId="s2" text="While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline and pimozide should be contraindicated (see CONTRAINDICATIONS)."/>
	<sentencespan id="DBMI.pac14.sp0" origId="sp0" text="In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.)co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%, but was not associated with any changes in EKG. Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline and pimozide should be contraindicated (see CONTRAINDICATIONS).">
		<entity charOffset="66-77" id="DBMI.pac14.sp0.e0" origId="sp0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="49-58" id="DBMI.pac14.sp0.e1" origId="sp0.e1" text="pimozide " type="Active ingredient"/>
		<pair e1="DBMI.pac14.sp0.e0" e2="DBMI.pac14.sp0.e1" id="DBMI.pac14.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pimozide " precipitant="sertraline "/>
		<pair e1="DBMI.pac14.sp0.e1" e2="DBMI.pac14.sp0.e0" id="DBMI.pac14.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac141" origId="pac141">
	<sentence id="DBMI.pac141.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 In Vitro Data\n\nIn vitro data indicate that amlodipine besylate has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin."/>
	<sentence id="DBMI.pac141.s1" origId="s1" text="7.2 Cimetidine\n\nCoadministration of amlodipine besylate with cimetidine did not alter the pharmacokinetics of amlodipine besylate.">
		<entity charOffset="251-262" id="DBMI.pac141.s1.e0" origId="s1.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="226-237" id="DBMI.pac141.s1.e1" origId="s1.e1" text="amlodipine " type="Active ingredient"/>
		<pair e1="DBMI.pac141.s1.e0" e2="DBMI.pac141.s1.e1" id="DBMI.pac141.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac141.s1.e1" e2="DBMI.pac141.s1.e0" id="DBMI.pac141.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s2" origId="s2" text="7.3 Grapefruit Juice\n\nCoadministration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine."/>
	<sentence id="DBMI.pac141.s3" origId="s3" text="7.4 Magnesium and Aluminum Hydroxide Antacid\n\nCoadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate.">
		<entity charOffset="594-604" id="DBMI.pac141.s3.e0" origId="s3.e0" text="magnesium " type="Active ingredient"/>
		<entity charOffset="657-668" id="DBMI.pac141.s3.e1" origId="s3.e1" text="amlodipine " type="Active ingredient"/>
		<entity charOffset="608-617" id="DBMI.pac141.s3.e2" origId="s3.e2" text="aluminum " type="Active ingredient"/>
		<pair e1="DBMI.pac141.s3.e0" e2="DBMI.pac141.s3.e1" id="DBMI.pac141.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine " precipitant="magnesium "/>
		<pair e1="DBMI.pac141.s3.e0" e2="DBMI.pac141.s3.e2" id="DBMI.pac141.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.s3.e1" e2="DBMI.pac141.s3.e0" id="DBMI.pac141.s3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.s3.e1" e2="DBMI.pac141.s3.e2" id="DBMI.pac141.s3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.s3.e2" e2="DBMI.pac141.s3.e0" id="DBMI.pac141.s3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.s3.e2" e2="DBMI.pac141.s3.e1" id="DBMI.pac141.s3.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine " precipitant="aluminum "/>
	</sentence>
	<sentence id="DBMI.pac141.s4" origId="s4" text="7.5 Sildenafil\n\nA single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine besylate.">
		<entity charOffset="792-803" id="DBMI.pac141.s4.e0" origId="s4.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="894-905" id="DBMI.pac141.s4.e1" origId="s4.e1" text="amlodipine " type="Active ingredient"/>
		<pair e1="DBMI.pac141.s4.e0" e2="DBMI.pac141.s4.e1" id="DBMI.pac141.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine " precipitant="sildenafil "/>
		<pair e1="DBMI.pac141.s4.e1" e2="DBMI.pac141.s4.e0" id="DBMI.pac141.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s5" origId="s5" text="When amlodipine besylate and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect."/>
	<sentence id="DBMI.pac141.s6" origId="s6" text="7.6 Atorvastatin\n\nCoadministration of multiple 10 mg doses of amlodipine besylate with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.">
		<entity charOffset="1117-1128" id="DBMI.pac141.s6.e0" origId="s6.e0" text="amlodipine " type="Active ingredient"/>
		<entity charOffset="1151-1164" id="DBMI.pac141.s6.e1" origId="s6.e1" text="atorvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac141.s6.e0" e2="DBMI.pac141.s6.e1" id="DBMI.pac141.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin " precipitant="amlodipine "/>
		<pair e1="DBMI.pac141.s6.e1" e2="DBMI.pac141.s6.e0" id="DBMI.pac141.s6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s7" origId="s7" text="7.7 Digoxin\n\nCoadministration of amlodipine besylate with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.">
		<entity charOffset="1296-1307" id="DBMI.pac141.s7.e0" origId="s7.e0" text="amlodipine " type="Active ingredient"/>
		<entity charOffset="1321-1329" id="DBMI.pac141.s7.e1" origId="s7.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac141.s7.e0" e2="DBMI.pac141.s7.e1" id="DBMI.pac141.s7.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="amlodipine "/>
		<pair e1="DBMI.pac141.s7.e1" e2="DBMI.pac141.s7.e0" id="DBMI.pac141.s7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s8" origId="s8" text="7.8 Ethanol (Alcohol)\n\nSingle and multiple 10 mg doses of amlodipine besylate had no significant effect on the pharmacokinetics of ethanol.">
		<entity charOffset="1473-1484" id="DBMI.pac141.s8.e0" origId="s8.e0" text="amlodipine " type="Active ingredient"/>
		<entity charOffset="1546-1554" id="DBMI.pac141.s8.e1" origId="s8.e1" text="ethanol " type="Active ingredient"/>
		<pair e1="DBMI.pac141.s8.e0" e2="DBMI.pac141.s8.e1" id="DBMI.pac141.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethanol " precipitant="amlodipine "/>
		<pair e1="DBMI.pac141.s8.e1" e2="DBMI.pac141.s8.e0" id="DBMI.pac141.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s9" origId="s9" text="7.9 Warfarin\n\nCoadministration of amlodipine besylate with warfarin did not change the warfarin prothrombin response time.">
		<entity charOffset="1590-1601" id="DBMI.pac141.s9.e0" origId="s9.e0" text="amlodipine " type="Active ingredient"/>
		<entity charOffset="1615-1624" id="DBMI.pac141.s9.e1" origId="s9.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac141.s9.e0" e2="DBMI.pac141.s9.e1" id="DBMI.pac141.s9.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="amlodipine "/>
		<pair e1="DBMI.pac141.s9.e1" e2="DBMI.pac141.s9.e0" id="DBMI.pac141.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s10" origId="s10" text="7.10 Drug/Laboratory Test Interactions\n\nNone known."/>
	<sentencespan id="DBMI.pac141.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 In Vitro Data\n\nIn vitro data indicate that amlodipine besylate has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin. 7.2 Cimetidine\n\nCoadministration of amlodipine besylate with cimetidine did not alter the pharmacokinetics of amlodipine besylate. 7.3 Grapefruit Juice\n\nCoadministration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.">
		<entity charOffset="251-262" id="DBMI.pac141.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="226-237" id="DBMI.pac141.sp0.e1" origId="sp0.e1" text="amlodipine " type="Active ingredient"/>
		<pair e1="DBMI.pac141.sp0.e0" e2="DBMI.pac141.sp0.e1" id="DBMI.pac141.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac141.sp0.e1" e2="DBMI.pac141.sp0.e0" id="DBMI.pac141.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac141.sp1" origId="sp1" text="7.4 Magnesium and Aluminum Hydroxide Antacid\n\nCoadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate. 7.5 Sildenafil\n\nA single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine besylate. When amlodipine besylate and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.">
		<entity charOffset="594-604" id="DBMI.pac141.sp1.e0" origId="sp1.e0" text="magnesium " type="Active ingredient"/>
		<entity charOffset="657-668" id="DBMI.pac141.sp1.e1" origId="sp1.e1" text="amlodipine " type="Active ingredient"/>
		<entity charOffset="608-617" id="DBMI.pac141.sp1.e2" origId="sp1.e2" text="aluminum " type="Active ingredient"/>
		<entity charOffset="792-803" id="DBMI.pac141.sp1.e3" origId="sp1.e3" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac141.sp1.e0" e2="DBMI.pac141.sp1.e1" id="DBMI.pac141.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine " precipitant="magnesium "/>
		<pair e1="DBMI.pac141.sp1.e0" e2="DBMI.pac141.sp1.e2" id="DBMI.pac141.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e0" e2="DBMI.pac141.sp1.e3" id="DBMI.pac141.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e1" e2="DBMI.pac141.sp1.e0" id="DBMI.pac141.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e1" e2="DBMI.pac141.sp1.e2" id="DBMI.pac141.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e1" e2="DBMI.pac141.sp1.e3" id="DBMI.pac141.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e2" e2="DBMI.pac141.sp1.e0" id="DBMI.pac141.sp1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e2" e2="DBMI.pac141.sp1.e1" id="DBMI.pac141.sp1.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine " precipitant="aluminum "/>
		<pair e1="DBMI.pac141.sp1.e2" e2="DBMI.pac141.sp1.e3" id="DBMI.pac141.sp1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e3" e2="DBMI.pac141.sp1.e0" id="DBMI.pac141.sp1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e3" e2="DBMI.pac141.sp1.e1" id="DBMI.pac141.sp1.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine " precipitant="sildenafil "/>
		<pair e1="DBMI.pac141.sp1.e3" e2="DBMI.pac141.sp1.e2" id="DBMI.pac141.sp1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac141.sp2" origId="sp2" text="7.6 Atorvastatin\n\nCoadministration of multiple 10 mg doses of amlodipine besylate with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin. 7.7 Digoxin\n\nCoadministration of amlodipine besylate with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers. 7.8 Ethanol (Alcohol)\n\nSingle and multiple 10 mg doses of amlodipine besylate had no significant effect on the pharmacokinetics of ethanol.">
		<entity charOffset="1117-1128" id="DBMI.pac141.sp2.e0" origId="sp2.e0" text="amlodipine " type="Active ingredient"/>
		<entity charOffset="1151-1164" id="DBMI.pac141.sp2.e1" origId="sp2.e1" text="atorvastatin " type="Active ingredient"/>
		<entity charOffset="1321-1329" id="DBMI.pac141.sp2.e2" origId="sp2.e2" text="digoxin " type="Active ingredient"/>
		<entity charOffset="1546-1554" id="DBMI.pac141.sp2.e3" origId="sp2.e3" text="ethanol " type="Active ingredient"/>
		<pair e1="DBMI.pac141.sp2.e0" e2="DBMI.pac141.sp2.e1" id="DBMI.pac141.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin " precipitant="amlodipine "/>
		<pair e1="DBMI.pac141.sp2.e0" e2="DBMI.pac141.sp2.e2" id="DBMI.pac141.sp2.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="amlodipine "/>
		<pair e1="DBMI.pac141.sp2.e0" e2="DBMI.pac141.sp2.e3" id="DBMI.pac141.sp2.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethanol " precipitant="amlodipine "/>
		<pair e1="DBMI.pac141.sp2.e1" e2="DBMI.pac141.sp2.e0" id="DBMI.pac141.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e1" e2="DBMI.pac141.sp2.e2" id="DBMI.pac141.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e1" e2="DBMI.pac141.sp2.e3" id="DBMI.pac141.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e2" e2="DBMI.pac141.sp2.e0" id="DBMI.pac141.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e2" e2="DBMI.pac141.sp2.e1" id="DBMI.pac141.sp2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e2" e2="DBMI.pac141.sp2.e3" id="DBMI.pac141.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e3" e2="DBMI.pac141.sp2.e0" id="DBMI.pac141.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e3" e2="DBMI.pac141.sp2.e1" id="DBMI.pac141.sp2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e3" e2="DBMI.pac141.sp2.e2" id="DBMI.pac141.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac141.sp3" origId="sp3" text="7.9 Warfarin\n\nCoadministration of amlodipine besylate with warfarin did not change the warfarin prothrombin response time. 7.10 Drug/Laboratory Test Interactions\n\nNone known.">
		<entity charOffset="1590-1601" id="DBMI.pac141.sp3.e0" origId="sp3.e0" text="amlodipine " type="Active ingredient"/>
		<entity charOffset="1615-1624" id="DBMI.pac141.sp3.e1" origId="sp3.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac141.sp3.e0" e2="DBMI.pac141.sp3.e1" id="DBMI.pac141.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="amlodipine "/>
		<pair e1="DBMI.pac141.sp3.e1" e2="DBMI.pac141.sp3.e0" id="DBMI.pac141.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac145" origId="pac145">
	<sentence id="DBMI.pac145.s0" origId="s0" text="Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol at steady-state.">
		<entity charOffset="73-83" id="DBMI.pac145.s0.e0" origId="s0.e0" text="valproate " type="Active ingredient"/>
		<entity charOffset="103-112" id="DBMI.pac145.s0.e1" origId="s0.e1" text="Felbatol " type="Drug product"/>
		<pair e1="DBMI.pac145.s0.e0" e2="DBMI.pac145.s0.e1" id="DBMI.pac145.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Felbatol " precipitant="valproate "/>
		<pair e1="DBMI.pac145.s0.e1" e2="DBMI.pac145.s0.e0" id="DBMI.pac145.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac145.s1" origId="s1" text="Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol (felbamate) plasma concentrations.">
		<entity charOffset="157-167" id="DBMI.pac145.s1.e0" origId="s1.e0" text="valproate " type="Active ingredient"/>
		<entity charOffset="236-246" id="DBMI.pac145.s1.e1" origId="s1.e1" text="felbamate " type="Active ingredient"/>
		<pair e1="DBMI.pac145.s1.e0" e2="DBMI.pac145.s1.e1" id="DBMI.pac145.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="felbamate " precipitant="valproate "/>
		<pair e1="DBMI.pac145.s1.e1" e2="DBMI.pac145.s1.e0" id="DBMI.pac145.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac145.sp0" origId="sp0" text="Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol at steady-state. Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol (felbamate) plasma concentrations.">
		<entity charOffset="157-167" id="DBMI.pac145.sp0.e0" origId="sp0.e0" text="valproate " type="Active ingredient"/>
		<entity charOffset="236-246" id="DBMI.pac145.sp0.e1" origId="sp0.e1" text="felbamate " type="Active ingredient"/>
		<entity charOffset="103-112" id="DBMI.pac145.sp0.e2" origId="sp0.e2" text="Felbatol " type="Drug product"/>
		<pair e1="DBMI.pac145.sp0.e0" e2="DBMI.pac145.sp0.e1" id="DBMI.pac145.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="felbamate " precipitant="valproate "/>
		<pair e1="DBMI.pac145.sp0.e0" e2="DBMI.pac145.sp0.e2" id="DBMI.pac145.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Felbatol " precipitant="valproate "/>
		<pair e1="DBMI.pac145.sp0.e1" e2="DBMI.pac145.sp0.e0" id="DBMI.pac145.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac145.sp0.e1" e2="DBMI.pac145.sp0.e2" id="DBMI.pac145.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac145.sp0.e2" e2="DBMI.pac145.sp0.e0" id="DBMI.pac145.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac145.sp0.e2" e2="DBMI.pac145.sp0.e1" id="DBMI.pac145.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac146" origId="pac146">
	<sentence id="DBMI.pac146.s0" origId="s0" text="Effects of Felbatol on Low-Dose Combination Oral Contraceptives:\nA group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 g ethinyl estradiol and 75 g gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles."/>
	<sentence id="DBMI.pac146.s1" origId="s1" text="Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.">
		<entity charOffset="370-380" id="DBMI.pac146.s1.e0" origId="s1.e0" text="Felbamate " type="Active ingredient"/>
		<entity charOffset="424-434" id="DBMI.pac146.s1.e1" origId="s1.e1" text="gestodene " type="Active ingredient"/>
		<entity charOffset="536-546" id="DBMI.pac146.s1.e2" origId="s1.e2" text="estradiol " type="Active ingredient"/>
		<pair e1="DBMI.pac146.s1.e0" e2="DBMI.pac146.s1.e1" id="DBMI.pac146.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="gestodene " precipitant="Felbamate "/>
		<pair e1="DBMI.pac146.s1.e0" e2="DBMI.pac146.s1.e2" id="DBMI.pac146.s1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="estradiol " precipitant="Felbamate "/>
		<pair e1="DBMI.pac146.s1.e1" e2="DBMI.pac146.s1.e0" id="DBMI.pac146.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.s1.e1" e2="DBMI.pac146.s1.e2" id="DBMI.pac146.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.s1.e2" e2="DBMI.pac146.s1.e0" id="DBMI.pac146.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.s1.e2" e2="DBMI.pac146.s1.e1" id="DBMI.pac146.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac146.s2" origId="s2" text="No volunteer showed hormonal evidence of ovulation, but one volunteer reported intermenstrual bleeding during felbamate treatment."/>
	<sentencespan id="DBMI.pac146.sp0" origId="sp0" text="Effects of Felbatol on Low-Dose Combination Oral Contraceptives:\nA group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 g ethinyl estradiol and 75 g gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles. Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol. No volunteer showed hormonal evidence of ovulation, but one volunteer reported intermenstrual bleeding during felbamate treatment.">
		<entity charOffset="370-380" id="DBMI.pac146.sp0.e0" origId="sp0.e0" text="Felbamate " type="Active ingredient"/>
		<entity charOffset="424-434" id="DBMI.pac146.sp0.e1" origId="sp0.e1" text="gestodene " type="Active ingredient"/>
		<entity charOffset="536-546" id="DBMI.pac146.sp0.e2" origId="sp0.e2" text="estradiol " type="Active ingredient"/>
		<pair e1="DBMI.pac146.sp0.e0" e2="DBMI.pac146.sp0.e1" id="DBMI.pac146.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="gestodene " precipitant="Felbamate "/>
		<pair e1="DBMI.pac146.sp0.e0" e2="DBMI.pac146.sp0.e2" id="DBMI.pac146.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="estradiol " precipitant="Felbamate "/>
		<pair e1="DBMI.pac146.sp0.e1" e2="DBMI.pac146.sp0.e0" id="DBMI.pac146.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.sp0.e1" e2="DBMI.pac146.sp0.e2" id="DBMI.pac146.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.sp0.e2" e2="DBMI.pac146.sp0.e0" id="DBMI.pac146.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.sp0.e2" e2="DBMI.pac146.sp0.e1" id="DBMI.pac146.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac147" origId="pac147">
	<sentence id="DBMI.pac147.s0" origId="s0" text="Phenytoin: Felbatol causes an increase in steady-state phenytoin plasma concentrations.">
		<entity charOffset="11-20" id="DBMI.pac147.s0.e0" origId="s0.e0" text="Felbatol " type="Drug product"/>
		<entity charOffset="56-66" id="DBMI.pac147.s0.e1" origId="s0.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac147.s0.e0" e2="DBMI.pac147.s0.e1" id="DBMI.pac147.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="Felbatol "/>
		<pair e1="DBMI.pac147.s0.e1" e2="DBMI.pac147.s0.e0" id="DBMI.pac147.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac147.s1" origId="s1" text="In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 175 micrograms/mL."/>
	<sentence id="DBMI.pac147.s2" origId="s2" text="The steady-state Cmin increased to 215 micrograms/mL when 1200 mg/day of felbamate was coadministered."/>
	<sentence id="DBMI.pac147.s3" origId="s3" text="Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 257 micrograms/mL.">
		<entity charOffset="362-372" id="DBMI.pac147.s3.e0" origId="s3.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="444-454" id="DBMI.pac147.s3.e1" origId="s3.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac147.s3.e0" e2="DBMI.pac147.s3.e1" id="DBMI.pac147.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="felbamate "/>
		<pair e1="DBMI.pac147.s3.e1" e2="DBMI.pac147.s3.e0" id="DBMI.pac147.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac147.s4" origId="s4" text="In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects."/>
	<sentence id="DBMI.pac147.s5" origId="s5" text="In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol therapy resulted in phenytoin levels comparable to those prior to Felbatol administration."/>
	<sentencespan id="DBMI.pac147.sp0" origId="sp0" text="Phenytoin: Felbatol causes an increase in steady-state phenytoin plasma concentrations. In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 175 micrograms/mL. The steady-state Cmin increased to 215 micrograms/mL when 1200 mg/day of felbamate was coadministered.">
		<entity charOffset="11-20" id="DBMI.pac147.sp0.e0" origId="sp0.e0" text="Felbatol " type="Drug product"/>
		<entity charOffset="56-66" id="DBMI.pac147.sp0.e1" origId="sp0.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac147.sp0.e0" e2="DBMI.pac147.sp0.e1" id="DBMI.pac147.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="Felbatol "/>
		<pair e1="DBMI.pac147.sp0.e1" e2="DBMI.pac147.sp0.e0" id="DBMI.pac147.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac147.sp1" origId="sp1" text="Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 257 micrograms/mL. In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects. In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol therapy resulted in phenytoin levels comparable to those prior to Felbatol administration.">
		<entity charOffset="362-372" id="DBMI.pac147.sp1.e0" origId="sp1.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="444-454" id="DBMI.pac147.sp1.e1" origId="sp1.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac147.sp1.e0" e2="DBMI.pac147.sp1.e1" id="DBMI.pac147.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="felbamate "/>
		<pair e1="DBMI.pac147.sp1.e1" e2="DBMI.pac147.sp1.e0" id="DBMI.pac147.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac148" origId="pac148">
	<sentence id="DBMI.pac148.s0" origId="s0" text="Carbamazepine: Felbatol causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.">
		<entity charOffset="15-24" id="DBMI.pac148.s0.e0" origId="s0.e0" text="Felbatol " type="Drug product"/>
		<entity charOffset="63-77" id="DBMI.pac148.s0.e1" origId="s0.e1" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="135-157" id="DBMI.pac148.s0.e2" origId="s0.e2" text="carbamazepine epoxide " type="Metabolite"/>
		<pair e1="DBMI.pac148.s0.e0" e2="DBMI.pac148.s0.e1" id="DBMI.pac148.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine " precipitant="Felbatol "/>
		<pair e1="DBMI.pac148.s0.e0" e2="DBMI.pac148.s0.e2" id="DBMI.pac148.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine epoxide " precipitant="Felbatol "/>
		<pair e1="DBMI.pac148.s0.e1" e2="DBMI.pac148.s0.e0" id="DBMI.pac148.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.s0.e1" e2="DBMI.pac148.s0.e2" id="DBMI.pac148.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.s0.e2" e2="DBMI.pac148.s0.e0" id="DBMI.pac148.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.s0.e2" e2="DBMI.pac148.s0.e1" id="DBMI.pac148.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac148.s1" origId="s1" text="In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 82 micrograms/mL."/>
	<sentence id="DBMI.pac148.s2" origId="s2" text="The carbamazepine steady-state Cmin decreased 31% to 51 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.">
		<entity charOffset="411-421" id="DBMI.pac148.s2.e0" origId="s2.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="339-353" id="DBMI.pac148.s2.e1" origId="s2.e1" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac148.s2.e0" e2="DBMI.pac148.s2.e1" id="DBMI.pac148.s2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="carbamazepine " precipitant="felbamate "/>
		<pair e1="DBMI.pac148.s2.e1" e2="DBMI.pac148.s2.e0" id="DBMI.pac148.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac148.s3" origId="s3" text="Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.00.3 to 1.60.4 micrograms/mL with the addition of felbamate.">
		<entity charOffset="609-619" id="DBMI.pac148.s3.e0" origId="s3.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="481-503" id="DBMI.pac148.s3.e1" origId="s3.e1" text="Carbamazepine epoxide " type="Metabolite"/>
		<pair e1="DBMI.pac148.s3.e0" e2="DBMI.pac148.s3.e1" id="DBMI.pac148.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Carbamazepine epoxide " precipitant="felbamate "/>
		<pair e1="DBMI.pac148.s3.e1" e2="DBMI.pac148.s3.e0" id="DBMI.pac148.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac148.s4" origId="s4" text="In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen."/>
	<sentencespan id="DBMI.pac148.sp0" origId="sp0" text="Carbamazepine: Felbatol causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration. In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 82 micrograms/mL. The carbamazepine steady-state Cmin decreased 31% to 51 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.">
		<entity charOffset="15-24" id="DBMI.pac148.sp0.e0" origId="sp0.e0" text="Felbatol " type="Drug product"/>
		<entity charOffset="63-77" id="DBMI.pac148.sp0.e1" origId="sp0.e1" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="135-157" id="DBMI.pac148.sp0.e2" origId="sp0.e2" text="carbamazepine epoxide " type="Metabolite"/>
		<entity charOffset="411-421" id="DBMI.pac148.sp0.e3" origId="sp0.e3" text="felbamate " type="Active ingredient"/>
		<pair e1="DBMI.pac148.sp0.e0" e2="DBMI.pac148.sp0.e1" id="DBMI.pac148.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine " precipitant="Felbatol "/>
		<pair e1="DBMI.pac148.sp0.e0" e2="DBMI.pac148.sp0.e2" id="DBMI.pac148.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine epoxide " precipitant="Felbatol "/>
		<pair e1="DBMI.pac148.sp0.e0" e2="DBMI.pac148.sp0.e3" id="DBMI.pac148.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e1" e2="DBMI.pac148.sp0.e0" id="DBMI.pac148.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e1" e2="DBMI.pac148.sp0.e2" id="DBMI.pac148.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e1" e2="DBMI.pac148.sp0.e3" id="DBMI.pac148.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e2" e2="DBMI.pac148.sp0.e0" id="DBMI.pac148.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e2" e2="DBMI.pac148.sp0.e1" id="DBMI.pac148.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e2" e2="DBMI.pac148.sp0.e3" id="DBMI.pac148.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e3" e2="DBMI.pac148.sp0.e0" id="DBMI.pac148.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e3" e2="DBMI.pac148.sp0.e1" id="DBMI.pac148.sp0.p10" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="carbamazepine " precipitant="felbamate "/>
		<pair e1="DBMI.pac148.sp0.e3" e2="DBMI.pac148.sp0.e2" id="DBMI.pac148.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac148.sp1" origId="sp1" text="Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.00.3 to 1.60.4 micrograms/mL with the addition of felbamate. In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen.">
		<entity charOffset="609-619" id="DBMI.pac148.sp1.e0" origId="sp1.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="481-503" id="DBMI.pac148.sp1.e1" origId="sp1.e1" text="Carbamazepine epoxide " type="Metabolite"/>
		<pair e1="DBMI.pac148.sp1.e0" e2="DBMI.pac148.sp1.e1" id="DBMI.pac148.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Carbamazepine epoxide " precipitant="felbamate "/>
		<pair e1="DBMI.pac148.sp1.e1" e2="DBMI.pac148.sp1.e0" id="DBMI.pac148.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac149" origId="pac149">
	<sentence id="DBMI.pac149.s0" origId="s0" text="Valproate: Felbatol causes an increase in steady-state valproate concentrations.">
		<entity charOffset="11-20" id="DBMI.pac149.s0.e0" origId="s0.e0" text="Felbatol " type="Drug product"/>
		<entity charOffset="56-66" id="DBMI.pac149.s0.e1" origId="s0.e1" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac149.s0.e0" e2="DBMI.pac149.s0.e1" id="DBMI.pac149.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="valproate " precipitant="Felbatol "/>
		<pair e1="DBMI.pac149.s0.e1" e2="DBMI.pac149.s0.e0" id="DBMI.pac149.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac149.s1" origId="s1" text="In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 6316 micrograms/mL."/>
	<sentence id="DBMI.pac149.s2" origId="s2" text="The steady-state Cmin increased to 7814 micrograms/mL when 1200 mg/day of felbamate was coadministered."/>
	<sentence id="DBMI.pac149.s3" origId="s3" text="Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 9625 micrograms/mL.">
		<entity charOffset="341-351" id="DBMI.pac149.s3.e0" origId="s3.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="398-408" id="DBMI.pac149.s3.e1" origId="s3.e1" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac149.s3.e0" e2="DBMI.pac149.s3.e1" id="DBMI.pac149.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="valproate " precipitant="felbamate "/>
		<pair e1="DBMI.pac149.s3.e1" e2="DBMI.pac149.s3.e0" id="DBMI.pac149.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac149.s4" origId="s4" text="Corresponding values for free valproate Cmin concentrations were 73, 94, and 116 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol, respectively."/>
	<sentence id="DBMI.pac149.s5" origId="s5" text="The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol, respectively."/>
	<sentence id="DBMI.pac149.s6" origId="s6" text="This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol. ">
		<entity charOffset="881-890" id="DBMI.pac149.s6.e0" origId="s6.e0" text="Felbatol " type="Drug product"/>
		<entity charOffset="819-829" id="DBMI.pac149.s6.e1" origId="s6.e1" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac149.s6.e0" e2="DBMI.pac149.s6.e1" id="DBMI.pac149.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valproate " precipitant="Felbatol "/>
		<pair e1="DBMI.pac149.s6.e1" e2="DBMI.pac149.s6.e0" id="DBMI.pac149.s6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac149.sp0" origId="sp0" text="Valproate: Felbatol causes an increase in steady-state valproate concentrations. In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 6316 micrograms/mL. The steady-state Cmin increased to 7814 micrograms/mL when 1200 mg/day of felbamate was coadministered.">
		<entity charOffset="11-20" id="DBMI.pac149.sp0.e0" origId="sp0.e0" text="Felbatol " type="Drug product"/>
		<entity charOffset="56-66" id="DBMI.pac149.sp0.e1" origId="sp0.e1" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac149.sp0.e0" e2="DBMI.pac149.sp0.e1" id="DBMI.pac149.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="valproate " precipitant="Felbatol "/>
		<pair e1="DBMI.pac149.sp0.e1" e2="DBMI.pac149.sp0.e0" id="DBMI.pac149.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac149.sp1" origId="sp1" text="Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 9625 micrograms/mL. Corresponding values for free valproate Cmin concentrations were 73, 94, and 116 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol, respectively. The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol, respectively.">
		<entity charOffset="341-351" id="DBMI.pac149.sp1.e0" origId="sp1.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="398-408" id="DBMI.pac149.sp1.e1" origId="sp1.e1" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac149.sp1.e0" e2="DBMI.pac149.sp1.e1" id="DBMI.pac149.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="valproate " precipitant="felbamate "/>
		<pair e1="DBMI.pac149.sp1.e1" e2="DBMI.pac149.sp1.e0" id="DBMI.pac149.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac149.sp2" origId="sp2" text="This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol. ">
		<entity charOffset="881-890" id="DBMI.pac149.sp2.e0" origId="sp2.e0" text="Felbatol " type="Drug product"/>
		<entity charOffset="819-829" id="DBMI.pac149.sp2.e1" origId="sp2.e1" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac149.sp2.e0" e2="DBMI.pac149.sp2.e1" id="DBMI.pac149.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valproate " precipitant="Felbatol "/>
		<pair e1="DBMI.pac149.sp2.e1" e2="DBMI.pac149.sp2.e0" id="DBMI.pac149.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac15" origId="pac15">
	<sentence id="DBMI.pac15.s0" origId="s0" text="Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism.">
		<entity charOffset="98-109" id="DBMI.pac15.s0.e0" origId="s0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="172-182" id="DBMI.pac15.s0.e1" origId="s0.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac15.s0.e0" e2="DBMI.pac15.s0.e1" id="DBMI.pac15.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="sertraline "/>
		<pair e1="DBMI.pac15.s0.e1" e2="DBMI.pac15.s0.e0" id="DBMI.pac15.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac15.s1" origId="s1" text="Nonetheless, at this time, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline therapy with appropriate adjustments to the phenytoin dose, particularly in patients with multiple underlying medical conditions and/or those receiving multiple concomitant medications."/>
	<sentencespan id="DBMI.pac15.sp0" origId="sp0" text="Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. Nonetheless, at this time, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline therapy with appropriate adjustments to the phenytoin dose, particularly in patients with multiple underlying medical conditions and/or those receiving multiple concomitant medications.">
		<entity charOffset="98-109" id="DBMI.pac15.sp0.e0" origId="sp0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="172-182" id="DBMI.pac15.sp0.e1" origId="sp0.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac15.sp0.e0" e2="DBMI.pac15.sp0.e1" id="DBMI.pac15.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="sertraline "/>
		<pair e1="DBMI.pac15.sp0.e1" e2="DBMI.pac15.sp0.e0" id="DBMI.pac15.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac150" origId="pac150">
	<sentence id="DBMI.pac150.s0" origId="s0" text="Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations.">
		<entity charOffset="35-45" id="DBMI.pac150.s0.e0" origId="s0.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="50-64" id="DBMI.pac150.s0.e1" origId="s0.e1" text="phenobarbital " type="Active ingredient"/>
		<pair e1="DBMI.pac150.s0.e0" e2="DBMI.pac150.s0.e1" id="DBMI.pac150.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenobarbital " precipitant="felbamate "/>
		<pair e1="DBMI.pac150.s0.e1" e2="DBMI.pac150.s0.e0" id="DBMI.pac150.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac150.s1" origId="s1" text="In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL."/>
	<sentence id="DBMI.pac150.s2" origId="s2" text="The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.">
		<entity charOffset="359-369" id="DBMI.pac150.s2.e0" origId="s2.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="219-233" id="DBMI.pac150.s2.e1" origId="s2.e1" text="phenobarbital " type="Active ingredient"/>
		<pair e1="DBMI.pac150.s2.e0" e2="DBMI.pac150.s2.e1" id="DBMI.pac150.s2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenobarbital " precipitant="felbamate "/>
		<pair e1="DBMI.pac150.s2.e1" e2="DBMI.pac150.s2.e0" id="DBMI.pac150.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac150.sp0" origId="sp0" text="Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations. In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL. The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.">
		<entity charOffset="35-45" id="DBMI.pac150.sp0.e0" origId="sp0.e0" text="felbamate " type="Active ingredient"/>
		<entity charOffset="50-64" id="DBMI.pac150.sp0.e1" origId="sp0.e1" text="phenobarbital " type="Active ingredient"/>
		<pair e1="DBMI.pac150.sp0.e0" e2="DBMI.pac150.sp0.e1" id="DBMI.pac150.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenobarbital " precipitant="felbamate "/>
		<pair e1="DBMI.pac150.sp0.e0" e2="DBMI.pac150.sp0.e1" id="DBMI.pac150.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenobarbital " precipitant="felbamate "/>
		<pair e1="DBMI.pac150.sp0.e1" e2="DBMI.pac150.sp0.e0" id="DBMI.pac150.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac151" origId="pac151">
	<sentence id="DBMI.pac151.s0" origId="s0" text="Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.">
		<entity charOffset="11-21" id="DBMI.pac151.s0.e0" origId="s0.e0" text="Phenytoin " type="Active ingredient"/>
		<entity charOffset="83-93" id="DBMI.pac151.s0.e1" origId="s0.e1" text="felbamate " type="Active ingredient"/>
		<entity charOffset="142-152" id="DBMI.pac151.s0.e2" origId="s0.e2" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="232-241" id="DBMI.pac151.s0.e3" origId="s0.e3" text="Felbatol " type="Drug product"/>
		<pair e1="DBMI.pac151.s0.e0" e2="DBMI.pac151.s0.e1" id="DBMI.pac151.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="felbamate " precipitant="Phenytoin "/>
		<pair e1="DBMI.pac151.s0.e0" e2="DBMI.pac151.s0.e2" id="DBMI.pac151.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e0" e2="DBMI.pac151.s0.e3" id="DBMI.pac151.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e1" e2="DBMI.pac151.s0.e0" id="DBMI.pac151.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e1" e2="DBMI.pac151.s0.e2" id="DBMI.pac151.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e1" e2="DBMI.pac151.s0.e3" id="DBMI.pac151.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e2" e2="DBMI.pac151.s0.e0" id="DBMI.pac151.s0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e2" e2="DBMI.pac151.s0.e1" id="DBMI.pac151.s0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e2" e2="DBMI.pac151.s0.e3" id="DBMI.pac151.s0.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Felbatol " precipitant="phenytoin "/>
		<pair e1="DBMI.pac151.s0.e3" e2="DBMI.pac151.s0.e0" id="DBMI.pac151.s0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e3" e2="DBMI.pac151.s0.e1" id="DBMI.pac151.s0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e3" e2="DBMI.pac151.s0.e2" id="DBMI.pac151.s0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac151.sp0" origId="sp0" text="Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.">
		<entity charOffset="11-21" id="DBMI.pac151.sp0.e0" origId="sp0.e0" text="Phenytoin " type="Active ingredient"/>
		<entity charOffset="83-93" id="DBMI.pac151.sp0.e1" origId="sp0.e1" text="felbamate " type="Active ingredient"/>
		<entity charOffset="142-152" id="DBMI.pac151.sp0.e2" origId="sp0.e2" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="232-241" id="DBMI.pac151.sp0.e3" origId="sp0.e3" text="Felbatol " type="Drug product"/>
		<pair e1="DBMI.pac151.sp0.e0" e2="DBMI.pac151.sp0.e1" id="DBMI.pac151.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="felbamate " precipitant="Phenytoin "/>
		<pair e1="DBMI.pac151.sp0.e0" e2="DBMI.pac151.sp0.e2" id="DBMI.pac151.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.sp0.e0" e2="DBMI.pac151.sp0.e3" id="DBMI.pac151.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.sp0.e1" e2="DBMI.pac151.sp0.e0" id="DBMI.pac151.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.sp0.e1" e2="DBMI.pac151.sp0.e2" id="DBMI.pac151.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.sp0.e1" e2="DBMI.pac151.sp0.e3" id="DBMI.pac151.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.sp0.e2" e2="DBMI.pac151.sp0.e0" id="DBMI.pac151.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.sp0.e2" e2="DBMI.pac151.sp0.e1" id="DBMI.pac151.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.sp0.e2" e2="DBMI.pac151.sp0.e3" id="DBMI.pac151.sp0.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Felbatol " precipitant="phenytoin "/>
		<pair e1="DBMI.pac151.sp0.e3" e2="DBMI.pac151.sp0.e0" id="DBMI.pac151.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.sp0.e3" e2="DBMI.pac151.sp0.e1" id="DBMI.pac151.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.sp0.e3" e2="DBMI.pac151.sp0.e2" id="DBMI.pac151.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac152" origId="pac152">
	<sentence id="DBMI.pac152.s0" origId="s0" text="Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy. ">
		<entity charOffset="142-156" id="DBMI.pac152.s0.e0" origId="s0.e0" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="240-249" id="DBMI.pac152.s0.e1" origId="s0.e1" text="Felbatol " type="Drug product"/>
		<entity charOffset="15-29" id="DBMI.pac152.s0.e2" origId="s0.e2" text="Carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac152.s0.e0" e2="DBMI.pac152.s0.e1" id="DBMI.pac152.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Felbatol " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac152.s0.e0" e2="DBMI.pac152.s0.e2" id="DBMI.pac152.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.s0.e1" e2="DBMI.pac152.s0.e0" id="DBMI.pac152.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.s0.e1" e2="DBMI.pac152.s0.e2" id="DBMI.pac152.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.s0.e2" e2="DBMI.pac152.s0.e0" id="DBMI.pac152.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.s0.e2" e2="DBMI.pac152.s0.e1" id="DBMI.pac152.s0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Felbatol " precipitant="Carbamazepine "/>
	</sentence>
	<sentencespan id="DBMI.pac152.sp0" origId="sp0" text="Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy. ">
		<entity charOffset="142-156" id="DBMI.pac152.sp0.e0" origId="sp0.e0" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="240-249" id="DBMI.pac152.sp0.e1" origId="sp0.e1" text="Felbatol " type="Drug product"/>
		<entity charOffset="15-29" id="DBMI.pac152.sp0.e2" origId="sp0.e2" text="Carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac152.sp0.e0" e2="DBMI.pac152.sp0.e1" id="DBMI.pac152.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Felbatol " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac152.sp0.e0" e2="DBMI.pac152.sp0.e2" id="DBMI.pac152.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.sp0.e1" e2="DBMI.pac152.sp0.e0" id="DBMI.pac152.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.sp0.e1" e2="DBMI.pac152.sp0.e2" id="DBMI.pac152.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.sp0.e2" e2="DBMI.pac152.sp0.e0" id="DBMI.pac152.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.sp0.e2" e2="DBMI.pac152.sp0.e1" id="DBMI.pac152.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Felbatol " precipitant="Carbamazepine "/>
	</sentencespan>
</document>

<document id="DBMI.pac155" origId="pac155">
	<sentence id="DBMI.pac155.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSildenafil is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP."/>
	<sentence id="DBMI.pac155.s1" origId="s1" text="Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation."/>
	<sentence id="DBMI.pac155.s2" origId="s2" text="In patients with pulmonary hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation."/>
	<sentence id="DBMI.pac155.s3" origId="s3" text="Studies in vitro have shown that sildenafil is selective for PDE5."/>
	<sentence id="DBMI.pac155.s4" origId="s4" text="Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11)."/>
	<sentence id="DBMI.pac155.s5" origId="s5" text="The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility."/>
	<sentence id="DBMI.pac155.s6" origId="s6" text="Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina."/>
	<sentence id="DBMI.pac155.s7" origId="s7" text="This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels [see Clinical Pharmacology (12.2)]."/>
	<sentence id="DBMI.pac155.s8" origId="s8" text="In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE5 is also found in other tissues including vascular and visceral smooth muscle and in platelets."/>
	<sentence id="DBMI.pac155.s9" origId="s9" text="The inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed in vitro, and the mild peripheral arterial-venous dilatation in vivo."/>
	<sentence id="DBMI.pac155.s10" origId="s10" text="12.2 Pharmacodynamics\n\nEffects of REVATIO on Blood Pressure\n\nSingle oral doses of sildenafil 100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg)."/>
	<sentence id="DBMI.pac155.s11" origId="s11" text="The decrease in blood pressure was most notable approximately 12 hours after dosing, and was not different from placebo at 8 hours."/>
	<sentence id="DBMI.pac155.s12" origId="s12" text="Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range."/>
	<sentence id="DBMI.pac155.s13" origId="s13" text="Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)]."/>
	<sentence id="DBMI.pac155.s14" origId="s14" text="Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG."/>
	<sentence id="DBMI.pac155.s15" origId="s15" text="After chronic dosing of 80 mg TID to patients with pulmonary arterial hypertension, no clinically relevant effects on ECG were reported."/>
	<sentence id="DBMI.pac155.s16" origId="s16" text="After chronic dosing of 80 mg TID sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively."/>
	<sentence id="DBMI.pac155.s17" origId="s17" text="After chronic dosing of 80 mg TID sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively."/>
	<sentence id="DBMI.pac155.s18" origId="s18" text="After chronic dosing of 80 mg TID sildenafil to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg)."/>
	<sentence id="DBMI.pac155.s19" origId="s19" text="Effects of REVATIO on Vision\n\nAt single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels."/>
	<sentence id="DBMI.pac155.s20" origId="s20" text="This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina."/>
	<sentence id="DBMI.pac155.s21" origId="s21" text="An evaluation of visual function at doses up to 200 mg revealed no effects of REVATIO on visual acuity, intraocular pressure, or pupillometry."/>
	<sentence id="DBMI.pac155.s22" origId="s22" text="12.3 Pharmacokinetics\n\nAbsorption and Distribution\n\nREVATIO is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (2563%)."/>
	<sentence id="DBMI.pac155.s23" origId="s23" text="Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state."/>
	<sentence id="DBMI.pac155.s24" origId="s24" text="When REVATIO is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%."/>
	<sentence id="DBMI.pac155.s25" origId="s25" text="The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues."/>
	<sentence id="DBMI.pac155.s26" origId="s26" text="Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins."/>
	<sentence id="DBMI.pac155.s27" origId="s27" text="Protein binding is independent of total drug concentrations."/>
	<sentence id="DBMI.pac155.s28" origId="s28" text="Metabolism and Excretion\n\nSildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes."/>
	<sentence id="DBMI.pac155.s29" origId="s29" text="The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized."/>
	<sentence id="DBMI.pac155.s30" origId="s30" text="This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug."/>
	<sentence id="DBMI.pac155.s31" origId="s31" text="In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects."/>
	<sentence id="DBMI.pac155.s32" origId="s32" text="In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher."/>
	<sentence id="DBMI.pac155.s33" origId="s33" text="Both sildenafil and the active metabolite have terminal half-lives of about 4 hours."/>
	<sentence id="DBMI.pac155.s34" origId="s34" text="After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose)."/>
	<sentence id="DBMI.pac155.s35" origId="s35" text="REVATIO Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration."/>
	<sentence id="DBMI.pac155.s36" origId="s36" text="A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose."/>
	<sentence id="DBMI.pac155.s37" origId="s37" text="Population Pharmacokinetics\n\nAge, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH."/>
	<sentence id="DBMI.pac155.s38" origId="s38" text="The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function."/>
	<sentence id="DBMI.pac155.s39" origId="s39" text="None of these factors had a significant impact on sildenafil pharmacokinetics in patients with PAH."/>
	<sentence id="DBMI.pac155.s40" origId="s40" text="In patients with PAH, the average steady-state concentrations were 2050% higher when compared to those of healthy volunteers."/>
	<sentence id="DBMI.pac155.s41" origId="s41" text="There was also a doubling of Cmin levels compared to healthy volunteers."/>
	<sentence id="DBMI.pac155.s42" origId="s42" text="Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with pulmonary hypertension compared to healthy volunteers."/>
	<sentence id="DBMI.pac155.s43" origId="s43" text="Geriatric Patients\n\nHealthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (1845 years)."/>
	<sentence id="DBMI.pac155.s44" origId="s44" text="Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively."/>
	<sentence id="DBMI.pac155.s45" origId="s45" text="Renal Impairment\n\nIn volunteers with mild (CLcr = 5080 mL/min) and moderate (CLcr = 3049 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) was not altered."/>
	<sentence id="DBMI.pac155.s46" origId="s46" text="In volunteers with severe (CLcr &lt; 30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and Cmax compared to age-matched volunteers with no renal impairment."/>
	<sentence id="DBMI.pac155.s47" origId="s47" text="In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200 % and 79 %, respectively, in subjects with severe renal impairment compared to subjects with normal renal function."/>
	<sentence id="DBMI.pac155.s48" origId="s48" text="Hepatic Impairment\n\nIn volunteers with mild to moderate hepatic cirrhosis (Child-Pugh class A and B), sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment."/>
	<sentence id="DBMI.pac155.s49" origId="s49" text="Patients with severe hepatic impairment (Child-Pugh class C) have not been studied."/>
	<sentence id="DBMI.pac155.s50" origId="s50" text="Drug Interaction Studies\n\nSildenafil metabolism is principally mediated by the CYP3A (major route) and CYP2C9 (minor route) cytochrome P450 isoforms."/>
	<sentence id="DBMI.pac155.s51" origId="s51" text="Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance."/>
	<sentence id="DBMI.pac155.s52" origId="s52" text="Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 &gt;150 M)."/>
	<sentence id="DBMI.pac155.s53" origId="s53" text="Ritonavir and other CYP3A Inhibitors\n\nIn study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.">
		<entity charOffset="8627-8637" id="DBMI.pac155.s53.e0" origId="s53.e0" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="8770-8781" id="DBMI.pac155.s53.e1" origId="s53.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s53.e0" e2="DBMI.pac155.s53.e1" id="DBMI.pac155.s53.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="ritonavir "/>
		<pair e1="DBMI.pac155.s53.e0" e2="DBMI.pac155.s53.e1" id="DBMI.pac155.s53.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="ritonavir "/>
		<pair e1="DBMI.pac155.s53.e1" e2="DBMI.pac155.s53.e0" id="DBMI.pac155.s53.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s54" origId="s54" text="At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone."/>
	<sentence id="DBMI.pac155.s55" origId="s55" text="This is consistent with ritonavir's marked effects on a broad range of P450 substrates."/>
	<sentence id="DBMI.pac155.s56" origId="s56" text="Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.">
		<entity charOffset="9146-9157" id="DBMI.pac155.s56.e0" origId="s56.e0" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="9238-9249" id="DBMI.pac155.s56.e1" origId="s56.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s56.e0" e2="DBMI.pac155.s56.e1" id="DBMI.pac155.s56.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.s56.e1" e2="DBMI.pac155.s56.e0" id="DBMI.pac155.s56.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s57" origId="s57" text="Population data from patients in clinical trials indicated a reduction in sildenafil clearance when it was co-administered with CYP3A inhibitors."/>
	<sentence id="DBMI.pac155.s58" origId="s58" text="Sildenafil exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID."/>
	<sentence id="DBMI.pac155.s59" origId="s59" text="This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir)."/>
	<sentence id="DBMI.pac155.s60" origId="s60" text="Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.">
		<entity charOffset="9791-9802" id="DBMI.pac155.s60.e0" origId="s60.e0" text="Cimetidine " type="Active ingredient"/>
		<entity charOffset="9873-9884" id="DBMI.pac155.s60.e1" origId="s60.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s60.e0" e2="DBMI.pac155.s60.e1" id="DBMI.pac155.s60.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac155.s60.e1" e2="DBMI.pac155.s60.e0" id="DBMI.pac155.s60.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s61" origId="s61" text="When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).">
		<entity charOffset="10033-10046" id="DBMI.pac155.s61.e0" origId="s61.e0" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="10136-10147" id="DBMI.pac155.s61.e1" origId="s61.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s61.e0" e2="DBMI.pac155.s61.e1" id="DBMI.pac155.s61.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="erythromycin "/>
		<pair e1="DBMI.pac155.s61.e1" e2="DBMI.pac155.s61.e0" id="DBMI.pac155.s61.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s62" origId="s62" text="In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.">
		<entity charOffset="10265-10276" id="DBMI.pac155.s62.e0" origId="s62.e0" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="10394-10405" id="DBMI.pac155.s62.e1" origId="s62.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s62.e0" e2="DBMI.pac155.s62.e1" id="DBMI.pac155.s62.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.s62.e0" e2="DBMI.pac155.s62.e1" id="DBMI.pac155.s62.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.s62.e1" e2="DBMI.pac155.s62.e0" id="DBMI.pac155.s62.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s63" origId="s63" text="REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration."/>
	<sentence id="DBMI.pac155.s64" origId="s64" text="Bosentan\n\nIn a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.">
		<entity charOffset="10714-10725" id="DBMI.pac155.s64.e0" origId="s64.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="11010-11019" id="DBMI.pac155.s64.e1" origId="s64.e1" text="bosentan " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s64.e0" e2="DBMI.pac155.s64.e1" id="DBMI.pac155.s64.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="bosentan " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.s64.e1" e2="DBMI.pac155.s64.e0" id="DBMI.pac155.s64.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="bosentan "/>
		<pair e1="DBMI.pac155.s64.e1" e2="DBMI.pac155.s64.e0" id="DBMI.pac155.s64.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="bosentan "/>
	</sentence>
	<sentence id="DBMI.pac155.s65" origId="s65" text="Co-administration resulted in a 50% increase in AUC of bosentan."/>
	<sentence id="DBMI.pac155.s66" origId="s66" text="The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing)."/>
	<sentence id="DBMI.pac155.s67" origId="s67" text="Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil."/>
	<sentence id="DBMI.pac155.s68" origId="s68" text="Epoprostenol\n\nThe mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.">
		<entity charOffset="11364-11377" id="DBMI.pac155.s68.e0" origId="s68.e0" text="epoprostenol " type="Active ingredient"/>
		<entity charOffset="11297-11308" id="DBMI.pac155.s68.e1" origId="s68.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s68.e0" e2="DBMI.pac155.s68.e1" id="DBMI.pac155.s68.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="epoprostenol "/>
		<pair e1="DBMI.pac155.s68.e1" e2="DBMI.pac155.s68.e0" id="DBMI.pac155.s68.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s69" origId="s69" text="Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant."/>
	<sentence id="DBMI.pac155.s70" origId="s70" text="The effect of sildenafil on epoprostenol pharmacokinetics is not known."/>
	<sentence id="DBMI.pac155.s71" origId="s71" text="CYP Substrates and Beta-blockers\n\nPopulation pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance or an increase of oral bioavailability when co-administered with CYP3A substrates and the combination of CYP3A substrates and beta-blockers."/>
	<sentence id="DBMI.pac155.s72" origId="s72" text="In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates.">
		<entity charOffset="11970-11981" id="DBMI.pac155.s72.e0" origId="s72.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12085-12095" id="DBMI.pac155.s72.e1" origId="s72.e1" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="12070-12081" id="DBMI.pac155.s72.e2" origId="s72.e2" text="saquinavir " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s72.e0" e2="DBMI.pac155.s72.e1" id="DBMI.pac155.s72.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ritonavir " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.s72.e0" e2="DBMI.pac155.s72.e2" id="DBMI.pac155.s72.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="saquinavir " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.s72.e1" e2="DBMI.pac155.s72.e0" id="DBMI.pac155.s72.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s72.e1" e2="DBMI.pac155.s72.e2" id="DBMI.pac155.s72.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s72.e2" e2="DBMI.pac155.s72.e0" id="DBMI.pac155.s72.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s72.e2" e2="DBMI.pac155.s72.e1" id="DBMI.pac155.s72.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s73" origId="s73" text="No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9."/>
	<sentence id="DBMI.pac155.s74" origId="s74" text="Oral Contraceptives\n\nConcomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil.">
		<entity charOffset="12333-12351" id="DBMI.pac155.s74.e0" origId="s74.e0" text="ethinyl estradiol " type="Active ingredient"/>
		<entity charOffset="12425-12436" id="DBMI.pac155.s74.e1" origId="s74.e1" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12362-12377" id="DBMI.pac155.s74.e2" origId="s74.e2" text="levonorgestrel " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s74.e0" e2="DBMI.pac155.s74.e1" id="DBMI.pac155.s74.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="ethinyl estradiol "/>
		<pair e1="DBMI.pac155.s74.e0" e2="DBMI.pac155.s74.e2" id="DBMI.pac155.s74.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s74.e1" e2="DBMI.pac155.s74.e0" id="DBMI.pac155.s74.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s74.e1" e2="DBMI.pac155.s74.e2" id="DBMI.pac155.s74.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s74.e2" e2="DBMI.pac155.s74.e0" id="DBMI.pac155.s74.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s74.e2" e2="DBMI.pac155.s74.e1" id="DBMI.pac155.s74.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="levonorgestrel "/>
	</sentence>
	<sentence id="DBMI.pac155.s75" origId="s75" text="Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).">
		<entity charOffset="12437-12448" id="DBMI.pac155.s75.e0" origId="s75.e0" text="Sildenafil " type="Active ingredient"/>
		<entity charOffset="12536-12551" id="DBMI.pac155.s75.e1" origId="s75.e1" text="levonorgestrel " type="Active ingredient"/>
		<entity charOffset="12507-12525" id="DBMI.pac155.s75.e2" origId="s75.e2" text="ethinyl estradiol " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s75.e0" e2="DBMI.pac155.s75.e1" id="DBMI.pac155.s75.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="levonorgestrel " precipitant="Sildenafil "/>
		<pair e1="DBMI.pac155.s75.e0" e2="DBMI.pac155.s75.e2" id="DBMI.pac155.s75.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol " precipitant="Sildenafil "/>
		<pair e1="DBMI.pac155.s75.e1" e2="DBMI.pac155.s75.e0" id="DBMI.pac155.s75.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e1" e2="DBMI.pac155.s75.e2" id="DBMI.pac155.s75.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e2" e2="DBMI.pac155.s75.e0" id="DBMI.pac155.s75.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e2" e2="DBMI.pac155.s75.e1" id="DBMI.pac155.s75.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s76" origId="s76" text="Atorvastatin\n\nConcomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.">
		<entity charOffset="12630-12641" id="DBMI.pac155.s76.e0" origId="s76.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12727-12740" id="DBMI.pac155.s76.e1" origId="s76.e1" text="atorvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s76.e0" e2="DBMI.pac155.s76.e1" id="DBMI.pac155.s76.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.s76.e1" e2="DBMI.pac155.s76.e0" id="DBMI.pac155.s76.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="atorvastatin "/>
	</sentence>
	<sentence id="DBMI.pac155.s77" origId="s77" text="Antacids\n\nSingle doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.">
		<entity charOffset="12777-12797" id="DBMI.pac155.s77.e0" origId="s77.e0" text="magnesium hydroxide " type="Active ingredient"/>
		<entity charOffset="12855-12866" id="DBMI.pac155.s77.e1" origId="s77.e1" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12797-12816" id="DBMI.pac155.s77.e2" origId="s77.e2" text="aluminum hydroxide " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s77.e0" e2="DBMI.pac155.s77.e1" id="DBMI.pac155.s77.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="magnesium hydroxide "/>
		<pair e1="DBMI.pac155.s77.e0" e2="DBMI.pac155.s77.e2" id="DBMI.pac155.s77.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e1" e2="DBMI.pac155.s77.e0" id="DBMI.pac155.s77.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e1" e2="DBMI.pac155.s77.e2" id="DBMI.pac155.s77.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e2" e2="DBMI.pac155.s77.e0" id="DBMI.pac155.s77.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e2" e2="DBMI.pac155.s77.e1" id="DBMI.pac155.s77.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="aluminum hydroxide "/>
	</sentence>
	<sentence id="DBMI.pac155.s78" origId="s78" text="Aspirin\n\nSildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg)."/>
	<sentence id="DBMI.pac155.s79" origId="s79" text="Alcohol\n\nSildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%."/>
	<sentencespan id="DBMI.pac155.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSildenafil is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation."/>
	<sentencespan id="DBMI.pac155.sp1" origId="sp1" text="Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility."/>
	<sentencespan id="DBMI.pac155.sp2" origId="sp2" text="Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels [see Clinical Pharmacology (12.2)]. In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE5 is also found in other tissues including vascular and visceral smooth muscle and in platelets."/>
	<sentencespan id="DBMI.pac155.sp3" origId="sp3" text="The inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed in vitro, and the mild peripheral arterial-venous dilatation in vivo. 12.2 Pharmacodynamics\n\nEffects of REVATIO on Blood Pressure\n\nSingle oral doses of sildenafil 100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg). The decrease in blood pressure was most notable approximately 12 hours after dosing, and was not different from placebo at 8 hours."/>
	<sentencespan id="DBMI.pac155.sp4" origId="sp4" text="Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)]. Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG."/>
	<sentencespan id="DBMI.pac155.sp5" origId="sp5" text="After chronic dosing of 80 mg TID to patients with pulmonary arterial hypertension, no clinically relevant effects on ECG were reported. After chronic dosing of 80 mg TID sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively. After chronic dosing of 80 mg TID sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively."/>
	<sentencespan id="DBMI.pac155.sp6" origId="sp6" text="After chronic dosing of 80 mg TID sildenafil to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg). Effects of REVATIO on Vision\n\nAt single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina."/>
	<sentencespan id="DBMI.pac155.sp7" origId="sp7" text="An evaluation of visual function at doses up to 200 mg revealed no effects of REVATIO on visual acuity, intraocular pressure, or pupillometry. 12.3 Pharmacokinetics\n\nAbsorption and Distribution\n\nREVATIO is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (2563%). Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state."/>
	<sentencespan id="DBMI.pac155.sp8" origId="sp8" text="When REVATIO is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins."/>
	<sentencespan id="DBMI.pac155.sp9" origId="sp9" text="Protein binding is independent of total drug concentrations. Metabolism and Excretion\n\nSildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized."/>
	<sentencespan id="DBMI.pac155.sp10" origId="sp10" text="This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects. In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher."/>
	<sentencespan id="DBMI.pac155.sp11" origId="sp11" text="Both sildenafil and the active metabolite have terminal half-lives of about 4 hours. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose). REVATIO Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration."/>
	<sentencespan id="DBMI.pac155.sp12" origId="sp12" text="A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose. Population Pharmacokinetics\n\nAge, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function."/>
	<sentencespan id="DBMI.pac155.sp13" origId="sp13" text="None of these factors had a significant impact on sildenafil pharmacokinetics in patients with PAH. In patients with PAH, the average steady-state concentrations were 2050% higher when compared to those of healthy volunteers. There was also a doubling of Cmin levels compared to healthy volunteers."/>
	<sentencespan id="DBMI.pac155.sp14" origId="sp14" text="Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with pulmonary hypertension compared to healthy volunteers. Geriatric Patients\n\nHealthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (1845 years). Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively."/>
	<sentencespan id="DBMI.pac155.sp15" origId="sp15" text="Renal Impairment\n\nIn volunteers with mild (CLcr = 5080 mL/min) and moderate (CLcr = 3049 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) was not altered. In volunteers with severe (CLcr &lt; 30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and Cmax compared to age-matched volunteers with no renal impairment. In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200 % and 79 %, respectively, in subjects with severe renal impairment compared to subjects with normal renal function."/>
	<sentencespan id="DBMI.pac155.sp16" origId="sp16" text="Hepatic Impairment\n\nIn volunteers with mild to moderate hepatic cirrhosis (Child-Pugh class A and B), sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment. Patients with severe hepatic impairment (Child-Pugh class C) have not been studied. Drug Interaction Studies\n\nSildenafil metabolism is principally mediated by the CYP3A (major route) and CYP2C9 (minor route) cytochrome P450 isoforms."/>
	<sentencespan id="DBMI.pac155.sp17" origId="sp17" text="Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 &gt;150 M). Ritonavir and other CYP3A Inhibitors\n\nIn study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.">
		<entity charOffset="8627-8637" id="DBMI.pac155.sp17.e0" origId="sp17.e0" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="8770-8781" id="DBMI.pac155.sp17.e1" origId="sp17.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp17.e0" e2="DBMI.pac155.sp17.e1" id="DBMI.pac155.sp17.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="ritonavir "/>
		<pair e1="DBMI.pac155.sp17.e0" e2="DBMI.pac155.sp17.e1" id="DBMI.pac155.sp17.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="ritonavir "/>
		<pair e1="DBMI.pac155.sp17.e1" e2="DBMI.pac155.sp17.e0" id="DBMI.pac155.sp17.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp18" origId="sp18" text="At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.">
		<entity charOffset="9146-9157" id="DBMI.pac155.sp18.e0" origId="sp18.e0" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="9238-9249" id="DBMI.pac155.sp18.e1" origId="sp18.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp18.e0" e2="DBMI.pac155.sp18.e1" id="DBMI.pac155.sp18.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.sp18.e1" e2="DBMI.pac155.sp18.e0" id="DBMI.pac155.sp18.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp19" origId="sp19" text="Population data from patients in clinical trials indicated a reduction in sildenafil clearance when it was co-administered with CYP3A inhibitors. Sildenafil exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir)."/>
	<sentencespan id="DBMI.pac155.sp20" origId="sp20" text="Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.">
		<entity charOffset="10033-10046" id="DBMI.pac155.sp20.e0" origId="sp20.e0" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="10136-10147" id="DBMI.pac155.sp20.e1" origId="sp20.e1" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="10265-10276" id="DBMI.pac155.sp20.e2" origId="sp20.e2" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="9791-9802" id="DBMI.pac155.sp20.e3" origId="sp20.e3" text="Cimetidine " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp20.e0" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="erythromycin "/>
		<pair e1="DBMI.pac155.sp20.e0" e2="DBMI.pac155.sp20.e2" id="DBMI.pac155.sp20.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e0" e2="DBMI.pac155.sp20.e3" id="DBMI.pac155.sp20.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e1" e2="DBMI.pac155.sp20.e0" id="DBMI.pac155.sp20.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e1" e2="DBMI.pac155.sp20.e2" id="DBMI.pac155.sp20.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e1" e2="DBMI.pac155.sp20.e3" id="DBMI.pac155.sp20.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e0" id="DBMI.pac155.sp20.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p7" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e3" id="DBMI.pac155.sp20.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e3" e2="DBMI.pac155.sp20.e0" id="DBMI.pac155.sp20.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e3" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p11" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac155.sp20.e3" e2="DBMI.pac155.sp20.e2" id="DBMI.pac155.sp20.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp21" origId="sp21" text="REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration. Bosentan\n\nIn a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administration resulted in a 50% increase in AUC of bosentan.">
		<entity charOffset="10714-10725" id="DBMI.pac155.sp21.e0" origId="sp21.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="11010-11019" id="DBMI.pac155.sp21.e1" origId="sp21.e1" text="bosentan " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp21.e0" e2="DBMI.pac155.sp21.e1" id="DBMI.pac155.sp21.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="bosentan " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.sp21.e1" e2="DBMI.pac155.sp21.e0" id="DBMI.pac155.sp21.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="bosentan "/>
		<pair e1="DBMI.pac155.sp21.e1" e2="DBMI.pac155.sp21.e0" id="DBMI.pac155.sp21.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="bosentan "/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp22" origId="sp22" text="The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil. Epoprostenol\n\nThe mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.">
		<entity charOffset="11364-11377" id="DBMI.pac155.sp22.e0" origId="sp22.e0" text="epoprostenol " type="Active ingredient"/>
		<entity charOffset="11297-11308" id="DBMI.pac155.sp22.e1" origId="sp22.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp22.e0" e2="DBMI.pac155.sp22.e1" id="DBMI.pac155.sp22.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="epoprostenol "/>
		<pair e1="DBMI.pac155.sp22.e1" e2="DBMI.pac155.sp22.e0" id="DBMI.pac155.sp22.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp23" origId="sp23" text="Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmacokinetics is not known. CYP Substrates and Beta-blockers\n\nPopulation pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance or an increase of oral bioavailability when co-administered with CYP3A substrates and the combination of CYP3A substrates and beta-blockers."/>
	<sentencespan id="DBMI.pac155.sp24" origId="sp24" text="In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates. No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9. Oral Contraceptives\n\nConcomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil.">
		<entity charOffset="11970-11981" id="DBMI.pac155.sp24.e0" origId="sp24.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12085-12095" id="DBMI.pac155.sp24.e1" origId="sp24.e1" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="12070-12081" id="DBMI.pac155.sp24.e2" origId="sp24.e2" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="12333-12351" id="DBMI.pac155.sp24.e3" origId="sp24.e3" text="ethinyl estradiol " type="Active ingredient"/>
		<entity charOffset="12362-12377" id="DBMI.pac155.sp24.e4" origId="sp24.e4" text="levonorgestrel " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ritonavir " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="saquinavir " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="ethinyl estradiol "/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="levonorgestrel "/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp25" origId="sp25" text="Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg). Atorvastatin\n\nConcomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin. Antacids\n\nSingle doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.">
		<entity charOffset="12437-12448" id="DBMI.pac155.sp25.e0" origId="sp25.e0" text="Sildenafil " type="Active ingredient"/>
		<entity charOffset="12536-12551" id="DBMI.pac155.sp25.e1" origId="sp25.e1" text="levonorgestrel " type="Active ingredient"/>
		<entity charOffset="12507-12525" id="DBMI.pac155.sp25.e2" origId="sp25.e2" text="ethinyl estradiol " type="Active ingredient"/>
		<entity charOffset="12630-12641" id="DBMI.pac155.sp25.e3" origId="sp25.e3" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12727-12740" id="DBMI.pac155.sp25.e4" origId="sp25.e4" text="atorvastatin " type="Active ingredient"/>
		<entity charOffset="12777-12797" id="DBMI.pac155.sp25.e5" origId="sp25.e5" text="magnesium hydroxide " type="Active ingredient"/>
		<entity charOffset="12797-12816" id="DBMI.pac155.sp25.e6" origId="sp25.e6" text="aluminum hydroxide " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="levonorgestrel " precipitant="Sildenafil "/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol " precipitant="Sildenafil "/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p21" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p27" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="atorvastatin "/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p33" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="magnesium hydroxide "/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p39" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="aluminum hydroxide "/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp26" origId="sp26" text="Aspirin\n\nSildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). Alcohol\n\nSildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%."/>
</document>

<document id="DBMI.pac156" origId="pac156">
	<sentence id="DBMI.pac156.s0" origId="s0" text="7  DRUG INTERACTIONS\n\n7.1 Effects of Other Drugs on Aliskiren\n\nBased on in vitro studies, aliskiren is metabolized by CYP 3A4."/>
	<sentence id="DBMI.pac156.s1" origId="s1" text="Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.">
		<entity charOffset="160-171" id="DBMI.pac156.s1.e0" origId="s1.e0" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="179-189" id="DBMI.pac156.s1.e1" origId="s1.e1" text="aliskiren " type="Active ingredient"/>
		<pair e1="DBMI.pac156.s1.e0" e2="DBMI.pac156.s1.e1" id="DBMI.pac156.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="irbesartan "/>
		<pair e1="DBMI.pac156.s1.e1" e2="DBMI.pac156.s1.e0" id="DBMI.pac156.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s2" origId="s2" text="P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies."/>
	<sentence id="DBMI.pac156.s3" origId="s3" text="The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter."/>
	<sentence id="DBMI.pac156.s4" origId="s4" text="Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.">
		<entity charOffset="543-556" id="DBMI.pac156.s4.e0" origId="s4.e0" text="atorvastatin " type="Active ingredient"/>
		<entity charOffset="592-602" id="DBMI.pac156.s4.e1" origId="s4.e1" text="aliskiren " type="Active ingredient"/>
		<pair e1="DBMI.pac156.s4.e0" e2="DBMI.pac156.s4.e1" id="DBMI.pac156.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="atorvastatin "/>
		<pair e1="DBMI.pac156.s4.e1" e2="DBMI.pac156.s4.e0" id="DBMI.pac156.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s5" origId="s5" text="Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.">
		<entity charOffset="692-705" id="DBMI.pac156.s5.e0" origId="s5.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="710-720" id="DBMI.pac156.s5.e1" origId="s5.e1" text="aliskiren " type="Active ingredient"/>
		<pair e1="DBMI.pac156.s5.e0" e2="DBMI.pac156.s5.e1" id="DBMI.pac156.s5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac156.s5.e1" e2="DBMI.pac156.s5.e0" id="DBMI.pac156.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s6" origId="s6" text="A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further."/>
	<sentence id="DBMI.pac156.s7" origId="s7" text="Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.">
		<entity charOffset="940-953" id="DBMI.pac156.s7.e0" origId="s7.e0" text="itraconazole " type="Active ingredient"/>
		<entity charOffset="965-975" id="DBMI.pac156.s7.e1" origId="s7.e1" text="aliskiren " type="Active ingredient"/>
		<pair e1="DBMI.pac156.s7.e0" e2="DBMI.pac156.s7.e1" id="DBMI.pac156.s7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="itraconazole "/>
		<pair e1="DBMI.pac156.s7.e1" e2="DBMI.pac156.s7.e0" id="DBMI.pac156.s7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s8" origId="s8" text="Concomitant use of aliskiren with itraconazole is not recommended."/>
	<sentence id="DBMI.pac156.s9" origId="s9" text="Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.">
		<entity charOffset="1190-1203" id="DBMI.pac156.s9.e0" origId="s9.e0" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="1214-1224" id="DBMI.pac156.s9.e1" origId="s9.e1" text="aliskiren " type="Active ingredient"/>
		<pair e1="DBMI.pac156.s9.e0" e2="DBMI.pac156.s9.e1" id="DBMI.pac156.s9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="cyclosporine "/>
		<pair e1="DBMI.pac156.s9.e1" e2="DBMI.pac156.s9.e0" id="DBMI.pac156.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s10" origId="s10" text="Concomitant use of aliskiren with cyclosporine is not recommended."/>
	<sentence id="DBMI.pac156.s11" origId="s11" text="Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.">
		<entity charOffset="1430-1440" id="DBMI.pac156.s11.e0" origId="s11.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="1452-1462" id="DBMI.pac156.s11.e1" origId="s11.e1" text="aliskiren " type="Active ingredient"/>
		<pair e1="DBMI.pac156.s11.e0" e2="DBMI.pac156.s11.e1" id="DBMI.pac156.s11.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="verapamil "/>
		<pair e1="DBMI.pac156.s11.e1" e2="DBMI.pac156.s11.e0" id="DBMI.pac156.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s12" origId="s12" text="However, no dosage adjustment is necessary."/>
	<sentence id="DBMI.pac156.s13" origId="s13" text="Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.">
		<entity charOffset="1648-1659" id="DBMI.pac156.s13.e0" origId="s13.e0" text="lovastatin " type="Active ingredient"/>
		<entity charOffset="1833-1843" id="DBMI.pac156.s13.e1" origId="s13.e1" text="aliskiren " type="Active ingredient"/>
		<entity charOffset="1660-1669" id="DBMI.pac156.s13.e2" origId="s13.e2" text="atenolol " type="Active ingredient"/>
		<entity charOffset="1670-1679" id="DBMI.pac156.s13.e3" origId="s13.e3" text="warfarin " type="Active ingredient"/>
		<entity charOffset="1680-1691" id="DBMI.pac156.s13.e4" origId="s13.e4" text="furosemide " type="Active ingredient"/>
		<entity charOffset="1692-1700" id="DBMI.pac156.s13.e5" origId="s13.e5" text="digoxin " type="Active ingredient"/>
		<entity charOffset="1701-1711" id="DBMI.pac156.s13.e6" origId="s13.e6" text="celecoxib " type="Active ingredient"/>
		<entity charOffset="1712-1732" id="DBMI.pac156.s13.e7" origId="s13.e7" text="hydrochlorothiazide " type="Active ingredient"/>
		<entity charOffset="1733-1742" id="DBMI.pac156.s13.e8" origId="s13.e8" text="ramipril " type="Active ingredient"/>
		<entity charOffset="1743-1753" id="DBMI.pac156.s13.e9" origId="s13.e9" text="valsartan " type="Active ingredient"/>
		<entity charOffset="1754-1764" id="DBMI.pac156.s13.e10" origId="s13.e10" text="metformin " type="Active ingredient"/>
		<entity charOffset="1768-1779" id="DBMI.pac156.s13.e11" origId="s13.e11" text="amlodipine " type="Active ingredient"/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="lovastatin "/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p23" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="atenolol "/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p34" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="warfarin "/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p45" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="furosemide "/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p56" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="digoxin "/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p64" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p67" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="celecoxib "/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p74" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p78" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="hydrochlorothiazide "/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p79" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p80" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p81" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p82" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p83" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p84" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p85" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p86" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p87" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p88" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p89" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="ramipril "/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p90" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p91" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p92" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p93" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p94" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p95" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p96" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p97" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p98" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p99" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p100" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="valsartan "/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p101" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p102" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p103" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p104" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p105" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p106" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p107" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p108" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p109" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p110" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p111" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="metformin "/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p112" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p113" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p114" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p115" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p116" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p117" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p118" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p119" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p120" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p121" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p122" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="amlodipine "/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p123" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p124" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p125" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p126" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p127" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p128" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p129" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p130" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p131" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s14" origId="s14" text="7.2 Effects of Aliskiren on Other Drugs\n\nAliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4."/>
	<sentence id="DBMI.pac156.s15" origId="s15" text="Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.">
		<entity charOffset="2024-2034" id="DBMI.pac156.s15.e0" origId="s15.e0" text="aliskiren " type="Active ingredient"/>
		<entity charOffset="2058-2069" id="DBMI.pac156.s15.e1" origId="s15.e1" text="furosemide " type="Active ingredient"/>
		<pair e1="DBMI.pac156.s15.e0" e2="DBMI.pac156.s15.e1" id="DBMI.pac156.s15.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="furosemide " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.s15.e1" e2="DBMI.pac156.s15.e0" id="DBMI.pac156.s15.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s16" origId="s16" text="Patients receiving furosemide could find its effect diminished after starting aliskiren."/>
	<sentence id="DBMI.pac156.s17" origId="s17" text="Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.">
		<entity charOffset="2306-2316" id="DBMI.pac156.s17.e0" origId="s17.e0" text="aliskiren " type="Active ingredient"/>
		<entity charOffset="2459-2468" id="DBMI.pac156.s17.e1" origId="s17.e1" text="ramipril " type="Active ingredient"/>
		<entity charOffset="2471-2491" id="DBMI.pac156.s17.e2" origId="s17.e2" text="hydrochlorothiazide " type="Active ingredient"/>
		<entity charOffset="2369-2380" id="DBMI.pac156.s17.e3" origId="s17.e3" text="lovastatin " type="Active ingredient"/>
		<entity charOffset="2381-2389" id="DBMI.pac156.s17.e4" origId="s17.e4" text="digoxin " type="Active ingredient"/>
		<entity charOffset="2390-2400" id="DBMI.pac156.s17.e5" origId="s17.e5" text="valsartan " type="Active ingredient"/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ramipril " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="hydrochlorothiazide " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lovastatin " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valsartan " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s18" origId="s18" text="Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated."/>
	<sentencespan id="DBMI.pac156.sp0" origId="sp0" text="7  DRUG INTERACTIONS\n\n7.1 Effects of Other Drugs on Aliskiren\n\nBased on in vitro studies, aliskiren is metabolized by CYP 3A4. Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing. P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.">
		<entity charOffset="160-171" id="DBMI.pac156.sp0.e0" origId="sp0.e0" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="179-189" id="DBMI.pac156.sp0.e1" origId="sp0.e1" text="aliskiren " type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp0.e0" e2="DBMI.pac156.sp0.e1" id="DBMI.pac156.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="irbesartan "/>
		<pair e1="DBMI.pac156.sp0.e1" e2="DBMI.pac156.sp0.e0" id="DBMI.pac156.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp1" origId="sp1" text="The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter. Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing. Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.">
		<entity charOffset="543-556" id="DBMI.pac156.sp1.e0" origId="sp1.e0" text="atorvastatin " type="Active ingredient"/>
		<entity charOffset="592-602" id="DBMI.pac156.sp1.e1" origId="sp1.e1" text="aliskiren " type="Active ingredient"/>
		<entity charOffset="692-705" id="DBMI.pac156.sp1.e2" origId="sp1.e2" text="ketoconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp1.e0" e2="DBMI.pac156.sp1.e1" id="DBMI.pac156.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="atorvastatin "/>
		<pair e1="DBMI.pac156.sp1.e0" e2="DBMI.pac156.sp1.e2" id="DBMI.pac156.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp1.e1" e2="DBMI.pac156.sp1.e0" id="DBMI.pac156.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp1.e1" e2="DBMI.pac156.sp1.e2" id="DBMI.pac156.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp1.e2" e2="DBMI.pac156.sp1.e0" id="DBMI.pac156.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp1.e2" e2="DBMI.pac156.sp1.e1" id="DBMI.pac156.sp1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="ketoconazole "/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp2" origId="sp2" text="A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further. Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren. Concomitant use of aliskiren with itraconazole is not recommended.">
		<entity charOffset="940-953" id="DBMI.pac156.sp2.e0" origId="sp2.e0" text="itraconazole " type="Active ingredient"/>
		<entity charOffset="965-975" id="DBMI.pac156.sp2.e1" origId="sp2.e1" text="aliskiren " type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp2.e0" e2="DBMI.pac156.sp2.e1" id="DBMI.pac156.sp2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="itraconazole "/>
		<pair e1="DBMI.pac156.sp2.e1" e2="DBMI.pac156.sp2.e0" id="DBMI.pac156.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp3" origId="sp3" text="Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren. Concomitant use of aliskiren with cyclosporine is not recommended. Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.">
		<entity charOffset="1190-1203" id="DBMI.pac156.sp3.e0" origId="sp3.e0" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="1214-1224" id="DBMI.pac156.sp3.e1" origId="sp3.e1" text="aliskiren " type="Active ingredient"/>
		<entity charOffset="1430-1440" id="DBMI.pac156.sp3.e2" origId="sp3.e2" text="verapamil " type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp3.e0" e2="DBMI.pac156.sp3.e1" id="DBMI.pac156.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="cyclosporine "/>
		<pair e1="DBMI.pac156.sp3.e0" e2="DBMI.pac156.sp3.e2" id="DBMI.pac156.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp3.e1" e2="DBMI.pac156.sp3.e0" id="DBMI.pac156.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp3.e1" e2="DBMI.pac156.sp3.e2" id="DBMI.pac156.sp3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp3.e2" e2="DBMI.pac156.sp3.e0" id="DBMI.pac156.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp3.e2" e2="DBMI.pac156.sp3.e1" id="DBMI.pac156.sp3.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren " precipitant="verapamil "/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp4" origId="sp4" text="However, no dosage adjustment is necessary. Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. 7.2 Effects of Aliskiren on Other Drugs\n\nAliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.">
		<entity charOffset="1648-1659" id="DBMI.pac156.sp4.e0" origId="sp4.e0" text="lovastatin " type="Active ingredient"/>
		<entity charOffset="1833-1843" id="DBMI.pac156.sp4.e1" origId="sp4.e1" text="aliskiren " type="Active ingredient"/>
		<entity charOffset="1660-1669" id="DBMI.pac156.sp4.e2" origId="sp4.e2" text="atenolol " type="Active ingredient"/>
		<entity charOffset="1670-1679" id="DBMI.pac156.sp4.e3" origId="sp4.e3" text="warfarin " type="Active ingredient"/>
		<entity charOffset="1680-1691" id="DBMI.pac156.sp4.e4" origId="sp4.e4" text="furosemide " type="Active ingredient"/>
		<entity charOffset="1692-1700" id="DBMI.pac156.sp4.e5" origId="sp4.e5" text="digoxin " type="Active ingredient"/>
		<entity charOffset="1701-1711" id="DBMI.pac156.sp4.e6" origId="sp4.e6" text="celecoxib " type="Active ingredient"/>
		<entity charOffset="1712-1732" id="DBMI.pac156.sp4.e7" origId="sp4.e7" text="hydrochlorothiazide " type="Active ingredient"/>
		<entity charOffset="1733-1742" id="DBMI.pac156.sp4.e8" origId="sp4.e8" text="ramipril " type="Active ingredient"/>
		<entity charOffset="1743-1753" id="DBMI.pac156.sp4.e9" origId="sp4.e9" text="valsartan " type="Active ingredient"/>
		<entity charOffset="1754-1764" id="DBMI.pac156.sp4.e10" origId="sp4.e10" text="metformin " type="Active ingredient"/>
		<entity charOffset="1768-1779" id="DBMI.pac156.sp4.e11" origId="sp4.e11" text="amlodipine " type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="lovastatin "/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p23" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="atenolol "/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p34" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="warfarin "/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p45" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="furosemide "/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p56" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="digoxin "/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p64" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p67" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="celecoxib "/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p74" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p78" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="hydrochlorothiazide "/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p79" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p80" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p81" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p82" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p83" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p84" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p85" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p86" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p87" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p88" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p89" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="ramipril "/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p90" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p91" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p92" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p93" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p94" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p95" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p96" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p97" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p98" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p99" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p100" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="valsartan "/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p101" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p102" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p103" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p104" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p105" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p106" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p107" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p108" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p109" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p110" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p111" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="metformin "/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p112" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p113" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p114" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p115" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p116" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p117" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p118" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p119" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p120" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p121" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p122" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren " precipitant="amlodipine "/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p123" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p124" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p125" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p126" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p127" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p128" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p129" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p130" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p131" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp5" origId="sp5" text="Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively. Patients receiving furosemide could find its effect diminished after starting aliskiren. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.">
		<entity charOffset="2024-2034" id="DBMI.pac156.sp5.e0" origId="sp5.e0" text="aliskiren " type="Active ingredient"/>
		<entity charOffset="2058-2069" id="DBMI.pac156.sp5.e1" origId="sp5.e1" text="furosemide " type="Active ingredient"/>
		<entity charOffset="2459-2468" id="DBMI.pac156.sp5.e2" origId="sp5.e2" text="ramipril " type="Active ingredient"/>
		<entity charOffset="2471-2491" id="DBMI.pac156.sp5.e3" origId="sp5.e3" text="hydrochlorothiazide " type="Active ingredient"/>
		<entity charOffset="2369-2380" id="DBMI.pac156.sp5.e4" origId="sp5.e4" text="lovastatin " type="Active ingredient"/>
		<entity charOffset="2381-2389" id="DBMI.pac156.sp5.e5" origId="sp5.e5" text="digoxin " type="Active ingredient"/>
		<entity charOffset="2390-2400" id="DBMI.pac156.sp5.e6" origId="sp5.e6" text="valsartan " type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="furosemide " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ramipril " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="hydrochlorothiazide " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lovastatin " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valsartan " precipitant="aliskiren "/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp6" origId="sp6" text="Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated."/>
</document>

<document id="DBMI.pac158" origId="pac158">
	<sentence id="DBMI.pac158.s0" origId="s0" text="Since mexiletine is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations."/>
	<sentence id="DBMI.pac158.s1" origId="s1" text="In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.">
		<entity charOffset="348-360" id="DBMI.pac158.s1.e0" origId="s1.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="282-293" id="DBMI.pac158.s1.e1" origId="s1.e1" text="mexiletine " type="Active ingredient"/>
		<pair e1="DBMI.pac158.s1.e0" e2="DBMI.pac158.s1.e1" id="DBMI.pac158.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mexiletine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac158.s1.e1" e2="DBMI.pac158.s1.e0" id="DBMI.pac158.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac158.s2" origId="s2" text="In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.">
		<entity charOffset="486-498" id="DBMI.pac158.s2.e0" origId="s2.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="528-539" id="DBMI.pac158.s2.e1" origId="s2.e1" text="mexiletine " type="Active ingredient"/>
		<pair e1="DBMI.pac158.s2.e0" e2="DBMI.pac158.s2.e1" id="DBMI.pac158.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="mexiletine " precipitant="propafenone "/>
		<pair e1="DBMI.pac158.s2.e0" e2="DBMI.pac158.s2.e1" id="DBMI.pac158.s2.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mexiletine " precipitant="propafenone "/>
		<pair e1="DBMI.pac158.s2.e1" e2="DBMI.pac158.s2.e0" id="DBMI.pac158.s2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac158.s3" origId="s3" text="However, the metabolic clearance of mexiletine in the extensive metabolizer phenotype decreased by about 70% making the poor and extensive metabolizer groups indistinguishable."/>
	<sentence id="DBMI.pac158.s4" origId="s4" text="In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine.">
		<entity charOffset="891-902" id="DBMI.pac158.s4.e0" origId="s4.e0" text="mexiletine " type="Active ingredient"/>
		<entity charOffset="816-828" id="DBMI.pac158.s4.e1" origId="s4.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac158.s4.e0" e2="DBMI.pac158.s4.e1" id="DBMI.pac158.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone " precipitant="mexiletine "/>
		<pair e1="DBMI.pac158.s4.e1" e2="DBMI.pac158.s4.e0" id="DBMI.pac158.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac158.s5" origId="s5" text="Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone."/>
	<sentence id="DBMI.pac158.s6" origId="s6" text="When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect."/>
	<sentencespan id="DBMI.pac158.sp0" origId="sp0" text="Since mexiletine is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations. In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.">
		<entity charOffset="348-360" id="DBMI.pac158.sp0.e0" origId="sp0.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="282-293" id="DBMI.pac158.sp0.e1" origId="sp0.e1" text="mexiletine " type="Active ingredient"/>
		<entity charOffset="486-498" id="DBMI.pac158.sp0.e2" origId="sp0.e2" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac158.sp0.e0" e2="DBMI.pac158.sp0.e1" id="DBMI.pac158.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mexiletine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac158.sp0.e0" e2="DBMI.pac158.sp0.e2" id="DBMI.pac158.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac158.sp0.e1" e2="DBMI.pac158.sp0.e0" id="DBMI.pac158.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac158.sp0.e1" e2="DBMI.pac158.sp0.e2" id="DBMI.pac158.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac158.sp0.e2" e2="DBMI.pac158.sp0.e0" id="DBMI.pac158.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac158.sp0.e2" e2="DBMI.pac158.sp0.e1" id="DBMI.pac158.sp0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="mexiletine " precipitant="propafenone "/>
		<pair e1="DBMI.pac158.sp0.e2" e2="DBMI.pac158.sp0.e1" id="DBMI.pac158.sp0.p6" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mexiletine " precipitant="propafenone "/>
	</sentencespan>
	<sentencespan id="DBMI.pac158.sp1" origId="sp1" text="However, the metabolic clearance of mexiletine in the extensive metabolizer phenotype decreased by about 70% making the poor and extensive metabolizer groups indistinguishable. In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine. Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone.">
		<entity charOffset="891-902" id="DBMI.pac158.sp1.e0" origId="sp1.e0" text="mexiletine " type="Active ingredient"/>
		<entity charOffset="816-828" id="DBMI.pac158.sp1.e1" origId="sp1.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac158.sp1.e0" e2="DBMI.pac158.sp1.e1" id="DBMI.pac158.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone " precipitant="mexiletine "/>
		<pair e1="DBMI.pac158.sp1.e1" e2="DBMI.pac158.sp1.e0" id="DBMI.pac158.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac158.sp2" origId="sp2" text="When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect."/>
</document>

<document id="DBMI.pac159" origId="pac159">
	<sentence id="DBMI.pac159.s0" origId="s0" text="Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.">
		<entity charOffset="0-11" id="DBMI.pac159.s0.e0" origId="s0.e0" text="Mexiletine " type="Active ingredient"/>
		<entity charOffset="32-40" id="DBMI.pac159.s0.e1" origId="s0.e1" text="digoxin " type="Active ingredient"/>
		<entity charOffset="51-61" id="DBMI.pac159.s0.e2" origId="s0.e2" text="magnesium " type="Active ingredient"/>
		<entity charOffset="61-70" id="DBMI.pac159.s0.e3" origId="s0.e3" text="aluminum " type="Active ingredient"/>
		<pair e1="DBMI.pac159.s0.e0" e2="DBMI.pac159.s0.e1" id="DBMI.pac159.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="Mexiletine "/>
		<pair e1="DBMI.pac159.s0.e0" e2="DBMI.pac159.s0.e2" id="DBMI.pac159.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e0" e2="DBMI.pac159.s0.e3" id="DBMI.pac159.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e1" e2="DBMI.pac159.s0.e0" id="DBMI.pac159.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e1" e2="DBMI.pac159.s0.e2" id="DBMI.pac159.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e1" e2="DBMI.pac159.s0.e3" id="DBMI.pac159.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e2" e2="DBMI.pac159.s0.e0" id="DBMI.pac159.s0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e2" e2="DBMI.pac159.s0.e1" id="DBMI.pac159.s0.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="magnesium "/>
		<pair e1="DBMI.pac159.s0.e2" e2="DBMI.pac159.s0.e3" id="DBMI.pac159.s0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e3" e2="DBMI.pac159.s0.e0" id="DBMI.pac159.s0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e3" e2="DBMI.pac159.s0.e1" id="DBMI.pac159.s0.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="aluminum "/>
		<pair e1="DBMI.pac159.s0.e3" e2="DBMI.pac159.s0.e2" id="DBMI.pac159.s0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac159.sp0" origId="sp0" text="Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.">
		<entity charOffset="0-11" id="DBMI.pac159.sp0.e0" origId="sp0.e0" text="Mexiletine " type="Active ingredient"/>
		<entity charOffset="32-40" id="DBMI.pac159.sp0.e1" origId="sp0.e1" text="digoxin " type="Active ingredient"/>
		<entity charOffset="51-61" id="DBMI.pac159.sp0.e2" origId="sp0.e2" text="magnesium " type="Active ingredient"/>
		<entity charOffset="61-70" id="DBMI.pac159.sp0.e3" origId="sp0.e3" text="aluminum " type="Active ingredient"/>
		<pair e1="DBMI.pac159.sp0.e0" e2="DBMI.pac159.sp0.e1" id="DBMI.pac159.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="Mexiletine "/>
		<pair e1="DBMI.pac159.sp0.e0" e2="DBMI.pac159.sp0.e2" id="DBMI.pac159.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.sp0.e0" e2="DBMI.pac159.sp0.e3" id="DBMI.pac159.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.sp0.e1" e2="DBMI.pac159.sp0.e0" id="DBMI.pac159.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.sp0.e1" e2="DBMI.pac159.sp0.e2" id="DBMI.pac159.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.sp0.e1" e2="DBMI.pac159.sp0.e3" id="DBMI.pac159.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.sp0.e2" e2="DBMI.pac159.sp0.e0" id="DBMI.pac159.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.sp0.e2" e2="DBMI.pac159.sp0.e1" id="DBMI.pac159.sp0.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="magnesium "/>
		<pair e1="DBMI.pac159.sp0.e2" e2="DBMI.pac159.sp0.e3" id="DBMI.pac159.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.sp0.e3" e2="DBMI.pac159.sp0.e0" id="DBMI.pac159.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.sp0.e3" e2="DBMI.pac159.sp0.e1" id="DBMI.pac159.sp0.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="aluminum "/>
		<pair e1="DBMI.pac159.sp0.e3" e2="DBMI.pac159.sp0.e2" id="DBMI.pac159.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac16" origId="pac16">
	<sentence id="DBMI.pac16.s0" origId="s0" text="In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions."/>
	<sentence id="DBMI.pac16.s1" origId="s1" text="The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.">
		<entity charOffset="231-242" id="DBMI.pac16.s1.e0" origId="s1.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="315-325" id="DBMI.pac16.s1.e1" origId="s1.e1" text="cisapride " type="Active ingredient"/>
		<entity charOffset="284-296" id="DBMI.pac16.s1.e2" origId="s1.e2" text="terfenadine " type="Active ingredient"/>
		<entity charOffset="297-311" id="DBMI.pac16.s1.e3" origId="s1.e3" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac16.s1.e0" e2="DBMI.pac16.s1.e1" id="DBMI.pac16.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="cisapride " precipitant="sertraline "/>
		<pair e1="DBMI.pac16.s1.e0" e2="DBMI.pac16.s1.e2" id="DBMI.pac16.s1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="terfenadine " precipitant="sertraline "/>
		<pair e1="DBMI.pac16.s1.e0" e2="DBMI.pac16.s1.e3" id="DBMI.pac16.s1.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine " precipitant="sertraline "/>
		<pair e1="DBMI.pac16.s1.e1" e2="DBMI.pac16.s1.e0" id="DBMI.pac16.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e1" e2="DBMI.pac16.s1.e2" id="DBMI.pac16.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e1" e2="DBMI.pac16.s1.e3" id="DBMI.pac16.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e2" e2="DBMI.pac16.s1.e0" id="DBMI.pac16.s1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e2" e2="DBMI.pac16.s1.e1" id="DBMI.pac16.s1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e2" e2="DBMI.pac16.s1.e3" id="DBMI.pac16.s1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e3" e2="DBMI.pac16.s1.e0" id="DBMI.pac16.s1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e3" e2="DBMI.pac16.s1.e1" id="DBMI.pac16.s1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e3" e2="DBMI.pac16.s1.e2" id="DBMI.pac16.s1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac16.s2" origId="s2" text="These data indicate that sertralines extent of inhibition of P450 3A4 activity is not likely to be of clinical significance."/>
	<sentence id="DBMI.pac16.s3" origId="s3" text="Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.)induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).">
		<entity charOffset="514-525" id="DBMI.pac16.s3.e0" origId="s3.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="490-500" id="DBMI.pac16.s3.e1" origId="s3.e1" text="cisapride " type="Active ingredient"/>
		<pair e1="DBMI.pac16.s3.e0" e2="DBMI.pac16.s3.e1" id="DBMI.pac16.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="cisapride " precipitant="sertraline "/>
		<pair e1="DBMI.pac16.s3.e1" e2="DBMI.pac16.s3.e0" id="DBMI.pac16.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac16.sp0" origId="sp0" text="In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertralines extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.">
		<entity charOffset="231-242" id="DBMI.pac16.sp0.e0" origId="sp0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="315-325" id="DBMI.pac16.sp0.e1" origId="sp0.e1" text="cisapride " type="Active ingredient"/>
		<entity charOffset="284-296" id="DBMI.pac16.sp0.e2" origId="sp0.e2" text="terfenadine " type="Active ingredient"/>
		<entity charOffset="297-311" id="DBMI.pac16.sp0.e3" origId="sp0.e3" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac16.sp0.e0" e2="DBMI.pac16.sp0.e1" id="DBMI.pac16.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="cisapride " precipitant="sertraline "/>
		<pair e1="DBMI.pac16.sp0.e0" e2="DBMI.pac16.sp0.e2" id="DBMI.pac16.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="terfenadine " precipitant="sertraline "/>
		<pair e1="DBMI.pac16.sp0.e0" e2="DBMI.pac16.sp0.e3" id="DBMI.pac16.sp0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine " precipitant="sertraline "/>
		<pair e1="DBMI.pac16.sp0.e1" e2="DBMI.pac16.sp0.e0" id="DBMI.pac16.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e1" e2="DBMI.pac16.sp0.e2" id="DBMI.pac16.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e1" e2="DBMI.pac16.sp0.e3" id="DBMI.pac16.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e2" e2="DBMI.pac16.sp0.e0" id="DBMI.pac16.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e2" e2="DBMI.pac16.sp0.e1" id="DBMI.pac16.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e2" e2="DBMI.pac16.sp0.e3" id="DBMI.pac16.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e3" e2="DBMI.pac16.sp0.e0" id="DBMI.pac16.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e3" e2="DBMI.pac16.sp0.e1" id="DBMI.pac16.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e3" e2="DBMI.pac16.sp0.e2" id="DBMI.pac16.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac16.sp1" origId="sp1" text="Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.)induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).">
		<entity charOffset="514-525" id="DBMI.pac16.sp1.e0" origId="sp1.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="490-500" id="DBMI.pac16.sp1.e1" origId="sp1.e1" text="cisapride " type="Active ingredient"/>
		<pair e1="DBMI.pac16.sp1.e0" e2="DBMI.pac16.sp1.e1" id="DBMI.pac16.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="cisapride " precipitant="sertraline "/>
		<pair e1="DBMI.pac16.sp1.e1" e2="DBMI.pac16.sp1.e0" id="DBMI.pac16.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac161" origId="pac161">
	<sentence id="DBMI.pac161.s0" origId="s0" text="Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations.">
		<entity charOffset="20-31" id="DBMI.pac161.s0.e0" origId="s0.e0" text="nelfinavir " type="Active ingredient"/>
		<entity charOffset="74-87" id="DBMI.pac161.s0.e1" origId="s0.e1" text="azithromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac161.s0.e0" e2="DBMI.pac161.s0.e1" id="DBMI.pac161.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="azithromycin " precipitant="nelfinavir "/>
		<pair e1="DBMI.pac161.s0.e1" e2="DBMI.pac161.s0.e0" id="DBMI.pac161.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac161.s1" origId="s1" text="Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted (see ADVERSE REACTIONS)."/>
	<sentencespan id="DBMI.pac161.sp0" origId="sp0" text="Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted (see ADVERSE REACTIONS).">
		<entity charOffset="20-31" id="DBMI.pac161.sp0.e0" origId="sp0.e0" text="nelfinavir " type="Active ingredient"/>
		<entity charOffset="74-87" id="DBMI.pac161.sp0.e1" origId="sp0.e1" text="azithromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac161.sp0.e0" e2="DBMI.pac161.sp0.e1" id="DBMI.pac161.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="azithromycin " precipitant="nelfinavir "/>
		<pair e1="DBMI.pac161.sp0.e1" e2="DBMI.pac161.sp0.e0" id="DBMI.pac161.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac163" origId="pac163">
	<sentence id="DBMI.pac163.s0" origId="s0" text="Acyclovir\n\nPlasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.">
		<entity charOffset="102-112" id="DBMI.pac163.s0.e0" origId="s0.e0" text="acyclovir " type="Active ingredient"/>
		<entity charOffset="36-47" id="DBMI.pac163.s0.e1" origId="s0.e1" text="meperidine " type="Active ingredient"/>
		<entity charOffset="67-81" id="DBMI.pac163.s0.e2" origId="s0.e2" text="normeperidine " type="Metabolite"/>
		<pair e1="DBMI.pac163.s0.e0" e2="DBMI.pac163.s0.e1" id="DBMI.pac163.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="meperidine " precipitant="acyclovir "/>
		<pair e1="DBMI.pac163.s0.e0" e2="DBMI.pac163.s0.e2" id="DBMI.pac163.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="normeperidine " precipitant="acyclovir "/>
		<pair e1="DBMI.pac163.s0.e1" e2="DBMI.pac163.s0.e0" id="DBMI.pac163.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac163.s0.e1" e2="DBMI.pac163.s0.e2" id="DBMI.pac163.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac163.s0.e2" e2="DBMI.pac163.s0.e0" id="DBMI.pac163.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac163.s0.e2" e2="DBMI.pac163.s0.e1" id="DBMI.pac163.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac163.sp0" origId="sp0" text="Acyclovir\n\nPlasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.">
		<entity charOffset="102-112" id="DBMI.pac163.sp0.e0" origId="sp0.e0" text="acyclovir " type="Active ingredient"/>
		<entity charOffset="36-47" id="DBMI.pac163.sp0.e1" origId="sp0.e1" text="meperidine " type="Active ingredient"/>
		<entity charOffset="67-81" id="DBMI.pac163.sp0.e2" origId="sp0.e2" text="normeperidine " type="Metabolite"/>
		<pair e1="DBMI.pac163.sp0.e0" e2="DBMI.pac163.sp0.e1" id="DBMI.pac163.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="meperidine " precipitant="acyclovir "/>
		<pair e1="DBMI.pac163.sp0.e0" e2="DBMI.pac163.sp0.e2" id="DBMI.pac163.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="normeperidine " precipitant="acyclovir "/>
		<pair e1="DBMI.pac163.sp0.e1" e2="DBMI.pac163.sp0.e0" id="DBMI.pac163.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac163.sp0.e1" e2="DBMI.pac163.sp0.e2" id="DBMI.pac163.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac163.sp0.e2" e2="DBMI.pac163.sp0.e0" id="DBMI.pac163.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac163.sp0.e2" e2="DBMI.pac163.sp0.e1" id="DBMI.pac163.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac164" origId="pac164">
	<sentence id="DBMI.pac164.s0" origId="s0" text="Cimetidine\n\nCimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.">
		<entity charOffset="12-23" id="DBMI.pac164.s0.e0" origId="s0.e0" text="Cimetidine " type="Active ingredient"/>
		<entity charOffset="75-86" id="DBMI.pac164.s0.e1" origId="s0.e1" text="meperidine " type="Active ingredient"/>
		<entity charOffset="128-142" id="DBMI.pac164.s0.e2" origId="s0.e2" text="normeperidine " type="Metabolite"/>
		<pair e1="DBMI.pac164.s0.e0" e2="DBMI.pac164.s0.e1" id="DBMI.pac164.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="meperidine " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac164.s0.e0" e2="DBMI.pac164.s0.e2" id="DBMI.pac164.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="normeperidine " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac164.s0.e1" e2="DBMI.pac164.s0.e0" id="DBMI.pac164.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac164.s0.e1" e2="DBMI.pac164.s0.e2" id="DBMI.pac164.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac164.s0.e2" e2="DBMI.pac164.s0.e0" id="DBMI.pac164.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac164.s0.e2" e2="DBMI.pac164.s0.e1" id="DBMI.pac164.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac164.sp0" origId="sp0" text="Cimetidine\n\nCimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.">
		<entity charOffset="12-23" id="DBMI.pac164.sp0.e0" origId="sp0.e0" text="Cimetidine " type="Active ingredient"/>
		<entity charOffset="75-86" id="DBMI.pac164.sp0.e1" origId="sp0.e1" text="meperidine " type="Active ingredient"/>
		<entity charOffset="128-142" id="DBMI.pac164.sp0.e2" origId="sp0.e2" text="normeperidine " type="Metabolite"/>
		<pair e1="DBMI.pac164.sp0.e0" e2="DBMI.pac164.sp0.e1" id="DBMI.pac164.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="meperidine " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac164.sp0.e0" e2="DBMI.pac164.sp0.e2" id="DBMI.pac164.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="normeperidine " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac164.sp0.e1" e2="DBMI.pac164.sp0.e0" id="DBMI.pac164.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac164.sp0.e1" e2="DBMI.pac164.sp0.e2" id="DBMI.pac164.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac164.sp0.e2" e2="DBMI.pac164.sp0.e0" id="DBMI.pac164.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac164.sp0.e2" e2="DBMI.pac164.sp0.e1" id="DBMI.pac164.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac166" origId="pac166">
	<sentence id="DBMI.pac166.s0" origId="s0" text="Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate.">
		<entity charOffset="0-11" id="DBMI.pac166.s0.e0" origId="s0.e0" text="Penicillin " type="Active ingredient"/>
		<entity charOffset="46-59" id="DBMI.pac166.s0.e1" origId="s0.e1" text="methotrexate " type="Active ingredient"/>
		<pair e1="DBMI.pac166.s0.e0" e2="DBMI.pac166.s0.e1" id="DBMI.pac166.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="methotrexate " precipitant="Penicillin "/>
		<pair e1="DBMI.pac166.s0.e1" e2="DBMI.pac166.s0.e0" id="DBMI.pac166.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac166.s1" origId="s1" text="Use of methotrexate with penicillins should be carefully monitored."/>
	<sentencespan id="DBMI.pac166.sp0" origId="sp0" text="Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate. Use of methotrexate with penicillins should be carefully monitored.">
		<entity charOffset="0-11" id="DBMI.pac166.sp0.e0" origId="sp0.e0" text="Penicillin " type="Active ingredient"/>
		<entity charOffset="46-59" id="DBMI.pac166.sp0.e1" origId="sp0.e1" text="methotrexate " type="Active ingredient"/>
		<pair e1="DBMI.pac166.sp0.e0" e2="DBMI.pac166.sp0.e1" id="DBMI.pac166.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="methotrexate " precipitant="Penicillin "/>
		<pair e1="DBMI.pac166.sp0.e1" e2="DBMI.pac166.sp0.e0" id="DBMI.pac166.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac168" origId="pac168">
	<sentence id="DBMI.pac168.s0" origId="s0" text="Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.">
		<entity charOffset="61-72" id="DBMI.pac168.s0.e0" origId="s0.e0" text="Clonazepam " type="Active ingredient"/>
		<entity charOffset="132-146" id="DBMI.pac168.s0.e1" origId="s0.e1" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="121-131" id="DBMI.pac168.s0.e2" origId="s0.e2" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="149-163" id="DBMI.pac168.s0.e3" origId="s0.e3" text="phenobarbital " type="Active ingredient"/>
		<pair e1="DBMI.pac168.s0.e0" e2="DBMI.pac168.s0.e1" id="DBMI.pac168.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine " precipitant="Clonazepam "/>
		<pair e1="DBMI.pac168.s0.e0" e2="DBMI.pac168.s0.e1" id="DBMI.pac168.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine " precipitant="Clonazepam "/>
		<pair e1="DBMI.pac168.s0.e0" e2="DBMI.pac168.s0.e2" id="DBMI.pac168.s0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="Clonazepam "/>
		<pair e1="DBMI.pac168.s0.e0" e2="DBMI.pac168.s0.e3" id="DBMI.pac168.s0.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenobarbital " precipitant="Clonazepam "/>
		<pair e1="DBMI.pac168.s0.e1" e2="DBMI.pac168.s0.e0" id="DBMI.pac168.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e1" e2="DBMI.pac168.s0.e2" id="DBMI.pac168.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e1" e2="DBMI.pac168.s0.e3" id="DBMI.pac168.s0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e2" e2="DBMI.pac168.s0.e0" id="DBMI.pac168.s0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e2" e2="DBMI.pac168.s0.e1" id="DBMI.pac168.s0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e2" e2="DBMI.pac168.s0.e3" id="DBMI.pac168.s0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e3" e2="DBMI.pac168.s0.e0" id="DBMI.pac168.s0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e3" e2="DBMI.pac168.s0.e1" id="DBMI.pac168.s0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e3" e2="DBMI.pac168.s0.e2" id="DBMI.pac168.s0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac168.s1" origId="s1" text="The effect of clonazepam on the metabolism of other drugs has not been investigated."/>
	<sentencespan id="DBMI.pac168.sp0" origId="sp0" text="Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. The effect of clonazepam on the metabolism of other drugs has not been investigated.">
		<entity charOffset="61-72" id="DBMI.pac168.sp0.e0" origId="sp0.e0" text="Clonazepam " type="Active ingredient"/>
		<entity charOffset="132-146" id="DBMI.pac168.sp0.e1" origId="sp0.e1" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="121-131" id="DBMI.pac168.sp0.e2" origId="sp0.e2" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="149-163" id="DBMI.pac168.sp0.e3" origId="sp0.e3" text="phenobarbital " type="Active ingredient"/>
		<pair e1="DBMI.pac168.sp0.e0" e2="DBMI.pac168.sp0.e1" id="DBMI.pac168.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine " precipitant="Clonazepam "/>
		<pair e1="DBMI.pac168.sp0.e0" e2="DBMI.pac168.sp0.e1" id="DBMI.pac168.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine " precipitant="Clonazepam "/>
		<pair e1="DBMI.pac168.sp0.e0" e2="DBMI.pac168.sp0.e2" id="DBMI.pac168.sp0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="Clonazepam "/>
		<pair e1="DBMI.pac168.sp0.e0" e2="DBMI.pac168.sp0.e3" id="DBMI.pac168.sp0.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenobarbital " precipitant="Clonazepam "/>
		<pair e1="DBMI.pac168.sp0.e1" e2="DBMI.pac168.sp0.e0" id="DBMI.pac168.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e1" e2="DBMI.pac168.sp0.e2" id="DBMI.pac168.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e1" e2="DBMI.pac168.sp0.e3" id="DBMI.pac168.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e2" e2="DBMI.pac168.sp0.e0" id="DBMI.pac168.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e2" e2="DBMI.pac168.sp0.e1" id="DBMI.pac168.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e2" e2="DBMI.pac168.sp0.e3" id="DBMI.pac168.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e3" e2="DBMI.pac168.sp0.e0" id="DBMI.pac168.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e3" e2="DBMI.pac168.sp0.e1" id="DBMI.pac168.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e3" e2="DBMI.pac168.sp0.e2" id="DBMI.pac168.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac17" origId="pac17">
	<sentence id="DBMI.pac17.s0" origId="s0" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose.">
		<entity charOffset="70-81" id="DBMI.pac17.s0.e0" origId="s0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="220-232" id="DBMI.pac17.s0.e1" origId="s0.e1" text="tolbutamide " type="Active ingredient"/>
		<pair e1="DBMI.pac17.s0.e0" e2="DBMI.pac17.s0.e1" id="DBMI.pac17.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tolbutamide " precipitant="sertraline "/>
		<pair e1="DBMI.pac17.s0.e1" e2="DBMI.pac17.s0.e0" id="DBMI.pac17.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac17.s1" origId="s1" text="Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug."/>
	<sentence id="DBMI.pac17.s2" origId="s2" text="The clinical significance of this decrease in tolbutamide clearance is unknown."/>
	<sentencespan id="DBMI.pac17.sp0" origId="sp0" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.">
		<entity charOffset="70-81" id="DBMI.pac17.sp0.e0" origId="sp0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="220-232" id="DBMI.pac17.sp0.e1" origId="sp0.e1" text="tolbutamide " type="Active ingredient"/>
		<pair e1="DBMI.pac17.sp0.e0" e2="DBMI.pac17.sp0.e1" id="DBMI.pac17.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tolbutamide " precipitant="sertraline "/>
		<pair e1="DBMI.pac17.sp0.e1" e2="DBMI.pac17.sp0.e0" id="DBMI.pac17.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac170" origId="pac170">
	<sentence id="DBMI.pac170.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nIrbesartan\n\nNo significant drug-drug interactions have been reported with irbesartan."/>
	<sentence id="DBMI.pac170.s1" origId="s1" text="[See Clinical Pharmacology (12.3).]"/>
	<sentence id="DBMI.pac170.s2" origId="s2" text="Hydrochlorothiazide\n\nWhen administered concurrently the following drugs may interact with thiazide diuretics:\n\nAlcohol, Barbiturates, or Narcotics: potentiation of orthostatic hypotension may occur."/>
	<sentence id="DBMI.pac170.s3" origId="s3" text="Antidiabetic Drugs (oral agents and insulin): dosage adjustment of the antidiabetic drug may be required."/>
	<sentence id="DBMI.pac170.s4" origId="s4" text="Other Antihypertensive Drugs: additive effect or potentiation."/>
	<sentence id="DBMI.pac170.s5" origId="s5" text="Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins."/>
	<sentence id="DBMI.pac170.s6" origId="s6" text="Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.">
		<entity charOffset="666-681" id="DBMI.pac170.s6.e0" origId="s6.e0" text="cholestyramine " type="Active ingredient"/>
		<entity charOffset="711-731" id="DBMI.pac170.s6.e1" origId="s6.e1" text="hydrochlorothiazide " type="Active ingredient"/>
		<entity charOffset="684-695" id="DBMI.pac170.s6.e2" origId="s6.e2" text="colestipol " type="Active ingredient"/>
		<pair e1="DBMI.pac170.s6.e0" e2="DBMI.pac170.s6.e1" id="DBMI.pac170.s6.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="hydrochlorothiazide " precipitant="cholestyramine "/>
		<pair e1="DBMI.pac170.s6.e0" e2="DBMI.pac170.s6.e2" id="DBMI.pac170.s6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.s6.e1" e2="DBMI.pac170.s6.e0" id="DBMI.pac170.s6.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.s6.e1" e2="DBMI.pac170.s6.e2" id="DBMI.pac170.s6.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.s6.e2" e2="DBMI.pac170.s6.e0" id="DBMI.pac170.s6.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.s6.e2" e2="DBMI.pac170.s6.e1" id="DBMI.pac170.s6.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="hydrochlorothiazide " precipitant="colestipol "/>
	</sentence>
	<sentence id="DBMI.pac170.s7" origId="s7" text="Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia."/>
	<sentence id="DBMI.pac170.s8" origId="s8" text="Pressor Amines (e.g., Norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use."/>
	<sentence id="DBMI.pac170.s9" origId="s9" text="Skeletal Muscle Relaxants, Nondepolarizing (e.g., Tubocurarine): possible increased responsiveness to the muscle relaxant."/>
	<sentence id="DBMI.pac170.s10" origId="s10" text="Lithium: should not generally be given with diuretics."/>
	<sentence id="DBMI.pac170.s11" origId="s11" text="Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity."/>
	<sentence id="DBMI.pac170.s12" origId="s12" text="Refer to the package insert for lithium preparations before use of such preparations with AVALIDE.">
		<entity charOffset="1403-1411" id="DBMI.pac170.s12.e0" origId="s12.e0" text="AVALIDE " type="Drug product"/>
		<entity charOffset="1264-1272" id="DBMI.pac170.s12.e1" origId="s12.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac170.s12.e0" e2="DBMI.pac170.s12.e1" id="DBMI.pac170.s12.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium " precipitant="AVALIDE "/>
		<pair e1="DBMI.pac170.s12.e1" e2="DBMI.pac170.s12.e0" id="DBMI.pac170.s12.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac170.s13" origId="s13" text="[See Warnings and Precautions (5.5).]"/>
	<sentence id="DBMI.pac170.s14" origId="s14" text="Non-steroidal Anti-inflammatory Drugs: in some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics."/>
	<sentence id="DBMI.pac170.s15" origId="s15" text="Therefore, when AVALIDE (irbesartan-hydrochlorothiazide) Tablets and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."/>
	<sentencespan id="DBMI.pac170.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nIrbesartan\n\nNo significant drug-drug interactions have been reported with irbesartan. [See Clinical Pharmacology (12.3).] Hydrochlorothiazide\n\nWhen administered concurrently the following drugs may interact with thiazide diuretics:\n\nAlcohol, Barbiturates, or Narcotics: potentiation of orthostatic hypotension may occur."/>
	<sentencespan id="DBMI.pac170.sp1" origId="sp1" text="Antidiabetic Drugs (oral agents and insulin): dosage adjustment of the antidiabetic drug may be required. Other Antihypertensive Drugs: additive effect or potentiation. Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins."/>
	<sentencespan id="DBMI.pac170.sp2" origId="sp2" text="Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia. Pressor Amines (e.g., Norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.">
		<entity charOffset="666-681" id="DBMI.pac170.sp2.e0" origId="sp2.e0" text="cholestyramine " type="Active ingredient"/>
		<entity charOffset="711-731" id="DBMI.pac170.sp2.e1" origId="sp2.e1" text="hydrochlorothiazide " type="Active ingredient"/>
		<entity charOffset="684-695" id="DBMI.pac170.sp2.e2" origId="sp2.e2" text="colestipol " type="Active ingredient"/>
		<pair e1="DBMI.pac170.sp2.e0" e2="DBMI.pac170.sp2.e1" id="DBMI.pac170.sp2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="hydrochlorothiazide " precipitant="cholestyramine "/>
		<pair e1="DBMI.pac170.sp2.e0" e2="DBMI.pac170.sp2.e2" id="DBMI.pac170.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.sp2.e1" e2="DBMI.pac170.sp2.e0" id="DBMI.pac170.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.sp2.e1" e2="DBMI.pac170.sp2.e2" id="DBMI.pac170.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.sp2.e2" e2="DBMI.pac170.sp2.e0" id="DBMI.pac170.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.sp2.e2" e2="DBMI.pac170.sp2.e1" id="DBMI.pac170.sp2.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="hydrochlorothiazide " precipitant="colestipol "/>
	</sentencespan>
	<sentencespan id="DBMI.pac170.sp3" origId="sp3" text="Skeletal Muscle Relaxants, Nondepolarizing (e.g., Tubocurarine): possible increased responsiveness to the muscle relaxant. Lithium: should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity."/>
	<sentencespan id="DBMI.pac170.sp4" origId="sp4" text="Refer to the package insert for lithium preparations before use of such preparations with AVALIDE. [See Warnings and Precautions (5.5).] Non-steroidal Anti-inflammatory Drugs: in some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.">
		<entity charOffset="1403-1411" id="DBMI.pac170.sp4.e0" origId="sp4.e0" text="AVALIDE " type="Drug product"/>
		<entity charOffset="1264-1272" id="DBMI.pac170.sp4.e1" origId="sp4.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac170.sp4.e0" e2="DBMI.pac170.sp4.e1" id="DBMI.pac170.sp4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium " precipitant="AVALIDE "/>
		<pair e1="DBMI.pac170.sp4.e1" e2="DBMI.pac170.sp4.e0" id="DBMI.pac170.sp4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac170.sp5" origId="sp5" text="Therefore, when AVALIDE (irbesartan-hydrochlorothiazide) Tablets and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."/>
</document>

<document id="DBMI.pac171" origId="pac171">
	<sentence id="DBMI.pac171.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nIrbesartan\n\nAngiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II)."/>
	<sentence id="DBMI.pac171.s1" origId="s1" text="Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth."/>
	<sentence id="DBMI.pac171.s2" origId="s2" text="Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor."/>
	<sentence id="DBMI.pac171.s3" origId="s3" text="There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis."/>
	<sentence id="DBMI.pac171.s4" origId="s4" text="Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity."/>
	<sentence id="DBMI.pac171.s5" origId="s5" text="Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure."/>
	<sentence id="DBMI.pac171.s6" origId="s6" text="Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis."/>
	<sentence id="DBMI.pac171.s7" origId="s7" text="Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known."/>
	<sentence id="DBMI.pac171.s8" origId="s8" text="Hydrochlorothiazide\n\nHydrochlorothiazide is a thiazide diuretic."/>
	<sentence id="DBMI.pac171.s9" origId="s9" text="Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts."/>
	<sentence id="DBMI.pac171.s10" origId="s10" text="Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium."/>
	<sentence id="DBMI.pac171.s11" origId="s11" text="The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics."/>
	<sentence id="DBMI.pac171.s12" origId="s12" text="The mechanism of the antihypertensive effect of thiazides is not fully understood."/>
	<sentence id="DBMI.pac171.s13" origId="s13" text="12.2 Pharmacodynamics\n\nIrbesartan\n\nIn healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions."/>
	<sentence id="DBMI.pac171.s14" origId="s14" text="Inhibition was complete (100%) 4 hours following oral doses of 150 mg or 300 mg and partial inhibition was sustained for 24 hours (60% and 40% at 300 mg and 150 mg, respectively)."/>
	<sentence id="DBMI.pac171.s15" origId="s15" text="In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels."/>
	<sentence id="DBMI.pac171.s16" origId="s16" text="Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses."/>
	<sentence id="DBMI.pac171.s17" origId="s17" text="In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction."/>
	<sentence id="DBMI.pac171.s18" origId="s18" text="In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations."/>
	<sentence id="DBMI.pac171.s19" origId="s19" text="There was no effect on serum uric acid during chronic oral administration and no uricosuric effect."/>
	<sentence id="DBMI.pac171.s20" origId="s20" text="Hydrochlorothiazide\n\nAfter oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours."/>
	<sentence id="DBMI.pac171.s21" origId="s21" text="12.3 Pharmacokinetics\n\nIrbesartan\n\nIrbesartan is an orally active agent that does not require biotransformation into an active form."/>
	<sentence id="DBMI.pac171.s22" origId="s22" text="The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%."/>
	<sentence id="DBMI.pac171.s23" origId="s23" text="Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing."/>
	<sentence id="DBMI.pac171.s24" origId="s24" text="Food does not affect the bioavailability of irbesartan."/>
	<sentence id="DBMI.pac171.s25" origId="s25" text="Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range."/>
	<sentence id="DBMI.pac171.s26" origId="s26" text="The terminal elimination half-life of irbesartan averaged 11 to 15 hours."/>
	<sentence id="DBMI.pac171.s27" origId="s27" text="Steady-state concentrations are achieved within 3 days."/>
	<sentence id="DBMI.pac171.s28" origId="s28" text="Limited accumulation of irbesartan (&lt;20%) is observed in plasma upon repeated once-daily dosing."/>
	<sentence id="DBMI.pac171.s29" origId="s29" text="Hydrochlorothiazide\n\nWhen plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours."/>
	<sentence id="DBMI.pac171.s30" origId="s30" text="Metabolism and Elimination\n\nIrbesartan\n\nIrbesartan is metabolized via glucuronide conjugation and oxidation."/>
	<sentence id="DBMI.pac171.s31" origId="s31" text="Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan."/>
	<sentence id="DBMI.pac171.s32" origId="s32" text="The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%)."/>
	<sentence id="DBMI.pac171.s33" origId="s33" text="The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity."/>
	<sentence id="DBMI.pac171.s34" origId="s34" text="Irbesartan and its metabolites are excreted by both biliary and renal routes."/>
	<sentence id="DBMI.pac171.s35" origId="s35" text="Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide."/>
	<sentence id="DBMI.pac171.s36" origId="s36" text="In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible."/>
	<sentence id="DBMI.pac171.s37" origId="s37" text="Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1)."/>
	<sentence id="DBMI.pac171.s38" origId="s38" text="There was no induction or inhibition of 3A4."/>
	<sentence id="DBMI.pac171.s39" origId="s39" text="Hydrochlorothiazide\n\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney."/>
	<sentence id="DBMI.pac171.s40" origId="s40" text="At least 61% of the oral dose is eliminated unchanged within 24 hours."/>
	<sentence id="DBMI.pac171.s41" origId="s41" text="Distribution\n\nIrbesartan\n\nIrbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood."/>
	<sentence id="DBMI.pac171.s42" origId="s42" text="The average volume of distribution is 53 to 93 liters."/>
	<sentence id="DBMI.pac171.s43" origId="s43" text="Total plasma and renal clearances are in the range of 157 to 176 mL/min and 3.0 to 3.5 mL/min, respectively."/>
	<sentence id="DBMI.pac171.s44" origId="s44" text="With repetitive dosing, irbesartan accumulates to no clinically relevant extent."/>
	<sentence id="DBMI.pac171.s45" origId="s45" text="Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta."/>
	<sentence id="DBMI.pac171.s46" origId="s46" text="Irbesartan is excreted in the milk of lactating rats."/>
	<sentence id="DBMI.pac171.s47" origId="s47" text="Hydrochlorothiazide\n\nHydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk."/>
	<sentence id="DBMI.pac171.s48" origId="s48" text="Pediatric\n\nIrbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients &lt;18 years of age."/>
	<sentence id="DBMI.pac171.s49" origId="s49" text="Gender\n\nNo gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects."/>
	<sentence id="DBMI.pac171.s50" origId="s50" text="In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%)."/>
	<sentence id="DBMI.pac171.s51" origId="s51" text="No gender-related dosage adjustment is necessary."/>
	<sentence id="DBMI.pac171.s52" origId="s52" text="Geriatric\n\nIn elderly subjects (age 65 to 80 years), irbesartan elimination half-life was not significantly altered, but AUC and Cmax values were about 20% to 50% greater than those of young subjects (age 18 to 40 years)."/>
	<sentence id="DBMI.pac171.s53" origId="s53" text="No dosage adjustment is necessary in the elderly."/>
	<sentence id="DBMI.pac171.s54" origId="s54" text="Race\n\nIn healthy black subjects, irbesartan AUC values were approximately 25% greater than whites; there were no differences in Cmax values."/>
	<sentence id="DBMI.pac171.s55" origId="s55" text="Renal Insufficiency\n\nThe pharmacokinetics of irbesartan were not altered in patients with renal impairment or in patients on hemodialysis."/>
	<sentence id="DBMI.pac171.s56" origId="s56" text="Irbesartan is not removed by hemodialysis."/>
	<sentence id="DBMI.pac171.s57" origId="s57" text="No dosage adjustment is necessary in patients with mild to severe renal impairment unless a patient with renal impairment is also volume depleted."/>
	<sentence id="DBMI.pac171.s58" origId="s58" text="[See Warnings and Precautions (5.2).]"/>
	<sentence id="DBMI.pac171.s59" origId="s59" text="Hepatic Insufficiency\n\nThe pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver."/>
	<sentence id="DBMI.pac171.s60" origId="s60" text="No dosage adjustment is necessary in patients with hepatic insufficiency."/>
	<sentence id="DBMI.pac171.s61" origId="s61" text="Drug-Drug Interactions\n\nNo significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine."/>
	<sentence id="DBMI.pac171.s62" origId="s62" text="In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine."/>
	<sentence id="DBMI.pac171.s63" origId="s63" text="However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible."/>
	<sentence id="DBMI.pac171.s64" origId="s64" text="Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.">
		<entity charOffset="8604-8615" id="DBMI.pac171.s64.e0" origId="s64.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="8655-8666" id="DBMI.pac171.s64.e1" origId="s64.e1" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="8618-8638" id="DBMI.pac171.s64.e2" origId="s64.e2" text="hydrochlorothiazide " type="Active ingredient"/>
		<pair e1="DBMI.pac171.s64.e0" e2="DBMI.pac171.s64.e1" id="DBMI.pac171.s64.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac171.s64.e0" e2="DBMI.pac171.s64.e2" id="DBMI.pac171.s64.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s64.e1" e2="DBMI.pac171.s64.e0" id="DBMI.pac171.s64.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s64.e1" e2="DBMI.pac171.s64.e2" id="DBMI.pac171.s64.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s64.e2" e2="DBMI.pac171.s64.e0" id="DBMI.pac171.s64.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s64.e2" e2="DBMI.pac171.s64.e1" id="DBMI.pac171.s64.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="hydrochlorothiazide "/>
	</sentence>
	<sentence id="DBMI.pac171.s65" origId="s65" text="Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4."/>
	<sentence id="DBMI.pac171.s66" origId="s66" text="In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.">
		<entity charOffset="8959-8970" id="DBMI.pac171.s66.e0" origId="s66.e0" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="8916-8925" id="DBMI.pac171.s66.e1" origId="s66.e1" text="warfarin " type="Active ingredient"/>
		<entity charOffset="8950-8958" id="DBMI.pac171.s66.e2" origId="s66.e2" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac171.s66.e0" e2="DBMI.pac171.s66.e1" id="DBMI.pac171.s66.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="irbesartan "/>
		<pair e1="DBMI.pac171.s66.e0" e2="DBMI.pac171.s66.e2" id="DBMI.pac171.s66.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="irbesartan "/>
		<pair e1="DBMI.pac171.s66.e1" e2="DBMI.pac171.s66.e0" id="DBMI.pac171.s66.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s66.e1" e2="DBMI.pac171.s66.e2" id="DBMI.pac171.s66.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s66.e2" e2="DBMI.pac171.s66.e0" id="DBMI.pac171.s66.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s66.e2" e2="DBMI.pac171.s66.e1" id="DBMI.pac171.s66.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac171.s67" origId="s67" text="The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.">
		<entity charOffset="9177-9188" id="DBMI.pac171.s67.e0" origId="s67.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="9125-9136" id="DBMI.pac171.s67.e1" origId="s67.e1" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="9191-9210" id="DBMI.pac171.s67.e2" origId="s67.e2" text="hydrochlorothiazide " type="Active ingredient"/>
		<pair e1="DBMI.pac171.s67.e0" e2="DBMI.pac171.s67.e1" id="DBMI.pac171.s67.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac171.s67.e0" e2="DBMI.pac171.s67.e2" id="DBMI.pac171.s67.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s67.e1" e2="DBMI.pac171.s67.e0" id="DBMI.pac171.s67.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s67.e1" e2="DBMI.pac171.s67.e2" id="DBMI.pac171.s67.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s67.e2" e2="DBMI.pac171.s67.e0" id="DBMI.pac171.s67.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s67.e2" e2="DBMI.pac171.s67.e1" id="DBMI.pac171.s67.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="hydrochlorothiazide "/>
	</sentence>
	<sentencespan id="DBMI.pac171.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nIrbesartan\n\nAngiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor."/>
	<sentencespan id="DBMI.pac171.sp1" origId="sp1" text="There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity. Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure."/>
	<sentencespan id="DBMI.pac171.sp2" origId="sp2" text="Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis. Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known. Hydrochlorothiazide\n\nHydrochlorothiazide is a thiazide diuretic."/>
	<sentencespan id="DBMI.pac171.sp3" origId="sp3" text="Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics."/>
	<sentencespan id="DBMI.pac171.sp4" origId="sp4" text="The mechanism of the antihypertensive effect of thiazides is not fully understood. 12.2 Pharmacodynamics\n\nIrbesartan\n\nIn healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions. Inhibition was complete (100%) 4 hours following oral doses of 150 mg or 300 mg and partial inhibition was sustained for 24 hours (60% and 40% at 300 mg and 150 mg, respectively)."/>
	<sentencespan id="DBMI.pac171.sp5" origId="sp5" text="In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels. Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses. In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction."/>
	<sentencespan id="DBMI.pac171.sp6" origId="sp6" text="In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations. There was no effect on serum uric acid during chronic oral administration and no uricosuric effect. Hydrochlorothiazide\n\nAfter oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours."/>
	<sentencespan id="DBMI.pac171.sp7" origId="sp7" text="12.3 Pharmacokinetics\n\nIrbesartan\n\nIrbesartan is an orally active agent that does not require biotransformation into an active form. The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%. Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing."/>
	<sentencespan id="DBMI.pac171.sp8" origId="sp8" text="Food does not affect the bioavailability of irbesartan. Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range. The terminal elimination half-life of irbesartan averaged 11 to 15 hours."/>
	<sentencespan id="DBMI.pac171.sp9" origId="sp9" text="Steady-state concentrations are achieved within 3 days. Limited accumulation of irbesartan (&lt;20%) is observed in plasma upon repeated once-daily dosing. Hydrochlorothiazide\n\nWhen plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours."/>
	<sentencespan id="DBMI.pac171.sp10" origId="sp10" text="Metabolism and Elimination\n\nIrbesartan\n\nIrbesartan is metabolized via glucuronide conjugation and oxidation. Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan. The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%)."/>
	<sentencespan id="DBMI.pac171.sp11" origId="sp11" text="The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity. Irbesartan and its metabolites are excreted by both biliary and renal routes. Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide."/>
	<sentencespan id="DBMI.pac171.sp12" origId="sp12" text="In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible. Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1). There was no induction or inhibition of 3A4."/>
	<sentencespan id="DBMI.pac171.sp13" origId="sp13" text="Hydrochlorothiazide\n\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated unchanged within 24 hours. Distribution\n\nIrbesartan\n\nIrbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood."/>
	<sentencespan id="DBMI.pac171.sp14" origId="sp14" text="The average volume of distribution is 53 to 93 liters. Total plasma and renal clearances are in the range of 157 to 176 mL/min and 3.0 to 3.5 mL/min, respectively. With repetitive dosing, irbesartan accumulates to no clinically relevant extent."/>
	<sentencespan id="DBMI.pac171.sp15" origId="sp15" text="Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta. Irbesartan is excreted in the milk of lactating rats. Hydrochlorothiazide\n\nHydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk."/>
	<sentencespan id="DBMI.pac171.sp16" origId="sp16" text="Pediatric\n\nIrbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients &lt;18 years of age. Gender\n\nNo gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects. In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%)."/>
	<sentencespan id="DBMI.pac171.sp17" origId="sp17" text="No gender-related dosage adjustment is necessary. Geriatric\n\nIn elderly subjects (age 65 to 80 years), irbesartan elimination half-life was not significantly altered, but AUC and Cmax values were about 20% to 50% greater than those of young subjects (age 18 to 40 years). No dosage adjustment is necessary in the elderly."/>
	<sentencespan id="DBMI.pac171.sp18" origId="sp18" text="Race\n\nIn healthy black subjects, irbesartan AUC values were approximately 25% greater than whites; there were no differences in Cmax values. Renal Insufficiency\n\nThe pharmacokinetics of irbesartan were not altered in patients with renal impairment or in patients on hemodialysis. Irbesartan is not removed by hemodialysis."/>
	<sentencespan id="DBMI.pac171.sp19" origId="sp19" text="No dosage adjustment is necessary in patients with mild to severe renal impairment unless a patient with renal impairment is also volume depleted. [See Warnings and Precautions (5.2).] Hepatic Insufficiency\n\nThe pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver."/>
	<sentencespan id="DBMI.pac171.sp20" origId="sp20" text="No dosage adjustment is necessary in patients with hepatic insufficiency. Drug-Drug Interactions\n\nNo significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine. In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine."/>
	<sentencespan id="DBMI.pac171.sp21" origId="sp21" text="However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible. Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics. Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.">
		<entity charOffset="8604-8615" id="DBMI.pac171.sp21.e0" origId="sp21.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="8655-8666" id="DBMI.pac171.sp21.e1" origId="sp21.e1" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="8618-8638" id="DBMI.pac171.sp21.e2" origId="sp21.e2" text="hydrochlorothiazide " type="Active ingredient"/>
		<pair e1="DBMI.pac171.sp21.e0" e2="DBMI.pac171.sp21.e1" id="DBMI.pac171.sp21.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac171.sp21.e0" e2="DBMI.pac171.sp21.e2" id="DBMI.pac171.sp21.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e1" e2="DBMI.pac171.sp21.e0" id="DBMI.pac171.sp21.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e1" e2="DBMI.pac171.sp21.e2" id="DBMI.pac171.sp21.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e2" e2="DBMI.pac171.sp21.e0" id="DBMI.pac171.sp21.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e2" e2="DBMI.pac171.sp21.e1" id="DBMI.pac171.sp21.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="hydrochlorothiazide "/>
	</sentencespan>
	<sentencespan id="DBMI.pac171.sp22" origId="sp22" text="In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin. The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.">
		<entity charOffset="8959-8970" id="DBMI.pac171.sp22.e0" origId="sp22.e0" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="8916-8925" id="DBMI.pac171.sp22.e1" origId="sp22.e1" text="warfarin " type="Active ingredient"/>
		<entity charOffset="8950-8958" id="DBMI.pac171.sp22.e2" origId="sp22.e2" text="digoxin " type="Active ingredient"/>
		<entity charOffset="9177-9188" id="DBMI.pac171.sp22.e3" origId="sp22.e3" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="9191-9211" id="DBMI.pac171.sp22.e4" origId="sp22.e4" text="hydrochlorothiazide " type="Active ingredient"/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="irbesartan "/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="irbesartan "/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="hydrochlorothiazide "/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac172" origId="pac172">
	<sentence id="DBMI.pac172.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nThe risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see Warnings and Precautions, Skeletal Muscle (5.1) and Clinical Pharmacology (12.3)]."/>
	<sentence id="DBMI.pac172.s1" origId="s1" text="7.1 Strong Inhibitors of CYP 3A4\n\nLIPITOR is metabolized by cytochrome P450 3A4."/>
	<sentence id="DBMI.pac172.s2" origId="s2" text="Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin."/>
	<sentence id="DBMI.pac172.s3" origId="s3" text="The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4."/>
	<sentence id="DBMI.pac172.s4" origId="s4" text="Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].">
		<entity charOffset="816-831" id="DBMI.pac172.s4.e0" origId="s4.e0" text="clarithromycin " type="Active ingredient"/>
		<entity charOffset="797-805" id="DBMI.pac172.s4.e1" origId="s4.e1" text="LIPITOR " type="Drug product"/>
		<entity charOffset="717-730" id="DBMI.pac172.s4.e2" origId="s4.e2" text="Atorvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac172.s4.e0" e2="DBMI.pac172.s4.e1" id="DBMI.pac172.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="clarithromycin "/>
		<pair e1="DBMI.pac172.s4.e0" e2="DBMI.pac172.s4.e2" id="DBMI.pac172.s4.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="clarithromycin "/>
		<pair e1="DBMI.pac172.s4.e1" e2="DBMI.pac172.s4.e0" id="DBMI.pac172.s4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s4.e1" e2="DBMI.pac172.s4.e2" id="DBMI.pac172.s4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s4.e2" e2="DBMI.pac172.s4.e0" id="DBMI.pac172.s4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s4.e2" e2="DBMI.pac172.s4.e1" id="DBMI.pac172.s4.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s5" origId="s5" text="Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]."/>
	<sentence id="DBMI.pac172.s6" origId="s6" text="Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].">
		<entity charOffset="1260-1270" id="DBMI.pac172.s6.e0" origId="s6.e0" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="1241-1249" id="DBMI.pac172.s6.e1" origId="s6.e1" text="LIPITOR " type="Drug product"/>
		<entity charOffset="1161-1174" id="DBMI.pac172.s6.e2" origId="s6.e2" text="Atorvastatin " type="Active ingredient"/>
		<entity charOffset="1275-1286" id="DBMI.pac172.s6.e3" origId="s6.e3" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="1329-1339" id="DBMI.pac172.s6.e4" origId="s6.e4" text="lopinavir " type="Active ingredient"/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e1" id="DBMI.pac172.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="ritonavir "/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="ritonavir "/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="ritonavir "/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e3" id="DBMI.pac172.s6.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e4" id="DBMI.pac172.s6.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e1" e2="DBMI.pac172.s6.e0" id="DBMI.pac172.s6.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e1" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e1" e2="DBMI.pac172.s6.e3" id="DBMI.pac172.s6.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e1" e2="DBMI.pac172.s6.e4" id="DBMI.pac172.s6.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e2" e2="DBMI.pac172.s6.e0" id="DBMI.pac172.s6.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e2" e2="DBMI.pac172.s6.e1" id="DBMI.pac172.s6.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e2" e2="DBMI.pac172.s6.e3" id="DBMI.pac172.s6.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e2" e2="DBMI.pac172.s6.e4" id="DBMI.pac172.s6.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e3" e2="DBMI.pac172.s6.e0" id="DBMI.pac172.s6.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e3" e2="DBMI.pac172.s6.e1" id="DBMI.pac172.s6.p14" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="saquinavir "/>
		<pair e1="DBMI.pac172.s6.e3" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p15" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="saquinavir "/>
		<pair e1="DBMI.pac172.s6.e3" e2="DBMI.pac172.s6.e4" id="DBMI.pac172.s6.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e4" e2="DBMI.pac172.s6.e0" id="DBMI.pac172.s6.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e4" e2="DBMI.pac172.s6.e1" id="DBMI.pac172.s6.p18" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="lopinavir "/>
		<pair e1="DBMI.pac172.s6.e4" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p19" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="lopinavir "/>
		<pair e1="DBMI.pac172.s6.e4" e2="DBMI.pac172.s6.e3" id="DBMI.pac172.s6.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s7" origId="s7" text="Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]."/>
	<sentence id="DBMI.pac172.s8" origId="s8" text="Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].">
		<entity charOffset="1778-1791" id="DBMI.pac172.s8.e0" origId="s8.e0" text="itraconazole " type="Active ingredient"/>
		<entity charOffset="1680-1693" id="DBMI.pac172.s8.e1" origId="s8.e1" text="Atorvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac172.s8.e0" e2="DBMI.pac172.s8.e1" id="DBMI.pac172.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="itraconazole "/>
		<pair e1="DBMI.pac172.s8.e1" e2="DBMI.pac172.s8.e0" id="DBMI.pac172.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s9" origId="s9" text="Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]."/>
	<sentence id="DBMI.pac172.s10" origId="s10" text="7.2 Grapefruit Juice\n\nContains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day)."/>
	<sentence id="DBMI.pac172.s11" origId="s11" text="7.3 Cyclosporine\n\nAtorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter."/>
	<sentence id="DBMI.pac172.s12" origId="s12" text="Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin."/>
	<sentence id="DBMI.pac172.s13" origId="s13" text="Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].">
		<entity charOffset="2537-2550" id="DBMI.pac172.s13.e0" origId="s13.e0" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="2439-2452" id="DBMI.pac172.s13.e1" origId="s13.e1" text="Atorvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac172.s13.e0" e2="DBMI.pac172.s13.e1" id="DBMI.pac172.s13.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="cyclosporine "/>
		<pair e1="DBMI.pac172.s13.e1" e2="DBMI.pac172.s13.e0" id="DBMI.pac172.s13.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s14" origId="s14" text="In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)]."/>
	<sentence id="DBMI.pac172.s15" origId="s15" text="7.4 Rifampin or other Inducers of Cytochrome P450 3A4\n\nConcomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.">
		<entity charOffset="2947-2957" id="DBMI.pac172.s15.e0" origId="s15.e0" text="efavirenz " type="Active ingredient"/>
		<entity charOffset="2895-2903" id="DBMI.pac172.s15.e1" origId="s15.e1" text="LIPITOR " type="Drug product"/>
		<entity charOffset="2958-2967" id="DBMI.pac172.s15.e2" origId="s15.e2" text="rifampin " type="Active ingredient"/>
		<pair e1="DBMI.pac172.s15.e0" e2="DBMI.pac172.s15.e1" id="DBMI.pac172.s15.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="efavirenz "/>
		<pair e1="DBMI.pac172.s15.e0" e2="DBMI.pac172.s15.e2" id="DBMI.pac172.s15.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s15.e1" e2="DBMI.pac172.s15.e0" id="DBMI.pac172.s15.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s15.e1" e2="DBMI.pac172.s15.e2" id="DBMI.pac172.s15.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s15.e2" e2="DBMI.pac172.s15.e0" id="DBMI.pac172.s15.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s15.e2" e2="DBMI.pac172.s15.e1" id="DBMI.pac172.s15.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="rifampin "/>
	</sentence>
	<sentence id="DBMI.pac172.s16" origId="s16" text="Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.">
		<entity charOffset="3226-3235" id="DBMI.pac172.s16.e0" origId="s16.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="3287-3300" id="DBMI.pac172.s16.e1" origId="s16.e1" text="atorvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac172.s16.e0" e2="DBMI.pac172.s16.e1" id="DBMI.pac172.s16.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atorvastatin " precipitant="rifampin "/>
		<pair e1="DBMI.pac172.s16.e1" e2="DBMI.pac172.s16.e0" id="DBMI.pac172.s16.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s17" origId="s17" text="7.5 Digoxin\n\nWhen multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.">
		<entity charOffset="3360-3368" id="DBMI.pac172.s17.e0" origId="s17.e0" text="LIPITOR " type="Drug product"/>
		<entity charOffset="3372-3380" id="DBMI.pac172.s17.e1" origId="s17.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac172.s17.e0" e2="DBMI.pac172.s17.e1" id="DBMI.pac172.s17.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="LIPITOR "/>
		<pair e1="DBMI.pac172.s17.e0" e2="DBMI.pac172.s17.e1" id="DBMI.pac172.s17.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="LIPITOR "/>
		<pair e1="DBMI.pac172.s17.e1" e2="DBMI.pac172.s17.e0" id="DBMI.pac172.s17.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s18" origId="s18" text="Patients taking digoxin should be monitored appropriately."/>
	<sentence id="DBMI.pac172.s19" origId="s19" text="7.6 Oral Contraceptives\n\nCo-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].">
		<entity charOffset="3582-3590" id="DBMI.pac172.s19.e0" origId="s19.e0" text="LIPITOR " type="Drug product"/>
		<entity charOffset="3641-3655" id="DBMI.pac172.s19.e1" origId="s19.e1" text="norethindrone " type="Active ingredient"/>
		<entity charOffset="3659-3677" id="DBMI.pac172.s19.e2" origId="s19.e2" text="ethinyl estradiol " type="Active ingredient"/>
		<pair e1="DBMI.pac172.s19.e0" e2="DBMI.pac172.s19.e1" id="DBMI.pac172.s19.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="norethindrone " precipitant="LIPITOR "/>
		<pair e1="DBMI.pac172.s19.e0" e2="DBMI.pac172.s19.e2" id="DBMI.pac172.s19.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethinyl estradiol " precipitant="LIPITOR "/>
		<pair e1="DBMI.pac172.s19.e1" e2="DBMI.pac172.s19.e0" id="DBMI.pac172.s19.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s19.e1" e2="DBMI.pac172.s19.e2" id="DBMI.pac172.s19.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s19.e2" e2="DBMI.pac172.s19.e0" id="DBMI.pac172.s19.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s19.e2" e2="DBMI.pac172.s19.e1" id="DBMI.pac172.s19.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s20" origId="s20" text="These increases should be considered when selecting an oral contraceptive for a woman taking LIPITOR."/>
	<sentence id="DBMI.pac172.s21" origId="s21" text="7.7 Warfarin\n\nLIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment. "/>
	<sentencespan id="DBMI.pac172.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nThe risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see Warnings and Precautions, Skeletal Muscle (5.1) and Clinical Pharmacology (12.3)]. 7.1 Strong Inhibitors of CYP 3A4\n\nLIPITOR is metabolized by cytochrome P450 3A4. Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin."/>
	<sentencespan id="DBMI.pac172.sp1" origId="sp1" text="The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4. Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].">
		<entity charOffset="816-831" id="DBMI.pac172.sp1.e0" origId="sp1.e0" text="clarithromycin " type="Active ingredient"/>
		<entity charOffset="797-805" id="DBMI.pac172.sp1.e1" origId="sp1.e1" text="LIPITOR " type="Drug product"/>
		<entity charOffset="717-730" id="DBMI.pac172.sp1.e2" origId="sp1.e2" text="Atorvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp1.e0" e2="DBMI.pac172.sp1.e1" id="DBMI.pac172.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="clarithromycin "/>
		<pair e1="DBMI.pac172.sp1.e0" e2="DBMI.pac172.sp1.e2" id="DBMI.pac172.sp1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="clarithromycin "/>
		<pair e1="DBMI.pac172.sp1.e1" e2="DBMI.pac172.sp1.e0" id="DBMI.pac172.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp1.e1" e2="DBMI.pac172.sp1.e2" id="DBMI.pac172.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp1.e2" e2="DBMI.pac172.sp1.e0" id="DBMI.pac172.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp1.e2" e2="DBMI.pac172.sp1.e1" id="DBMI.pac172.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp2" origId="sp2" text="Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]. Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].">
		<entity charOffset="1260-1270" id="DBMI.pac172.sp2.e0" origId="sp2.e0" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="1241-1249" id="DBMI.pac172.sp2.e1" origId="sp2.e1" text="LIPITOR " type="Drug product"/>
		<entity charOffset="1161-1174" id="DBMI.pac172.sp2.e2" origId="sp2.e2" text="Atorvastatin " type="Active ingredient"/>
		<entity charOffset="1275-1286" id="DBMI.pac172.sp2.e3" origId="sp2.e3" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="1329-1339" id="DBMI.pac172.sp2.e4" origId="sp2.e4" text="lopinavir " type="Active ingredient"/>
		<entity charOffset="1778-1791" id="DBMI.pac172.sp2.e5" origId="sp2.e5" text="itraconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="ritonavir "/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="ritonavir "/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="ritonavir "/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="saquinavir "/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p18" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="saquinavir "/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p22" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="lopinavir "/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p23" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="lopinavir "/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p28" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="itraconazole "/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp3" origId="sp3" text="Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]. 7.2 Grapefruit Juice\n\nContains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day). 7.3 Cyclosporine\n\nAtorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter."/>
	<sentencespan id="DBMI.pac172.sp4" origId="sp4" text="Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].">
		<entity charOffset="2537-2550" id="DBMI.pac172.sp4.e0" origId="sp4.e0" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="2439-2452" id="DBMI.pac172.sp4.e1" origId="sp4.e1" text="Atorvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp4.e0" e2="DBMI.pac172.sp4.e1" id="DBMI.pac172.sp4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin " precipitant="cyclosporine "/>
		<pair e1="DBMI.pac172.sp4.e1" e2="DBMI.pac172.sp4.e0" id="DBMI.pac172.sp4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp5" origId="sp5" text="7.4 Rifampin or other Inducers of Cytochrome P450 3A4\n\nConcomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. 7.5 Digoxin\n\nWhen multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.">
		<entity charOffset="2947-2957" id="DBMI.pac172.sp5.e0" origId="sp5.e0" text="efavirenz " type="Active ingredient"/>
		<entity charOffset="2895-2903" id="DBMI.pac172.sp5.e1" origId="sp5.e1" text="LIPITOR " type="Drug product"/>
		<entity charOffset="2958-2967" id="DBMI.pac172.sp5.e2" origId="sp5.e2" text="rifampin " type="Active ingredient"/>
		<entity charOffset="3287-3300" id="DBMI.pac172.sp5.e3" origId="sp5.e3" text="atorvastatin " type="Active ingredient"/>
		<entity charOffset="3372-3380" id="DBMI.pac172.sp5.e4" origId="sp5.e4" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp5.e0" e2="DBMI.pac172.sp5.e1" id="DBMI.pac172.sp5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="efavirenz "/>
		<pair e1="DBMI.pac172.sp5.e0" e2="DBMI.pac172.sp5.e2" id="DBMI.pac172.sp5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e0" e2="DBMI.pac172.sp5.e3" id="DBMI.pac172.sp5.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e0" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e0" id="DBMI.pac172.sp5.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e2" id="DBMI.pac172.sp5.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e3" id="DBMI.pac172.sp5.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p7" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="LIPITOR "/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="LIPITOR "/>
		<pair e1="DBMI.pac172.sp5.e2" e2="DBMI.pac172.sp5.e0" id="DBMI.pac172.sp5.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e2" e2="DBMI.pac172.sp5.e1" id="DBMI.pac172.sp5.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR " precipitant="rifampin "/>
		<pair e1="DBMI.pac172.sp5.e2" e2="DBMI.pac172.sp5.e3" id="DBMI.pac172.sp5.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atorvastatin " precipitant="rifampin "/>
		<pair e1="DBMI.pac172.sp5.e2" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e3" e2="DBMI.pac172.sp5.e0" id="DBMI.pac172.sp5.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e3" e2="DBMI.pac172.sp5.e1" id="DBMI.pac172.sp5.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e3" e2="DBMI.pac172.sp5.e2" id="DBMI.pac172.sp5.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e3" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e4" e2="DBMI.pac172.sp5.e0" id="DBMI.pac172.sp5.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e4" e2="DBMI.pac172.sp5.e1" id="DBMI.pac172.sp5.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e4" e2="DBMI.pac172.sp5.e2" id="DBMI.pac172.sp5.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e4" e2="DBMI.pac172.sp5.e3" id="DBMI.pac172.sp5.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp6" origId="sp6" text="Patients taking digoxin should be monitored appropriately. 7.6 Oral Contraceptives\n\nCo-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)]. These increases should be considered when selecting an oral contraceptive for a woman taking LIPITOR.">
		<entity charOffset="3582-3590" id="DBMI.pac172.sp6.e0" origId="sp6.e0" text="LIPITOR " type="Drug product"/>
		<entity charOffset="3641-3655" id="DBMI.pac172.sp6.e1" origId="sp6.e1" text="norethindrone " type="Active ingredient"/>
		<entity charOffset="3659-3677" id="DBMI.pac172.sp6.e2" origId="sp6.e2" text="ethinyl estradiol " type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp6.e0" e2="DBMI.pac172.sp6.e1" id="DBMI.pac172.sp6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="norethindrone " precipitant="LIPITOR "/>
		<pair e1="DBMI.pac172.sp6.e0" e2="DBMI.pac172.sp6.e2" id="DBMI.pac172.sp6.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethinyl estradiol " precipitant="LIPITOR "/>
		<pair e1="DBMI.pac172.sp6.e1" e2="DBMI.pac172.sp6.e0" id="DBMI.pac172.sp6.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp6.e1" e2="DBMI.pac172.sp6.e2" id="DBMI.pac172.sp6.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp6.e2" e2="DBMI.pac172.sp6.e0" id="DBMI.pac172.sp6.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp6.e2" e2="DBMI.pac172.sp6.e1" id="DBMI.pac172.sp6.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp7" origId="sp7" text="7.7 Warfarin\n\nLIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment. "/>
</document>

<document id="DBMI.pac174" origId="pac174">
	<sentence id="DBMI.pac174.s0" origId="s0" text="In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (146% vs. 73%) was observed with concomitant rifampin administration (600 mg).">
		<entity charOffset="140-149" id="DBMI.pac174.s0.e0" origId="s0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="61-72" id="DBMI.pac174.s0.e1" origId="s0.e1" text="tacrolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac174.s0.e0" e2="DBMI.pac174.s0.e1" id="DBMI.pac174.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrolimus " precipitant="rifampin "/>
		<pair e1="DBMI.pac174.s0.e1" e2="DBMI.pac174.s0.e0" id="DBMI.pac174.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac174.s1" origId="s1" text="In addition, there was a significant increase in tacrolimus clearance (0.0360.008 L/hr/kg vs. 0.0530.010 L/hr/kg) with concomitant rifampin administration.">
		<entity charOffset="307-316" id="DBMI.pac174.s1.e0" origId="s1.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="223-234" id="DBMI.pac174.s1.e1" origId="s1.e1" text="tacrolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac174.s1.e0" e2="DBMI.pac174.s1.e1" id="DBMI.pac174.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrolimus " precipitant="rifampin "/>
		<pair e1="DBMI.pac174.s1.e1" e2="DBMI.pac174.s1.e0" id="DBMI.pac174.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac174.sp0" origId="sp0" text="In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (146% vs. 73%) was observed with concomitant rifampin administration (600 mg). In addition, there was a significant increase in tacrolimus clearance (0.0360.008 L/hr/kg vs. 0.0530.010 L/hr/kg) with concomitant rifampin administration.">
		<entity charOffset="140-149" id="DBMI.pac174.sp0.e0" origId="sp0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="61-72" id="DBMI.pac174.sp0.e1" origId="sp0.e1" text="tacrolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac174.sp0.e0" e2="DBMI.pac174.sp0.e1" id="DBMI.pac174.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrolimus " precipitant="rifampin "/>
		<pair e1="DBMI.pac174.sp0.e0" e2="DBMI.pac174.sp0.e1" id="DBMI.pac174.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrolimus " precipitant="rifampin "/>
		<pair e1="DBMI.pac174.sp0.e1" e2="DBMI.pac174.sp0.e0" id="DBMI.pac174.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac175" origId="pac175">
	<sentence id="DBMI.pac175.s0" origId="s0" text="Interaction studies with drugs used in HIV therapy have not been conducted."/>
	<sentence id="DBMI.pac175.s1" origId="s1" text="However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus."/>
	<sentence id="DBMI.pac175.s2" origId="s2" text="Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL.">
		<entity charOffset="369-380" id="DBMI.pac175.s2.e0" origId="s2.e0" text="nelfinavir " type="Active ingredient"/>
		<entity charOffset="353-364" id="DBMI.pac175.s2.e1" origId="s2.e1" text="tacrolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac175.s2.e0" e2="DBMI.pac175.s2.e1" id="DBMI.pac175.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus " precipitant="nelfinavir "/>
		<pair e1="DBMI.pac175.s2.e1" e2="DBMI.pac175.s2.e0" id="DBMI.pac175.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac175.s3" origId="s3" text="Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly."/>
	<sentence id="DBMI.pac175.s4" origId="s4" text="Tacrolimus may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration.">
		<entity charOffset="747-758" id="DBMI.pac175.s4.e0" origId="s4.e0" text="Tacrolimus " type="Active ingredient"/>
		<entity charOffset="812-822" id="DBMI.pac175.s4.e1" origId="s4.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac175.s4.e0" e2="DBMI.pac175.s4.e1" id="DBMI.pac175.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="phenytoin " precipitant="Tacrolimus "/>
		<pair e1="DBMI.pac175.s4.e1" e2="DBMI.pac175.s4.e0" id="DBMI.pac175.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac175.s5" origId="s5" text="Grapefruit juice affects CYP3A-mediated metabolism and should be avoided (see DOSAGE AND ADMINISTRATION)."/>
	<sentencespan id="DBMI.pac175.sp0" origId="sp0" text="Interaction studies with drugs used in HIV therapy have not been conducted. However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus. Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL.">
		<entity charOffset="369-380" id="DBMI.pac175.sp0.e0" origId="sp0.e0" text="nelfinavir " type="Active ingredient"/>
		<entity charOffset="353-364" id="DBMI.pac175.sp0.e1" origId="sp0.e1" text="tacrolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac175.sp0.e0" e2="DBMI.pac175.sp0.e1" id="DBMI.pac175.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus " precipitant="nelfinavir "/>
		<pair e1="DBMI.pac175.sp0.e1" e2="DBMI.pac175.sp0.e0" id="DBMI.pac175.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac175.sp1" origId="sp1" text="Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly. Tacrolimus may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration. Grapefruit juice affects CYP3A-mediated metabolism and should be avoided (see DOSAGE AND ADMINISTRATION).">
		<entity charOffset="747-758" id="DBMI.pac175.sp1.e0" origId="sp1.e0" text="Tacrolimus " type="Active ingredient"/>
		<entity charOffset="812-822" id="DBMI.pac175.sp1.e1" origId="sp1.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac175.sp1.e0" e2="DBMI.pac175.sp1.e1" id="DBMI.pac175.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="phenytoin " precipitant="Tacrolimus "/>
		<pair e1="DBMI.pac175.sp1.e1" e2="DBMI.pac175.sp1.e0" id="DBMI.pac175.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac177" origId="pac177">
	<sentence id="DBMI.pac177.s0" origId="s0" text="There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19)."/>
	<sentence id="DBMI.pac177.s1" origId="s1" text="Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation."/>
	<sentence id="DBMI.pac177.s2" origId="s2" text="At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.">
		<entity charOffset="334-345" id="DBMI.pac177.s2.e0" origId="s2.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="226-235" id="DBMI.pac177.s2.e1" origId="s2.e1" text="diazepam " type="Active ingredient"/>
		<entity charOffset="346-359" id="DBMI.pac177.s2.e2" origId="s2.e2" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="360-372" id="DBMI.pac177.s2.e3" origId="s2.e3" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="373-384" id="DBMI.pac177.s2.e4" origId="s2.e4" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="389-400" id="DBMI.pac177.s2.e5" origId="s2.e5" text="omeprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac177.s2.e0" e2="DBMI.pac177.s2.e1" id="DBMI.pac177.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="cimetidine "/>
		<pair e1="DBMI.pac177.s2.e0" e2="DBMI.pac177.s2.e2" id="DBMI.pac177.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e0" e2="DBMI.pac177.s2.e3" id="DBMI.pac177.s2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e0" e2="DBMI.pac177.s2.e4" id="DBMI.pac177.s2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e0" e2="DBMI.pac177.s2.e5" id="DBMI.pac177.s2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e1" e2="DBMI.pac177.s2.e0" id="DBMI.pac177.s2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e1" e2="DBMI.pac177.s2.e2" id="DBMI.pac177.s2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e1" e2="DBMI.pac177.s2.e3" id="DBMI.pac177.s2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e1" e2="DBMI.pac177.s2.e4" id="DBMI.pac177.s2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e1" e2="DBMI.pac177.s2.e5" id="DBMI.pac177.s2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e2" e2="DBMI.pac177.s2.e0" id="DBMI.pac177.s2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e2" e2="DBMI.pac177.s2.e1" id="DBMI.pac177.s2.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac177.s2.e2" e2="DBMI.pac177.s2.e3" id="DBMI.pac177.s2.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e2" e2="DBMI.pac177.s2.e4" id="DBMI.pac177.s2.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e2" e2="DBMI.pac177.s2.e5" id="DBMI.pac177.s2.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e3" e2="DBMI.pac177.s2.e0" id="DBMI.pac177.s2.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e3" e2="DBMI.pac177.s2.e1" id="DBMI.pac177.s2.p16" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac177.s2.e3" e2="DBMI.pac177.s2.e2" id="DBMI.pac177.s2.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e3" e2="DBMI.pac177.s2.e4" id="DBMI.pac177.s2.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e3" e2="DBMI.pac177.s2.e5" id="DBMI.pac177.s2.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e4" e2="DBMI.pac177.s2.e0" id="DBMI.pac177.s2.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e4" e2="DBMI.pac177.s2.e1" id="DBMI.pac177.s2.p21" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac177.s2.e4" e2="DBMI.pac177.s2.e2" id="DBMI.pac177.s2.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e4" e2="DBMI.pac177.s2.e3" id="DBMI.pac177.s2.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e4" e2="DBMI.pac177.s2.e5" id="DBMI.pac177.s2.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e5" e2="DBMI.pac177.s2.e0" id="DBMI.pac177.s2.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e5" e2="DBMI.pac177.s2.e1" id="DBMI.pac177.s2.p26" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="omeprazole "/>
		<pair e1="DBMI.pac177.s2.e5" e2="DBMI.pac177.s2.e2" id="DBMI.pac177.s2.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e5" e2="DBMI.pac177.s2.e3" id="DBMI.pac177.s2.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e5" e2="DBMI.pac177.s2.e4" id="DBMI.pac177.s2.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac177.sp0" origId="sp0" text="There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.">
		<entity charOffset="334-345" id="DBMI.pac177.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="226-235" id="DBMI.pac177.sp0.e1" origId="sp0.e1" text="diazepam " type="Active ingredient"/>
		<entity charOffset="346-359" id="DBMI.pac177.sp0.e2" origId="sp0.e2" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="360-372" id="DBMI.pac177.sp0.e3" origId="sp0.e3" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="373-384" id="DBMI.pac177.sp0.e4" origId="sp0.e4" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="389-400" id="DBMI.pac177.sp0.e5" origId="sp0.e5" text="omeprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="cimetidine "/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p16" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p21" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p26" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="omeprazole "/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac179" origId="pac179">
	<sentence id="DBMI.pac179.s0" origId="s0" text="Carbamazepine\n\nIsoniazid is known to slow the metabolism of carbamazepine and increase its serum levels.">
		<entity charOffset="15-25" id="DBMI.pac179.s0.e0" origId="s0.e0" text="Isoniazid " type="Active ingredient"/>
		<entity charOffset="60-74" id="DBMI.pac179.s0.e1" origId="s0.e1" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac179.s0.e0" e2="DBMI.pac179.s0.e1" id="DBMI.pac179.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine " precipitant="Isoniazid "/>
		<pair e1="DBMI.pac179.s0.e1" e2="DBMI.pac179.s0.e0" id="DBMI.pac179.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac179.s1" origId="s1" text="Carbamazepine levels should be determined prior to concurrent administration with isonia-\n\nzid, signs and symptoms of carbamazepine toxicity should be monitored closely, and ap- propriate dosage adjustment of the anticonvulsant should be made3."/>
	<sentencespan id="DBMI.pac179.sp0" origId="sp0" text="Carbamazepine\n\nIsoniazid is known to slow the metabolism of carbamazepine and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isonia-\n\nzid, signs and symptoms of carbamazepine toxicity should be monitored closely, and ap- propriate dosage adjustment of the anticonvulsant should be made3.">
		<entity charOffset="15-25" id="DBMI.pac179.sp0.e0" origId="sp0.e0" text="Isoniazid " type="Active ingredient"/>
		<entity charOffset="60-74" id="DBMI.pac179.sp0.e1" origId="sp0.e1" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac179.sp0.e0" e2="DBMI.pac179.sp0.e1" id="DBMI.pac179.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine " precipitant="Isoniazid "/>
		<pair e1="DBMI.pac179.sp0.e1" e2="DBMI.pac179.sp0.e0" id="DBMI.pac179.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac181" origId="pac181">
	<sentence id="DBMI.pac181.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A4 Inhibitors and Inducers\n\nIn vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C."/>
	<sentence id="DBMI.pac181.s1" origId="s1" text="Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.">
		<entity charOffset="257-270" id="DBMI.pac181.s1.e0" origId="s1.e0" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="320-330" id="DBMI.pac181.s1.e1" origId="s1.e1" text="verapamil " type="Active ingredient"/>
		<entity charOffset="271-281" id="DBMI.pac181.s1.e2" origId="s1.e2" text="ritonavir " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s1.e0" e2="DBMI.pac181.s1.e1" id="DBMI.pac181.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="erythromycin "/>
		<pair e1="DBMI.pac181.s1.e0" e2="DBMI.pac181.s1.e2" id="DBMI.pac181.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s1.e1" e2="DBMI.pac181.s1.e0" id="DBMI.pac181.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s1.e1" e2="DBMI.pac181.s1.e2" id="DBMI.pac181.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s1.e2" e2="DBMI.pac181.s1.e0" id="DBMI.pac181.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s1.e2" e2="DBMI.pac181.s1.e1" id="DBMI.pac181.s1.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="ritonavir "/>
	</sentence>
	<sentence id="DBMI.pac181.s2" origId="s2" text="Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics."/>
	<sentence id="DBMI.pac181.s3" origId="s3" text="Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.">
		<entity charOffset="527-536" id="DBMI.pac181.s3.e0" origId="s3.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="580-590" id="DBMI.pac181.s3.e1" origId="s3.e1" text="verapamil " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s3.e0" e2="DBMI.pac181.s3.e1" id="DBMI.pac181.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="rifampin "/>
		<pair e1="DBMI.pac181.s3.e1" e2="DBMI.pac181.s3.e0" id="DBMI.pac181.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s4" origId="s4" text="7.2 Grapefruit Juice\n\nGrapefruit juice may significantly increase concentrations of verapamil."/>
	<sentence id="DBMI.pac181.s5" origId="s5" text="Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively."/>
	<sentence id="DBMI.pac181.s6" origId="s6" text="Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control."/>
	<sentence id="DBMI.pac181.s7" origId="s7" text="Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively."/>
	<sentence id="DBMI.pac181.s8" origId="s8" text="Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control."/>
	<sentence id="DBMI.pac181.s9" origId="s9" text="Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil."/>
	<sentence id="DBMI.pac181.s10" origId="s10" text="This increase in verapamil plasma concentration is not expected to have any clinical consequences."/>
	<sentence id="DBMI.pac181.s11" origId="s11" text="7.3 Beta-Blockers\n\nConcomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility."/>
	<sentence id="DBMI.pac181.s12" origId="s12" text="The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied."/>
	<sentence id="DBMI.pac181.s13" origId="s13" text="However, there have been reports of excess bradycardia and AV block, including complete heart block, when the combination has been used for the treatment of hypertension."/>
	<sentence id="DBMI.pac181.s14" origId="s14" text="For hypertensive patients, the risk of combined therapy may outweigh the potential benefits."/>
	<sentence id="DBMI.pac181.s15" origId="s15" text="The combination should be used only with caution and close monitoring."/>
	<sentence id="DBMI.pac181.s16" origId="s16" text="Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil."/>
	<sentence id="DBMI.pac181.s17" origId="s17" text="A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.">
		<entity charOffset="2278-2288" id="DBMI.pac181.s17.e0" origId="s17.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="2171-2182" id="DBMI.pac181.s17.e1" origId="s17.e1" text="metoprolol " type="Active ingredient"/>
		<entity charOffset="2186-2198" id="DBMI.pac181.s17.e2" origId="s17.e2" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s17.e0" e2="DBMI.pac181.s17.e1" id="DBMI.pac181.s17.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.s17.e0" e2="DBMI.pac181.s17.e2" id="DBMI.pac181.s17.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.s17.e1" e2="DBMI.pac181.s17.e0" id="DBMI.pac181.s17.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s17.e1" e2="DBMI.pac181.s17.e2" id="DBMI.pac181.s17.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s17.e2" e2="DBMI.pac181.s17.e0" id="DBMI.pac181.s17.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s17.e2" e2="DBMI.pac181.s17.e1" id="DBMI.pac181.s17.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s18" origId="s18" text="A variable effect has been seen when verapamil and atenolol were given together."/>
	<sentence id="DBMI.pac181.s19" origId="s19" text="7.4 Digitalis\n\nConsider reducing digoxin dose when verapamil and digoxin are to be given together."/>
	<sentence id="DBMI.pac181.s20" origId="s20" text="Monitor digoxin level periodically during therapy."/>
	<sentence id="DBMI.pac181.s21" origId="s21" text="Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.">
		<entity charOffset="2529-2539" id="DBMI.pac181.s21.e0" origId="s21.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="2568-2576" id="DBMI.pac181.s21.e1" origId="s21.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s21.e0" e2="DBMI.pac181.s21.e1" id="DBMI.pac181.s21.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.s21.e1" e2="DBMI.pac181.s21.e0" id="DBMI.pac181.s21.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s22" origId="s22" text="In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified."/>
	<sentence id="DBMI.pac181.s23" origId="s23" text="Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.">
		<entity charOffset="2778-2788" id="DBMI.pac181.s23.e0" origId="s23.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="2848-2858" id="DBMI.pac181.s23.e1" origId="s23.e1" text="digitoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s23.e0" e2="DBMI.pac181.s23.e1" id="DBMI.pac181.s23.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digitoxin " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.s23.e1" e2="DBMI.pac181.s23.e0" id="DBMI.pac181.s23.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s24" origId="s24" text="If digoxin toxicity is suspected, suspend or discontinue digoxin therapy."/>
	<sentence id="DBMI.pac181.s25" origId="s25" text="In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients."/>
	<sentence id="DBMI.pac181.s26" origId="s26" text="7.5 Alcohol\n\nVerapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.">
		<entity charOffset="3285-3295" id="DBMI.pac181.s26.e0" origId="s26.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="3335-3343" id="DBMI.pac181.s26.e1" origId="s26.e1" text="ethanol " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s26.e0" e2="DBMI.pac181.s26.e1" id="DBMI.pac181.s26.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethanol " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.s26.e1" e2="DBMI.pac181.s26.e0" id="DBMI.pac181.s26.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s27" origId="s27" text="7.6 Clonidine\n\nSinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil."/>
	<sentence id="DBMI.pac181.s28" origId="s28" text="Monitor heart rate in patients receiving concomitant verapamil and clonidine."/>
	<sentence id="DBMI.pac181.s29" origId="s29" text="7.7 Telithromycin\n\nHypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics."/>
	<sentence id="DBMI.pac181.s30" origId="s30" text="7.8 Antineoplastic Agents\n\nVerapamil can increase doxorubicin levels.">
		<entity charOffset="3930-3940" id="DBMI.pac181.s30.e0" origId="s30.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="3953-3965" id="DBMI.pac181.s30.e1" origId="s30.e1" text="doxorubicin " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s30.e0" e2="DBMI.pac181.s30.e1" id="DBMI.pac181.s30.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="doxorubicin " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.s30.e1" e2="DBMI.pac181.s30.e0" id="DBMI.pac181.s30.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s31" origId="s31" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.">
		<entity charOffset="4023-4040" id="DBMI.pac181.s31.e0" origId="s31.e0" text="cyclophosphamide " type="Active ingredient"/>
		<entity charOffset="3991-4001" id="DBMI.pac181.s31.e1" origId="s31.e1" text="verapamil " type="Active ingredient"/>
		<entity charOffset="4041-4049" id="DBMI.pac181.s31.e2" origId="s31.e2" text="oncovin " type="Drug product"/>
		<entity charOffset="4050-4063" id="DBMI.pac181.s31.e3" origId="s31.e3" text="procarbazine " type="Active ingredient"/>
		<entity charOffset="4064-4075" id="DBMI.pac181.s31.e4" origId="s31.e4" text="prednisone " type="Active ingredient"/>
		<entity charOffset="4090-4100" id="DBMI.pac181.s31.e5" origId="s31.e5" text="vindesine " type="Active ingredient"/>
		<entity charOffset="4101-4112" id="DBMI.pac181.s31.e6" origId="s31.e6" text="adriamycin " type="Drug product"/>
		<entity charOffset="4113-4123" id="DBMI.pac181.s31.e7" origId="s31.e7" text="cisplatin " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="cyclophosphamide "/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p15" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="oncovin "/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p16" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="oncovin "/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p23" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="procarbazine "/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p30" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="prednisone "/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p37" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="vindesine "/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p44" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="adriamycin "/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p45" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="adriamycin "/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p52" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="cisplatin "/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s32" origId="s32" text="Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.">
		<entity charOffset="4186-4196" id="DBMI.pac181.s32.e0" origId="s32.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="4226-4237" id="DBMI.pac181.s32.e1" origId="s32.e1" text="paclitaxel " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s32.e0" e2="DBMI.pac181.s32.e1" id="DBMI.pac181.s32.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="paclitaxel " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.s32.e1" e2="DBMI.pac181.s32.e0" id="DBMI.pac181.s32.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s33" origId="s33" text="7.9 Quinidine\n\nIn a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension."/>
	<sentence id="DBMI.pac181.s34" origId="s34" text="Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy."/>
	<sentence id="DBMI.pac181.s35" origId="s35" text="The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients."/>
	<sentence id="DBMI.pac181.s36" origId="s36" text="Verapamil significantly counteracted the effects of quinidine on AV conduction."/>
	<sentence id="DBMI.pac181.s37" origId="s37" text="There has been a report of increased quinidine levels during verapamil therapy.">
		<entity charOffset="4778-4788" id="DBMI.pac181.s37.e0" origId="s37.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="4754-4764" id="DBMI.pac181.s37.e1" origId="s37.e1" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s37.e0" e2="DBMI.pac181.s37.e1" id="DBMI.pac181.s37.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="quinidine " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.s37.e1" e2="DBMI.pac181.s37.e0" id="DBMI.pac181.s37.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s38" origId="s38" text="7.10 Aspirin\n\nIn a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone."/>
	<sentence id="DBMI.pac181.s39" origId="s39" text="7.11 Antihypertensive agents\n\nVerapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure."/>
	<sentence id="DBMI.pac181.s40" origId="s40" text="Monitor patients receiving these combinations appropriately."/>
	<sentence id="DBMI.pac181.s41" origId="s41" text="Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients."/>
	<sentence id="DBMI.pac181.s42" origId="s42" text="Such an effect was observed in one study following the concomitant administration of verapamil and prazosin."/>
	<sentence id="DBMI.pac181.s43" origId="s43" text="7.12 Disopyramide\n\nUntil data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration."/>
	<sentence id="DBMI.pac181.s44" origId="s44" text="7.13 Flecainide\n\nA study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization."/>
	<sentence id="DBMI.pac181.s45" origId="s45" text="Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction."/>
	<sentence id="DBMI.pac181.s46" origId="s46" text="7.14 Carbamazepine\n\nVerapamil therapy may increase carbamazepine concentrations during combined therapy.">
		<entity charOffset="6125-6135" id="DBMI.pac181.s46.e0" origId="s46.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="6156-6170" id="DBMI.pac181.s46.e1" origId="s46.e1" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s46.e0" e2="DBMI.pac181.s46.e1" id="DBMI.pac181.s46.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.s46.e1" e2="DBMI.pac181.s46.e0" id="DBMI.pac181.s46.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s47" origId="s47" text="This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness."/>
	<sentence id="DBMI.pac181.s48" origId="s48" text="7.15 Cyclosporine\n\nVerapamil therapy may increase serum levels of cyclosporine.">
		<entity charOffset="6323-6333" id="DBMI.pac181.s48.e0" origId="s48.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="6370-6383" id="DBMI.pac181.s48.e1" origId="s48.e1" text="cyclosporine " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s48.e0" e2="DBMI.pac181.s48.e1" id="DBMI.pac181.s48.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.s48.e1" e2="DBMI.pac181.s48.e0" id="DBMI.pac181.s48.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s49" origId="s49" text="7.16 Lithium\n\nIncreased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.">
		<entity charOffset="6500-6510" id="DBMI.pac181.s49.e0" origId="s49.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="6510-6518" id="DBMI.pac181.s49.e1" origId="s49.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s49.e0" e2="DBMI.pac181.s49.e1" id="DBMI.pac181.s49.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.s49.e0" e2="DBMI.pac181.s49.e1" id="DBMI.pac181.s49.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.s49.e1" e2="DBMI.pac181.s49.e0" id="DBMI.pac181.s49.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s50" origId="s50" text="However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.">
		<entity charOffset="6613-6623" id="DBMI.pac181.s50.e0" origId="s50.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="6666-6674" id="DBMI.pac181.s50.e1" origId="s50.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s50.e0" e2="DBMI.pac181.s50.e1" id="DBMI.pac181.s50.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.s50.e1" e2="DBMI.pac181.s50.e0" id="DBMI.pac181.s50.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s51" origId="s51" text="Patients receiving both drugs must be monitored carefully."/>
	<sentence id="DBMI.pac181.s52" origId="s52" text="7.17 Inhalation Anesthetics\n\nAnimal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions."/>
	<sentence id="DBMI.pac181.s53" origId="s53" text="When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression."/>
	<sentence id="DBMI.pac181.s54" origId="s54" text="7.18 Neuromuscular Blocking Agents\n\nClinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing)."/>
	<sentence id="DBMI.pac181.s55" origId="s55" text="It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly."/>
	<sentence id="DBMI.pac181.s56" origId="s56" text="7.19 Phenobarbital\n\nPhenobarbital therapy may increase verapamil clearance.">
		<entity charOffset="7467-7481" id="DBMI.pac181.s56.e0" origId="s56.e0" text="Phenobarbital " type="Active ingredient"/>
		<entity charOffset="7502-7512" id="DBMI.pac181.s56.e1" origId="s56.e1" text="verapamil " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s56.e0" e2="DBMI.pac181.s56.e1" id="DBMI.pac181.s56.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="Phenobarbital "/>
		<pair e1="DBMI.pac181.s56.e1" e2="DBMI.pac181.s56.e0" id="DBMI.pac181.s56.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s57" origId="s57" text="7.20 Rifampin\n\nTherapy with rifampin may markedly reduce oral verapamil bioavailability.">
		<entity charOffset="7552-7561" id="DBMI.pac181.s57.e0" origId="s57.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="7586-7596" id="DBMI.pac181.s57.e1" origId="s57.e1" text="verapamil " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s57.e0" e2="DBMI.pac181.s57.e1" id="DBMI.pac181.s57.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="rifampin "/>
		<pair e1="DBMI.pac181.s57.e1" e2="DBMI.pac181.s57.e0" id="DBMI.pac181.s57.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s58" origId="s58" text="7.21 Theophylline\n\nVerapamil may inhibit the clearance and increase the plasma levels of theophylline.">
		<entity charOffset="7633-7643" id="DBMI.pac181.s58.e0" origId="s58.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="7703-7716" id="DBMI.pac181.s58.e1" origId="s58.e1" text="theophylline " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s58.e0" e2="DBMI.pac181.s58.e1" id="DBMI.pac181.s58.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="theophylline " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.s58.e1" e2="DBMI.pac181.s58.e0" id="DBMI.pac181.s58.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s59" origId="s59" text="7.22 Cimetidine\n\nThe interaction between cimetidine and chronically administered verapamil has not been studied.">
		<entity charOffset="7759-7770" id="DBMI.pac181.s59.e0" origId="s59.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="7933-7943" id="DBMI.pac181.s59.e1" origId="s59.e1" text="verapamil " type="Active ingredient"/>
		<pair e1="DBMI.pac181.s59.e0" e2="DBMI.pac181.s59.e1" id="DBMI.pac181.s59.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="cimetidine "/>
		<pair e1="DBMI.pac181.s59.e0" e2="DBMI.pac181.s59.e1" id="DBMI.pac181.s59.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="verapamil " precipitant="cimetidine "/>
		<pair e1="DBMI.pac181.s59.e1" e2="DBMI.pac181.s59.e0" id="DBMI.pac181.s59.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s60" origId="s60" text="Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged."/>
	<sentence id="DBMI.pac181.s61" origId="s61" text="7.23 Nitrates\n\nVerapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions."/>
	<sentence id="DBMI.pac181.s62" origId="s62" text="The pharmacologic profile of both drugs and the clinical experience suggest beneficial interactions."/>
	<sentencespan id="DBMI.pac181.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A4 Inhibitors and Inducers\n\nIn vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C. Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil. Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.">
		<entity charOffset="257-270" id="DBMI.pac181.sp0.e0" origId="sp0.e0" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="320-330" id="DBMI.pac181.sp0.e1" origId="sp0.e1" text="verapamil " type="Active ingredient"/>
		<entity charOffset="271-281" id="DBMI.pac181.sp0.e2" origId="sp0.e2" text="ritonavir " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp0.e0" e2="DBMI.pac181.sp0.e1" id="DBMI.pac181.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="erythromycin "/>
		<pair e1="DBMI.pac181.sp0.e0" e2="DBMI.pac181.sp0.e2" id="DBMI.pac181.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp0.e1" e2="DBMI.pac181.sp0.e0" id="DBMI.pac181.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp0.e1" e2="DBMI.pac181.sp0.e2" id="DBMI.pac181.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp0.e2" e2="DBMI.pac181.sp0.e0" id="DBMI.pac181.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp0.e2" e2="DBMI.pac181.sp0.e1" id="DBMI.pac181.sp0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="ritonavir "/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp1" origId="sp1" text="Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil. 7.2 Grapefruit Juice\n\nGrapefruit juice may significantly increase concentrations of verapamil. Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.">
		<entity charOffset="527-536" id="DBMI.pac181.sp1.e0" origId="sp1.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="580-590" id="DBMI.pac181.sp1.e1" origId="sp1.e1" text="verapamil " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp1.e0" e2="DBMI.pac181.sp1.e1" id="DBMI.pac181.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="rifampin "/>
		<pair e1="DBMI.pac181.sp1.e1" e2="DBMI.pac181.sp1.e0" id="DBMI.pac181.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp2" origId="sp2" text="Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control. Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively. Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control."/>
	<sentencespan id="DBMI.pac181.sp3" origId="sp3" text="Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil. This increase in verapamil plasma concentration is not expected to have any clinical consequences. 7.3 Beta-Blockers\n\nConcomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility."/>
	<sentencespan id="DBMI.pac181.sp4" origId="sp4" text="The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied. However, there have been reports of excess bradycardia and AV block, including complete heart block, when the combination has been used for the treatment of hypertension. For hypertensive patients, the risk of combined therapy may outweigh the potential benefits."/>
	<sentencespan id="DBMI.pac181.sp5" origId="sp5" text="The combination should be used only with caution and close monitoring. Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil. A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.">
		<entity charOffset="2278-2288" id="DBMI.pac181.sp5.e0" origId="sp5.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="2171-2182" id="DBMI.pac181.sp5.e1" origId="sp5.e1" text="metoprolol " type="Active ingredient"/>
		<entity charOffset="2186-2198" id="DBMI.pac181.sp5.e2" origId="sp5.e2" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp5.e0" e2="DBMI.pac181.sp5.e1" id="DBMI.pac181.sp5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.sp5.e0" e2="DBMI.pac181.sp5.e2" id="DBMI.pac181.sp5.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.sp5.e1" e2="DBMI.pac181.sp5.e0" id="DBMI.pac181.sp5.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp5.e1" e2="DBMI.pac181.sp5.e2" id="DBMI.pac181.sp5.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp5.e2" e2="DBMI.pac181.sp5.e0" id="DBMI.pac181.sp5.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp5.e2" e2="DBMI.pac181.sp5.e1" id="DBMI.pac181.sp5.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp6" origId="sp6" text="A variable effect has been seen when verapamil and atenolol were given together. 7.4 Digitalis\n\nConsider reducing digoxin dose when verapamil and digoxin are to be given together. Monitor digoxin level periodically during therapy."/>
	<sentencespan id="DBMI.pac181.sp7" origId="sp7" text="Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.">
		<entity charOffset="2529-2539" id="DBMI.pac181.sp7.e0" origId="sp7.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="2568-2576" id="DBMI.pac181.sp7.e1" origId="sp7.e1" text="digoxin " type="Active ingredient"/>
		<entity charOffset="2778-2788" id="DBMI.pac181.sp7.e2" origId="sp7.e2" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="2848-2858" id="DBMI.pac181.sp7.e3" origId="sp7.e3" text="digitoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp7.e0" e2="DBMI.pac181.sp7.e1" id="DBMI.pac181.sp7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.sp7.e0" e2="DBMI.pac181.sp7.e2" id="DBMI.pac181.sp7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e0" e2="DBMI.pac181.sp7.e3" id="DBMI.pac181.sp7.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e1" e2="DBMI.pac181.sp7.e0" id="DBMI.pac181.sp7.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e1" e2="DBMI.pac181.sp7.e2" id="DBMI.pac181.sp7.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e1" e2="DBMI.pac181.sp7.e3" id="DBMI.pac181.sp7.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e2" e2="DBMI.pac181.sp7.e0" id="DBMI.pac181.sp7.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e2" e2="DBMI.pac181.sp7.e1" id="DBMI.pac181.sp7.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e2" e2="DBMI.pac181.sp7.e3" id="DBMI.pac181.sp7.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digitoxin " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.sp7.e3" e2="DBMI.pac181.sp7.e0" id="DBMI.pac181.sp7.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e3" e2="DBMI.pac181.sp7.e1" id="DBMI.pac181.sp7.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e3" e2="DBMI.pac181.sp7.e2" id="DBMI.pac181.sp7.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp8" origId="sp8" text="If digoxin toxicity is suspected, suspend or discontinue digoxin therapy. In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients. 7.5 Alcohol\n\nVerapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.">
		<entity charOffset="3285-3295" id="DBMI.pac181.sp8.e0" origId="sp8.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="3335-3343" id="DBMI.pac181.sp8.e1" origId="sp8.e1" text="ethanol " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp8.e0" e2="DBMI.pac181.sp8.e1" id="DBMI.pac181.sp8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethanol " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.sp8.e1" e2="DBMI.pac181.sp8.e0" id="DBMI.pac181.sp8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp9" origId="sp9" text="7.6 Clonidine\n\nSinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. Monitor heart rate in patients receiving concomitant verapamil and clonidine. 7.7 Telithromycin\n\nHypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics."/>
	<sentencespan id="DBMI.pac181.sp10" origId="sp10" text="7.8 Antineoplastic Agents\n\nVerapamil can increase doxorubicin levels. The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.">
		<entity charOffset="3930-3940" id="DBMI.pac181.sp10.e0" origId="sp10.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="3953-3965" id="DBMI.pac181.sp10.e1" origId="sp10.e1" text="doxorubicin " type="Active ingredient"/>
		<entity charOffset="4023-4040" id="DBMI.pac181.sp10.e2" origId="sp10.e2" text="cyclophosphamide " type="Active ingredient"/>
		<entity charOffset="3991-4001" id="DBMI.pac181.sp10.e3" origId="sp10.e3" text="verapamil " type="Active ingredient"/>
		<entity charOffset="4041-4049" id="DBMI.pac181.sp10.e4" origId="sp10.e4" text="oncovin " type="Drug product"/>
		<entity charOffset="4050-4063" id="DBMI.pac181.sp10.e5" origId="sp10.e5" text="procarbazine " type="Active ingredient"/>
		<entity charOffset="4064-4075" id="DBMI.pac181.sp10.e6" origId="sp10.e6" text="prednisone " type="Active ingredient"/>
		<entity charOffset="4090-4100" id="DBMI.pac181.sp10.e7" origId="sp10.e7" text="vindesine " type="Active ingredient"/>
		<entity charOffset="4101-4112" id="DBMI.pac181.sp10.e8" origId="sp10.e8" text="adriamycin " type="Drug product"/>
		<entity charOffset="4113-4123" id="DBMI.pac181.sp10.e9" origId="sp10.e9" text="cisplatin " type="Active ingredient"/>
		<entity charOffset="4226-4237" id="DBMI.pac181.sp10.e10" origId="sp10.e10" text="paclitaxel " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="doxorubicin " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p22" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="cyclophosphamide "/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p39" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="paclitaxel " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p43" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="oncovin "/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p44" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="oncovin "/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p54" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="procarbazine "/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p64" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="prednisone "/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p67" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p74" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="vindesine "/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p78" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p79" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p80" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p81" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p82" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p83" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p84" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="adriamycin "/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p85" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="adriamycin "/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p86" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p87" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p88" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p89" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p90" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p91" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p92" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p93" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p94" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p95" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="cisplatin "/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p96" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p97" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p98" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p99" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p100" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p101" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p102" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p103" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p104" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p105" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p106" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p107" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p108" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p109" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p110" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p111" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp11" origId="sp11" text="7.9 Quinidine\n\nIn a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy. The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients."/>
	<sentencespan id="DBMI.pac181.sp12" origId="sp12" text="Verapamil significantly counteracted the effects of quinidine on AV conduction. There has been a report of increased quinidine levels during verapamil therapy. 7.10 Aspirin\n\nIn a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.">
		<entity charOffset="4778-4788" id="DBMI.pac181.sp12.e0" origId="sp12.e0" text="verapamil " type="Active ingredient"/>
		<entity charOffset="4754-4764" id="DBMI.pac181.sp12.e1" origId="sp12.e1" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp12.e0" e2="DBMI.pac181.sp12.e1" id="DBMI.pac181.sp12.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="quinidine " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.sp12.e1" e2="DBMI.pac181.sp12.e0" id="DBMI.pac181.sp12.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp13" origId="sp13" text="7.11 Antihypertensive agents\n\nVerapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure. Monitor patients receiving these combinations appropriately. Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients."/>
	<sentencespan id="DBMI.pac181.sp14" origId="sp14" text="Such an effect was observed in one study following the concomitant administration of verapamil and prazosin. 7.12 Disopyramide\n\nUntil data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration. 7.13 Flecainide\n\nA study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization."/>
	<sentencespan id="DBMI.pac181.sp15" origId="sp15" text="Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction. 7.14 Carbamazepine\n\nVerapamil therapy may increase carbamazepine concentrations during combined therapy. This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.">
		<entity charOffset="6125-6135" id="DBMI.pac181.sp15.e0" origId="sp15.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="6156-6170" id="DBMI.pac181.sp15.e1" origId="sp15.e1" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp15.e0" e2="DBMI.pac181.sp15.e1" id="DBMI.pac181.sp15.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.sp15.e1" e2="DBMI.pac181.sp15.e0" id="DBMI.pac181.sp15.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp16" origId="sp16" text="7.15 Cyclosporine\n\nVerapamil therapy may increase serum levels of cyclosporine. 7.16 Lithium\n\nIncreased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels. However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.">
		<entity charOffset="6323-6333" id="DBMI.pac181.sp16.e0" origId="sp16.e0" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="6370-6383" id="DBMI.pac181.sp16.e1" origId="sp16.e1" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="6500-6510" id="DBMI.pac181.sp16.e2" origId="sp16.e2" text="verapamil " type="Active ingredient"/>
		<entity charOffset="6510-6518" id="DBMI.pac181.sp16.e3" origId="sp16.e3" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp16.e0" e2="DBMI.pac181.sp16.e1" id="DBMI.pac181.sp16.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.sp16.e0" e2="DBMI.pac181.sp16.e2" id="DBMI.pac181.sp16.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e0" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e1" e2="DBMI.pac181.sp16.e0" id="DBMI.pac181.sp16.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e1" e2="DBMI.pac181.sp16.e2" id="DBMI.pac181.sp16.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e1" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e0" id="DBMI.pac181.sp16.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e1" id="DBMI.pac181.sp16.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p9" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium " precipitant="verapamil "/>
		<pair e1="DBMI.pac181.sp16.e3" e2="DBMI.pac181.sp16.e0" id="DBMI.pac181.sp16.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e3" e2="DBMI.pac181.sp16.e1" id="DBMI.pac181.sp16.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e3" e2="DBMI.pac181.sp16.e2" id="DBMI.pac181.sp16.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp17" origId="sp17" text="Patients receiving both drugs must be monitored carefully. 7.17 Inhalation Anesthetics\n\nAnimal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression."/>
	<sentencespan id="DBMI.pac181.sp18" origId="sp18" text="7.18 Neuromuscular Blocking Agents\n\nClinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly. 7.19 Phenobarbital\n\nPhenobarbital therapy may increase verapamil clearance.">
		<entity charOffset="7467-7481" id="DBMI.pac181.sp18.e0" origId="sp18.e0" text="Phenobarbital " type="Active ingredient"/>
		<entity charOffset="7502-7512" id="DBMI.pac181.sp18.e1" origId="sp18.e1" text="verapamil " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp18.e0" e2="DBMI.pac181.sp18.e1" id="DBMI.pac181.sp18.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="Phenobarbital "/>
		<pair e1="DBMI.pac181.sp18.e1" e2="DBMI.pac181.sp18.e0" id="DBMI.pac181.sp18.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp19" origId="sp19" text="7.20 Rifampin\n\nTherapy with rifampin may markedly reduce oral verapamil bioavailability. 7.21 Theophylline\n\nVerapamil may inhibit the clearance and increase the plasma levels of theophylline. 7.22 Cimetidine\n\nThe interaction between cimetidine and chronically administered verapamil has not been studied.">
		<entity charOffset="7552-7561" id="DBMI.pac181.sp19.e0" origId="sp19.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="7586-7596" id="DBMI.pac181.sp19.e1" origId="sp19.e1" text="verapamil " type="Active ingredient"/>
		<entity charOffset="7633-7643" id="DBMI.pac181.sp19.e2" origId="sp19.e2" text="Verapamil " type="Active ingredient"/>
		<entity charOffset="7703-7716" id="DBMI.pac181.sp19.e3" origId="sp19.e3" text="theophylline " type="Active ingredient"/>
		<entity charOffset="7759-7770" id="DBMI.pac181.sp19.e4" origId="sp19.e4" text="cimetidine " type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp19.e0" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="rifampin "/>
		<pair e1="DBMI.pac181.sp19.e0" e2="DBMI.pac181.sp19.e2" id="DBMI.pac181.sp19.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e0" e2="DBMI.pac181.sp19.e3" id="DBMI.pac181.sp19.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e0" e2="DBMI.pac181.sp19.e4" id="DBMI.pac181.sp19.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e1" e2="DBMI.pac181.sp19.e0" id="DBMI.pac181.sp19.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e1" e2="DBMI.pac181.sp19.e2" id="DBMI.pac181.sp19.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e1" e2="DBMI.pac181.sp19.e3" id="DBMI.pac181.sp19.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e1" e2="DBMI.pac181.sp19.e4" id="DBMI.pac181.sp19.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e2" e2="DBMI.pac181.sp19.e0" id="DBMI.pac181.sp19.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e2" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e2" e2="DBMI.pac181.sp19.e3" id="DBMI.pac181.sp19.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="theophylline " precipitant="Verapamil "/>
		<pair e1="DBMI.pac181.sp19.e2" e2="DBMI.pac181.sp19.e4" id="DBMI.pac181.sp19.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e3" e2="DBMI.pac181.sp19.e0" id="DBMI.pac181.sp19.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e3" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e3" e2="DBMI.pac181.sp19.e2" id="DBMI.pac181.sp19.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e3" e2="DBMI.pac181.sp19.e4" id="DBMI.pac181.sp19.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e0" id="DBMI.pac181.sp19.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil " precipitant="cimetidine "/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p18" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="verapamil " precipitant="cimetidine "/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e2" id="DBMI.pac181.sp19.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e3" id="DBMI.pac181.sp19.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp20" origId="sp20" text="Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged. 7.23 Nitrates\n\nVerapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions. The pharmacologic profile of both drugs and the clinical experience suggest beneficial interactions."/>
</document>

<document id="DBMI.pac183" origId="pac183">
	<sentence id="DBMI.pac183.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nDrugs with pH-Dependent Absorption Kinetics\n\nLansoprazole delayed-release capsules causes long-lasting inhibition of gastric acid secretion."/>
	<sentence id="DBMI.pac183.s1" origId="s1" text="Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.">
		<entity charOffset="162-175" id="DBMI.pac183.s1.e0" origId="s1.e0" text="Lansoprazole " type="Active ingredient"/>
		<entity charOffset="310-321" id="DBMI.pac183.s1.e1" origId="s1.e1" text="atazanavir " type="Active ingredient"/>
		<pair e1="DBMI.pac183.s1.e0" e2="DBMI.pac183.s1.e1" id="DBMI.pac183.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir " precipitant="Lansoprazole "/>
		<pair e1="DBMI.pac183.s1.e1" e2="DBMI.pac183.s1.e0" id="DBMI.pac183.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s2" origId="s2" text="Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir."/>
	<sentence id="DBMI.pac183.s3" origId="s3" text="[See Clinical Pharmacology (12.5)]\n\nIt is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).">
		<entity charOffset="672-685" id="DBMI.pac183.s3.e0" origId="s3.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="890-903" id="DBMI.pac183.s3.e1" origId="s3.e1" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="878-883" id="DBMI.pac183.s3.e2" origId="s3.e2" text="iron " type="Active ingredient"/>
		<entity charOffset="850-861" id="DBMI.pac183.s3.e3" origId="s3.e3" text="ampicillin " type="Active ingredient"/>
		<entity charOffset="869-877" id="DBMI.pac183.s3.e4" origId="s3.e4" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac183.s3.e0" e2="DBMI.pac183.s3.e1" id="DBMI.pac183.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.s3.e0" e2="DBMI.pac183.s3.e2" id="DBMI.pac183.s3.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="iron " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.s3.e0" e2="DBMI.pac183.s3.e3" id="DBMI.pac183.s3.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.s3.e0" e2="DBMI.pac183.s3.e4" id="DBMI.pac183.s3.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.s3.e1" e2="DBMI.pac183.s3.e0" id="DBMI.pac183.s3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e1" e2="DBMI.pac183.s3.e2" id="DBMI.pac183.s3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e1" e2="DBMI.pac183.s3.e3" id="DBMI.pac183.s3.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e1" e2="DBMI.pac183.s3.e4" id="DBMI.pac183.s3.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e2" e2="DBMI.pac183.s3.e0" id="DBMI.pac183.s3.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e2" e2="DBMI.pac183.s3.e1" id="DBMI.pac183.s3.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e2" e2="DBMI.pac183.s3.e3" id="DBMI.pac183.s3.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e2" e2="DBMI.pac183.s3.e4" id="DBMI.pac183.s3.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e3" e2="DBMI.pac183.s3.e0" id="DBMI.pac183.s3.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e3" e2="DBMI.pac183.s3.e1" id="DBMI.pac183.s3.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e3" e2="DBMI.pac183.s3.e2" id="DBMI.pac183.s3.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e3" e2="DBMI.pac183.s3.e4" id="DBMI.pac183.s3.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e4" e2="DBMI.pac183.s3.e0" id="DBMI.pac183.s3.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e4" e2="DBMI.pac183.s3.e1" id="DBMI.pac183.s3.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e4" e2="DBMI.pac183.s3.e2" id="DBMI.pac183.s3.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e4" e2="DBMI.pac183.s3.e3" id="DBMI.pac183.s3.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s4" origId="s4" text="[See Clinical Pharmacology (12.5)]\n\nWarfarin\n\nIn a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).">
		<entity charOffset="1038-1051" id="DBMI.pac183.s4.e0" origId="s4.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="1128-1137" id="DBMI.pac183.s4.e1" origId="s4.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac183.s4.e0" e2="DBMI.pac183.s4.e1" id="DBMI.pac183.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.s4.e1" e2="DBMI.pac183.s4.e0" id="DBMI.pac183.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s5" origId="s5" text="However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly."/>
	<sentence id="DBMI.pac183.s6" origId="s6" text="Increases in INR and prothrombin time may lead to abnormal bleeding and even death."/>
	<sentence id="DBMI.pac183.s7" origId="s7" text="Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time."/>
	<sentence id="DBMI.pac183.s8" origId="s8" text="[See Clinical Pharmacology (12.5)]\n\nTacrolimus\n\nConcomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.">
		<entity charOffset="1603-1616" id="DBMI.pac183.s8.e0" origId="s8.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="1620-1631" id="DBMI.pac183.s8.e1" origId="s8.e1" text="tacrolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac183.s8.e0" e2="DBMI.pac183.s8.e1" id="DBMI.pac183.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.s8.e1" e2="DBMI.pac183.s8.e0" id="DBMI.pac183.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s9" origId="s9" text="Theophylline\n\nA minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.">
		<entity charOffset="1882-1895" id="DBMI.pac183.s9.e0" origId="s9.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="1824-1837" id="DBMI.pac183.s9.e1" origId="s9.e1" text="theophylline " type="Active ingredient"/>
		<pair e1="DBMI.pac183.s9.e0" e2="DBMI.pac183.s9.e1" id="DBMI.pac183.s9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="theophylline " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.s9.e1" e2="DBMI.pac183.s9.e0" id="DBMI.pac183.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s10" origId="s10" text="Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels."/>
	<sentence id="DBMI.pac183.s11" origId="s11" text="[See Clinical Pharmacology (12.5)]\n\nFor information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections."/>
	<sentencespan id="DBMI.pac183.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nDrugs with pH-Dependent Absorption Kinetics\n\nLansoprazole delayed-release capsules causes long-lasting inhibition of gastric acid secretion. Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.">
		<entity charOffset="162-175" id="DBMI.pac183.sp0.e0" origId="sp0.e0" text="Lansoprazole " type="Active ingredient"/>
		<entity charOffset="310-321" id="DBMI.pac183.sp0.e1" origId="sp0.e1" text="atazanavir " type="Active ingredient"/>
		<pair e1="DBMI.pac183.sp0.e0" e2="DBMI.pac183.sp0.e1" id="DBMI.pac183.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir " precipitant="Lansoprazole "/>
		<pair e1="DBMI.pac183.sp0.e1" e2="DBMI.pac183.sp0.e0" id="DBMI.pac183.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac183.sp1" origId="sp1" text="[See Clinical Pharmacology (12.5)]\n\nIt is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). [See Clinical Pharmacology (12.5)]\n\nWarfarin\n\nIn a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5). However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.">
		<entity charOffset="1038-1051" id="DBMI.pac183.sp1.e0" origId="sp1.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="1128-1137" id="DBMI.pac183.sp1.e1" origId="sp1.e1" text="warfarin " type="Active ingredient"/>
		<entity charOffset="890-903" id="DBMI.pac183.sp1.e2" origId="sp1.e2" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="878-883" id="DBMI.pac183.sp1.e3" origId="sp1.e3" text="iron " type="Active ingredient"/>
		<entity charOffset="850-861" id="DBMI.pac183.sp1.e4" origId="sp1.e4" text="ampicillin " type="Active ingredient"/>
		<entity charOffset="869-877" id="DBMI.pac183.sp1.e5" origId="sp1.e5" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="iron " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p4" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac183.sp2" origId="sp2" text="Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. [See Clinical Pharmacology (12.5)]\n\nTacrolimus\n\nConcomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.">
		<entity charOffset="1603-1616" id="DBMI.pac183.sp2.e0" origId="sp2.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="1620-1631" id="DBMI.pac183.sp2.e1" origId="sp2.e1" text="tacrolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac183.sp2.e0" e2="DBMI.pac183.sp2.e1" id="DBMI.pac183.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.sp2.e1" e2="DBMI.pac183.sp2.e0" id="DBMI.pac183.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac183.sp3" origId="sp3" text="Theophylline\n\nA minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline. Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels. [See Clinical Pharmacology (12.5)]\n\nFor information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.">
		<entity charOffset="1882-1895" id="DBMI.pac183.sp3.e0" origId="sp3.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="1824-1837" id="DBMI.pac183.sp3.e1" origId="sp3.e1" text="theophylline " type="Active ingredient"/>
		<pair e1="DBMI.pac183.sp3.e0" e2="DBMI.pac183.sp3.e1" id="DBMI.pac183.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="theophylline " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac183.sp3.e1" e2="DBMI.pac183.sp3.e0" id="DBMI.pac183.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac184" origId="pac184">
	<sentence id="DBMI.pac184.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nLansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell."/>
	<sentence id="DBMI.pac184.s1" origId="s1" text="Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production."/>
	<sentence id="DBMI.pac184.s2" origId="s2" text="This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus."/>
	<sentence id="DBMI.pac184.s3" origId="s3" text="Lansoprazole does not exhibit anticholinergic or histamine type-2 antagonist activity."/>
	<sentence id="DBMI.pac184.s4" origId="s4" text="12.2 Pharmacodynamics\n\nAntisecretory Activity: After oral administration, lansoprazole was shown to significantly decrease the basal acid output and significantly increase the mean gastric pH and percent of time the gastric pH was greater than 3 and greater than 4."/>
	<sentence id="DBMI.pac184.s5" origId="s5" text="Lansoprazole also significantly reduced meal-stimulated gastric acid output and secretion volume, as well as pentagastrin-stimulated acid output."/>
	<sentence id="DBMI.pac184.s6" origId="s6" text="In patients with hypersecretion of acid, lansoprazole significantly reduced basal and pentagastrin-stimulated gastric acid secretion."/>
	<sentence id="DBMI.pac184.s7" origId="s7" text="Lansoprazole inhibited the normal increases in secretion volume, acidity and acid output induced by insulin."/>
	<sentence id="DBMI.pac184.s8" origId="s8" text="The intragastric pH results of a five-day, pharmacodynamic, crossover study of 15 mg and 30 mg of once daily lansoprazole are presented in Table 4:\n\nAfter the initial dose in this study, increased gastric pH was seen within 1 to 2 hours with 30 mg of lansoprazole and 2 to 3 hours with 15 mg of lansoprazole."/>
	<sentence id="DBMI.pac184.s9" origId="s9" text="After multiple daily dosing, increased gastric pH was seen within the first hour post-dosing with 30 mg of lansoprazole and within 1 to 2 hours post-dosing with 15 mg of lansoprazole."/>
	<sentence id="DBMI.pac184.s10" origId="s10" text="Acid suppression may enhance the effect of antimicrobials in eradicating Helicobacter pylori (H. pylori)."/>
	<sentence id="DBMI.pac184.s11" origId="s11" text="The percentage of time gastric pH was elevated above 5 and 6 was evaluated in a crossover study of lansoprazole delayed-release capsules given daily, twice daily and three times daily (Table 5)."/>
	<sentence id="DBMI.pac184.s12" origId="s12" text="The inhibition of gastric acid secretion as measured by intragastric pH gradually returned to normal over two to four days after multiple doses."/>
	<sentence id="DBMI.pac184.s13" origId="s13" text="There was no indication of rebound gastric acidity."/>
	<sentence id="DBMI.pac184.s14" origId="s14" text="Enterochromaffin-like (ECL) Cell Effects\n\nDuring lifetime exposure of rats with up to 150 mg/kg/day of lansoprazole dosed seven days per week, marked hypergastrinemia was observed followed by ECL cell proliferation and formation of carcinoid tumors, especially in female rats."/>
	<sentence id="DBMI.pac184.s15" origId="s15" text="Gastric biopsy specimens from the body of the stomach from approximately 150 patients treated continuously with lansoprazole for at least one year did not show evidence of ECL cell effects similar to those seen in rat studies."/>
	<sentence id="DBMI.pac184.s16" origId="s16" text="Longer term data are needed to rule out the possibility of an increased risk of the development of gastric tumors in patients receiving long-term therapy with lansoprazole."/>
	<sentence id="DBMI.pac184.s17" origId="s17" text="[See Nonclinical Toxicology (13.1)]\n\nOther Gastric Effects in Humans\n\nLansoprazole did not significantly affect mucosal blood flow in the fundus of the stomach."/>
	<sentence id="DBMI.pac184.s18" origId="s18" text="Due to the normal physiologic effect caused by the inhibition of gastric acid secretion, a decrease of about 17% in blood flow in the antrum, pylorus, and duodenal bulb was seen."/>
	<sentence id="DBMI.pac184.s19" origId="s19" text="Lansoprazole significantly slowed the gastric emptying of digestible solids."/>
	<sentence id="DBMI.pac184.s20" origId="s20" text="Lansoprazole increased serum pepsinogen levels and decreased pepsin activity under basal conditions and in response to meal stimulation or insulin injection."/>
	<sentence id="DBMI.pac184.s21" origId="s21" text="As with other agents that elevate intragastric pH, increases in gastric pH were associated with increases in nitrate-reducing bacteria and elevation of nitrite concentration in gastric juice in patients with gastric ulcer."/>
	<sentence id="DBMI.pac184.s22" origId="s22" text="No significant increase in nitrosamine concentrations was observed."/>
	<sentence id="DBMI.pac184.s23" origId="s23" text="Serum Gastrin Effects\n\nIn over 2100 patients, median fasting serum gastrin levels increased 50% to 100% from baseline but remained within normal range after treatment with 15 to 60 mg of oral lansoprazole."/>
	<sentence id="DBMI.pac184.s24" origId="s24" text="These elevations reached a plateau within two months of therapy and returned to pretreatment levels within four weeks after discontinuation of therapy."/>
	<sentence id="DBMI.pac184.s25" origId="s25" text="Endocrine Effects\n\nHuman studies for up to one year have not detected any clinically significant effects on the endocrine system."/>
	<sentence id="DBMI.pac184.s26" origId="s26" text="Hormones studied include testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEA-S), prolactin, cortisol, estradiol, insulin, aldosterone, parathormone, glucagon, thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and somatotropic hormone (STH)."/>
	<sentence id="DBMI.pac184.s27" origId="s27" text="Lansoprazole in oral doses of 15 to 60 mg for up to one year had no clinically significant effect on sexual function."/>
	<sentence id="DBMI.pac184.s28" origId="s28" text="In addition, lansoprazole in oral doses of 15 to 60 mg for two to eight weeks had no clinically significant effect on thyroid function."/>
	<sentence id="DBMI.pac184.s29" origId="s29" text="In 24-month carcinogenicity studies in Sprague-Dawley rats with daily lansoprazole dosages up to 150 mg/kg, proliferative changes in the Leydig cells of the testes, including benign neoplasm, were increased compared to control rats."/>
	<sentence id="DBMI.pac184.s30" origId="s30" text="Other Effects\n\nNo systemic effects of lansoprazole on the central nervous system, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems have been found in humans."/>
	<sentence id="DBMI.pac184.s31" origId="s31" text="Among 56 patients who had extensive baseline eye evaluations, no visual toxicity was observed after lansoprazole treatment (up to 180 mg/day) for up to 58 months."/>
	<sentence id="DBMI.pac184.s32" origId="s32" text="After lifetime lansoprazole exposure in rats, focal pancreatic atrophy, diffuse lymphoid hyperplasia in the thymus, and spontaneous retinal atrophy were seen."/>
	<sentence id="DBMI.pac184.s33" origId="s33" text="Microbiology\n\nLansoprazole, clarithromycin and/or amoxicillin have been shown to be active against most strains of Helicobacter pylori in vitro and in clinical infections as described in the INDICATIONS AND USAGE section."/>
	<sentence id="DBMI.pac184.s34" origId="s34" text="[SeeIndications and Usage (1.2)]  \n\nHelicobacter pylori Pretreatment Resistance\n\nClarithromycin pretreatment resistance (2.0 mcg/mL) was 9.5% (91/960) by E-test and 11.3% (12/106) by agar dilution in the dual and triple therapy clinical trials (M93-125, M93-130, M93-131, M95-392, and M95-399)."/>
	<sentence id="DBMI.pac184.s35" origId="s35" text="Amoxicillin pretreatment susceptible isolates (0.25 mcg/mL) occurred in 97.8% (936/957) and 98 % (98/100) of the patients in the dual and triple therapy clinical trials by E-test and agar dilution, respectively."/>
	<sentence id="DBMI.pac184.s36" origId="s36" text="Twenty-one of 957 patients (2.2%) by E-test and 2 of 100 patients (2%) by agar dilution had amoxicillin pretreatment MICs of greater than 0.25 mcg/mL."/>
	<sentence id="DBMI.pac184.s37" origId="s37" text="One patient on the 14-day triple therapy regimen had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of greater than 256 mcg/mL by E-test and the patient was eradicated of H. pylori (Table 6)."/>
	<sentence id="DBMI.pac184.s38" origId="s38" text="Patients not eradicated of H. pylori following lansoprazole/amoxicillin/clarithromycin triple therapy will likely have clarithromycin resistant H. pylori."/>
	<sentence id="DBMI.pac184.s39" origId="s39" text="Therefore, for those patients who fail therapy, clarithromycin susceptibility testing should be done when possible."/>
	<sentence id="DBMI.pac184.s40" origId="s40" text="Patients with clarithromycin resistant H. pylori should not be treated withlansoprazole/amoxicillin/clarithromycin triple therapy or with regimens which include clarithromycin as the sole antimicrobial agent."/>
	<sentence id="DBMI.pac184.s41" origId="s41" text="Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes: In the dual and triple therapy clinical trials, 82.6% (195/236) of the patients that had pretreatment amoxicillin susceptible MICs (0.25 mcg/mL) were eradicated of H. pylori."/>
	<sentence id="DBMI.pac184.s42" origId="s42" text="Of those with pretreatment amoxicillin MICs of greater than 0.25 mcg/mL, three of six had the H. pylori eradicated."/>
	<sentence id="DBMI.pac184.s43" origId="s43" text="A total of 30% (21/70) of the patients failed lansoprazole 30 mg three times daily /amoxicillin 1 gm three times daily dual therapy and a total of 12.8% (22/172) of the patients failed the 10 and 14 day triple therapy regimens."/>
	<sentence id="DBMI.pac184.s44" origId="s44" text="Post-treatment susceptibility results were not obtained on 11 of the patients who failed therapy."/>
	<sentence id="DBMI.pac184.s45" origId="s45" text="Nine of the 11 patients with amoxicillin post-treatment MICs that failed the triple therapy regimen also had clarithromycin resistant H. pylori isolates."/>
	<sentence id="DBMI.pac184.s46" origId="s46" text="Susceptibility Test for Helicobacter pylori: The reference methodology for susceptibility testing of H. pylori is agar dilution MICs.1 One to three microliters of an inoculum equivalent to a No."/>
	<sentence id="DBMI.pac184.s47" origId="s47" text="2 McFarland standard (1 x 107 to 1 x 108 CFU/mL for H. pylori) are inoculated directly onto freshly prepared antimicrobial-containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood (2 weeks old)."/>
	<sentence id="DBMI.pac184.s48" origId="s48" text="The agar dilution plates are incubated at 35C in a microaerobic environment produced by a gas generating system suitable for campylobacters."/>
	<sentence id="DBMI.pac184.s49" origId="s49" text="After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism."/>
	<sentence id="DBMI.pac184.s50" origId="s50" text="The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria (Table 7):\n\nStandardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures."/>
	<sentence id="DBMI.pac184.s51" origId="s51" text="Standard clarithromycin and amoxicillin powders should provide the following MIC values (Table 8):\n\n12.3 Pharmacokinetics\n\nLansoprazole delayed-release capsules contain an enteric-coated granule formulation of lansoprazole."/>
	<sentence id="DBMI.pac184.s52" origId="s52" text="Absorption of lansoprazole begins only after the granules leave the stomach."/>
	<sentence id="DBMI.pac184.s53" origId="s53" text="Absorption is rapid, with mean peak plasma levels of lansoprazole occurring after approximately 1.7 hours."/>
	<sentence id="DBMI.pac184.s54" origId="s54" text="After a single-dose administration of 15 mg to 60 mg of oral lansoprazole, the peak plasma concentrations (Cmax) of lansoprazole and the area under the plasma concentration curves (AUCs) of lansoprazole were approximately proportional to the administered dose."/>
	<sentence id="DBMI.pac184.s55" origId="s55" text="Lansoprazole does not accumulate and its pharmacokinetics are unaltered by multiple dosing."/>
	<sentence id="DBMI.pac184.s56" origId="s56" text="Absorption: The absorption of lansoprazole is rapid, with the mean Cmax occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%."/>
	<sentence id="DBMI.pac184.s57" origId="s57" text="In healthy subjects, the mean (SD) plasma half-life was 1.5 (1.0) hours."/>
	<sentence id="DBMI.pac184.s58" origId="s58" text="Both the Cmax and AUC are diminished by about 50% to 70% if lansoprazole is given 30 minutes after food, compared to the fasting condition."/>
	<sentence id="DBMI.pac184.s59" origId="s59" text="There is no significant food effect if lansoprazole is given before meals."/>
	<sentence id="DBMI.pac184.s60" origId="s60" text="Distribution: Lansoprazole is 97% bound to plasma proteins."/>
	<sentence id="DBMI.pac184.s61" origId="s61" text="Plasma protein binding is constant over the concentration range of 0.05 to 5.0 mcg/mL."/>
	<sentence id="DBMI.pac184.s62" origId="s62" text="Metabolism: Lansoprazole is extensively metabolized in the liver."/>
	<sentence id="DBMI.pac184.s63" origId="s63" text="Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole)."/>
	<sentence id="DBMI.pac184.s64" origId="s64" text="These metabolites have very little or no antisecretory activity."/>
	<sentence id="DBMI.pac184.s65" origId="s65" text="Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by blocking the proton pump [(H+, K+)-ATPase enzyme system] at the secretory surface of the gastric parietal cell."/>
	<sentence id="DBMI.pac184.s66" origId="s66" text="The two active species are not present in the systemic circulation."/>
	<sentence id="DBMI.pac184.s67" origId="s67" text="The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours."/>
	<sentence id="DBMI.pac184.s68" origId="s68" text="Therefore, the plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion."/>
	<sentence id="DBMI.pac184.s69" origId="s69" text="Elimination: Following single-dose oral administration of lansoprazole delayed-release capsules, virtually no unchanged lansoprazole was excreted in the urine."/>
	<sentence id="DBMI.pac184.s70" origId="s70" text="In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces."/>
	<sentence id="DBMI.pac184.s71" origId="s71" text="This implies a significant biliary excretion of the lansoprazole metabolites."/>
	<sentence id="DBMI.pac184.s72" origId="s72" text="12.4 Specific Populations\n\nPediatric Use:\n\nOne to 17 years of age\n\nThe pharmacokinetics of lansoprazole were studied in pediatric patients with GERD aged 1 to 11 years and 12 to 17 years in two separate clinical studies."/>
	<sentence id="DBMI.pac184.s73" origId="s73" text="In children aged 1 to 11 years, lansoprazole was dosed 15 mg daily for subjects weighing  30 kg and 30 mg daily for subjects weighing greater than 30 kg."/>
	<sentence id="DBMI.pac184.s74" origId="s74" text="Mean Cmax and AUC values observed on Day 5 of dosing were similar between the two dose groups and were not affected by weight or age within each weight-adjusted dose group used in the study."/>
	<sentence id="DBMI.pac184.s75" origId="s75" text="In adolescent subjects aged 12 to 17 years, subjects were randomized to receive lansoprazole at 15 mg or 30 mg daily."/>
	<sentence id="DBMI.pac184.s76" origId="s76" text="Mean Cmax and AUC values of lansoprazole were not affected by body weight or age; and nearly dose-proportional increases in mean Cmax and AUC values were observed between the two dose groups in the study."/>
	<sentence id="DBMI.pac184.s77" origId="s77" text="Overall, lansoprazole pharmacokinetics in pediatric patients aged 1 to 17 years were similar to those observed in healthy adult subjects."/>
	<sentence id="DBMI.pac184.s78" origId="s78" text="Geriatric Use: The clearance of lansoprazole is decreased in the elderly, with elimination half-life increased approximately 50% to 100%."/>
	<sentence id="DBMI.pac184.s79" origId="s79" text="Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole."/>
	<sentence id="DBMI.pac184.s80" origId="s80" text="Peak plasma levels were not increased in the elderly."/>
	<sentence id="DBMI.pac184.s81" origId="s81" text="No dosage adjustment is necessary in the elderly [See Use in Specific Populations (8.5)]."/>
	<sentence id="DBMI.pac184.s82" origId="s82" text="Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1% to 1.5% after administration of 60 mg of lansoprazole."/>
	<sentence id="DBMI.pac184.s83" origId="s83" text="Patients with renal impairment had a shortened elimination half-life and decreased total AUC (free and bound)."/>
	<sentence id="DBMI.pac184.s84" origId="s84" text="The AUC for free lansoprazole in plasma, however, was not related to the degree of renal impairment; and the Cmax and tmax (time to reach the maximum concentration) were not different than the Cmax and tmax from subjects with normal renal function."/>
	<sentence id="DBMI.pac184.s85" origId="s85" text="No dosage adjustment is necessary in patients with renal impairment [See Use in Specific Populations (8.6])."/>
	<sentence id="DBMI.pac184.s86" origId="s86" text="Hepatic Impairment: In patients with various degrees of chronic hepatic impairment, the mean plasma half-life of lansoprazole was prolonged from 1.5 hours to 3.2 to 7.2 hours."/>
	<sentence id="DBMI.pac184.s87" origId="s87" text="An increase in the mean AUC of up to 500% was observed at steady state in hepatically-impaired patients compared to healthy subjects."/>
	<sentence id="DBMI.pac184.s88" origId="s88" text="Consider dose reduction in patients with severe hepatic impairment [See Use in Specific Populations (8.7)]."/>
	<sentence id="DBMI.pac184.s89" origId="s89" text="Gender: In a study comparing 12 male and 6 female human subjects who received lansoprazole, no gender differences were found in pharmacokinetics and intragastric pH results [See Use in Specific Populations (8.5)]."/>
	<sentence id="DBMI.pac184.s90" origId="s90" text="12.5 Drug-Drug Interactions\n\nIt is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).">
		<entity charOffset="14590-14603" id="DBMI.pac184.s90.e0" origId="s90.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="14768-14776" id="DBMI.pac184.s90.e1" origId="s90.e1" text="digoxin " type="Active ingredient"/>
		<entity charOffset="14756-14761" id="DBMI.pac184.s90.e2" origId="s90.e2" text="iron " type="Active ingredient"/>
		<entity charOffset="14723-14736" id="DBMI.pac184.s90.e3" origId="s90.e3" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="14737-14748" id="DBMI.pac184.s90.e4" origId="s90.e4" text="ampicillin " type="Active ingredient"/>
		<pair e1="DBMI.pac184.s90.e0" e2="DBMI.pac184.s90.e1" id="DBMI.pac184.s90.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s90.e0" e2="DBMI.pac184.s90.e2" id="DBMI.pac184.s90.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="iron " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s90.e0" e2="DBMI.pac184.s90.e3" id="DBMI.pac184.s90.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s90.e0" e2="DBMI.pac184.s90.e4" id="DBMI.pac184.s90.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s90.e1" e2="DBMI.pac184.s90.e0" id="DBMI.pac184.s90.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e1" e2="DBMI.pac184.s90.e2" id="DBMI.pac184.s90.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e1" e2="DBMI.pac184.s90.e3" id="DBMI.pac184.s90.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e1" e2="DBMI.pac184.s90.e4" id="DBMI.pac184.s90.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e2" e2="DBMI.pac184.s90.e0" id="DBMI.pac184.s90.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e2" e2="DBMI.pac184.s90.e1" id="DBMI.pac184.s90.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e2" e2="DBMI.pac184.s90.e3" id="DBMI.pac184.s90.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e2" e2="DBMI.pac184.s90.e4" id="DBMI.pac184.s90.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e3" e2="DBMI.pac184.s90.e0" id="DBMI.pac184.s90.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e3" e2="DBMI.pac184.s90.e1" id="DBMI.pac184.s90.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e3" e2="DBMI.pac184.s90.e2" id="DBMI.pac184.s90.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e3" e2="DBMI.pac184.s90.e4" id="DBMI.pac184.s90.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e4" e2="DBMI.pac184.s90.e0" id="DBMI.pac184.s90.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e4" e2="DBMI.pac184.s90.e1" id="DBMI.pac184.s90.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e4" e2="DBMI.pac184.s90.e2" id="DBMI.pac184.s90.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e4" e2="DBMI.pac184.s90.e3" id="DBMI.pac184.s90.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s91" origId="s91" text="Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes."/>
	<sentence id="DBMI.pac184.s92" origId="s92" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.">
		<entity charOffset="14920-14933" id="DBMI.pac184.s92.e0" origId="s92.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="15134-15143" id="DBMI.pac184.s92.e1" origId="s92.e1" text="diazepam " type="Active ingredient"/>
		<entity charOffset="15122-15133" id="DBMI.pac184.s92.e2" origId="s92.e2" text="prednisone " type="Active ingredient"/>
		<entity charOffset="15147-15162" id="DBMI.pac184.s92.e3" origId="s92.e3" text="clarithromycin " type="Active ingredient"/>
		<entity charOffset="15061-15072" id="DBMI.pac184.s92.e4" origId="s92.e4" text="antipyrine " type="Active ingredient"/>
		<entity charOffset="15109-15121" id="DBMI.pac184.s92.e5" origId="s92.e5" text="propranolol " type="Active ingredient"/>
		<entity charOffset="15087-15097" id="DBMI.pac184.s92.e6" origId="s92.e6" text="ibuprofen " type="Active ingredient"/>
		<entity charOffset="15098-15108" id="DBMI.pac184.s92.e7" origId="s92.e7" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="15051-15060" id="DBMI.pac184.s92.e8" origId="s92.e8" text="warfarin " type="Active ingredient"/>
		<entity charOffset="15073-15086" id="DBMI.pac184.s92.e9" origId="s92.e9" text="indomethacin " type="Active ingredient"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="prednisone " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="prednisone " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="clarithromycin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="clarithromycin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p6" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="antipyrine " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="antipyrine " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p9" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ibuprofen " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p11" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ibuprofen " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p13" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p14" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p15" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e9" id="DBMI.pac184.s92.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="indomethacin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e9" id="DBMI.pac184.s92.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e9" id="DBMI.pac184.s92.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e9" id="DBMI.pac184.s92.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e9" id="DBMI.pac184.s92.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e9" id="DBMI.pac184.s92.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p64" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p67" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e9" id="DBMI.pac184.s92.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p74" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p78" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e9" id="DBMI.pac184.s92.p79" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p80" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p81" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p82" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p83" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p84" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p85" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p86" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p87" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e9" id="DBMI.pac184.s92.p88" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e9" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p89" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e9" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p90" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e9" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p91" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e9" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p92" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e9" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p93" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e9" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p94" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e9" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p95" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e9" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p96" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e9" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p97" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s93" origId="s93" text="These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A."/>
	<sentence id="DBMI.pac184.s94" origId="s94" text="Atazanavir: Lansoprazole delayed-release capsules causes long-lasting inhibition of gastric acid secretion.lansoprazole delayed-release capsules substantially decreases the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.">
		<entity charOffset="15419-15432" id="DBMI.pac184.s94.e0" origId="s94.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="15539-15550" id="DBMI.pac184.s94.e1" origId="s94.e1" text="atazanavir " type="Active ingredient"/>
		<pair e1="DBMI.pac184.s94.e0" e2="DBMI.pac184.s94.e1" id="DBMI.pac184.s94.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s94.e1" e2="DBMI.pac184.s94.e0" id="DBMI.pac184.s94.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s95" origId="s95" text="Therefore, lansoprazole delayed-release capsules, or other proton pump inhibitors, should not be co-administered with atazanavir."/>
	<sentence id="DBMI.pac184.s96" origId="s96" text="Theophylline: When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.">
		<entity charOffset="15870-15883" id="DBMI.pac184.s96.e0" origId="s96.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="16018-16031" id="DBMI.pac184.s96.e1" origId="s96.e1" text="theophylline " type="Active ingredient"/>
		<pair e1="DBMI.pac184.s96.e0" e2="DBMI.pac184.s96.e1" id="DBMI.pac184.s96.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="theophylline " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s96.e1" e2="DBMI.pac184.s96.e0" id="DBMI.pac184.s96.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s97" origId="s97" text="Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern."/>
	<sentence id="DBMI.pac184.s98" origId="s98" text="Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels."/>
	<sentence id="DBMI.pac184.s99" origId="s99" text="Warfarin: In a study of healthy subjects neither the pharmacokinetics of warfarin enantiomers nor prothrombin time were affected following single or multiple 60 mg doses of lansoprazole."/>
	<sentence id="DBMI.pac184.s100" origId="s100" text="However, there have been reports of increased International Normalized Ratio (INR) and prothrombin time in patients receiving proton pump inhibitors, including lansoprazole delayed-release capsules, and warfarin concomitantly.">
		<entity charOffset="16566-16579" id="DBMI.pac184.s100.e0" origId="s100.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="16466-16475" id="DBMI.pac184.s100.e1" origId="s100.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac184.s100.e0" e2="DBMI.pac184.s100.e1" id="DBMI.pac184.s100.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s100.e1" e2="DBMI.pac184.s100.e0" id="DBMI.pac184.s100.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s101" origId="s101" text="Increases in INR and prothrombin time may lead to abnormal bleeding and even death."/>
	<sentence id="DBMI.pac184.s102" origId="s102" text="Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time."/>
	<sentence id="DBMI.pac184.s103" origId="s103" text="Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.">
		<entity charOffset="17280-17289" id="DBMI.pac184.s103.e0" origId="s103.e0" text="naproxen " type="Active ingredient"/>
		<entity charOffset="17403-17416" id="DBMI.pac184.s103.e1" origId="s103.e1" text="methotrexate " type="Active ingredient"/>
		<entity charOffset="17420-17442" id="DBMI.pac184.s103.e2" origId="s103.e2" text="7-hydroxymethotrexate " type="Metabolite"/>
		<entity charOffset="17312-17325" id="DBMI.pac184.s103.e3" origId="s103.e3" text="lansoprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac184.s103.e0" e2="DBMI.pac184.s103.e1" id="DBMI.pac184.s103.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate " precipitant="naproxen "/>
		<pair e1="DBMI.pac184.s103.e0" e2="DBMI.pac184.s103.e2" id="DBMI.pac184.s103.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="7-hydroxymethotrexate " precipitant="naproxen "/>
		<pair e1="DBMI.pac184.s103.e0" e2="DBMI.pac184.s103.e3" id="DBMI.pac184.s103.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e1" e2="DBMI.pac184.s103.e0" id="DBMI.pac184.s103.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e1" e2="DBMI.pac184.s103.e2" id="DBMI.pac184.s103.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e1" e2="DBMI.pac184.s103.e3" id="DBMI.pac184.s103.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e2" e2="DBMI.pac184.s103.e0" id="DBMI.pac184.s103.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e2" e2="DBMI.pac184.s103.e1" id="DBMI.pac184.s103.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e2" e2="DBMI.pac184.s103.e3" id="DBMI.pac184.s103.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e3" e2="DBMI.pac184.s103.e0" id="DBMI.pac184.s103.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e3" e2="DBMI.pac184.s103.e1" id="DBMI.pac184.s103.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s103.e3" e2="DBMI.pac184.s103.e1" id="DBMI.pac184.s103.p11" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.s103.e3" e2="DBMI.pac184.s103.e2" id="DBMI.pac184.s103.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="7-hydroxymethotrexate " precipitant="lansoprazole "/>
	</sentence>
	<sentence id="DBMI.pac184.s104" origId="s104" text="While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted."/>
	<sentence id="DBMI.pac184.s105" origId="s105" text="Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.">
		<entity charOffset="17581-17594" id="DBMI.pac184.s105.e0" origId="s105.e0" text="Lansoprazole " type="Active ingredient"/>
		<entity charOffset="17690-17702" id="DBMI.pac184.s105.e1" origId="s105.e1" text="amoxicillin " type="Active ingredient"/>
		<pair e1="DBMI.pac184.s105.e0" e2="DBMI.pac184.s105.e1" id="DBMI.pac184.s105.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amoxicillin " precipitant="Lansoprazole "/>
		<pair e1="DBMI.pac184.s105.e1" e2="DBMI.pac184.s105.e0" id="DBMI.pac184.s105.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s106" origId="s106" text="Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.">
		<entity charOffset="17871-17882" id="DBMI.pac184.s106.e0" origId="s106.e0" text="sucralfate " type="Active ingredient"/>
		<entity charOffset="17759-17772" id="DBMI.pac184.s106.e1" origId="s106.e1" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="17807-17818" id="DBMI.pac184.s106.e2" origId="s106.e2" text="omeprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac184.s106.e0" e2="DBMI.pac184.s106.e1" id="DBMI.pac184.s106.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="lansoprazole " precipitant="sucralfate "/>
		<pair e1="DBMI.pac184.s106.e0" e2="DBMI.pac184.s106.e2" id="DBMI.pac184.s106.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole " precipitant="sucralfate "/>
		<pair e1="DBMI.pac184.s106.e1" e2="DBMI.pac184.s106.e0" id="DBMI.pac184.s106.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e1" e2="DBMI.pac184.s106.e2" id="DBMI.pac184.s106.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e2" e2="DBMI.pac184.s106.e0" id="DBMI.pac184.s106.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e2" e2="DBMI.pac184.s106.e1" id="DBMI.pac184.s106.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s107" origId="s107" text="Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate."/>
	<sentence id="DBMI.pac184.s108" origId="s108" text="In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules and there was no evidence of a change in the efficacy of lansoprazole delayed-release capsules."/>
	<sentencespan id="DBMI.pac184.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nLansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus."/>
	<sentencespan id="DBMI.pac184.sp1" origId="sp1" text="Lansoprazole does not exhibit anticholinergic or histamine type-2 antagonist activity. 12.2 Pharmacodynamics\n\nAntisecretory Activity: After oral administration, lansoprazole was shown to significantly decrease the basal acid output and significantly increase the mean gastric pH and percent of time the gastric pH was greater than 3 and greater than 4. Lansoprazole also significantly reduced meal-stimulated gastric acid output and secretion volume, as well as pentagastrin-stimulated acid output."/>
	<sentencespan id="DBMI.pac184.sp2" origId="sp2" text="In patients with hypersecretion of acid, lansoprazole significantly reduced basal and pentagastrin-stimulated gastric acid secretion. Lansoprazole inhibited the normal increases in secretion volume, acidity and acid output induced by insulin. The intragastric pH results of a five-day, pharmacodynamic, crossover study of 15 mg and 30 mg of once daily lansoprazole are presented in Table 4:\n\nAfter the initial dose in this study, increased gastric pH was seen within 1 to 2 hours with 30 mg of lansoprazole and 2 to 3 hours with 15 mg of lansoprazole."/>
	<sentencespan id="DBMI.pac184.sp3" origId="sp3" text="After multiple daily dosing, increased gastric pH was seen within the first hour post-dosing with 30 mg of lansoprazole and within 1 to 2 hours post-dosing with 15 mg of lansoprazole. Acid suppression may enhance the effect of antimicrobials in eradicating Helicobacter pylori (H. pylori). The percentage of time gastric pH was elevated above 5 and 6 was evaluated in a crossover study of lansoprazole delayed-release capsules given daily, twice daily and three times daily (Table 5)."/>
	<sentencespan id="DBMI.pac184.sp4" origId="sp4" text="The inhibition of gastric acid secretion as measured by intragastric pH gradually returned to normal over two to four days after multiple doses. There was no indication of rebound gastric acidity. Enterochromaffin-like (ECL) Cell Effects\n\nDuring lifetime exposure of rats with up to 150 mg/kg/day of lansoprazole dosed seven days per week, marked hypergastrinemia was observed followed by ECL cell proliferation and formation of carcinoid tumors, especially in female rats."/>
	<sentencespan id="DBMI.pac184.sp5" origId="sp5" text="Gastric biopsy specimens from the body of the stomach from approximately 150 patients treated continuously with lansoprazole for at least one year did not show evidence of ECL cell effects similar to those seen in rat studies. Longer term data are needed to rule out the possibility of an increased risk of the development of gastric tumors in patients receiving long-term therapy with lansoprazole. [See Nonclinical Toxicology (13.1)]\n\nOther Gastric Effects in Humans\n\nLansoprazole did not significantly affect mucosal blood flow in the fundus of the stomach."/>
	<sentencespan id="DBMI.pac184.sp6" origId="sp6" text="Due to the normal physiologic effect caused by the inhibition of gastric acid secretion, a decrease of about 17% in blood flow in the antrum, pylorus, and duodenal bulb was seen. Lansoprazole significantly slowed the gastric emptying of digestible solids. Lansoprazole increased serum pepsinogen levels and decreased pepsin activity under basal conditions and in response to meal stimulation or insulin injection."/>
	<sentencespan id="DBMI.pac184.sp7" origId="sp7" text="As with other agents that elevate intragastric pH, increases in gastric pH were associated with increases in nitrate-reducing bacteria and elevation of nitrite concentration in gastric juice in patients with gastric ulcer. No significant increase in nitrosamine concentrations was observed. Serum Gastrin Effects\n\nIn over 2100 patients, median fasting serum gastrin levels increased 50% to 100% from baseline but remained within normal range after treatment with 15 to 60 mg of oral lansoprazole."/>
	<sentencespan id="DBMI.pac184.sp8" origId="sp8" text="These elevations reached a plateau within two months of therapy and returned to pretreatment levels within four weeks after discontinuation of therapy. Endocrine Effects\n\nHuman studies for up to one year have not detected any clinically significant effects on the endocrine system. Hormones studied include testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEA-S), prolactin, cortisol, estradiol, insulin, aldosterone, parathormone, glucagon, thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and somatotropic hormone (STH)."/>
	<sentencespan id="DBMI.pac184.sp9" origId="sp9" text="Lansoprazole in oral doses of 15 to 60 mg for up to one year had no clinically significant effect on sexual function. In addition, lansoprazole in oral doses of 15 to 60 mg for two to eight weeks had no clinically significant effect on thyroid function. In 24-month carcinogenicity studies in Sprague-Dawley rats with daily lansoprazole dosages up to 150 mg/kg, proliferative changes in the Leydig cells of the testes, including benign neoplasm, were increased compared to control rats."/>
	<sentencespan id="DBMI.pac184.sp10" origId="sp10" text="Other Effects\n\nNo systemic effects of lansoprazole on the central nervous system, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems have been found in humans. Among 56 patients who had extensive baseline eye evaluations, no visual toxicity was observed after lansoprazole treatment (up to 180 mg/day) for up to 58 months. After lifetime lansoprazole exposure in rats, focal pancreatic atrophy, diffuse lymphoid hyperplasia in the thymus, and spontaneous retinal atrophy were seen."/>
	<sentencespan id="DBMI.pac184.sp11" origId="sp11" text="Microbiology\n\nLansoprazole, clarithromycin and/or amoxicillin have been shown to be active against most strains of Helicobacter pylori in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. [SeeIndications and Usage (1.2)]  \n\nHelicobacter pylori Pretreatment Resistance\n\nClarithromycin pretreatment resistance (2.0 mcg/mL) was 9.5% (91/960) by E-test and 11.3% (12/106) by agar dilution in the dual and triple therapy clinical trials (M93-125, M93-130, M93-131, M95-392, and M95-399). Amoxicillin pretreatment susceptible isolates (0.25 mcg/mL) occurred in 97.8% (936/957) and 98 % (98/100) of the patients in the dual and triple therapy clinical trials by E-test and agar dilution, respectively."/>
	<sentencespan id="DBMI.pac184.sp12" origId="sp12" text="Twenty-one of 957 patients (2.2%) by E-test and 2 of 100 patients (2%) by agar dilution had amoxicillin pretreatment MICs of greater than 0.25 mcg/mL. One patient on the 14-day triple therapy regimen had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of greater than 256 mcg/mL by E-test and the patient was eradicated of H. pylori (Table 6). Patients not eradicated of H. pylori following lansoprazole/amoxicillin/clarithromycin triple therapy will likely have clarithromycin resistant H. pylori."/>
	<sentencespan id="DBMI.pac184.sp13" origId="sp13" text="Therefore, for those patients who fail therapy, clarithromycin susceptibility testing should be done when possible. Patients with clarithromycin resistant H. pylori should not be treated withlansoprazole/amoxicillin/clarithromycin triple therapy or with regimens which include clarithromycin as the sole antimicrobial agent. Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes: In the dual and triple therapy clinical trials, 82.6% (195/236) of the patients that had pretreatment amoxicillin susceptible MICs (0.25 mcg/mL) were eradicated of H. pylori."/>
	<sentencespan id="DBMI.pac184.sp14" origId="sp14" text="Of those with pretreatment amoxicillin MICs of greater than 0.25 mcg/mL, three of six had the H. pylori eradicated. A total of 30% (21/70) of the patients failed lansoprazole 30 mg three times daily /amoxicillin 1 gm three times daily dual therapy and a total of 12.8% (22/172) of the patients failed the 10 and 14 day triple therapy regimens. Post-treatment susceptibility results were not obtained on 11 of the patients who failed therapy."/>
	<sentencespan id="DBMI.pac184.sp15" origId="sp15" text="Nine of the 11 patients with amoxicillin post-treatment MICs that failed the triple therapy regimen also had clarithromycin resistant H. pylori isolates. Susceptibility Test for Helicobacter pylori: The reference methodology for susceptibility testing of H. pylori is agar dilution MICs.1 One to three microliters of an inoculum equivalent to a No. 2 McFarland standard (1 x 107 to 1 x 108 CFU/mL for H. pylori) are inoculated directly onto freshly prepared antimicrobial-containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood (2 weeks old)."/>
	<sentencespan id="DBMI.pac184.sp16" origId="sp16" text="The agar dilution plates are incubated at 35C in a microaerobic environment produced by a gas generating system suitable for campylobacters. After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism. The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria (Table 7):\n\nStandardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures."/>
	<sentencespan id="DBMI.pac184.sp17" origId="sp17" text="Standard clarithromycin and amoxicillin powders should provide the following MIC values (Table 8):\n\n12.3 Pharmacokinetics\n\nLansoprazole delayed-release capsules contain an enteric-coated granule formulation of lansoprazole. Absorption of lansoprazole begins only after the granules leave the stomach. Absorption is rapid, with mean peak plasma levels of lansoprazole occurring after approximately 1.7 hours."/>
	<sentencespan id="DBMI.pac184.sp18" origId="sp18" text="After a single-dose administration of 15 mg to 60 mg of oral lansoprazole, the peak plasma concentrations (Cmax) of lansoprazole and the area under the plasma concentration curves (AUCs) of lansoprazole were approximately proportional to the administered dose. Lansoprazole does not accumulate and its pharmacokinetics are unaltered by multiple dosing. Absorption: The absorption of lansoprazole is rapid, with the mean Cmax occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%."/>
	<sentencespan id="DBMI.pac184.sp19" origId="sp19" text="In healthy subjects, the mean (SD) plasma half-life was 1.5 (1.0) hours. Both the Cmax and AUC are diminished by about 50% to 70% if lansoprazole is given 30 minutes after food, compared to the fasting condition. There is no significant food effect if lansoprazole is given before meals."/>
	<sentencespan id="DBMI.pac184.sp20" origId="sp20" text="Distribution: Lansoprazole is 97% bound to plasma proteins. Plasma protein binding is constant over the concentration range of 0.05 to 5.0 mcg/mL. Metabolism: Lansoprazole is extensively metabolized in the liver."/>
	<sentencespan id="DBMI.pac184.sp21" origId="sp21" text="Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by blocking the proton pump [(H+, K+)-ATPase enzyme system] at the secretory surface of the gastric parietal cell."/>
	<sentencespan id="DBMI.pac184.sp22" origId="sp22" text="The two active species are not present in the systemic circulation. The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours. Therefore, the plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion."/>
	<sentencespan id="DBMI.pac184.sp23" origId="sp23" text="Elimination: Following single-dose oral administration of lansoprazole delayed-release capsules, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites."/>
	<sentencespan id="DBMI.pac184.sp24" origId="sp24" text="12.4 Specific Populations\n\nPediatric Use:\n\nOne to 17 years of age\n\nThe pharmacokinetics of lansoprazole were studied in pediatric patients with GERD aged 1 to 11 years and 12 to 17 years in two separate clinical studies. In children aged 1 to 11 years, lansoprazole was dosed 15 mg daily for subjects weighing  30 kg and 30 mg daily for subjects weighing greater than 30 kg. Mean Cmax and AUC values observed on Day 5 of dosing were similar between the two dose groups and were not affected by weight or age within each weight-adjusted dose group used in the study."/>
	<sentencespan id="DBMI.pac184.sp25" origId="sp25" text="In adolescent subjects aged 12 to 17 years, subjects were randomized to receive lansoprazole at 15 mg or 30 mg daily. Mean Cmax and AUC values of lansoprazole were not affected by body weight or age; and nearly dose-proportional increases in mean Cmax and AUC values were observed between the two dose groups in the study. Overall, lansoprazole pharmacokinetics in pediatric patients aged 1 to 17 years were similar to those observed in healthy adult subjects."/>
	<sentencespan id="DBMI.pac184.sp26" origId="sp26" text="Geriatric Use: The clearance of lansoprazole is decreased in the elderly, with elimination half-life increased approximately 50% to 100%. Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole. Peak plasma levels were not increased in the elderly."/>
	<sentencespan id="DBMI.pac184.sp27" origId="sp27" text="No dosage adjustment is necessary in the elderly [See Use in Specific Populations (8.5)]. Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1% to 1.5% after administration of 60 mg of lansoprazole. Patients with renal impairment had a shortened elimination half-life and decreased total AUC (free and bound)."/>
	<sentencespan id="DBMI.pac184.sp28" origId="sp28" text="The AUC for free lansoprazole in plasma, however, was not related to the degree of renal impairment; and the Cmax and tmax (time to reach the maximum concentration) were not different than the Cmax and tmax from subjects with normal renal function. No dosage adjustment is necessary in patients with renal impairment [See Use in Specific Populations (8.6]). Hepatic Impairment: In patients with various degrees of chronic hepatic impairment, the mean plasma half-life of lansoprazole was prolonged from 1.5 hours to 3.2 to 7.2 hours."/>
	<sentencespan id="DBMI.pac184.sp29" origId="sp29" text="An increase in the mean AUC of up to 500% was observed at steady state in hepatically-impaired patients compared to healthy subjects. Consider dose reduction in patients with severe hepatic impairment [See Use in Specific Populations (8.7)]. Gender: In a study comparing 12 male and 6 female human subjects who received lansoprazole, no gender differences were found in pharmacokinetics and intragastric pH results [See Use in Specific Populations (8.5)]."/>
	<sentencespan id="DBMI.pac184.sp30" origId="sp30" text="12.5 Drug-Drug Interactions\n\nIt is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin). Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.">
		<entity charOffset="14590-14603" id="DBMI.pac184.sp30.e0" origId="sp30.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="14768-14776" id="DBMI.pac184.sp30.e1" origId="sp30.e1" text="digoxin " type="Active ingredient"/>
		<entity charOffset="14756-14761" id="DBMI.pac184.sp30.e2" origId="sp30.e2" text="iron " type="Active ingredient"/>
		<entity charOffset="14723-14736" id="DBMI.pac184.sp30.e3" origId="sp30.e3" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="14737-14748" id="DBMI.pac184.sp30.e4" origId="sp30.e4" text="ampicillin " type="Active ingredient"/>
		<entity charOffset="15134-15143" id="DBMI.pac184.sp30.e5" origId="sp30.e5" text="diazepam " type="Active ingredient"/>
		<entity charOffset="15122-15133" id="DBMI.pac184.sp30.e6" origId="sp30.e6" text="prednisone " type="Active ingredient"/>
		<entity charOffset="15147-15162" id="DBMI.pac184.sp30.e7" origId="sp30.e7" text="clarithromycin " type="Active ingredient"/>
		<entity charOffset="15061-15072" id="DBMI.pac184.sp30.e8" origId="sp30.e8" text="antipyrine " type="Active ingredient"/>
		<entity charOffset="15109-15121" id="DBMI.pac184.sp30.e9" origId="sp30.e9" text="propranolol " type="Active ingredient"/>
		<entity charOffset="15087-15097" id="DBMI.pac184.sp30.e10" origId="sp30.e10" text="ibuprofen " type="Active ingredient"/>
		<entity charOffset="15098-15108" id="DBMI.pac184.sp30.e11" origId="sp30.e11" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="15051-15060" id="DBMI.pac184.sp30.e12" origId="sp30.e12" text="warfarin " type="Active ingredient"/>
		<entity charOffset="15073-15086" id="DBMI.pac184.sp30.e13" origId="sp30.e13" text="indomethacin " type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="iron " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p6" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="prednisone " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="prednisone " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="clarithromycin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p9" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="clarithromycin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="antipyrine " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p11" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="antipyrine " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p13" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p14" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ibuprofen " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p15" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ibuprofen " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p17" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p18" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p19" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p20" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="indomethacin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p64" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p67" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p74" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p78" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p79" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p80" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p81" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p82" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p83" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p84" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p85" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p86" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p87" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p88" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p89" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p90" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p91" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p92" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p93" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p94" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p95" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p96" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p97" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p98" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p99" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p100" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p101" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p102" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p103" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p104" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p105" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p106" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p107" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p108" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p109" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p110" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p111" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p112" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p113" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p114" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p115" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p116" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p117" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p118" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p119" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p120" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p121" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p122" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p123" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p124" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p125" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p126" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p127" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p128" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p129" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p130" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p131" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p132" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p133" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p134" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p135" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p136" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p137" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p138" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p139" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p140" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p141" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p142" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p143" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p144" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p145" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p146" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p147" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p148" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p149" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p150" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p151" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p152" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p153" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p154" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p155" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p156" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p157" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p158" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p159" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p160" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p161" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p162" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p163" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p164" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p165" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p166" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p167" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p168" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p169" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p170" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p171" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p172" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p173" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p174" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p175" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p176" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p177" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p178" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p179" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p180" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p181" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p182" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p183" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p184" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p185" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p186" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p187" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p188" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p189" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp31" origId="sp31" text="These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. Atazanavir: Lansoprazole delayed-release capsules causes long-lasting inhibition of gastric acid secretion.lansoprazole delayed-release capsules substantially decreases the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, lansoprazole delayed-release capsules, or other proton pump inhibitors, should not be co-administered with atazanavir.">
		<entity charOffset="15419-15432" id="DBMI.pac184.sp31.e0" origId="sp31.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="15539-15550" id="DBMI.pac184.sp31.e1" origId="sp31.e1" text="atazanavir " type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp31.e0" e2="DBMI.pac184.sp31.e1" id="DBMI.pac184.sp31.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp31.e1" e2="DBMI.pac184.sp31.e0" id="DBMI.pac184.sp31.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp32" origId="sp32" text="Theophylline: When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern. Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.">
		<entity charOffset="15870-15883" id="DBMI.pac184.sp32.e0" origId="sp32.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="16018-16031" id="DBMI.pac184.sp32.e1" origId="sp32.e1" text="theophylline " type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp32.e0" e2="DBMI.pac184.sp32.e1" id="DBMI.pac184.sp32.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="theophylline " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp32.e1" e2="DBMI.pac184.sp32.e0" id="DBMI.pac184.sp32.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp33" origId="sp33" text="Warfarin: In a study of healthy subjects neither the pharmacokinetics of warfarin enantiomers nor prothrombin time were affected following single or multiple 60 mg doses of lansoprazole. However, there have been reports of increased International Normalized Ratio (INR) and prothrombin time in patients receiving proton pump inhibitors, including lansoprazole delayed-release capsules, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.">
		<entity charOffset="16566-16579" id="DBMI.pac184.sp33.e0" origId="sp33.e0" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="16466-16475" id="DBMI.pac184.sp33.e1" origId="sp33.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp33.e0" e2="DBMI.pac184.sp33.e1" id="DBMI.pac184.sp33.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp33.e1" e2="DBMI.pac184.sp33.e0" id="DBMI.pac184.sp33.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp34" origId="sp34" text="Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.">
		<entity charOffset="17280-17289" id="DBMI.pac184.sp34.e0" origId="sp34.e0" text="naproxen " type="Active ingredient"/>
		<entity charOffset="17403-17416" id="DBMI.pac184.sp34.e1" origId="sp34.e1" text="methotrexate " type="Active ingredient"/>
		<entity charOffset="17420-17442" id="DBMI.pac184.sp34.e2" origId="sp34.e2" text="7-hydroxymethotrexate " type="Metabolite"/>
		<entity charOffset="17312-17325" id="DBMI.pac184.sp34.e3" origId="sp34.e3" text="lansoprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp34.e0" e2="DBMI.pac184.sp34.e1" id="DBMI.pac184.sp34.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate " precipitant="naproxen "/>
		<pair e1="DBMI.pac184.sp34.e0" e2="DBMI.pac184.sp34.e2" id="DBMI.pac184.sp34.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="7-hydroxymethotrexate " precipitant="naproxen "/>
		<pair e1="DBMI.pac184.sp34.e0" e2="DBMI.pac184.sp34.e3" id="DBMI.pac184.sp34.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e1" e2="DBMI.pac184.sp34.e0" id="DBMI.pac184.sp34.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e1" e2="DBMI.pac184.sp34.e2" id="DBMI.pac184.sp34.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e1" e2="DBMI.pac184.sp34.e3" id="DBMI.pac184.sp34.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e2" e2="DBMI.pac184.sp34.e0" id="DBMI.pac184.sp34.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e2" e2="DBMI.pac184.sp34.e1" id="DBMI.pac184.sp34.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e2" e2="DBMI.pac184.sp34.e3" id="DBMI.pac184.sp34.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e3" e2="DBMI.pac184.sp34.e0" id="DBMI.pac184.sp34.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e3" e2="DBMI.pac184.sp34.e1" id="DBMI.pac184.sp34.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp34.e3" e2="DBMI.pac184.sp34.e1" id="DBMI.pac184.sp34.p11" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate " precipitant="lansoprazole "/>
		<pair e1="DBMI.pac184.sp34.e3" e2="DBMI.pac184.sp34.e2" id="DBMI.pac184.sp34.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="7-hydroxymethotrexate " precipitant="lansoprazole "/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp35" origId="sp35" text="Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin. Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate. Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.">
		<entity charOffset="17581-17594" id="DBMI.pac184.sp35.e0" origId="sp35.e0" text="Lansoprazole " type="Active ingredient"/>
		<entity charOffset="17690-17702" id="DBMI.pac184.sp35.e1" origId="sp35.e1" text="amoxicillin " type="Active ingredient"/>
		<entity charOffset="17871-17882" id="DBMI.pac184.sp35.e2" origId="sp35.e2" text="sucralfate " type="Active ingredient"/>
		<entity charOffset="17759-17772" id="DBMI.pac184.sp35.e3" origId="sp35.e3" text="lansoprazole " type="Active ingredient"/>
		<entity charOffset="17807-17818" id="DBMI.pac184.sp35.e4" origId="sp35.e4" text="omeprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp35.e0" e2="DBMI.pac184.sp35.e1" id="DBMI.pac184.sp35.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amoxicillin " precipitant="Lansoprazole "/>
		<pair e1="DBMI.pac184.sp35.e0" e2="DBMI.pac184.sp35.e2" id="DBMI.pac184.sp35.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e0" e2="DBMI.pac184.sp35.e3" id="DBMI.pac184.sp35.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e0" e2="DBMI.pac184.sp35.e4" id="DBMI.pac184.sp35.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e1" e2="DBMI.pac184.sp35.e0" id="DBMI.pac184.sp35.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e1" e2="DBMI.pac184.sp35.e2" id="DBMI.pac184.sp35.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e1" e2="DBMI.pac184.sp35.e3" id="DBMI.pac184.sp35.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e1" e2="DBMI.pac184.sp35.e4" id="DBMI.pac184.sp35.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e2" e2="DBMI.pac184.sp35.e0" id="DBMI.pac184.sp35.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e2" e2="DBMI.pac184.sp35.e1" id="DBMI.pac184.sp35.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e2" e2="DBMI.pac184.sp35.e3" id="DBMI.pac184.sp35.p10" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="lansoprazole " precipitant="sucralfate "/>
		<pair e1="DBMI.pac184.sp35.e2" e2="DBMI.pac184.sp35.e4" id="DBMI.pac184.sp35.p11" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole " precipitant="sucralfate "/>
		<pair e1="DBMI.pac184.sp35.e3" e2="DBMI.pac184.sp35.e0" id="DBMI.pac184.sp35.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e3" e2="DBMI.pac184.sp35.e1" id="DBMI.pac184.sp35.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e3" e2="DBMI.pac184.sp35.e2" id="DBMI.pac184.sp35.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e3" e2="DBMI.pac184.sp35.e4" id="DBMI.pac184.sp35.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e4" e2="DBMI.pac184.sp35.e0" id="DBMI.pac184.sp35.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e4" e2="DBMI.pac184.sp35.e1" id="DBMI.pac184.sp35.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e4" e2="DBMI.pac184.sp35.e2" id="DBMI.pac184.sp35.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e4" e2="DBMI.pac184.sp35.e3" id="DBMI.pac184.sp35.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp36" origId="sp36" text="In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules and there was no evidence of a change in the efficacy of lansoprazole delayed-release capsules."/>
</document>

<document id="DBMI.pac185" origId="pac185">
	<sentence id="DBMI.pac185.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A4 Interactions\n\nSimvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4."/>
	<sentence id="DBMI.pac185.s1" origId="s1" text="Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4."/>
	<sentence id="DBMI.pac185.s2" origId="s2" text="The risk of myopathy is increased by reducing the elimination of simvastatin."/>
	<sentence id="DBMI.pac185.s3" origId="s3" text="Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin."/>
	<sentence id="DBMI.pac185.s4" origId="s4" text="[See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]"/>
	<sentence id="DBMI.pac185.s5" origId="s5" text="Itraconazole, ketoconazole, and other antifungal azoles\n\nMacrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin\n\nHIV protease inhibitors\n\nAntidepressant nefazodone\n\nGrapefruit juice in large quantities (&gt;1 quart daily)\n\nConcomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk."/>
	<sentence id="DBMI.pac185.s6" origId="s6" text="If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment."/>
	<sentence id="DBMI.pac185.s7" origId="s7" text="7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone\n\nThe risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day)."/>
	<sentence id="DBMI.pac185.s8" origId="s8" text="[see Warnings and Precautions (5.1)]."/>
	<sentence id="DBMI.pac185.s9" origId="s9" text="7.3 Cyclosporine or Danazol\n\nThe risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]."/>
	<sentence id="DBMI.pac185.s10" origId="s10" text="7.4 Amiodarone or Verapamil\n\nThe risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)]."/>
	<sentence id="DBMI.pac185.s11" origId="s11" text="7.5 Digoxin\n\nIn one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.">
		<entity charOffset="2157-2169" id="DBMI.pac185.s11.e0" origId="s11.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="2144-2152" id="DBMI.pac185.s11.e1" origId="s11.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac185.s11.e0" e2="DBMI.pac185.s11.e1" id="DBMI.pac185.s11.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac185.s11.e1" e2="DBMI.pac185.s11.e0" id="DBMI.pac185.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac185.s12" origId="s12" text="Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)]."/>
	<sentence id="DBMI.pac185.s13" origId="s13" text="7.6 Coumarin Anticoagulants\n\nIn two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively."/>
	<sentence id="DBMI.pac185.s14" origId="s14" text="With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly."/>
	<sentence id="DBMI.pac185.s15" origId="s15" text="In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs."/>
	<sentence id="DBMI.pac185.s16" origId="s16" text="Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants."/>
	<sentence id="DBMI.pac185.s17" origId="s17" text="If the dose of simvastatin is changed or discontinued, the same procedure should be repeated."/>
	<sentence id="DBMI.pac185.s18" origId="s18" text="Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants."/>
	<sentencespan id="DBMI.pac185.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A4 Interactions\n\nSimvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4. Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. The risk of myopathy is increased by reducing the elimination of simvastatin."/>
	<sentencespan id="DBMI.pac185.sp1" origId="sp1" text="Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Itraconazole, ketoconazole, and other antifungal azoles\n\nMacrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin\n\nHIV protease inhibitors\n\nAntidepressant nefazodone\n\nGrapefruit juice in large quantities (&gt;1 quart daily)\n\nConcomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk."/>
	<sentencespan id="DBMI.pac185.sp2" origId="sp2" text="If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment. 7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone\n\nThe risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day). [see Warnings and Precautions (5.1)]."/>
	<sentencespan id="DBMI.pac185.sp3" origId="sp3" text="7.3 Cyclosporine or Danazol\n\nThe risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. 7.4 Amiodarone or Verapamil\n\nThe risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)]. 7.5 Digoxin\n\nIn one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.">
		<entity charOffset="2157-2169" id="DBMI.pac185.sp3.e0" origId="sp3.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="2144-2152" id="DBMI.pac185.sp3.e1" origId="sp3.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac185.sp3.e0" e2="DBMI.pac185.sp3.e1" id="DBMI.pac185.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac185.sp3.e1" e2="DBMI.pac185.sp3.e0" id="DBMI.pac185.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac185.sp4" origId="sp4" text="Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)]. 7.6 Coumarin Anticoagulants\n\nIn two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively. With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly."/>
	<sentencespan id="DBMI.pac185.sp5" origId="sp5" text="In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of simvastatin is changed or discontinued, the same procedure should be repeated."/>
	<sentencespan id="DBMI.pac185.sp6" origId="sp6" text="Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants."/>
</document>

<document id="DBMI.pac186" origId="pac186">
	<sentence id="DBMI.pac186.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSimvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration."/>
	<sentence id="DBMI.pac186.s1" origId="s1" text="Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol."/>
	<sentence id="DBMI.pac186.s2" origId="s2" text="In addition, simvastatin reduces VLDL and TG and increases HDL-C.\n\n12.2 Pharmacodynamics\n\nEpidemiological studies have demonstrated that elevated levels of total-C, LDL-C, as well as decreased levels of HDL-C are associated with the development of atherosclerosis and increased cardiovascular risk."/>
	<sentence id="DBMI.pac186.s3" origId="s3" text="Lowering LDL-C decreases this risk."/>
	<sentence id="DBMI.pac186.s4" origId="s4" text="However, the independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined."/>
	<sentence id="DBMI.pac186.s5" origId="s5" text="12.3 Pharmacokinetics\n\nSimvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding -hydroxyacid, a potent inhibitor of HMG-CoA reductase."/>
	<sentence id="DBMI.pac186.s6" origId="s6" text="Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the -hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin."/>
	<sentence id="DBMI.pac186.s7" origId="s7" text="Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces."/>
	<sentence id="DBMI.pac186.s8" origId="s8" text="Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose."/>
	<sentence id="DBMI.pac186.s9" origId="s9" text="Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (&lt;5%)."/>
	<sentence id="DBMI.pac186.s10" origId="s10" text="Both simvastatin and its -hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins."/>
	<sentence id="DBMI.pac186.s11" origId="s11" text="Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier."/>
	<sentence id="DBMI.pac186.s12" origId="s12" text="The major active metabolites of simvastatin present in human plasma are the -hydroxyacid of simvastatin and its 6-hydroxy, 6-hydroxymethyl, and 6-exomethylene derivatives."/>
	<sentence id="DBMI.pac186.s13" origId="s13" text="Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours postdose."/>
	<sentence id="DBMI.pac186.s14" origId="s14" text="While the recommended therapeutic dose range is 5 to 80 mg/day, there was no substantial deviation from linearity of AUC of inhibitors in the general circulation with an increase in dose to as high as 120 mg."/>
	<sentence id="DBMI.pac186.s15" origId="s15" text="Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal."/>
	<sentence id="DBMI.pac186.s16" origId="s16" text="In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age."/>
	<sentence id="DBMI.pac186.s17" origId="s17" text="Clinical study experience in the elderly (n=1 522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)]."/>
	<sentence id="DBMI.pac186.s18" origId="s18" text="Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance)."/>
	<sentence id="DBMI.pac186.s19" origId="s19" text="Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.">
		<entity charOffset="3444-3457" id="DBMI.pac186.s19.e0" origId="s19.e0" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="3528-3540" id="DBMI.pac186.s19.e1" origId="s19.e1" text="simvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac186.s19.e0" e2="DBMI.pac186.s19.e1" id="DBMI.pac186.s19.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="simvastatin " precipitant="cyclosporine "/>
		<pair e1="DBMI.pac186.s19.e1" e2="DBMI.pac186.s19.e0" id="DBMI.pac186.s19.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac186.s20" origId="s20" text="The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4."/>
	<sentence id="DBMI.pac186.s21" origId="s21" text="The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma."/>
	<sentence id="DBMI.pac186.s22" origId="s22" text="Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)]."/>
	<sentence id="DBMI.pac186.s23" origId="s23" text="In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.">
		<entity charOffset="3928-3940" id="DBMI.pac186.s23.e0" origId="s23.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="4065-4078" id="DBMI.pac186.s23.e1" origId="s23.e1" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="4051-4061" id="DBMI.pac186.s23.e2" origId="s23.e2" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac186.s23.e0" e2="DBMI.pac186.s23.e1" id="DBMI.pac186.s23.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.s23.e0" e2="DBMI.pac186.s23.e1" id="DBMI.pac186.s23.p1" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="erythromycin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.s23.e0" e2="DBMI.pac186.s23.e2" id="DBMI.pac186.s23.p2" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="midazolam " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.s23.e1" e2="DBMI.pac186.s23.e0" id="DBMI.pac186.s23.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.s23.e1" e2="DBMI.pac186.s23.e2" id="DBMI.pac186.s23.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.s23.e2" e2="DBMI.pac186.s23.e0" id="DBMI.pac186.s23.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.s23.e2" e2="DBMI.pac186.s23.e1" id="DBMI.pac186.s23.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac186.s24" origId="s24" text="This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4."/>
	<sentence id="DBMI.pac186.s25" origId="s25" text="Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.">
		<entity charOffset="4261-4273" id="DBMI.pac186.s25.e0" origId="s25.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="4363-4371" id="DBMI.pac186.s25.e1" origId="s25.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac186.s25.e0" e2="DBMI.pac186.s25.e1" id="DBMI.pac186.s25.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.s25.e1" e2="DBMI.pac186.s25.e0" id="DBMI.pac186.s25.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac186.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSimvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol. In addition, simvastatin reduces VLDL and TG and increases HDL-C.\n\n12.2 Pharmacodynamics\n\nEpidemiological studies have demonstrated that elevated levels of total-C, LDL-C, as well as decreased levels of HDL-C are associated with the development of atherosclerosis and increased cardiovascular risk."/>
	<sentencespan id="DBMI.pac186.sp1" origId="sp1" text="Lowering LDL-C decreases this risk. However, the independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined. 12.3 Pharmacokinetics\n\nSimvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding -hydroxyacid, a potent inhibitor of HMG-CoA reductase."/>
	<sentencespan id="DBMI.pac186.sp2" origId="sp2" text="Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the -hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin. Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose."/>
	<sentencespan id="DBMI.pac186.sp3" origId="sp3" text="Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (&lt;5%). Both simvastatin and its -hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier."/>
	<sentencespan id="DBMI.pac186.sp4" origId="sp4" text="The major active metabolites of simvastatin present in human plasma are the -hydroxyacid of simvastatin and its 6-hydroxy, 6-hydroxymethyl, and 6-exomethylene derivatives. Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours postdose. While the recommended therapeutic dose range is 5 to 80 mg/day, there was no substantial deviation from linearity of AUC of inhibitors in the general circulation with an increase in dose to as high as 120 mg."/>
	<sentencespan id="DBMI.pac186.sp5" origId="sp5" text="Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal. In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age. Clinical study experience in the elderly (n=1 522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)]."/>
	<sentencespan id="DBMI.pac186.sp6" origId="sp6" text="Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance). Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.">
		<entity charOffset="3444-3457" id="DBMI.pac186.sp6.e0" origId="sp6.e0" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="3528-3540" id="DBMI.pac186.sp6.e1" origId="sp6.e1" text="simvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac186.sp6.e0" e2="DBMI.pac186.sp6.e1" id="DBMI.pac186.sp6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="simvastatin " precipitant="cyclosporine "/>
		<pair e1="DBMI.pac186.sp6.e1" e2="DBMI.pac186.sp6.e0" id="DBMI.pac186.sp6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac186.sp7" origId="sp7" text="The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)]. In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.">
		<entity charOffset="3928-3940" id="DBMI.pac186.sp7.e0" origId="sp7.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="4065-4078" id="DBMI.pac186.sp7.e1" origId="sp7.e1" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="4051-4061" id="DBMI.pac186.sp7.e2" origId="sp7.e2" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac186.sp7.e0" e2="DBMI.pac186.sp7.e1" id="DBMI.pac186.sp7.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.sp7.e0" e2="DBMI.pac186.sp7.e1" id="DBMI.pac186.sp7.p1" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="erythromycin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.sp7.e0" e2="DBMI.pac186.sp7.e2" id="DBMI.pac186.sp7.p2" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="midazolam " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.sp7.e1" e2="DBMI.pac186.sp7.e0" id="DBMI.pac186.sp7.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.sp7.e1" e2="DBMI.pac186.sp7.e2" id="DBMI.pac186.sp7.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.sp7.e2" e2="DBMI.pac186.sp7.e0" id="DBMI.pac186.sp7.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.sp7.e2" e2="DBMI.pac186.sp7.e1" id="DBMI.pac186.sp7.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac186.sp8" origId="sp8" text="This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4. Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.">
		<entity charOffset="4261-4273" id="DBMI.pac186.sp8.e0" origId="sp8.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="4363-4371" id="DBMI.pac186.sp8.e1" origId="sp8.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac186.sp8.e0" e2="DBMI.pac186.sp8.e1" id="DBMI.pac186.sp8.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.sp8.e1" e2="DBMI.pac186.sp8.e0" id="DBMI.pac186.sp8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac187" origId="pac187">
	<sentence id="DBMI.pac187.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nSee also Contraindications (4) and Clinical Pharmacology (12.3)."/>
	<sentence id="DBMI.pac187.s1" origId="s1" text="7.1 Potential for REYATAZ to Affect Other Drugs\n\nAtazanavir is an inhibitor of CYP3A and UGT1A1."/>
	<sentence id="DBMI.pac187.s2" origId="s2" text="Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects."/>
	<sentence id="DBMI.pac187.s3" origId="s3" text="Atazanavir is a weak inhibitor of CYP2C8."/>
	<sentence id="DBMI.pac187.s4" origId="s4" text="Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).">
		<entity charOffset="466-474" id="DBMI.pac187.s4.e0" origId="s4.e0" text="REYATAZ " type="Drug product"/>
		<entity charOffset="597-609" id="DBMI.pac187.s4.e1" origId="s4.e1" text="repaglinide " type="Active ingredient"/>
		<entity charOffset="585-596" id="DBMI.pac187.s4.e2" origId="s4.e2" text="paclitaxel " type="Active ingredient"/>
		<pair e1="DBMI.pac187.s4.e0" e2="DBMI.pac187.s4.e1" id="DBMI.pac187.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="repaglinide " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s4.e0" e2="DBMI.pac187.s4.e2" id="DBMI.pac187.s4.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="paclitaxel " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s4.e1" e2="DBMI.pac187.s4.e0" id="DBMI.pac187.s4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s4.e1" e2="DBMI.pac187.s4.e2" id="DBMI.pac187.s4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s4.e2" e2="DBMI.pac187.s4.e0" id="DBMI.pac187.s4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s4.e2" e2="DBMI.pac187.s4.e1" id="DBMI.pac187.s4.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac187.s5" origId="s5" text="When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected."/>
	<sentence id="DBMI.pac187.s6" origId="s6" text="[See Clinical Pharmacology, Table 14 (12.3).]"/>
	<sentence id="DBMI.pac187.s7" origId="s7" text="The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir."/>
	<sentence id="DBMI.pac187.s8" origId="s8" text="See the complete prescribing information for NORVIR (ritonavir) for information on drug interactions with ritonavir."/>
	<sentence id="DBMI.pac187.s9" origId="s9" text="7.2 Potential for Other Drugs to Affect Atazanavir\n\nAtazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZs therapeutic effect."/>
	<sentence id="DBMI.pac187.s10" origId="s10" text="Atazanavir solubility decreases as pH increases."/>
	<sentence id="DBMI.pac187.s11" origId="s11" text="Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir."/>
	<sentence id="DBMI.pac187.s12" origId="s12" text="7.3 Established and Other Potentially Significant Drug Interactions\n\nTable 13 provides dosing recommendations as a result of drug interactions with REYATAZ."/>
	<sentence id="DBMI.pac187.s13" origId="s13" text="These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy."/>
	<sentence id="DBMI.pac187.s14" origId="s14" text="7.4 Drugs with No Observed or Predicted Interactions with REYATAZ\n\nClinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1."/>
	<sentence id="DBMI.pac187.s15" origId="s15" text="Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8."/>
	<sentence id="DBMI.pac187.s16" origId="s16" text="See the complete prescribing information for NORVIR for information on other potential drug interactions with ritonavir."/>
	<sentence id="DBMI.pac187.s17" origId="s17" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.">
		<entity charOffset="2403-2414" id="DBMI.pac187.s17.e0" origId="s17.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="2453-2461" id="DBMI.pac187.s17.e1" origId="s17.e1" text="dapsone " type="Active ingredient"/>
		<entity charOffset="2462-2475" id="DBMI.pac187.s17.e2" origId="s17.e2" text="trimethoprim " type="Active ingredient"/>
		<entity charOffset="2440-2452" id="DBMI.pac187.s17.e3" origId="s17.e3" text="pravastatin " type="Active ingredient"/>
		<entity charOffset="2493-2506" id="DBMI.pac187.s17.e4" origId="s17.e4" text="azithromycin " type="Active ingredient"/>
		<entity charOffset="2475-2492" id="DBMI.pac187.s17.e5" origId="s17.e5" text="sulfamethoxazole " type="Active ingredient"/>
		<entity charOffset="2510-2523" id="DBMI.pac187.s17.e6" origId="s17.e6" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="2427-2439" id="DBMI.pac187.s17.e7" origId="s17.e7" text="fluvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac187.s17.e0" e2="DBMI.pac187.s17.e1" id="DBMI.pac187.s17.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="dapsone " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.s17.e0" e2="DBMI.pac187.s17.e2" id="DBMI.pac187.s17.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="trimethoprim " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.s17.e0" e2="DBMI.pac187.s17.e3" id="DBMI.pac187.s17.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="pravastatin " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.s17.e0" e2="DBMI.pac187.s17.e4" id="DBMI.pac187.s17.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="azithromycin " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.s17.e0" e2="DBMI.pac187.s17.e5" id="DBMI.pac187.s17.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sulfamethoxazole " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.s17.e0" e2="DBMI.pac187.s17.e6" id="DBMI.pac187.s17.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.s17.e0" e2="DBMI.pac187.s17.e7" id="DBMI.pac187.s17.p6" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.s17.e1" e2="DBMI.pac187.s17.e0" id="DBMI.pac187.s17.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e1" e2="DBMI.pac187.s17.e2" id="DBMI.pac187.s17.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e1" e2="DBMI.pac187.s17.e3" id="DBMI.pac187.s17.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e1" e2="DBMI.pac187.s17.e4" id="DBMI.pac187.s17.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e1" e2="DBMI.pac187.s17.e5" id="DBMI.pac187.s17.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e1" e2="DBMI.pac187.s17.e6" id="DBMI.pac187.s17.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e1" e2="DBMI.pac187.s17.e7" id="DBMI.pac187.s17.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e2" e2="DBMI.pac187.s17.e0" id="DBMI.pac187.s17.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e2" e2="DBMI.pac187.s17.e1" id="DBMI.pac187.s17.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e2" e2="DBMI.pac187.s17.e3" id="DBMI.pac187.s17.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e2" e2="DBMI.pac187.s17.e4" id="DBMI.pac187.s17.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e2" e2="DBMI.pac187.s17.e5" id="DBMI.pac187.s17.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e2" e2="DBMI.pac187.s17.e6" id="DBMI.pac187.s17.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e2" e2="DBMI.pac187.s17.e7" id="DBMI.pac187.s17.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e3" e2="DBMI.pac187.s17.e0" id="DBMI.pac187.s17.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e3" e2="DBMI.pac187.s17.e1" id="DBMI.pac187.s17.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e3" e2="DBMI.pac187.s17.e2" id="DBMI.pac187.s17.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e3" e2="DBMI.pac187.s17.e4" id="DBMI.pac187.s17.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e3" e2="DBMI.pac187.s17.e5" id="DBMI.pac187.s17.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e3" e2="DBMI.pac187.s17.e6" id="DBMI.pac187.s17.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e3" e2="DBMI.pac187.s17.e7" id="DBMI.pac187.s17.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e4" e2="DBMI.pac187.s17.e0" id="DBMI.pac187.s17.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e4" e2="DBMI.pac187.s17.e1" id="DBMI.pac187.s17.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e4" e2="DBMI.pac187.s17.e2" id="DBMI.pac187.s17.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e4" e2="DBMI.pac187.s17.e3" id="DBMI.pac187.s17.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e4" e2="DBMI.pac187.s17.e5" id="DBMI.pac187.s17.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e4" e2="DBMI.pac187.s17.e6" id="DBMI.pac187.s17.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e4" e2="DBMI.pac187.s17.e7" id="DBMI.pac187.s17.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e5" e2="DBMI.pac187.s17.e0" id="DBMI.pac187.s17.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e5" e2="DBMI.pac187.s17.e1" id="DBMI.pac187.s17.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e5" e2="DBMI.pac187.s17.e2" id="DBMI.pac187.s17.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e5" e2="DBMI.pac187.s17.e3" id="DBMI.pac187.s17.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e5" e2="DBMI.pac187.s17.e4" id="DBMI.pac187.s17.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e5" e2="DBMI.pac187.s17.e6" id="DBMI.pac187.s17.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e5" e2="DBMI.pac187.s17.e7" id="DBMI.pac187.s17.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e6" e2="DBMI.pac187.s17.e0" id="DBMI.pac187.s17.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e6" e2="DBMI.pac187.s17.e1" id="DBMI.pac187.s17.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e6" e2="DBMI.pac187.s17.e2" id="DBMI.pac187.s17.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e6" e2="DBMI.pac187.s17.e3" id="DBMI.pac187.s17.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e6" e2="DBMI.pac187.s17.e4" id="DBMI.pac187.s17.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e6" e2="DBMI.pac187.s17.e5" id="DBMI.pac187.s17.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e6" e2="DBMI.pac187.s17.e7" id="DBMI.pac187.s17.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e7" e2="DBMI.pac187.s17.e0" id="DBMI.pac187.s17.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e7" e2="DBMI.pac187.s17.e1" id="DBMI.pac187.s17.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e7" e2="DBMI.pac187.s17.e2" id="DBMI.pac187.s17.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e7" e2="DBMI.pac187.s17.e3" id="DBMI.pac187.s17.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e7" e2="DBMI.pac187.s17.e4" id="DBMI.pac187.s17.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e7" e2="DBMI.pac187.s17.e5" id="DBMI.pac187.s17.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s17.e7" e2="DBMI.pac187.s17.e6" id="DBMI.pac187.s17.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac187.s18" origId="s18" text="REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).">
		<entity charOffset="2524-2532" id="DBMI.pac187.s18.e0" origId="s18.e0" text="REYATAZ " type="Drug product"/>
		<entity charOffset="2596-2608" id="DBMI.pac187.s18.e1" origId="s18.e1" text="desipramine " type="Active ingredient"/>
		<entity charOffset="2581-2595" id="DBMI.pac187.s18.e2" origId="s18.e2" text="nortriptyline " type="Active ingredient"/>
		<entity charOffset="2609-2620" id="DBMI.pac187.s18.e3" origId="s18.e3" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac187.s18.e0" e2="DBMI.pac187.s18.e1" id="DBMI.pac187.s18.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="desipramine " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s18.e0" e2="DBMI.pac187.s18.e1" id="DBMI.pac187.s18.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="desipramine " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s18.e0" e2="DBMI.pac187.s18.e2" id="DBMI.pac187.s18.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nortriptyline " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s18.e0" e2="DBMI.pac187.s18.e2" id="DBMI.pac187.s18.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nortriptyline " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s18.e0" e2="DBMI.pac187.s18.e3" id="DBMI.pac187.s18.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="metoprolol " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s18.e0" e2="DBMI.pac187.s18.e3" id="DBMI.pac187.s18.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="metoprolol " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s18.e1" e2="DBMI.pac187.s18.e0" id="DBMI.pac187.s18.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s18.e1" e2="DBMI.pac187.s18.e2" id="DBMI.pac187.s18.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s18.e1" e2="DBMI.pac187.s18.e3" id="DBMI.pac187.s18.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s18.e2" e2="DBMI.pac187.s18.e0" id="DBMI.pac187.s18.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s18.e2" e2="DBMI.pac187.s18.e1" id="DBMI.pac187.s18.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s18.e2" e2="DBMI.pac187.s18.e3" id="DBMI.pac187.s18.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s18.e3" e2="DBMI.pac187.s18.e0" id="DBMI.pac187.s18.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s18.e3" e2="DBMI.pac187.s18.e1" id="DBMI.pac187.s18.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s18.e3" e2="DBMI.pac187.s18.e2" id="DBMI.pac187.s18.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac187.s19" origId="s19" text="Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.">
		<entity charOffset="2699-2707" id="DBMI.pac187.s19.e0" origId="s19.e0" text="REYATAZ " type="Drug product"/>
		<entity charOffset="2731-2741" id="DBMI.pac187.s19.e1" origId="s19.e1" text="methadone " type="Active ingredient"/>
		<entity charOffset="2755-2769" id="DBMI.pac187.s19.e2" origId="s19.e2" text="acetaminophen " type="Active ingredient"/>
		<entity charOffset="2742-2754" id="DBMI.pac187.s19.e3" origId="s19.e3" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="2773-2782" id="DBMI.pac187.s19.e4" origId="s19.e4" text="atenolol " type="Active ingredient"/>
		<pair e1="DBMI.pac187.s19.e0" e2="DBMI.pac187.s19.e1" id="DBMI.pac187.s19.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methadone " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s19.e0" e2="DBMI.pac187.s19.e1" id="DBMI.pac187.s19.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methadone " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s19.e0" e2="DBMI.pac187.s19.e2" id="DBMI.pac187.s19.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="acetaminophen " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s19.e0" e2="DBMI.pac187.s19.e3" id="DBMI.pac187.s19.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluconazole " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s19.e0" e2="DBMI.pac187.s19.e4" id="DBMI.pac187.s19.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.s19.e1" e2="DBMI.pac187.s19.e0" id="DBMI.pac187.s19.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e1" e2="DBMI.pac187.s19.e2" id="DBMI.pac187.s19.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e1" e2="DBMI.pac187.s19.e3" id="DBMI.pac187.s19.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e1" e2="DBMI.pac187.s19.e4" id="DBMI.pac187.s19.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e2" e2="DBMI.pac187.s19.e0" id="DBMI.pac187.s19.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e2" e2="DBMI.pac187.s19.e1" id="DBMI.pac187.s19.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e2" e2="DBMI.pac187.s19.e3" id="DBMI.pac187.s19.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e2" e2="DBMI.pac187.s19.e4" id="DBMI.pac187.s19.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e3" e2="DBMI.pac187.s19.e0" id="DBMI.pac187.s19.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e3" e2="DBMI.pac187.s19.e1" id="DBMI.pac187.s19.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e3" e2="DBMI.pac187.s19.e2" id="DBMI.pac187.s19.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e3" e2="DBMI.pac187.s19.e4" id="DBMI.pac187.s19.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e4" e2="DBMI.pac187.s19.e0" id="DBMI.pac187.s19.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e4" e2="DBMI.pac187.s19.e1" id="DBMI.pac187.s19.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e4" e2="DBMI.pac187.s19.e2" id="DBMI.pac187.s19.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.s19.e4" e2="DBMI.pac187.s19.e3" id="DBMI.pac187.s19.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac187.s20" origId="s20" text="[See Clinical Pharmacology, Tables 16 and 17 (12.3).]"/>
	<sentencespan id="DBMI.pac187.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nSee also Contraindications (4) and Clinical Pharmacology (12.3). 7.1 Potential for REYATAZ to Affect Other Drugs\n\nAtazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects."/>
	<sentencespan id="DBMI.pac187.sp1" origId="sp1" text="Atazanavir is a weak inhibitor of CYP2C8. Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide). When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.">
		<entity charOffset="466-474" id="DBMI.pac187.sp1.e0" origId="sp1.e0" text="REYATAZ " type="Drug product"/>
		<entity charOffset="597-609" id="DBMI.pac187.sp1.e1" origId="sp1.e1" text="repaglinide " type="Active ingredient"/>
		<entity charOffset="585-596" id="DBMI.pac187.sp1.e2" origId="sp1.e2" text="paclitaxel " type="Active ingredient"/>
		<pair e1="DBMI.pac187.sp1.e0" e2="DBMI.pac187.sp1.e1" id="DBMI.pac187.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="repaglinide " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp1.e0" e2="DBMI.pac187.sp1.e2" id="DBMI.pac187.sp1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="paclitaxel " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp1.e1" e2="DBMI.pac187.sp1.e0" id="DBMI.pac187.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp1.e1" e2="DBMI.pac187.sp1.e2" id="DBMI.pac187.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp1.e2" e2="DBMI.pac187.sp1.e0" id="DBMI.pac187.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp1.e2" e2="DBMI.pac187.sp1.e1" id="DBMI.pac187.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac187.sp2" origId="sp2" text="[See Clinical Pharmacology, Table 14 (12.3).] The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir. See the complete prescribing information for NORVIR (ritonavir) for information on drug interactions with ritonavir."/>
	<sentencespan id="DBMI.pac187.sp3" origId="sp3" text="7.2 Potential for Other Drugs to Affect Atazanavir\n\nAtazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZs therapeutic effect. Atazanavir solubility decreases as pH increases. Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir."/>
	<sentencespan id="DBMI.pac187.sp4" origId="sp4" text="7.3 Established and Other Potentially Significant Drug Interactions\n\nTable 13 provides dosing recommendations as a result of drug interactions with REYATAZ. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. 7.4 Drugs with No Observed or Predicted Interactions with REYATAZ\n\nClinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1."/>
	<sentencespan id="DBMI.pac187.sp5" origId="sp5" text="Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8. See the complete prescribing information for NORVIR for information on other potential drug interactions with ritonavir. Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.">
		<entity charOffset="2403-2414" id="DBMI.pac187.sp5.e0" origId="sp5.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="2453-2461" id="DBMI.pac187.sp5.e1" origId="sp5.e1" text="dapsone " type="Active ingredient"/>
		<entity charOffset="2462-2475" id="DBMI.pac187.sp5.e2" origId="sp5.e2" text="trimethoprim " type="Active ingredient"/>
		<entity charOffset="2440-2452" id="DBMI.pac187.sp5.e3" origId="sp5.e3" text="pravastatin " type="Active ingredient"/>
		<entity charOffset="2493-2506" id="DBMI.pac187.sp5.e4" origId="sp5.e4" text="azithromycin " type="Active ingredient"/>
		<entity charOffset="2475-2492" id="DBMI.pac187.sp5.e5" origId="sp5.e5" text="sulfamethoxazole " type="Active ingredient"/>
		<entity charOffset="2510-2523" id="DBMI.pac187.sp5.e6" origId="sp5.e6" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="2427-2439" id="DBMI.pac187.sp5.e7" origId="sp5.e7" text="fluvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac187.sp5.e0" e2="DBMI.pac187.sp5.e1" id="DBMI.pac187.sp5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="dapsone " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.sp5.e0" e2="DBMI.pac187.sp5.e2" id="DBMI.pac187.sp5.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="trimethoprim " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.sp5.e0" e2="DBMI.pac187.sp5.e3" id="DBMI.pac187.sp5.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="pravastatin " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.sp5.e0" e2="DBMI.pac187.sp5.e4" id="DBMI.pac187.sp5.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="azithromycin " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.sp5.e0" e2="DBMI.pac187.sp5.e5" id="DBMI.pac187.sp5.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sulfamethoxazole " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.sp5.e0" e2="DBMI.pac187.sp5.e6" id="DBMI.pac187.sp5.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.sp5.e0" e2="DBMI.pac187.sp5.e7" id="DBMI.pac187.sp5.p6" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin " precipitant="atazanavir "/>
		<pair e1="DBMI.pac187.sp5.e1" e2="DBMI.pac187.sp5.e0" id="DBMI.pac187.sp5.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e1" e2="DBMI.pac187.sp5.e2" id="DBMI.pac187.sp5.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e1" e2="DBMI.pac187.sp5.e3" id="DBMI.pac187.sp5.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e1" e2="DBMI.pac187.sp5.e4" id="DBMI.pac187.sp5.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e1" e2="DBMI.pac187.sp5.e5" id="DBMI.pac187.sp5.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e1" e2="DBMI.pac187.sp5.e6" id="DBMI.pac187.sp5.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e1" e2="DBMI.pac187.sp5.e7" id="DBMI.pac187.sp5.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e2" e2="DBMI.pac187.sp5.e0" id="DBMI.pac187.sp5.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e2" e2="DBMI.pac187.sp5.e1" id="DBMI.pac187.sp5.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e2" e2="DBMI.pac187.sp5.e3" id="DBMI.pac187.sp5.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e2" e2="DBMI.pac187.sp5.e4" id="DBMI.pac187.sp5.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e2" e2="DBMI.pac187.sp5.e5" id="DBMI.pac187.sp5.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e2" e2="DBMI.pac187.sp5.e6" id="DBMI.pac187.sp5.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e2" e2="DBMI.pac187.sp5.e7" id="DBMI.pac187.sp5.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e3" e2="DBMI.pac187.sp5.e0" id="DBMI.pac187.sp5.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e3" e2="DBMI.pac187.sp5.e1" id="DBMI.pac187.sp5.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e3" e2="DBMI.pac187.sp5.e2" id="DBMI.pac187.sp5.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e3" e2="DBMI.pac187.sp5.e4" id="DBMI.pac187.sp5.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e3" e2="DBMI.pac187.sp5.e5" id="DBMI.pac187.sp5.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e3" e2="DBMI.pac187.sp5.e6" id="DBMI.pac187.sp5.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e3" e2="DBMI.pac187.sp5.e7" id="DBMI.pac187.sp5.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e4" e2="DBMI.pac187.sp5.e0" id="DBMI.pac187.sp5.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e4" e2="DBMI.pac187.sp5.e1" id="DBMI.pac187.sp5.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e4" e2="DBMI.pac187.sp5.e2" id="DBMI.pac187.sp5.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e4" e2="DBMI.pac187.sp5.e3" id="DBMI.pac187.sp5.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e4" e2="DBMI.pac187.sp5.e5" id="DBMI.pac187.sp5.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e4" e2="DBMI.pac187.sp5.e6" id="DBMI.pac187.sp5.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e4" e2="DBMI.pac187.sp5.e7" id="DBMI.pac187.sp5.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e5" e2="DBMI.pac187.sp5.e0" id="DBMI.pac187.sp5.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e5" e2="DBMI.pac187.sp5.e1" id="DBMI.pac187.sp5.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e5" e2="DBMI.pac187.sp5.e2" id="DBMI.pac187.sp5.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e5" e2="DBMI.pac187.sp5.e3" id="DBMI.pac187.sp5.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e5" e2="DBMI.pac187.sp5.e4" id="DBMI.pac187.sp5.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e5" e2="DBMI.pac187.sp5.e6" id="DBMI.pac187.sp5.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e5" e2="DBMI.pac187.sp5.e7" id="DBMI.pac187.sp5.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e6" e2="DBMI.pac187.sp5.e0" id="DBMI.pac187.sp5.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e6" e2="DBMI.pac187.sp5.e1" id="DBMI.pac187.sp5.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e6" e2="DBMI.pac187.sp5.e2" id="DBMI.pac187.sp5.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e6" e2="DBMI.pac187.sp5.e3" id="DBMI.pac187.sp5.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e6" e2="DBMI.pac187.sp5.e4" id="DBMI.pac187.sp5.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e6" e2="DBMI.pac187.sp5.e5" id="DBMI.pac187.sp5.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e6" e2="DBMI.pac187.sp5.e7" id="DBMI.pac187.sp5.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e7" e2="DBMI.pac187.sp5.e0" id="DBMI.pac187.sp5.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e7" e2="DBMI.pac187.sp5.e1" id="DBMI.pac187.sp5.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e7" e2="DBMI.pac187.sp5.e2" id="DBMI.pac187.sp5.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e7" e2="DBMI.pac187.sp5.e3" id="DBMI.pac187.sp5.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e7" e2="DBMI.pac187.sp5.e4" id="DBMI.pac187.sp5.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e7" e2="DBMI.pac187.sp5.e5" id="DBMI.pac187.sp5.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp5.e7" e2="DBMI.pac187.sp5.e6" id="DBMI.pac187.sp5.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac187.sp6" origId="sp6" text="REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]">
		<entity charOffset="2524-2532" id="DBMI.pac187.sp6.e0" origId="sp6.e0" text="REYATAZ " type="Drug product"/>
		<entity charOffset="2596-2608" id="DBMI.pac187.sp6.e1" origId="sp6.e1" text="desipramine " type="Active ingredient"/>
		<entity charOffset="2581-2595" id="DBMI.pac187.sp6.e2" origId="sp6.e2" text="nortriptyline " type="Active ingredient"/>
		<entity charOffset="2609-2620" id="DBMI.pac187.sp6.e3" origId="sp6.e3" text="metoprolol " type="Active ingredient"/>
		<entity charOffset="2731-2741" id="DBMI.pac187.sp6.e4" origId="sp6.e4" text="methadone " type="Active ingredient"/>
		<entity charOffset="2755-2769" id="DBMI.pac187.sp6.e5" origId="sp6.e5" text="acetaminophen " type="Active ingredient"/>
		<entity charOffset="2742-2754" id="DBMI.pac187.sp6.e6" origId="sp6.e6" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="2773-2782" id="DBMI.pac187.sp6.e7" origId="sp6.e7" text="atenolol " type="Active ingredient"/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e1" id="DBMI.pac187.sp6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="desipramine " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e1" id="DBMI.pac187.sp6.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="desipramine " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e2" id="DBMI.pac187.sp6.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nortriptyline " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e2" id="DBMI.pac187.sp6.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nortriptyline " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e3" id="DBMI.pac187.sp6.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="metoprolol " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e3" id="DBMI.pac187.sp6.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="metoprolol " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e4" id="DBMI.pac187.sp6.p6" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methadone " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e4" id="DBMI.pac187.sp6.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methadone " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e5" id="DBMI.pac187.sp6.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="acetaminophen " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e6" id="DBMI.pac187.sp6.p9" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluconazole " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e0" e2="DBMI.pac187.sp6.e7" id="DBMI.pac187.sp6.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="REYATAZ "/>
		<pair e1="DBMI.pac187.sp6.e1" e2="DBMI.pac187.sp6.e0" id="DBMI.pac187.sp6.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e1" e2="DBMI.pac187.sp6.e2" id="DBMI.pac187.sp6.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e1" e2="DBMI.pac187.sp6.e3" id="DBMI.pac187.sp6.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e1" e2="DBMI.pac187.sp6.e4" id="DBMI.pac187.sp6.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e1" e2="DBMI.pac187.sp6.e5" id="DBMI.pac187.sp6.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e1" e2="DBMI.pac187.sp6.e6" id="DBMI.pac187.sp6.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e1" e2="DBMI.pac187.sp6.e7" id="DBMI.pac187.sp6.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e2" e2="DBMI.pac187.sp6.e0" id="DBMI.pac187.sp6.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e2" e2="DBMI.pac187.sp6.e1" id="DBMI.pac187.sp6.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e2" e2="DBMI.pac187.sp6.e3" id="DBMI.pac187.sp6.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e2" e2="DBMI.pac187.sp6.e4" id="DBMI.pac187.sp6.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e2" e2="DBMI.pac187.sp6.e5" id="DBMI.pac187.sp6.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e2" e2="DBMI.pac187.sp6.e6" id="DBMI.pac187.sp6.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e2" e2="DBMI.pac187.sp6.e7" id="DBMI.pac187.sp6.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e3" e2="DBMI.pac187.sp6.e0" id="DBMI.pac187.sp6.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e3" e2="DBMI.pac187.sp6.e1" id="DBMI.pac187.sp6.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e3" e2="DBMI.pac187.sp6.e2" id="DBMI.pac187.sp6.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e3" e2="DBMI.pac187.sp6.e4" id="DBMI.pac187.sp6.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e3" e2="DBMI.pac187.sp6.e5" id="DBMI.pac187.sp6.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e3" e2="DBMI.pac187.sp6.e6" id="DBMI.pac187.sp6.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e3" e2="DBMI.pac187.sp6.e7" id="DBMI.pac187.sp6.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e4" e2="DBMI.pac187.sp6.e0" id="DBMI.pac187.sp6.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e4" e2="DBMI.pac187.sp6.e1" id="DBMI.pac187.sp6.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e4" e2="DBMI.pac187.sp6.e2" id="DBMI.pac187.sp6.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e4" e2="DBMI.pac187.sp6.e3" id="DBMI.pac187.sp6.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e4" e2="DBMI.pac187.sp6.e5" id="DBMI.pac187.sp6.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e4" e2="DBMI.pac187.sp6.e6" id="DBMI.pac187.sp6.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e4" e2="DBMI.pac187.sp6.e7" id="DBMI.pac187.sp6.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e5" e2="DBMI.pac187.sp6.e0" id="DBMI.pac187.sp6.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e5" e2="DBMI.pac187.sp6.e1" id="DBMI.pac187.sp6.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e5" e2="DBMI.pac187.sp6.e2" id="DBMI.pac187.sp6.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e5" e2="DBMI.pac187.sp6.e3" id="DBMI.pac187.sp6.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e5" e2="DBMI.pac187.sp6.e4" id="DBMI.pac187.sp6.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e5" e2="DBMI.pac187.sp6.e6" id="DBMI.pac187.sp6.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e5" e2="DBMI.pac187.sp6.e7" id="DBMI.pac187.sp6.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e6" e2="DBMI.pac187.sp6.e0" id="DBMI.pac187.sp6.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e6" e2="DBMI.pac187.sp6.e1" id="DBMI.pac187.sp6.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e6" e2="DBMI.pac187.sp6.e2" id="DBMI.pac187.sp6.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e6" e2="DBMI.pac187.sp6.e3" id="DBMI.pac187.sp6.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e6" e2="DBMI.pac187.sp6.e4" id="DBMI.pac187.sp6.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e6" e2="DBMI.pac187.sp6.e5" id="DBMI.pac187.sp6.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e6" e2="DBMI.pac187.sp6.e7" id="DBMI.pac187.sp6.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e7" e2="DBMI.pac187.sp6.e0" id="DBMI.pac187.sp6.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e7" e2="DBMI.pac187.sp6.e1" id="DBMI.pac187.sp6.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e7" e2="DBMI.pac187.sp6.e2" id="DBMI.pac187.sp6.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e7" e2="DBMI.pac187.sp6.e3" id="DBMI.pac187.sp6.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e7" e2="DBMI.pac187.sp6.e4" id="DBMI.pac187.sp6.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e7" e2="DBMI.pac187.sp6.e5" id="DBMI.pac187.sp6.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac187.sp6.e7" e2="DBMI.pac187.sp6.e6" id="DBMI.pac187.sp6.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac188" origId="pac188">
	<sentence id="DBMI.pac188.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nAtazanavir is an antiviral drug [see Clinical Pharmacology (12.4)]."/>
	<sentence id="DBMI.pac188.s1" origId="s1" text="12.2 Pharmacodynamics\n\nEffects on Electrocardiogram\n\nConcentration- and dose-dependent prolongation of the PR interval in the electrocardiogram has been observed in healthy volunteers receiving atazanavir."/>
	<sentence id="DBMI.pac188.s2" origId="s2" text="In a placebo-controlled study (AI424-076), the mean (SD) maximum change in PR interval from the predose value was 24 (15) msec following oral dosing with 400 mg of atazanavir (n=65) compared to 13 (11) msec following dosing with placebo (n=67)."/>
	<sentence id="DBMI.pac188.s3" origId="s3" text="The PR interval prolongations in this study were asymptomatic."/>
	<sentence id="DBMI.pac188.s4" origId="s4" text="There is limited information on the potential for a pharmacodynamic interaction in humans between atazanavir and other drugs that prolong the PR interval of the electrocardiogram."/>
	<sentence id="DBMI.pac188.s5" origId="s5" text="[See Warnings and Precautions (5.2).]"/>
	<sentence id="DBMI.pac188.s6" origId="s6" text="Electrocardiographic effects of atazanavir were determined in a clinical pharmacology study of 72 healthy subjects."/>
	<sentence id="DBMI.pac188.s7" origId="s7" text="Oral doses of 400 mg and 800 mg were compared with placebo; there was no concentration-dependent effect of atazanavir on the QTc interval (using Fridericias correction)."/>
	<sentence id="DBMI.pac188.s8" origId="s8" text="In 1793 HIV-infected patients receiving antiretroviral regimens, QTc prolongation was comparable in the atazanavir and comparator regimens."/>
	<sentence id="DBMI.pac188.s9" origId="s9" text="No atazanavir-treated healthy subject or HIV-infected patient in clinical trials had a QTc interval &gt;500 msec."/>
	<sentence id="DBMI.pac188.s10" origId="s10" text="[See Warnings and Precautions (5.2).]"/>
	<sentence id="DBMI.pac188.s11" origId="s11" text="In a pharmacokinetic study between atazanavir 400 mg once daily and diltiazem 180 mg once daily, a CYP3A substrate, there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval.">
		<entity charOffset="1469-1480" id="DBMI.pac188.s11.e0" origId="s11.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="1502-1512" id="DBMI.pac188.s11.e1" origId="s11.e1" text="diltiazem " type="Active ingredient"/>
		<pair e1="DBMI.pac188.s11.e0" e2="DBMI.pac188.s11.e1" id="DBMI.pac188.s11.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="diltiazem " precipitant="atazanavir "/>
		<pair e1="DBMI.pac188.s11.e1" e2="DBMI.pac188.s11.e0" id="DBMI.pac188.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac188.s12" origId="s12" text="In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, there was no substantial additive effect of atazanavir and atenolol on the PR interval.">
		<entity charOffset="1694-1705" id="DBMI.pac188.s12.e0" origId="s12.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="1727-1736" id="DBMI.pac188.s12.e1" origId="s12.e1" text="atenolol " type="Active ingredient"/>
		<pair e1="DBMI.pac188.s12.e0" e2="DBMI.pac188.s12.e1" id="DBMI.pac188.s12.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="atazanavir "/>
		<pair e1="DBMI.pac188.s12.e1" e2="DBMI.pac188.s12.e0" id="DBMI.pac188.s12.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac188.s13" origId="s13" text="[See Warnings and Precautions (5.2).]"/>
	<sentence id="DBMI.pac188.s14" origId="s14" text="12.3 Pharmacokinetics\n\nThe pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV-infected patients after administration of REYATAZ 400 mg once daily and after administration of REYATAZ 300 mg with ritonavir 100 mg once daily (see Table 14)."/>
	<sentence id="DBMI.pac188.s15" origId="s15" text="Figure 1 displays the mean plasma concentrations of atazanavir at steady state after REYATAZ 400 mg once daily (as two 200-mg capsules) with a light meal and after REYATAZ 300 mg (as two 150-mg capsules) with ritonavir 100 mg once daily with a light meal in HIV-infected adult patients."/>
	<sentence id="DBMI.pac188.s16" origId="s16" text="Absorption\n\nAtazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours."/>
	<sentence id="DBMI.pac188.s17" origId="s17" text="Atazanavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC and Cmax values over the dose range of 200800 mg once daily."/>
	<sentence id="DBMI.pac188.s18" origId="s18" text="Steady-state is achieved between Days 4 and 8, with an accumulation of approximately 2.3-fold."/>
	<sentence id="DBMI.pac188.s19" origId="s19" text="Food Effect\n\nAdministration of REYATAZ with food enhances bioavailability and reduces pharmacokinetic variability."/>
	<sentence id="DBMI.pac188.s20" origId="s20" text="Administration of a single 400-mg dose of REYATAZ with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) resulted in a 70% increase in AUC and 57% increase in Cmax relative to the fasting state."/>
	<sentence id="DBMI.pac188.s21" origId="s21" text="Administration of a single 400-mg dose of REYATAZ with a high-fat meal (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% with no change in Cmax relative to the fasting state."/>
	<sentence id="DBMI.pac188.s22" origId="s22" text="Administration of REYATAZ (atazanavir sulfate) with either a light meal or high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately one half compared to the fasting state."/>
	<sentence id="DBMI.pac188.s23" origId="s23" text="Coadministration of a single 300-mg dose of REYATAZ and a 100-mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the Cmax and the 24-hour concentration of atazanavir relative to the fasting state."/>
	<sentence id="DBMI.pac188.s24" origId="s24" text="Coadministration with a high-fat meal (951 kcal, 54.7 g fat, 35.9 g protein) did not affect the AUC of atazanavir relative to fasting conditions and the Cmax was within 11% of fasting values."/>
	<sentence id="DBMI.pac188.s25" origId="s25" text="The 24-hour concentration following a high-fat meal was increased by approximately 33% due to delayed absorption; the median Tmax increased from 2.0 to 5.0 hours."/>
	<sentence id="DBMI.pac188.s26" origId="s26" text="Coadministration of REYATAZ with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately 25% compared to the fasting state."/>
	<sentence id="DBMI.pac188.s27" origId="s27" text="Distribution\n\nAtazanavir is 86% bound to human serum proteins and protein binding is independent of concentration."/>
	<sentence id="DBMI.pac188.s28" origId="s28" text="Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively)."/>
	<sentence id="DBMI.pac188.s29" origId="s29" text="In a multiple-dose study in HIV-infected patients dosed with REYATAZ 400 mg once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen."/>
	<sentence id="DBMI.pac188.s30" origId="s30" text="The cerebrospinal fluid/plasma ratio for atazanavir (n=4) ranged between 0.0021 and 0.0226 and seminal fluid/plasma ratio (n=5) ranged between 0.11 and 4.42."/>
	<sentence id="DBMI.pac188.s31" origId="s31" text="Metabolism\n\nAtazanavir is extensively metabolized in humans."/>
	<sentence id="DBMI.pac188.s32" origId="s32" text="The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation."/>
	<sentence id="DBMI.pac188.s33" origId="s33" text="Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation."/>
	<sentence id="DBMI.pac188.s34" origId="s34" text="Two minor metabolites of atazanavir in plasma have been characterized."/>
	<sentence id="DBMI.pac188.s35" origId="s35" text="Neither metabolite demonstrated in vitro antiviral activity."/>
	<sentence id="DBMI.pac188.s36" origId="s36" text="In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A."/>
	<sentence id="DBMI.pac188.s37" origId="s37" text="Elimination\n\nFollowing a single 400-mg dose of 14C-atazanavir, 79% and 13% of the total radioactivity was recovered in the feces and urine, respectively."/>
	<sentence id="DBMI.pac188.s38" origId="s38" text="Unchanged drug accounted for approximately 20% and 7% of the administered dose in the feces and urine, respectively."/>
	<sentence id="DBMI.pac188.s39" origId="s39" text="The mean elimination half-life of atazanavir in healthy volunteers (n=214) and HIV-infected adult patients (n=13) was approximately 7 hours at steady state following a dose of 400 mg daily with a light meal."/>
	<sentence id="DBMI.pac188.s40" origId="s40" text="Special Populations\n\nPediatrics\n\nThe pharmacokinetic data from pediatric patients receiving REYATAZ Capsules with ritonavir based on body surface area are presented in Table 15."/>
	<sentence id="DBMI.pac188.s41" origId="s41" text="Drug Interaction Data\n\nAtazanavir is a metabolism-dependent CYP3A inhibitor, with a Kinact value of 0.05 to 0.06 min-1 and Ki value of 0.84 to 1.0 M. Atazanavir is also a direct inhibitor for UGT1A1 (Ki=1.9 M) and CYP2C8 (Ki=2.1 M)."/>
	<sentence id="DBMI.pac188.s42" origId="s42" text="Atazanavir has been shown in vivo not to induce its own metabolism, nor to increase the biotransformation of some drugs metabolized by CYP3A."/>
	<sentence id="DBMI.pac188.s43" origId="s43" text="In a multiple-dose study, REYATAZ decreased the urinary ratio of endogenous 6-OH cortisol to cortisol versus baseline, indicating that CYP3A production was not induced."/>
	<sentence id="DBMI.pac188.s44" origId="s44" text="Drug interaction studies were performed with REYATAZ and other drugs likely to be coadministered and some drugs commonly used as probes for pharmacokinetic interactions."/>
	<sentence id="DBMI.pac188.s45" origId="s45" text="The effects of coadministration of REYATAZ on the AUC, Cmax, and Cmin are summarized in Tables 16 and 17."/>
	<sentence id="DBMI.pac188.s46" origId="s46" text="For information regarding clinical recommendations, see Drug Interactions (7)."/>
	<sentence id="DBMI.pac188.s47" origId="s47" text="12.4 Microbiology\n\nMechanism of Action\n\nAtazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI)."/>
	<sentence id="DBMI.pac188.s48" origId="s48" text="The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions."/>
	<sentence id="DBMI.pac188.s49" origId="s49" text="Antiviral Activity in Cell Culture\n\nAtazanavir exhibits anti-HIV-1 activity with a mean 50% effective concentration (EC50) in the absence of human serum of 2 to 5 nM against a variety of laboratory and clinical HIV-1 isolates grown in peripheral blood mononuclear cells, macrophages, CEM-SS cells, and MT-2 cells."/>
	<sentence id="DBMI.pac188.s50" origId="s50" text="ATV has activity against HIV-1 Group M subtype viruses A, B, C, D, AE, AG, F, G, and J isolates in cell culture."/>
	<sentence id="DBMI.pac188.s51" origId="s51" text="ATV has variable activity against HIV-2 isolates (1.9 to 32 nM), with EC50 values above the EC50 values of failure isolates."/>
	<sentence id="DBMI.pac188.s52" origId="s52" text="Two-drug combination antiviral activity studies with ATV showed no antagonism in cell culture with NNRTIs (delavirdine, efavirenz, and nevirapine), PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine), the HIV-1 fusion inhibitor enfuvirtide, and two compounds used in the treatment of viral hepatitis, adefovir and ribavirin, without enhanced cytotoxicity."/>
	<sentence id="DBMI.pac188.s53" origId="s53" text="Resistance\n\nIn Cell Culture: HIV-1 isolates with a decreased susceptibility to ATV have been selected in cell culture and obtained from patients treated with ATV or atazanavir/ritonavir (ATV/RTV)."/>
	<sentence id="DBMI.pac188.s54" origId="s54" text="HIV-1 isolates with 93- to 183-fold reduced susceptibility to ATV from three different viral strains were selected in cell culture by 5 months."/>
	<sentence id="DBMI.pac188.s55" origId="s55" text="The substitutions in these HIV-1 viruses that contributed to ATV resistance include I50L, N88S, I84V, A71V, and M46I."/>
	<sentence id="DBMI.pac188.s56" origId="s56" text="Changes were also observed at the protease cleavage sites following drug selection."/>
	<sentence id="DBMI.pac188.s57" origId="s57" text="Recombinant viruses containing the I50L substitution without other major PI substitutions were growth impaired and displayed increased susceptibility in cell culture to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir)."/>
	<sentence id="DBMI.pac188.s58" origId="s58" text="The I50L and I50V substitutions yielded selective resistance to ATV and amprenavir, respectively, and did not appear to be cross-resistant."/>
	<sentence id="DBMI.pac188.s59" origId="s59" text="Clinical Studies of Treatment-Naive Patients: Comparison of Ritonavir-Boosted REYATAZ vs. Unboosted REYATAZ: Study AI424-089 compared REYATAZ 300 mg once daily with ritonavir 100 mg vs. REYATAZ 400 mg once daily when administered with lamivudine and extended-release stavudine in HIV-infected treatment-naive patients."/>
	<sentence id="DBMI.pac188.s60" origId="s60" text="A summary of the number of virologic failures and virologic failure isolates with ATV resistance in each arm is shown in Table 18."/>
	<sentence id="DBMI.pac188.s61" origId="s61" text="Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 300 mg With Ritonavir 100 mg: In Phase III study AI424-138, an as-treated genotypic and phenotypic analysis was conducted on samples from patients who experienced virologic failure (HIV-1 RNA 400 copies/mL) or discontinued before achieving suppression on ATV/RTV (n=39; 9%) and LPV/RTV (n=39; 9%) through 96 weeks of treatment."/>
	<sentence id="DBMI.pac188.s62" origId="s62" text="In the ATV/RTV arm, one of the virologic failure isolates had a 56-fold decrease in ATV susceptibility emerge on therapy with the development of PI resistance-associated substitutions L10F, V32I, K43T, M46I, A71I, G73S, I85I/V, and L90M."/>
	<sentence id="DBMI.pac188.s63" origId="s63" text="The NRTI resistance-associated substitution M184V also emerged on treatment in this isolate conferring emtricitabine resistance."/>
	<sentence id="DBMI.pac188.s64" origId="s64" text="Two ATV/RTV-virologic failure isolates had baseline phenotypic ATV resistance and IAS-defined major PI resistance-associated substitutions at baseline."/>
	<sentence id="DBMI.pac188.s65" origId="s65" text="The 150L substitution emerged on study in one of these failure isolates and was associated with a 17-fold decrease in ATV susceptibility from baseline and the other failure isolate with baseline ATV resistance and PI substitutions (M46M/I and I84I/V) had additional IAS-defined major PI substitutions (V32I, M46I, and I84V) emerge on ATV treatment associated with a 3-fold decrease in ATV susceptibiity from baseline."/>
	<sentence id="DBMI.pac188.s66" origId="s66" text="Five of the treatment failure isolates in the ATV/RTV arm developed phenotypic emtricitabine resistance with the emergence of either the M184I (n=1) or the M184V (n=4) substitution on therapy and none developed phenotypic tenofovir disoproxil resistance."/>
	<sentence id="DBMI.pac188.s67" origId="s67" text="In the LPV/RTV arm, one of the virologic failure patient isolates had a 69-fold decrease in LPV susceptibility emerge on therapy with the development of PI substitutions L10V, V11I, I54V, G73S, and V82A in addition to baseline PI substitutions L10L/I, V32I, I54I/V, A71I, G73G/S, V82V/A, L89V, and L90M."/>
	<sentence id="DBMI.pac188.s68" origId="s68" text="Six LPV/RTV virologic failure isolates developed the M184V substitution and phenotypic emtricitabine resistance and two developed phenotypic tenofovir disoproxil resistance."/>
	<sentence id="DBMI.pac188.s69" origId="s69" text="Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 400 mg Without Ritonavir: ATV-resistant clinical isolates from treatment-naive patients who experienced virologic failure on REYATAZ 400 mg treatment without ritonavir often developed an I50L substitution (after an average of 50 weeks of ATV therapy), often in combination with an A71V substitution, but also developed one or more other PI substitutions (eg, V32I, L33F, G73S, V82A, I85V, or N88S) with or without the I50L substitution."/>
	<sentence id="DBMI.pac188.s70" origId="s70" text="In treatment-naive patients, viral isolates that developed the I50L substitution, without other major PI substitutions, showed phenotypic resistance to ATV but retained in cell culture susceptibility to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir); however, there are no clinical data available to demonstrate the effect of the I50L substitution on the efficacy of subsequently administered PIs."/>
	<sentence id="DBMI.pac188.s71" origId="s71" text="Clinical Studies of Treatment-Experienced Patients: In studies of treatment-experienced patients treated with ATV or ATV/RTV, most ATV-resistant isolates from patients who experienced virologic failure developed substitutions that were associated with resistance to multiple PIs and displayed decreased susceptibility to multiple PIs."/>
	<sentence id="DBMI.pac188.s72" origId="s72" text="The most common protease substitutions to develop in the viral isolates of patients who failed treatment with ATV 300 mg once daily and RTV 100 mg once daily (together with tenofovir and an NRTI) included V32I, L33F/V/I, E35D/G, M46I/L, I50L, F53L/V, I54V, A71V/T/I, G73S/T/C, V82A/T/L, I85V, and L89V/Q/M/T."/>
	<sentence id="DBMI.pac188.s73" origId="s73" text="Other substitutions that developed on ATV/RTV treatment including E34K/A/Q, G48V, I84V, N88S/D/T, and L90M occurred in less than 10% of patient isolates."/>
	<sentence id="DBMI.pac188.s74" origId="s74" text="Generally, if multiple PI resistance substitutions were present in the HIV-1 virus of the patient at baseline, ATV resistance developed through substitutions associated with resistance to other PIs and could include the development of the I50L substitution."/>
	<sentence id="DBMI.pac188.s75" origId="s75" text="The I50L substitution has been detected in treatment-experienced patients experiencing virologic failure after long-term treatment."/>
	<sentence id="DBMI.pac188.s76" origId="s76" text="Protease cleavage site changes also emerged on ATV treatment but their presence did not correlate with the level of ATV resistance."/>
	<sentence id="DBMI.pac188.s77" origId="s77" text="Cross-Resistance\n\nCross-resistance among PIs has been observed."/>
	<sentence id="DBMI.pac188.s78" origId="s78" text="Baseline phenotypic and genotypic analyses of clinical isolates from ATV clinical trials of PI-experienced patients showed that isolates cross-resistant to multiple PIs were cross-resistant to ATV."/>
	<sentence id="DBMI.pac188.s79" origId="s79" text="Greater than 90% of the isolates with substitutions that included I84V or G48V were resistant to ATV."/>
	<sentence id="DBMI.pac188.s80" origId="s80" text="Greater than 60% of isolates containing L90M, G73S/T/C, A71V/T, I54V, M46I/L, or a change at V82 were resistant to ATV, and 38% of isolates containing a D30N substitution in addition to other changes were resistant to ATV."/>
	<sentence id="DBMI.pac188.s81" origId="s81" text="Isolates resistant to ATV were also cross-resistant to other PIs with &gt;90% of the isolates resistant to indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir, and 80% resistant to amprenavir."/>
	<sentence id="DBMI.pac188.s82" origId="s82" text="In treatment-experienced patients, PI-resistant viral isolates that developed the I50L substitution in addition to other PI resistance-associated substitution were also cross-resistant to other PIs."/>
	<sentence id="DBMI.pac188.s83" origId="s83" text="Baseline Genotype/Phenotype and Virologic Outcome Analyses\n\nGenotypic and/or phenotypic analysis of baseline virus may aid in determining ATV susceptibility before initiation of ATV/RTV therapy."/>
	<sentence id="DBMI.pac188.s84" origId="s84" text="An association between virologic response at 48 weeks and the number and type of primary PI resistance-associated substitutions detected in baseline HIV-1 isolates from antiretroviral-experienced patients receiving ATV/RTV once daily or lopinavir (LPV)/RTV twice daily in Study AI424-045 is shown in Table 19."/>
	<sentence id="DBMI.pac188.s85" origId="s85" text="Overall, both the number and type of baseline PI substitutions affected response rates in treatment-experienced patients."/>
	<sentence id="DBMI.pac188.s86" origId="s86" text="In the ATV/RTV group, patients had lower response rates when 3 or more baseline PI substitutions, including a substitution at position 36, 71, 77, 82, or 90, were present compared to patients with 12 PI substitutions, including one of these substitutions."/>
	<sentence id="DBMI.pac188.s87" origId="s87" text="The response rates of antiretroviral-experienced patients in Study AI424-045 were analyzed by baseline phenotype (shift in susceptibility in cell culture relative to reference, Table 20)."/>
	<sentence id="DBMI.pac188.s88" origId="s88" text="The analyses are based on a select patient population with 62% of patients receiving an NNRTI-based regimen before study entry compared to 35% receiving a PI-based regimen."/>
	<sentence id="DBMI.pac188.s89" origId="s89" text="Additional data are needed to determine clinically relevant break points for REYATAZ."/>
	<sentencespan id="DBMI.pac188.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nAtazanavir is an antiviral drug [see Clinical Pharmacology (12.4)]. 12.2 Pharmacodynamics\n\nEffects on Electrocardiogram\n\nConcentration- and dose-dependent prolongation of the PR interval in the electrocardiogram has been observed in healthy volunteers receiving atazanavir. In a placebo-controlled study (AI424-076), the mean (SD) maximum change in PR interval from the predose value was 24 (15) msec following oral dosing with 400 mg of atazanavir (n=65) compared to 13 (11) msec following dosing with placebo (n=67)."/>
	<sentencespan id="DBMI.pac188.sp1" origId="sp1" text="The PR interval prolongations in this study were asymptomatic. There is limited information on the potential for a pharmacodynamic interaction in humans between atazanavir and other drugs that prolong the PR interval of the electrocardiogram. [See Warnings and Precautions (5.2).]"/>
	<sentencespan id="DBMI.pac188.sp2" origId="sp2" text="Electrocardiographic effects of atazanavir were determined in a clinical pharmacology study of 72 healthy subjects. Oral doses of 400 mg and 800 mg were compared with placebo; there was no concentration-dependent effect of atazanavir on the QTc interval (using Fridericias correction). In 1793 HIV-infected patients receiving antiretroviral regimens, QTc prolongation was comparable in the atazanavir and comparator regimens."/>
	<sentencespan id="DBMI.pac188.sp3" origId="sp3" text="No atazanavir-treated healthy subject or HIV-infected patient in clinical trials had a QTc interval &gt;500 msec. [See Warnings and Precautions (5.2).] In a pharmacokinetic study between atazanavir 400 mg once daily and diltiazem 180 mg once daily, a CYP3A substrate, there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval.">
		<entity charOffset="1469-1480" id="DBMI.pac188.sp3.e0" origId="sp3.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="1502-1512" id="DBMI.pac188.sp3.e1" origId="sp3.e1" text="diltiazem " type="Active ingredient"/>
		<pair e1="DBMI.pac188.sp3.e0" e2="DBMI.pac188.sp3.e1" id="DBMI.pac188.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="diltiazem " precipitant="atazanavir "/>
		<pair e1="DBMI.pac188.sp3.e1" e2="DBMI.pac188.sp3.e0" id="DBMI.pac188.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac188.sp4" origId="sp4" text="In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, there was no substantial additive effect of atazanavir and atenolol on the PR interval. [See Warnings and Precautions (5.2).] 12.3 Pharmacokinetics\n\nThe pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV-infected patients after administration of REYATAZ 400 mg once daily and after administration of REYATAZ 300 mg with ritonavir 100 mg once daily (see Table 14).">
		<entity charOffset="1694-1705" id="DBMI.pac188.sp4.e0" origId="sp4.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="1727-1736" id="DBMI.pac188.sp4.e1" origId="sp4.e1" text="atenolol " type="Active ingredient"/>
		<pair e1="DBMI.pac188.sp4.e0" e2="DBMI.pac188.sp4.e1" id="DBMI.pac188.sp4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="atazanavir "/>
		<pair e1="DBMI.pac188.sp4.e1" e2="DBMI.pac188.sp4.e0" id="DBMI.pac188.sp4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac188.sp5" origId="sp5" text="Figure 1 displays the mean plasma concentrations of atazanavir at steady state after REYATAZ 400 mg once daily (as two 200-mg capsules) with a light meal and after REYATAZ 300 mg (as two 150-mg capsules) with ritonavir 100 mg once daily with a light meal in HIV-infected adult patients. Absorption\n\nAtazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Atazanavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC and Cmax values over the dose range of 200800 mg once daily."/>
	<sentencespan id="DBMI.pac188.sp6" origId="sp6" text="Steady-state is achieved between Days 4 and 8, with an accumulation of approximately 2.3-fold. Food Effect\n\nAdministration of REYATAZ with food enhances bioavailability and reduces pharmacokinetic variability. Administration of a single 400-mg dose of REYATAZ with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) resulted in a 70% increase in AUC and 57% increase in Cmax relative to the fasting state."/>
	<sentencespan id="DBMI.pac188.sp7" origId="sp7" text="Administration of a single 400-mg dose of REYATAZ with a high-fat meal (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% with no change in Cmax relative to the fasting state. Administration of REYATAZ (atazanavir sulfate) with either a light meal or high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately one half compared to the fasting state. Coadministration of a single 300-mg dose of REYATAZ and a 100-mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the Cmax and the 24-hour concentration of atazanavir relative to the fasting state."/>
	<sentencespan id="DBMI.pac188.sp8" origId="sp8" text="Coadministration with a high-fat meal (951 kcal, 54.7 g fat, 35.9 g protein) did not affect the AUC of atazanavir relative to fasting conditions and the Cmax was within 11% of fasting values. The 24-hour concentration following a high-fat meal was increased by approximately 33% due to delayed absorption; the median Tmax increased from 2.0 to 5.0 hours. Coadministration of REYATAZ with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately 25% compared to the fasting state."/>
	<sentencespan id="DBMI.pac188.sp9" origId="sp9" text="Distribution\n\nAtazanavir is 86% bound to human serum proteins and protein binding is independent of concentration. Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively). In a multiple-dose study in HIV-infected patients dosed with REYATAZ 400 mg once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen."/>
	<sentencespan id="DBMI.pac188.sp10" origId="sp10" text="The cerebrospinal fluid/plasma ratio for atazanavir (n=4) ranged between 0.0021 and 0.0226 and seminal fluid/plasma ratio (n=5) ranged between 0.11 and 4.42. Metabolism\n\nAtazanavir is extensively metabolized in humans. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation."/>
	<sentencespan id="DBMI.pac188.sp11" origId="sp11" text="Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation. Two minor metabolites of atazanavir in plasma have been characterized. Neither metabolite demonstrated in vitro antiviral activity."/>
	<sentencespan id="DBMI.pac188.sp12" origId="sp12" text="In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A. Elimination\n\nFollowing a single 400-mg dose of 14C-atazanavir, 79% and 13% of the total radioactivity was recovered in the feces and urine, respectively. Unchanged drug accounted for approximately 20% and 7% of the administered dose in the feces and urine, respectively."/>
	<sentencespan id="DBMI.pac188.sp13" origId="sp13" text="The mean elimination half-life of atazanavir in healthy volunteers (n=214) and HIV-infected adult patients (n=13) was approximately 7 hours at steady state following a dose of 400 mg daily with a light meal. Special Populations\n\nPediatrics\n\nThe pharmacokinetic data from pediatric patients receiving REYATAZ Capsules with ritonavir based on body surface area are presented in Table 15. Drug Interaction Data\n\nAtazanavir is a metabolism-dependent CYP3A inhibitor, with a Kinact value of 0.05 to 0.06 min-1 and Ki value of 0.84 to 1.0 M. Atazanavir is also a direct inhibitor for UGT1A1 (Ki=1.9 M) and CYP2C8 (Ki=2.1 M)."/>
	<sentencespan id="DBMI.pac188.sp14" origId="sp14" text="Atazanavir has been shown in vivo not to induce its own metabolism, nor to increase the biotransformation of some drugs metabolized by CYP3A. In a multiple-dose study, REYATAZ decreased the urinary ratio of endogenous 6-OH cortisol to cortisol versus baseline, indicating that CYP3A production was not induced. Drug interaction studies were performed with REYATAZ and other drugs likely to be coadministered and some drugs commonly used as probes for pharmacokinetic interactions."/>
	<sentencespan id="DBMI.pac188.sp15" origId="sp15" text="The effects of coadministration of REYATAZ on the AUC, Cmax, and Cmin are summarized in Tables 16 and 17. For information regarding clinical recommendations, see Drug Interactions (7). 12.4 Microbiology\n\nMechanism of Action\n\nAtazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI)."/>
	<sentencespan id="DBMI.pac188.sp16" origId="sp16" text="The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions. Antiviral Activity in Cell Culture\n\nAtazanavir exhibits anti-HIV-1 activity with a mean 50% effective concentration (EC50) in the absence of human serum of 2 to 5 nM against a variety of laboratory and clinical HIV-1 isolates grown in peripheral blood mononuclear cells, macrophages, CEM-SS cells, and MT-2 cells. ATV has activity against HIV-1 Group M subtype viruses A, B, C, D, AE, AG, F, G, and J isolates in cell culture."/>
	<sentencespan id="DBMI.pac188.sp17" origId="sp17" text="ATV has variable activity against HIV-2 isolates (1.9 to 32 nM), with EC50 values above the EC50 values of failure isolates. Two-drug combination antiviral activity studies with ATV showed no antagonism in cell culture with NNRTIs (delavirdine, efavirenz, and nevirapine), PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine), the HIV-1 fusion inhibitor enfuvirtide, and two compounds used in the treatment of viral hepatitis, adefovir and ribavirin, without enhanced cytotoxicity. Resistance\n\nIn Cell Culture: HIV-1 isolates with a decreased susceptibility to ATV have been selected in cell culture and obtained from patients treated with ATV or atazanavir/ritonavir (ATV/RTV)."/>
	<sentencespan id="DBMI.pac188.sp18" origId="sp18" text="HIV-1 isolates with 93- to 183-fold reduced susceptibility to ATV from three different viral strains were selected in cell culture by 5 months. The substitutions in these HIV-1 viruses that contributed to ATV resistance include I50L, N88S, I84V, A71V, and M46I. Changes were also observed at the protease cleavage sites following drug selection."/>
	<sentencespan id="DBMI.pac188.sp19" origId="sp19" text="Recombinant viruses containing the I50L substitution without other major PI substitutions were growth impaired and displayed increased susceptibility in cell culture to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir). The I50L and I50V substitutions yielded selective resistance to ATV and amprenavir, respectively, and did not appear to be cross-resistant. Clinical Studies of Treatment-Naive Patients: Comparison of Ritonavir-Boosted REYATAZ vs. Unboosted REYATAZ: Study AI424-089 compared REYATAZ 300 mg once daily with ritonavir 100 mg vs. REYATAZ 400 mg once daily when administered with lamivudine and extended-release stavudine in HIV-infected treatment-naive patients."/>
	<sentencespan id="DBMI.pac188.sp20" origId="sp20" text="A summary of the number of virologic failures and virologic failure isolates with ATV resistance in each arm is shown in Table 18. Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 300 mg With Ritonavir 100 mg: In Phase III study AI424-138, an as-treated genotypic and phenotypic analysis was conducted on samples from patients who experienced virologic failure (HIV-1 RNA 400 copies/mL) or discontinued before achieving suppression on ATV/RTV (n=39; 9%) and LPV/RTV (n=39; 9%) through 96 weeks of treatment. In the ATV/RTV arm, one of the virologic failure isolates had a 56-fold decrease in ATV susceptibility emerge on therapy with the development of PI resistance-associated substitutions L10F, V32I, K43T, M46I, A71I, G73S, I85I/V, and L90M."/>
	<sentencespan id="DBMI.pac188.sp21" origId="sp21" text="The NRTI resistance-associated substitution M184V also emerged on treatment in this isolate conferring emtricitabine resistance. Two ATV/RTV-virologic failure isolates had baseline phenotypic ATV resistance and IAS-defined major PI resistance-associated substitutions at baseline. The 150L substitution emerged on study in one of these failure isolates and was associated with a 17-fold decrease in ATV susceptibility from baseline and the other failure isolate with baseline ATV resistance and PI substitutions (M46M/I and I84I/V) had additional IAS-defined major PI substitutions (V32I, M46I, and I84V) emerge on ATV treatment associated with a 3-fold decrease in ATV susceptibiity from baseline."/>
	<sentencespan id="DBMI.pac188.sp22" origId="sp22" text="Five of the treatment failure isolates in the ATV/RTV arm developed phenotypic emtricitabine resistance with the emergence of either the M184I (n=1) or the M184V (n=4) substitution on therapy and none developed phenotypic tenofovir disoproxil resistance. In the LPV/RTV arm, one of the virologic failure patient isolates had a 69-fold decrease in LPV susceptibility emerge on therapy with the development of PI substitutions L10V, V11I, I54V, G73S, and V82A in addition to baseline PI substitutions L10L/I, V32I, I54I/V, A71I, G73G/S, V82V/A, L89V, and L90M. Six LPV/RTV virologic failure isolates developed the M184V substitution and phenotypic emtricitabine resistance and two developed phenotypic tenofovir disoproxil resistance."/>
	<sentencespan id="DBMI.pac188.sp23" origId="sp23" text="Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 400 mg Without Ritonavir: ATV-resistant clinical isolates from treatment-naive patients who experienced virologic failure on REYATAZ 400 mg treatment without ritonavir often developed an I50L substitution (after an average of 50 weeks of ATV therapy), often in combination with an A71V substitution, but also developed one or more other PI substitutions (eg, V32I, L33F, G73S, V82A, I85V, or N88S) with or without the I50L substitution. In treatment-naive patients, viral isolates that developed the I50L substitution, without other major PI substitutions, showed phenotypic resistance to ATV but retained in cell culture susceptibility to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir); however, there are no clinical data available to demonstrate the effect of the I50L substitution on the efficacy of subsequently administered PIs. Clinical Studies of Treatment-Experienced Patients: In studies of treatment-experienced patients treated with ATV or ATV/RTV, most ATV-resistant isolates from patients who experienced virologic failure developed substitutions that were associated with resistance to multiple PIs and displayed decreased susceptibility to multiple PIs."/>
	<sentencespan id="DBMI.pac188.sp24" origId="sp24" text="The most common protease substitutions to develop in the viral isolates of patients who failed treatment with ATV 300 mg once daily and RTV 100 mg once daily (together with tenofovir and an NRTI) included V32I, L33F/V/I, E35D/G, M46I/L, I50L, F53L/V, I54V, A71V/T/I, G73S/T/C, V82A/T/L, I85V, and L89V/Q/M/T. Other substitutions that developed on ATV/RTV treatment including E34K/A/Q, G48V, I84V, N88S/D/T, and L90M occurred in less than 10% of patient isolates. Generally, if multiple PI resistance substitutions were present in the HIV-1 virus of the patient at baseline, ATV resistance developed through substitutions associated with resistance to other PIs and could include the development of the I50L substitution."/>
	<sentencespan id="DBMI.pac188.sp25" origId="sp25" text="The I50L substitution has been detected in treatment-experienced patients experiencing virologic failure after long-term treatment. Protease cleavage site changes also emerged on ATV treatment but their presence did not correlate with the level of ATV resistance. Cross-Resistance\n\nCross-resistance among PIs has been observed."/>
	<sentencespan id="DBMI.pac188.sp26" origId="sp26" text="Baseline phenotypic and genotypic analyses of clinical isolates from ATV clinical trials of PI-experienced patients showed that isolates cross-resistant to multiple PIs were cross-resistant to ATV. Greater than 90% of the isolates with substitutions that included I84V or G48V were resistant to ATV. Greater than 60% of isolates containing L90M, G73S/T/C, A71V/T, I54V, M46I/L, or a change at V82 were resistant to ATV, and 38% of isolates containing a D30N substitution in addition to other changes were resistant to ATV."/>
	<sentencespan id="DBMI.pac188.sp27" origId="sp27" text="Isolates resistant to ATV were also cross-resistant to other PIs with &gt;90% of the isolates resistant to indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir, and 80% resistant to amprenavir. In treatment-experienced patients, PI-resistant viral isolates that developed the I50L substitution in addition to other PI resistance-associated substitution were also cross-resistant to other PIs. Baseline Genotype/Phenotype and Virologic Outcome Analyses\n\nGenotypic and/or phenotypic analysis of baseline virus may aid in determining ATV susceptibility before initiation of ATV/RTV therapy."/>
	<sentencespan id="DBMI.pac188.sp28" origId="sp28" text="An association between virologic response at 48 weeks and the number and type of primary PI resistance-associated substitutions detected in baseline HIV-1 isolates from antiretroviral-experienced patients receiving ATV/RTV once daily or lopinavir (LPV)/RTV twice daily in Study AI424-045 is shown in Table 19. Overall, both the number and type of baseline PI substitutions affected response rates in treatment-experienced patients. In the ATV/RTV group, patients had lower response rates when 3 or more baseline PI substitutions, including a substitution at position 36, 71, 77, 82, or 90, were present compared to patients with 12 PI substitutions, including one of these substitutions."/>
	<sentencespan id="DBMI.pac188.sp29" origId="sp29" text="The response rates of antiretroviral-experienced patients in Study AI424-045 were analyzed by baseline phenotype (shift in susceptibility in cell culture relative to reference, Table 20). The analyses are based on a select patient population with 62% of patients receiving an NNRTI-based regimen before study entry compared to 35% receiving a PI-based regimen. Additional data are needed to determine clinically relevant break points for REYATAZ."/>
</document>

<document id="DBMI.pac19" origId="pac19">
	<sentence id="DBMI.pac19.s0" origId="s0" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.">
		<entity charOffset="70-81" id="DBMI.pac19.s0.e0" origId="s0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="158-166" id="DBMI.pac19.s0.e1" origId="s0.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac19.s0.e0" e2="DBMI.pac19.s0.e1" id="DBMI.pac19.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="sertraline "/>
		<pair e1="DBMI.pac19.s0.e1" e2="DBMI.pac19.s0.e0" id="DBMI.pac19.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac19.sp0" origId="sp0" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.">
		<entity charOffset="70-81" id="DBMI.pac19.sp0.e0" origId="sp0.e0" text="sertraline " type="Active ingredient"/>
		<entity charOffset="158-166" id="DBMI.pac19.sp0.e1" origId="sp0.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac19.sp0.e0" e2="DBMI.pac19.sp0.e1" id="DBMI.pac19.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="sertraline "/>
		<pair e1="DBMI.pac19.sp0.e1" e2="DBMI.pac19.sp0.e0" id="DBMI.pac19.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac191" origId="pac191">
	<sentence id="DBMI.pac191.s0" origId="s0" text="Itraconazole:\n\nConcomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.">
		<entity charOffset="45-57" id="DBMI.pac191.s0.e0" origId="s0.e0" text="fluvastatin " type="Active ingredient"/>
		<entity charOffset="69-82" id="DBMI.pac191.s0.e1" origId="s0.e1" text="itraconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac191.s0.e0" e2="DBMI.pac191.s0.e1" id="DBMI.pac191.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="itraconazole " precipitant="fluvastatin "/>
		<pair e1="DBMI.pac191.s0.e1" e2="DBMI.pac191.s0.e0" id="DBMI.pac191.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin " precipitant="itraconazole "/>
	</sentence>
	<sentencespan id="DBMI.pac191.sp0" origId="sp0" text="Itraconazole:\n\nConcomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.">
		<entity charOffset="45-57" id="DBMI.pac191.sp0.e0" origId="sp0.e0" text="fluvastatin " type="Active ingredient"/>
		<entity charOffset="69-82" id="DBMI.pac191.sp0.e1" origId="sp0.e1" text="itraconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac191.sp0.e0" e2="DBMI.pac191.sp0.e1" id="DBMI.pac191.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="itraconazole " precipitant="fluvastatin "/>
		<pair e1="DBMI.pac191.sp0.e1" e2="DBMI.pac191.sp0.e0" id="DBMI.pac191.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin " precipitant="itraconazole "/>
	</sentencespan>
</document>

<document id="DBMI.pac192" origId="pac192">
	<sentence id="DBMI.pac192.s0" origId="s0" text="Erythromycin:\n\nErythromycin (500 mg, single dose) did not affect steady-state plasma levels of fluvastatin (40 mg daily).">
		<entity charOffset="15-28" id="DBMI.pac192.s0.e0" origId="s0.e0" text="Erythromycin " type="Active ingredient"/>
		<entity charOffset="95-107" id="DBMI.pac192.s0.e1" origId="s0.e1" text="fluvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac192.s0.e0" e2="DBMI.pac192.s0.e1" id="DBMI.pac192.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin " precipitant="Erythromycin "/>
		<pair e1="DBMI.pac192.s0.e1" e2="DBMI.pac192.s0.e0" id="DBMI.pac192.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac192.sp0" origId="sp0" text="Erythromycin:\n\nErythromycin (500 mg, single dose) did not affect steady-state plasma levels of fluvastatin (40 mg daily).">
		<entity charOffset="15-28" id="DBMI.pac192.sp0.e0" origId="sp0.e0" text="Erythromycin " type="Active ingredient"/>
		<entity charOffset="95-107" id="DBMI.pac192.sp0.e1" origId="sp0.e1" text="fluvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac192.sp0.e0" e2="DBMI.pac192.sp0.e1" id="DBMI.pac192.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin " precipitant="Erythromycin "/>
		<pair e1="DBMI.pac192.sp0.e1" e2="DBMI.pac192.sp0.e0" id="DBMI.pac192.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac194" origId="pac194">
	<sentence id="DBMI.pac194.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP2D6 and CYP3A4 Inhibitors\n\nDrugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone.">
		<entity charOffset="103-114" id="DBMI.pac194.s0.e0" origId="s0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="283-295" id="DBMI.pac194.s0.e1" origId="s0.e1" text="propafenone " type="Active ingredient"/>
		<entity charOffset="115-125" id="DBMI.pac194.s0.e2" origId="s0.e2" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="126-137" id="DBMI.pac194.s0.e3" origId="s0.e3" text="sertraline " type="Active ingredient"/>
		<entity charOffset="158-171" id="DBMI.pac194.s0.e4" origId="s0.e4" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="183-194" id="DBMI.pac194.s0.e5" origId="s0.e5" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="195-208" id="DBMI.pac194.s0.e6" origId="s0.e6" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="90-102" id="DBMI.pac194.s0.e7" origId="s0.e7" text="desipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s0.e0" e2="DBMI.pac194.s0.e1" id="DBMI.pac194.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="paroxetine "/>
		<pair e1="DBMI.pac194.s0.e0" e2="DBMI.pac194.s0.e2" id="DBMI.pac194.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e0" e2="DBMI.pac194.s0.e3" id="DBMI.pac194.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e0" e2="DBMI.pac194.s0.e4" id="DBMI.pac194.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e0" e2="DBMI.pac194.s0.e5" id="DBMI.pac194.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e0" e2="DBMI.pac194.s0.e6" id="DBMI.pac194.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e0" e2="DBMI.pac194.s0.e7" id="DBMI.pac194.s0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e1" e2="DBMI.pac194.s0.e0" id="DBMI.pac194.s0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e1" e2="DBMI.pac194.s0.e2" id="DBMI.pac194.s0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e1" e2="DBMI.pac194.s0.e3" id="DBMI.pac194.s0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e1" e2="DBMI.pac194.s0.e4" id="DBMI.pac194.s0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e1" e2="DBMI.pac194.s0.e5" id="DBMI.pac194.s0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e1" e2="DBMI.pac194.s0.e6" id="DBMI.pac194.s0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e1" e2="DBMI.pac194.s0.e7" id="DBMI.pac194.s0.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e2" e2="DBMI.pac194.s0.e0" id="DBMI.pac194.s0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e2" e2="DBMI.pac194.s0.e1" id="DBMI.pac194.s0.p15" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="ritonavir "/>
		<pair e1="DBMI.pac194.s0.e2" e2="DBMI.pac194.s0.e1" id="DBMI.pac194.s0.p16" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="ritonavir "/>
		<pair e1="DBMI.pac194.s0.e2" e2="DBMI.pac194.s0.e3" id="DBMI.pac194.s0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e2" e2="DBMI.pac194.s0.e4" id="DBMI.pac194.s0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e2" e2="DBMI.pac194.s0.e5" id="DBMI.pac194.s0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e2" e2="DBMI.pac194.s0.e6" id="DBMI.pac194.s0.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e2" e2="DBMI.pac194.s0.e7" id="DBMI.pac194.s0.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e3" e2="DBMI.pac194.s0.e0" id="DBMI.pac194.s0.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e3" e2="DBMI.pac194.s0.e1" id="DBMI.pac194.s0.p23" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="sertraline "/>
		<pair e1="DBMI.pac194.s0.e3" e2="DBMI.pac194.s0.e2" id="DBMI.pac194.s0.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e3" e2="DBMI.pac194.s0.e4" id="DBMI.pac194.s0.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e3" e2="DBMI.pac194.s0.e5" id="DBMI.pac194.s0.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e3" e2="DBMI.pac194.s0.e6" id="DBMI.pac194.s0.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e3" e2="DBMI.pac194.s0.e7" id="DBMI.pac194.s0.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e4" e2="DBMI.pac194.s0.e0" id="DBMI.pac194.s0.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e4" e2="DBMI.pac194.s0.e1" id="DBMI.pac194.s0.p30" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac194.s0.e4" e2="DBMI.pac194.s0.e2" id="DBMI.pac194.s0.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e4" e2="DBMI.pac194.s0.e3" id="DBMI.pac194.s0.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e4" e2="DBMI.pac194.s0.e5" id="DBMI.pac194.s0.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e4" e2="DBMI.pac194.s0.e6" id="DBMI.pac194.s0.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e4" e2="DBMI.pac194.s0.e7" id="DBMI.pac194.s0.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e5" e2="DBMI.pac194.s0.e0" id="DBMI.pac194.s0.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e5" e2="DBMI.pac194.s0.e1" id="DBMI.pac194.s0.p37" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="saquinavir "/>
		<pair e1="DBMI.pac194.s0.e5" e2="DBMI.pac194.s0.e2" id="DBMI.pac194.s0.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e5" e2="DBMI.pac194.s0.e3" id="DBMI.pac194.s0.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e5" e2="DBMI.pac194.s0.e4" id="DBMI.pac194.s0.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e5" e2="DBMI.pac194.s0.e6" id="DBMI.pac194.s0.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e5" e2="DBMI.pac194.s0.e7" id="DBMI.pac194.s0.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e6" e2="DBMI.pac194.s0.e0" id="DBMI.pac194.s0.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e6" e2="DBMI.pac194.s0.e1" id="DBMI.pac194.s0.p44" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="erythromycin "/>
		<pair e1="DBMI.pac194.s0.e6" e2="DBMI.pac194.s0.e2" id="DBMI.pac194.s0.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e6" e2="DBMI.pac194.s0.e3" id="DBMI.pac194.s0.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e6" e2="DBMI.pac194.s0.e4" id="DBMI.pac194.s0.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e6" e2="DBMI.pac194.s0.e5" id="DBMI.pac194.s0.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e6" e2="DBMI.pac194.s0.e7" id="DBMI.pac194.s0.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e7" e2="DBMI.pac194.s0.e0" id="DBMI.pac194.s0.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e7" e2="DBMI.pac194.s0.e1" id="DBMI.pac194.s0.p51" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="desipramine "/>
		<pair e1="DBMI.pac194.s0.e7" e2="DBMI.pac194.s0.e2" id="DBMI.pac194.s0.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e7" e2="DBMI.pac194.s0.e3" id="DBMI.pac194.s0.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e7" e2="DBMI.pac194.s0.e4" id="DBMI.pac194.s0.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e7" e2="DBMI.pac194.s0.e5" id="DBMI.pac194.s0.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s0.e7" e2="DBMI.pac194.s0.e6" id="DBMI.pac194.s0.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s1" origId="s1" text="The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia."/>
	<sentence id="DBMI.pac194.s2" origId="s2" text="Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided [see Warnings and Precautions (5.2) and Dosage and Administration (2)]."/>
	<sentence id="DBMI.pac194.s3" origId="s3" text="Amiodarone\n\nConcomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended."/>
	<sentence id="DBMI.pac194.s4" origId="s4" text="Cimetidine\n\nConcomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.">
		<entity charOffset="891-902" id="DBMI.pac194.s4.e0" origId="s4.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="849-861" id="DBMI.pac194.s4.e1" origId="s4.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s4.e0" e2="DBMI.pac194.s4.e1" id="DBMI.pac194.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="cimetidine "/>
		<pair e1="DBMI.pac194.s4.e1" e2="DBMI.pac194.s4.e0" id="DBMI.pac194.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s5" origId="s5" text="Fluoxetine\n\nConcomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.">
		<entity charOffset="1065-1076" id="DBMI.pac194.s5.e0" origId="s5.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="1049-1061" id="DBMI.pac194.s5.e1" origId="s5.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s5.e0" e2="DBMI.pac194.s5.e1" id="DBMI.pac194.s5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac194.s5.e1" e2="DBMI.pac194.s5.e0" id="DBMI.pac194.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s6" origId="s6" text="Quinidine\n\nSmall doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)]."/>
	<sentence id="DBMI.pac194.s7" origId="s7" text="Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM.">
		<entity charOffset="1421-1431" id="DBMI.pac194.s7.e0" origId="s7.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="1487-1499" id="DBMI.pac194.s7.e1" origId="s7.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s7.e0" e2="DBMI.pac194.s7.e1" id="DBMI.pac194.s7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="quinidine "/>
		<pair e1="DBMI.pac194.s7.e1" e2="DBMI.pac194.s7.e0" id="DBMI.pac194.s7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s8" origId="s8" text="Steady-state plasma concentrations increased by more that 2-fold for propafenone, and decreased 50% for 5OH-propafenone."/>
	<sentence id="DBMI.pac194.s9" origId="s9" text="A 100 mg dose of quinidine increased steady state concentrations of propafenone 3-fold.">
		<entity charOffset="1724-1734" id="DBMI.pac194.s9.e0" origId="s9.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="1775-1787" id="DBMI.pac194.s9.e1" origId="s9.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s9.e0" e2="DBMI.pac194.s9.e1" id="DBMI.pac194.s9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="quinidine "/>
		<pair e1="DBMI.pac194.s9.e1" e2="DBMI.pac194.s9.e0" id="DBMI.pac194.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s10" origId="s10" text="Avoid concomitant use of propafenone and quinidine."/>
	<sentence id="DBMI.pac194.s11" origId="s11" text="Rifampin\n\nConcomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%.">
		<entity charOffset="1888-1897" id="DBMI.pac194.s11.e0" origId="s11.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="1901-1913" id="DBMI.pac194.s11.e1" origId="s11.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s11.e0" e2="DBMI.pac194.s11.e1" id="DBMI.pac194.s11.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.s11.e0" e2="DBMI.pac194.s11.e1" id="DBMI.pac194.s11.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.s11.e0" e2="DBMI.pac194.s11.e1" id="DBMI.pac194.s11.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.s11.e0" e2="DBMI.pac194.s11.e1" id="DBMI.pac194.s11.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.s11.e0" e2="DBMI.pac194.s11.e1" id="DBMI.pac194.s11.p4" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.s11.e0" e2="DBMI.pac194.s11.e1" id="DBMI.pac194.s11.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.s11.e1" e2="DBMI.pac194.s11.e0" id="DBMI.pac194.s11.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s12" origId="s12" text="The concentrations of norpropafenone increased by 30%."/>
	<sentence id="DBMI.pac194.s13" origId="s13" text="In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively."/>
	<sentence id="DBMI.pac194.s14" origId="s14" text="Urinary excretion of propafenone and its metabolites decreased significantly."/>
	<sentence id="DBMI.pac194.s15" origId="s15" text="Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%."/>
	<sentence id="DBMI.pac194.s16" origId="s16" text="7.2 Digoxin\n\nConcomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.">
		<entity charOffset="2562-2574" id="DBMI.pac194.s16.e0" origId="s16.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="2578-2586" id="DBMI.pac194.s16.e1" origId="s16.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s16.e0" e2="DBMI.pac194.s16.e1" id="DBMI.pac194.s16.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.s16.e1" e2="DBMI.pac194.s16.e0" id="DBMI.pac194.s16.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s17" origId="s17" text="Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed."/>
	<sentence id="DBMI.pac194.s18" origId="s18" text="7.3 Warfarin\n\nThe concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.">
		<entity charOffset="2868-2880" id="DBMI.pac194.s18.e0" origId="s18.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="2884-2893" id="DBMI.pac194.s18.e1" origId="s18.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s18.e0" e2="DBMI.pac194.s18.e1" id="DBMI.pac194.s18.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="warfarin " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.s18.e1" e2="DBMI.pac194.s18.e0" id="DBMI.pac194.s18.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s19" origId="s19" text="Adjust the warfarin dose as needed by monitoring INR (international normalized ratio)."/>
	<sentence id="DBMI.pac194.s20" origId="s20" text="7.4 Orlistat\n\nOrlistat may limit the fraction of propafenone available for absorption."/>
	<sentence id="DBMI.pac194.s21" origId="s21" text="In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure."/>
	<sentence id="DBMI.pac194.s22" origId="s22" text="7.5 Beta-Antagonists\n\nConcomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.">
		<entity charOffset="3474-3486" id="DBMI.pac194.s22.e0" origId="s22.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="3490-3502" id="DBMI.pac194.s22.e1" origId="s22.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s22.e0" e2="DBMI.pac194.s22.e1" id="DBMI.pac194.s22.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.s22.e1" e2="DBMI.pac194.s22.e0" id="DBMI.pac194.s22.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s23" origId="s23" text="In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.">
		<entity charOffset="3640-3652" id="DBMI.pac194.s23.e0" origId="s23.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="3624-3635" id="DBMI.pac194.s23.e1" origId="s23.e1" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s23.e0" e2="DBMI.pac194.s23.e1" id="DBMI.pac194.s23.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.s23.e1" e2="DBMI.pac194.s23.e0" id="DBMI.pac194.s23.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac194.s24" origId="s24" text="The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol.">
		<entity charOffset="3815-3827" id="DBMI.pac194.s24.e0" origId="s24.e0" text="propranolol " type="Active ingredient"/>
		<entity charOffset="3752-3764" id="DBMI.pac194.s24.e1" origId="s24.e1" text="propafenone " type="Active ingredient"/>
		<entity charOffset="3830-3841" id="DBMI.pac194.s24.e2" origId="s24.e2" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s24.e0" e2="DBMI.pac194.s24.e1" id="DBMI.pac194.s24.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone " precipitant="propranolol "/>
		<pair e1="DBMI.pac194.s24.e0" e2="DBMI.pac194.s24.e2" id="DBMI.pac194.s24.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s24.e1" e2="DBMI.pac194.s24.e0" id="DBMI.pac194.s24.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s24.e1" e2="DBMI.pac194.s24.e2" id="DBMI.pac194.s24.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s24.e2" e2="DBMI.pac194.s24.e0" id="DBMI.pac194.s24.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.s24.e2" e2="DBMI.pac194.s24.e1" id="DBMI.pac194.s24.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone " precipitant="metoprolol "/>
	</sentence>
	<sentence id="DBMI.pac194.s25" origId="s25" text="In clinical trials using propafenone immediate release tablets, patients who were receiving beta-blockers concurrently did not experience an increased incidence of side effects."/>
	<sentence id="DBMI.pac194.s26" origId="s26" text="7.6 Lidocaine\n\nNo significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients.">
		<entity charOffset="4086-4098" id="DBMI.pac194.s26.e0" origId="s26.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="4101-4111" id="DBMI.pac194.s26.e1" origId="s26.e1" text="lidocaine " type="Active ingredient"/>
		<pair e1="DBMI.pac194.s26.e0" e2="DBMI.pac194.s26.e1" id="DBMI.pac194.s26.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lidocaine " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.s26.e1" e2="DBMI.pac194.s26.e0" id="DBMI.pac194.s26.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone " precipitant="lidocaine "/>
	</sentence>
	<sentence id="DBMI.pac194.s27" origId="s27" text="However, concomitant use of propafenone and lidocaine has been reported to increase the risks of central nervous system side effects of lidocaine."/>
	<sentencespan id="DBMI.pac194.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP2D6 and CYP3A4 Inhibitors\n\nDrugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided [see Warnings and Precautions (5.2) and Dosage and Administration (2)].">
		<entity charOffset="103-114" id="DBMI.pac194.sp0.e0" origId="sp0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="283-295" id="DBMI.pac194.sp0.e1" origId="sp0.e1" text="propafenone " type="Active ingredient"/>
		<entity charOffset="115-125" id="DBMI.pac194.sp0.e2" origId="sp0.e2" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="126-137" id="DBMI.pac194.sp0.e3" origId="sp0.e3" text="sertraline " type="Active ingredient"/>
		<entity charOffset="158-171" id="DBMI.pac194.sp0.e4" origId="sp0.e4" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="183-194" id="DBMI.pac194.sp0.e5" origId="sp0.e5" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="195-208" id="DBMI.pac194.sp0.e6" origId="sp0.e6" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="90-102" id="DBMI.pac194.sp0.e7" origId="sp0.e7" text="desipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac194.sp0.e0" e2="DBMI.pac194.sp0.e1" id="DBMI.pac194.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="paroxetine "/>
		<pair e1="DBMI.pac194.sp0.e0" e2="DBMI.pac194.sp0.e2" id="DBMI.pac194.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e0" e2="DBMI.pac194.sp0.e3" id="DBMI.pac194.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e0" e2="DBMI.pac194.sp0.e4" id="DBMI.pac194.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e0" e2="DBMI.pac194.sp0.e5" id="DBMI.pac194.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e0" e2="DBMI.pac194.sp0.e6" id="DBMI.pac194.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e0" e2="DBMI.pac194.sp0.e7" id="DBMI.pac194.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e1" e2="DBMI.pac194.sp0.e0" id="DBMI.pac194.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e1" e2="DBMI.pac194.sp0.e2" id="DBMI.pac194.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e1" e2="DBMI.pac194.sp0.e3" id="DBMI.pac194.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e1" e2="DBMI.pac194.sp0.e4" id="DBMI.pac194.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e1" e2="DBMI.pac194.sp0.e5" id="DBMI.pac194.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e1" e2="DBMI.pac194.sp0.e6" id="DBMI.pac194.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e1" e2="DBMI.pac194.sp0.e7" id="DBMI.pac194.sp0.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e2" e2="DBMI.pac194.sp0.e0" id="DBMI.pac194.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e2" e2="DBMI.pac194.sp0.e1" id="DBMI.pac194.sp0.p15" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="ritonavir "/>
		<pair e1="DBMI.pac194.sp0.e2" e2="DBMI.pac194.sp0.e1" id="DBMI.pac194.sp0.p16" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="ritonavir "/>
		<pair e1="DBMI.pac194.sp0.e2" e2="DBMI.pac194.sp0.e3" id="DBMI.pac194.sp0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e2" e2="DBMI.pac194.sp0.e4" id="DBMI.pac194.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e2" e2="DBMI.pac194.sp0.e5" id="DBMI.pac194.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e2" e2="DBMI.pac194.sp0.e6" id="DBMI.pac194.sp0.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e2" e2="DBMI.pac194.sp0.e7" id="DBMI.pac194.sp0.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e3" e2="DBMI.pac194.sp0.e0" id="DBMI.pac194.sp0.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e3" e2="DBMI.pac194.sp0.e1" id="DBMI.pac194.sp0.p23" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="sertraline "/>
		<pair e1="DBMI.pac194.sp0.e3" e2="DBMI.pac194.sp0.e2" id="DBMI.pac194.sp0.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e3" e2="DBMI.pac194.sp0.e4" id="DBMI.pac194.sp0.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e3" e2="DBMI.pac194.sp0.e5" id="DBMI.pac194.sp0.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e3" e2="DBMI.pac194.sp0.e6" id="DBMI.pac194.sp0.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e3" e2="DBMI.pac194.sp0.e7" id="DBMI.pac194.sp0.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e4" e2="DBMI.pac194.sp0.e0" id="DBMI.pac194.sp0.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e4" e2="DBMI.pac194.sp0.e1" id="DBMI.pac194.sp0.p30" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac194.sp0.e4" e2="DBMI.pac194.sp0.e2" id="DBMI.pac194.sp0.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e4" e2="DBMI.pac194.sp0.e3" id="DBMI.pac194.sp0.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e4" e2="DBMI.pac194.sp0.e5" id="DBMI.pac194.sp0.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e4" e2="DBMI.pac194.sp0.e6" id="DBMI.pac194.sp0.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e4" e2="DBMI.pac194.sp0.e7" id="DBMI.pac194.sp0.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e5" e2="DBMI.pac194.sp0.e0" id="DBMI.pac194.sp0.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e5" e2="DBMI.pac194.sp0.e1" id="DBMI.pac194.sp0.p37" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="saquinavir "/>
		<pair e1="DBMI.pac194.sp0.e5" e2="DBMI.pac194.sp0.e2" id="DBMI.pac194.sp0.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e5" e2="DBMI.pac194.sp0.e3" id="DBMI.pac194.sp0.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e5" e2="DBMI.pac194.sp0.e4" id="DBMI.pac194.sp0.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e5" e2="DBMI.pac194.sp0.e6" id="DBMI.pac194.sp0.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e5" e2="DBMI.pac194.sp0.e7" id="DBMI.pac194.sp0.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e6" e2="DBMI.pac194.sp0.e0" id="DBMI.pac194.sp0.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e6" e2="DBMI.pac194.sp0.e1" id="DBMI.pac194.sp0.p44" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="erythromycin "/>
		<pair e1="DBMI.pac194.sp0.e6" e2="DBMI.pac194.sp0.e2" id="DBMI.pac194.sp0.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e6" e2="DBMI.pac194.sp0.e3" id="DBMI.pac194.sp0.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e6" e2="DBMI.pac194.sp0.e4" id="DBMI.pac194.sp0.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e6" e2="DBMI.pac194.sp0.e5" id="DBMI.pac194.sp0.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e6" e2="DBMI.pac194.sp0.e7" id="DBMI.pac194.sp0.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e7" e2="DBMI.pac194.sp0.e0" id="DBMI.pac194.sp0.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e7" e2="DBMI.pac194.sp0.e1" id="DBMI.pac194.sp0.p51" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propafenone " precipitant="desipramine "/>
		<pair e1="DBMI.pac194.sp0.e7" e2="DBMI.pac194.sp0.e2" id="DBMI.pac194.sp0.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e7" e2="DBMI.pac194.sp0.e3" id="DBMI.pac194.sp0.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e7" e2="DBMI.pac194.sp0.e4" id="DBMI.pac194.sp0.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e7" e2="DBMI.pac194.sp0.e5" id="DBMI.pac194.sp0.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp0.e7" e2="DBMI.pac194.sp0.e6" id="DBMI.pac194.sp0.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac194.sp1" origId="sp1" text="Amiodarone\n\nConcomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended. Cimetidine\n\nConcomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone. Fluoxetine\n\nConcomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.">
		<entity charOffset="1065-1076" id="DBMI.pac194.sp1.e0" origId="sp1.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="1049-1061" id="DBMI.pac194.sp1.e1" origId="sp1.e1" text="propafenone " type="Active ingredient"/>
		<entity charOffset="891-902" id="DBMI.pac194.sp1.e2" origId="sp1.e2" text="cimetidine " type="Active ingredient"/>
		<pair e1="DBMI.pac194.sp1.e0" e2="DBMI.pac194.sp1.e1" id="DBMI.pac194.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac194.sp1.e0" e2="DBMI.pac194.sp1.e2" id="DBMI.pac194.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp1.e1" e2="DBMI.pac194.sp1.e0" id="DBMI.pac194.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp1.e1" e2="DBMI.pac194.sp1.e2" id="DBMI.pac194.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp1.e2" e2="DBMI.pac194.sp1.e0" id="DBMI.pac194.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp1.e2" e2="DBMI.pac194.sp1.e1" id="DBMI.pac194.sp1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="cimetidine "/>
	</sentencespan>
	<sentencespan id="DBMI.pac194.sp2" origId="sp2" text="Quinidine\n\nSmall doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)]. Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM. Steady-state plasma concentrations increased by more that 2-fold for propafenone, and decreased 50% for 5OH-propafenone.">
		<entity charOffset="1421-1431" id="DBMI.pac194.sp2.e0" origId="sp2.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="1487-1499" id="DBMI.pac194.sp2.e1" origId="sp2.e1" text="propafenone " type="Active ingredient"/>
		<pair e1="DBMI.pac194.sp2.e0" e2="DBMI.pac194.sp2.e1" id="DBMI.pac194.sp2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="quinidine "/>
		<pair e1="DBMI.pac194.sp2.e1" e2="DBMI.pac194.sp2.e0" id="DBMI.pac194.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac194.sp3" origId="sp3" text="A 100 mg dose of quinidine increased steady state concentrations of propafenone 3-fold. Avoid concomitant use of propafenone and quinidine. Rifampin\n\nConcomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%.">
		<entity charOffset="1724-1734" id="DBMI.pac194.sp3.e0" origId="sp3.e0" text="quinidine " type="Active ingredient"/>
		<entity charOffset="1775-1787" id="DBMI.pac194.sp3.e1" origId="sp3.e1" text="propafenone " type="Active ingredient"/>
		<entity charOffset="1888-1897" id="DBMI.pac194.sp3.e2" origId="sp3.e2" text="rifampin " type="Active ingredient"/>
		<pair e1="DBMI.pac194.sp3.e0" e2="DBMI.pac194.sp3.e1" id="DBMI.pac194.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="quinidine "/>
		<pair e1="DBMI.pac194.sp3.e0" e2="DBMI.pac194.sp3.e2" id="DBMI.pac194.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp3.e1" e2="DBMI.pac194.sp3.e0" id="DBMI.pac194.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp3.e1" e2="DBMI.pac194.sp3.e2" id="DBMI.pac194.sp3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp3.e2" e2="DBMI.pac194.sp3.e0" id="DBMI.pac194.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp3.e2" e2="DBMI.pac194.sp3.e1" id="DBMI.pac194.sp3.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.sp3.e2" e2="DBMI.pac194.sp3.e1" id="DBMI.pac194.sp3.p6" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.sp3.e2" e2="DBMI.pac194.sp3.e1" id="DBMI.pac194.sp3.p7" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.sp3.e2" e2="DBMI.pac194.sp3.e1" id="DBMI.pac194.sp3.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.sp3.e2" e2="DBMI.pac194.sp3.e1" id="DBMI.pac194.sp3.p9" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
		<pair e1="DBMI.pac194.sp3.e2" e2="DBMI.pac194.sp3.e1" id="DBMI.pac194.sp3.p10" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone " precipitant="rifampin "/>
	</sentencespan>
	<sentencespan id="DBMI.pac194.sp4" origId="sp4" text="The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly."/>
	<sentencespan id="DBMI.pac194.sp5" origId="sp5" text="Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%. 7.2 Digoxin\n\nConcomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%. Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.">
		<entity charOffset="2562-2574" id="DBMI.pac194.sp5.e0" origId="sp5.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="2578-2586" id="DBMI.pac194.sp5.e1" origId="sp5.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac194.sp5.e0" e2="DBMI.pac194.sp5.e1" id="DBMI.pac194.sp5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.sp5.e1" e2="DBMI.pac194.sp5.e0" id="DBMI.pac194.sp5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac194.sp6" origId="sp6" text="7.3 Warfarin\n\nThe concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin. Adjust the warfarin dose as needed by monitoring INR (international normalized ratio). 7.4 Orlistat\n\nOrlistat may limit the fraction of propafenone available for absorption.">
		<entity charOffset="2868-2880" id="DBMI.pac194.sp6.e0" origId="sp6.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="2884-2893" id="DBMI.pac194.sp6.e1" origId="sp6.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac194.sp6.e0" e2="DBMI.pac194.sp6.e1" id="DBMI.pac194.sp6.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="warfarin " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.sp6.e1" e2="DBMI.pac194.sp6.e0" id="DBMI.pac194.sp6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac194.sp7" origId="sp7" text="In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure. 7.5 Beta-Antagonists\n\nConcomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%. In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.">
		<entity charOffset="3474-3486" id="DBMI.pac194.sp7.e0" origId="sp7.e0" text="propafenone " type="Active ingredient"/>
		<entity charOffset="3490-3502" id="DBMI.pac194.sp7.e1" origId="sp7.e1" text="propranolol " type="Active ingredient"/>
		<entity charOffset="3624-3635" id="DBMI.pac194.sp7.e2" origId="sp7.e2" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac194.sp7.e0" e2="DBMI.pac194.sp7.e1" id="DBMI.pac194.sp7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.sp7.e0" e2="DBMI.pac194.sp7.e2" id="DBMI.pac194.sp7.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.sp7.e1" e2="DBMI.pac194.sp7.e0" id="DBMI.pac194.sp7.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp7.e1" e2="DBMI.pac194.sp7.e2" id="DBMI.pac194.sp7.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp7.e2" e2="DBMI.pac194.sp7.e0" id="DBMI.pac194.sp7.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp7.e2" e2="DBMI.pac194.sp7.e1" id="DBMI.pac194.sp7.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac194.sp8" origId="sp8" text="The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol. In clinical trials using propafenone immediate release tablets, patients who were receiving beta-blockers concurrently did not experience an increased incidence of side effects. 7.6 Lidocaine\n\nNo significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients.">
		<entity charOffset="3815-3827" id="DBMI.pac194.sp8.e0" origId="sp8.e0" text="propranolol " type="Active ingredient"/>
		<entity charOffset="3752-3764" id="DBMI.pac194.sp8.e1" origId="sp8.e1" text="propafenone " type="Active ingredient"/>
		<entity charOffset="3830-3841" id="DBMI.pac194.sp8.e2" origId="sp8.e2" text="metoprolol " type="Active ingredient"/>
		<entity charOffset="4101-4111" id="DBMI.pac194.sp8.e3" origId="sp8.e3" text="lidocaine " type="Active ingredient"/>
		<pair e1="DBMI.pac194.sp8.e0" e2="DBMI.pac194.sp8.e1" id="DBMI.pac194.sp8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone " precipitant="propranolol "/>
		<pair e1="DBMI.pac194.sp8.e0" e2="DBMI.pac194.sp8.e2" id="DBMI.pac194.sp8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp8.e0" e2="DBMI.pac194.sp8.e3" id="DBMI.pac194.sp8.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp8.e1" e2="DBMI.pac194.sp8.e0" id="DBMI.pac194.sp8.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp8.e1" e2="DBMI.pac194.sp8.e2" id="DBMI.pac194.sp8.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp8.e1" e2="DBMI.pac194.sp8.e3" id="DBMI.pac194.sp8.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lidocaine " precipitant="propafenone "/>
		<pair e1="DBMI.pac194.sp8.e2" e2="DBMI.pac194.sp8.e0" id="DBMI.pac194.sp8.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp8.e2" e2="DBMI.pac194.sp8.e1" id="DBMI.pac194.sp8.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone " precipitant="metoprolol "/>
		<pair e1="DBMI.pac194.sp8.e2" e2="DBMI.pac194.sp8.e3" id="DBMI.pac194.sp8.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp8.e3" e2="DBMI.pac194.sp8.e0" id="DBMI.pac194.sp8.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac194.sp8.e3" e2="DBMI.pac194.sp8.e1" id="DBMI.pac194.sp8.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone " precipitant="lidocaine "/>
		<pair e1="DBMI.pac194.sp8.e3" e2="DBMI.pac194.sp8.e2" id="DBMI.pac194.sp8.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac194.sp9" origId="sp9" text="However, concomitant use of propafenone and lidocaine has been reported to increase the risks of central nervous system side effects of lidocaine."/>
</document>

<document id="DBMI.pac197" origId="pac197">
	<sentence id="DBMI.pac197.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nZidovudine is an antiviral agent [see Clinical Pharmacology (12.4)]."/>
	<sentence id="DBMI.pac197.s1" origId="s1" text="12.3 Pharmacokinetics\n\nAbsorption and Bioavailability:  In adults, following oral administration, zidovudine is rapidly absorbed and extensively distributed, with peak serum concentrations occurring within 0.5 to 1.5 hours."/>
	<sentence id="DBMI.pac197.s2" origId="s2" text="The extent of absorption (AUC) was equivalent when zidovudine was administered as zidovudine tablets or syrup compared with zidovudine capsules."/>
	<sentence id="DBMI.pac197.s3" origId="s3" text="The pharmacokinetic properties of zidovudine in fasting adult patients are summarized in Table 6."/>
	<sentence id="DBMI.pac197.s4" origId="s4" text="Distribution:  The apparent volume of distribution of zidovudine, following oral administration, is 1.6  0.6 L/kg; and binding to plasma protein is low, &lt;38% (Table 6)."/>
	<sentence id="DBMI.pac197.s5" origId="s5" text="Metabolism and Elimination:  Zidovudine is primarily eliminated by hepatic metabolism."/>
	<sentence id="DBMI.pac197.s6" origId="s6" text="The major metabolite of zidovudine is GZDV."/>
	<sentence id="DBMI.pac197.s7" origId="s7" text="GZDV AUC is about 3-fold greater than the zidovudine AUC."/>
	<sentence id="DBMI.pac197.s8" origId="s8" text="Urinary recovery of zidovudine and GZDV accounts for 14% and 74%, respectively, of the dose following oral administration."/>
	<sentence id="DBMI.pac197.s9" origId="s9" text="A second metabolite, 3'-amino-3'-deoxythymidine (AMT), has been identified in the plasma following single-dose intravenous (IV) administration of zidovudine."/>
	<sentence id="DBMI.pac197.s10" origId="s10" text="The AMT AUC was one fifth of the zidovudine AUC."/>
	<sentence id="DBMI.pac197.s11" origId="s11" text="Pharmacokinetics of zidovudine were dose independent at oral dosing regimens ranging from 2 mg/kg every 8 hours to 10 mg/kg every 4 hours."/>
	<sentence id="DBMI.pac197.s12" origId="s12" text="Effect of Food on Absorption:  Zidovudine may be administered with or without food."/>
	<sentence id="DBMI.pac197.s13" origId="s13" text="The extent of zidovudine absorption (AUC) was similar when a single dose of zidovudine was administered with food."/>
	<sentence id="DBMI.pac197.s14" origId="s14" text="Special Populations:  Renal Impairment:  Zidovudine clearance was decreased resulting in increased zidovudine and GZDV half-life and AUC in patients with impaired renal function (n = 14) following a single 200 mg oral dose (Table 7)."/>
	<sentence id="DBMI.pac197.s15" origId="s15" text="Plasma concentrations of AMT were not determined."/>
	<sentence id="DBMI.pac197.s16" origId="s16" text="A dose adjustment should not be necessary for patients with creatinine clearance (CrCl) 15 mL/min."/>
	<sentence id="DBMI.pac197.s17" origId="s17" text="Hemodialysis and Peritoneal Dialysis:  The pharmacokinetics and tolerance of zidovudine were evaluated in a multiple-dose study in patients undergoing hemodialysis (n = 5) or peritoneal dialysis (n = 6) receiving escalating doses up to 200 mg 5 times daily for 8 weeks."/>
	<sentence id="DBMI.pac197.s18" origId="s18" text="Daily doses of 500 mg or less were well tolerated despite significantly elevated GZDV plasma concentrations."/>
	<sentence id="DBMI.pac197.s19" origId="s19" text="Apparent zidovudine oral clearance was approximately 50% of that reported in patients with normal renal function."/>
	<sentence id="DBMI.pac197.s20" origId="s20" text="Hemodialysis and peritoneal dialysis appeared to have a negligible effect on the removal of zidovudine, whereas GZDV elimination was enhanced."/>
	<sentence id="DBMI.pac197.s21" origId="s21" text="A dosage adjustment is recommended for patients undergoing hemodialysis or peritoneal dialysis [see Dosage and Administration (2.4)]."/>
	<sentence id="DBMI.pac197.s22" origId="s22" text="Hepatic Impairment:  Data describing the effect of hepatic impairment on the pharmacokinetics of zidovudine are limited."/>
	<sentence id="DBMI.pac197.s23" origId="s23" text="However, because zidovudine is eliminated primarily by hepatic metabolism, it is expected that zidovudine clearance would be decreased and plasma concentrations would be increased following administration of the recommended adult doses to patients with hepatic impairment [see Dosage and Administration (2.5)]."/>
	<sentence id="DBMI.pac197.s24" origId="s24" text="Pediatric Patients:  Zidovudine pharmacokinetics have been evaluated in HIV-1-infected pediatric patients (Table 8)."/>
	<sentence id="DBMI.pac197.s25" origId="s25" text="Patients 3 Months to 12 Years of Age:  Overall, zidovudine pharmacokinetics in pediatric patients greater than 3 months of age are similar to those in adult patients."/>
	<sentence id="DBMI.pac197.s26" origId="s26" text="Proportional increases in plasma zidovudine concentrations were observed following administration of oral solution from 90 to 240 mg/m2 every 6 hours."/>
	<sentence id="DBMI.pac197.s27" origId="s27" text="Oral bioavailability, terminal half-life, and oral clearance were comparable to adult values."/>
	<sentence id="DBMI.pac197.s28" origId="s28" text="As in adult patients, the major route of elimination was by metabolism to GZDV."/>
	<sentence id="DBMI.pac197.s29" origId="s29" text="After intravenous dosing, about 29% of the dose was excreted in the urine unchanged, and about 45% of the dose was excreted as GZDV [see Dosage and Administration (2.1)]."/>
	<sentence id="DBMI.pac197.s30" origId="s30" text="Patients &lt;3 Months of Age:  Zidovudine pharmacokinetics have been evaluated in pediatric patients from birth to 3 months of life."/>
	<sentence id="DBMI.pac197.s31" origId="s31" text="Zidovudine elimination was determined immediately following birth in 8 neonates who were exposed to zidovudine in utero."/>
	<sentence id="DBMI.pac197.s32" origId="s32" text="The half-life was 13  5.8 hours."/>
	<sentence id="DBMI.pac197.s33" origId="s33" text="In neonates 14 days old, bioavailability was greater, total body clearance was slower, and half-life was longer than in pediatric patients &gt;14 days old."/>
	<sentence id="DBMI.pac197.s34" origId="s34" text="For dose recommendations for neonates [see Dosage and Administration (2.2)]."/>
	<sentence id="DBMI.pac197.s35" origId="s35" text="Pregnancy:  Zidovudine pharmacokinetics have been studied in a Phase I study of 8 women during the last trimester of pregnancy."/>
	<sentence id="DBMI.pac197.s36" origId="s36" text="Zidovudine pharmacokinetics were similar to those of nonpregnant adults."/>
	<sentence id="DBMI.pac197.s37" origId="s37" text="Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery [see Use in Specific Populations (8.1)]."/>
	<sentence id="DBMI.pac197.s38" origId="s38" text="Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics."/>
	<sentence id="DBMI.pac197.s39" origId="s39" text="Nursing Mothers:  The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1."/>
	<sentence id="DBMI.pac197.s40" origId="s40" text="After administration of a single dose of 200 mg zidovudine to 13 HIV-1-infected women, the mean concentration of zidovudine was similar in human milk and serum [see Use In Specific Populations (8.3)]."/>
	<sentence id="DBMI.pac197.s41" origId="s41" text="Geriatric Patients:  Zidovudine pharmacokinetics have not been studied in patients over 65 years of age."/>
	<sentence id="DBMI.pac197.s42" origId="s42" text="Gender:  A pharmacokinetic study in healthy male (n = 12) and female (n = 12) subjects showed no differences in zidovudine exposure (AUC) when a single dose of zidovudine was administered as the 300 mg zidovudine tablet."/>
	<sentence id="DBMI.pac197.s43" origId="s43" text="Drug Interactions:  [See Drug Interactions (7)]."/>
	<sentence id="DBMI.pac197.s44" origId="s44" text="Phenytoin:  Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented.">
		<entity charOffset="5923-5934" id="DBMI.pac197.s44.e0" origId="s44.e0" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="5843-5853" id="DBMI.pac197.s44.e1" origId="s44.e1" text="Phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac197.s44.e0" e2="DBMI.pac197.s44.e1" id="DBMI.pac197.s44.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Phenytoin " precipitant="zidovudine "/>
		<pair e1="DBMI.pac197.s44.e1" e2="DBMI.pac197.s44.e0" id="DBMI.pac197.s44.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac197.s45" origId="s45" text="However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed.">
		<entity charOffset="6138-6149" id="DBMI.pac197.s45.e0" origId="s45.e0" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="6093-6103" id="DBMI.pac197.s45.e1" origId="s45.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac197.s45.e0" e2="DBMI.pac197.s45.e1" id="DBMI.pac197.s45.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="zidovudine "/>
		<pair e1="DBMI.pac197.s45.e1" e2="DBMI.pac197.s45.e0" id="DBMI.pac197.s45.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac197.s46" origId="s46" text="Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.">
		<entity charOffset="6286-6296" id="DBMI.pac197.s46.e0" origId="s46.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="6299-6310" id="DBMI.pac197.s46.e1" origId="s46.e1" text="zidovudine " type="Active ingredient"/>
		<pair e1="DBMI.pac197.s46.e0" e2="DBMI.pac197.s46.e1" id="DBMI.pac197.s46.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="zidovudine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac197.s46.e1" e2="DBMI.pac197.s46.e0" id="DBMI.pac197.s46.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac197.s47" origId="s47" text="Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine."/>
	<sentence id="DBMI.pac197.s48" origId="s48" text="However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].">
		<entity charOffset="6728-6738" id="DBMI.pac197.s48.e0" origId="s48.e0" text="ribavirin " type="Active ingredient"/>
		<entity charOffset="6763-6773" id="DBMI.pac197.s48.e1" origId="s48.e1" text="stavudine " type="Active ingredient"/>
		<entity charOffset="6786-6797" id="DBMI.pac197.s48.e2" origId="s48.e2" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="6742-6753" id="DBMI.pac197.s48.e3" origId="s48.e3" text="lamivudine " type="Active ingredient"/>
		<pair e1="DBMI.pac197.s48.e0" e2="DBMI.pac197.s48.e1" id="DBMI.pac197.s48.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="stavudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.s48.e0" e2="DBMI.pac197.s48.e2" id="DBMI.pac197.s48.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="zidovudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.s48.e0" e2="DBMI.pac197.s48.e3" id="DBMI.pac197.s48.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lamivudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.s48.e1" e2="DBMI.pac197.s48.e0" id="DBMI.pac197.s48.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e1" e2="DBMI.pac197.s48.e2" id="DBMI.pac197.s48.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e1" e2="DBMI.pac197.s48.e3" id="DBMI.pac197.s48.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e2" e2="DBMI.pac197.s48.e0" id="DBMI.pac197.s48.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e2" e2="DBMI.pac197.s48.e1" id="DBMI.pac197.s48.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e2" e2="DBMI.pac197.s48.e3" id="DBMI.pac197.s48.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e3" e2="DBMI.pac197.s48.e0" id="DBMI.pac197.s48.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e3" e2="DBMI.pac197.s48.e1" id="DBMI.pac197.s48.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e3" e2="DBMI.pac197.s48.e2" id="DBMI.pac197.s48.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac197.s49" origId="s49" text="12.4 Microbiology\n\nMechanism of Action:  Zidovudine is a synthetic nucleoside analogue."/>
	<sentence id="DBMI.pac197.s50" origId="s50" text="Intracellularly, zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP)."/>
	<sentence id="DBMI.pac197.s51" origId="s51" text="The principal mode of action of ZDV-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue."/>
	<sentence id="DBMI.pac197.s52" origId="s52" text="ZDV-TP is a weak inhibitor of the cellular DNA polymerases  and  and has been reported to be incorporated into the DNA of cells in culture."/>
	<sentence id="DBMI.pac197.s53" origId="s53" text="Antiviral Activity:  The antiviral activity of zidovudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood lymphocytes)."/>
	<sentence id="DBMI.pac197.s54" origId="s54" text="The EC50 and EC90 values for zidovudine were 0.01 to 0.49 M (1 M = 0.27 mcg/mL) and 0.1 to 9 M, respectively."/>
	<sentence id="DBMI.pac197.s55" origId="s55" text="HIV-1 from therapy-naive subjects with no mutations associated with resistance gave median EC50 values of 0.011 M (range: 0.005 to 0.11 M) from Virco (n = 92 baseline samples from COLA40263) and 0.0017 M (0.006 to 0.034 M) from Monogram Biosciences (n = 135 baseline samples from ESS30009)."/>
	<sentence id="DBMI.pac197.s56" origId="s56" text="The EC50 values of zidovudine against different HIV-1 clades (A-G) ranged from 0.00018 to 0.02 M, and against HIV-2 isolates from 0.00049 to 0.004 M. In cell culture drug combination studies, zidovudine demonstrates synergistic activity with the nucleoside reverse transcriptase inhibitors abacavir, didanosine, and lamivudine; the non-nucleoside reverse transcriptase inhibitors delavirdine and nevirapine; and the protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir; and additive activity with interferon alfa."/>
	<sentence id="DBMI.pac197.s57" origId="s57" text="Ribavirin has been found to inhibit the phosphorylation of zidovudine in cell culture."/>
	<sentence id="DBMI.pac197.s58" origId="s58" text="Resistance:  Genotypic analyses of the isolates selected in cell culture and recovered from zidovudine-treated patients showed mutations in the HIV-1 RT gene resulting in 6 amino acid substitutions (M41L, D67N, K70R, L210W, T215Y or F, and K219Q) that confer zidovudine resistance."/>
	<sentence id="DBMI.pac197.s59" origId="s59" text="In general, higher levels of resistance were associated with greater number of amino acid substitutions."/>
	<sentence id="DBMI.pac197.s60" origId="s60" text="In some patients harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine."/>
	<sentence id="DBMI.pac197.s61" origId="s61" text="Combination therapy with lamivudine plus zidovudine delayed the emergence of substitutions conferring resistance to zidovudine."/>
	<sentence id="DBMI.pac197.s62" origId="s62" text="Cross-Resistance:  In a study of 167 HIV-1-infected patients, isolates (n = 2) with multi-drug resistance to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine were recovered from patients treated for 1 year with zidovudine plus didanosine or zidovudine plus zalcitabine."/>
	<sentence id="DBMI.pac197.s63" origId="s63" text="The pattern of resistance-associated amino acid substitutions with such combination therapies was different (A62V, V75I, F77L, F116Y, Q151M) from the pattern with zidovudine monotherapy, with the Q151M substitution being most commonly associated with multi-drug resistance."/>
	<sentence id="DBMI.pac197.s64" origId="s64" text="The substitution at codon 151 in combination with substitutions at 62, 75, 77, and 116 results in a virus with reduced susceptibility to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine."/>
	<sentence id="DBMI.pac197.s65" origId="s65" text="Thymidine analogue mutations (TAMs) are selected by zidovudine and confer cross-resistance to abacavir, didanosine, stavudine, tenofovir, and zalcitabine."/>
	<sentencespan id="DBMI.pac197.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nZidovudine is an antiviral agent [see Clinical Pharmacology (12.4)]. 12.3 Pharmacokinetics\n\nAbsorption and Bioavailability:  In adults, following oral administration, zidovudine is rapidly absorbed and extensively distributed, with peak serum concentrations occurring within 0.5 to 1.5 hours. The extent of absorption (AUC) was equivalent when zidovudine was administered as zidovudine tablets or syrup compared with zidovudine capsules."/>
	<sentencespan id="DBMI.pac197.sp1" origId="sp1" text="The pharmacokinetic properties of zidovudine in fasting adult patients are summarized in Table 6. Distribution:  The apparent volume of distribution of zidovudine, following oral administration, is 1.6  0.6 L/kg; and binding to plasma protein is low, &lt;38% (Table 6). Metabolism and Elimination:  Zidovudine is primarily eliminated by hepatic metabolism."/>
	<sentencespan id="DBMI.pac197.sp2" origId="sp2" text="The major metabolite of zidovudine is GZDV. GZDV AUC is about 3-fold greater than the zidovudine AUC. Urinary recovery of zidovudine and GZDV accounts for 14% and 74%, respectively, of the dose following oral administration."/>
	<sentencespan id="DBMI.pac197.sp3" origId="sp3" text="A second metabolite, 3'-amino-3'-deoxythymidine (AMT), has been identified in the plasma following single-dose intravenous (IV) administration of zidovudine. The AMT AUC was one fifth of the zidovudine AUC. Pharmacokinetics of zidovudine were dose independent at oral dosing regimens ranging from 2 mg/kg every 8 hours to 10 mg/kg every 4 hours."/>
	<sentencespan id="DBMI.pac197.sp4" origId="sp4" text="Effect of Food on Absorption:  Zidovudine may be administered with or without food. The extent of zidovudine absorption (AUC) was similar when a single dose of zidovudine was administered with food. Special Populations:  Renal Impairment:  Zidovudine clearance was decreased resulting in increased zidovudine and GZDV half-life and AUC in patients with impaired renal function (n = 14) following a single 200 mg oral dose (Table 7)."/>
	<sentencespan id="DBMI.pac197.sp5" origId="sp5" text="Plasma concentrations of AMT were not determined. A dose adjustment should not be necessary for patients with creatinine clearance (CrCl) 15 mL/min. Hemodialysis and Peritoneal Dialysis:  The pharmacokinetics and tolerance of zidovudine were evaluated in a multiple-dose study in patients undergoing hemodialysis (n = 5) or peritoneal dialysis (n = 6) receiving escalating doses up to 200 mg 5 times daily for 8 weeks."/>
	<sentencespan id="DBMI.pac197.sp6" origId="sp6" text="Daily doses of 500 mg or less were well tolerated despite significantly elevated GZDV plasma concentrations. Apparent zidovudine oral clearance was approximately 50% of that reported in patients with normal renal function. Hemodialysis and peritoneal dialysis appeared to have a negligible effect on the removal of zidovudine, whereas GZDV elimination was enhanced."/>
	<sentencespan id="DBMI.pac197.sp7" origId="sp7" text="A dosage adjustment is recommended for patients undergoing hemodialysis or peritoneal dialysis [see Dosage and Administration (2.4)]. Hepatic Impairment:  Data describing the effect of hepatic impairment on the pharmacokinetics of zidovudine are limited. However, because zidovudine is eliminated primarily by hepatic metabolism, it is expected that zidovudine clearance would be decreased and plasma concentrations would be increased following administration of the recommended adult doses to patients with hepatic impairment [see Dosage and Administration (2.5)]."/>
	<sentencespan id="DBMI.pac197.sp8" origId="sp8" text="Pediatric Patients:  Zidovudine pharmacokinetics have been evaluated in HIV-1-infected pediatric patients (Table 8). Patients 3 Months to 12 Years of Age:  Overall, zidovudine pharmacokinetics in pediatric patients greater than 3 months of age are similar to those in adult patients. Proportional increases in plasma zidovudine concentrations were observed following administration of oral solution from 90 to 240 mg/m2 every 6 hours."/>
	<sentencespan id="DBMI.pac197.sp9" origId="sp9" text="Oral bioavailability, terminal half-life, and oral clearance were comparable to adult values. As in adult patients, the major route of elimination was by metabolism to GZDV. After intravenous dosing, about 29% of the dose was excreted in the urine unchanged, and about 45% of the dose was excreted as GZDV [see Dosage and Administration (2.1)]."/>
	<sentencespan id="DBMI.pac197.sp10" origId="sp10" text="Patients &lt;3 Months of Age:  Zidovudine pharmacokinetics have been evaluated in pediatric patients from birth to 3 months of life. Zidovudine elimination was determined immediately following birth in 8 neonates who were exposed to zidovudine in utero. The half-life was 13  5.8 hours."/>
	<sentencespan id="DBMI.pac197.sp11" origId="sp11" text="In neonates 14 days old, bioavailability was greater, total body clearance was slower, and half-life was longer than in pediatric patients &gt;14 days old. For dose recommendations for neonates [see Dosage and Administration (2.2)]. Pregnancy:  Zidovudine pharmacokinetics have been studied in a Phase I study of 8 women during the last trimester of pregnancy."/>
	<sentencespan id="DBMI.pac197.sp12" origId="sp12" text="Zidovudine pharmacokinetics were similar to those of nonpregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery [see Use in Specific Populations (8.1)]. Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics."/>
	<sentencespan id="DBMI.pac197.sp13" origId="sp13" text="Nursing Mothers:  The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1. After administration of a single dose of 200 mg zidovudine to 13 HIV-1-infected women, the mean concentration of zidovudine was similar in human milk and serum [see Use In Specific Populations (8.3)]. Geriatric Patients:  Zidovudine pharmacokinetics have not been studied in patients over 65 years of age."/>
	<sentencespan id="DBMI.pac197.sp14" origId="sp14" text="Gender:  A pharmacokinetic study in healthy male (n = 12) and female (n = 12) subjects showed no differences in zidovudine exposure (AUC) when a single dose of zidovudine was administered as the 300 mg zidovudine tablet. Drug Interactions:  [See Drug Interactions (7)]. Phenytoin:  Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented.">
		<entity charOffset="5923-5934" id="DBMI.pac197.sp14.e0" origId="sp14.e0" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="5843-5853" id="DBMI.pac197.sp14.e1" origId="sp14.e1" text="Phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac197.sp14.e0" e2="DBMI.pac197.sp14.e1" id="DBMI.pac197.sp14.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Phenytoin " precipitant="zidovudine "/>
		<pair e1="DBMI.pac197.sp14.e1" e2="DBMI.pac197.sp14.e0" id="DBMI.pac197.sp14.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac197.sp15" origId="sp15" text="However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin. Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.">
		<entity charOffset="6138-6149" id="DBMI.pac197.sp15.e0" origId="sp15.e0" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="6093-6103" id="DBMI.pac197.sp15.e1" origId="sp15.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac197.sp15.e0" e2="DBMI.pac197.sp15.e1" id="DBMI.pac197.sp15.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="zidovudine "/>
		<pair e1="DBMI.pac197.sp15.e1" e2="DBMI.pac197.sp15.e0" id="DBMI.pac197.sp15.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="zidovudine " precipitant="phenytoin "/>
	</sentencespan>
	<sentencespan id="DBMI.pac197.sp16" origId="sp16" text="However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)]. 12.4 Microbiology\n\nMechanism of Action:  Zidovudine is a synthetic nucleoside analogue. Intracellularly, zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP).">
		<entity charOffset="6728-6738" id="DBMI.pac197.sp16.e0" origId="sp16.e0" text="ribavirin " type="Active ingredient"/>
		<entity charOffset="6763-6773" id="DBMI.pac197.sp16.e1" origId="sp16.e1" text="stavudine " type="Active ingredient"/>
		<entity charOffset="6786-6797" id="DBMI.pac197.sp16.e2" origId="sp16.e2" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="6742-6753" id="DBMI.pac197.sp16.e3" origId="sp16.e3" text="lamivudine " type="Active ingredient"/>
		<pair e1="DBMI.pac197.sp16.e0" e2="DBMI.pac197.sp16.e1" id="DBMI.pac197.sp16.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="stavudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.sp16.e0" e2="DBMI.pac197.sp16.e2" id="DBMI.pac197.sp16.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="zidovudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.sp16.e0" e2="DBMI.pac197.sp16.e3" id="DBMI.pac197.sp16.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lamivudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.sp16.e1" e2="DBMI.pac197.sp16.e0" id="DBMI.pac197.sp16.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e1" e2="DBMI.pac197.sp16.e2" id="DBMI.pac197.sp16.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e1" e2="DBMI.pac197.sp16.e3" id="DBMI.pac197.sp16.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e2" e2="DBMI.pac197.sp16.e0" id="DBMI.pac197.sp16.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e2" e2="DBMI.pac197.sp16.e1" id="DBMI.pac197.sp16.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e2" e2="DBMI.pac197.sp16.e3" id="DBMI.pac197.sp16.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e3" e2="DBMI.pac197.sp16.e0" id="DBMI.pac197.sp16.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e3" e2="DBMI.pac197.sp16.e1" id="DBMI.pac197.sp16.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e3" e2="DBMI.pac197.sp16.e2" id="DBMI.pac197.sp16.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac197.sp17" origId="sp17" text="The principal mode of action of ZDV-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases  and  and has been reported to be incorporated into the DNA of cells in culture. Antiviral Activity:  The antiviral activity of zidovudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood lymphocytes)."/>
	<sentencespan id="DBMI.pac197.sp18" origId="sp18" text="The EC50 and EC90 values for zidovudine were 0.01 to 0.49 M (1 M = 0.27 mcg/mL) and 0.1 to 9 M, respectively. HIV-1 from therapy-naive subjects with no mutations associated with resistance gave median EC50 values of 0.011 M (range: 0.005 to 0.11 M) from Virco (n = 92 baseline samples from COLA40263) and 0.0017 M (0.006 to 0.034 M) from Monogram Biosciences (n = 135 baseline samples from ESS30009). The EC50 values of zidovudine against different HIV-1 clades (A-G) ranged from 0.00018 to 0.02 M, and against HIV-2 isolates from 0.00049 to 0.004 M. In cell culture drug combination studies, zidovudine demonstrates synergistic activity with the nucleoside reverse transcriptase inhibitors abacavir, didanosine, and lamivudine; the non-nucleoside reverse transcriptase inhibitors delavirdine and nevirapine; and the protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir; and additive activity with interferon alfa."/>
	<sentencespan id="DBMI.pac197.sp19" origId="sp19" text="Ribavirin has been found to inhibit the phosphorylation of zidovudine in cell culture. Resistance:  Genotypic analyses of the isolates selected in cell culture and recovered from zidovudine-treated patients showed mutations in the HIV-1 RT gene resulting in 6 amino acid substitutions (M41L, D67N, K70R, L210W, T215Y or F, and K219Q) that confer zidovudine resistance. In general, higher levels of resistance were associated with greater number of amino acid substitutions."/>
	<sentencespan id="DBMI.pac197.sp20" origId="sp20" text="In some patients harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of substitutions conferring resistance to zidovudine. Cross-Resistance:  In a study of 167 HIV-1-infected patients, isolates (n = 2) with multi-drug resistance to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine were recovered from patients treated for 1 year with zidovudine plus didanosine or zidovudine plus zalcitabine."/>
	<sentencespan id="DBMI.pac197.sp21" origId="sp21" text="The pattern of resistance-associated amino acid substitutions with such combination therapies was different (A62V, V75I, F77L, F116Y, Q151M) from the pattern with zidovudine monotherapy, with the Q151M substitution being most commonly associated with multi-drug resistance. The substitution at codon 151 in combination with substitutions at 62, 75, 77, and 116 results in a virus with reduced susceptibility to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine. Thymidine analogue mutations (TAMs) are selected by zidovudine and confer cross-resistance to abacavir, didanosine, stavudine, tenofovir, and zalcitabine."/>
</document>

<document id="DBMI.pac198" origId="pac198">
	<sentence id="DBMI.pac198.s0" origId="s0" text="Didanosine and Stavudine\n\nExperimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine.">
		<entity charOffset="66-76" id="DBMI.pac198.s0.e0" origId="s0.e0" text="methadone " type="Active ingredient"/>
		<entity charOffset="114-125" id="DBMI.pac198.s0.e1" origId="s0.e1" text="didanosine " type="Active ingredient"/>
		<entity charOffset="129-139" id="DBMI.pac198.s0.e2" origId="s0.e2" text="stavudine " type="Active ingredient"/>
		<pair e1="DBMI.pac198.s0.e0" e2="DBMI.pac198.s0.e1" id="DBMI.pac198.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="didanosine " precipitant="methadone "/>
		<pair e1="DBMI.pac198.s0.e0" e2="DBMI.pac198.s0.e2" id="DBMI.pac198.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="stavudine " precipitant="methadone "/>
		<pair e1="DBMI.pac198.s0.e1" e2="DBMI.pac198.s0.e0" id="DBMI.pac198.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac198.s0.e1" e2="DBMI.pac198.s0.e2" id="DBMI.pac198.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac198.s0.e2" e2="DBMI.pac198.s0.e0" id="DBMI.pac198.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac198.s0.e2" e2="DBMI.pac198.s0.e1" id="DBMI.pac198.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac198.s1" origId="s1" text="Methadone disposition was not substantially altered."/>
	<sentencespan id="DBMI.pac198.sp0" origId="sp0" text="Didanosine and Stavudine\n\nExperimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered.">
		<entity charOffset="66-76" id="DBMI.pac198.sp0.e0" origId="sp0.e0" text="methadone " type="Active ingredient"/>
		<entity charOffset="114-125" id="DBMI.pac198.sp0.e1" origId="sp0.e1" text="didanosine " type="Active ingredient"/>
		<entity charOffset="129-139" id="DBMI.pac198.sp0.e2" origId="sp0.e2" text="stavudine " type="Active ingredient"/>
		<pair e1="DBMI.pac198.sp0.e0" e2="DBMI.pac198.sp0.e1" id="DBMI.pac198.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="didanosine " precipitant="methadone "/>
		<pair e1="DBMI.pac198.sp0.e0" e2="DBMI.pac198.sp0.e2" id="DBMI.pac198.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="stavudine " precipitant="methadone "/>
		<pair e1="DBMI.pac198.sp0.e1" e2="DBMI.pac198.sp0.e0" id="DBMI.pac198.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac198.sp0.e1" e2="DBMI.pac198.sp0.e2" id="DBMI.pac198.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac198.sp0.e2" e2="DBMI.pac198.sp0.e0" id="DBMI.pac198.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac198.sp0.e2" e2="DBMI.pac198.sp0.e1" id="DBMI.pac198.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac199" origId="pac199">
	<sentence id="DBMI.pac199.s0" origId="s0" text="Zidovudine\n\nExperimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.">
		<entity charOffset="52-62" id="DBMI.pac199.s0.e0" origId="s0.e0" text="methadone " type="Active ingredient"/>
		<entity charOffset="125-136" id="DBMI.pac199.s0.e1" origId="s0.e1" text="zidovudine " type="Active ingredient"/>
		<pair e1="DBMI.pac199.s0.e0" e2="DBMI.pac199.s0.e1" id="DBMI.pac199.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="zidovudine " precipitant="methadone "/>
		<pair e1="DBMI.pac199.s0.e1" e2="DBMI.pac199.s0.e0" id="DBMI.pac199.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac199.sp0" origId="sp0" text="Zidovudine\n\nExperimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.">
		<entity charOffset="52-62" id="DBMI.pac199.sp0.e0" origId="sp0.e0" text="methadone " type="Active ingredient"/>
		<entity charOffset="125-136" id="DBMI.pac199.sp0.e1" origId="sp0.e1" text="zidovudine " type="Active ingredient"/>
		<pair e1="DBMI.pac199.sp0.e0" e2="DBMI.pac199.sp0.e1" id="DBMI.pac199.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="zidovudine " precipitant="methadone "/>
		<pair e1="DBMI.pac199.sp0.e1" e2="DBMI.pac199.sp0.e0" id="DBMI.pac199.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac200" origId="pac200">
	<sentence id="DBMI.pac200.s0" origId="s0" text="Rifampin\n\nIn patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.">
		<entity charOffset="82-91" id="DBMI.pac200.s0.e0" origId="s0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="41-51" id="DBMI.pac200.s0.e1" origId="s0.e1" text="methadone " type="Active ingredient"/>
		<pair e1="DBMI.pac200.s0.e0" e2="DBMI.pac200.s0.e1" id="DBMI.pac200.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="methadone " precipitant="rifampin "/>
		<pair e1="DBMI.pac200.s0.e1" e2="DBMI.pac200.s0.e0" id="DBMI.pac200.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac200.sp0" origId="sp0" text="Rifampin\n\nIn patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.">
		<entity charOffset="82-91" id="DBMI.pac200.sp0.e0" origId="sp0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="41-51" id="DBMI.pac200.sp0.e1" origId="sp0.e1" text="methadone " type="Active ingredient"/>
		<pair e1="DBMI.pac200.sp0.e0" e2="DBMI.pac200.sp0.e1" id="DBMI.pac200.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="methadone " precipitant="rifampin "/>
		<pair e1="DBMI.pac200.sp0.e1" e2="DBMI.pac200.sp0.e0" id="DBMI.pac200.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac201" origId="pac201">
	<sentence id="DBMI.pac201.s0" origId="s0" text="Phenytoin\n\nIn a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d.initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently.">
		<entity charOffset="86-96" id="DBMI.pac201.s0.e0" origId="s0.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="55-65" id="DBMI.pac201.s0.e1" origId="s0.e1" text="methadone " type="Active ingredient"/>
		<pair e1="DBMI.pac201.s0.e0" e2="DBMI.pac201.s0.e1" id="DBMI.pac201.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="methadone " precipitant="phenytoin "/>
		<pair e1="DBMI.pac201.s0.e1" e2="DBMI.pac201.s0.e0" id="DBMI.pac201.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac201.s1" origId="s1" text="Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration."/>
	<sentencespan id="DBMI.pac201.sp0" origId="sp0" text="Phenytoin\n\nIn a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d.initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration.">
		<entity charOffset="86-96" id="DBMI.pac201.sp0.e0" origId="sp0.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="55-65" id="DBMI.pac201.sp0.e1" origId="sp0.e1" text="methadone " type="Active ingredient"/>
		<pair e1="DBMI.pac201.sp0.e0" e2="DBMI.pac201.sp0.e1" id="DBMI.pac201.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="methadone " precipitant="phenytoin "/>
		<pair e1="DBMI.pac201.sp0.e1" e2="DBMI.pac201.sp0.e0" id="DBMI.pac201.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac202" origId="pac202">
	<sentence id="DBMI.pac202.s0" origId="s0" text="Voriconazole\n\nRepeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD).">
		<entity charOffset="49-62" id="DBMI.pac202.s0.e0" origId="s0.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="147-157" id="DBMI.pac202.s0.e1" origId="s0.e1" text="methadone " type="Active ingredient"/>
		<pair e1="DBMI.pac202.s0.e0" e2="DBMI.pac202.s0.e1" id="DBMI.pac202.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="methadone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac202.s0.e0" e2="DBMI.pac202.s0.e1" id="DBMI.pac202.s0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="methadone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac202.s0.e1" e2="DBMI.pac202.s0.e0" id="DBMI.pac202.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac202.s1" origId="s1" text="The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively."/>
	<sentence id="DBMI.pac202.s2" origId="s2" text="Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation."/>
	<sentence id="DBMI.pac202.s3" origId="s3" text="Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration."/>
	<sentence id="DBMI.pac202.s4" origId="s4" text="Dose reduction of methadone may be needed."/>
	<sentencespan id="DBMI.pac202.sp0" origId="sp0" text="Voriconazole\n\nRepeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD). The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively. Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation.">
		<entity charOffset="49-62" id="DBMI.pac202.sp0.e0" origId="sp0.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="147-157" id="DBMI.pac202.sp0.e1" origId="sp0.e1" text="methadone " type="Active ingredient"/>
		<pair e1="DBMI.pac202.sp0.e0" e2="DBMI.pac202.sp0.e1" id="DBMI.pac202.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="methadone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac202.sp0.e0" e2="DBMI.pac202.sp0.e1" id="DBMI.pac202.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="methadone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac202.sp0.e1" e2="DBMI.pac202.sp0.e0" id="DBMI.pac202.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac202.sp1" origId="sp1" text="Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed."/>
</document>

<document id="DBMI.pac203" origId="pac203">
	<sentence id="DBMI.pac203.s0" origId="s0" text="Desipramine\n\nBlood levels of desipramine have increased with concurrent methadone administration.">
		<entity charOffset="72-82" id="DBMI.pac203.s0.e0" origId="s0.e0" text="methadone " type="Active ingredient"/>
		<entity charOffset="29-41" id="DBMI.pac203.s0.e1" origId="s0.e1" text="desipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac203.s0.e0" e2="DBMI.pac203.s0.e1" id="DBMI.pac203.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="desipramine " precipitant="methadone "/>
		<pair e1="DBMI.pac203.s0.e1" e2="DBMI.pac203.s0.e0" id="DBMI.pac203.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac203.sp0" origId="sp0" text="Desipramine\n\nBlood levels of desipramine have increased with concurrent methadone administration.">
		<entity charOffset="72-82" id="DBMI.pac203.sp0.e0" origId="sp0.e0" text="methadone " type="Active ingredient"/>
		<entity charOffset="29-41" id="DBMI.pac203.sp0.e1" origId="sp0.e1" text="desipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac203.sp0.e0" e2="DBMI.pac203.sp0.e1" id="DBMI.pac203.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="desipramine " precipitant="methadone "/>
		<pair e1="DBMI.pac203.sp0.e1" e2="DBMI.pac203.sp0.e0" id="DBMI.pac203.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac207" origId="pac207">
	<sentence id="DBMI.pac207.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP2C19 Inhibitors\n\nClopidogrel is metabolized to its active metabolite in part by CYP2C19."/>
	<sentence id="DBMI.pac207.s1" origId="s1" text="Concomitant use of drugs that inhibit the activity of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition."/>
	<sentence id="DBMI.pac207.s2" origId="s2" text="Avoid concomitant use of drugs that inhibit CYP2C19, e.g., omeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.5)]."/>
	<sentence id="DBMI.pac207.s3" origId="s3" text="Omeprazole\n\nIn a crossover clinical study, 72 healthy subjects were administered Plavix (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as Plavix) for 5 days.">
		<entity charOffset="597-608" id="DBMI.pac207.s3.e0" origId="s3.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="696-708" id="DBMI.pac207.s3.e1" origId="s3.e1" text="clopidogrel " type="Active ingredient"/>
		<pair e1="DBMI.pac207.s3.e0" e2="DBMI.pac207.s3.e1" id="DBMI.pac207.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="clopidogrel " precipitant="omeprazole "/>
		<pair e1="DBMI.pac207.s3.e1" e2="DBMI.pac207.s3.e0" id="DBMI.pac207.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac207.s4" origId="s4" text="The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when Plavix and omeprazole were administered together.">
		<entity charOffset="769-780" id="DBMI.pac207.s4.e0" origId="s4.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="758-765" id="DBMI.pac207.s4.e1" origId="s4.e1" text="Plavix " type="Drug product"/>
		<pair e1="DBMI.pac207.s4.e0" e2="DBMI.pac207.s4.e1" id="DBMI.pac207.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Plavix " precipitant="omeprazole "/>
		<pair e1="DBMI.pac207.s4.e1" e2="DBMI.pac207.s4.e0" id="DBMI.pac207.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac207.s5" origId="s5" text="Mean inhibition of platelet aggregation was diminished by 47% (24 hours) and 30% (Day 5) when Plavix and omeprazole were administered together."/>
	<sentence id="DBMI.pac207.s6" origId="s6" text="In another study, 72 healthy subjects were given the same doses of Plavix and omeprazole but the drugs were administered 12 hours apart; the results were similar, indicating that administering Plavix and omeprazole at different times does not prevent their interaction [see Warnings and Precautions (5.1)]."/>
	<sentence id="DBMI.pac207.s7" origId="s7" text="7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)\n\nCoadministration of Plavix and NSAIDs increases the risk of gastrointestinal bleeding."/>
	<sentence id="DBMI.pac207.s8" origId="s8" text="7.3 Warfarin (CYP2C9 Substrates)\n\nAlthough the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of Plavix with warfarin increases the risk of bleeding because of independent effects on hemostasis.">
		<entity charOffset="1465-1477" id="DBMI.pac207.s8.e0" origId="s8.e0" text="clopidogrel " type="Active ingredient"/>
		<entity charOffset="1532-1541" id="DBMI.pac207.s8.e1" origId="s8.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac207.s8.e0" e2="DBMI.pac207.s8.e1" id="DBMI.pac207.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="clopidogrel "/>
		<pair e1="DBMI.pac207.s8.e1" e2="DBMI.pac207.s8.e0" id="DBMI.pac207.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac207.s9" origId="s9" text="However, at high concentrations in vitro, clopidogrel inhibits CYP2C9."/>
	<sentencespan id="DBMI.pac207.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP2C19 Inhibitors\n\nClopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of drugs that inhibit the activity of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Avoid concomitant use of drugs that inhibit CYP2C19, e.g., omeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.5)]."/>
	<sentencespan id="DBMI.pac207.sp1" origId="sp1" text="Omeprazole\n\nIn a crossover clinical study, 72 healthy subjects were administered Plavix (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as Plavix) for 5 days. The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when Plavix and omeprazole were administered together. Mean inhibition of platelet aggregation was diminished by 47% (24 hours) and 30% (Day 5) when Plavix and omeprazole were administered together.">
		<entity charOffset="597-608" id="DBMI.pac207.sp1.e0" origId="sp1.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="696-708" id="DBMI.pac207.sp1.e1" origId="sp1.e1" text="clopidogrel " type="Active ingredient"/>
		<entity charOffset="758-765" id="DBMI.pac207.sp1.e2" origId="sp1.e2" text="Plavix " type="Drug product"/>
		<pair e1="DBMI.pac207.sp1.e0" e2="DBMI.pac207.sp1.e1" id="DBMI.pac207.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="clopidogrel " precipitant="omeprazole "/>
		<pair e1="DBMI.pac207.sp1.e0" e2="DBMI.pac207.sp1.e2" id="DBMI.pac207.sp1.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Plavix " precipitant="omeprazole "/>
		<pair e1="DBMI.pac207.sp1.e1" e2="DBMI.pac207.sp1.e0" id="DBMI.pac207.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac207.sp1.e1" e2="DBMI.pac207.sp1.e2" id="DBMI.pac207.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac207.sp1.e2" e2="DBMI.pac207.sp1.e0" id="DBMI.pac207.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac207.sp1.e2" e2="DBMI.pac207.sp1.e1" id="DBMI.pac207.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac207.sp2" origId="sp2" text="In another study, 72 healthy subjects were given the same doses of Plavix and omeprazole but the drugs were administered 12 hours apart; the results were similar, indicating that administering Plavix and omeprazole at different times does not prevent their interaction [see Warnings and Precautions (5.1)]. 7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)\n\nCoadministration of Plavix and NSAIDs increases the risk of gastrointestinal bleeding. 7.3 Warfarin (CYP2C9 Substrates)\n\nAlthough the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of Plavix with warfarin increases the risk of bleeding because of independent effects on hemostasis.">
		<entity charOffset="1465-1477" id="DBMI.pac207.sp2.e0" origId="sp2.e0" text="clopidogrel " type="Active ingredient"/>
		<entity charOffset="1532-1541" id="DBMI.pac207.sp2.e1" origId="sp2.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac207.sp2.e0" e2="DBMI.pac207.sp2.e1" id="DBMI.pac207.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="clopidogrel "/>
		<pair e1="DBMI.pac207.sp2.e1" e2="DBMI.pac207.sp2.e0" id="DBMI.pac207.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac207.sp3" origId="sp3" text="However, at high concentrations in vitro, clopidogrel inhibits CYP2C9."/>
</document>

<document id="DBMI.pac21" origId="pac21">
	<sentence id="DBMI.pac21.s0" origId="s0" text="A third study evaluated the potential interaction of once weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone."/>
	<sentence id="DBMI.pac21.s1" origId="s1" text="In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing.">
		<entity charOffset="333-345" id="DBMI.pac21.s1.e0" origId="s1.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="511-525" id="DBMI.pac21.s1.e1" origId="s1.e1" text="norethindrone " type="Active ingredient"/>
		<entity charOffset="489-507" id="DBMI.pac21.s1.e2" origId="s1.e2" text="ethinyl estradiol " type="Active ingredient"/>
		<pair e1="DBMI.pac21.s1.e0" e2="DBMI.pac21.s1.e1" id="DBMI.pac21.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="norethindrone " precipitant="fluconazole "/>
		<pair e1="DBMI.pac21.s1.e0" e2="DBMI.pac21.s1.e2" id="DBMI.pac21.s1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethinyl estradiol " precipitant="fluconazole "/>
		<pair e1="DBMI.pac21.s1.e1" e2="DBMI.pac21.s1.e0" id="DBMI.pac21.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac21.s1.e1" e2="DBMI.pac21.s1.e2" id="DBMI.pac21.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac21.s1.e2" e2="DBMI.pac21.s1.e0" id="DBMI.pac21.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac21.s1.e2" e2="DBMI.pac21.s1.e1" id="DBMI.pac21.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac21.s2" origId="s2" text="The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I.range 18 to 31%) and 13% (95% C.I.range 8 to 18%), respectively relative to placebo."/>
	<sentence id="DBMI.pac21.s3" origId="s3" text="Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing."/>
	<sentence id="DBMI.pac21.s4" origId="s4" text="The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment."/>
	<sentencespan id="DBMI.pac21.sp0" origId="sp0" text="A third study evaluated the potential interaction of once weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I.range 18 to 31%) and 13% (95% C.I.range 8 to 18%), respectively relative to placebo.">
		<entity charOffset="333-345" id="DBMI.pac21.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="511-525" id="DBMI.pac21.sp0.e1" origId="sp0.e1" text="norethindrone " type="Active ingredient"/>
		<entity charOffset="489-507" id="DBMI.pac21.sp0.e2" origId="sp0.e2" text="ethinyl estradiol " type="Active ingredient"/>
		<pair e1="DBMI.pac21.sp0.e0" e2="DBMI.pac21.sp0.e1" id="DBMI.pac21.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="norethindrone " precipitant="fluconazole "/>
		<pair e1="DBMI.pac21.sp0.e0" e2="DBMI.pac21.sp0.e2" id="DBMI.pac21.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethinyl estradiol " precipitant="fluconazole "/>
		<pair e1="DBMI.pac21.sp0.e1" e2="DBMI.pac21.sp0.e0" id="DBMI.pac21.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac21.sp0.e1" e2="DBMI.pac21.sp0.e2" id="DBMI.pac21.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac21.sp0.e2" e2="DBMI.pac21.sp0.e0" id="DBMI.pac21.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac21.sp0.e2" e2="DBMI.pac21.sp0.e1" id="DBMI.pac21.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac21.sp1" origId="sp1" text="Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment."/>
</document>

<document id="DBMI.pac22" origId="pac22">
	<sentence id="DBMI.pac22.s0" origId="s0" text="Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women."/>
	<sentence id="DBMI.pac22.s1" origId="s1" text="There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.">
		<entity charOffset="282-294" id="DBMI.pac22.s1.e0" origId="s1.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="316-334" id="DBMI.pac22.s1.e1" origId="s1.e1" text="ethinyl estradiol " type="Active ingredient"/>
		<entity charOffset="226-241" id="DBMI.pac22.s1.e2" origId="s1.e2" text="levonorgestrel " type="Active ingredient"/>
		<pair e1="DBMI.pac22.s1.e0" e2="DBMI.pac22.s1.e1" id="DBMI.pac22.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol " precipitant="fluconazole "/>
		<pair e1="DBMI.pac22.s1.e0" e2="DBMI.pac22.s1.e2" id="DBMI.pac22.s1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="levonorgestrel " precipitant="fluconazole "/>
		<pair e1="DBMI.pac22.s1.e1" e2="DBMI.pac22.s1.e0" id="DBMI.pac22.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac22.s1.e1" e2="DBMI.pac22.s1.e2" id="DBMI.pac22.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac22.s1.e2" e2="DBMI.pac22.s1.e0" id="DBMI.pac22.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac22.s1.e2" e2="DBMI.pac22.s1.e1" id="DBMI.pac22.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac22.s2" origId="s2" text="The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%)."/>
	<sentencespan id="DBMI.pac22.sp0" origId="sp0" text="Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).">
		<entity charOffset="282-294" id="DBMI.pac22.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="316-334" id="DBMI.pac22.sp0.e1" origId="sp0.e1" text="ethinyl estradiol " type="Active ingredient"/>
		<entity charOffset="226-241" id="DBMI.pac22.sp0.e2" origId="sp0.e2" text="levonorgestrel " type="Active ingredient"/>
		<pair e1="DBMI.pac22.sp0.e0" e2="DBMI.pac22.sp0.e1" id="DBMI.pac22.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol " precipitant="fluconazole "/>
		<pair e1="DBMI.pac22.sp0.e0" e2="DBMI.pac22.sp0.e2" id="DBMI.pac22.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="levonorgestrel " precipitant="fluconazole "/>
		<pair e1="DBMI.pac22.sp0.e1" e2="DBMI.pac22.sp0.e0" id="DBMI.pac22.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac22.sp0.e1" e2="DBMI.pac22.sp0.e2" id="DBMI.pac22.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac22.sp0.e2" e2="DBMI.pac22.sp0.e0" id="DBMI.pac22.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac22.sp0.e2" e2="DBMI.pac22.sp0.e1" id="DBMI.pac22.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac23" origId="pac23">
	<sentence id="DBMI.pac23.s0" origId="s0" text="Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers."/>
	<sentence id="DBMI.pac23.s1" origId="s1" text="After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax.">
		<entity charOffset="179-190" id="DBMI.pac23.s1.e0" origId="s1.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="287-299" id="DBMI.pac23.s1.e1" origId="s1.e1" text="fluconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac23.s1.e0" e2="DBMI.pac23.s1.e1" id="DBMI.pac23.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fluconazole " precipitant="cimetidine "/>
		<pair e1="DBMI.pac23.s1.e1" e2="DBMI.pac23.s1.e0" id="DBMI.pac23.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac23.s2" origId="s2" text="There was a mean  SD decrease in fluconazole AUC of 13%  11% (range: -3.4 to -31%) and Cmax decreased 19%  14% (range: -5 to -40%)."/>
	<sentence id="DBMI.pac23.s3" origId="s3" text="However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.">
		<entity charOffset="419-430" id="DBMI.pac23.s3.e0" origId="s3.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="546-558" id="DBMI.pac23.s3.e1" origId="s3.e1" text="fluconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac23.s3.e0" e2="DBMI.pac23.s3.e1" id="DBMI.pac23.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluconazole " precipitant="cimetidine "/>
		<pair e1="DBMI.pac23.s3.e1" e2="DBMI.pac23.s3.e0" id="DBMI.pac23.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac23.sp0" origId="sp0" text="Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean  SD decrease in fluconazole AUC of 13%  11% (range: -3.4 to -31%) and Cmax decreased 19%  14% (range: -5 to -40%).">
		<entity charOffset="179-190" id="DBMI.pac23.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="287-299" id="DBMI.pac23.sp0.e1" origId="sp0.e1" text="fluconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac23.sp0.e0" e2="DBMI.pac23.sp0.e1" id="DBMI.pac23.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fluconazole " precipitant="cimetidine "/>
		<pair e1="DBMI.pac23.sp0.e1" e2="DBMI.pac23.sp0.e0" id="DBMI.pac23.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac23.sp1" origId="sp1" text="However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.">
		<entity charOffset="419-430" id="DBMI.pac23.sp1.e0" origId="sp1.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="546-558" id="DBMI.pac23.sp1.e1" origId="sp1.e1" text="fluconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac23.sp1.e0" e2="DBMI.pac23.sp1.e1" id="DBMI.pac23.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluconazole " precipitant="cimetidine "/>
		<pair e1="DBMI.pac23.sp1.e1" e2="DBMI.pac23.sp1.e0" id="DBMI.pac23.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac24" origId="pac24">
	<sentence id="DBMI.pac24.s0" origId="s0" text="Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole.">
		<entity charOffset="76-85" id="DBMI.pac24.s0.e0" origId="s0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="435-447" id="DBMI.pac24.s0.e1" origId="s0.e1" text="Fluconazole " type="Active ingredient"/>
		<entity charOffset="47-59" id="DBMI.pac24.s0.e2" origId="s0.e2" text="fluconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac24.s0.e0" e2="DBMI.pac24.s0.e1" id="DBMI.pac24.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Fluconazole " precipitant="rifampin "/>
		<pair e1="DBMI.pac24.s0.e0" e2="DBMI.pac24.s0.e2" id="DBMI.pac24.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluconazole " precipitant="rifampin "/>
		<pair e1="DBMI.pac24.s0.e1" e2="DBMI.pac24.s0.e0" id="DBMI.pac24.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac24.s0.e1" e2="DBMI.pac24.s0.e2" id="DBMI.pac24.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac24.s0.e2" e2="DBMI.pac24.s0.e0" id="DBMI.pac24.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac24.s0.e2" e2="DBMI.pac24.s0.e1" id="DBMI.pac24.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac24.s1" origId="s1" text="There was a mean  SD reduction in fluconazole AUC of 23%  9% (range: -13 to -42%)."/>
	<sentence id="DBMI.pac24.s2" origId="s2" text="Apparent oral clearance of fluconazole increased 32%  17% (range: 16 to 72%)."/>
	<sentence id="DBMI.pac24.s3" origId="s3" text="Fluconazole half-life decreased from 33.4  4.4 hours to 26.8  3.9 hours."/>
	<sentence id="DBMI.pac24.s4" origId="s4" text="(See PRECAUTIONS.)"/>
	<sentencespan id="DBMI.pac24.sp0" origId="sp0" text="Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean  SD reduction in fluconazole AUC of 23%  9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32%  17% (range: 16 to 72%).">
		<entity charOffset="76-85" id="DBMI.pac24.sp0.e0" origId="sp0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="435-447" id="DBMI.pac24.sp0.e1" origId="sp0.e1" text="Fluconazole " type="Active ingredient"/>
		<entity charOffset="47-59" id="DBMI.pac24.sp0.e2" origId="sp0.e2" text="fluconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac24.sp0.e0" e2="DBMI.pac24.sp0.e1" id="DBMI.pac24.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Fluconazole " precipitant="rifampin "/>
		<pair e1="DBMI.pac24.sp0.e0" e2="DBMI.pac24.sp0.e2" id="DBMI.pac24.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluconazole " precipitant="rifampin "/>
		<pair e1="DBMI.pac24.sp0.e1" e2="DBMI.pac24.sp0.e0" id="DBMI.pac24.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac24.sp0.e1" e2="DBMI.pac24.sp0.e2" id="DBMI.pac24.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac24.sp0.e2" e2="DBMI.pac24.sp0.e0" id="DBMI.pac24.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac24.sp0.e2" e2="DBMI.pac24.sp0.e1" id="DBMI.pac24.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac24.sp1" origId="sp1" text="Fluconazole half-life decreased from 33.4  4.4 hours to 26.8  3.9 hours. (See PRECAUTIONS.)"/>
</document>

<document id="DBMI.pac25" origId="pac25">
	<sentence id="DBMI.pac25.s0" origId="s0" text="Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers.">
		<entity charOffset="186-198" id="DBMI.pac25.s0.e0" origId="s0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="349-359" id="DBMI.pac25.s0.e1" origId="s0.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac25.s0.e0" e2="DBMI.pac25.s0.e1" id="DBMI.pac25.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="fluconazole "/>
		<pair e1="DBMI.pac25.s0.e1" e2="DBMI.pac25.s0.e0" id="DBMI.pac25.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac25.s1" origId="s1" text="There was a significant increase in phenytoin AUC."/>
	<sentence id="DBMI.pac25.s2" origId="s2" text="The mean  SD increase in phenytoin AUC was 88%  68% (range: 16 to 247%)."/>
	<sentence id="DBMI.pac25.s3" origId="s3" text="The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin."/>
	<sentence id="DBMI.pac25.s4" origId="s4" text="(See PRECAUTIONS.)"/>
	<sentencespan id="DBMI.pac25.sp0" origId="sp0" text="Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean  SD increase in phenytoin AUC was 88%  68% (range: 16 to 247%).">
		<entity charOffset="186-198" id="DBMI.pac25.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="349-359" id="DBMI.pac25.sp0.e1" origId="sp0.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac25.sp0.e0" e2="DBMI.pac25.sp0.e1" id="DBMI.pac25.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="fluconazole "/>
		<pair e1="DBMI.pac25.sp0.e1" e2="DBMI.pac25.sp0.e0" id="DBMI.pac25.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac25.sp1" origId="sp1" text="The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin. (See PRECAUTIONS.)"/>
</document>

<document id="DBMI.pac26" origId="pac26">
	<sentence id="DBMI.pac26.s0" origId="s0" text="Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks.">
		<entity charOffset="81-93" id="DBMI.pac26.s0.e0" origId="s0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="304-317" id="DBMI.pac26.s0.e1" origId="s0.e1" text="cyclosporine " type="Active ingredient"/>
		<pair e1="DBMI.pac26.s0.e0" e2="DBMI.pac26.s0.e1" id="DBMI.pac26.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine " precipitant="fluconazole "/>
		<pair e1="DBMI.pac26.s0.e1" e2="DBMI.pac26.s0.e0" id="DBMI.pac26.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac26.s1" origId="s1" text="There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole."/>
	<sentence id="DBMI.pac26.s2" origId="s2" text="The mean  SD increase in AUC was 92%  43% (range: 18 to 147%)."/>
	<sentence id="DBMI.pac26.s3" origId="s3" text="The Cmax increased 60%  48% (range: -5 to 133%)."/>
	<sentence id="DBMI.pac26.s4" origId="s4" text="The Cmin increased 157%  96% (range: 33 to 360%)."/>
	<sentence id="DBMI.pac26.s5" origId="s5" text="The apparent oral clearance decreased 45%  15% (range: -15 to -60%)."/>
	<sentence id="DBMI.pac26.s6" origId="s6" text="(See PRECAUTIONS.)"/>
	<sentencespan id="DBMI.pac26.sp0" origId="sp0" text="Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean  SD increase in AUC was 92%  43% (range: 18 to 147%).">
		<entity charOffset="81-93" id="DBMI.pac26.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="304-317" id="DBMI.pac26.sp0.e1" origId="sp0.e1" text="cyclosporine " type="Active ingredient"/>
		<pair e1="DBMI.pac26.sp0.e0" e2="DBMI.pac26.sp0.e1" id="DBMI.pac26.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine " precipitant="fluconazole "/>
		<pair e1="DBMI.pac26.sp0.e1" e2="DBMI.pac26.sp0.e0" id="DBMI.pac26.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac26.sp1" origId="sp1" text="The Cmax increased 60%  48% (range: -5 to 133%). The Cmin increased 157%  96% (range: 33 to 360%). The apparent oral clearance decreased 45%  15% (range: -15 to -60%)."/>
	<sentencespan id="DBMI.pac26.sp2" origId="sp2" text="(See PRECAUTIONS.)"/>
</document>

<document id="DBMI.pac27" origId="pac27">
	<sentence id="DBMI.pac27.s0" origId="s0" text="Plasma zidovudine concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks."/>
	<sentence id="DBMI.pac27.s1" origId="s1" text="There was a significant increase in zidovudine AUC following the administration of fluconazole.">
		<entity charOffset="304-316" id="DBMI.pac27.s1.e0" origId="s1.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="257-268" id="DBMI.pac27.s1.e1" origId="s1.e1" text="zidovudine " type="Active ingredient"/>
		<pair e1="DBMI.pac27.s1.e0" e2="DBMI.pac27.s1.e1" id="DBMI.pac27.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="zidovudine " precipitant="fluconazole "/>
		<pair e1="DBMI.pac27.s1.e1" e2="DBMI.pac27.s1.e0" id="DBMI.pac27.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac27.s2" origId="s2" text="The mean  SD increase in AUC was 20%  32% (range: -27 to 104%)."/>
	<sentence id="DBMI.pac27.s3" origId="s3" text="The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6  3.6 to 5.7  2.2."/>
	<sentencespan id="DBMI.pac27.sp0" origId="sp0" text="Plasma zidovudine concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean  SD increase in AUC was 20%  32% (range: -27 to 104%).">
		<entity charOffset="304-316" id="DBMI.pac27.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="257-268" id="DBMI.pac27.sp0.e1" origId="sp0.e1" text="zidovudine " type="Active ingredient"/>
		<pair e1="DBMI.pac27.sp0.e0" e2="DBMI.pac27.sp0.e1" id="DBMI.pac27.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="zidovudine " precipitant="fluconazole "/>
		<pair e1="DBMI.pac27.sp0.e1" e2="DBMI.pac27.sp0.e0" id="DBMI.pac27.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac27.sp1" origId="sp1" text="The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6  3.6 to 5.7  2.2."/>
</document>

<document id="DBMI.pac28" origId="pac28">
	<sentence id="DBMI.pac28.s0" origId="s0" text="The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers.">
		<entity charOffset="155-167" id="DBMI.pac28.s0.e0" origId="s0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="354-367" id="DBMI.pac28.s0.e1" origId="s0.e1" text="theophylline " type="Active ingredient"/>
		<pair e1="DBMI.pac28.s0.e0" e2="DBMI.pac28.s0.e1" id="DBMI.pac28.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="theophylline " precipitant="fluconazole "/>
		<pair e1="DBMI.pac28.s0.e0" e2="DBMI.pac28.s0.e1" id="DBMI.pac28.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="theophylline " precipitant="fluconazole "/>
		<pair e1="DBMI.pac28.s0.e1" e2="DBMI.pac28.s0.e0" id="DBMI.pac28.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac28.s1" origId="s1" text="There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance."/>
	<sentence id="DBMI.pac28.s2" origId="s2" text="The mean  SD theophylline AUC increased 21%  16% (range: -5 to 48%)."/>
	<sentence id="DBMI.pac28.s3" origId="s3" text="The Cmax increased 13%  17% (range: -13 to 40%)."/>
	<sentence id="DBMI.pac28.s4" origId="s4" text="Theophylline clearance decreased 16%  11 % (range: -32 to 5%)."/>
	<sentence id="DBMI.pac28.s5" origId="s5" text="The half-life of theophylline increased from 6.6  1.7 hours to 7.9  1.5 hours."/>
	<sentence id="DBMI.pac28.s6" origId="s6" text="(See PRECAUTIONS.)"/>
	<sentencespan id="DBMI.pac28.sp0" origId="sp0" text="The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean  SD theophylline AUC increased 21%  16% (range: -5 to 48%).">
		<entity charOffset="155-167" id="DBMI.pac28.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="354-367" id="DBMI.pac28.sp0.e1" origId="sp0.e1" text="theophylline " type="Active ingredient"/>
		<pair e1="DBMI.pac28.sp0.e0" e2="DBMI.pac28.sp0.e1" id="DBMI.pac28.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="theophylline " precipitant="fluconazole "/>
		<pair e1="DBMI.pac28.sp0.e0" e2="DBMI.pac28.sp0.e1" id="DBMI.pac28.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="theophylline " precipitant="fluconazole "/>
		<pair e1="DBMI.pac28.sp0.e1" e2="DBMI.pac28.sp0.e0" id="DBMI.pac28.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac28.sp1" origId="sp1" text="The Cmax increased 13%  17% (range: -13 to 40%). Theophylline clearance decreased 16%  11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6  1.7 hours to 7.9  1.5 hours."/>
	<sentencespan id="DBMI.pac28.sp2" origId="sp2" text="(See PRECAUTIONS.)"/>
</document>

<document id="DBMI.pac29" origId="pac29">
	<sentence id="DBMI.pac29.s0" origId="s0" text="In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole.">
		<entity charOffset="142-154" id="DBMI.pac29.s0.e0" origId="s0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="237-249" id="DBMI.pac29.s0.e1" origId="s0.e1" text="Tolbutamide " type="Active ingredient"/>
		<entity charOffset="189-201" id="DBMI.pac29.s0.e2" origId="s0.e2" text="tolbutamide " type="Active ingredient"/>
		<pair e1="DBMI.pac29.s0.e0" e2="DBMI.pac29.s0.e1" id="DBMI.pac29.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Tolbutamide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac29.s0.e0" e2="DBMI.pac29.s0.e2" id="DBMI.pac29.s0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tolbutamide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac29.s0.e1" e2="DBMI.pac29.s0.e0" id="DBMI.pac29.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac29.s0.e1" e2="DBMI.pac29.s0.e2" id="DBMI.pac29.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac29.s0.e2" e2="DBMI.pac29.s0.e0" id="DBMI.pac29.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac29.s0.e2" e2="DBMI.pac29.s0.e1" id="DBMI.pac29.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac29.s1" origId="s1" text="There was a mean  SD increase in tolbutamide AUC of 26%  9% (range: 12 to 39%)."/>
	<sentence id="DBMI.pac29.s2" origId="s2" text="Tolbutamide Cmax increased 11%  9% (range: -6 to 27%)."/>
	<sentence id="DBMI.pac29.s3" origId="s3" text="(See PRECAUTIONS.)"/>
	<sentencespan id="DBMI.pac29.sp0" origId="sp0" text="In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole. There was a mean  SD increase in tolbutamide AUC of 26%  9% (range: 12 to 39%). Tolbutamide Cmax increased 11%  9% (range: -6 to 27%).">
		<entity charOffset="142-154" id="DBMI.pac29.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="237-249" id="DBMI.pac29.sp0.e1" origId="sp0.e1" text="Tolbutamide " type="Active ingredient"/>
		<entity charOffset="189-201" id="DBMI.pac29.sp0.e2" origId="sp0.e2" text="tolbutamide " type="Active ingredient"/>
		<pair e1="DBMI.pac29.sp0.e0" e2="DBMI.pac29.sp0.e1" id="DBMI.pac29.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Tolbutamide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac29.sp0.e0" e2="DBMI.pac29.sp0.e2" id="DBMI.pac29.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tolbutamide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac29.sp0.e1" e2="DBMI.pac29.sp0.e0" id="DBMI.pac29.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac29.sp0.e1" e2="DBMI.pac29.sp0.e2" id="DBMI.pac29.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac29.sp0.e2" e2="DBMI.pac29.sp0.e0" id="DBMI.pac29.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac29.sp0.e2" e2="DBMI.pac29.sp0.e1" id="DBMI.pac29.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac29.sp1" origId="sp1" text="(See PRECAUTIONS.)"/>
</document>

<document id="DBMI.pac30" origId="pac30">
	<sentence id="DBMI.pac30.s0" origId="s0" text="The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers.">
		<entity charOffset="112-124" id="DBMI.pac30.s0.e0" origId="s0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="20-30" id="DBMI.pac30.s0.e1" origId="s0.e1" text="glipizide " type="Active ingredient"/>
		<pair e1="DBMI.pac30.s0.e0" e2="DBMI.pac30.s0.e1" id="DBMI.pac30.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="glipizide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac30.s0.e1" e2="DBMI.pac30.s0.e0" id="DBMI.pac30.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac30.s1" origId="s1" text="There was a mean  SD increase in AUC of 49%  13% (range: 27 to 73%) and an increase in Cmax of 19%  23% (range: -11 to 79%)."/>
	<sentence id="DBMI.pac30.s2" origId="s2" text="(See PRECAUTIONS.)"/>
	<sentencespan id="DBMI.pac30.sp0" origId="sp0" text="The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers. There was a mean  SD increase in AUC of 49%  13% (range: 27 to 73%) and an increase in Cmax of 19%  23% (range: -11 to 79%). (See PRECAUTIONS.)">
		<entity charOffset="112-124" id="DBMI.pac30.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="20-30" id="DBMI.pac30.sp0.e1" origId="sp0.e1" text="glipizide " type="Active ingredient"/>
		<pair e1="DBMI.pac30.sp0.e0" e2="DBMI.pac30.sp0.e1" id="DBMI.pac30.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="glipizide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac30.sp0.e1" e2="DBMI.pac30.sp0.e0" id="DBMI.pac30.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac31" origId="pac31">
	<sentence id="DBMI.pac31.s0" origId="s0" text="The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers.">
		<entity charOffset="110-122" id="DBMI.pac31.s0.e0" origId="s0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="20-30" id="DBMI.pac31.s0.e1" origId="s0.e1" text="glyburide " type="Active ingredient"/>
		<pair e1="DBMI.pac31.s0.e0" e2="DBMI.pac31.s0.e1" id="DBMI.pac31.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="glyburide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac31.s0.e1" e2="DBMI.pac31.s0.e0" id="DBMI.pac31.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac31.s1" origId="s1" text="There was a mean  SD increase in AUC of 44%  29% (range: -13 to 115%) and Cmax increased 19%  19% (range: -23 to 62%)."/>
	<sentence id="DBMI.pac31.s2" origId="s2" text="Five subjects required oral glucose following the ingestion of glyburide after 7 days of fluconazole administration."/>
	<sentence id="DBMI.pac31.s3" origId="s3" text="(See PRECAUTIONS.)"/>
	<sentencespan id="DBMI.pac31.sp0" origId="sp0" text="The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers. There was a mean  SD increase in AUC of 44%  29% (range: -13 to 115%) and Cmax increased 19%  19% (range: -23 to 62%). Five subjects required oral glucose following the ingestion of glyburide after 7 days of fluconazole administration.">
		<entity charOffset="110-122" id="DBMI.pac31.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="20-30" id="DBMI.pac31.sp0.e1" origId="sp0.e1" text="glyburide " type="Active ingredient"/>
		<pair e1="DBMI.pac31.sp0.e0" e2="DBMI.pac31.sp0.e1" id="DBMI.pac31.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="glyburide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac31.sp0.e1" e2="DBMI.pac31.sp0.e0" id="DBMI.pac31.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac31.sp1" origId="sp1" text="(See PRECAUTIONS.)"/>
</document>

<document id="DBMI.pac32" origId="pac32">
	<sentence id="DBMI.pac32.s0" origId="s0" text="The effect of fluconazole on the pharmacokinetics and pharmacodynamics of midazolam was examined in a randomized, cross-over study in 12 volunteers."/>
	<sentence id="DBMI.pac32.s1" origId="s1" text="In the study, subjects ingested placebo or 400 mg fluconazole on Day 1 followed by 200 mg daily from Day 2 to Day 6."/>
	<sentence id="DBMI.pac32.s2" origId="s2" text="In addition, a 7.5 mg dose of midazolam was orally ingested on the first day, 0.05 mg/kg was administered intravenously on the fourth day, and 7.5 mg orally on the sixth day."/>
	<sentence id="DBMI.pac32.s3" origId="s3" text="Fluconazole reduced the clearance of IV midazolam by 51%.">
		<entity charOffset="441-453" id="DBMI.pac32.s3.e0" origId="s3.e0" text="Fluconazole " type="Active ingredient"/>
		<entity charOffset="481-491" id="DBMI.pac32.s3.e1" origId="s3.e1" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac32.s3.e0" e2="DBMI.pac32.s3.e1" id="DBMI.pac32.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="Fluconazole "/>
		<pair e1="DBMI.pac32.s3.e1" e2="DBMI.pac32.s3.e0" id="DBMI.pac32.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac32.s4" origId="s4" text="On the first day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 150%, respectively.">
		<entity charOffset="527-539" id="DBMI.pac32.s4.e0" origId="s4.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="553-563" id="DBMI.pac32.s4.e1" origId="s4.e1" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac32.s4.e0" e2="DBMI.pac32.s4.e1" id="DBMI.pac32.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="fluconazole "/>
		<pair e1="DBMI.pac32.s4.e1" e2="DBMI.pac32.s4.e0" id="DBMI.pac32.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac32.s5" origId="s5" text="On the sixth day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 74%, respectively.">
		<entity charOffset="636-648" id="DBMI.pac32.s5.e0" origId="s5.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="662-672" id="DBMI.pac32.s5.e1" origId="s5.e1" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac32.s5.e0" e2="DBMI.pac32.s5.e1" id="DBMI.pac32.s5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="fluconazole "/>
		<pair e1="DBMI.pac32.s5.e1" e2="DBMI.pac32.s5.e0" id="DBMI.pac32.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac32.s6" origId="s6" text="The psychomotor effects of midazolam were significantly increased after oral administration of midazolam but not significantly affected following intravenous midazolam."/>
	<sentencespan id="DBMI.pac32.sp0" origId="sp0" text="The effect of fluconazole on the pharmacokinetics and pharmacodynamics of midazolam was examined in a randomized, cross-over study in 12 volunteers. In the study, subjects ingested placebo or 400 mg fluconazole on Day 1 followed by 200 mg daily from Day 2 to Day 6. In addition, a 7.5 mg dose of midazolam was orally ingested on the first day, 0.05 mg/kg was administered intravenously on the fourth day, and 7.5 mg orally on the sixth day.">
		<entity charOffset="441-453" id="DBMI.pac32.sp0.e0" origId="sp0.e0" text="Fluconazole " type="Active ingredient"/>
		<entity charOffset="481-491" id="DBMI.pac32.sp0.e1" origId="sp0.e1" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac32.sp0.e0" e2="DBMI.pac32.sp0.e1" id="DBMI.pac32.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="Fluconazole "/>
		<pair e1="DBMI.pac32.sp0.e1" e2="DBMI.pac32.sp0.e0" id="DBMI.pac32.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac32.sp1" origId="sp1" text="Fluconazole reduced the clearance of IV midazolam by 51%. On the first day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 150%, respectively. On the sixth day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 74%, respectively.">
		<entity charOffset="441-453" id="DBMI.pac32.sp1.e0" origId="sp1.e0" text="Fluconazole " type="Active ingredient"/>
		<entity charOffset="481-491" id="DBMI.pac32.sp1.e1" origId="sp1.e1" text="midazolam " type="Active ingredient"/>
		<entity charOffset="527-539" id="DBMI.pac32.sp1.e2" origId="sp1.e2" text="fluconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac32.sp1.e0" e2="DBMI.pac32.sp1.e1" id="DBMI.pac32.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="Fluconazole "/>
		<pair e1="DBMI.pac32.sp1.e0" e2="DBMI.pac32.sp1.e2" id="DBMI.pac32.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac32.sp1.e1" e2="DBMI.pac32.sp1.e0" id="DBMI.pac32.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac32.sp1.e1" e2="DBMI.pac32.sp1.e2" id="DBMI.pac32.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac32.sp1.e2" e2="DBMI.pac32.sp1.e0" id="DBMI.pac32.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac32.sp1.e2" e2="DBMI.pac32.sp1.e1" id="DBMI.pac32.sp1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="fluconazole "/>
		<pair e1="DBMI.pac32.sp1.e2" e2="DBMI.pac32.sp1.e1" id="DBMI.pac32.sp1.p6" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="fluconazole "/>
	</sentencespan>
	<sentencespan id="DBMI.pac32.sp2" origId="sp2" text="The psychomotor effects of midazolam were significantly increased after oral administration of midazolam but not significantly affected following intravenous midazolam."/>
</document>

<document id="DBMI.pac33" origId="pac33">
	<sentence id="DBMI.pac33.s0" origId="s0" text="An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 800 mg oral dose of fluconazole on the pharmacokinetics of a single 1200 mg oral dose of azithromycin as well as the effects of azithromycin on the pharmacokinetics of fluconazole."/>
	<sentence id="DBMI.pac33.s1" origId="s1" text="There was no significant pharmacokinetic interaction between fluconazole and azithromycin.">
		<entity charOffset="350-362" id="DBMI.pac33.s1.e0" origId="s1.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="366-379" id="DBMI.pac33.s1.e1" origId="s1.e1" text="azithromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac33.s1.e0" e2="DBMI.pac33.s1.e1" id="DBMI.pac33.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="azithromycin " precipitant="fluconazole "/>
		<pair e1="DBMI.pac33.s1.e1" e2="DBMI.pac33.s1.e0" id="DBMI.pac33.s1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluconazole " precipitant="azithromycin "/>
	</sentence>
	<sentencespan id="DBMI.pac33.sp0" origId="sp0" text="An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 800 mg oral dose of fluconazole on the pharmacokinetics of a single 1200 mg oral dose of azithromycin as well as the effects of azithromycin on the pharmacokinetics of fluconazole. There was no significant pharmacokinetic interaction between fluconazole and azithromycin.">
		<entity charOffset="350-362" id="DBMI.pac33.sp0.e0" origId="sp0.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="366-379" id="DBMI.pac33.sp0.e1" origId="sp0.e1" text="azithromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac33.sp0.e0" e2="DBMI.pac33.sp0.e1" id="DBMI.pac33.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="azithromycin " precipitant="fluconazole "/>
		<pair e1="DBMI.pac33.sp0.e1" e2="DBMI.pac33.sp0.e0" id="DBMI.pac33.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluconazole " precipitant="azithromycin "/>
	</sentencespan>
</document>

<document id="DBMI.pac35" origId="pac35">
	<sentence id="DBMI.pac35.s0" origId="s0" text="Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.">
		<entity charOffset="20-30" id="DBMI.pac35.s0.e0" origId="s0.e0" text="magnesium " type="Active ingredient"/>
		<entity charOffset="80-95" id="DBMI.pac35.s0.e1" origId="s0.e1" text="nitrofurantoin " type="Active ingredient"/>
		<pair e1="DBMI.pac35.s0.e0" e2="DBMI.pac35.s0.e1" id="DBMI.pac35.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nitrofurantoin " precipitant="magnesium "/>
		<pair e1="DBMI.pac35.s0.e1" e2="DBMI.pac35.s0.e0" id="DBMI.pac35.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac35.s1" origId="s1" text="The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate."/>
	<sentencespan id="DBMI.pac35.sp0" origId="sp0" text="Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.">
		<entity charOffset="20-30" id="DBMI.pac35.sp0.e0" origId="sp0.e0" text="magnesium " type="Active ingredient"/>
		<entity charOffset="80-95" id="DBMI.pac35.sp0.e1" origId="sp0.e1" text="nitrofurantoin " type="Active ingredient"/>
		<pair e1="DBMI.pac35.sp0.e0" e2="DBMI.pac35.sp0.e1" id="DBMI.pac35.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nitrofurantoin " precipitant="magnesium "/>
		<pair e1="DBMI.pac35.sp0.e1" e2="DBMI.pac35.sp0.e0" id="DBMI.pac35.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac36" origId="pac36">
	<sentence id="DBMI.pac36.s0" origId="s0" text="Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.">
		<entity charOffset="26-37" id="DBMI.pac36.s0.e0" origId="s0.e0" text="probenecid " type="Active ingredient"/>
		<entity charOffset="138-153" id="DBMI.pac36.s0.e1" origId="s0.e1" text="nitrofurantoin " type="Active ingredient"/>
		<entity charOffset="41-56" id="DBMI.pac36.s0.e2" origId="s0.e2" text="sulfinpyrazone " type="Active ingredient"/>
		<pair e1="DBMI.pac36.s0.e0" e2="DBMI.pac36.s0.e1" id="DBMI.pac36.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nitrofurantoin " precipitant="probenecid "/>
		<pair e1="DBMI.pac36.s0.e0" e2="DBMI.pac36.s0.e2" id="DBMI.pac36.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac36.s0.e1" e2="DBMI.pac36.s0.e0" id="DBMI.pac36.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac36.s0.e1" e2="DBMI.pac36.s0.e2" id="DBMI.pac36.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac36.s0.e2" e2="DBMI.pac36.s0.e0" id="DBMI.pac36.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac36.s0.e2" e2="DBMI.pac36.s0.e1" id="DBMI.pac36.s0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nitrofurantoin " precipitant="sulfinpyrazone "/>
	</sentence>
	<sentence id="DBMI.pac36.s1" origId="s1" text="The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial."/>
	<sentencespan id="DBMI.pac36.sp0" origId="sp0" text="Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.">
		<entity charOffset="26-37" id="DBMI.pac36.sp0.e0" origId="sp0.e0" text="probenecid " type="Active ingredient"/>
		<entity charOffset="138-153" id="DBMI.pac36.sp0.e1" origId="sp0.e1" text="nitrofurantoin " type="Active ingredient"/>
		<entity charOffset="41-56" id="DBMI.pac36.sp0.e2" origId="sp0.e2" text="sulfinpyrazone " type="Active ingredient"/>
		<pair e1="DBMI.pac36.sp0.e0" e2="DBMI.pac36.sp0.e1" id="DBMI.pac36.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nitrofurantoin " precipitant="probenecid "/>
		<pair e1="DBMI.pac36.sp0.e0" e2="DBMI.pac36.sp0.e2" id="DBMI.pac36.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac36.sp0.e1" e2="DBMI.pac36.sp0.e0" id="DBMI.pac36.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac36.sp0.e1" e2="DBMI.pac36.sp0.e2" id="DBMI.pac36.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac36.sp0.e2" e2="DBMI.pac36.sp0.e0" id="DBMI.pac36.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac36.sp0.e2" e2="DBMI.pac36.sp0.e1" id="DBMI.pac36.sp0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nitrofurantoin " precipitant="sulfinpyrazone "/>
	</sentencespan>
</document>

<document id="DBMI.pac38" origId="pac38">
	<sentence id="DBMI.pac38.s0" origId="s0" text="The effect of fluvoxamine (25 mg b.i.d.for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia."/>
	<sentence id="DBMI.pac38.s1" origId="s1" text="Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.">
		<entity charOffset="296-308" id="DBMI.pac38.s1.e0" origId="s1.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="172-185" id="DBMI.pac38.s1.e1" origId="s1.e1" text="thioridazine " type="Active ingredient"/>
		<entity charOffset="217-230" id="DBMI.pac38.s1.e2" origId="s1.e2" text="mesoridazine " type="Metabolite"/>
		<entity charOffset="234-248" id="DBMI.pac38.s1.e3" origId="s1.e3" text="sulforidazine " type="Metabolite"/>
		<pair e1="DBMI.pac38.s1.e0" e2="DBMI.pac38.s1.e1" id="DBMI.pac38.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="thioridazine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac38.s1.e0" e2="DBMI.pac38.s1.e2" id="DBMI.pac38.s1.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mesoridazine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac38.s1.e0" e2="DBMI.pac38.s1.e3" id="DBMI.pac38.s1.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sulforidazine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac38.s1.e1" e2="DBMI.pac38.s1.e0" id="DBMI.pac38.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.s1.e1" e2="DBMI.pac38.s1.e2" id="DBMI.pac38.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.s1.e1" e2="DBMI.pac38.s1.e3" id="DBMI.pac38.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.s1.e2" e2="DBMI.pac38.s1.e0" id="DBMI.pac38.s1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.s1.e2" e2="DBMI.pac38.s1.e1" id="DBMI.pac38.s1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.s1.e2" e2="DBMI.pac38.s1.e3" id="DBMI.pac38.s1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.s1.e3" e2="DBMI.pac38.s1.e0" id="DBMI.pac38.s1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.s1.e3" e2="DBMI.pac38.s1.e1" id="DBMI.pac38.s1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.s1.e3" e2="DBMI.pac38.s1.e2" id="DBMI.pac38.s1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac38.s2" origId="s2" text="Fluvoxamine and thioridazine should not be coadministered."/>
	<sentencespan id="DBMI.pac38.sp0" origId="sp0" text="The effect of fluvoxamine (25 mg b.i.d.for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered.">
		<entity charOffset="296-308" id="DBMI.pac38.sp0.e0" origId="sp0.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="172-185" id="DBMI.pac38.sp0.e1" origId="sp0.e1" text="thioridazine " type="Active ingredient"/>
		<entity charOffset="217-230" id="DBMI.pac38.sp0.e2" origId="sp0.e2" text="mesoridazine " type="Metabolite"/>
		<entity charOffset="234-248" id="DBMI.pac38.sp0.e3" origId="sp0.e3" text="sulforidazine " type="Metabolite"/>
		<pair e1="DBMI.pac38.sp0.e0" e2="DBMI.pac38.sp0.e1" id="DBMI.pac38.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="thioridazine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac38.sp0.e0" e2="DBMI.pac38.sp0.e2" id="DBMI.pac38.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mesoridazine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac38.sp0.e0" e2="DBMI.pac38.sp0.e3" id="DBMI.pac38.sp0.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sulforidazine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac38.sp0.e1" e2="DBMI.pac38.sp0.e0" id="DBMI.pac38.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.sp0.e1" e2="DBMI.pac38.sp0.e2" id="DBMI.pac38.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.sp0.e1" e2="DBMI.pac38.sp0.e3" id="DBMI.pac38.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.sp0.e2" e2="DBMI.pac38.sp0.e0" id="DBMI.pac38.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.sp0.e2" e2="DBMI.pac38.sp0.e1" id="DBMI.pac38.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.sp0.e2" e2="DBMI.pac38.sp0.e3" id="DBMI.pac38.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.sp0.e3" e2="DBMI.pac38.sp0.e0" id="DBMI.pac38.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.sp0.e3" e2="DBMI.pac38.sp0.e1" id="DBMI.pac38.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac38.sp0.e3" e2="DBMI.pac38.sp0.e2" id="DBMI.pac38.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac40" origId="pac40">
	<sentence id="DBMI.pac40.s0" origId="s0" text="A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported."/>
	<sentence id="DBMI.pac40.s1" origId="s1" text="Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known."/>
	<sentence id="DBMI.pac40.s2" origId="s2" text="The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers."/>
	<sentence id="DBMI.pac40.s3" origId="s3" text="All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for 7 days."/>
	<sentence id="DBMI.pac40.s4" origId="s4" text="The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).">
		<entity charOffset="586-598" id="DBMI.pac40.s4.e0" origId="s4.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="566-576" id="DBMI.pac40.s4.e1" origId="s4.e1" text="glipizide " type="Active ingredient"/>
		<pair e1="DBMI.pac40.s4.e0" e2="DBMI.pac40.s4.e1" id="DBMI.pac40.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="glipizide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac40.s4.e1" e2="DBMI.pac40.s4.e0" id="DBMI.pac40.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac40.sp0" origId="sp0" text="A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers."/>
	<sentencespan id="DBMI.pac40.sp1" origId="sp1" text="All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for 7 days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).">
		<entity charOffset="586-598" id="DBMI.pac40.sp1.e0" origId="sp1.e0" text="fluconazole " type="Active ingredient"/>
		<entity charOffset="566-576" id="DBMI.pac40.sp1.e1" origId="sp1.e1" text="glipizide " type="Active ingredient"/>
		<pair e1="DBMI.pac40.sp1.e0" e2="DBMI.pac40.sp1.e1" id="DBMI.pac40.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="glipizide " precipitant="fluconazole "/>
		<pair e1="DBMI.pac40.sp1.e1" e2="DBMI.pac40.sp1.e0" id="DBMI.pac40.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac42" origId="pac42">
	<sentence id="DBMI.pac42.s0" origId="s0" text="In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.">
		<entity charOffset="105-117" id="DBMI.pac42.s0.e0" origId="s0.e0" text="allopurinol " type="Active ingredient"/>
		<entity charOffset="241-256" id="DBMI.pac42.s0.e1" origId="s0.e1" text="mercaptopurine " type="Active ingredient"/>
		<entity charOffset="259-272" id="DBMI.pac42.s0.e2" origId="s0.e2" text="azathioprine " type="Active ingredient"/>
		<pair e1="DBMI.pac42.s0.e0" e2="DBMI.pac42.s0.e1" id="DBMI.pac42.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mercaptopurine " precipitant="allopurinol "/>
		<pair e1="DBMI.pac42.s0.e0" e2="DBMI.pac42.s0.e2" id="DBMI.pac42.s0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="azathioprine " precipitant="allopurinol "/>
		<pair e1="DBMI.pac42.s0.e1" e2="DBMI.pac42.s0.e0" id="DBMI.pac42.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac42.s0.e1" e2="DBMI.pac42.s0.e2" id="DBMI.pac42.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac42.s0.e2" e2="DBMI.pac42.s0.e0" id="DBMI.pac42.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac42.s0.e2" e2="DBMI.pac42.s0.e1" id="DBMI.pac42.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac42.s1" origId="s1" text="Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions)."/>
	<sentencespan id="DBMI.pac42.sp0" origId="sp0" text="In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions).">
		<entity charOffset="105-117" id="DBMI.pac42.sp0.e0" origId="sp0.e0" text="allopurinol " type="Active ingredient"/>
		<entity charOffset="241-256" id="DBMI.pac42.sp0.e1" origId="sp0.e1" text="mercaptopurine " type="Active ingredient"/>
		<entity charOffset="259-272" id="DBMI.pac42.sp0.e2" origId="sp0.e2" text="azathioprine " type="Active ingredient"/>
		<pair e1="DBMI.pac42.sp0.e0" e2="DBMI.pac42.sp0.e1" id="DBMI.pac42.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mercaptopurine " precipitant="allopurinol "/>
		<pair e1="DBMI.pac42.sp0.e0" e2="DBMI.pac42.sp0.e2" id="DBMI.pac42.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="azathioprine " precipitant="allopurinol "/>
		<pair e1="DBMI.pac42.sp0.e1" e2="DBMI.pac42.sp0.e0" id="DBMI.pac42.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac42.sp0.e1" e2="DBMI.pac42.sp0.e2" id="DBMI.pac42.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac42.sp0.e2" e2="DBMI.pac42.sp0.e0" id="DBMI.pac42.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac42.sp0.e2" e2="DBMI.pac42.sp0.e1" id="DBMI.pac42.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac44" origId="pac44">
	<sentence id="DBMI.pac44.s0" origId="s0" text="In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone.">
		<entity charOffset="69-80" id="DBMI.pac44.s0.e0" origId="s0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="213-222" id="DBMI.pac44.s0.e1" origId="s0.e1" text="pimozide " type="Active ingredient"/>
		<pair e1="DBMI.pac44.s0.e0" e2="DBMI.pac44.s0.e1" id="DBMI.pac44.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pimozide " precipitant="paroxetine "/>
		<pair e1="DBMI.pac44.s0.e1" e2="DBMI.pac44.s0.e0" id="DBMI.pac44.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac44.s1" origId="s1" text="The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine."/>
	<sentence id="DBMI.pac44.s2" origId="s2" text="Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and Paroxetine Hydrochloride Controlled-Release Tablets is contraindicated (see CONTRAINDICATIONS)."/>
	<sentencespan id="DBMI.pac44.sp0" origId="sp0" text="In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone. The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and Paroxetine Hydrochloride Controlled-Release Tablets is contraindicated (see CONTRAINDICATIONS).">
		<entity charOffset="69-80" id="DBMI.pac44.sp0.e0" origId="sp0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="213-222" id="DBMI.pac44.sp0.e1" origId="sp0.e1" text="pimozide " type="Active ingredient"/>
		<pair e1="DBMI.pac44.sp0.e0" e2="DBMI.pac44.sp0.e1" id="DBMI.pac44.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pimozide " precipitant="paroxetine "/>
		<pair e1="DBMI.pac44.sp0.e1" e2="DBMI.pac44.sp0.e0" id="DBMI.pac44.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac45" origId="pac45">
	<sentence id="DBMI.pac45.s0" origId="s0" text="Phenobarbital induces many cytochrome P450 (oxidative) enzymes."/>
	<sentence id="DBMI.pac45.s1" origId="s1" text="When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone.">
		<entity charOffset="147-161" id="DBMI.pac45.s1.e0" origId="s1.e0" text="phenobarbital " type="Active ingredient"/>
		<entity charOffset="115-126" id="DBMI.pac45.s1.e1" origId="s1.e1" text="paroxetine " type="Active ingredient"/>
		<pair e1="DBMI.pac45.s1.e0" e2="DBMI.pac45.s1.e1" id="DBMI.pac45.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="paroxetine " precipitant="phenobarbital "/>
		<pair e1="DBMI.pac45.s1.e1" e2="DBMI.pac45.s1.e0" id="DBMI.pac45.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac45.s2" origId="s2" text="The effect of paroxetine on phenobarbital pharmacokinetics was not studied."/>
	<sentence id="DBMI.pac45.s3" origId="s3" text="Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed."/>
	<sentence id="DBMI.pac45.s4" origId="s4" text="No initial dosage adjustment with Paroxetine Hydrochloride Controlled-Release Tablets is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect."/>
	<sentencespan id="DBMI.pac45.sp0" origId="sp0" text="Phenobarbital induces many cytochrome P450 (oxidative) enzymes. When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied.">
		<entity charOffset="147-161" id="DBMI.pac45.sp0.e0" origId="sp0.e0" text="phenobarbital " type="Active ingredient"/>
		<entity charOffset="115-126" id="DBMI.pac45.sp0.e1" origId="sp0.e1" text="paroxetine " type="Active ingredient"/>
		<pair e1="DBMI.pac45.sp0.e0" e2="DBMI.pac45.sp0.e1" id="DBMI.pac45.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="paroxetine " precipitant="phenobarbital "/>
		<pair e1="DBMI.pac45.sp0.e1" e2="DBMI.pac45.sp0.e0" id="DBMI.pac45.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac45.sp1" origId="sp1" text="Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment with Paroxetine Hydrochloride Controlled-Release Tablets is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect."/>
</document>

<document id="DBMI.pac46" origId="pac46">
	<sentence id="DBMI.pac46.s0" origId="s0" text="When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.">
		<entity charOffset="83-93" id="DBMI.pac46.s0.e0" origId="s0.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="51-62" id="DBMI.pac46.s0.e1" origId="s0.e1" text="paroxetine " type="Active ingredient"/>
		<pair e1="DBMI.pac46.s0.e0" e2="DBMI.pac46.s0.e1" id="DBMI.pac46.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="paroxetine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac46.s0.e1" e2="DBMI.pac46.s0.e0" id="DBMI.pac46.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac46.s1" origId="s1" text="In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.">
		<entity charOffset="365-376" id="DBMI.pac46.s1.e0" origId="s1.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="335-345" id="DBMI.pac46.s1.e1" origId="s1.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac46.s1.e0" e2="DBMI.pac46.s1.e1" id="DBMI.pac46.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="paroxetine "/>
		<pair e1="DBMI.pac46.s1.e1" e2="DBMI.pac46.s1.e0" id="DBMI.pac46.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac46.s2" origId="s2" text="Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed."/>
	<sentence id="DBMI.pac46.s3" origId="s3" text="No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONSPostmarketing Reports)."/>
	<sentencespan id="DBMI.pac46.sp0" origId="sp0" text="When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone. In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.">
		<entity charOffset="365-376" id="DBMI.pac46.sp0.e0" origId="sp0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="335-345" id="DBMI.pac46.sp0.e1" origId="sp0.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac46.sp0.e0" e2="DBMI.pac46.sp0.e1" id="DBMI.pac46.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="paroxetine "/>
		<pair e1="DBMI.pac46.sp0.e1" e2="DBMI.pac46.sp0.e0" id="DBMI.pac46.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="paroxetine " precipitant="phenytoin "/>
	</sentencespan>
	<sentencespan id="DBMI.pac46.sp1" origId="sp1" text="No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONSPostmarketing Reports)."/>
</document>

<document id="DBMI.pac47" origId="pac47">
	<sentence id="DBMI.pac47.s0" origId="s0" text="Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6."/>
	<sentence id="DBMI.pac47.s1" origId="s1" text="Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme."/>
	<sentence id="DBMI.pac47.s2" origId="s2" text="In most patients (&gt;90%), this CYP2D6 isozyme is saturated early during paroxetine dosing."/>
	<sentence id="DBMI.pac47.s3" origId="s3" text="In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T by an average of approximately 2-, 5-, and 3-fold, respectively.">
		<entity charOffset="445-456" id="DBMI.pac47.s3.e0" origId="s3.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="528-540" id="DBMI.pac47.s3.e1" origId="s3.e1" text="desipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac47.s3.e0" e2="DBMI.pac47.s3.e1" id="DBMI.pac47.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desipramine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.s3.e1" e2="DBMI.pac47.s3.e0" id="DBMI.pac47.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac47.s4" origId="s4" text="Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated."/>
	<sentence id="DBMI.pac47.s5" origId="s5" text="In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.">
		<entity charOffset="752-763" id="DBMI.pac47.s5.e0" origId="s5.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="1024-1036" id="DBMI.pac47.s5.e1" origId="s5.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="907-928" id="DBMI.pac47.s5.e2" origId="s5.e2" text="9-hydroxyrisperidone " type="Metabolite"/>
		<pair e1="DBMI.pac47.s5.e0" e2="DBMI.pac47.s5.e1" id="DBMI.pac47.s5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.s5.e0" e2="DBMI.pac47.s5.e1" id="DBMI.pac47.s5.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.s5.e0" e2="DBMI.pac47.s5.e2" id="DBMI.pac47.s5.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="9-hydroxyrisperidone " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.s5.e1" e2="DBMI.pac47.s5.e0" id="DBMI.pac47.s5.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.s5.e1" e2="DBMI.pac47.s5.e2" id="DBMI.pac47.s5.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.s5.e2" e2="DBMI.pac47.s5.e0" id="DBMI.pac47.s5.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.s5.e2" e2="DBMI.pac47.s5.e1" id="DBMI.pac47.s5.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac47.s6" origId="s6" text="The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state."/>
	<sentence id="DBMI.pac47.s7" origId="s7" text="In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.">
		<entity charOffset="1273-1284" id="DBMI.pac47.s7.e0" origId="s7.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="1464-1476" id="DBMI.pac47.s7.e1" origId="s7.e1" text="atomoxetine " type="Active ingredient"/>
		<pair e1="DBMI.pac47.s7.e0" e2="DBMI.pac47.s7.e1" id="DBMI.pac47.s7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.s7.e0" e2="DBMI.pac47.s7.e1" id="DBMI.pac47.s7.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.s7.e1" e2="DBMI.pac47.s7.e0" id="DBMI.pac47.s7.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac47.s8" origId="s8" text="This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone."/>
	<sentence id="DBMI.pac47.s9" origId="s9" text="Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine."/>
	<sentencespan id="DBMI.pac47.sp0" origId="sp0" text="Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme is saturated early during paroxetine dosing."/>
	<sentencespan id="DBMI.pac47.sp1" origId="sp1" text="In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T by an average of approximately 2-, 5-, and 3-fold, respectively. Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.">
		<entity charOffset="445-456" id="DBMI.pac47.sp1.e0" origId="sp1.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="528-540" id="DBMI.pac47.sp1.e1" origId="sp1.e1" text="desipramine " type="Active ingredient"/>
		<entity charOffset="1024-1036" id="DBMI.pac47.sp1.e2" origId="sp1.e2" text="risperidone " type="Active ingredient"/>
		<entity charOffset="907-928" id="DBMI.pac47.sp1.e3" origId="sp1.e3" text="9-hydroxyrisperidone " type="Metabolite"/>
		<pair e1="DBMI.pac47.sp1.e0" e2="DBMI.pac47.sp1.e1" id="DBMI.pac47.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desipramine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.sp1.e0" e2="DBMI.pac47.sp1.e2" id="DBMI.pac47.sp1.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.sp1.e0" e2="DBMI.pac47.sp1.e2" id="DBMI.pac47.sp1.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.sp1.e0" e2="DBMI.pac47.sp1.e3" id="DBMI.pac47.sp1.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="9-hydroxyrisperidone " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.sp1.e1" e2="DBMI.pac47.sp1.e0" id="DBMI.pac47.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.sp1.e1" e2="DBMI.pac47.sp1.e2" id="DBMI.pac47.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.sp1.e1" e2="DBMI.pac47.sp1.e3" id="DBMI.pac47.sp1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.sp1.e2" e2="DBMI.pac47.sp1.e0" id="DBMI.pac47.sp1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.sp1.e2" e2="DBMI.pac47.sp1.e1" id="DBMI.pac47.sp1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.sp1.e2" e2="DBMI.pac47.sp1.e3" id="DBMI.pac47.sp1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.sp1.e3" e2="DBMI.pac47.sp1.e0" id="DBMI.pac47.sp1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.sp1.e3" e2="DBMI.pac47.sp1.e1" id="DBMI.pac47.sp1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac47.sp1.e3" e2="DBMI.pac47.sp1.e2" id="DBMI.pac47.sp1.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac47.sp2" origId="sp2" text="The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.">
		<entity charOffset="1273-1284" id="DBMI.pac47.sp2.e0" origId="sp2.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="1464-1476" id="DBMI.pac47.sp2.e1" origId="sp2.e1" text="atomoxetine " type="Active ingredient"/>
		<pair e1="DBMI.pac47.sp2.e0" e2="DBMI.pac47.sp2.e1" id="DBMI.pac47.sp2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.sp2.e0" e2="DBMI.pac47.sp2.e1" id="DBMI.pac47.sp2.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac47.sp2.e1" e2="DBMI.pac47.sp2.e0" id="DBMI.pac47.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac47.sp3" origId="sp3" text="Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine."/>
</document>

<document id="DBMI.pac48" origId="pac48">
	<sentence id="DBMI.pac48.s0" origId="s0" text="An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for  CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.">
		<entity charOffset="93-104" id="DBMI.pac48.s0.e0" origId="s0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="108-120" id="DBMI.pac48.s0.e1" origId="s0.e1" text="terfenadine " type="Active ingredient"/>
		<pair e1="DBMI.pac48.s0.e0" e2="DBMI.pac48.s0.e1" id="DBMI.pac48.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="terfenadine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac48.s0.e1" e2="DBMI.pac48.s0.e0" id="DBMI.pac48.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac48.s1" origId="s1" text="In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including terfenadine, astemizole, cisapride, triazolam, and cyclosporine."/>
	<sentence id="DBMI.pac48.s2" origId="s2" text="Based on the assumption that the relationship between paroxetines in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetines extent of inhibition of CYP3A4 activity is not likely to be of clinical significance."/>
	<sentencespan id="DBMI.pac48.sp0" origId="sp0" text="An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for  CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics. In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including terfenadine, astemizole, cisapride, triazolam, and cyclosporine. Based on the assumption that the relationship between paroxetines in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetines extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.">
		<entity charOffset="93-104" id="DBMI.pac48.sp0.e0" origId="sp0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="108-120" id="DBMI.pac48.sp0.e1" origId="sp0.e1" text="terfenadine " type="Active ingredient"/>
		<pair e1="DBMI.pac48.sp0.e0" e2="DBMI.pac48.sp0.e1" id="DBMI.pac48.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="terfenadine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac48.sp0.e1" e2="DBMI.pac48.sp0.e0" id="DBMI.pac48.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac49" origId="pac49">
	<sentence id="DBMI.pac49.s0" origId="s0" text="A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.">
		<entity charOffset="133-144" id="DBMI.pac49.s0.e0" origId="s0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="148-156" id="DBMI.pac49.s0.e1" origId="s0.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac49.s0.e0" e2="DBMI.pac49.s0.e1" id="DBMI.pac49.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="paroxetine "/>
		<pair e1="DBMI.pac49.s0.e1" e2="DBMI.pac49.s0.e0" id="DBMI.pac49.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="paroxetine " precipitant="lithium "/>
	</sentence>
	<sentence id="DBMI.pac49.s1" origId="s1" text="However, due to the potential for serotonin syndrome, caution is advised when immediate-release paroxetine hydrochloride is coadministered with lithium."/>
	<sentencespan id="DBMI.pac49.sp0" origId="sp0" text="A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate. However, due to the potential for serotonin syndrome, caution is advised when immediate-release paroxetine hydrochloride is coadministered with lithium.">
		<entity charOffset="133-144" id="DBMI.pac49.sp0.e0" origId="sp0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="148-156" id="DBMI.pac49.sp0.e1" origId="sp0.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac49.sp0.e0" e2="DBMI.pac49.sp0.e1" id="DBMI.pac49.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="paroxetine "/>
		<pair e1="DBMI.pac49.sp0.e1" e2="DBMI.pac49.sp0.e0" id="DBMI.pac49.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="paroxetine " precipitant="lithium "/>
	</sentencespan>
</document>

<document id="DBMI.pac5" origId="pac5">
	<sentence id="DBMI.pac5.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Alcohol\n\nA single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects.">
		<entity charOffset="51-59" id="DBMI.pac5.s0.e0" origId="s0.e0" text="ethanol " type="Active ingredient"/>
		<entity charOffset="126-149" id="DBMI.pac5.s0.e1" origId="s0.e1" text="O-desmethylvenlafaxine " type="Metabolite"/>
		<entity charOffset="111-123" id="DBMI.pac5.s0.e2" origId="s0.e2" text="venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s0.e0" e2="DBMI.pac5.s0.e1" id="DBMI.pac5.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="O-desmethylvenlafaxine " precipitant="ethanol "/>
		<pair e1="DBMI.pac5.s0.e0" e2="DBMI.pac5.s0.e2" id="DBMI.pac5.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="ethanol "/>
		<pair e1="DBMI.pac5.s0.e1" e2="DBMI.pac5.s0.e0" id="DBMI.pac5.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s0.e1" e2="DBMI.pac5.s0.e2" id="DBMI.pac5.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s0.e2" e2="DBMI.pac5.s0.e0" id="DBMI.pac5.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s0.e2" e2="DBMI.pac5.s0.e1" id="DBMI.pac5.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s1" origId="s1" text="Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine."/>
	<sentence id="DBMI.pac5.s2" origId="s2" text="7.2 Cimetidine\n\nConcomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.">
		<entity charOffset="487-498" id="DBMI.pac5.s2.e0" origId="s2.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="502-514" id="DBMI.pac5.s2.e1" origId="s2.e1" text="venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s2.e0" e2="DBMI.pac5.s2.e1" id="DBMI.pac5.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="venlafaxine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac5.s2.e0" e2="DBMI.pac5.s2.e1" id="DBMI.pac5.s2.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="venlafaxine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac5.s2.e1" e2="DBMI.pac5.s2.e0" id="DBMI.pac5.s2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s3" origId="s3" text="The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%."/>
	<sentence id="DBMI.pac5.s4" origId="s4" text="However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.">
		<entity charOffset="826-837" id="DBMI.pac5.s4.e0" origId="s4.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="887-891" id="DBMI.pac5.s4.e1" origId="s4.e1" text="ODV " type="Metabolite"/>
		<pair e1="DBMI.pac5.s4.e0" e2="DBMI.pac5.s4.e1" id="DBMI.pac5.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="cimetidine "/>
		<pair e1="DBMI.pac5.s4.e1" e2="DBMI.pac5.s4.e0" id="DBMI.pac5.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s5" origId="s5" text="The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults."/>
	<sentence id="DBMI.pac5.s6" origId="s6" text="However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced."/>
	<sentence id="DBMI.pac5.s7" origId="s7" text="Therefore, caution is advised with such patients."/>
	<sentence id="DBMI.pac5.s8" origId="s8" text="7.3 Diazepam\n\nUnder steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.">
		<entity charOffset="1556-1565" id="DBMI.pac5.s8.e0" origId="s8.e0" text="diazepam " type="Active ingredient"/>
		<entity charOffset="1493-1505" id="DBMI.pac5.s8.e1" origId="s8.e1" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="1636-1640" id="DBMI.pac5.s8.e2" origId="s8.e2" text="ODV " type="Metabolite"/>
		<pair e1="DBMI.pac5.s8.e0" e2="DBMI.pac5.s8.e1" id="DBMI.pac5.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="diazepam "/>
		<pair e1="DBMI.pac5.s8.e0" e2="DBMI.pac5.s8.e1" id="DBMI.pac5.s8.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="diazepam "/>
		<pair e1="DBMI.pac5.s8.e0" e2="DBMI.pac5.s8.e2" id="DBMI.pac5.s8.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="diazepam "/>
		<pair e1="DBMI.pac5.s8.e1" e2="DBMI.pac5.s8.e0" id="DBMI.pac5.s8.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s8.e1" e2="DBMI.pac5.s8.e2" id="DBMI.pac5.s8.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s8.e2" e2="DBMI.pac5.s8.e0" id="DBMI.pac5.s8.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s8.e2" e2="DBMI.pac5.s8.e1" id="DBMI.pac5.s8.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s9" origId="s9" text="Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.">
		<entity charOffset="1669-1681" id="DBMI.pac5.s9.e0" origId="s9.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="1737-1746" id="DBMI.pac5.s9.e1" origId="s9.e1" text="diazepam " type="Active ingredient"/>
		<entity charOffset="1772-1790" id="DBMI.pac5.s9.e2" origId="s9.e2" text="desmethyldiazepam " type="Metabolite"/>
		<pair e1="DBMI.pac5.s9.e0" e2="DBMI.pac5.s9.e1" id="DBMI.pac5.s9.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s9.e0" e2="DBMI.pac5.s9.e2" id="DBMI.pac5.s9.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="desmethyldiazepam " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s9.e1" e2="DBMI.pac5.s9.e0" id="DBMI.pac5.s9.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s9.e1" e2="DBMI.pac5.s9.e2" id="DBMI.pac5.s9.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s9.e2" e2="DBMI.pac5.s9.e0" id="DBMI.pac5.s9.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s9.e2" e2="DBMI.pac5.s9.e1" id="DBMI.pac5.s9.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s10" origId="s10" text="7.4 Haloperidol\n\nVenlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.">
		<entity charOffset="1881-1893" id="DBMI.pac5.s10.e0" origId="s10.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="2131-2143" id="DBMI.pac5.s10.e1" origId="s10.e1" text="haloperidol " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s10.e0" e2="DBMI.pac5.s10.e1" id="DBMI.pac5.s10.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="haloperidol " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s10.e0" e2="DBMI.pac5.s10.e1" id="DBMI.pac5.s10.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="haloperidol " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s10.e1" e2="DBMI.pac5.s10.e0" id="DBMI.pac5.s10.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s11" origId="s11" text="In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.">
		<entity charOffset="2187-2199" id="DBMI.pac5.s11.e0" origId="s11.e0" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="2131-2143" id="DBMI.pac5.s11.e1" origId="s11.e1" text="haloperidol " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s11.e0" e2="DBMI.pac5.s11.e1" id="DBMI.pac5.s11.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="haloperidol " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s11.e1" e2="DBMI.pac5.s11.e0" id="DBMI.pac5.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s12" origId="s12" text="The mechanism explaining this finding is unknown."/>
	<sentence id="DBMI.pac5.s13" origId="s13" text="7.5 Lithium\n\nThe steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.">
		<entity charOffset="2456-2464" id="DBMI.pac5.s13.e0" origId="s13.e0" text="lithium " type="Active ingredient"/>
		<entity charOffset="2510-2514" id="DBMI.pac5.s13.e1" origId="s13.e1" text="ODV " type="Metabolite"/>
		<entity charOffset="2365-2377" id="DBMI.pac5.s13.e2" origId="s13.e2" text="venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s13.e0" e2="DBMI.pac5.s13.e1" id="DBMI.pac5.s13.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="lithium "/>
		<pair e1="DBMI.pac5.s13.e0" e2="DBMI.pac5.s13.e2" id="DBMI.pac5.s13.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="lithium "/>
		<pair e1="DBMI.pac5.s13.e1" e2="DBMI.pac5.s13.e0" id="DBMI.pac5.s13.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s13.e1" e2="DBMI.pac5.s13.e2" id="DBMI.pac5.s13.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s13.e2" e2="DBMI.pac5.s13.e0" id="DBMI.pac5.s13.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s13.e2" e2="DBMI.pac5.s13.e1" id="DBMI.pac5.s13.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s14" origId="s14" text="ODV also was unaffected."/>
	<sentence id="DBMI.pac5.s15" origId="s15" text="Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).">
		<entity charOffset="2535-2547" id="DBMI.pac5.s15.e0" origId="s15.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="2588-2596" id="DBMI.pac5.s15.e1" origId="s15.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s15.e0" e2="DBMI.pac5.s15.e1" id="DBMI.pac5.s15.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s15.e1" e2="DBMI.pac5.s15.e0" id="DBMI.pac5.s15.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s16" origId="s16" text="7.6 Drugs Highly Bound to Plasma Proteins\n\nVenlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug."/>
	<sentence id="DBMI.pac5.s17" origId="s17" text="7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes\n\nCYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants."/>
	<sentence id="DBMI.pac5.s18" origId="s18" text="Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite."/>
	<sentence id="DBMI.pac5.s19" origId="s19" text="CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)]."/>
	<sentence id="DBMI.pac5.s20" origId="s20" text="Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor."/>
	<sentence id="DBMI.pac5.s21" origId="s21" text="Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d.with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.">
		<entity charOffset="3872-3885" id="DBMI.pac5.s21.e0" origId="s21.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="3921-3933" id="DBMI.pac5.s21.e1" origId="s21.e1" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="4091-4114" id="DBMI.pac5.s21.e2" origId="s21.e2" text="O-desmethylvenlafaxine " type="Metabolite"/>
		<entity charOffset="4454-4458" id="DBMI.pac5.s21.e3" origId="s21.e3" text="ODV " type="Metabolite"/>
		<entity charOffset="4335-4347" id="DBMI.pac5.s21.e4" origId="s21.e4" text="Venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s21.e0" e2="DBMI.pac5.s21.e1" id="DBMI.pac5.s21.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="venlafaxine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.s21.e0" e2="DBMI.pac5.s21.e2" id="DBMI.pac5.s21.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="O-desmethylvenlafaxine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.s21.e0" e2="DBMI.pac5.s21.e3" id="DBMI.pac5.s21.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="ODV " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.s21.e0" e2="DBMI.pac5.s21.e3" id="DBMI.pac5.s21.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="ODV " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.s21.e0" e2="DBMI.pac5.s21.e4" id="DBMI.pac5.s21.p4" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Venlafaxine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.s21.e0" e2="DBMI.pac5.s21.e4" id="DBMI.pac5.s21.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Venlafaxine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.s21.e1" e2="DBMI.pac5.s21.e0" id="DBMI.pac5.s21.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e1" e2="DBMI.pac5.s21.e2" id="DBMI.pac5.s21.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e1" e2="DBMI.pac5.s21.e3" id="DBMI.pac5.s21.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e1" e2="DBMI.pac5.s21.e4" id="DBMI.pac5.s21.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e2" e2="DBMI.pac5.s21.e0" id="DBMI.pac5.s21.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e2" e2="DBMI.pac5.s21.e1" id="DBMI.pac5.s21.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e2" e2="DBMI.pac5.s21.e3" id="DBMI.pac5.s21.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e2" e2="DBMI.pac5.s21.e4" id="DBMI.pac5.s21.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e3" e2="DBMI.pac5.s21.e0" id="DBMI.pac5.s21.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e3" e2="DBMI.pac5.s21.e1" id="DBMI.pac5.s21.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e3" e2="DBMI.pac5.s21.e2" id="DBMI.pac5.s21.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e3" e2="DBMI.pac5.s21.e4" id="DBMI.pac5.s21.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e4" e2="DBMI.pac5.s21.e0" id="DBMI.pac5.s21.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e4" e2="DBMI.pac5.s21.e1" id="DBMI.pac5.s21.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e4" e2="DBMI.pac5.s21.e2" id="DBMI.pac5.s21.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s21.e4" e2="DBMI.pac5.s21.e3" id="DBMI.pac5.s21.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s22" origId="s22" text="Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects."/>
	<sentence id="DBMI.pac5.s23" origId="s23" text="Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively."/>
	<sentence id="DBMI.pac5.s24" origId="s24" text="Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively."/>
	<sentence id="DBMI.pac5.s25" origId="s25" text="Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%)."/>
	<sentence id="DBMI.pac5.s26" origId="s26" text="Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV."/>
	<sentence id="DBMI.pac5.s27" origId="s27" text="Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly."/>
	<sentence id="DBMI.pac5.s28" origId="s28" text="7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes\n\nCYP2D6\n\nIn vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6."/>
	<sentence id="DBMI.pac5.s29" origId="s29" text="These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan."/>
	<sentence id="DBMI.pac5.s30" origId="s30" text="Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.">
		<entity charOffset="5256-5268" id="DBMI.pac5.s30.e0" origId="s30.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="5322-5338" id="DBMI.pac5.s30.e1" origId="s30.e1" text="2-OH-imipramine " type="Metabolite"/>
		<entity charOffset="5307-5318" id="DBMI.pac5.s30.e2" origId="s30.e2" text="imipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s30.e0" e2="DBMI.pac5.s30.e1" id="DBMI.pac5.s30.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="2-OH-imipramine " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s30.e0" e2="DBMI.pac5.s30.e2" id="DBMI.pac5.s30.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="imipramine " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s30.e1" e2="DBMI.pac5.s30.e0" id="DBMI.pac5.s30.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s30.e1" e2="DBMI.pac5.s30.e2" id="DBMI.pac5.s30.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s30.e2" e2="DBMI.pac5.s30.e0" id="DBMI.pac5.s30.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s30.e2" e2="DBMI.pac5.s30.e1" id="DBMI.pac5.s30.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s31" origId="s31" text="However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine."/>
	<sentence id="DBMI.pac5.s32" origId="s32" text="The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).">
		<entity charOffset="5422-5434" id="DBMI.pac5.s32.e0" origId="s32.e0" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="5348-5360" id="DBMI.pac5.s32.e1" origId="s32.e1" text="desipramine " type="Active ingredient"/>
		<entity charOffset="5439-5456" id="DBMI.pac5.s32.e2" origId="s32.e2" text="2-OH-desipramine " type="Metabolite"/>
		<pair e1="DBMI.pac5.s32.e0" e2="DBMI.pac5.s32.e1" id="DBMI.pac5.s32.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desipramine " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s32.e0" e2="DBMI.pac5.s32.e2" id="DBMI.pac5.s32.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="2-OH-desipramine " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s32.e1" e2="DBMI.pac5.s32.e0" id="DBMI.pac5.s32.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s32.e1" e2="DBMI.pac5.s32.e2" id="DBMI.pac5.s32.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s32.e2" e2="DBMI.pac5.s32.e0" id="DBMI.pac5.s32.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s32.e2" e2="DBMI.pac5.s32.e1" id="DBMI.pac5.s32.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s33" origId="s33" text="Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.">
		<entity charOffset="5572-5583" id="DBMI.pac5.s33.e0" origId="s33.e0" text="Imipramine " type="Active ingredient"/>
		<entity charOffset="5638-5642" id="DBMI.pac5.s33.e1" origId="s33.e1" text="ODV " type="Metabolite"/>
		<entity charOffset="5622-5634" id="DBMI.pac5.s33.e2" origId="s33.e2" text="venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s33.e0" e2="DBMI.pac5.s33.e1" id="DBMI.pac5.s33.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="Imipramine "/>
		<pair e1="DBMI.pac5.s33.e0" e2="DBMI.pac5.s33.e2" id="DBMI.pac5.s33.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="Imipramine "/>
		<pair e1="DBMI.pac5.s33.e1" e2="DBMI.pac5.s33.e0" id="DBMI.pac5.s33.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s33.e1" e2="DBMI.pac5.s33.e2" id="DBMI.pac5.s33.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s33.e2" e2="DBMI.pac5.s33.e0" id="DBMI.pac5.s33.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s33.e2" e2="DBMI.pac5.s33.e1" id="DBMI.pac5.s33.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s34" origId="s34" text="The clinical significance of elevated 2-OH-desipramine levels is unknown."/>
	<sentence id="DBMI.pac5.s35" origId="s35" text="Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.">
		<entity charOffset="5761-5773" id="DBMI.pac5.s35.e0" origId="s35.e0" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="6097-6117" id="DBMI.pac5.s35.e1" origId="s35.e1" text="?-hydroxymetoprolol " type="Metabolite"/>
		<entity charOffset="5990-6001" id="DBMI.pac5.s35.e2" origId="s35.e2" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s35.e0" e2="DBMI.pac5.s35.e1" id="DBMI.pac5.s35.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="?-hydroxymetoprolol " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s35.e0" e2="DBMI.pac5.s35.e2" id="DBMI.pac5.s35.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s35.e1" e2="DBMI.pac5.s35.e0" id="DBMI.pac5.s35.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s35.e1" e2="DBMI.pac5.s35.e2" id="DBMI.pac5.s35.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s35.e2" e2="DBMI.pac5.s35.e0" id="DBMI.pac5.s35.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s35.e2" e2="DBMI.pac5.s35.e1" id="DBMI.pac5.s35.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s36" origId="s36" text="Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.">
		<entity charOffset="6118-6129" id="DBMI.pac5.s36.e0" origId="s36.e0" text="Metoprolol " type="Active ingredient"/>
		<entity charOffset="6174-6186" id="DBMI.pac5.s36.e1" origId="s36.e1" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="6212-6235" id="DBMI.pac5.s36.e2" origId="s36.e2" text="O-desmethylvenlafaxine " type="Metabolite"/>
		<pair e1="DBMI.pac5.s36.e0" e2="DBMI.pac5.s36.e1" id="DBMI.pac5.s36.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="Metoprolol "/>
		<pair e1="DBMI.pac5.s36.e0" e2="DBMI.pac5.s36.e2" id="DBMI.pac5.s36.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="O-desmethylvenlafaxine " precipitant="Metoprolol "/>
		<pair e1="DBMI.pac5.s36.e1" e2="DBMI.pac5.s36.e0" id="DBMI.pac5.s36.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s36.e1" e2="DBMI.pac5.s36.e2" id="DBMI.pac5.s36.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s36.e2" e2="DBMI.pac5.s36.e0" id="DBMI.pac5.s36.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s36.e2" e2="DBMI.pac5.s36.e1" id="DBMI.pac5.s36.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s37" origId="s37" text="Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study."/>
	<sentence id="DBMI.pac5.s38" origId="s38" text="The clinical relevance of this finding for hypertensive patients is unknown."/>
	<sentence id="DBMI.pac5.s39" origId="s39" text="Caution should be exercised with co-administration of venlafaxine and metoprolol."/>
	<sentence id="DBMI.pac5.s40" origId="s40" text="Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients."/>
	<sentence id="DBMI.pac5.s41" origId="s41" text="It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)]."/>
	<sentence id="DBMI.pac5.s42" origId="s42" text="Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.">
		<entity charOffset="6788-6800" id="DBMI.pac5.s42.e0" origId="s42.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="7056-7068" id="DBMI.pac5.s42.e1" origId="s42.e1" text="risperidone " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s42.e0" e2="DBMI.pac5.s42.e1" id="DBMI.pac5.s42.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s42.e1" e2="DBMI.pac5.s42.e0" id="DBMI.pac5.s42.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s43" origId="s43" text="However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).">
		<entity charOffset="7082-7094" id="DBMI.pac5.s43.e0" origId="s43.e0" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="7195-7207" id="DBMI.pac5.s43.e1" origId="s43.e1" text="risperidone " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s43.e0" e2="DBMI.pac5.s43.e1" id="DBMI.pac5.s43.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="risperidone " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s43.e1" e2="DBMI.pac5.s43.e0" id="DBMI.pac5.s43.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s44" origId="s44" text="CYP3A4\n\nVenlafaxine did not inhibit CYP3A4 in vitro."/>
	<sentence id="DBMI.pac5.s45" origId="s45" text="This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.">
		<entity charOffset="7370-7382" id="DBMI.pac5.s45.e0" origId="s45.e0" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="7479-7491" id="DBMI.pac5.s45.e1" origId="s45.e1" text="terfenadine " type="Active ingredient"/>
		<entity charOffset="7465-7474" id="DBMI.pac5.s45.e2" origId="s45.e2" text="diazepam " type="Active ingredient"/>
		<entity charOffset="7453-7464" id="DBMI.pac5.s45.e3" origId="s45.e3" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s45.e0" e2="DBMI.pac5.s45.e1" id="DBMI.pac5.s45.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="terfenadine " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s45.e0" e2="DBMI.pac5.s45.e2" id="DBMI.pac5.s45.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s45.e0" e2="DBMI.pac5.s45.e3" id="DBMI.pac5.s45.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="alprazolam " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s45.e1" e2="DBMI.pac5.s45.e0" id="DBMI.pac5.s45.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s45.e1" e2="DBMI.pac5.s45.e2" id="DBMI.pac5.s45.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s45.e1" e2="DBMI.pac5.s45.e3" id="DBMI.pac5.s45.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s45.e2" e2="DBMI.pac5.s45.e0" id="DBMI.pac5.s45.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s45.e2" e2="DBMI.pac5.s45.e1" id="DBMI.pac5.s45.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s45.e2" e2="DBMI.pac5.s45.e3" id="DBMI.pac5.s45.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s45.e3" e2="DBMI.pac5.s45.e0" id="DBMI.pac5.s45.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s45.e3" e2="DBMI.pac5.s45.e1" id="DBMI.pac5.s45.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s45.e3" e2="DBMI.pac5.s45.e2" id="DBMI.pac5.s45.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s46" origId="s46" text="Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax."/>
	<sentence id="DBMI.pac5.s47" origId="s47" text="Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.">
		<entity charOffset="7728-7738" id="DBMI.pac5.s47.e0" origId="s47.e0" text="Indinavir " type="Active ingredient"/>
		<entity charOffset="7793-7797" id="DBMI.pac5.s47.e1" origId="s47.e1" text="ODV " type="Metabolite"/>
		<entity charOffset="7777-7789" id="DBMI.pac5.s47.e2" origId="s47.e2" text="venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s47.e0" e2="DBMI.pac5.s47.e1" id="DBMI.pac5.s47.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="Indinavir "/>
		<pair e1="DBMI.pac5.s47.e0" e2="DBMI.pac5.s47.e2" id="DBMI.pac5.s47.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="Indinavir "/>
		<pair e1="DBMI.pac5.s47.e1" e2="DBMI.pac5.s47.e0" id="DBMI.pac5.s47.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s47.e1" e2="DBMI.pac5.s47.e2" id="DBMI.pac5.s47.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s47.e2" e2="DBMI.pac5.s47.e0" id="DBMI.pac5.s47.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.s47.e2" e2="DBMI.pac5.s47.e1" id="DBMI.pac5.s47.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s48" origId="s48" text="The clinical significance of this finding is unknown."/>
	<sentence id="DBMI.pac5.s49" origId="s49" text="CYP1A2\n\nVenlafaxine did not inhibit CYP1A2 in vitro.">
		<entity charOffset="7861-7873" id="DBMI.pac5.s49.e0" origId="s49.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="8033-8042" id="DBMI.pac5.s49.e1" origId="s49.e1" text="caffeine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s49.e0" e2="DBMI.pac5.s49.e1" id="DBMI.pac5.s49.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="caffeine " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s49.e1" e2="DBMI.pac5.s49.e0" id="DBMI.pac5.s49.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s50" origId="s50" text="This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate."/>
	<sentence id="DBMI.pac5.s51" origId="s51" text="CYP2C9\n \nVenlafaxine did not inhibit CYP2C9 in vitro.">
		<entity charOffset="8073-8085" id="DBMI.pac5.s51.e0" origId="s51.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="8231-8243" id="DBMI.pac5.s51.e1" origId="s51.e1" text="tolbutamide " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s51.e0" e2="DBMI.pac5.s51.e1" id="DBMI.pac5.s51.p0" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="tolbutamide " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s51.e1" e2="DBMI.pac5.s51.e0" id="DBMI.pac5.s51.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s52" origId="s52" text="In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide."/>
	<sentence id="DBMI.pac5.s53" origId="s53" text="CYP2C19\n\nVenlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).">
		<entity charOffset="8312-8324" id="DBMI.pac5.s53.e0" origId="s53.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="8358-8367" id="DBMI.pac5.s53.e1" origId="s53.e1" text="diazepam " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s53.e0" e2="DBMI.pac5.s53.e1" id="DBMI.pac5.s53.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.s53.e1" e2="DBMI.pac5.s53.e0" id="DBMI.pac5.s53.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac5.s54" origId="s54" text="7.9 Monoamine Oxidase Inhibitors\n\nSee Contraindications (4) and Warnings and Precautions (5.2)."/>
	<sentence id="DBMI.pac5.s55" origId="s55" text="7.10 Other CNS-Active Drugs\n\nThe risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above)."/>
	<sentence id="DBMI.pac5.s56" origId="s56" text="Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required."/>
	<sentence id="DBMI.pac5.s57" origId="s57" text="Serotonergic Drugs\n\nBased on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)]."/>
	<sentence id="DBMI.pac5.s58" origId="s58" text="If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)]."/>
	<sentence id="DBMI.pac5.s59" origId="s59" text="The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)]."/>
	<sentence id="DBMI.pac5.s60" origId="s60" text="Triptans\n\nThere have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan."/>
	<sentence id="DBMI.pac5.s61" origId="s61" text="If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)]."/>
	<sentence id="DBMI.pac5.s62" origId="s62" text="7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)\n\nSerotonin release by platelets plays an important role in hemostasis."/>
	<sentence id="DBMI.pac5.s63" origId="s63" text="Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding."/>
	<sentence id="DBMI.pac5.s64" origId="s64" text="These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding."/>
	<sentence id="DBMI.pac5.s65" origId="s65" text="Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin."/>
	<sentence id="DBMI.pac5.s66" origId="s66" text="Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued."/>
	<sentence id="DBMI.pac5.s67" origId="s67" text="[See Warnings and Precautions (5.14)]\n\n7.12 Electroconvulsive Therapy\n\nThere are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment."/>
	<sentence id="DBMI.pac5.s68" origId="s68" text="7.13 Postmarketing Spontaneous Drug Interaction Reports\n\nThere have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine."/>
	<sentence id="DBMI.pac5.s69" origId="s69" text="There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.">
		<entity charOffset="11366-11378" id="DBMI.pac5.s69.e0" origId="s69.e0" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="11247-11257" id="DBMI.pac5.s69.e1" origId="s69.e1" text="clozapine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.s69.e0" e2="DBMI.pac5.s69.e1" id="DBMI.pac5.s69.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="clozapine " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.s69.e1" e2="DBMI.pac5.s69.e0" id="DBMI.pac5.s69.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac5.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Alcohol\n\nA single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects. Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine. 7.2 Cimetidine\n\nConcomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.">
		<entity charOffset="487-498" id="DBMI.pac5.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="502-514" id="DBMI.pac5.sp0.e1" origId="sp0.e1" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="51-59" id="DBMI.pac5.sp0.e2" origId="sp0.e2" text="ethanol " type="Active ingredient"/>
		<entity charOffset="126-149" id="DBMI.pac5.sp0.e3" origId="sp0.e3" text="O-desmethylvenlafaxine " type="Metabolite"/>
		<pair e1="DBMI.pac5.sp0.e0" e2="DBMI.pac5.sp0.e1" id="DBMI.pac5.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="venlafaxine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac5.sp0.e0" e2="DBMI.pac5.sp0.e1" id="DBMI.pac5.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="venlafaxine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac5.sp0.e0" e2="DBMI.pac5.sp0.e2" id="DBMI.pac5.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp0.e0" e2="DBMI.pac5.sp0.e3" id="DBMI.pac5.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp0.e1" e2="DBMI.pac5.sp0.e0" id="DBMI.pac5.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp0.e1" e2="DBMI.pac5.sp0.e2" id="DBMI.pac5.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp0.e1" e2="DBMI.pac5.sp0.e3" id="DBMI.pac5.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp0.e2" e2="DBMI.pac5.sp0.e0" id="DBMI.pac5.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp0.e2" e2="DBMI.pac5.sp0.e1" id="DBMI.pac5.sp0.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="ethanol "/>
		<pair e1="DBMI.pac5.sp0.e2" e2="DBMI.pac5.sp0.e3" id="DBMI.pac5.sp0.p9" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="O-desmethylvenlafaxine " precipitant="ethanol "/>
		<pair e1="DBMI.pac5.sp0.e3" e2="DBMI.pac5.sp0.e0" id="DBMI.pac5.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp0.e3" e2="DBMI.pac5.sp0.e1" id="DBMI.pac5.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp0.e3" e2="DBMI.pac5.sp0.e2" id="DBMI.pac5.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp1" origId="sp1" text="The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%. However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine. The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults.">
		<entity charOffset="826-837" id="DBMI.pac5.sp1.e0" origId="sp1.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="887-891" id="DBMI.pac5.sp1.e1" origId="sp1.e1" text="ODV " type="Metabolite"/>
		<pair e1="DBMI.pac5.sp1.e0" e2="DBMI.pac5.sp1.e1" id="DBMI.pac5.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="cimetidine "/>
		<pair e1="DBMI.pac5.sp1.e1" e2="DBMI.pac5.sp1.e0" id="DBMI.pac5.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp2" origId="sp2" text="However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced. Therefore, caution is advised with such patients. 7.3 Diazepam\n\nUnder steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.">
		<entity charOffset="1556-1565" id="DBMI.pac5.sp2.e0" origId="sp2.e0" text="diazepam " type="Active ingredient"/>
		<entity charOffset="1493-1505" id="DBMI.pac5.sp2.e1" origId="sp2.e1" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="1636-1640" id="DBMI.pac5.sp2.e2" origId="sp2.e2" text="ODV " type="Metabolite"/>
		<entity charOffset="1669-1681" id="DBMI.pac5.sp2.e3" origId="sp2.e3" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="1772-1790" id="DBMI.pac5.sp2.e4" origId="sp2.e4" text="desmethyldiazepam " type="Metabolite"/>
		<pair e1="DBMI.pac5.sp2.e0" e2="DBMI.pac5.sp2.e1" id="DBMI.pac5.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="diazepam "/>
		<pair e1="DBMI.pac5.sp2.e0" e2="DBMI.pac5.sp2.e1" id="DBMI.pac5.sp2.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="diazepam "/>
		<pair e1="DBMI.pac5.sp2.e0" e2="DBMI.pac5.sp2.e2" id="DBMI.pac5.sp2.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="diazepam "/>
		<pair e1="DBMI.pac5.sp2.e0" e2="DBMI.pac5.sp2.e3" id="DBMI.pac5.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e0" e2="DBMI.pac5.sp2.e4" id="DBMI.pac5.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e1" e2="DBMI.pac5.sp2.e0" id="DBMI.pac5.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e1" e2="DBMI.pac5.sp2.e2" id="DBMI.pac5.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e1" e2="DBMI.pac5.sp2.e3" id="DBMI.pac5.sp2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e1" e2="DBMI.pac5.sp2.e4" id="DBMI.pac5.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e2" e2="DBMI.pac5.sp2.e0" id="DBMI.pac5.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e2" e2="DBMI.pac5.sp2.e1" id="DBMI.pac5.sp2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e2" e2="DBMI.pac5.sp2.e3" id="DBMI.pac5.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e2" e2="DBMI.pac5.sp2.e4" id="DBMI.pac5.sp2.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e3" e2="DBMI.pac5.sp2.e0" id="DBMI.pac5.sp2.p13" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp2.e3" e2="DBMI.pac5.sp2.e1" id="DBMI.pac5.sp2.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e3" e2="DBMI.pac5.sp2.e2" id="DBMI.pac5.sp2.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e3" e2="DBMI.pac5.sp2.e4" id="DBMI.pac5.sp2.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="desmethyldiazepam " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp2.e4" e2="DBMI.pac5.sp2.e0" id="DBMI.pac5.sp2.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e4" e2="DBMI.pac5.sp2.e1" id="DBMI.pac5.sp2.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e4" e2="DBMI.pac5.sp2.e2" id="DBMI.pac5.sp2.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp2.e4" e2="DBMI.pac5.sp2.e3" id="DBMI.pac5.sp2.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp3" origId="sp3" text="Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam. 7.4 Haloperidol\n\nVenlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC. In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged.">
		<entity charOffset="1669-1681" id="DBMI.pac5.sp3.e0" origId="sp3.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="1737-1746" id="DBMI.pac5.sp3.e1" origId="sp3.e1" text="diazepam " type="Active ingredient"/>
		<entity charOffset="1772-1790" id="DBMI.pac5.sp3.e2" origId="sp3.e2" text="desmethyldiazepam " type="Metabolite"/>
		<entity charOffset="2131-2143" id="DBMI.pac5.sp3.e3" origId="sp3.e3" text="haloperidol " type="Active ingredient"/>
		<entity charOffset="2187-2199" id="DBMI.pac5.sp3.e4" origId="sp3.e4" text="venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.sp3.e0" e2="DBMI.pac5.sp3.e1" id="DBMI.pac5.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp3.e0" e2="DBMI.pac5.sp3.e2" id="DBMI.pac5.sp3.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="desmethyldiazepam " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp3.e0" e2="DBMI.pac5.sp3.e3" id="DBMI.pac5.sp3.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="haloperidol " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp3.e0" e2="DBMI.pac5.sp3.e3" id="DBMI.pac5.sp3.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="haloperidol " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp3.e0" e2="DBMI.pac5.sp3.e4" id="DBMI.pac5.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e1" e2="DBMI.pac5.sp3.e0" id="DBMI.pac5.sp3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e1" e2="DBMI.pac5.sp3.e2" id="DBMI.pac5.sp3.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e1" e2="DBMI.pac5.sp3.e3" id="DBMI.pac5.sp3.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e1" e2="DBMI.pac5.sp3.e4" id="DBMI.pac5.sp3.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e2" e2="DBMI.pac5.sp3.e0" id="DBMI.pac5.sp3.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e2" e2="DBMI.pac5.sp3.e1" id="DBMI.pac5.sp3.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e2" e2="DBMI.pac5.sp3.e3" id="DBMI.pac5.sp3.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e2" e2="DBMI.pac5.sp3.e4" id="DBMI.pac5.sp3.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e3" e2="DBMI.pac5.sp3.e0" id="DBMI.pac5.sp3.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e3" e2="DBMI.pac5.sp3.e1" id="DBMI.pac5.sp3.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e3" e2="DBMI.pac5.sp3.e2" id="DBMI.pac5.sp3.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e3" e2="DBMI.pac5.sp3.e4" id="DBMI.pac5.sp3.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e4" e2="DBMI.pac5.sp3.e0" id="DBMI.pac5.sp3.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e4" e2="DBMI.pac5.sp3.e1" id="DBMI.pac5.sp3.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e4" e2="DBMI.pac5.sp3.e2" id="DBMI.pac5.sp3.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp3.e4" e2="DBMI.pac5.sp3.e3" id="DBMI.pac5.sp3.p20" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="haloperidol " precipitant="venlafaxine "/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp4" origId="sp4" text="The mechanism explaining this finding is unknown. 7.5 Lithium\n\nThe steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected.">
		<entity charOffset="2456-2464" id="DBMI.pac5.sp4.e0" origId="sp4.e0" text="lithium " type="Active ingredient"/>
		<entity charOffset="2510-2514" id="DBMI.pac5.sp4.e1" origId="sp4.e1" text="ODV " type="Metabolite"/>
		<entity charOffset="2365-2377" id="DBMI.pac5.sp4.e2" origId="sp4.e2" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="2535-2547" id="DBMI.pac5.sp4.e3" origId="sp4.e3" text="Venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.sp4.e0" e2="DBMI.pac5.sp4.e1" id="DBMI.pac5.sp4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="lithium "/>
		<pair e1="DBMI.pac5.sp4.e0" e2="DBMI.pac5.sp4.e2" id="DBMI.pac5.sp4.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="lithium "/>
		<pair e1="DBMI.pac5.sp4.e0" e2="DBMI.pac5.sp4.e3" id="DBMI.pac5.sp4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp4.e1" e2="DBMI.pac5.sp4.e0" id="DBMI.pac5.sp4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp4.e1" e2="DBMI.pac5.sp4.e2" id="DBMI.pac5.sp4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp4.e1" e2="DBMI.pac5.sp4.e3" id="DBMI.pac5.sp4.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp4.e2" e2="DBMI.pac5.sp4.e0" id="DBMI.pac5.sp4.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp4.e2" e2="DBMI.pac5.sp4.e1" id="DBMI.pac5.sp4.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp4.e2" e2="DBMI.pac5.sp4.e3" id="DBMI.pac5.sp4.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp4.e3" e2="DBMI.pac5.sp4.e0" id="DBMI.pac5.sp4.p9" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp4.e3" e2="DBMI.pac5.sp4.e1" id="DBMI.pac5.sp4.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp4.e3" e2="DBMI.pac5.sp4.e2" id="DBMI.pac5.sp4.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp5" origId="sp5" text="Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below). 7.6 Drugs Highly Bound to Plasma Proteins\n\nVenlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release tablets to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug. 7.7 Drugs that Inhibit Cytochrome P450 Isoenzymes\n\nCYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants.">
		<entity charOffset="2535-2547" id="DBMI.pac5.sp5.e0" origId="sp5.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="2588-2596" id="DBMI.pac5.sp5.e1" origId="sp5.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac5.sp5.e0" e2="DBMI.pac5.sp5.e1" id="DBMI.pac5.sp5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp5.e1" e2="DBMI.pac5.sp5.e0" id="DBMI.pac5.sp5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp6" origId="sp6" text="Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers [see Clinical Pharmacology (12.3)]. Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor."/>
	<sentencespan id="DBMI.pac5.sp7" origId="sp7" text="Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d.with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.">
		<entity charOffset="3872-3885" id="DBMI.pac5.sp7.e0" origId="sp7.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="3921-3933" id="DBMI.pac5.sp7.e1" origId="sp7.e1" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="4091-4114" id="DBMI.pac5.sp7.e2" origId="sp7.e2" text="O-desmethylvenlafaxine " type="Metabolite"/>
		<entity charOffset="4454-4458" id="DBMI.pac5.sp7.e3" origId="sp7.e3" text="ODV " type="Metabolite"/>
		<entity charOffset="4335-4347" id="DBMI.pac5.sp7.e4" origId="sp7.e4" text="Venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.sp7.e0" e2="DBMI.pac5.sp7.e1" id="DBMI.pac5.sp7.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="venlafaxine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.sp7.e0" e2="DBMI.pac5.sp7.e2" id="DBMI.pac5.sp7.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="O-desmethylvenlafaxine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.sp7.e0" e2="DBMI.pac5.sp7.e3" id="DBMI.pac5.sp7.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="ODV " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.sp7.e0" e2="DBMI.pac5.sp7.e3" id="DBMI.pac5.sp7.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="ODV " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.sp7.e0" e2="DBMI.pac5.sp7.e4" id="DBMI.pac5.sp7.p4" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Venlafaxine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.sp7.e0" e2="DBMI.pac5.sp7.e4" id="DBMI.pac5.sp7.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Venlafaxine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac5.sp7.e1" e2="DBMI.pac5.sp7.e0" id="DBMI.pac5.sp7.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e1" e2="DBMI.pac5.sp7.e2" id="DBMI.pac5.sp7.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e1" e2="DBMI.pac5.sp7.e3" id="DBMI.pac5.sp7.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e1" e2="DBMI.pac5.sp7.e4" id="DBMI.pac5.sp7.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e2" e2="DBMI.pac5.sp7.e0" id="DBMI.pac5.sp7.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e2" e2="DBMI.pac5.sp7.e1" id="DBMI.pac5.sp7.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e2" e2="DBMI.pac5.sp7.e3" id="DBMI.pac5.sp7.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e2" e2="DBMI.pac5.sp7.e4" id="DBMI.pac5.sp7.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e3" e2="DBMI.pac5.sp7.e0" id="DBMI.pac5.sp7.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e3" e2="DBMI.pac5.sp7.e1" id="DBMI.pac5.sp7.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e3" e2="DBMI.pac5.sp7.e2" id="DBMI.pac5.sp7.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e3" e2="DBMI.pac5.sp7.e4" id="DBMI.pac5.sp7.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e4" e2="DBMI.pac5.sp7.e0" id="DBMI.pac5.sp7.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e4" e2="DBMI.pac5.sp7.e1" id="DBMI.pac5.sp7.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e4" e2="DBMI.pac5.sp7.e2" id="DBMI.pac5.sp7.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp7.e4" e2="DBMI.pac5.sp7.e3" id="DBMI.pac5.sp7.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp8" origId="sp8" text="Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively. Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%). Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV."/>
	<sentencespan id="DBMI.pac5.sp9" origId="sp9" text="Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly. 7.8 Drugs Metabolized by Cytochrome P450 Isoenzymes\n\nCYP2D6\n\nIn vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6. These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan."/>
	<sentencespan id="DBMI.pac5.sp10" origId="sp10" text="Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine. The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).">
		<entity charOffset="5256-5268" id="DBMI.pac5.sp10.e0" origId="sp10.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="5322-5338" id="DBMI.pac5.sp10.e1" origId="sp10.e1" text="2-OH-imipramine " type="Metabolite"/>
		<entity charOffset="5307-5318" id="DBMI.pac5.sp10.e2" origId="sp10.e2" text="imipramine " type="Active ingredient"/>
		<entity charOffset="5422-5434" id="DBMI.pac5.sp10.e3" origId="sp10.e3" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="5348-5360" id="DBMI.pac5.sp10.e4" origId="sp10.e4" text="desipramine " type="Active ingredient"/>
		<entity charOffset="5439-5456" id="DBMI.pac5.sp10.e5" origId="sp10.e5" text="2-OH-desipramine " type="Metabolite"/>
		<pair e1="DBMI.pac5.sp10.e0" e2="DBMI.pac5.sp10.e1" id="DBMI.pac5.sp10.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="2-OH-imipramine " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp10.e0" e2="DBMI.pac5.sp10.e2" id="DBMI.pac5.sp10.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="imipramine " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp10.e0" e2="DBMI.pac5.sp10.e3" id="DBMI.pac5.sp10.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e0" e2="DBMI.pac5.sp10.e4" id="DBMI.pac5.sp10.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e0" e2="DBMI.pac5.sp10.e5" id="DBMI.pac5.sp10.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e1" e2="DBMI.pac5.sp10.e0" id="DBMI.pac5.sp10.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e1" e2="DBMI.pac5.sp10.e2" id="DBMI.pac5.sp10.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e1" e2="DBMI.pac5.sp10.e3" id="DBMI.pac5.sp10.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e1" e2="DBMI.pac5.sp10.e4" id="DBMI.pac5.sp10.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e1" e2="DBMI.pac5.sp10.e5" id="DBMI.pac5.sp10.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e2" e2="DBMI.pac5.sp10.e0" id="DBMI.pac5.sp10.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e2" e2="DBMI.pac5.sp10.e1" id="DBMI.pac5.sp10.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e2" e2="DBMI.pac5.sp10.e3" id="DBMI.pac5.sp10.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e2" e2="DBMI.pac5.sp10.e4" id="DBMI.pac5.sp10.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e2" e2="DBMI.pac5.sp10.e5" id="DBMI.pac5.sp10.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e3" e2="DBMI.pac5.sp10.e0" id="DBMI.pac5.sp10.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e3" e2="DBMI.pac5.sp10.e1" id="DBMI.pac5.sp10.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e3" e2="DBMI.pac5.sp10.e2" id="DBMI.pac5.sp10.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e3" e2="DBMI.pac5.sp10.e4" id="DBMI.pac5.sp10.p18" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desipramine " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.sp10.e3" e2="DBMI.pac5.sp10.e5" id="DBMI.pac5.sp10.p19" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="2-OH-desipramine " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.sp10.e4" e2="DBMI.pac5.sp10.e0" id="DBMI.pac5.sp10.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e4" e2="DBMI.pac5.sp10.e1" id="DBMI.pac5.sp10.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e4" e2="DBMI.pac5.sp10.e2" id="DBMI.pac5.sp10.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e4" e2="DBMI.pac5.sp10.e3" id="DBMI.pac5.sp10.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e4" e2="DBMI.pac5.sp10.e5" id="DBMI.pac5.sp10.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e5" e2="DBMI.pac5.sp10.e0" id="DBMI.pac5.sp10.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e5" e2="DBMI.pac5.sp10.e1" id="DBMI.pac5.sp10.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e5" e2="DBMI.pac5.sp10.e2" id="DBMI.pac5.sp10.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e5" e2="DBMI.pac5.sp10.e3" id="DBMI.pac5.sp10.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp10.e5" e2="DBMI.pac5.sp10.e4" id="DBMI.pac5.sp10.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp11" origId="sp11" text="Imipramine did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of elevated 2-OH-desipramine levels is unknown. Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, -hydroxymetoprolol.">
		<entity charOffset="5572-5583" id="DBMI.pac5.sp11.e0" origId="sp11.e0" text="Imipramine " type="Active ingredient"/>
		<entity charOffset="5638-5642" id="DBMI.pac5.sp11.e1" origId="sp11.e1" text="ODV " type="Metabolite"/>
		<entity charOffset="5622-5634" id="DBMI.pac5.sp11.e2" origId="sp11.e2" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="6097-6117" id="DBMI.pac5.sp11.e3" origId="sp11.e3" text="?-hydroxymetoprolol " type="Metabolite"/>
		<entity charOffset="5990-6001" id="DBMI.pac5.sp11.e4" origId="sp11.e4" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac5.sp11.e0" e2="DBMI.pac5.sp11.e1" id="DBMI.pac5.sp11.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="Imipramine "/>
		<pair e1="DBMI.pac5.sp11.e0" e2="DBMI.pac5.sp11.e2" id="DBMI.pac5.sp11.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="Imipramine "/>
		<pair e1="DBMI.pac5.sp11.e0" e2="DBMI.pac5.sp11.e3" id="DBMI.pac5.sp11.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e0" e2="DBMI.pac5.sp11.e4" id="DBMI.pac5.sp11.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e1" e2="DBMI.pac5.sp11.e0" id="DBMI.pac5.sp11.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e1" e2="DBMI.pac5.sp11.e2" id="DBMI.pac5.sp11.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e1" e2="DBMI.pac5.sp11.e3" id="DBMI.pac5.sp11.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e1" e2="DBMI.pac5.sp11.e4" id="DBMI.pac5.sp11.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e2" e2="DBMI.pac5.sp11.e0" id="DBMI.pac5.sp11.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e2" e2="DBMI.pac5.sp11.e1" id="DBMI.pac5.sp11.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e2" e2="DBMI.pac5.sp11.e3" id="DBMI.pac5.sp11.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="?-hydroxymetoprolol " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.sp11.e2" e2="DBMI.pac5.sp11.e4" id="DBMI.pac5.sp11.p11" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.sp11.e3" e2="DBMI.pac5.sp11.e0" id="DBMI.pac5.sp11.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e3" e2="DBMI.pac5.sp11.e1" id="DBMI.pac5.sp11.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e3" e2="DBMI.pac5.sp11.e2" id="DBMI.pac5.sp11.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e3" e2="DBMI.pac5.sp11.e4" id="DBMI.pac5.sp11.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e4" e2="DBMI.pac5.sp11.e0" id="DBMI.pac5.sp11.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e4" e2="DBMI.pac5.sp11.e1" id="DBMI.pac5.sp11.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e4" e2="DBMI.pac5.sp11.e2" id="DBMI.pac5.sp11.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp11.e4" e2="DBMI.pac5.sp11.e3" id="DBMI.pac5.sp11.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp12" origId="sp12" text="Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine. Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study. The clinical relevance of this finding for hypertensive patients is unknown.">
		<entity charOffset="6118-6129" id="DBMI.pac5.sp12.e0" origId="sp12.e0" text="Metoprolol " type="Active ingredient"/>
		<entity charOffset="6174-6186" id="DBMI.pac5.sp12.e1" origId="sp12.e1" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="6212-6235" id="DBMI.pac5.sp12.e2" origId="sp12.e2" text="O-desmethylvenlafaxine " type="Metabolite"/>
		<pair e1="DBMI.pac5.sp12.e0" e2="DBMI.pac5.sp12.e1" id="DBMI.pac5.sp12.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="Metoprolol "/>
		<pair e1="DBMI.pac5.sp12.e0" e2="DBMI.pac5.sp12.e2" id="DBMI.pac5.sp12.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="O-desmethylvenlafaxine " precipitant="Metoprolol "/>
		<pair e1="DBMI.pac5.sp12.e1" e2="DBMI.pac5.sp12.e0" id="DBMI.pac5.sp12.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp12.e1" e2="DBMI.pac5.sp12.e2" id="DBMI.pac5.sp12.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp12.e2" e2="DBMI.pac5.sp12.e0" id="DBMI.pac5.sp12.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp12.e2" e2="DBMI.pac5.sp12.e1" id="DBMI.pac5.sp12.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp13" origId="sp13" text="Caution should be exercised with co-administration of venlafaxine and metoprolol. Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients. It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)]."/>
	<sentencespan id="DBMI.pac5.sp14" origId="sp14" text="Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone). CYP3A4\n\nVenlafaxine did not inhibit CYP3A4 in vitro.">
		<entity charOffset="6788-6800" id="DBMI.pac5.sp14.e0" origId="sp14.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="7056-7068" id="DBMI.pac5.sp14.e1" origId="sp14.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="7082-7094" id="DBMI.pac5.sp14.e2" origId="sp14.e2" text="venlafaxine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.sp14.e0" e2="DBMI.pac5.sp14.e1" id="DBMI.pac5.sp14.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp14.e0" e2="DBMI.pac5.sp14.e2" id="DBMI.pac5.sp14.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp14.e1" e2="DBMI.pac5.sp14.e0" id="DBMI.pac5.sp14.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp14.e1" e2="DBMI.pac5.sp14.e2" id="DBMI.pac5.sp14.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp14.e2" e2="DBMI.pac5.sp14.e0" id="DBMI.pac5.sp14.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp14.e2" e2="DBMI.pac5.sp14.e1" id="DBMI.pac5.sp14.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="risperidone " precipitant="venlafaxine "/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp15" origId="sp15" text="This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine. Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.">
		<entity charOffset="7370-7382" id="DBMI.pac5.sp15.e0" origId="sp15.e0" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="7479-7491" id="DBMI.pac5.sp15.e1" origId="sp15.e1" text="terfenadine " type="Active ingredient"/>
		<entity charOffset="7465-7474" id="DBMI.pac5.sp15.e2" origId="sp15.e2" text="diazepam " type="Active ingredient"/>
		<entity charOffset="7453-7464" id="DBMI.pac5.sp15.e3" origId="sp15.e3" text="alprazolam " type="Active ingredient"/>
		<entity charOffset="7728-7738" id="DBMI.pac5.sp15.e4" origId="sp15.e4" text="Indinavir " type="Active ingredient"/>
		<entity charOffset="7793-7797" id="DBMI.pac5.sp15.e5" origId="sp15.e5" text="ODV " type="Metabolite"/>
		<pair e1="DBMI.pac5.sp15.e0" e2="DBMI.pac5.sp15.e1" id="DBMI.pac5.sp15.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="terfenadine " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.sp15.e0" e2="DBMI.pac5.sp15.e2" id="DBMI.pac5.sp15.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.sp15.e0" e2="DBMI.pac5.sp15.e3" id="DBMI.pac5.sp15.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="alprazolam " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.sp15.e0" e2="DBMI.pac5.sp15.e4" id="DBMI.pac5.sp15.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e0" e2="DBMI.pac5.sp15.e5" id="DBMI.pac5.sp15.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e1" e2="DBMI.pac5.sp15.e0" id="DBMI.pac5.sp15.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e1" e2="DBMI.pac5.sp15.e2" id="DBMI.pac5.sp15.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e1" e2="DBMI.pac5.sp15.e3" id="DBMI.pac5.sp15.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e1" e2="DBMI.pac5.sp15.e4" id="DBMI.pac5.sp15.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e1" e2="DBMI.pac5.sp15.e5" id="DBMI.pac5.sp15.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e2" e2="DBMI.pac5.sp15.e0" id="DBMI.pac5.sp15.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e2" e2="DBMI.pac5.sp15.e1" id="DBMI.pac5.sp15.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e2" e2="DBMI.pac5.sp15.e3" id="DBMI.pac5.sp15.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e2" e2="DBMI.pac5.sp15.e4" id="DBMI.pac5.sp15.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e2" e2="DBMI.pac5.sp15.e5" id="DBMI.pac5.sp15.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e3" e2="DBMI.pac5.sp15.e0" id="DBMI.pac5.sp15.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e3" e2="DBMI.pac5.sp15.e1" id="DBMI.pac5.sp15.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e3" e2="DBMI.pac5.sp15.e2" id="DBMI.pac5.sp15.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e3" e2="DBMI.pac5.sp15.e4" id="DBMI.pac5.sp15.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e3" e2="DBMI.pac5.sp15.e5" id="DBMI.pac5.sp15.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e4" e2="DBMI.pac5.sp15.e0" id="DBMI.pac5.sp15.p20" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="venlafaxine " precipitant="Indinavir "/>
		<pair e1="DBMI.pac5.sp15.e4" e2="DBMI.pac5.sp15.e1" id="DBMI.pac5.sp15.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e4" e2="DBMI.pac5.sp15.e2" id="DBMI.pac5.sp15.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e4" e2="DBMI.pac5.sp15.e3" id="DBMI.pac5.sp15.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e4" e2="DBMI.pac5.sp15.e5" id="DBMI.pac5.sp15.p24" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ODV " precipitant="Indinavir "/>
		<pair e1="DBMI.pac5.sp15.e5" e2="DBMI.pac5.sp15.e0" id="DBMI.pac5.sp15.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e5" e2="DBMI.pac5.sp15.e1" id="DBMI.pac5.sp15.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e5" e2="DBMI.pac5.sp15.e2" id="DBMI.pac5.sp15.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e5" e2="DBMI.pac5.sp15.e3" id="DBMI.pac5.sp15.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp15.e5" e2="DBMI.pac5.sp15.e4" id="DBMI.pac5.sp15.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp16" origId="sp16" text="The clinical significance of this finding is unknown. CYP1A2\n\nVenlafaxine did not inhibit CYP1A2 in vitro. This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.">
		<entity charOffset="7861-7873" id="DBMI.pac5.sp16.e0" origId="sp16.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="8033-8042" id="DBMI.pac5.sp16.e1" origId="sp16.e1" text="caffeine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.sp16.e0" e2="DBMI.pac5.sp16.e1" id="DBMI.pac5.sp16.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="caffeine " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp16.e1" e2="DBMI.pac5.sp16.e0" id="DBMI.pac5.sp16.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp17" origId="sp17" text="CYP2C9\n \nVenlafaxine did not inhibit CYP2C9 in vitro. In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide. CYP2C19\n\nVenlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).">
		<entity charOffset="8073-8085" id="DBMI.pac5.sp17.e0" origId="sp17.e0" text="Venlafaxine " type="Active ingredient"/>
		<entity charOffset="8231-8243" id="DBMI.pac5.sp17.e1" origId="sp17.e1" text="tolbutamide " type="Active ingredient"/>
		<entity charOffset="8358-8367" id="DBMI.pac5.sp17.e2" origId="sp17.e2" text="diazepam " type="Active ingredient"/>
		<pair e1="DBMI.pac5.sp17.e0" e2="DBMI.pac5.sp17.e1" id="DBMI.pac5.sp17.p0" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="tolbutamide " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp17.e0" e2="DBMI.pac5.sp17.e2" id="DBMI.pac5.sp17.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam " precipitant="Venlafaxine "/>
		<pair e1="DBMI.pac5.sp17.e1" e2="DBMI.pac5.sp17.e0" id="DBMI.pac5.sp17.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp17.e1" e2="DBMI.pac5.sp17.e2" id="DBMI.pac5.sp17.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp17.e2" e2="DBMI.pac5.sp17.e0" id="DBMI.pac5.sp17.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac5.sp17.e2" e2="DBMI.pac5.sp17.e1" id="DBMI.pac5.sp17.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp18" origId="sp18" text="7.9 Monoamine Oxidase Inhibitors\n\nSee Contraindications (4) and Warnings and Precautions (5.2). 7.10 Other CNS-Active Drugs\n\nThe risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above). Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required."/>
	<sentencespan id="DBMI.pac5.sp19" origId="sp19" text="Serotonergic Drugs\n\nBased on the mechanism of action of venlafaxine hydrochloride extended-release tablets and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [see Warnings and Precautions (5.3)]. If concomitant treatment of venlafaxine hydrochloride extended-release tablets with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)]. The concomitant use of venlafaxine hydrochloride extended-release tablets with tryptophan supplements is not recommended [see Warnings and Precautions (5.3)]."/>
	<sentencespan id="DBMI.pac5.sp20" origId="sp20" text="Triptans\n\nThere have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan. If concomitant treatment of venlafaxine hydrochloride extended-release tablets with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Warnings and Precautions (5.3)]. 7.11 Drugs that Interfere with Hemostasis (e.g., NSAID's, Aspirin, and Warfarin)\n\nSerotonin release by platelets plays an important role in hemostasis."/>
	<sentencespan id="DBMI.pac5.sp21" origId="sp21" text="Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRI's and SNRI's are coadministered with warfarin."/>
	<sentencespan id="DBMI.pac5.sp22" origId="sp22" text="Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release tablets are initiated or discontinued. [See Warnings and Precautions (5.14)]\n\n7.12 Electroconvulsive Therapy\n\nThere are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine hydrochloride extended-release tablets treatment. 7.13 Postmarketing Spontaneous Drug Interaction Reports\n\nThere have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine.">
		<entity charOffset="11366-11378" id="DBMI.pac5.sp22.e0" origId="sp22.e0" text="venlafaxine " type="Active ingredient"/>
		<entity charOffset="11247-11257" id="DBMI.pac5.sp22.e1" origId="sp22.e1" text="clozapine " type="Active ingredient"/>
		<pair e1="DBMI.pac5.sp22.e0" e2="DBMI.pac5.sp22.e1" id="DBMI.pac5.sp22.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="clozapine " precipitant="venlafaxine "/>
		<pair e1="DBMI.pac5.sp22.e1" e2="DBMI.pac5.sp22.e0" id="DBMI.pac5.sp22.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac5.sp23" origId="sp23" text="There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy."/>
</document>

<document id="DBMI.pac50" origId="pac50">
	<sentence id="DBMI.pac50.s0" origId="s0" text="Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state.">
		<entity charOffset="39-50" id="DBMI.pac50.s0.e0" origId="s0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="126-139" id="DBMI.pac50.s0.e1" origId="s0.e1" text="procyclidine " type="Active ingredient"/>
		<pair e1="DBMI.pac50.s0.e0" e2="DBMI.pac50.s0.e1" id="DBMI.pac50.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="procyclidine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac50.s0.e1" e2="DBMI.pac50.s0.e0" id="DBMI.pac50.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac50.s1" origId="s1" text="If anticholinergic effects are seen, the dose of procyclidine should be reduced."/>
	<sentencespan id="DBMI.pac50.sp0" origId="sp0" text="Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.">
		<entity charOffset="39-50" id="DBMI.pac50.sp0.e0" origId="sp0.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="126-139" id="DBMI.pac50.sp0.e1" origId="sp0.e1" text="procyclidine " type="Active ingredient"/>
		<pair e1="DBMI.pac50.sp0.e0" e2="DBMI.pac50.sp0.e1" id="DBMI.pac50.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="procyclidine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac50.sp0.e1" e2="DBMI.pac50.sp0.e0" id="DBMI.pac50.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac51" origId="pac51">
	<sentence id="DBMI.pac51.s0" origId="s0" text="Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.">
		<entity charOffset="21-45" id="DBMI.pac51.s0.e0" origId="s0.e0" text="fosamprenavir/ritonavir " type="Active ingredient"/>
		<entity charOffset="50-61" id="DBMI.pac51.s0.e1" origId="s0.e1" text="paroxetine " type="Active ingredient"/>
		<pair e1="DBMI.pac51.s0.e0" e2="DBMI.pac51.s0.e1" id="DBMI.pac51.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="paroxetine " precipitant="fosamprenavir/ritonavir "/>
		<pair e1="DBMI.pac51.s0.e1" e2="DBMI.pac51.s0.e0" id="DBMI.pac51.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac51.s1" origId="s1" text="Any dose adjustment should be guided by clinical effect (tolerability and efficacy). "/>
	<sentencespan id="DBMI.pac51.sp0" origId="sp0" text="Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy). ">
		<entity charOffset="21-45" id="DBMI.pac51.sp0.e0" origId="sp0.e0" text="fosamprenavir/ritonavir " type="Active ingredient"/>
		<entity charOffset="50-61" id="DBMI.pac51.sp0.e1" origId="sp0.e1" text="paroxetine " type="Active ingredient"/>
		<pair e1="DBMI.pac51.sp0.e0" e2="DBMI.pac51.sp0.e1" id="DBMI.pac51.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="paroxetine " precipitant="fosamprenavir/ritonavir "/>
		<pair e1="DBMI.pac51.sp0.e1" e2="DBMI.pac51.sp0.e0" id="DBMI.pac51.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac53" origId="pac53">
	<sentence id="DBMI.pac53.s0" origId="s0" text="Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered.">
		<entity charOffset="93-106" id="DBMI.pac53.s0.e0" origId="s0.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="66-76" id="DBMI.pac53.s0.e1" origId="s0.e1" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac53.s0.e0" e2="DBMI.pac53.s0.e1" id="DBMI.pac53.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="quinidine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac53.s0.e1" e2="DBMI.pac53.s0.e0" id="DBMI.pac53.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac53.sp0" origId="sp0" text="Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered.">
		<entity charOffset="93-106" id="DBMI.pac53.sp0.e0" origId="sp0.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="66-76" id="DBMI.pac53.sp0.e1" origId="sp0.e1" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac53.sp0.e0" e2="DBMI.pac53.sp0.e1" id="DBMI.pac53.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="quinidine " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac53.sp0.e1" e2="DBMI.pac53.sp0.e0" id="DBMI.pac53.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac54" origId="pac54">
	<sentence id="DBMI.pac54.s0" origId="s0" text="Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.">
		<entity charOffset="0-10" id="DBMI.pac54.s0.e0" origId="s0.e0" text="Diltiazem " type="Active ingredient"/>
		<entity charOffset="74-84" id="DBMI.pac54.s0.e1" origId="s0.e1" text="quinidine " type="Active ingredient"/>
		<entity charOffset="130-140" id="DBMI.pac54.s0.e2" origId="s0.e2" text="diltiazem " type="Active ingredient"/>
		<pair e1="DBMI.pac54.s0.e0" e2="DBMI.pac54.s0.e1" id="DBMI.pac54.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="quinidine " precipitant="Diltiazem "/>
		<pair e1="DBMI.pac54.s0.e0" e2="DBMI.pac54.s0.e2" id="DBMI.pac54.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac54.s0.e1" e2="DBMI.pac54.s0.e0" id="DBMI.pac54.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac54.s0.e1" e2="DBMI.pac54.s0.e2" id="DBMI.pac54.s0.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diltiazem " precipitant="quinidine "/>
		<pair e1="DBMI.pac54.s0.e2" e2="DBMI.pac54.s0.e0" id="DBMI.pac54.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac54.s0.e2" e2="DBMI.pac54.s0.e1" id="DBMI.pac54.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac54.sp0" origId="sp0" text="Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.">
		<entity charOffset="0-10" id="DBMI.pac54.sp0.e0" origId="sp0.e0" text="Diltiazem " type="Active ingredient"/>
		<entity charOffset="74-84" id="DBMI.pac54.sp0.e1" origId="sp0.e1" text="quinidine " type="Active ingredient"/>
		<entity charOffset="130-140" id="DBMI.pac54.sp0.e2" origId="sp0.e2" text="diltiazem " type="Active ingredient"/>
		<pair e1="DBMI.pac54.sp0.e0" e2="DBMI.pac54.sp0.e1" id="DBMI.pac54.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="quinidine " precipitant="Diltiazem "/>
		<pair e1="DBMI.pac54.sp0.e0" e2="DBMI.pac54.sp0.e2" id="DBMI.pac54.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac54.sp0.e1" e2="DBMI.pac54.sp0.e0" id="DBMI.pac54.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac54.sp0.e1" e2="DBMI.pac54.sp0.e2" id="DBMI.pac54.sp0.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diltiazem " precipitant="quinidine "/>
		<pair e1="DBMI.pac54.sp0.e2" e2="DBMI.pac54.sp0.e0" id="DBMI.pac54.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac54.sp0.e2" e2="DBMI.pac54.sp0.e1" id="DBMI.pac54.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac56" origId="pac56">
	<sentence id="DBMI.pac56.s0" origId="s0" text="Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.">
		<entity charOffset="0-11" id="DBMI.pac56.s0.e0" origId="s0.e0" text="Zonisamide " type="Active ingredient"/>
		<entity charOffset="82-92" id="DBMI.pac56.s0.e1" origId="s0.e1" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="93-107" id="DBMI.pac56.s0.e2" origId="s0.e2" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="111-121" id="DBMI.pac56.s0.e3" origId="s0.e3" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac56.s0.e0" e2="DBMI.pac56.s0.e1" id="DBMI.pac56.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="Zonisamide "/>
		<pair e1="DBMI.pac56.s0.e0" e2="DBMI.pac56.s0.e2" id="DBMI.pac56.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine " precipitant="Zonisamide "/>
		<pair e1="DBMI.pac56.s0.e0" e2="DBMI.pac56.s0.e3" id="DBMI.pac56.s0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valproate " precipitant="Zonisamide "/>
		<pair e1="DBMI.pac56.s0.e1" e2="DBMI.pac56.s0.e0" id="DBMI.pac56.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.s0.e1" e2="DBMI.pac56.s0.e2" id="DBMI.pac56.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.s0.e1" e2="DBMI.pac56.s0.e3" id="DBMI.pac56.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.s0.e2" e2="DBMI.pac56.s0.e0" id="DBMI.pac56.s0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.s0.e2" e2="DBMI.pac56.s0.e1" id="DBMI.pac56.s0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.s0.e2" e2="DBMI.pac56.s0.e3" id="DBMI.pac56.s0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.s0.e3" e2="DBMI.pac56.s0.e0" id="DBMI.pac56.s0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.s0.e3" e2="DBMI.pac56.s0.e1" id="DBMI.pac56.s0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.s0.e3" e2="DBMI.pac56.s0.e2" id="DBMI.pac56.s0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac56.s1" origId="s1" text="Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro."/>
	<sentence id="DBMI.pac56.s2" origId="s2" text="Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes."/>
	<sentencespan id="DBMI.pac56.sp0" origId="sp0" text="Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.">
		<entity charOffset="0-11" id="DBMI.pac56.sp0.e0" origId="sp0.e0" text="Zonisamide " type="Active ingredient"/>
		<entity charOffset="82-92" id="DBMI.pac56.sp0.e1" origId="sp0.e1" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="93-107" id="DBMI.pac56.sp0.e2" origId="sp0.e2" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="111-121" id="DBMI.pac56.sp0.e3" origId="sp0.e3" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac56.sp0.e0" e2="DBMI.pac56.sp0.e1" id="DBMI.pac56.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="Zonisamide "/>
		<pair e1="DBMI.pac56.sp0.e0" e2="DBMI.pac56.sp0.e2" id="DBMI.pac56.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine " precipitant="Zonisamide "/>
		<pair e1="DBMI.pac56.sp0.e0" e2="DBMI.pac56.sp0.e3" id="DBMI.pac56.sp0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valproate " precipitant="Zonisamide "/>
		<pair e1="DBMI.pac56.sp0.e1" e2="DBMI.pac56.sp0.e0" id="DBMI.pac56.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.sp0.e1" e2="DBMI.pac56.sp0.e2" id="DBMI.pac56.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.sp0.e1" e2="DBMI.pac56.sp0.e3" id="DBMI.pac56.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.sp0.e2" e2="DBMI.pac56.sp0.e0" id="DBMI.pac56.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.sp0.e2" e2="DBMI.pac56.sp0.e1" id="DBMI.pac56.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.sp0.e2" e2="DBMI.pac56.sp0.e3" id="DBMI.pac56.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.sp0.e3" e2="DBMI.pac56.sp0.e0" id="DBMI.pac56.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.sp0.e3" e2="DBMI.pac56.sp0.e1" id="DBMI.pac56.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac56.sp0.e3" e2="DBMI.pac56.sp0.e2" id="DBMI.pac56.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac57" origId="pac57">
	<sentence id="DBMI.pac57.s0" origId="s0" text="Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days).">
		<entity charOffset="71-82" id="DBMI.pac57.s0.e0" origId="s0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="0-11" id="DBMI.pac57.s0.e1" origId="s0.e1" text="Zonisamide " type="Active ingredient"/>
		<pair e1="DBMI.pac57.s0.e0" e2="DBMI.pac57.s0.e1" id="DBMI.pac57.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Zonisamide " precipitant="cimetidine "/>
		<pair e1="DBMI.pac57.s0.e1" e2="DBMI.pac57.s0.e0" id="DBMI.pac57.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac57.sp0" origId="sp0" text="Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days).">
		<entity charOffset="71-82" id="DBMI.pac57.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="0-11" id="DBMI.pac57.sp0.e1" origId="sp0.e1" text="Zonisamide " type="Active ingredient"/>
		<pair e1="DBMI.pac57.sp0.e0" e2="DBMI.pac57.sp0.e1" id="DBMI.pac57.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Zonisamide " precipitant="cimetidine "/>
		<pair e1="DBMI.pac57.sp0.e1" e2="DBMI.pac57.sp0.e0" id="DBMI.pac57.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac59" origId="pac59">
	<sentence id="DBMI.pac59.s0" origId="s0" text="Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect.">
		<entity charOffset="20-34" id="DBMI.pac59.s0.e0" origId="s0.e0" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="39-50" id="DBMI.pac59.s0.e1" origId="s0.e1" text="nefazodone " type="Active ingredient"/>
		<pair e1="DBMI.pac59.s0.e0" e2="DBMI.pac59.s0.e1" id="DBMI.pac59.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nefazodone " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac59.s0.e1" e2="DBMI.pac59.s0.e0" id="DBMI.pac59.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac59.s1" origId="s1" text="Coadministration of carbamazepine with nefazodone is contraindicated (see CONTRAINDICATIONS)."/>
	<sentencespan id="DBMI.pac59.sp0" origId="sp0" text="Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated (see CONTRAINDICATIONS).">
		<entity charOffset="20-34" id="DBMI.pac59.sp0.e0" origId="sp0.e0" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="39-50" id="DBMI.pac59.sp0.e1" origId="sp0.e1" text="nefazodone " type="Active ingredient"/>
		<pair e1="DBMI.pac59.sp0.e0" e2="DBMI.pac59.sp0.e1" id="DBMI.pac59.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nefazodone " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac59.sp0.e1" e2="DBMI.pac59.sp0.e0" id="DBMI.pac59.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac63" origId="pac63">
	<sentence id="DBMI.pac63.s0" origId="s0" text="A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.">
		<entity charOffset="100-111" id="DBMI.pac63.s0.e0" origId="s0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="40-52" id="DBMI.pac63.s0.e1" origId="s0.e1" text="nisoldipine " type="Active ingredient"/>
		<pair e1="DBMI.pac63.s0.e0" e2="DBMI.pac63.s0.e1" id="DBMI.pac63.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nisoldipine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac63.s0.e1" e2="DBMI.pac63.s0.e0" id="DBMI.pac63.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac63.s1" origId="s1" text="Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).">
		<entity charOffset="131-142" id="DBMI.pac63.s1.e0" origId="s1.e0" text="Ranitidine " type="Active ingredient"/>
		<entity charOffset="197-209" id="DBMI.pac63.s1.e1" origId="s1.e1" text="nisoldipine " type="Active ingredient"/>
		<pair e1="DBMI.pac63.s1.e0" e2="DBMI.pac63.s1.e1" id="DBMI.pac63.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="nisoldipine " precipitant="Ranitidine "/>
		<pair e1="DBMI.pac63.s1.e1" e2="DBMI.pac63.s1.e0" id="DBMI.pac63.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac63.s2" origId="s2" text="No pharmacodynamic effects of either histamine H2 receptor antagonist were observed."/>
	<sentence id="DBMI.pac63.s3" origId="s3" text="CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general."/>
	<sentence id="DBMI.pac63.s4" origId="s4" text="Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.">
		<entity charOffset="465-475" id="DBMI.pac63.s4.e0" origId="s4.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="564-576" id="DBMI.pac63.s4.e1" origId="s4.e1" text="nisoldipine " type="Active ingredient"/>
		<entity charOffset="510-522" id="DBMI.pac63.s4.e2" origId="s4.e2" text="Nisoldipine " type="Active ingredient"/>
		<pair e1="DBMI.pac63.s4.e0" e2="DBMI.pac63.s4.e1" id="DBMI.pac63.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nisoldipine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac63.s4.e0" e2="DBMI.pac63.s4.e2" id="DBMI.pac63.s4.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Nisoldipine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac63.s4.e1" e2="DBMI.pac63.s4.e0" id="DBMI.pac63.s4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.s4.e1" e2="DBMI.pac63.s4.e2" id="DBMI.pac63.s4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.s4.e2" e2="DBMI.pac63.s4.e0" id="DBMI.pac63.s4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.s4.e2" e2="DBMI.pac63.s4.e1" id="DBMI.pac63.s4.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac63.s5" origId="s5" text="Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered."/>
	<sentence id="DBMI.pac63.s6" origId="s6" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.">
		<entity charOffset="787-799" id="DBMI.pac63.s6.e0" origId="s6.e0" text="nisoldipine " type="Active ingredient"/>
		<entity charOffset="818-827" id="DBMI.pac63.s6.e1" origId="s6.e1" text="atenolol " type="Active ingredient"/>
		<entity charOffset="828-840" id="DBMI.pac63.s6.e2" origId="s6.e2" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac63.s6.e0" e2="DBMI.pac63.s6.e1" id="DBMI.pac63.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="nisoldipine "/>
		<pair e1="DBMI.pac63.s6.e0" e2="DBMI.pac63.s6.e2" id="DBMI.pac63.s6.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="nisoldipine "/>
		<pair e1="DBMI.pac63.s6.e1" e2="DBMI.pac63.s6.e0" id="DBMI.pac63.s6.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nisoldipine " precipitant="atenolol "/>
		<pair e1="DBMI.pac63.s6.e1" e2="DBMI.pac63.s6.e2" id="DBMI.pac63.s6.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.s6.e2" e2="DBMI.pac63.s6.e0" id="DBMI.pac63.s6.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nisoldipine " precipitant="propranolol "/>
		<pair e1="DBMI.pac63.s6.e2" e2="DBMI.pac63.s6.e1" id="DBMI.pac63.s6.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac63.s7" origId="s7" text="Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine."/>
	<sentence id="DBMI.pac63.s8" origId="s8" text="The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy."/>
	<sentence id="DBMI.pac63.s9" origId="s9" text="Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.">
		<entity charOffset="1123-1133" id="DBMI.pac63.s9.e0" origId="s9.e0" text="Quinidine " type="Active ingredient"/>
		<entity charOffset="1186-1198" id="DBMI.pac63.s9.e1" origId="s9.e1" text="nisoldipine " type="Active ingredient"/>
		<pair e1="DBMI.pac63.s9.e0" e2="DBMI.pac63.s9.e1" id="DBMI.pac63.s9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nisoldipine " precipitant="Quinidine "/>
		<pair e1="DBMI.pac63.s9.e1" e2="DBMI.pac63.s9.e0" id="DBMI.pac63.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac63.s10" origId="s10" text="Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.">
		<entity charOffset="1256-1268" id="DBMI.pac63.s10.e0" origId="s10.e0" text="nisoldipine " type="Active ingredient"/>
		<entity charOffset="1285-1295" id="DBMI.pac63.s10.e1" origId="s10.e1" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac63.s10.e0" e2="DBMI.pac63.s10.e1" id="DBMI.pac63.s10.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="quinidine " precipitant="nisoldipine "/>
		<pair e1="DBMI.pac63.s10.e1" e2="DBMI.pac63.s10.e0" id="DBMI.pac63.s10.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac63.s11" origId="s11" text="This interaction was not accompanied by ECG changes and its clinical significance is not known."/>
	<sentence id="DBMI.pac63.s12" origId="s12" text="No significant interactions were found between nisoldipine and warfarin or digoxin."/>
	<sentencespan id="DBMI.pac63.sp0" origId="sp0" text="A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily. Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%). No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.">
		<entity charOffset="100-111" id="DBMI.pac63.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="40-52" id="DBMI.pac63.sp0.e1" origId="sp0.e1" text="nisoldipine " type="Active ingredient"/>
		<entity charOffset="131-142" id="DBMI.pac63.sp0.e2" origId="sp0.e2" text="Ranitidine " type="Active ingredient"/>
		<pair e1="DBMI.pac63.sp0.e0" e2="DBMI.pac63.sp0.e1" id="DBMI.pac63.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nisoldipine " precipitant="cimetidine "/>
		<pair e1="DBMI.pac63.sp0.e0" e2="DBMI.pac63.sp0.e2" id="DBMI.pac63.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp0.e1" e2="DBMI.pac63.sp0.e0" id="DBMI.pac63.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp0.e1" e2="DBMI.pac63.sp0.e2" id="DBMI.pac63.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp0.e2" e2="DBMI.pac63.sp0.e0" id="DBMI.pac63.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp0.e2" e2="DBMI.pac63.sp0.e1" id="DBMI.pac63.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="nisoldipine " precipitant="Ranitidine "/>
	</sentencespan>
	<sentencespan id="DBMI.pac63.sp1" origId="sp1" text="CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general. Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels. Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.">
		<entity charOffset="465-475" id="DBMI.pac63.sp1.e0" origId="sp1.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="564-576" id="DBMI.pac63.sp1.e1" origId="sp1.e1" text="nisoldipine " type="Active ingredient"/>
		<entity charOffset="510-522" id="DBMI.pac63.sp1.e2" origId="sp1.e2" text="Nisoldipine " type="Active ingredient"/>
		<pair e1="DBMI.pac63.sp1.e0" e2="DBMI.pac63.sp1.e1" id="DBMI.pac63.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nisoldipine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac63.sp1.e0" e2="DBMI.pac63.sp1.e2" id="DBMI.pac63.sp1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Nisoldipine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac63.sp1.e1" e2="DBMI.pac63.sp1.e0" id="DBMI.pac63.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp1.e1" e2="DBMI.pac63.sp1.e2" id="DBMI.pac63.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp1.e2" e2="DBMI.pac63.sp1.e0" id="DBMI.pac63.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp1.e2" e2="DBMI.pac63.sp1.e1" id="DBMI.pac63.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac63.sp2" origId="sp2" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant. Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine. The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.">
		<entity charOffset="1123-1133" id="DBMI.pac63.sp2.e0" origId="sp2.e0" text="Quinidine " type="Active ingredient"/>
		<entity charOffset="1186-1198" id="DBMI.pac63.sp2.e1" origId="sp2.e1" text="nisoldipine " type="Active ingredient"/>
		<entity charOffset="818-827" id="DBMI.pac63.sp2.e2" origId="sp2.e2" text="atenolol " type="Active ingredient"/>
		<entity charOffset="828-840" id="DBMI.pac63.sp2.e3" origId="sp2.e3" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac63.sp2.e0" e2="DBMI.pac63.sp2.e1" id="DBMI.pac63.sp2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nisoldipine " precipitant="Quinidine "/>
		<pair e1="DBMI.pac63.sp2.e0" e2="DBMI.pac63.sp2.e2" id="DBMI.pac63.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp2.e0" e2="DBMI.pac63.sp2.e3" id="DBMI.pac63.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp2.e1" e2="DBMI.pac63.sp2.e0" id="DBMI.pac63.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp2.e1" e2="DBMI.pac63.sp2.e2" id="DBMI.pac63.sp2.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="nisoldipine "/>
		<pair e1="DBMI.pac63.sp2.e1" e2="DBMI.pac63.sp2.e3" id="DBMI.pac63.sp2.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="nisoldipine "/>
		<pair e1="DBMI.pac63.sp2.e2" e2="DBMI.pac63.sp2.e0" id="DBMI.pac63.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp2.e2" e2="DBMI.pac63.sp2.e1" id="DBMI.pac63.sp2.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nisoldipine " precipitant="atenolol "/>
		<pair e1="DBMI.pac63.sp2.e2" e2="DBMI.pac63.sp2.e3" id="DBMI.pac63.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp2.e3" e2="DBMI.pac63.sp2.e0" id="DBMI.pac63.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac63.sp2.e3" e2="DBMI.pac63.sp2.e1" id="DBMI.pac63.sp2.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nisoldipine " precipitant="propranolol "/>
		<pair e1="DBMI.pac63.sp2.e3" e2="DBMI.pac63.sp2.e2" id="DBMI.pac63.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac63.sp3" origId="sp3" text="Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration. Immediate release nisoldipine increased plasma quinidine concentrations by about 20%. This interaction was not accompanied by ECG changes and its clinical significance is not known.">
		<entity charOffset="1256-1268" id="DBMI.pac63.sp3.e0" origId="sp3.e0" text="nisoldipine " type="Active ingredient"/>
		<entity charOffset="1285-1295" id="DBMI.pac63.sp3.e1" origId="sp3.e1" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac63.sp3.e0" e2="DBMI.pac63.sp3.e1" id="DBMI.pac63.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="quinidine " precipitant="nisoldipine "/>
		<pair e1="DBMI.pac63.sp3.e1" e2="DBMI.pac63.sp3.e0" id="DBMI.pac63.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac63.sp4" origId="sp4" text="No significant interactions were found between nisoldipine and warfarin or digoxin."/>
</document>

<document id="DBMI.pac65" origId="pac65">
	<sentence id="DBMI.pac65.s0" origId="s0" text="When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold.">
		<entity charOffset="69-80" id="DBMI.pac65.s0.e0" origId="s0.e0" text="nefazodone " type="Active ingredient"/>
		<entity charOffset="110-120" id="DBMI.pac65.s0.e1" origId="s0.e1" text="triazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac65.s0.e0" e2="DBMI.pac65.s0.e1" id="DBMI.pac65.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="triazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac65.s0.e1" e2="DBMI.pac65.s0.e0" id="DBMI.pac65.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac65.s1" origId="s1" text="Nefazodone plasma concentrations were unaffected by triazolam.">
		<entity charOffset="251-261" id="DBMI.pac65.s1.e0" origId="s1.e0" text="triazolam " type="Active ingredient"/>
		<entity charOffset="199-210" id="DBMI.pac65.s1.e1" origId="s1.e1" text="Nefazodone " type="Active ingredient"/>
		<pair e1="DBMI.pac65.s1.e0" e2="DBMI.pac65.s1.e1" id="DBMI.pac65.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Nefazodone " precipitant="triazolam "/>
		<pair e1="DBMI.pac65.s1.e1" e2="DBMI.pac65.s1.e0" id="DBMI.pac65.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac65.s2" origId="s2" text="Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests."/>
	<sentence id="DBMI.pac65.s3" origId="s3" text="If triazolam is coadministered with nefazodone, a 75% reduction in the initial triazolam dosage is recommended."/>
	<sentence id="DBMI.pac65.s4" origId="s4" text="Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, including the elderly."/>
	<sentence id="DBMI.pac65.s5" origId="s5" text="In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see CONTRAINDICATIONS and PRECAUTIONS)."/>
	<sentencespan id="DBMI.pac65.sp0" origId="sp0" text="When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. Nefazodone plasma concentrations were unaffected by triazolam. Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests.">
		<entity charOffset="251-261" id="DBMI.pac65.sp0.e0" origId="sp0.e0" text="triazolam " type="Active ingredient"/>
		<entity charOffset="199-210" id="DBMI.pac65.sp0.e1" origId="sp0.e1" text="Nefazodone " type="Active ingredient"/>
		<entity charOffset="69-80" id="DBMI.pac65.sp0.e2" origId="sp0.e2" text="nefazodone " type="Active ingredient"/>
		<pair e1="DBMI.pac65.sp0.e0" e2="DBMI.pac65.sp0.e1" id="DBMI.pac65.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Nefazodone " precipitant="triazolam "/>
		<pair e1="DBMI.pac65.sp0.e0" e2="DBMI.pac65.sp0.e2" id="DBMI.pac65.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac65.sp0.e1" e2="DBMI.pac65.sp0.e0" id="DBMI.pac65.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac65.sp0.e1" e2="DBMI.pac65.sp0.e2" id="DBMI.pac65.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac65.sp0.e2" e2="DBMI.pac65.sp0.e0" id="DBMI.pac65.sp0.p4" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="triazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac65.sp0.e2" e2="DBMI.pac65.sp0.e1" id="DBMI.pac65.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac65.sp1" origId="sp1" text="If triazolam is coadministered with nefazodone, a 75% reduction in the initial triazolam dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see CONTRAINDICATIONS and PRECAUTIONS)."/>
</document>

<document id="DBMI.pac66" origId="pac66">
	<sentence id="DBMI.pac66.s0" origId="s0" text="When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold.">
		<entity charOffset="31-42" id="DBMI.pac66.s0.e0" origId="s0.e0" text="nefazodone " type="Active ingredient"/>
		<entity charOffset="5-16" id="DBMI.pac66.s0.e1" origId="s0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac66.s0.e0" e2="DBMI.pac66.s0.e1" id="DBMI.pac66.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac66.s0.e1" e2="DBMI.pac66.s0.e0" id="DBMI.pac66.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac66.s1" origId="s1" text="Nefazodone plasma concentrations were unaffected by alprazolam.">
		<entity charOffset="237-248" id="DBMI.pac66.s1.e0" origId="s1.e0" text="alprazolam " type="Active ingredient"/>
		<entity charOffset="185-196" id="DBMI.pac66.s1.e1" origId="s1.e1" text="Nefazodone " type="Active ingredient"/>
		<pair e1="DBMI.pac66.s1.e0" e2="DBMI.pac66.s1.e1" id="DBMI.pac66.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Nefazodone " precipitant="alprazolam "/>
		<pair e1="DBMI.pac66.s1.e1" e2="DBMI.pac66.s1.e0" id="DBMI.pac66.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac66.s2" origId="s2" text="If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended."/>
	<sentence id="DBMI.pac66.s3" origId="s3" text="No dosage adjustment is required for nefazodone hydrochloride."/>
	<sentencespan id="DBMI.pac66.sp0" origId="sp0" text="When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended.">
		<entity charOffset="237-248" id="DBMI.pac66.sp0.e0" origId="sp0.e0" text="alprazolam " type="Active ingredient"/>
		<entity charOffset="185-196" id="DBMI.pac66.sp0.e1" origId="sp0.e1" text="Nefazodone " type="Active ingredient"/>
		<entity charOffset="31-42" id="DBMI.pac66.sp0.e2" origId="sp0.e2" text="nefazodone " type="Active ingredient"/>
		<pair e1="DBMI.pac66.sp0.e0" e2="DBMI.pac66.sp0.e1" id="DBMI.pac66.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Nefazodone " precipitant="alprazolam "/>
		<pair e1="DBMI.pac66.sp0.e0" e2="DBMI.pac66.sp0.e2" id="DBMI.pac66.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac66.sp0.e1" e2="DBMI.pac66.sp0.e0" id="DBMI.pac66.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac66.sp0.e1" e2="DBMI.pac66.sp0.e2" id="DBMI.pac66.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac66.sp0.e2" e2="DBMI.pac66.sp0.e0" id="DBMI.pac66.sp0.p4" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac66.sp0.e2" e2="DBMI.pac66.sp0.e1" id="DBMI.pac66.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac66.sp1" origId="sp1" text="No dosage adjustment is required for nefazodone hydrochloride."/>
</document>

<document id="DBMI.pac68" origId="pac68">
	<sentence id="DBMI.pac68.s0" origId="s0" text="Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.">
		<entity charOffset="18-27" id="DBMI.pac68.s0.e0" origId="s0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="64-75" id="DBMI.pac68.s0.e1" origId="s0.e1" text="bisoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac68.s0.e0" e2="DBMI.pac68.s0.e1" id="DBMI.pac68.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="bisoprolol " precipitant="rifampin "/>
		<pair e1="DBMI.pac68.s0.e1" e2="DBMI.pac68.s0.e0" id="DBMI.pac68.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac68.s1" origId="s1" text="However, initial dose modification is generally not necessary."/>
	<sentence id="DBMI.pac68.s2" origId="s2" text="Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.">
		<entity charOffset="326-337" id="DBMI.pac68.s2.e0" origId="s2.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="64-75" id="DBMI.pac68.s2.e1" origId="s2.e1" text="bisoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac68.s2.e0" e2="DBMI.pac68.s2.e1" id="DBMI.pac68.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="bisoprolol " precipitant="cimetidine "/>
		<pair e1="DBMI.pac68.s2.e1" e2="DBMI.pac68.s2.e0" id="DBMI.pac68.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac68.s3" origId="s3" text="There was no effect of bisoprolol fumarate on prothrombin times in patients on stable doses of warfarin."/>
	<sentencespan id="DBMI.pac68.sp0" origId="sp0" text="Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.">
		<entity charOffset="18-27" id="DBMI.pac68.sp0.e0" origId="sp0.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="64-75" id="DBMI.pac68.sp0.e1" origId="sp0.e1" text="bisoprolol " type="Active ingredient"/>
		<entity charOffset="326-337" id="DBMI.pac68.sp0.e2" origId="sp0.e2" text="cimetidine " type="Active ingredient"/>
		<pair e1="DBMI.pac68.sp0.e0" e2="DBMI.pac68.sp0.e1" id="DBMI.pac68.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="bisoprolol " precipitant="rifampin "/>
		<pair e1="DBMI.pac68.sp0.e0" e2="DBMI.pac68.sp0.e2" id="DBMI.pac68.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac68.sp0.e1" e2="DBMI.pac68.sp0.e0" id="DBMI.pac68.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac68.sp0.e1" e2="DBMI.pac68.sp0.e2" id="DBMI.pac68.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac68.sp0.e2" e2="DBMI.pac68.sp0.e0" id="DBMI.pac68.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac68.sp0.e2" e2="DBMI.pac68.sp0.e1" id="DBMI.pac68.sp0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="bisoprolol " precipitant="cimetidine "/>
	</sentencespan>
	<sentencespan id="DBMI.pac68.sp1" origId="sp1" text="There was no effect of bisoprolol fumarate on prothrombin times in patients on stable doses of warfarin."/>
</document>

<document id="DBMI.pac7" origId="pac7">
	<sentence id="DBMI.pac7.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Centrally-Acting Drugs and Alcohol\n\nGiven the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol."/>
	<sentence id="DBMI.pac7.s1" origId="s1" text="7.2 Drugs with Hypotensive Effects\n\nBecause of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential."/>
	<sentence id="DBMI.pac7.s2" origId="s2" text="7.3 Levodopa and Dopamine Agonists\n\nRisperidone may antagonize the effects of levodopa and dopamine agonists."/>
	<sentence id="DBMI.pac7.s3" origId="s3" text="7.4 Amitriptyline\n\nAmitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.">
		<entity charOffset="534-548" id="DBMI.pac7.s3.e0" origId="s3.e0" text="Amitriptyline " type="Active ingredient"/>
		<entity charOffset="618-639" id="DBMI.pac7.s3.e1" origId="s3.e1" text="9-hydroxyrisperidone " type="Metabolite"/>
		<entity charOffset="587-599" id="DBMI.pac7.s3.e2" origId="s3.e2" text="risperidone " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s3.e0" e2="DBMI.pac7.s3.e1" id="DBMI.pac7.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="9-hydroxyrisperidone " precipitant="Amitriptyline "/>
		<pair e1="DBMI.pac7.s3.e0" e2="DBMI.pac7.s3.e2" id="DBMI.pac7.s3.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="risperidone " precipitant="Amitriptyline "/>
		<pair e1="DBMI.pac7.s3.e1" e2="DBMI.pac7.s3.e0" id="DBMI.pac7.s3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s3.e1" e2="DBMI.pac7.s3.e2" id="DBMI.pac7.s3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s3.e2" e2="DBMI.pac7.s3.e0" id="DBMI.pac7.s3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s3.e2" e2="DBMI.pac7.s3.e1" id="DBMI.pac7.s3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s4" origId="s4" text="7.5 Cimetidine and Ranitidine\n\nCimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.">
		<entity charOffset="681-692" id="DBMI.pac7.s4.e0" origId="s4.e0" text="Cimetidine " type="Active ingredient"/>
		<entity charOffset="740-752" id="DBMI.pac7.s4.e1" origId="s4.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="696-707" id="DBMI.pac7.s4.e2" origId="s4.e2" text="ranitidine " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s4.e0" e2="DBMI.pac7.s4.e1" id="DBMI.pac7.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac7.s4.e0" e2="DBMI.pac7.s4.e2" id="DBMI.pac7.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s4.e1" e2="DBMI.pac7.s4.e0" id="DBMI.pac7.s4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s4.e1" e2="DBMI.pac7.s4.e2" id="DBMI.pac7.s4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s4.e2" e2="DBMI.pac7.s4.e0" id="DBMI.pac7.s4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s4.e2" e2="DBMI.pac7.s4.e1" id="DBMI.pac7.s4.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="ranitidine "/>
	</sentence>
	<sentence id="DBMI.pac7.s5" origId="s5" text="However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.">
		<entity charOffset="883-894" id="DBMI.pac7.s5.e0" origId="s5.e0" text="ranitidine " type="Active ingredient"/>
		<entity charOffset="915-927" id="DBMI.pac7.s5.e1" origId="s5.e1" text="risperidone " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s5.e0" e2="DBMI.pac7.s5.e1" id="DBMI.pac7.s5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="ranitidine "/>
		<pair e1="DBMI.pac7.s5.e1" e2="DBMI.pac7.s5.e0" id="DBMI.pac7.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s6" origId="s6" text="7.6 Clozapine\n\nChronic administration of clozapine with risperidone may decrease the clearance of risperidone.">
		<entity charOffset="1011-1021" id="DBMI.pac7.s6.e0" origId="s6.e0" text="clozapine " type="Active ingredient"/>
		<entity charOffset="1026-1038" id="DBMI.pac7.s6.e1" origId="s6.e1" text="risperidone " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s6.e0" e2="DBMI.pac7.s6.e1" id="DBMI.pac7.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="clozapine "/>
		<pair e1="DBMI.pac7.s6.e1" e2="DBMI.pac7.s6.e0" id="DBMI.pac7.s6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s7" origId="s7" text="7.7 Lithium\n\nRepeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).">
		<entity charOffset="1118-1130" id="DBMI.pac7.s7.e0" origId="s7.e0" text="risperidone " type="Active ingredient"/>
		<entity charOffset="1223-1231" id="DBMI.pac7.s7.e1" origId="s7.e1" text="lithium " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s7.e0" e2="DBMI.pac7.s7.e1" id="DBMI.pac7.s7.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.s7.e1" e2="DBMI.pac7.s7.e0" id="DBMI.pac7.s7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s8" origId="s8" text="7.8 Valproate\n\nRepeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).">
		<entity charOffset="1278-1290" id="DBMI.pac7.s8.e0" origId="s8.e0" text="risperidone " type="Active ingredient"/>
		<entity charOffset="1391-1401" id="DBMI.pac7.s8.e1" origId="s8.e1" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s8.e0" e2="DBMI.pac7.s8.e1" id="DBMI.pac7.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valproate " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.s8.e1" e2="DBMI.pac7.s8.e0" id="DBMI.pac7.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s9" origId="s9" text="However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.">
		<entity charOffset="1582-1594" id="DBMI.pac7.s9.e0" origId="s9.e0" text="risperidone " type="Active ingredient"/>
		<entity charOffset="1503-1513" id="DBMI.pac7.s9.e1" origId="s9.e1" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s9.e0" e2="DBMI.pac7.s9.e1" id="DBMI.pac7.s9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="valproate " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.s9.e1" e2="DBMI.pac7.s9.e0" id="DBMI.pac7.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s10" origId="s10" text="7.9 Digoxin\n\nRisperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.">
		<entity charOffset="1609-1621" id="DBMI.pac7.s10.e0" origId="s10.e0" text="Risperidone " type="Active ingredient"/>
		<entity charOffset="1712-1720" id="DBMI.pac7.s10.e1" origId="s10.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s10.e0" e2="DBMI.pac7.s10.e1" id="DBMI.pac7.s10.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="Risperidone "/>
		<pair e1="DBMI.pac7.s10.e1" e2="DBMI.pac7.s10.e0" id="DBMI.pac7.s10.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s11" origId="s11" text="7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes\n\nRisperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY]."/>
	<sentence id="DBMI.pac7.s12" origId="s12" text="Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone."/>
	<sentence id="DBMI.pac7.s13" origId="s13" text="Analysis of clinical studies involving a modest number of poor metabolizers (N70) does not suggest that poor and extensive metabolizers have different rates of adverse effects."/>
	<sentence id="DBMI.pac7.s14" origId="s14" text="No comparison of effectiveness in the two groups has been made."/>
	<sentence id="DBMI.pac7.s15" origId="s15" text="In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism."/>
	<sentence id="DBMI.pac7.s16" origId="s16" text="Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.">
		<entity charOffset="2619-2630" id="DBMI.pac7.s16.e0" origId="s16.e0" text="Fluoxetine " type="Active ingredient"/>
		<entity charOffset="2739-2751" id="DBMI.pac7.s16.e1" origId="s16.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="2653-2664" id="DBMI.pac7.s16.e2" origId="s16.e2" text="paroxetine " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s16.e0" e2="DBMI.pac7.s16.e1" id="DBMI.pac7.s16.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="Fluoxetine "/>
		<pair e1="DBMI.pac7.s16.e0" e2="DBMI.pac7.s16.e2" id="DBMI.pac7.s16.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s16.e1" e2="DBMI.pac7.s16.e0" id="DBMI.pac7.s16.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s16.e1" e2="DBMI.pac7.s16.e2" id="DBMI.pac7.s16.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s16.e2" e2="DBMI.pac7.s16.e0" id="DBMI.pac7.s16.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s16.e2" e2="DBMI.pac7.s16.e1" id="DBMI.pac7.s16.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="paroxetine "/>
	</sentence>
	<sentence id="DBMI.pac7.s17" origId="s17" text="Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.">
		<entity charOffset="2798-2809" id="DBMI.pac7.s17.e0" origId="s17.e0" text="Fluoxetine " type="Active ingredient"/>
		<entity charOffset="2852-2873" id="DBMI.pac7.s17.e1" origId="s17.e1" text="9-hydroxyrisperidone " type="Metabolite"/>
		<pair e1="DBMI.pac7.s17.e0" e2="DBMI.pac7.s17.e1" id="DBMI.pac7.s17.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="9-hydroxyrisperidone " precipitant="Fluoxetine "/>
		<pair e1="DBMI.pac7.s17.e1" e2="DBMI.pac7.s17.e0" id="DBMI.pac7.s17.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s18" origId="s18" text="Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.">
		<entity charOffset="2874-2885" id="DBMI.pac7.s18.e0" origId="s18.e0" text="Paroxetine " type="Active ingredient"/>
		<entity charOffset="2914-2935" id="DBMI.pac7.s18.e1" origId="s18.e1" text="9-hydroxyrisperidone " type="Metabolite"/>
		<pair e1="DBMI.pac7.s18.e0" e2="DBMI.pac7.s18.e1" id="DBMI.pac7.s18.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="9-hydroxyrisperidone " precipitant="Paroxetine "/>
		<pair e1="DBMI.pac7.s18.e1" e2="DBMI.pac7.s18.e0" id="DBMI.pac7.s18.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s19" origId="s19" text="When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone."/>
	<sentence id="DBMI.pac7.s20" origId="s20" text="The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied."/>
	<sentence id="DBMI.pac7.s21" origId="s21" text="Erythromycin:There were no significant interactions between risperidone and erythromycin.">
		<entity charOffset="3315-3327" id="DBMI.pac7.s21.e0" origId="s21.e0" text="risperidone " type="Active ingredient"/>
		<entity charOffset="3331-3344" id="DBMI.pac7.s21.e1" origId="s21.e1" text="erythromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s21.e0" e2="DBMI.pac7.s21.e1" id="DBMI.pac7.s21.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.s21.e1" e2="DBMI.pac7.s21.e0" id="DBMI.pac7.s21.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s22" origId="s22" text="7.11 Carbamazepine and Other Enzyme Inducers\n\nCarbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.">
		<entity charOffset="3392-3406" id="DBMI.pac7.s22.e0" origId="s22.e0" text="Carbamazepine " type="Active ingredient"/>
		<entity charOffset="3492-3513" id="DBMI.pac7.s22.e1" origId="s22.e1" text="9-hydroxyrisperidone " type="Metabolite"/>
		<entity charOffset="3476-3488" id="DBMI.pac7.s22.e2" origId="s22.e2" text="risperidone " type="Active ingredient"/>
		<entity charOffset="3552-3566" id="DBMI.pac7.s22.e3" origId="s22.e3" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s22.e0" e2="DBMI.pac7.s22.e1" id="DBMI.pac7.s22.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="9-hydroxyrisperidone " precipitant="Carbamazepine "/>
		<pair e1="DBMI.pac7.s22.e0" e2="DBMI.pac7.s22.e2" id="DBMI.pac7.s22.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="Carbamazepine "/>
		<pair e1="DBMI.pac7.s22.e0" e2="DBMI.pac7.s22.e3" id="DBMI.pac7.s22.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s22.e1" e2="DBMI.pac7.s22.e0" id="DBMI.pac7.s22.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s22.e1" e2="DBMI.pac7.s22.e2" id="DBMI.pac7.s22.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s22.e1" e2="DBMI.pac7.s22.e3" id="DBMI.pac7.s22.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s22.e2" e2="DBMI.pac7.s22.e0" id="DBMI.pac7.s22.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s22.e2" e2="DBMI.pac7.s22.e1" id="DBMI.pac7.s22.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s22.e2" e2="DBMI.pac7.s22.e3" id="DBMI.pac7.s22.p8" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="carbamazepine " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.s22.e3" e2="DBMI.pac7.s22.e0" id="DBMI.pac7.s22.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s22.e3" e2="DBMI.pac7.s22.e1" id="DBMI.pac7.s22.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s22.e3" e2="DBMI.pac7.s22.e2" id="DBMI.pac7.s22.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s23" origId="s23" text="Plasma concentrations of carbamazepine did not appear to be affected."/>
	<sentence id="DBMI.pac7.s24" origId="s24" text="The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy."/>
	<sentence id="DBMI.pac7.s25" origId="s25" text="Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.">
		<entity charOffset="3827-3837" id="DBMI.pac7.s25.e0" origId="s25.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="3872-3884" id="DBMI.pac7.s25.e1" origId="s25.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="3838-3847" id="DBMI.pac7.s25.e2" origId="s25.e2" text="rifampin " type="Active ingredient"/>
		<entity charOffset="3852-3866" id="DBMI.pac7.s25.e3" origId="s25.e3" text="phenobarbital " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s25.e0" e2="DBMI.pac7.s25.e1" id="DBMI.pac7.s25.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="phenytoin "/>
		<pair e1="DBMI.pac7.s25.e0" e2="DBMI.pac7.s25.e2" id="DBMI.pac7.s25.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s25.e0" e2="DBMI.pac7.s25.e3" id="DBMI.pac7.s25.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s25.e1" e2="DBMI.pac7.s25.e0" id="DBMI.pac7.s25.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s25.e1" e2="DBMI.pac7.s25.e2" id="DBMI.pac7.s25.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s25.e1" e2="DBMI.pac7.s25.e3" id="DBMI.pac7.s25.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s25.e2" e2="DBMI.pac7.s25.e0" id="DBMI.pac7.s25.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s25.e2" e2="DBMI.pac7.s25.e1" id="DBMI.pac7.s25.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="rifampin "/>
		<pair e1="DBMI.pac7.s25.e2" e2="DBMI.pac7.s25.e3" id="DBMI.pac7.s25.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s25.e3" e2="DBMI.pac7.s25.e0" id="DBMI.pac7.s25.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s25.e3" e2="DBMI.pac7.s25.e1" id="DBMI.pac7.s25.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="phenobarbital "/>
		<pair e1="DBMI.pac7.s25.e3" e2="DBMI.pac7.s25.e2" id="DBMI.pac7.s25.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac7.s26" origId="s26" text="7.12 Drugs Metabolized by CYP 2D6\n\nIn vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6."/>
	<sentence id="DBMI.pac7.s27" origId="s27" text="Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway."/>
	<sentence id="DBMI.pac7.s28" origId="s28" text="In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.">
		<entity charOffset="4342-4354" id="DBMI.pac7.s28.e0" origId="s28.e0" text="risperidone " type="Active ingredient"/>
		<entity charOffset="4421-4433" id="DBMI.pac7.s28.e1" origId="s28.e1" text="galantamine " type="Active ingredient"/>
		<entity charOffset="4407-4417" id="DBMI.pac7.s28.e2" origId="s28.e2" text="donepezil " type="Active ingredient"/>
		<pair e1="DBMI.pac7.s28.e0" e2="DBMI.pac7.s28.e1" id="DBMI.pac7.s28.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="galantamine " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.s28.e0" e2="DBMI.pac7.s28.e1" id="DBMI.pac7.s28.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="galantamine " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.s28.e0" e2="DBMI.pac7.s28.e2" id="DBMI.pac7.s28.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="donepezil " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.s28.e1" e2="DBMI.pac7.s28.e0" id="DBMI.pac7.s28.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s28.e1" e2="DBMI.pac7.s28.e2" id="DBMI.pac7.s28.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s28.e2" e2="DBMI.pac7.s28.e0" id="DBMI.pac7.s28.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.s28.e2" e2="DBMI.pac7.s28.e1" id="DBMI.pac7.s28.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac7.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Centrally-Acting Drugs and Alcohol\n\nGiven the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol. 7.2 Drugs with Hypotensive Effects\n\nBecause of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential. 7.3 Levodopa and Dopamine Agonists\n\nRisperidone may antagonize the effects of levodopa and dopamine agonists."/>
	<sentencespan id="DBMI.pac7.sp1" origId="sp1" text="7.4 Amitriptyline\n\nAmitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined. 7.5 Cimetidine and Ranitidine\n\nCimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively. However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.">
		<entity charOffset="534-548" id="DBMI.pac7.sp1.e0" origId="sp1.e0" text="Amitriptyline " type="Active ingredient"/>
		<entity charOffset="618-639" id="DBMI.pac7.sp1.e1" origId="sp1.e1" text="9-hydroxyrisperidone " type="Metabolite"/>
		<entity charOffset="587-599" id="DBMI.pac7.sp1.e2" origId="sp1.e2" text="risperidone " type="Active ingredient"/>
		<entity charOffset="681-692" id="DBMI.pac7.sp1.e3" origId="sp1.e3" text="Cimetidine " type="Active ingredient"/>
		<entity charOffset="696-707" id="DBMI.pac7.sp1.e4" origId="sp1.e4" text="ranitidine " type="Active ingredient"/>
		<pair e1="DBMI.pac7.sp1.e0" e2="DBMI.pac7.sp1.e1" id="DBMI.pac7.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="9-hydroxyrisperidone " precipitant="Amitriptyline "/>
		<pair e1="DBMI.pac7.sp1.e0" e2="DBMI.pac7.sp1.e2" id="DBMI.pac7.sp1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="risperidone " precipitant="Amitriptyline "/>
		<pair e1="DBMI.pac7.sp1.e0" e2="DBMI.pac7.sp1.e3" id="DBMI.pac7.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e0" e2="DBMI.pac7.sp1.e4" id="DBMI.pac7.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e1" e2="DBMI.pac7.sp1.e0" id="DBMI.pac7.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e1" e2="DBMI.pac7.sp1.e2" id="DBMI.pac7.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e1" e2="DBMI.pac7.sp1.e3" id="DBMI.pac7.sp1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e1" e2="DBMI.pac7.sp1.e4" id="DBMI.pac7.sp1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e2" e2="DBMI.pac7.sp1.e0" id="DBMI.pac7.sp1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e2" e2="DBMI.pac7.sp1.e1" id="DBMI.pac7.sp1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e2" e2="DBMI.pac7.sp1.e3" id="DBMI.pac7.sp1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e2" e2="DBMI.pac7.sp1.e4" id="DBMI.pac7.sp1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e3" e2="DBMI.pac7.sp1.e0" id="DBMI.pac7.sp1.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e3" e2="DBMI.pac7.sp1.e1" id="DBMI.pac7.sp1.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e3" e2="DBMI.pac7.sp1.e2" id="DBMI.pac7.sp1.p14" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac7.sp1.e3" e2="DBMI.pac7.sp1.e4" id="DBMI.pac7.sp1.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e4" e2="DBMI.pac7.sp1.e0" id="DBMI.pac7.sp1.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e4" e2="DBMI.pac7.sp1.e1" id="DBMI.pac7.sp1.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp1.e4" e2="DBMI.pac7.sp1.e2" id="DBMI.pac7.sp1.p18" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="ranitidine "/>
		<pair e1="DBMI.pac7.sp1.e4" e2="DBMI.pac7.sp1.e2" id="DBMI.pac7.sp1.p19" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="ranitidine "/>
		<pair e1="DBMI.pac7.sp1.e4" e2="DBMI.pac7.sp1.e3" id="DBMI.pac7.sp1.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac7.sp2" origId="sp2" text="7.6 Clozapine\n\nChronic administration of clozapine with risperidone may decrease the clearance of risperidone. 7.7 Lithium\n\nRepeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13). 7.8 Valproate\n\nRepeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).">
		<entity charOffset="1011-1021" id="DBMI.pac7.sp2.e0" origId="sp2.e0" text="clozapine " type="Active ingredient"/>
		<entity charOffset="1026-1038" id="DBMI.pac7.sp2.e1" origId="sp2.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="1223-1231" id="DBMI.pac7.sp2.e2" origId="sp2.e2" text="lithium " type="Active ingredient"/>
		<entity charOffset="1391-1401" id="DBMI.pac7.sp2.e3" origId="sp2.e3" text="valproate " type="Active ingredient"/>
		<pair e1="DBMI.pac7.sp2.e0" e2="DBMI.pac7.sp2.e1" id="DBMI.pac7.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="clozapine "/>
		<pair e1="DBMI.pac7.sp2.e0" e2="DBMI.pac7.sp2.e2" id="DBMI.pac7.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp2.e0" e2="DBMI.pac7.sp2.e3" id="DBMI.pac7.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp2.e1" e2="DBMI.pac7.sp2.e0" id="DBMI.pac7.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp2.e1" e2="DBMI.pac7.sp2.e2" id="DBMI.pac7.sp2.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.sp2.e1" e2="DBMI.pac7.sp2.e3" id="DBMI.pac7.sp2.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valproate " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.sp2.e2" e2="DBMI.pac7.sp2.e0" id="DBMI.pac7.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp2.e2" e2="DBMI.pac7.sp2.e1" id="DBMI.pac7.sp2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp2.e2" e2="DBMI.pac7.sp2.e3" id="DBMI.pac7.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp2.e3" e2="DBMI.pac7.sp2.e0" id="DBMI.pac7.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp2.e3" e2="DBMI.pac7.sp2.e1" id="DBMI.pac7.sp2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp2.e3" e2="DBMI.pac7.sp2.e2" id="DBMI.pac7.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac7.sp3" origId="sp3" text="However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. 7.9 Digoxin\n\nRisperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. 7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes\n\nRisperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].">
		<entity charOffset="1582-1594" id="DBMI.pac7.sp3.e0" origId="sp3.e0" text="risperidone " type="Active ingredient"/>
		<entity charOffset="1503-1513" id="DBMI.pac7.sp3.e1" origId="sp3.e1" text="valproate " type="Active ingredient"/>
		<entity charOffset="1609-1621" id="DBMI.pac7.sp3.e2" origId="sp3.e2" text="Risperidone " type="Active ingredient"/>
		<entity charOffset="1712-1720" id="DBMI.pac7.sp3.e3" origId="sp3.e3" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac7.sp3.e0" e2="DBMI.pac7.sp3.e1" id="DBMI.pac7.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="valproate " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.sp3.e0" e2="DBMI.pac7.sp3.e2" id="DBMI.pac7.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp3.e0" e2="DBMI.pac7.sp3.e3" id="DBMI.pac7.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp3.e1" e2="DBMI.pac7.sp3.e0" id="DBMI.pac7.sp3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp3.e1" e2="DBMI.pac7.sp3.e2" id="DBMI.pac7.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp3.e1" e2="DBMI.pac7.sp3.e3" id="DBMI.pac7.sp3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp3.e2" e2="DBMI.pac7.sp3.e0" id="DBMI.pac7.sp3.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp3.e2" e2="DBMI.pac7.sp3.e1" id="DBMI.pac7.sp3.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp3.e2" e2="DBMI.pac7.sp3.e3" id="DBMI.pac7.sp3.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="Risperidone "/>
		<pair e1="DBMI.pac7.sp3.e3" e2="DBMI.pac7.sp3.e0" id="DBMI.pac7.sp3.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp3.e3" e2="DBMI.pac7.sp3.e1" id="DBMI.pac7.sp3.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp3.e3" e2="DBMI.pac7.sp3.e2" id="DBMI.pac7.sp3.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac7.sp4" origId="sp4" text="Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone. Analysis of clinical studies involving a modest number of poor metabolizers (N70) does not suggest that poor and extensive metabolizers have different rates of adverse effects. No comparison of effectiveness in the two groups has been made."/>
	<sentencespan id="DBMI.pac7.sp5" origId="sp5" text="In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism. Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.">
		<entity charOffset="2619-2630" id="DBMI.pac7.sp5.e0" origId="sp5.e0" text="Fluoxetine " type="Active ingredient"/>
		<entity charOffset="2739-2751" id="DBMI.pac7.sp5.e1" origId="sp5.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="2653-2664" id="DBMI.pac7.sp5.e2" origId="sp5.e2" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="2852-2873" id="DBMI.pac7.sp5.e3" origId="sp5.e3" text="9-hydroxyrisperidone " type="Metabolite"/>
		<pair e1="DBMI.pac7.sp5.e0" e2="DBMI.pac7.sp5.e1" id="DBMI.pac7.sp5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="Fluoxetine "/>
		<pair e1="DBMI.pac7.sp5.e0" e2="DBMI.pac7.sp5.e2" id="DBMI.pac7.sp5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp5.e0" e2="DBMI.pac7.sp5.e3" id="DBMI.pac7.sp5.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="9-hydroxyrisperidone " precipitant="Fluoxetine "/>
		<pair e1="DBMI.pac7.sp5.e1" e2="DBMI.pac7.sp5.e0" id="DBMI.pac7.sp5.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp5.e1" e2="DBMI.pac7.sp5.e2" id="DBMI.pac7.sp5.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp5.e1" e2="DBMI.pac7.sp5.e3" id="DBMI.pac7.sp5.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp5.e2" e2="DBMI.pac7.sp5.e0" id="DBMI.pac7.sp5.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp5.e2" e2="DBMI.pac7.sp5.e1" id="DBMI.pac7.sp5.p7" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="paroxetine "/>
		<pair e1="DBMI.pac7.sp5.e2" e2="DBMI.pac7.sp5.e3" id="DBMI.pac7.sp5.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp5.e3" e2="DBMI.pac7.sp5.e0" id="DBMI.pac7.sp5.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp5.e3" e2="DBMI.pac7.sp5.e1" id="DBMI.pac7.sp5.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp5.e3" e2="DBMI.pac7.sp5.e2" id="DBMI.pac7.sp5.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac7.sp6" origId="sp6" text="Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%. When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone. The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.">
		<entity charOffset="2874-2885" id="DBMI.pac7.sp6.e0" origId="sp6.e0" text="Paroxetine " type="Active ingredient"/>
		<entity charOffset="2914-2935" id="DBMI.pac7.sp6.e1" origId="sp6.e1" text="9-hydroxyrisperidone " type="Metabolite"/>
		<pair e1="DBMI.pac7.sp6.e0" e2="DBMI.pac7.sp6.e1" id="DBMI.pac7.sp6.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="9-hydroxyrisperidone " precipitant="Paroxetine "/>
		<pair e1="DBMI.pac7.sp6.e1" e2="DBMI.pac7.sp6.e0" id="DBMI.pac7.sp6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac7.sp7" origId="sp7" text="Erythromycin:There were no significant interactions between risperidone and erythromycin. 7.11 Carbamazepine and Other Enzyme Inducers\n\nCarbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected.">
		<entity charOffset="3315-3327" id="DBMI.pac7.sp7.e0" origId="sp7.e0" text="risperidone " type="Active ingredient"/>
		<entity charOffset="3331-3344" id="DBMI.pac7.sp7.e1" origId="sp7.e1" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="3392-3406" id="DBMI.pac7.sp7.e2" origId="sp7.e2" text="Carbamazepine " type="Active ingredient"/>
		<entity charOffset="3492-3513" id="DBMI.pac7.sp7.e3" origId="sp7.e3" text="9-hydroxyrisperidone " type="Metabolite"/>
		<entity charOffset="3552-3566" id="DBMI.pac7.sp7.e4" origId="sp7.e4" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac7.sp7.e0" e2="DBMI.pac7.sp7.e1" id="DBMI.pac7.sp7.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.sp7.e0" e2="DBMI.pac7.sp7.e2" id="DBMI.pac7.sp7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e0" e2="DBMI.pac7.sp7.e3" id="DBMI.pac7.sp7.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e0" e2="DBMI.pac7.sp7.e4" id="DBMI.pac7.sp7.p3" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="carbamazepine " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.sp7.e1" e2="DBMI.pac7.sp7.e0" id="DBMI.pac7.sp7.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e1" e2="DBMI.pac7.sp7.e2" id="DBMI.pac7.sp7.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e1" e2="DBMI.pac7.sp7.e3" id="DBMI.pac7.sp7.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e1" e2="DBMI.pac7.sp7.e4" id="DBMI.pac7.sp7.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e2" e2="DBMI.pac7.sp7.e0" id="DBMI.pac7.sp7.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="risperidone " precipitant="Carbamazepine "/>
		<pair e1="DBMI.pac7.sp7.e2" e2="DBMI.pac7.sp7.e1" id="DBMI.pac7.sp7.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e2" e2="DBMI.pac7.sp7.e3" id="DBMI.pac7.sp7.p10" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="9-hydroxyrisperidone " precipitant="Carbamazepine "/>
		<pair e1="DBMI.pac7.sp7.e2" e2="DBMI.pac7.sp7.e4" id="DBMI.pac7.sp7.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e3" e2="DBMI.pac7.sp7.e0" id="DBMI.pac7.sp7.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e3" e2="DBMI.pac7.sp7.e1" id="DBMI.pac7.sp7.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e3" e2="DBMI.pac7.sp7.e2" id="DBMI.pac7.sp7.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e3" e2="DBMI.pac7.sp7.e4" id="DBMI.pac7.sp7.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e4" e2="DBMI.pac7.sp7.e0" id="DBMI.pac7.sp7.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e4" e2="DBMI.pac7.sp7.e1" id="DBMI.pac7.sp7.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e4" e2="DBMI.pac7.sp7.e2" id="DBMI.pac7.sp7.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp7.e4" e2="DBMI.pac7.sp7.e3" id="DBMI.pac7.sp7.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac7.sp8" origId="sp8" text="The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy. Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment. 7.12 Drugs Metabolized by CYP 2D6\n\nIn vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.">
		<entity charOffset="3827-3837" id="DBMI.pac7.sp8.e0" origId="sp8.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="3872-3884" id="DBMI.pac7.sp8.e1" origId="sp8.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="3838-3847" id="DBMI.pac7.sp8.e2" origId="sp8.e2" text="rifampin " type="Active ingredient"/>
		<entity charOffset="3852-3866" id="DBMI.pac7.sp8.e3" origId="sp8.e3" text="phenobarbital " type="Active ingredient"/>
		<pair e1="DBMI.pac7.sp8.e0" e2="DBMI.pac7.sp8.e1" id="DBMI.pac7.sp8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="phenytoin "/>
		<pair e1="DBMI.pac7.sp8.e0" e2="DBMI.pac7.sp8.e2" id="DBMI.pac7.sp8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp8.e0" e2="DBMI.pac7.sp8.e3" id="DBMI.pac7.sp8.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp8.e1" e2="DBMI.pac7.sp8.e0" id="DBMI.pac7.sp8.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp8.e1" e2="DBMI.pac7.sp8.e2" id="DBMI.pac7.sp8.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp8.e1" e2="DBMI.pac7.sp8.e3" id="DBMI.pac7.sp8.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp8.e2" e2="DBMI.pac7.sp8.e0" id="DBMI.pac7.sp8.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp8.e2" e2="DBMI.pac7.sp8.e1" id="DBMI.pac7.sp8.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="rifampin "/>
		<pair e1="DBMI.pac7.sp8.e2" e2="DBMI.pac7.sp8.e3" id="DBMI.pac7.sp8.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp8.e3" e2="DBMI.pac7.sp8.e0" id="DBMI.pac7.sp8.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp8.e3" e2="DBMI.pac7.sp8.e1" id="DBMI.pac7.sp8.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="phenobarbital "/>
		<pair e1="DBMI.pac7.sp8.e3" e2="DBMI.pac7.sp8.e2" id="DBMI.pac7.sp8.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac7.sp9" origId="sp9" text="Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.">
		<entity charOffset="4342-4354" id="DBMI.pac7.sp9.e0" origId="sp9.e0" text="risperidone " type="Active ingredient"/>
		<entity charOffset="4421-4433" id="DBMI.pac7.sp9.e1" origId="sp9.e1" text="galantamine " type="Active ingredient"/>
		<entity charOffset="4407-4417" id="DBMI.pac7.sp9.e2" origId="sp9.e2" text="donepezil " type="Active ingredient"/>
		<pair e1="DBMI.pac7.sp9.e0" e2="DBMI.pac7.sp9.e1" id="DBMI.pac7.sp9.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="galantamine " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.sp9.e0" e2="DBMI.pac7.sp9.e1" id="DBMI.pac7.sp9.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="galantamine " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.sp9.e0" e2="DBMI.pac7.sp9.e2" id="DBMI.pac7.sp9.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="donepezil " precipitant="risperidone "/>
		<pair e1="DBMI.pac7.sp9.e1" e2="DBMI.pac7.sp9.e0" id="DBMI.pac7.sp9.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp9.e1" e2="DBMI.pac7.sp9.e2" id="DBMI.pac7.sp9.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp9.e2" e2="DBMI.pac7.sp9.e0" id="DBMI.pac7.sp9.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac7.sp9.e2" e2="DBMI.pac7.sp9.e1" id="DBMI.pac7.sp9.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac70" origId="pac70">
	<sentence id="DBMI.pac70.s0" origId="s0" text="Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest.">
		<entity charOffset="64-73" id="DBMI.pac70.s0.e0" origId="s0.e0" text="aluminum " type="Active ingredient"/>
		<entity charOffset="18-26" id="DBMI.pac70.s0.e1" origId="s0.e1" text="sotalol " type="Active ingredient"/>
		<entity charOffset="83-93" id="DBMI.pac70.s0.e2" origId="s0.e2" text="magnesium " type="Active ingredient"/>
		<pair e1="DBMI.pac70.s0.e0" e2="DBMI.pac70.s0.e1" id="DBMI.pac70.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sotalol " precipitant="aluminum "/>
		<pair e1="DBMI.pac70.s0.e0" e2="DBMI.pac70.s0.e2" id="DBMI.pac70.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac70.s0.e1" e2="DBMI.pac70.s0.e0" id="DBMI.pac70.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac70.s0.e1" e2="DBMI.pac70.s0.e2" id="DBMI.pac70.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac70.s0.e2" e2="DBMI.pac70.s0.e0" id="DBMI.pac70.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac70.s0.e2" e2="DBMI.pac70.s0.e1" id="DBMI.pac70.s0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sotalol " precipitant="magnesium "/>
	</sentence>
	<sentence id="DBMI.pac70.s1" origId="s1" text="Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol."/>
	<sentencespan id="DBMI.pac70.sp0" origId="sp0" text="Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol.">
		<entity charOffset="64-73" id="DBMI.pac70.sp0.e0" origId="sp0.e0" text="aluminum " type="Active ingredient"/>
		<entity charOffset="18-26" id="DBMI.pac70.sp0.e1" origId="sp0.e1" text="sotalol " type="Active ingredient"/>
		<entity charOffset="83-93" id="DBMI.pac70.sp0.e2" origId="sp0.e2" text="magnesium " type="Active ingredient"/>
		<pair e1="DBMI.pac70.sp0.e0" e2="DBMI.pac70.sp0.e1" id="DBMI.pac70.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sotalol " precipitant="aluminum "/>
		<pair e1="DBMI.pac70.sp0.e0" e2="DBMI.pac70.sp0.e2" id="DBMI.pac70.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac70.sp0.e1" e2="DBMI.pac70.sp0.e0" id="DBMI.pac70.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac70.sp0.e1" e2="DBMI.pac70.sp0.e2" id="DBMI.pac70.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac70.sp0.e2" e2="DBMI.pac70.sp0.e0" id="DBMI.pac70.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac70.sp0.e2" e2="DBMI.pac70.sp0.e1" id="DBMI.pac70.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sotalol " precipitant="magnesium "/>
	</sentencespan>
</document>

<document id="DBMI.pac72" origId="pac72">
	<sentence id="DBMI.pac72.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CNS Depressants\nOther central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma."/>
	<sentence id="DBMI.pac72.s1" origId="s1" text="Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents."/>
	<sentence id="DBMI.pac72.s2" origId="s2" text="7.2 Muscle Relaxants\nOxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression."/>
	<sentence id="DBMI.pac72.s3" origId="s3" text="7.3 Mixed Agonist/Antagonist Opioid Analgesics\nDo not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride."/>
	<sentence id="DBMI.pac72.s4" origId="s4" text="In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms."/>
	<sentence id="DBMI.pac72.s5" origId="s5" text="7.4 Agents Affecting Cytochrome P450 Enzymes\n\nCYP3A4 Inhibitors\nA published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.">
		<entity charOffset="1123-1136" id="DBMI.pac72.s5.e0" origId="s5.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="1210-1220" id="DBMI.pac72.s5.e1" origId="s5.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac72.s5.e0" e2="DBMI.pac72.s5.e1" id="DBMI.pac72.s5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="oxycodone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac72.s5.e1" e2="DBMI.pac72.s5.e0" id="DBMI.pac72.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac72.s6" origId="s6" text="Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects."/>
	<sentence id="DBMI.pac72.s7" origId="s7" text="If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors."/>
	<sentence id="DBMI.pac72.s8" origId="s8" text="Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved."/>
	<sentence id="DBMI.pac72.s9" origId="s9" text="[see Clinical Pharmacology (12.3)]\n\nCYP3A4 Inducers\nA published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.">
		<entity charOffset="1800-1809" id="DBMI.pac72.s9.e0" origId="s9.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="1877-1887" id="DBMI.pac72.s9.e1" origId="s9.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac72.s9.e0" e2="DBMI.pac72.s9.e1" id="DBMI.pac72.s9.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="oxycodone " precipitant="rifampin "/>
		<pair e1="DBMI.pac72.s9.e1" e2="DBMI.pac72.s9.e0" id="DBMI.pac72.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac72.s10" origId="s10" text="Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone."/>
	<sentence id="DBMI.pac72.s11" origId="s11" text="If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inducers."/>
	<sentence id="DBMI.pac72.s12" origId="s12" text="Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved."/>
	<sentence id="DBMI.pac72.s13" origId="s13" text="[see Clinical Pharmacology (12.3)]\n\nCYP2D6 Inhibitors\nOxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6."/>
	<sentence id="DBMI.pac72.s14" origId="s14" text="While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent."/>
	<sentence id="DBMI.pac72.s15" origId="s15" text="However, clinicians should be aware of this possible interaction."/>
	<sentence id="DBMI.pac72.s16" origId="s16" text="7.5 Monoamine Oxidase Inhibitors (MAOIs)\n\nNo specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate."/>
	<sentence id="DBMI.pac72.s17" origId="s17" text="7.6 Anticholinergics\n\nAnticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus."/>
	<sentencespan id="DBMI.pac72.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CNS Depressants\nOther central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma. Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents. 7.2 Muscle Relaxants\nOxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression."/>
	<sentencespan id="DBMI.pac72.sp1" origId="sp1" text="7.3 Mixed Agonist/Antagonist Opioid Analgesics\nDo not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms. 7.4 Agents Affecting Cytochrome P450 Enzymes\n\nCYP3A4 Inhibitors\nA published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.">
		<entity charOffset="1123-1136" id="DBMI.pac72.sp1.e0" origId="sp1.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="1210-1220" id="DBMI.pac72.sp1.e1" origId="sp1.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac72.sp1.e0" e2="DBMI.pac72.sp1.e1" id="DBMI.pac72.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="oxycodone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac72.sp1.e1" e2="DBMI.pac72.sp1.e0" id="DBMI.pac72.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac72.sp2" origId="sp2" text="Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects. If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors. Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved."/>
	<sentencespan id="DBMI.pac72.sp3" origId="sp3" text="[see Clinical Pharmacology (12.3)]\n\nCYP3A4 Inducers\nA published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations. Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone. If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inducers.">
		<entity charOffset="1800-1809" id="DBMI.pac72.sp3.e0" origId="sp3.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="1877-1887" id="DBMI.pac72.sp3.e1" origId="sp3.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac72.sp3.e0" e2="DBMI.pac72.sp3.e1" id="DBMI.pac72.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="oxycodone " precipitant="rifampin "/>
		<pair e1="DBMI.pac72.sp3.e1" e2="DBMI.pac72.sp3.e0" id="DBMI.pac72.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac72.sp4" origId="sp4" text="Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved. [see Clinical Pharmacology (12.3)]\n\nCYP2D6 Inhibitors\nOxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent."/>
	<sentencespan id="DBMI.pac72.sp5" origId="sp5" text="However, clinicians should be aware of this possible interaction. 7.5 Monoamine Oxidase Inhibitors (MAOIs)\n\nNo specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate. 7.6 Anticholinergics\n\nAnticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus."/>
</document>

<document id="DBMI.pac73" origId="pac73">
	<sentence id="DBMI.pac73.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\nOxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses."/>
	<sentence id="DBMI.pac73.s1" origId="s1" text="In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system."/>
	<sentence id="DBMI.pac73.s2" origId="s2" text="Effects on the Central Nervous System (CNS)\nThe principal therapeutic action of oxycodone hydrochloride is analgesia."/>
	<sentence id="DBMI.pac73.s3" origId="s3" text="Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects."/>
	<sentence id="DBMI.pac73.s4" origId="s4" text="In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers."/>
	<sentence id="DBMI.pac73.s5" origId="s5" text="Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla."/>
	<sentence id="DBMI.pac73.s6" origId="s6" text="Oxycodone causes miosis, even in total darkness."/>
	<sentence id="DBMI.pac73.s7" origId="s7" text="Effects on the Gastrointestinal Tract And Other Smooth Muscle\nGastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride."/>
	<sentence id="DBMI.pac73.s8" origId="s8" text="Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla."/>
	<sentence id="DBMI.pac73.s9" origId="s9" text="The frequency and severity of emesis gradually diminishes with time."/>
	<sentence id="DBMI.pac73.s10" origId="s10" text="Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum."/>
	<sentence id="DBMI.pac73.s11" origId="s11" text="Digestion of food in the small intestine is delayed and propulsive contractions are decreased."/>
	<sentence id="DBMI.pac73.s12" origId="s12" text="Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm."/>
	<sentence id="DBMI.pac73.s13" origId="s13" text="The end result may be constipation."/>
	<sentence id="DBMI.pac73.s14" origId="s14" text="Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase."/>
	<sentence id="DBMI.pac73.s15" origId="s15" text="Effects on the Cardiovascular System\nIn therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes."/>
	<sentence id="DBMI.pac73.s16" origId="s16" text="Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension."/>
	<sentence id="DBMI.pac73.s17" origId="s17" text="Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension."/>
	<sentence id="DBMI.pac73.s18" origId="s18" text="Caution should also be used in patients with corpulmonale who have received therapeutic doses of opioids."/>
	<sentence id="DBMI.pac73.s19" origId="s19" text="Endocrine System\nOpioid agonists have been shown to have a variety of effects on the secretion of hormones."/>
	<sentence id="DBMI.pac73.s20" origId="s20" text="Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans."/>
	<sentence id="DBMI.pac73.s21" origId="s21" text="They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs."/>
	<sentence id="DBMI.pac73.s22" origId="s22" text="Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids."/>
	<sentence id="DBMI.pac73.s23" origId="s23" text="Immune System\nOpioids have been shown to have a variety of effects on components of the immune system in in-vitro and animal models."/>
	<sentence id="DBMI.pac73.s24" origId="s24" text="The clinical significance of these findings is unknown."/>
	<sentence id="DBMI.pac73.s25" origId="s25" text="12.3 Pharmacokinetics\nThe activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone."/>
	<sentence id="DBMI.pac73.s26" origId="s26" text="The oral bioavailability of oxycodone is 60% to 87%."/>
	<sentence id="DBMI.pac73.s27" origId="s27" text="Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites."/>
	<sentence id="DBMI.pac73.s28" origId="s28" text="The apparent elimination half-life of oxycodone is approximately 4 hours."/>
	<sentence id="DBMI.pac73.s29" origId="s29" text="Absorption\nAbout 60 to 87% of an oral dose reaches the systemic circulation in comparison to a parenteral dose."/>
	<sentence id="DBMI.pac73.s30" origId="s30" text="This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone."/>
	<sentence id="DBMI.pac73.s31" origId="s31" text="Food Effects\nWhen administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%."/>
	<sentence id="DBMI.pac73.s32" origId="s32" text="Food caused a delay in Tmax (1.00 to 3.00 hours)."/>
	<sentence id="DBMI.pac73.s33" origId="s33" text="Distribution\nFollowing intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg."/>
	<sentence id="DBMI.pac73.s34" origId="s34" text="Plasma protein binding of oxycodone at 37C and a pH of 7.4 was about 45%."/>
	<sentence id="DBMI.pac73.s35" origId="s35" text="Oxycodone has been found in breast milk."/>
	<sentence id="DBMI.pac73.s36" origId="s36" text="Metabolism\nOxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated."/>
	<sentence id="DBMI.pac73.s37" origId="s37" text="CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone."/>
	<sentence id="DBMI.pac73.s38" origId="s38" text="Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs."/>
	<sentence id="DBMI.pac73.s39" origId="s39" text="The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone."/>
	<sentence id="DBMI.pac73.s40" origId="s40" text="Noroxycodone is reported to be a considerably weaker analgesic than oxycodone."/>
	<sentence id="DBMI.pac73.s41" origId="s41" text="Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations."/>
	<sentence id="DBMI.pac73.s42" origId="s42" text="The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations."/>
	<sentence id="DBMI.pac73.s43" origId="s43" text="The analgesic activity profile of other metabolites is not known."/>
	<sentence id="DBMI.pac73.s44" origId="s44" text="Excretion\nOxycodone and its metabolites are excreted primarily via the kidney."/>
	<sentence id="DBMI.pac73.s45" origId="s45" text="The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone &lt;14%; both free and conjugated noroxycodone have been found in the urine but not quantified."/>
	<sentence id="DBMI.pac73.s46" origId="s46" text="The total plasma clearance was 0.8 L/min for adults."/>
	<sentence id="DBMI.pac73.s47" origId="s47" text="Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours."/>
	<sentence id="DBMI.pac73.s48" origId="s48" text="Special Populations\n\nElderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65."/>
	<sentence id="DBMI.pac73.s49" origId="s49" text="Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone."/>
	<sentence id="DBMI.pac73.s50" origId="s50" text="Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance &lt;60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function."/>
	<sentence id="DBMI.pac73.s51" origId="s51" text="Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment."/>
	<sentence id="DBMI.pac73.s52" origId="s52" text="Drug-Drug Interactions\n\nCYP3A4 Inhibitors\nCYP3A4 is the major enzyme involved in noroxycodone formation."/>
	<sentence id="DBMI.pac73.s53" origId="s53" text="A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.">
		<entity charOffset="6794-6807" id="DBMI.pac73.s53.e0" origId="s53.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="6838-6848" id="DBMI.pac73.s53.e1" origId="s53.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac73.s53.e0" e2="DBMI.pac73.s53.e1" id="DBMI.pac73.s53.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="oxycodone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac73.s53.e1" e2="DBMI.pac73.s53.e0" id="DBMI.pac73.s53.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac73.s54" origId="s54" text="CYP3A4 Inducers\nA published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.">
		<entity charOffset="6968-6977" id="DBMI.pac73.s54.e0" origId="s54.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="7024-7034" id="DBMI.pac73.s54.e1" origId="s54.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac73.s54.e0" e2="DBMI.pac73.s54.e1" id="DBMI.pac73.s54.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="oxycodone " precipitant="rifampin "/>
		<pair e1="DBMI.pac73.s54.e1" e2="DBMI.pac73.s54.e0" id="DBMI.pac73.s54.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac73.s55" origId="s55" text="CYP2D6 Inhibitors\nOxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6."/>
	<sentence id="DBMI.pac73.s56" origId="s56" text="While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent."/>
	<sentencespan id="DBMI.pac73.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\nOxycodone hydrochloride, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses. In addition to analgesia, the widely diverse effects of oxycodone hydrochloride include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system. Effects on the Central Nervous System (CNS)\nThe principal therapeutic action of oxycodone hydrochloride is analgesia."/>
	<sentencespan id="DBMI.pac73.sp1" origId="sp1" text="Although the precise mechanism of the analgesic action is unknown, specific CNS opioid receptors for endogenous compounds with oxycodone hydrochloride-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects. In common with other opioids, oxycodone hydrochloride causes respiratory depression, in part by a direct effect on the brainstem respiratory centers. Oxycodone and related opioids depress the cough reflex by direct effect on the cough center in the medulla."/>
	<sentencespan id="DBMI.pac73.sp2" origId="sp2" text="Oxycodone causes miosis, even in total darkness. Effects on the Gastrointestinal Tract And Other Smooth Muscle\nGastric, biliary and pancreatic secretions are decreased by Oxycodone hydrochloride. Oxycodone hydrochloride, like other opioid analgesics, produces some degree of nausea and vomiting which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla."/>
	<sentencespan id="DBMI.pac73.sp3" origId="sp3" text="The frequency and severity of emesis gradually diminishes with time. Oxycodone hydrochloride may cause a decrease in the secretion of hydrochloric acid in the stomach, may reduce motility, while increasing the tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased."/>
	<sentencespan id="DBMI.pac73.sp4" origId="sp4" text="Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm. The end result may be constipation. Oxycodone hydrochloride may also cause spasm of the sphincter of Oddi and transient elevations in serum amylase."/>
	<sentencespan id="DBMI.pac73.sp5" origId="sp5" text="Effects on the Cardiovascular System\nIn therapeutic doses, Oxycodone hydrochloride, produces peripheral vasodilatation (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes. Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension. Caution should be used in hypovolemic patients, such as those suffering acute myocardial infarction, because oxycodone may cause or further aggravate their hypotension."/>
	<sentencespan id="DBMI.pac73.sp6" origId="sp6" text="Caution should also be used in patients with corpulmonale who have received therapeutic doses of opioids. Endocrine System\nOpioid agonists have been shown to have a variety of effects on the secretion of hormones. Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans."/>
	<sentencespan id="DBMI.pac73.sp7" origId="sp7" text="They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs. Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids. Immune System\nOpioids have been shown to have a variety of effects on components of the immune system in in-vitro and animal models."/>
	<sentencespan id="DBMI.pac73.sp8" origId="sp8" text="The clinical significance of these findings is unknown. 12.3 Pharmacokinetics\nThe activity of oxycodone hydrochloride capsules is primarily due to the parent drug oxycodone. The oral bioavailability of oxycodone is 60% to 87%."/>
	<sentencespan id="DBMI.pac73.sp9" origId="sp9" text="Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated parent and its metabolites. The apparent elimination half-life of oxycodone is approximately 4 hours. Absorption\nAbout 60 to 87% of an oral dose reaches the systemic circulation in comparison to a parenteral dose."/>
	<sentencespan id="DBMI.pac73.sp10" origId="sp10" text="This high oral bioavailability (compared to other opioids) is due to lower pre-systemic and/or first-pass metabolism of oxycodone. Food Effects\nWhen administered with a high-fat meal mean AUC values are increased by 23% and peak concentrations are decreased by 14%. Food caused a delay in Tmax (1.00 to 3.00 hours)."/>
	<sentencespan id="DBMI.pac73.sp11" origId="sp11" text="Distribution\nFollowing intravenous administration, the volume of distribution (Vss) for oxycodone was 2.6 L/kg. Plasma protein binding of oxycodone at 37C and a pH of 7.4 was about 45%. Oxycodone has been found in breast milk."/>
	<sentencespan id="DBMI.pac73.sp12" origId="sp12" text="Metabolism\nOxycodone hydrochloride is extensively metabolized by multiple metabolic pathways to noroxycodone, oxymorphone, and noroxymorphone, which are subsequently glucuronidated. CYP3A4 mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with less contribution from CYP2D6 mediated O-demethylation to oxymorphone. Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs."/>
	<sentencespan id="DBMI.pac73.sp13" origId="sp13" text="The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone. Noroxycodone is reported to be a considerably weaker analgesic than oxycodone. Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations."/>
	<sentencespan id="DBMI.pac73.sp14" origId="sp14" text="The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations. The analgesic activity profile of other metabolites is not known. Excretion\nOxycodone and its metabolites are excreted primarily via the kidney."/>
	<sentencespan id="DBMI.pac73.sp15" origId="sp15" text="The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone &lt;14%; both free and conjugated noroxycodone have been found in the urine but not quantified. The total plasma clearance was 0.8 L/min for adults. Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours."/>
	<sentencespan id="DBMI.pac73.sp16" origId="sp16" text="Special Populations\n\nElderly: Information obtained from oxycodone tablets indicate that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65. Gender: Information obtained from oxycodone tablets support the lack of gender effect on the pharmacokinetics of oxycodone. Renal Impairment: Information obtained from oxycodone tablets indicate that patients with renal impairment (defined as creatinine clearance &lt;60 mL/min) had higher plasma concentrations of oxycodone than subjects with normal renal function."/>
	<sentencespan id="DBMI.pac73.sp17" origId="sp17" text="Hepatic Impairment: Since oxycodone is extensively metabolized, its clearance may decrease in patients with hepatic impairment. Drug-Drug Interactions\n\nCYP3A4 Inhibitors\nCYP3A4 is the major enzyme involved in noroxycodone formation. A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.">
		<entity charOffset="6794-6807" id="DBMI.pac73.sp17.e0" origId="sp17.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="6838-6848" id="DBMI.pac73.sp17.e1" origId="sp17.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac73.sp17.e0" e2="DBMI.pac73.sp17.e1" id="DBMI.pac73.sp17.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="oxycodone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac73.sp17.e1" e2="DBMI.pac73.sp17.e0" id="DBMI.pac73.sp17.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac73.sp18" origId="sp18" text="CYP3A4 Inducers\nA published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively. CYP2D6 Inhibitors\nOxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent.">
		<entity charOffset="6968-6977" id="DBMI.pac73.sp18.e0" origId="sp18.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="7024-7034" id="DBMI.pac73.sp18.e1" origId="sp18.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac73.sp18.e0" e2="DBMI.pac73.sp18.e1" id="DBMI.pac73.sp18.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="oxycodone " precipitant="rifampin "/>
		<pair e1="DBMI.pac73.sp18.e1" e2="DBMI.pac73.sp18.e0" id="DBMI.pac73.sp18.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac74" origId="pac74">
	<sentence id="DBMI.pac74.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nDrugs for which gastric pH can affect bioavailability\n\nBecause of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).">
		<entity charOffset="189-200" id="DBMI.pac74.s0.e0" origId="s0.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="353-358" id="DBMI.pac74.s0.e1" origId="s0.e1" text="iron " type="Active ingredient"/>
		<entity charOffset="330-341" id="DBMI.pac74.s0.e2" origId="s0.e2" text="ampicillin " type="Active ingredient"/>
		<entity charOffset="316-329" id="DBMI.pac74.s0.e3" origId="s0.e3" text="ketoconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s0.e0" e2="DBMI.pac74.s0.e1" id="DBMI.pac74.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="iron " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s0.e0" e2="DBMI.pac74.s0.e2" id="DBMI.pac74.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s0.e0" e2="DBMI.pac74.s0.e3" id="DBMI.pac74.s0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s0.e1" e2="DBMI.pac74.s0.e0" id="DBMI.pac74.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s0.e1" e2="DBMI.pac74.s0.e2" id="DBMI.pac74.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s0.e1" e2="DBMI.pac74.s0.e3" id="DBMI.pac74.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s0.e2" e2="DBMI.pac74.s0.e0" id="DBMI.pac74.s0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s0.e2" e2="DBMI.pac74.s0.e1" id="DBMI.pac74.s0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s0.e2" e2="DBMI.pac74.s0.e3" id="DBMI.pac74.s0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s0.e3" e2="DBMI.pac74.s0.e0" id="DBMI.pac74.s0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s0.e3" e2="DBMI.pac74.s0.e1" id="DBMI.pac74.s0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s0.e3" e2="DBMI.pac74.s0.e2" id="DBMI.pac74.s0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac74.s1" origId="s1" text="In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP."/>
	<sentence id="DBMI.pac74.s2" origId="s2" text="Drugs metabolized by cytochrome P450 (CYP)\n\nOmeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.">
		<entity charOffset="536-547" id="DBMI.pac74.s2.e0" origId="s2.e0" text="Omeprazole " type="Active ingredient"/>
		<entity charOffset="578-587" id="DBMI.pac74.s2.e1" origId="s2.e1" text="diazepam " type="Active ingredient"/>
		<entity charOffset="588-597" id="DBMI.pac74.s2.e2" origId="s2.e2" text="warfarin " type="Active ingredient"/>
		<entity charOffset="601-611" id="DBMI.pac74.s2.e3" origId="s2.e3" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s2.e0" e2="DBMI.pac74.s2.e1" id="DBMI.pac74.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="Omeprazole "/>
		<pair e1="DBMI.pac74.s2.e0" e2="DBMI.pac74.s2.e2" id="DBMI.pac74.s2.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="warfarin " precipitant="Omeprazole "/>
		<pair e1="DBMI.pac74.s2.e0" e2="DBMI.pac74.s2.e3" id="DBMI.pac74.s2.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="phenytoin " precipitant="Omeprazole "/>
		<pair e1="DBMI.pac74.s2.e1" e2="DBMI.pac74.s2.e0" id="DBMI.pac74.s2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s2.e1" e2="DBMI.pac74.s2.e2" id="DBMI.pac74.s2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s2.e1" e2="DBMI.pac74.s2.e3" id="DBMI.pac74.s2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s2.e2" e2="DBMI.pac74.s2.e0" id="DBMI.pac74.s2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s2.e2" e2="DBMI.pac74.s2.e1" id="DBMI.pac74.s2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s2.e2" e2="DBMI.pac74.s2.e3" id="DBMI.pac74.s2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s2.e3" e2="DBMI.pac74.s2.e0" id="DBMI.pac74.s2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s2.e3" e2="DBMI.pac74.s2.e1" id="DBMI.pac74.s2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s2.e3" e2="DBMI.pac74.s2.e2" id="DBMI.pac74.s2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac74.s3" origId="s3" text="There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly."/>
	<sentence id="DBMI.pac74.s4" origId="s4" text="Increases in INR and prothrombin time may lead to abnormal bleeding and even death."/>
	<sentence id="DBMI.pac74.s5" origId="s5" text="Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time."/>
	<sentence id="DBMI.pac74.s6" origId="s6" text="Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines)."/>
	<sentence id="DBMI.pac74.s7" origId="s7" text="Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.">
		<entity charOffset="1408-1419" id="DBMI.pac74.s7.e0" origId="s7.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="1083-1096" id="DBMI.pac74.s7.e1" origId="s7.e1" text="theophylline " type="Active ingredient"/>
		<entity charOffset="1099-1111" id="DBMI.pac74.s7.e2" origId="s7.e2" text="propranolol " type="Active ingredient"/>
		<entity charOffset="1237-1250" id="DBMI.pac74.s7.e3" origId="s7.e3" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="1251-1262" id="DBMI.pac74.s7.e4" origId="s7.e4" text="disulfiram " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s7.e0" e2="DBMI.pac74.s7.e1" id="DBMI.pac74.s7.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="theophylline " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s7.e0" e2="DBMI.pac74.s7.e2" id="DBMI.pac74.s7.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s7.e0" e2="DBMI.pac74.s7.e3" id="DBMI.pac74.s7.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s7.e0" e2="DBMI.pac74.s7.e4" id="DBMI.pac74.s7.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="disulfiram " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s7.e1" e2="DBMI.pac74.s7.e0" id="DBMI.pac74.s7.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e1" e2="DBMI.pac74.s7.e2" id="DBMI.pac74.s7.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e1" e2="DBMI.pac74.s7.e3" id="DBMI.pac74.s7.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e1" e2="DBMI.pac74.s7.e4" id="DBMI.pac74.s7.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e2" e2="DBMI.pac74.s7.e0" id="DBMI.pac74.s7.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e2" e2="DBMI.pac74.s7.e1" id="DBMI.pac74.s7.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e2" e2="DBMI.pac74.s7.e3" id="DBMI.pac74.s7.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e2" e2="DBMI.pac74.s7.e4" id="DBMI.pac74.s7.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e3" e2="DBMI.pac74.s7.e0" id="DBMI.pac74.s7.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e3" e2="DBMI.pac74.s7.e1" id="DBMI.pac74.s7.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e3" e2="DBMI.pac74.s7.e2" id="DBMI.pac74.s7.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e3" e2="DBMI.pac74.s7.e4" id="DBMI.pac74.s7.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e4" e2="DBMI.pac74.s7.e0" id="DBMI.pac74.s7.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e4" e2="DBMI.pac74.s7.e1" id="DBMI.pac74.s7.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e4" e2="DBMI.pac74.s7.e2" id="DBMI.pac74.s7.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s7.e4" e2="DBMI.pac74.s7.e3" id="DBMI.pac74.s7.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac74.s8" origId="s8" text="Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.">
		<entity charOffset="1495-1508" id="DBMI.pac74.s8.e0" origId="s8.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="1480-1491" id="DBMI.pac74.s8.e1" origId="s8.e1" text="omeprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s8.e0" e2="DBMI.pac74.s8.e1" id="DBMI.pac74.s8.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole " precipitant="voriconazole "/>
		<pair e1="DBMI.pac74.s8.e1" e2="DBMI.pac74.s8.e0" id="DBMI.pac74.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac74.s9" origId="s9" text="Dose adjustment of omeprazole is not normally required."/>
	<sentence id="DBMI.pac74.s10" origId="s10" text="However, in patients with Zollinger-Ellison syndrome, who may require higher doses up to 240 mg/day, dose adjustment may be considered."/>
	<sentence id="DBMI.pac74.s11" origId="s11" text="When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole.">
		<entity charOffset="1809-1822" id="DBMI.pac74.s11.e0" origId="s11.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="1881-1892" id="DBMI.pac74.s11.e1" origId="s11.e1" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="2364-2375" id="DBMI.pac74.s11.e2" origId="s11.e2" text="atazanavir " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s11.e0" e2="DBMI.pac74.s11.e1" id="DBMI.pac74.s11.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole " precipitant="voriconazole "/>
		<pair e1="DBMI.pac74.s11.e0" e2="DBMI.pac74.s11.e2" id="DBMI.pac74.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s11.e1" e2="DBMI.pac74.s11.e0" id="DBMI.pac74.s11.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s11.e1" e2="DBMI.pac74.s11.e2" id="DBMI.pac74.s11.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s11.e2" e2="DBMI.pac74.s11.e0" id="DBMI.pac74.s11.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s11.e2" e2="DBMI.pac74.s11.e1" id="DBMI.pac74.s11.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac74.s12" origId="s12" text="Antiretroviral Agents\n\nConcomitant use of atazanavir and proton pump inhibitors is not recommended."/>
	<sentence id="DBMI.pac74.s13" origId="s13" text="Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect."/>
	<sentence id="DBMI.pac74.s14" origId="s14" text="Omeprazole has been reported to interact with some antiretroviral drugs."/>
	<sentence id="DBMI.pac74.s15" origId="s15" text="The clinical importance and the mechanisms behind these interactions are not always known."/>
	<sentence id="DBMI.pac74.s16" origId="s16" text="Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug."/>
	<sentence id="DBMI.pac74.s17" origId="s17" text="Other possible interaction mechanisms are via CYP2C19."/>
	<sentence id="DBMI.pac74.s18" origId="s18" text="For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole.">
		<entity charOffset="2896-2907" id="DBMI.pac74.s18.e0" origId="s18.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="2817-2828" id="DBMI.pac74.s18.e1" origId="s18.e1" text="nelfinavir " type="Active ingredient"/>
		<entity charOffset="2802-2813" id="DBMI.pac74.s18.e2" origId="s18.e2" text="atazanavir " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s18.e0" e2="DBMI.pac74.s18.e1" id="DBMI.pac74.s18.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nelfinavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s18.e0" e2="DBMI.pac74.s18.e2" id="DBMI.pac74.s18.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s18.e1" e2="DBMI.pac74.s18.e0" id="DBMI.pac74.s18.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s18.e1" e2="DBMI.pac74.s18.e2" id="DBMI.pac74.s18.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s18.e2" e2="DBMI.pac74.s18.e0" id="DBMI.pac74.s18.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s18.e2" e2="DBMI.pac74.s18.e1" id="DBMI.pac74.s18.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac74.s19" origId="s19" text="Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8.">
		<entity charOffset="2966-2977" id="DBMI.pac74.s19.e0" origId="s19.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="3100-3103" id="DBMI.pac74.s19.e1" origId="s19.e1" text="M8 " type="Metabolite"/>
		<entity charOffset="2936-2947" id="DBMI.pac74.s19.e2" origId="s19.e2" text="nelfinavir " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s19.e0" e2="DBMI.pac74.s19.e1" id="DBMI.pac74.s19.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="M8 " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s19.e0" e2="DBMI.pac74.s19.e2" id="DBMI.pac74.s19.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nelfinavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s19.e1" e2="DBMI.pac74.s19.e0" id="DBMI.pac74.s19.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s19.e1" e2="DBMI.pac74.s19.e2" id="DBMI.pac74.s19.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s19.e2" e2="DBMI.pac74.s19.e0" id="DBMI.pac74.s19.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s19.e2" e2="DBMI.pac74.s19.e1" id="DBMI.pac74.s19.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac74.s20" origId="s20" text="Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.">
		<entity charOffset="3160-3171" id="DBMI.pac74.s20.e0" origId="s20.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="3132-3143" id="DBMI.pac74.s20.e1" origId="s20.e1" text="atazanavir " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s20.e0" e2="DBMI.pac74.s20.e1" id="DBMI.pac74.s20.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atazanavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s20.e1" e2="DBMI.pac74.s20.e0" id="DBMI.pac74.s20.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac74.s21" origId="s21" text="Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended."/>
	<sentence id="DBMI.pac74.s22" origId="s22" text="For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.">
		<entity charOffset="3626-3637" id="DBMI.pac74.s22.e0" origId="s22.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="3421-3432" id="DBMI.pac74.s22.e1" origId="s22.e1" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="3581-3591" id="DBMI.pac74.s22.e2" origId="s22.e2" text="ritonavir " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s22.e0" e2="DBMI.pac74.s22.e1" id="DBMI.pac74.s22.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="saquinavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s22.e0" e2="DBMI.pac74.s22.e1" id="DBMI.pac74.s22.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="saquinavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s22.e0" e2="DBMI.pac74.s22.e2" id="DBMI.pac74.s22.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="ritonavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s22.e1" e2="DBMI.pac74.s22.e0" id="DBMI.pac74.s22.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s22.e1" e2="DBMI.pac74.s22.e2" id="DBMI.pac74.s22.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s22.e2" e2="DBMI.pac74.s22.e0" id="DBMI.pac74.s22.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.s22.e2" e2="DBMI.pac74.s22.e1" id="DBMI.pac74.s22.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac74.s23" origId="s23" text="Dose reduction of saquinavir should be considered from the safety perspective for individual patients."/>
	<sentence id="DBMI.pac74.s24" origId="s24" text="There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole."/>
	<sentence id="DBMI.pac74.s25" origId="s25" text="Tacrolimus\n\nConcomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus. ">
		<entity charOffset="3943-3954" id="DBMI.pac74.s25.e0" origId="s25.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="3958-3969" id="DBMI.pac74.s25.e1" origId="s25.e1" text="tacrolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac74.s25.e0" e2="DBMI.pac74.s25.e1" id="DBMI.pac74.s25.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.s25.e1" e2="DBMI.pac74.s25.e0" id="DBMI.pac74.s25.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac74.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nDrugs for which gastric pH can affect bioavailability\n\nBecause of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP. Drugs metabolized by cytochrome P450 (CYP)\n\nOmeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.">
		<entity charOffset="189-200" id="DBMI.pac74.sp0.e0" origId="sp0.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="353-358" id="DBMI.pac74.sp0.e1" origId="sp0.e1" text="iron " type="Active ingredient"/>
		<entity charOffset="330-341" id="DBMI.pac74.sp0.e2" origId="sp0.e2" text="ampicillin " type="Active ingredient"/>
		<entity charOffset="316-329" id="DBMI.pac74.sp0.e3" origId="sp0.e3" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="536-547" id="DBMI.pac74.sp0.e4" origId="sp0.e4" text="Omeprazole " type="Active ingredient"/>
		<entity charOffset="578-587" id="DBMI.pac74.sp0.e5" origId="sp0.e5" text="diazepam " type="Active ingredient"/>
		<entity charOffset="588-597" id="DBMI.pac74.sp0.e6" origId="sp0.e6" text="warfarin " type="Active ingredient"/>
		<entity charOffset="601-611" id="DBMI.pac74.sp0.e7" origId="sp0.e7" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac74.sp0.e0" e2="DBMI.pac74.sp0.e1" id="DBMI.pac74.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="iron " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp0.e0" e2="DBMI.pac74.sp0.e2" id="DBMI.pac74.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp0.e0" e2="DBMI.pac74.sp0.e3" id="DBMI.pac74.sp0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp0.e0" e2="DBMI.pac74.sp0.e4" id="DBMI.pac74.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e0" e2="DBMI.pac74.sp0.e5" id="DBMI.pac74.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e0" e2="DBMI.pac74.sp0.e6" id="DBMI.pac74.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e0" e2="DBMI.pac74.sp0.e7" id="DBMI.pac74.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e1" e2="DBMI.pac74.sp0.e0" id="DBMI.pac74.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e1" e2="DBMI.pac74.sp0.e2" id="DBMI.pac74.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e1" e2="DBMI.pac74.sp0.e3" id="DBMI.pac74.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e1" e2="DBMI.pac74.sp0.e4" id="DBMI.pac74.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e1" e2="DBMI.pac74.sp0.e5" id="DBMI.pac74.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e1" e2="DBMI.pac74.sp0.e6" id="DBMI.pac74.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e1" e2="DBMI.pac74.sp0.e7" id="DBMI.pac74.sp0.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e2" e2="DBMI.pac74.sp0.e0" id="DBMI.pac74.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e2" e2="DBMI.pac74.sp0.e1" id="DBMI.pac74.sp0.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e2" e2="DBMI.pac74.sp0.e3" id="DBMI.pac74.sp0.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e2" e2="DBMI.pac74.sp0.e4" id="DBMI.pac74.sp0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e2" e2="DBMI.pac74.sp0.e5" id="DBMI.pac74.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e2" e2="DBMI.pac74.sp0.e6" id="DBMI.pac74.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e2" e2="DBMI.pac74.sp0.e7" id="DBMI.pac74.sp0.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e3" e2="DBMI.pac74.sp0.e0" id="DBMI.pac74.sp0.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e3" e2="DBMI.pac74.sp0.e1" id="DBMI.pac74.sp0.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e3" e2="DBMI.pac74.sp0.e2" id="DBMI.pac74.sp0.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e3" e2="DBMI.pac74.sp0.e4" id="DBMI.pac74.sp0.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e3" e2="DBMI.pac74.sp0.e5" id="DBMI.pac74.sp0.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e3" e2="DBMI.pac74.sp0.e6" id="DBMI.pac74.sp0.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e3" e2="DBMI.pac74.sp0.e7" id="DBMI.pac74.sp0.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e4" e2="DBMI.pac74.sp0.e0" id="DBMI.pac74.sp0.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e4" e2="DBMI.pac74.sp0.e1" id="DBMI.pac74.sp0.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e4" e2="DBMI.pac74.sp0.e2" id="DBMI.pac74.sp0.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e4" e2="DBMI.pac74.sp0.e3" id="DBMI.pac74.sp0.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e4" e2="DBMI.pac74.sp0.e5" id="DBMI.pac74.sp0.p32" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam " precipitant="Omeprazole "/>
		<pair e1="DBMI.pac74.sp0.e4" e2="DBMI.pac74.sp0.e6" id="DBMI.pac74.sp0.p33" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="warfarin " precipitant="Omeprazole "/>
		<pair e1="DBMI.pac74.sp0.e4" e2="DBMI.pac74.sp0.e7" id="DBMI.pac74.sp0.p34" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="phenytoin " precipitant="Omeprazole "/>
		<pair e1="DBMI.pac74.sp0.e5" e2="DBMI.pac74.sp0.e0" id="DBMI.pac74.sp0.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e5" e2="DBMI.pac74.sp0.e1" id="DBMI.pac74.sp0.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e5" e2="DBMI.pac74.sp0.e2" id="DBMI.pac74.sp0.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e5" e2="DBMI.pac74.sp0.e3" id="DBMI.pac74.sp0.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e5" e2="DBMI.pac74.sp0.e4" id="DBMI.pac74.sp0.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e5" e2="DBMI.pac74.sp0.e6" id="DBMI.pac74.sp0.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e5" e2="DBMI.pac74.sp0.e7" id="DBMI.pac74.sp0.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e6" e2="DBMI.pac74.sp0.e0" id="DBMI.pac74.sp0.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e6" e2="DBMI.pac74.sp0.e1" id="DBMI.pac74.sp0.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e6" e2="DBMI.pac74.sp0.e2" id="DBMI.pac74.sp0.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e6" e2="DBMI.pac74.sp0.e3" id="DBMI.pac74.sp0.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e6" e2="DBMI.pac74.sp0.e4" id="DBMI.pac74.sp0.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e6" e2="DBMI.pac74.sp0.e5" id="DBMI.pac74.sp0.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e6" e2="DBMI.pac74.sp0.e7" id="DBMI.pac74.sp0.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e7" e2="DBMI.pac74.sp0.e0" id="DBMI.pac74.sp0.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e7" e2="DBMI.pac74.sp0.e1" id="DBMI.pac74.sp0.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e7" e2="DBMI.pac74.sp0.e2" id="DBMI.pac74.sp0.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e7" e2="DBMI.pac74.sp0.e3" id="DBMI.pac74.sp0.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e7" e2="DBMI.pac74.sp0.e4" id="DBMI.pac74.sp0.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e7" e2="DBMI.pac74.sp0.e5" id="DBMI.pac74.sp0.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp0.e7" e2="DBMI.pac74.sp0.e6" id="DBMI.pac74.sp0.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac74.sp1" origId="sp1" text="There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time."/>
	<sentencespan id="DBMI.pac74.sp2" origId="sp2" text="Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP. Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.">
		<entity charOffset="1408-1419" id="DBMI.pac74.sp2.e0" origId="sp2.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="1083-1096" id="DBMI.pac74.sp2.e1" origId="sp2.e1" text="theophylline " type="Active ingredient"/>
		<entity charOffset="1099-1111" id="DBMI.pac74.sp2.e2" origId="sp2.e2" text="propranolol " type="Active ingredient"/>
		<entity charOffset="1237-1250" id="DBMI.pac74.sp2.e3" origId="sp2.e3" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="1251-1262" id="DBMI.pac74.sp2.e4" origId="sp2.e4" text="disulfiram " type="Active ingredient"/>
		<entity charOffset="1495-1508" id="DBMI.pac74.sp2.e5" origId="sp2.e5" text="voriconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac74.sp2.e0" e2="DBMI.pac74.sp2.e1" id="DBMI.pac74.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="theophylline " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp2.e0" e2="DBMI.pac74.sp2.e2" id="DBMI.pac74.sp2.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp2.e0" e2="DBMI.pac74.sp2.e3" id="DBMI.pac74.sp2.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp2.e0" e2="DBMI.pac74.sp2.e4" id="DBMI.pac74.sp2.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="disulfiram " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp2.e0" e2="DBMI.pac74.sp2.e5" id="DBMI.pac74.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e1" e2="DBMI.pac74.sp2.e0" id="DBMI.pac74.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e1" e2="DBMI.pac74.sp2.e2" id="DBMI.pac74.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e1" e2="DBMI.pac74.sp2.e3" id="DBMI.pac74.sp2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e1" e2="DBMI.pac74.sp2.e4" id="DBMI.pac74.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e1" e2="DBMI.pac74.sp2.e5" id="DBMI.pac74.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e2" e2="DBMI.pac74.sp2.e0" id="DBMI.pac74.sp2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e2" e2="DBMI.pac74.sp2.e1" id="DBMI.pac74.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e2" e2="DBMI.pac74.sp2.e3" id="DBMI.pac74.sp2.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e2" e2="DBMI.pac74.sp2.e4" id="DBMI.pac74.sp2.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e2" e2="DBMI.pac74.sp2.e5" id="DBMI.pac74.sp2.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e3" e2="DBMI.pac74.sp2.e0" id="DBMI.pac74.sp2.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e3" e2="DBMI.pac74.sp2.e1" id="DBMI.pac74.sp2.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e3" e2="DBMI.pac74.sp2.e2" id="DBMI.pac74.sp2.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e3" e2="DBMI.pac74.sp2.e4" id="DBMI.pac74.sp2.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e3" e2="DBMI.pac74.sp2.e5" id="DBMI.pac74.sp2.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e4" e2="DBMI.pac74.sp2.e0" id="DBMI.pac74.sp2.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e4" e2="DBMI.pac74.sp2.e1" id="DBMI.pac74.sp2.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e4" e2="DBMI.pac74.sp2.e2" id="DBMI.pac74.sp2.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e4" e2="DBMI.pac74.sp2.e3" id="DBMI.pac74.sp2.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e4" e2="DBMI.pac74.sp2.e5" id="DBMI.pac74.sp2.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e5" e2="DBMI.pac74.sp2.e0" id="DBMI.pac74.sp2.p25" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole " precipitant="voriconazole "/>
		<pair e1="DBMI.pac74.sp2.e5" e2="DBMI.pac74.sp2.e1" id="DBMI.pac74.sp2.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e5" e2="DBMI.pac74.sp2.e2" id="DBMI.pac74.sp2.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e5" e2="DBMI.pac74.sp2.e3" id="DBMI.pac74.sp2.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp2.e5" e2="DBMI.pac74.sp2.e4" id="DBMI.pac74.sp2.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac74.sp3" origId="sp3" text="Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses up to 240 mg/day, dose adjustment may be considered. When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole.">
		<entity charOffset="1809-1822" id="DBMI.pac74.sp3.e0" origId="sp3.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="1881-1892" id="DBMI.pac74.sp3.e1" origId="sp3.e1" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="2364-2375" id="DBMI.pac74.sp3.e2" origId="sp3.e2" text="atazanavir " type="Active ingredient"/>
		<pair e1="DBMI.pac74.sp3.e0" e2="DBMI.pac74.sp3.e1" id="DBMI.pac74.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole " precipitant="voriconazole "/>
		<pair e1="DBMI.pac74.sp3.e0" e2="DBMI.pac74.sp3.e2" id="DBMI.pac74.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp3.e1" e2="DBMI.pac74.sp3.e0" id="DBMI.pac74.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp3.e1" e2="DBMI.pac74.sp3.e2" id="DBMI.pac74.sp3.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp3.e2" e2="DBMI.pac74.sp3.e0" id="DBMI.pac74.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp3.e2" e2="DBMI.pac74.sp3.e1" id="DBMI.pac74.sp3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac74.sp4" origId="sp4" text="Antiretroviral Agents\n\nConcomitant use of atazanavir and proton pump inhibitors is not recommended. Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect. Omeprazole has been reported to interact with some antiretroviral drugs."/>
	<sentencespan id="DBMI.pac74.sp5" origId="sp5" text="The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19."/>
	<sentencespan id="DBMI.pac74.sp6" origId="sp6" text="For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.">
		<entity charOffset="2896-2907" id="DBMI.pac74.sp6.e0" origId="sp6.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="2817-2828" id="DBMI.pac74.sp6.e1" origId="sp6.e1" text="nelfinavir " type="Active ingredient"/>
		<entity charOffset="2802-2813" id="DBMI.pac74.sp6.e2" origId="sp6.e2" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="3100-3103" id="DBMI.pac74.sp6.e3" origId="sp6.e3" text="M8 " type="Metabolite"/>
		<pair e1="DBMI.pac74.sp6.e0" e2="DBMI.pac74.sp6.e1" id="DBMI.pac74.sp6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="nelfinavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp6.e0" e2="DBMI.pac74.sp6.e1" id="DBMI.pac74.sp6.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nelfinavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp6.e0" e2="DBMI.pac74.sp6.e2" id="DBMI.pac74.sp6.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp6.e0" e2="DBMI.pac74.sp6.e2" id="DBMI.pac74.sp6.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atazanavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp6.e0" e2="DBMI.pac74.sp6.e3" id="DBMI.pac74.sp6.p4" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="M8 " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp6.e1" e2="DBMI.pac74.sp6.e0" id="DBMI.pac74.sp6.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp6.e1" e2="DBMI.pac74.sp6.e2" id="DBMI.pac74.sp6.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp6.e1" e2="DBMI.pac74.sp6.e3" id="DBMI.pac74.sp6.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp6.e2" e2="DBMI.pac74.sp6.e0" id="DBMI.pac74.sp6.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp6.e2" e2="DBMI.pac74.sp6.e1" id="DBMI.pac74.sp6.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp6.e2" e2="DBMI.pac74.sp6.e3" id="DBMI.pac74.sp6.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp6.e3" e2="DBMI.pac74.sp6.e0" id="DBMI.pac74.sp6.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp6.e3" e2="DBMI.pac74.sp6.e1" id="DBMI.pac74.sp6.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp6.e3" e2="DBMI.pac74.sp6.e2" id="DBMI.pac74.sp6.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac74.sp7" origId="sp7" text="Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended. For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15. Dose reduction of saquinavir should be considered from the safety perspective for individual patients.">
		<entity charOffset="3626-3637" id="DBMI.pac74.sp7.e0" origId="sp7.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="3421-3432" id="DBMI.pac74.sp7.e1" origId="sp7.e1" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="3581-3591" id="DBMI.pac74.sp7.e2" origId="sp7.e2" text="ritonavir " type="Active ingredient"/>
		<pair e1="DBMI.pac74.sp7.e0" e2="DBMI.pac74.sp7.e1" id="DBMI.pac74.sp7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="saquinavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp7.e0" e2="DBMI.pac74.sp7.e1" id="DBMI.pac74.sp7.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="saquinavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp7.e0" e2="DBMI.pac74.sp7.e2" id="DBMI.pac74.sp7.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="ritonavir " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp7.e1" e2="DBMI.pac74.sp7.e0" id="DBMI.pac74.sp7.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp7.e1" e2="DBMI.pac74.sp7.e2" id="DBMI.pac74.sp7.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp7.e2" e2="DBMI.pac74.sp7.e0" id="DBMI.pac74.sp7.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac74.sp7.e2" e2="DBMI.pac74.sp7.e1" id="DBMI.pac74.sp7.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac74.sp8" origId="sp8" text="There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole. Tacrolimus\n\nConcomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus. ">
		<entity charOffset="3943-3954" id="DBMI.pac74.sp8.e0" origId="sp8.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="3958-3969" id="DBMI.pac74.sp8.e1" origId="sp8.e1" text="tacrolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac74.sp8.e0" e2="DBMI.pac74.sp8.e1" id="DBMI.pac74.sp8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus " precipitant="omeprazole "/>
		<pair e1="DBMI.pac74.sp8.e1" e2="DBMI.pac74.sp8.e0" id="DBMI.pac74.sp8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac75" origId="pac75">
	<sentence id="DBMI.pac75.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nOmeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell."/>
	<sentence id="DBMI.pac75.s1" origId="s1" text="Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production."/>
	<sentence id="DBMI.pac75.s2" origId="s2" text="This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus."/>
	<sentence id="DBMI.pac75.s3" origId="s3" text="Animal studies indicate that after rapid disappearance from plasma, omeprazole can be found within the gastric mucosa for a day or more."/>
	<sentence id="DBMI.pac75.s4" origId="s4" text="12.2 Pharmacodynamics\n\nAntisecretory Activity\n\nAfter oral administration, the onset of the antisecretory effect of omeprazole occurs within one hour, with the maximum effect occurring within two hours."/>
	<sentence id="DBMI.pac75.s5" origId="s5" text="Inhibition of secretion is about 50% of maximum at 24 hours and the duration of inhibition lasts up to 72 hours."/>
	<sentence id="DBMI.pac75.s6" origId="s6" text="The antisecretory effect thus lasts far longer than would be expected from the very short (less than one hour) plasma half-life, apparently due to prolonged binding to the parietal H+/K+ ATPase enzyme."/>
	<sentence id="DBMI.pac75.s7" origId="s7" text="When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days."/>
	<sentence id="DBMI.pac75.s8" origId="s8" text="The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days."/>
	<sentence id="DBMI.pac75.s9" origId="s9" text="Results from numerous studies of the antisecretory effect of multiple doses of 20 mg and 40 mg of omeprazole in normal volunteers and patients are shown below."/>
	<sentence id="DBMI.pac75.s10" origId="s10" text="The max value represents determinations at a time of maximum effect (2 to 6 hours after dosing), while min values are those 24 hours after the last dose of omeprazole."/>
	<sentence id="DBMI.pac75.s11" origId="s11" text="Single daily oral doses of omeprazole ranging from a dose of 10 mg to 40 mg have produced 100% inhibition of 24-hour intragastric acidity in some patients."/>
	<sentence id="DBMI.pac75.s12" origId="s12" text="Serum Gastrin Effects\n\nIn studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion."/>
	<sentence id="DBMI.pac75.s13" origId="s13" text="No further increase in serum gastrin occurred with continued treatment."/>
	<sentence id="DBMI.pac75.s14" origId="s14" text="In comparison with histamine H2-receptor antagonists, the median increases produced by 20 mg doses of omeprazole were higher (1.3 to 3.6 fold vs. 1.1 to 1.8 fold increase)."/>
	<sentence id="DBMI.pac75.s15" origId="s15" text="Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy."/>
	<sentence id="DBMI.pac75.s16" origId="s16" text="Enterochromaffin-like (ECL) Cell Effects\n\nHuman gastric biopsy specimens have been obtained from more than 3000 patients treated with omeprazole in long-term clinical trials."/>
	<sentence id="DBMI.pac75.s17" origId="s17" text="The incidence of ECL cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia has been found in these patients."/>
	<sentence id="DBMI.pac75.s18" origId="s18" text="[See Clinical Pharmacology (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions."/>
	<sentence id="DBMI.pac75.s19" origId="s19" text="Other Effects\n\nSystemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date."/>
	<sentence id="DBMI.pac75.s20" origId="s20" text="Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin."/>
	<sentence id="DBMI.pac75.s21" origId="s21" text="No effect on gastric emptying of the solid and liquid components of a test meal was demonstrated after a single dose of omeprazole 90 mg."/>
	<sentence id="DBMI.pac75.s22" origId="s22" text="In healthy subjects, a single I.V.dose of omeprazole (0.35 mg/kg) had no effect on intrinsic factor secretion."/>
	<sentence id="DBMI.pac75.s23" origId="s23" text="No systematic dose-dependent effect has been observed on basal or stimulated pepsin output in humans."/>
	<sentence id="DBMI.pac75.s24" origId="s24" text="However, when intragastric pH is maintained at 4.0 or above, basal pepsin output is low, and pepsin activity is decreased."/>
	<sentence id="DBMI.pac75.s25" origId="s25" text="As do other agents that elevate intragastric pH, omeprazole administered for 14 days in healthy subjects produced a significant increase in the intragastric concentrations of viable bacteria."/>
	<sentence id="DBMI.pac75.s26" origId="s26" text="The pattern of the bacterial species was unchanged from that commonly found in saliva."/>
	<sentence id="DBMI.pac75.s27" origId="s27" text="All changes resolved within three days of stopping treatment."/>
	<sentence id="DBMI.pac75.s28" origId="s28" text="The course of Barrett's esophagus in 106 patients was evaluated in a U.S. double-blind controlled study of omeprazole delayed-release capsules USP 40 mg twice daily for 12 months followed by 20 mg twice daily for 12 months or ranitidine 300 mg twice daily for 24 months."/>
	<sentence id="DBMI.pac75.s29" origId="s29" text="No clinically significant impact on Barrett's mucosa by antisecretory therapy was observed."/>
	<sentence id="DBMI.pac75.s30" origId="s30" text="Although neosquamous epithelium developed during antisecretory therapy, complete elimination of Barrett's mucosa was not achieved."/>
	<sentence id="DBMI.pac75.s31" origId="s31" text="No significant difference was observed between treatment groups in development of dysplasia in Barrett's mucosa and no patient developed esophageal carcinoma during treatment."/>
	<sentence id="DBMI.pac75.s32" origId="s32" text="No significant differences between treatment groups were observed in development of ECL cell hyperplasia, corpus atrophic gastritis, corpus intestinal metaplasia, or colon polyps exceeding 3 mm in diameter [See Clinical Pharmacology (12)]."/>
	<sentence id="DBMI.pac75.s33" origId="s33" text="12.3 Pharmacokinetics\n\nAbsorption\n\nOmeprazole delayed-release capsules USP contain an enteric-coated granule formulation of omeprazole (because omeprazole is acid-labile), so that absorption of omeprazole begins only after the granules leave the stomach."/>
	<sentence id="DBMI.pac75.s34" origId="s34" text="Absorption is rapid, with peak plasma levels of omeprazole occurring within 0.5 to 3.5 hours."/>
	<sentence id="DBMI.pac75.s35" origId="s35" text="Peak plasma concentrations of omeprazole and AUC are approximately proportional to doses up to 40 mg, but because of a saturable first-pass effect, a greater than linear response in peak plasma concentration and AUC occurs with doses greater than 40 mg. Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism."/>
	<sentence id="DBMI.pac75.s36" origId="s36" text="In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min."/>
	<sentence id="DBMI.pac75.s37" origId="s37" text="The bioavailability of omeprazole increases slightly upon repeated administration of omeprazole delayed-release capsules USP."/>
	<sentence id="DBMI.pac75.s38" origId="s38" text="Omeprazole delayed-release capsule USP 40 mg was bioequivalent when administered with and without applesauce."/>
	<sentence id="DBMI.pac75.s39" origId="s39" text="However, omeprazole delayed-release capsule USP 20 mg was not bioequivalent when administered with and without applesauce."/>
	<sentence id="DBMI.pac75.s40" origId="s40" text="When administered with applesauce, a mean 25% reduction in Cmax was observed without a significant change in AUC for omeprazole delayed-release capsule USP 20 mg."/>
	<sentence id="DBMI.pac75.s41" origId="s41" text="The clinical relevance of this finding is unknown."/>
	<sentence id="DBMI.pac75.s42" origId="s42" text="Distribution\n\nProtein binding is approximately 95%."/>
	<sentence id="DBMI.pac75.s43" origId="s43" text="Metabolism\n\nOmeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system."/>
	<sentence id="DBMI.pac75.s44" origId="s44" text="Excretion\n\nFollowing single dose oral administration of a buffered solution of omeprazole, little if any unchanged drug was excreted in urine."/>
	<sentence id="DBMI.pac75.s45" origId="s45" text="The majority of the dose (about 77%) was eliminated in urine as at least six metabolites."/>
	<sentence id="DBMI.pac75.s46" origId="s46" text="Two were identified as hydroxyomeprazole and the corresponding carboxylic acid."/>
	<sentence id="DBMI.pac75.s47" origId="s47" text="The remainder of the dose was recoverable in feces."/>
	<sentence id="DBMI.pac75.s48" origId="s48" text="This implies a significant biliary excretion of the metabolites of omeprazole."/>
	<sentence id="DBMI.pac75.s49" origId="s49" text="Three metabolites have been identified in plasma  the sulfide and sulfone derivatives of omeprazole, and hydroxyomeprazole."/>
	<sentence id="DBMI.pac75.s50" origId="s50" text="These metabolites have very little or no antisecretory activity."/>
	<sentence id="DBMI.pac75.s51" origId="s51" text="Combination Therapy with Antimicrobials\n\nOmeprazole 40 mg daily was given in combination with clarithromycin 500 mg every 8 hours to healthy adult male subjects.">
		<entity charOffset="7604-7619" id="DBMI.pac75.s51.e0" origId="s51.e0" text="clarithromycin " type="Active ingredient"/>
		<entity charOffset="7714-7725" id="DBMI.pac75.s51.e1" origId="s51.e1" text="omeprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac75.s51.e0" e2="DBMI.pac75.s51.e1" id="DBMI.pac75.s51.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole " precipitant="clarithromycin "/>
		<pair e1="DBMI.pac75.s51.e1" e2="DBMI.pac75.s51.e0" id="DBMI.pac75.s51.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac75.s52" origId="s52" text="The steady state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and T1/2 increases of 30%, 89% and 34% respectively) by the concomitant administration of clarithromycin."/>
	<sentence id="DBMI.pac75.s53" origId="s53" text="The observed increases in omeprazole plasma concentration were associated with the following pharmacological effects."/>
	<sentence id="DBMI.pac75.s54" origId="s54" text="The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when co-administered with clarithromycin."/>
	<sentence id="DBMI.pac75.s55" origId="s55" text="The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole."/>
	<sentence id="DBMI.pac75.s56" origId="s56" text="For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone.">
		<entity charOffset="8230-8241" id="DBMI.pac75.s56.e0" origId="s56.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="8152-8178" id="DBMI.pac75.s56.e1" origId="s56.e1" text="14-hydroxy-clarithromycin " type="Metabolite"/>
		<entity charOffset="8133-8148" id="DBMI.pac75.s56.e2" origId="s56.e2" text="clarithromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac75.s56.e0" e2="DBMI.pac75.s56.e1" id="DBMI.pac75.s56.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="14-hydroxy-clarithromycin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac75.s56.e0" e2="DBMI.pac75.s56.e1" id="DBMI.pac75.s56.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="14-hydroxy-clarithromycin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac75.s56.e0" e2="DBMI.pac75.s56.e2" id="DBMI.pac75.s56.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="clarithromycin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac75.s56.e0" e2="DBMI.pac75.s56.e2" id="DBMI.pac75.s56.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="clarithromycin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac75.s56.e1" e2="DBMI.pac75.s56.e0" id="DBMI.pac75.s56.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac75.s56.e1" e2="DBMI.pac75.s56.e2" id="DBMI.pac75.s56.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac75.s56.e2" e2="DBMI.pac75.s56.e0" id="DBMI.pac75.s56.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac75.s56.e2" e2="DBMI.pac75.s56.e1" id="DBMI.pac75.s56.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac75.s57" origId="s57" text="Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater."/>
	<sentence id="DBMI.pac75.s58" origId="s58" text="Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole."/>
	<sentence id="DBMI.pac75.s59" origId="s59" text="Special Populations\n\nGeriatric Population\n\nThe elimination rate of omeprazole was somewhat decreased in the elderly, and bioavailability was increased."/>
	<sentence id="DBMI.pac75.s60" origId="s60" text="Omeprazole was 76% bioavailable when a single 40 mg oral dose of omeprazole (buffered solution) was administered to healthy elderly volunteers, versus 58% in young volunteers given the same dose."/>
	<sentence id="DBMI.pac75.s61" origId="s61" text="Nearly 70% of the dose was recovered in urine as metabolites of omeprazole and no unchanged drug was detected."/>
	<sentence id="DBMI.pac75.s62" origId="s62" text="The plasma clearance of omeprazole was 250 mL/min (about half that of young volunteers) and its plasma half-life averaged one hour, about twice that of young healthy volunteers."/>
	<sentence id="DBMI.pac75.s63" origId="s63" text="Pediatric Use\n\nThe pharmacokinetics of omeprazole have been investigated in pediatric patients 2 to 16 years of age:\n\nFollowing comparable mg/kg doses of omeprazole, younger children (2 to 5 years of age) have lower AUCs than children 6 to 16 years of age or adults; AUCs of the latter two groups did not differ."/>
	<sentence id="DBMI.pac75.s64" origId="s64" text="[See Dosage and Administration (2)]\n\nHepatic Impairment\n\nIn patients with chronic hepatic disease, the bioavailability increased to approximately 100% compared with an I.V.dose, reflecting decreased first-pass effect, and the plasma half-life of the drug increased to nearly 3 hours compared with the half-life in normals of 0.5 to 1 hour."/>
	<sentence id="DBMI.pac75.s65" origId="s65" text="Plasma clearance averaged 70 mL/min, compared with a value of 500 to 600 mL/min in normal subjects."/>
	<sentence id="DBMI.pac75.s66" origId="s66" text="Dose reduction, particularly where maintenance of healing of erosive esophagitis is indicated, for the hepatically impaired should be considered."/>
	<sentence id="DBMI.pac75.s67" origId="s67" text="Renal Impairment\n\nIn patients with chronic renal impairment, whose creatinine clearance ranged between 10 and 62 mL/min/1.73 m2, the disposition of omeprazole was very similar to that in healthy volunteers, although there was a slight increase in bioavailability."/>
	<sentence id="DBMI.pac75.s68" origId="s68" text="Because urinary excretion is a primary route of excretion of omeprazole metabolites, their elimination slowed in proportion to the decreased creatinine clearance."/>
	<sentence id="DBMI.pac75.s69" origId="s69" text="No dose reduction is necessary in patients with renal impairment."/>
	<sentence id="DBMI.pac75.s70" origId="s70" text="Asian Population\n\nIn pharmacokinetic studies of single 20 mg omeprazole doses, an increase in AUC of approximately four-fold was noted in Asian subjects compared with Caucasians."/>
	<sentence id="DBMI.pac75.s71" origId="s71" text="Dose reduction, particularly where maintenance of healing of erosive esophagitis is indicated, for Asian subjects should be considered."/>
	<sentence id="DBMI.pac75.s72" origId="s72" text="12.4 Microbiology\n\nOmeprazole and clarithromycin dual therapy and omeprazole, clarithromycin and amoxicillin triple therapy have been shown to be active against most strains of Helicobacter pylori in vitro and in clinical infections as described in the Indications and Usage section (1.1)."/>
	<sentence id="DBMI.pac75.s73" origId="s73" text="Helicobacter\n\nHelicobacter pylori-Pretreatment Resistance Clarithromycin pretreatment resistance rates were 3.5% (4/113) in the omeprazole/clarithromycin dual therapy studies (4 and 5) and 9.3% (41/439) in omeprazole/clarithromycin/amoxicillin triple therapy studies (1, 2, and 3)."/>
	<sentence id="DBMI.pac75.s74" origId="s74" text="Amoxicillin pretreatment susceptible isolates ( 0.25 g/mL) were found in 99.3% (436/439) of the patients in the omeprazole/clarithromycin/amoxicillin triple therapy studies (1, 2, and 3)."/>
	<sentence id="DBMI.pac75.s75" origId="s75" text="Amoxicillin pretreatment minimum inhibitory concentrations (MICs) &gt; 0.25 g/mL occurred in 0.7% (3/439) of the patients, all of whom were in the clarithromycin and amoxicillin study arm."/>
	<sentence id="DBMI.pac75.s76" origId="s76" text="One patient had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of &gt; 256 g/mL by Etest."/>
	<sentence id="DBMI.pac75.s77" origId="s77" text="Patients not eradicated of H. pylori following omeprazole/clarithromycin/amoxicillin triple therapy or omeprazole/clarithromycin dual therapy will likely have clarithromycin resistant H. pylori isolates."/>
	<sentence id="DBMI.pac75.s78" origId="s78" text="Therefore, clarithromycin susceptibility testing should be done, if possible."/>
	<sentence id="DBMI.pac75.s79" origId="s79" text="Patients with clarithromycin resistant H. pylori should not be treated with any of the following: omeprazole/clarithromycin dual therapy, omeprazole/clarithromycin/amoxicillin triple therapy, or other regimens which include clarithromycin as the sole antimicrobial agent."/>
	<sentence id="DBMI.pac75.s80" origId="s80" text="Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes\n\nIn the triple therapy clinical trials, 84.9% (157/185) of the patients in the omeprazole/clarithromycin/amoxicillin treatment group who had pretreatment amoxicillin susceptible MICs ( 0.25 g/mL) were eradicated of H. pylori and 15.1% (28/185) failed therapy."/>
	<sentence id="DBMI.pac75.s81" origId="s81" text="Of the 28 patients who failed triple therapy, 11 had no post-treatment susceptibility test results and 17 had post-treatment H. pylori isolates with amoxicillin susceptible MICs."/>
	<sentence id="DBMI.pac75.s82" origId="s82" text="Eleven of the patients who failed triple therapy also had post-treatment H. pylori isolates with clarithromycin resistant MICs."/>
	<sentence id="DBMI.pac75.s83" origId="s83" text="Susceptibility Test for Helicobacter pylori\n\nThe reference methodology for susceptibility testing of H. pylori is agar dilution MICs1."/>
	<sentence id="DBMI.pac75.s84" origId="s84" text="One to three microliters of an inoculum equivalent to a No."/>
	<sentence id="DBMI.pac75.s85" origId="s85" text="2 McFarland standard (1 x 107 to 1 x 108 CFU/mL for H. pylori) are inoculated directly onto freshly prepared antimicrobial containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood ( 2 weeks old)."/>
	<sentence id="DBMI.pac75.s86" origId="s86" text="The agar dilution plates are incubated at 35C in a microaerobic environment produced by a gas generating system suitable for campylobacters."/>
	<sentence id="DBMI.pac75.s87" origId="s87" text="After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism."/>
	<sentence id="DBMI.pac75.s88" origId="s88" text="The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria:\n\nStandardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures."/>
	<sentence id="DBMI.pac75.s89" origId="s89" text="Standard clarithromycin and amoxicillin powders should provide the following MIC values:\n\nEffects on Gastrointestinal Microbial Ecology\n\nDecreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract."/>
	<sentence id="DBMI.pac75.s90" origId="s90" text="Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter. "/>
	<sentencespan id="DBMI.pac75.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nOmeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus."/>
	<sentencespan id="DBMI.pac75.sp1" origId="sp1" text="Animal studies indicate that after rapid disappearance from plasma, omeprazole can be found within the gastric mucosa for a day or more. 12.2 Pharmacodynamics\n\nAntisecretory Activity\n\nAfter oral administration, the onset of the antisecretory effect of omeprazole occurs within one hour, with the maximum effect occurring within two hours. Inhibition of secretion is about 50% of maximum at 24 hours and the duration of inhibition lasts up to 72 hours."/>
	<sentencespan id="DBMI.pac75.sp2" origId="sp2" text="The antisecretory effect thus lasts far longer than would be expected from the very short (less than one hour) plasma half-life, apparently due to prolonged binding to the parietal H+/K+ ATPase enzyme. When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days."/>
	<sentencespan id="DBMI.pac75.sp3" origId="sp3" text="Results from numerous studies of the antisecretory effect of multiple doses of 20 mg and 40 mg of omeprazole in normal volunteers and patients are shown below. The max value represents determinations at a time of maximum effect (2 to 6 hours after dosing), while min values are those 24 hours after the last dose of omeprazole. Single daily oral doses of omeprazole ranging from a dose of 10 mg to 40 mg have produced 100% inhibition of 24-hour intragastric acidity in some patients."/>
	<sentencespan id="DBMI.pac75.sp4" origId="sp4" text="Serum Gastrin Effects\n\nIn studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. No further increase in serum gastrin occurred with continued treatment. In comparison with histamine H2-receptor antagonists, the median increases produced by 20 mg doses of omeprazole were higher (1.3 to 3.6 fold vs. 1.1 to 1.8 fold increase)."/>
	<sentencespan id="DBMI.pac75.sp5" origId="sp5" text="Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy. Enterochromaffin-like (ECL) Cell Effects\n\nHuman gastric biopsy specimens have been obtained from more than 3000 patients treated with omeprazole in long-term clinical trials. The incidence of ECL cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia has been found in these patients."/>
	<sentencespan id="DBMI.pac75.sp6" origId="sp6" text="[See Clinical Pharmacology (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions. Other Effects\n\nSystemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin."/>
	<sentencespan id="DBMI.pac75.sp7" origId="sp7" text="No effect on gastric emptying of the solid and liquid components of a test meal was demonstrated after a single dose of omeprazole 90 mg. In healthy subjects, a single I.V.dose of omeprazole (0.35 mg/kg) had no effect on intrinsic factor secretion. No systematic dose-dependent effect has been observed on basal or stimulated pepsin output in humans."/>
	<sentencespan id="DBMI.pac75.sp8" origId="sp8" text="However, when intragastric pH is maintained at 4.0 or above, basal pepsin output is low, and pepsin activity is decreased. As do other agents that elevate intragastric pH, omeprazole administered for 14 days in healthy subjects produced a significant increase in the intragastric concentrations of viable bacteria. The pattern of the bacterial species was unchanged from that commonly found in saliva."/>
	<sentencespan id="DBMI.pac75.sp9" origId="sp9" text="All changes resolved within three days of stopping treatment. The course of Barrett's esophagus in 106 patients was evaluated in a U.S. double-blind controlled study of omeprazole delayed-release capsules USP 40 mg twice daily for 12 months followed by 20 mg twice daily for 12 months or ranitidine 300 mg twice daily for 24 months. No clinically significant impact on Barrett's mucosa by antisecretory therapy was observed."/>
	<sentencespan id="DBMI.pac75.sp10" origId="sp10" text="Although neosquamous epithelium developed during antisecretory therapy, complete elimination of Barrett's mucosa was not achieved. No significant difference was observed between treatment groups in development of dysplasia in Barrett's mucosa and no patient developed esophageal carcinoma during treatment. No significant differences between treatment groups were observed in development of ECL cell hyperplasia, corpus atrophic gastritis, corpus intestinal metaplasia, or colon polyps exceeding 3 mm in diameter [See Clinical Pharmacology (12)]."/>
	<sentencespan id="DBMI.pac75.sp11" origId="sp11" text="12.3 Pharmacokinetics\n\nAbsorption\n\nOmeprazole delayed-release capsules USP contain an enteric-coated granule formulation of omeprazole (because omeprazole is acid-labile), so that absorption of omeprazole begins only after the granules leave the stomach. Absorption is rapid, with peak plasma levels of omeprazole occurring within 0.5 to 3.5 hours. Peak plasma concentrations of omeprazole and AUC are approximately proportional to doses up to 40 mg, but because of a saturable first-pass effect, a greater than linear response in peak plasma concentration and AUC occurs with doses greater than 40 mg. Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism."/>
	<sentencespan id="DBMI.pac75.sp12" origId="sp12" text="In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min. The bioavailability of omeprazole increases slightly upon repeated administration of omeprazole delayed-release capsules USP. Omeprazole delayed-release capsule USP 40 mg was bioequivalent when administered with and without applesauce."/>
	<sentencespan id="DBMI.pac75.sp13" origId="sp13" text="However, omeprazole delayed-release capsule USP 20 mg was not bioequivalent when administered with and without applesauce. When administered with applesauce, a mean 25% reduction in Cmax was observed without a significant change in AUC for omeprazole delayed-release capsule USP 20 mg. The clinical relevance of this finding is unknown."/>
	<sentencespan id="DBMI.pac75.sp14" origId="sp14" text="Distribution\n\nProtein binding is approximately 95%. Metabolism\n\nOmeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. Excretion\n\nFollowing single dose oral administration of a buffered solution of omeprazole, little if any unchanged drug was excreted in urine."/>
	<sentencespan id="DBMI.pac75.sp15" origId="sp15" text="The majority of the dose (about 77%) was eliminated in urine as at least six metabolites. Two were identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recoverable in feces."/>
	<sentencespan id="DBMI.pac75.sp16" origId="sp16" text="This implies a significant biliary excretion of the metabolites of omeprazole. Three metabolites have been identified in plasma  the sulfide and sulfone derivatives of omeprazole, and hydroxyomeprazole. These metabolites have very little or no antisecretory activity."/>
	<sentencespan id="DBMI.pac75.sp17" origId="sp17" text="Combination Therapy with Antimicrobials\n\nOmeprazole 40 mg daily was given in combination with clarithromycin 500 mg every 8 hours to healthy adult male subjects. The steady state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and T1/2 increases of 30%, 89% and 34% respectively) by the concomitant administration of clarithromycin. The observed increases in omeprazole plasma concentration were associated with the following pharmacological effects.">
		<entity charOffset="7604-7619" id="DBMI.pac75.sp17.e0" origId="sp17.e0" text="clarithromycin " type="Active ingredient"/>
		<entity charOffset="7714-7725" id="DBMI.pac75.sp17.e1" origId="sp17.e1" text="omeprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac75.sp17.e0" e2="DBMI.pac75.sp17.e1" id="DBMI.pac75.sp17.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole " precipitant="clarithromycin "/>
		<pair e1="DBMI.pac75.sp17.e1" e2="DBMI.pac75.sp17.e0" id="DBMI.pac75.sp17.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac75.sp18" origId="sp18" text="The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when co-administered with clarithromycin. The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone.">
		<entity charOffset="8230-8241" id="DBMI.pac75.sp18.e0" origId="sp18.e0" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="8152-8178" id="DBMI.pac75.sp18.e1" origId="sp18.e1" text="14-hydroxy-clarithromycin " type="Metabolite"/>
		<entity charOffset="8133-8148" id="DBMI.pac75.sp18.e2" origId="sp18.e2" text="clarithromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac75.sp18.e0" e2="DBMI.pac75.sp18.e1" id="DBMI.pac75.sp18.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="14-hydroxy-clarithromycin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac75.sp18.e0" e2="DBMI.pac75.sp18.e1" id="DBMI.pac75.sp18.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="14-hydroxy-clarithromycin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac75.sp18.e0" e2="DBMI.pac75.sp18.e2" id="DBMI.pac75.sp18.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="clarithromycin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac75.sp18.e0" e2="DBMI.pac75.sp18.e2" id="DBMI.pac75.sp18.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="clarithromycin " precipitant="omeprazole "/>
		<pair e1="DBMI.pac75.sp18.e1" e2="DBMI.pac75.sp18.e0" id="DBMI.pac75.sp18.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac75.sp18.e1" e2="DBMI.pac75.sp18.e2" id="DBMI.pac75.sp18.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac75.sp18.e2" e2="DBMI.pac75.sp18.e0" id="DBMI.pac75.sp18.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac75.sp18.e2" e2="DBMI.pac75.sp18.e1" id="DBMI.pac75.sp18.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac75.sp19" origId="sp19" text="Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole. Special Populations\n\nGeriatric Population\n\nThe elimination rate of omeprazole was somewhat decreased in the elderly, and bioavailability was increased."/>
	<sentencespan id="DBMI.pac75.sp20" origId="sp20" text="Omeprazole was 76% bioavailable when a single 40 mg oral dose of omeprazole (buffered solution) was administered to healthy elderly volunteers, versus 58% in young volunteers given the same dose. Nearly 70% of the dose was recovered in urine as metabolites of omeprazole and no unchanged drug was detected. The plasma clearance of omeprazole was 250 mL/min (about half that of young volunteers) and its plasma half-life averaged one hour, about twice that of young healthy volunteers."/>
	<sentencespan id="DBMI.pac75.sp21" origId="sp21" text="Pediatric Use\n\nThe pharmacokinetics of omeprazole have been investigated in pediatric patients 2 to 16 years of age:\n\nFollowing comparable mg/kg doses of omeprazole, younger children (2 to 5 years of age) have lower AUCs than children 6 to 16 years of age or adults; AUCs of the latter two groups did not differ. [See Dosage and Administration (2)]\n\nHepatic Impairment\n\nIn patients with chronic hepatic disease, the bioavailability increased to approximately 100% compared with an I.V.dose, reflecting decreased first-pass effect, and the plasma half-life of the drug increased to nearly 3 hours compared with the half-life in normals of 0.5 to 1 hour. Plasma clearance averaged 70 mL/min, compared with a value of 500 to 600 mL/min in normal subjects."/>
	<sentencespan id="DBMI.pac75.sp22" origId="sp22" text="Dose reduction, particularly where maintenance of healing of erosive esophagitis is indicated, for the hepatically impaired should be considered. Renal Impairment\n\nIn patients with chronic renal impairment, whose creatinine clearance ranged between 10 and 62 mL/min/1.73 m2, the disposition of omeprazole was very similar to that in healthy volunteers, although there was a slight increase in bioavailability. Because urinary excretion is a primary route of excretion of omeprazole metabolites, their elimination slowed in proportion to the decreased creatinine clearance."/>
	<sentencespan id="DBMI.pac75.sp23" origId="sp23" text="No dose reduction is necessary in patients with renal impairment. Asian Population\n\nIn pharmacokinetic studies of single 20 mg omeprazole doses, an increase in AUC of approximately four-fold was noted in Asian subjects compared with Caucasians. Dose reduction, particularly where maintenance of healing of erosive esophagitis is indicated, for Asian subjects should be considered."/>
	<sentencespan id="DBMI.pac75.sp24" origId="sp24" text="12.4 Microbiology\n\nOmeprazole and clarithromycin dual therapy and omeprazole, clarithromycin and amoxicillin triple therapy have been shown to be active against most strains of Helicobacter pylori in vitro and in clinical infections as described in the Indications and Usage section (1.1). Helicobacter\n\nHelicobacter pylori-Pretreatment Resistance Clarithromycin pretreatment resistance rates were 3.5% (4/113) in the omeprazole/clarithromycin dual therapy studies (4 and 5) and 9.3% (41/439) in omeprazole/clarithromycin/amoxicillin triple therapy studies (1, 2, and 3). Amoxicillin pretreatment susceptible isolates ( 0.25 g/mL) were found in 99.3% (436/439) of the patients in the omeprazole/clarithromycin/amoxicillin triple therapy studies (1, 2, and 3)."/>
	<sentencespan id="DBMI.pac75.sp25" origId="sp25" text="Amoxicillin pretreatment minimum inhibitory concentrations (MICs) &gt; 0.25 g/mL occurred in 0.7% (3/439) of the patients, all of whom were in the clarithromycin and amoxicillin study arm. One patient had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of &gt; 256 g/mL by Etest. Patients not eradicated of H. pylori following omeprazole/clarithromycin/amoxicillin triple therapy or omeprazole/clarithromycin dual therapy will likely have clarithromycin resistant H. pylori isolates."/>
	<sentencespan id="DBMI.pac75.sp26" origId="sp26" text="Therefore, clarithromycin susceptibility testing should be done, if possible. Patients with clarithromycin resistant H. pylori should not be treated with any of the following: omeprazole/clarithromycin dual therapy, omeprazole/clarithromycin/amoxicillin triple therapy, or other regimens which include clarithromycin as the sole antimicrobial agent. Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes\n\nIn the triple therapy clinical trials, 84.9% (157/185) of the patients in the omeprazole/clarithromycin/amoxicillin treatment group who had pretreatment amoxicillin susceptible MICs ( 0.25 g/mL) were eradicated of H. pylori and 15.1% (28/185) failed therapy."/>
	<sentencespan id="DBMI.pac75.sp27" origId="sp27" text="Of the 28 patients who failed triple therapy, 11 had no post-treatment susceptibility test results and 17 had post-treatment H. pylori isolates with amoxicillin susceptible MICs. Eleven of the patients who failed triple therapy also had post-treatment H. pylori isolates with clarithromycin resistant MICs. Susceptibility Test for Helicobacter pylori\n\nThe reference methodology for susceptibility testing of H. pylori is agar dilution MICs1."/>
	<sentencespan id="DBMI.pac75.sp28" origId="sp28" text="One to three microliters of an inoculum equivalent to a No. 2 McFarland standard (1 x 107 to 1 x 108 CFU/mL for H. pylori) are inoculated directly onto freshly prepared antimicrobial containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood ( 2 weeks old). The agar dilution plates are incubated at 35C in a microaerobic environment produced by a gas generating system suitable for campylobacters."/>
	<sentencespan id="DBMI.pac75.sp29" origId="sp29" text="After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism. The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria:\n\nStandardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard clarithromycin and amoxicillin powders should provide the following MIC values:\n\nEffects on Gastrointestinal Microbial Ecology\n\nDecreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract."/>
	<sentencespan id="DBMI.pac75.sp30" origId="sp30" text="Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter. "/>
</document>

<document id="DBMI.pac76" origId="pac76">
	<sentence id="DBMI.pac76.s0" origId="s0" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.">
		<entity charOffset="100-111" id="DBMI.pac76.s0.e0" origId="s0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="50-61" id="DBMI.pac76.s0.e1" origId="s0.e1" text="citalopram " type="Active ingredient"/>
		<pair e1="DBMI.pac76.s0.e0" e2="DBMI.pac76.s0.e1" id="DBMI.pac76.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="citalopram " precipitant="cimetidine "/>
		<pair e1="DBMI.pac76.s0.e1" e2="DBMI.pac76.s0.e0" id="DBMI.pac76.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac76.s1" origId="s1" text="The clinical significance of these findings is unknown."/>
	<sentencespan id="DBMI.pac76.sp0" origId="sp0" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively. The clinical significance of these findings is unknown.">
		<entity charOffset="100-111" id="DBMI.pac76.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="50-61" id="DBMI.pac76.sp0.e1" origId="sp0.e1" text="citalopram " type="Active ingredient"/>
		<pair e1="DBMI.pac76.sp0.e0" e2="DBMI.pac76.sp0.e1" id="DBMI.pac76.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="citalopram " precipitant="cimetidine "/>
		<pair e1="DBMI.pac76.sp0.e1" e2="DBMI.pac76.sp0.e0" id="DBMI.pac76.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac77" origId="pac77">
	<sentence id="DBMI.pac77.s0" origId="s0" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.">
		<entity charOffset="104-112" id="DBMI.pac77.s0.e0" origId="s0.e0" text="digoxin " type="Active ingredient"/>
		<entity charOffset="89-100" id="DBMI.pac77.s0.e1" origId="s0.e1" text="citalopram " type="Active ingredient"/>
		<pair e1="DBMI.pac77.s0.e0" e2="DBMI.pac77.s0.e1" id="DBMI.pac77.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="citalopram " precipitant="digoxin "/>
		<pair e1="DBMI.pac77.s0.e1" e2="DBMI.pac77.s0.e0" id="DBMI.pac77.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="citalopram "/>
	</sentence>
	<sentencespan id="DBMI.pac77.sp0" origId="sp0" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.">
		<entity charOffset="104-112" id="DBMI.pac77.sp0.e0" origId="sp0.e0" text="digoxin " type="Active ingredient"/>
		<entity charOffset="89-100" id="DBMI.pac77.sp0.e1" origId="sp0.e1" text="citalopram " type="Active ingredient"/>
		<pair e1="DBMI.pac77.sp0.e0" e2="DBMI.pac77.sp0.e1" id="DBMI.pac77.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="citalopram " precipitant="digoxin "/>
		<pair e1="DBMI.pac77.sp0.e1" e2="DBMI.pac77.sp0.e0" id="DBMI.pac77.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="citalopram "/>
	</sentencespan>
</document>

<document id="DBMI.pac78" origId="pac78">
	<sentence id="DBMI.pac78.s0" origId="s0" text="In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone."/>
	<sentence id="DBMI.pac78.s1" origId="s1" text="Citalopram did not alter the mean AUC or Cmax of pimozide.">
		<entity charOffset="229-240" id="DBMI.pac78.s1.e0" origId="s1.e0" text="Citalopram " type="Active ingredient"/>
		<entity charOffset="278-287" id="DBMI.pac78.s1.e1" origId="s1.e1" text="pimozide " type="Active ingredient"/>
		<pair e1="DBMI.pac78.s1.e0" e2="DBMI.pac78.s1.e1" id="DBMI.pac78.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="pimozide " precipitant="Citalopram "/>
		<pair e1="DBMI.pac78.s1.e1" e2="DBMI.pac78.s1.e0" id="DBMI.pac78.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac78.s2" origId="s2" text="The mechanism of this pharmacodynamic interaction is not known."/>
	<sentencespan id="DBMI.pac78.sp0" origId="sp0" text="In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known.">
		<entity charOffset="229-240" id="DBMI.pac78.sp0.e0" origId="sp0.e0" text="Citalopram " type="Active ingredient"/>
		<entity charOffset="278-287" id="DBMI.pac78.sp0.e1" origId="sp0.e1" text="pimozide " type="Active ingredient"/>
		<pair e1="DBMI.pac78.sp0.e0" e2="DBMI.pac78.sp0.e1" id="DBMI.pac78.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="pimozide " precipitant="Citalopram "/>
		<pair e1="DBMI.pac78.sp0.e1" e2="DBMI.pac78.sp0.e0" id="DBMI.pac78.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac79" origId="pac79">
	<sentence id="DBMI.pac79.s0" origId="s0" text="Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.">
		<entity charOffset="28-39" id="DBMI.pac79.s0.e0" origId="s0.e0" text="citalopram " type="Active ingredient"/>
		<entity charOffset="90-99" id="DBMI.pac79.s0.e1" origId="s0.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac79.s0.e0" e2="DBMI.pac79.s0.e1" id="DBMI.pac79.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="citalopram "/>
		<pair e1="DBMI.pac79.s0.e1" e2="DBMI.pac79.s0.e0" id="DBMI.pac79.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac79.s1" origId="s1" text="Prothrombin time was increased by 5%, the clinical significance of which is unknown."/>
	<sentencespan id="DBMI.pac79.sp0" origId="sp0" text="Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown.">
		<entity charOffset="28-39" id="DBMI.pac79.sp0.e0" origId="sp0.e0" text="citalopram " type="Active ingredient"/>
		<entity charOffset="90-99" id="DBMI.pac79.sp0.e1" origId="sp0.e1" text="warfarin " type="Active ingredient"/>
		<pair e1="DBMI.pac79.sp0.e0" e2="DBMI.pac79.sp0.e1" id="DBMI.pac79.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="citalopram "/>
		<pair e1="DBMI.pac79.sp0.e1" e2="DBMI.pac79.sp0.e0" id="DBMI.pac79.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac8" origId="pac8">
	<sentence id="DBMI.pac8.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nThe mechanism of action of risperidone, as with other drugs used to treat schizophrenia, is unknown."/>
	<sentence id="DBMI.pac8.s1" origId="s1" text="However, it has been proposed that the drugs therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism."/>
	<sentence id="DBMI.pac8.s2" origId="s2" text="Risperidone is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors."/>
	<sentence id="DBMI.pac8.s3" origId="s3" text="Risperidone acts as an antagonist at other receptors, but with lower potency."/>
	<sentence id="DBMI.pac8.s4" origId="s4" text="Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations &gt;10-5 M) for cholinergic muscarinic or 1 and 2 adrenergic receptors."/>
	<sentence id="DBMI.pac8.s5" origId="s5" text="12.2 Pharmacodynamics\n\nThe clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]."/>
	<sentence id="DBMI.pac8.s6" origId="s6" text="Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone."/>
	<sentence id="DBMI.pac8.s7" origId="s7" text="12.3 Pharmacokinetics\n\nAbsorption: Risperidone is well absorbed."/>
	<sentence id="DBMI.pac8.s8" origId="s8" text="The absolute oral bioavailability of risperidone is 70% (CV=25%)."/>
	<sentence id="DBMI.pac8.s9" origId="s9" text="The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution."/>
	<sentence id="DBMI.pac8.s10" origId="s10" text="Pharmacokinetic studies showed that risperidone oral solution is bioequivalent to risperidone tablets."/>
	<sentence id="DBMI.pac8.s11" origId="s11" text="Plasma concentrations of risperidone, its major metabolite, 9-hydroxyrisperidone, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily)."/>
	<sentence id="DBMI.pac8.s12" origId="s12" text="Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour."/>
	<sentence id="DBMI.pac8.s13" origId="s13" text="Peak concentrations of 9-hydroxyrisperidone occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers."/>
	<sentence id="DBMI.pac8.s14" origId="s14" text="Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabolizers."/>
	<sentence id="DBMI.pac8.s15" origId="s15" text="Steady-state concentrations of 9-hydroxyrisperidone are reached in 5 to 6 days (measured in extensive metabolizers)."/>
	<sentence id="DBMI.pac8.s16" origId="s16" text="Food Effect: Food does not affect either the rate or extent of absorption of risperidone."/>
	<sentence id="DBMI.pac8.s17" origId="s17" text="Thus, risperidone can be given with or without meals."/>
	<sentence id="DBMI.pac8.s18" origId="s18" text="Distribution: Risperidone is rapidly distributed."/>
	<sentence id="DBMI.pac8.s19" origId="s19" text="The volume of distribution is 1 to 2 L/kg."/>
	<sentence id="DBMI.pac8.s20" origId="s20" text="In plasma, risperidone is bound to albumin and 1-acid glycoprotein."/>
	<sentence id="DBMI.pac8.s21" origId="s21" text="The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%."/>
	<sentence id="DBMI.pac8.s22" origId="s22" text="Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites."/>
	<sentence id="DBMI.pac8.s23" origId="s23" text="High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance."/>
	<sentence id="DBMI.pac8.s24" origId="s24" text="Metabolism and Drug Interactions: Risperidone is extensively metabolized in the liver."/>
	<sentence id="DBMI.pac8.s25" origId="s25" text="The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6."/>
	<sentence id="DBMI.pac8.s26" origId="s26" text="A minor metabolic pathway is through N-dealkylation."/>
	<sentence id="DBMI.pac8.s27" origId="s27" text="The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone."/>
	<sentence id="DBMI.pac8.s28" origId="s28" text="Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone."/>
	<sentence id="DBMI.pac8.s29" origId="s29" text="CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs."/>
	<sentence id="DBMI.pac8.s30" origId="s30" text="CYP 2D6 is subject to genetic polymorphism (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are poor metabolizers) and to inhibition by a variety of substrates and some non-substrates, notably quinidine."/>
	<sentence id="DBMI.pac8.s31" origId="s31" text="Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly."/>
	<sentence id="DBMI.pac8.s32" origId="s32" text="Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers."/>
	<sentence id="DBMI.pac8.s33" origId="s33" text="Risperidone could be subject to two kinds of drug-drug interactions."/>
	<sentence id="DBMI.pac8.s34" origId="s34" text="First, inhibitors of CYP 2D6 interfere with conversion of risperidone to 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]."/>
	<sentence id="DBMI.pac8.s35" origId="s35" text="This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers."/>
	<sentence id="DBMI.pac8.s36" origId="s36" text="The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have not been evaluated, but observations in a modest number (N70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers."/>
	<sentence id="DBMI.pac8.s37" origId="s37" text="Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS].">
		<entity charOffset="5158-5172" id="DBMI.pac8.s37.e0" origId="s37.e0" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="5218-5230" id="DBMI.pac8.s37.e1" origId="s37.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="5173-5183" id="DBMI.pac8.s37.e2" origId="s37.e2" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="5184-5193" id="DBMI.pac8.s37.e3" origId="s37.e3" text="rifampin " type="Active ingredient"/>
		<entity charOffset="5198-5212" id="DBMI.pac8.s37.e4" origId="s37.e4" text="phenobarbital " type="Active ingredient"/>
		<pair e1="DBMI.pac8.s37.e0" e2="DBMI.pac8.s37.e1" id="DBMI.pac8.s37.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac8.s37.e0" e2="DBMI.pac8.s37.e2" id="DBMI.pac8.s37.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e0" e2="DBMI.pac8.s37.e3" id="DBMI.pac8.s37.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e0" e2="DBMI.pac8.s37.e4" id="DBMI.pac8.s37.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e1" e2="DBMI.pac8.s37.e0" id="DBMI.pac8.s37.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e1" e2="DBMI.pac8.s37.e2" id="DBMI.pac8.s37.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e1" e2="DBMI.pac8.s37.e3" id="DBMI.pac8.s37.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e1" e2="DBMI.pac8.s37.e4" id="DBMI.pac8.s37.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e2" e2="DBMI.pac8.s37.e0" id="DBMI.pac8.s37.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e2" e2="DBMI.pac8.s37.e1" id="DBMI.pac8.s37.p9" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="phenytoin "/>
		<pair e1="DBMI.pac8.s37.e2" e2="DBMI.pac8.s37.e3" id="DBMI.pac8.s37.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e2" e2="DBMI.pac8.s37.e4" id="DBMI.pac8.s37.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e3" e2="DBMI.pac8.s37.e0" id="DBMI.pac8.s37.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e3" e2="DBMI.pac8.s37.e1" id="DBMI.pac8.s37.p13" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="rifampin "/>
		<pair e1="DBMI.pac8.s37.e3" e2="DBMI.pac8.s37.e2" id="DBMI.pac8.s37.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e3" e2="DBMI.pac8.s37.e4" id="DBMI.pac8.s37.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e4" e2="DBMI.pac8.s37.e0" id="DBMI.pac8.s37.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e4" e2="DBMI.pac8.s37.e1" id="DBMI.pac8.s37.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="phenobarbital "/>
		<pair e1="DBMI.pac8.s37.e4" e2="DBMI.pac8.s37.e2" id="DBMI.pac8.s37.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.s37.e4" e2="DBMI.pac8.s37.e3" id="DBMI.pac8.s37.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac8.s38" origId="s38" text="It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6."/>
	<sentence id="DBMI.pac8.s39" origId="s39" text="Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS]."/>
	<sentence id="DBMI.pac8.s40" origId="s40" text="Excretion: Risperidone and its metabolites are eliminated via the urine and, to a much lesser extent, via the feces."/>
	<sentence id="DBMI.pac8.s41" origId="s41" text="As illustrated by a mass balance study of a single 1 mg oral dose of 14C-risperidone administered as solution to three healthy male volunteers, total recovery of radioactivity at 1 week was 84%, including 70% in the urine and 14% in the feces."/>
	<sentence id="DBMI.pac8.s42" origId="s42" text="The apparent half-life of risperidone was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers."/>
	<sentence id="DBMI.pac8.s43" origId="s43" text="The apparent half-life of 9-hydroxyrisperidone was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers."/>
	<sentence id="DBMI.pac8.s44" origId="s44" text="The pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours."/>
	<sentence id="DBMI.pac8.s45" origId="s45" text="Renal Impairment: In patients with moderate to severe renal disease, clearance of the sum of risperidone and its active metabolite decreased by 60% compared to young healthy subjects."/>
	<sentence id="DBMI.pac8.s46" origId="s46" text="Risperidone doses should be reduced in patients with renal disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS]."/>
	<sentence id="DBMI.pac8.s47" origId="s47" text="Hepatic Impairment: While the pharmacokinetics of risperidone in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of risperidone in plasma was increased by about 35% because of the diminished concentration of both albumin and 1-acid glycoprotein."/>
	<sentence id="DBMI.pac8.s48" origId="s48" text="Risperidone doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS]."/>
	<sentence id="DBMI.pac8.s49" origId="s49" text="Elderly: In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects."/>
	<sentence id="DBMI.pac8.s50" origId="s50" text="Dosing should be modified accordingly in the elderly patients [see 2 DOSAGE AND ADMINISTRATION]."/>
	<sentence id="DBMI.pac8.s51" origId="s51" text="Pediatric: Due to Janssen Pharmaceuticals Corporations marketing exclusivity rights, this drugproduct is not labeled for use in pediatric patients with schizophrenia, bipolar mania or irritability associatedwith autistic disorder."/>
	<sentence id="DBMI.pac8.s52" origId="s52" text="Pharmacokinetic information for pediatric patients with schizophrenia, 13to 17 years of age, bipolar mania, 10 to 17 years old, and irritability associated with autistic disorder,5 to 16 years of age, is approved for Janssen Pharmaceuticals Corporations risperidone drug products."/>
	<sentence id="DBMI.pac8.s53" origId="s53" text="Race and Gender Effects: No specific pharmacokinetic study was conducted to investigate race and gender effects, but a population pharmacokinetic analysis did not identify important differences in the disposition of risperidone due to gender (whether corrected for body weight or not) or race."/>
	<sentencespan id="DBMI.pac8.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nThe mechanism of action of risperidone, as with other drugs used to treat schizophrenia, is unknown. However, it has been proposed that the drugs therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism. Risperidone is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors."/>
	<sentencespan id="DBMI.pac8.sp1" origId="sp1" text="Risperidone acts as an antagonist at other receptors, but with lower potency. Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations &gt;10-5 M) for cholinergic muscarinic or 1 and 2 adrenergic receptors. 12.2 Pharmacodynamics\n\nThe clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]."/>
	<sentencespan id="DBMI.pac8.sp2" origId="sp2" text="Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone. 12.3 Pharmacokinetics\n\nAbsorption: Risperidone is well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%)."/>
	<sentencespan id="DBMI.pac8.sp3" origId="sp3" text="The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution. Pharmacokinetic studies showed that risperidone oral solution is bioequivalent to risperidone tablets. Plasma concentrations of risperidone, its major metabolite, 9-hydroxyrisperidone, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily)."/>
	<sentencespan id="DBMI.pac8.sp4" origId="sp4" text="Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak concentrations of 9-hydroxyrisperidone occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabolizers."/>
	<sentencespan id="DBMI.pac8.sp5" origId="sp5" text="Steady-state concentrations of 9-hydroxyrisperidone are reached in 5 to 6 days (measured in extensive metabolizers). Food Effect: Food does not affect either the rate or extent of absorption of risperidone. Thus, risperidone can be given with or without meals."/>
	<sentencespan id="DBMI.pac8.sp6" origId="sp6" text="Distribution: Risperidone is rapidly distributed. The volume of distribution is 1 to 2 L/kg. In plasma, risperidone is bound to albumin and 1-acid glycoprotein."/>
	<sentencespan id="DBMI.pac8.sp7" origId="sp7" text="The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance."/>
	<sentencespan id="DBMI.pac8.sp8" origId="sp8" text="Metabolism and Drug Interactions: Risperidone is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation."/>
	<sentencespan id="DBMI.pac8.sp9" origId="sp9" text="The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone. CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs."/>
	<sentencespan id="DBMI.pac8.sp10" origId="sp10" text="CYP 2D6 is subject to genetic polymorphism (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are poor metabolizers) and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers."/>
	<sentencespan id="DBMI.pac8.sp11" origId="sp11" text="Risperidone could be subject to two kinds of drug-drug interactions. First, inhibitors of CYP 2D6 interfere with conversion of risperidone to 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers."/>
	<sentencespan id="DBMI.pac8.sp12" origId="sp12" text="The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have not been evaluated, but observations in a modest number (N70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6.">
		<entity charOffset="5158-5172" id="DBMI.pac8.sp12.e0" origId="sp12.e0" text="carbamazepine " type="Active ingredient"/>
		<entity charOffset="5218-5230" id="DBMI.pac8.sp12.e1" origId="sp12.e1" text="risperidone " type="Active ingredient"/>
		<entity charOffset="5173-5183" id="DBMI.pac8.sp12.e2" origId="sp12.e2" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="5184-5193" id="DBMI.pac8.sp12.e3" origId="sp12.e3" text="rifampin " type="Active ingredient"/>
		<entity charOffset="5198-5212" id="DBMI.pac8.sp12.e4" origId="sp12.e4" text="phenobarbital " type="Active ingredient"/>
		<pair e1="DBMI.pac8.sp12.e0" e2="DBMI.pac8.sp12.e1" id="DBMI.pac8.sp12.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="carbamazepine "/>
		<pair e1="DBMI.pac8.sp12.e0" e2="DBMI.pac8.sp12.e2" id="DBMI.pac8.sp12.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e0" e2="DBMI.pac8.sp12.e3" id="DBMI.pac8.sp12.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e0" e2="DBMI.pac8.sp12.e4" id="DBMI.pac8.sp12.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e1" e2="DBMI.pac8.sp12.e0" id="DBMI.pac8.sp12.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e1" e2="DBMI.pac8.sp12.e2" id="DBMI.pac8.sp12.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e1" e2="DBMI.pac8.sp12.e3" id="DBMI.pac8.sp12.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e1" e2="DBMI.pac8.sp12.e4" id="DBMI.pac8.sp12.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e2" e2="DBMI.pac8.sp12.e0" id="DBMI.pac8.sp12.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e2" e2="DBMI.pac8.sp12.e1" id="DBMI.pac8.sp12.p9" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="phenytoin "/>
		<pair e1="DBMI.pac8.sp12.e2" e2="DBMI.pac8.sp12.e3" id="DBMI.pac8.sp12.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e2" e2="DBMI.pac8.sp12.e4" id="DBMI.pac8.sp12.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e3" e2="DBMI.pac8.sp12.e0" id="DBMI.pac8.sp12.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e3" e2="DBMI.pac8.sp12.e1" id="DBMI.pac8.sp12.p13" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="rifampin "/>
		<pair e1="DBMI.pac8.sp12.e3" e2="DBMI.pac8.sp12.e2" id="DBMI.pac8.sp12.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e3" e2="DBMI.pac8.sp12.e4" id="DBMI.pac8.sp12.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e4" e2="DBMI.pac8.sp12.e0" id="DBMI.pac8.sp12.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e4" e2="DBMI.pac8.sp12.e1" id="DBMI.pac8.sp12.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="risperidone " precipitant="phenobarbital "/>
		<pair e1="DBMI.pac8.sp12.e4" e2="DBMI.pac8.sp12.e2" id="DBMI.pac8.sp12.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac8.sp12.e4" e2="DBMI.pac8.sp12.e3" id="DBMI.pac8.sp12.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac8.sp13" origId="sp13" text="Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS]. Excretion: Risperidone and its metabolites are eliminated via the urine and, to a much lesser extent, via the feces. As illustrated by a mass balance study of a single 1 mg oral dose of 14C-risperidone administered as solution to three healthy male volunteers, total recovery of radioactivity at 1 week was 84%, including 70% in the urine and 14% in the feces."/>
	<sentencespan id="DBMI.pac8.sp14" origId="sp14" text="The apparent half-life of risperidone was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers. The apparent half-life of 9-hydroxyrisperidone was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours."/>
	<sentencespan id="DBMI.pac8.sp15" origId="sp15" text="Renal Impairment: In patients with moderate to severe renal disease, clearance of the sum of risperidone and its active metabolite decreased by 60% compared to young healthy subjects. Risperidone doses should be reduced in patients with renal disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS]. Hepatic Impairment: While the pharmacokinetics of risperidone in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of risperidone in plasma was increased by about 35% because of the diminished concentration of both albumin and 1-acid glycoprotein."/>
	<sentencespan id="DBMI.pac8.sp16" origId="sp16" text="Risperidone doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS]. Elderly: In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects. Dosing should be modified accordingly in the elderly patients [see 2 DOSAGE AND ADMINISTRATION]."/>
	<sentencespan id="DBMI.pac8.sp17" origId="sp17" text="Pediatric: Due to Janssen Pharmaceuticals Corporations marketing exclusivity rights, this drugproduct is not labeled for use in pediatric patients with schizophrenia, bipolar mania or irritability associatedwith autistic disorder. Pharmacokinetic information for pediatric patients with schizophrenia, 13to 17 years of age, bipolar mania, 10 to 17 years old, and irritability associated with autistic disorder,5 to 16 years of age, is approved for Janssen Pharmaceuticals Corporations risperidone drug products. Race and Gender Effects: No specific pharmacokinetic study was conducted to investigate race and gender effects, but a population pharmacokinetic analysis did not identify important differences in the disposition of risperidone due to gender (whether corrected for body weight or not) or race."/>
</document>

<document id="DBMI.pac80" origId="pac80">
	<sentence id="DBMI.pac80.s0" origId="s0" text="Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.">
		<entity charOffset="27-38" id="DBMI.pac80.s0.e0" origId="s0.e0" text="citalopram " type="Active ingredient"/>
		<entity charOffset="50-63" id="DBMI.pac80.s0.e1" origId="s0.e1" text="ketoconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac80.s0.e0" e2="DBMI.pac80.s0.e1" id="DBMI.pac80.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="ketoconazole " precipitant="citalopram "/>
		<pair e1="DBMI.pac80.s0.e1" e2="DBMI.pac80.s0.e0" id="DBMI.pac80.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="citalopram " precipitant="ketoconazole "/>
	</sentence>
	<sentencespan id="DBMI.pac80.sp0" origId="sp0" text="Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.">
		<entity charOffset="27-38" id="DBMI.pac80.sp0.e0" origId="sp0.e0" text="citalopram " type="Active ingredient"/>
		<entity charOffset="50-63" id="DBMI.pac80.sp0.e1" origId="sp0.e1" text="ketoconazole " type="Active ingredient"/>
		<pair e1="DBMI.pac80.sp0.e0" e2="DBMI.pac80.sp0.e1" id="DBMI.pac80.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="ketoconazole " precipitant="citalopram "/>
		<pair e1="DBMI.pac80.sp0.e1" e2="DBMI.pac80.sp0.e0" id="DBMI.pac80.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="citalopram " precipitant="ketoconazole "/>
	</sentencespan>
</document>

<document id="DBMI.pac81" origId="pac81">
	<sentence id="DBMI.pac81.s0" origId="s0" text="Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol.">
		<entity charOffset="28-39" id="DBMI.pac81.s0.e0" origId="s0.e0" text="citalopram " type="Active ingredient"/>
		<entity charOffset="135-146" id="DBMI.pac81.s0.e1" origId="s0.e1" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac81.s0.e0" e2="DBMI.pac81.s0.e1" id="DBMI.pac81.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="citalopram "/>
		<pair e1="DBMI.pac81.s0.e1" e2="DBMI.pac81.s0.e0" id="DBMI.pac81.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac81.s1" origId="s1" text="Increased metoprolol plasma levels have been associated with decreased cardioselectivity."/>
	<sentence id="DBMI.pac81.s2" origId="s2" text="Coadministration of citalopram and metoprolol had no clinically significant effects on blood pressure or heart rate."/>
	<sentencespan id="DBMI.pac81.sp0" origId="sp0" text="Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of citalopram and metoprolol had no clinically significant effects on blood pressure or heart rate.">
		<entity charOffset="28-39" id="DBMI.pac81.sp0.e0" origId="sp0.e0" text="citalopram " type="Active ingredient"/>
		<entity charOffset="135-146" id="DBMI.pac81.sp0.e1" origId="sp0.e1" text="metoprolol " type="Active ingredient"/>
		<pair e1="DBMI.pac81.sp0.e0" e2="DBMI.pac81.sp0.e1" id="DBMI.pac81.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol " precipitant="citalopram "/>
		<pair e1="DBMI.pac81.sp0.e1" e2="DBMI.pac81.sp0.e0" id="DBMI.pac81.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac83" origId="pac83">
	<sentence id="DBMI.pac83.s0" origId="s0" text="Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold.">
		<entity charOffset="20-28" id="DBMI.pac83.s0.e0" origId="s0.e0" text="tacrine " type="Active ingredient"/>
		<entity charOffset="33-46" id="DBMI.pac83.s0.e1" origId="s0.e1" text="theophylline " type="Active ingredient"/>
		<pair e1="DBMI.pac83.s0.e0" e2="DBMI.pac83.s0.e1" id="DBMI.pac83.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="theophylline " precipitant="tacrine "/>
		<pair e1="DBMI.pac83.s0.e1" e2="DBMI.pac83.s0.e0" id="DBMI.pac83.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac83.s1" origId="s1" text="Therefore, monitoring of plasma theophylline concentrations and appropriate reduction of theophylline dose are recommended in patients receiving tacrine and theophylline concurrently."/>
	<sentence id="DBMI.pac83.s2" origId="s2" text="The effect of theophylline on tacrine pharmacokinetics has not been assessed."/>
	<sentencespan id="DBMI.pac83.sp0" origId="sp0" text="Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold. Therefore, monitoring of plasma theophylline concentrations and appropriate reduction of theophylline dose are recommended in patients receiving tacrine and theophylline concurrently. The effect of theophylline on tacrine pharmacokinetics has not been assessed.">
		<entity charOffset="20-28" id="DBMI.pac83.sp0.e0" origId="sp0.e0" text="tacrine " type="Active ingredient"/>
		<entity charOffset="33-46" id="DBMI.pac83.sp0.e1" origId="sp0.e1" text="theophylline " type="Active ingredient"/>
		<pair e1="DBMI.pac83.sp0.e0" e2="DBMI.pac83.sp0.e1" id="DBMI.pac83.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="theophylline " precipitant="tacrine "/>
		<pair e1="DBMI.pac83.sp0.e1" e2="DBMI.pac83.sp0.e0" id="DBMI.pac83.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac84" origId="pac84">
	<sentence id="DBMI.pac84.s0" origId="s0" text="Cimetidine increased the Cmax and AUC of tacrine by approximately 54% and 64%, respectively.">
		<entity charOffset="0-11" id="DBMI.pac84.s0.e0" origId="s0.e0" text="Cimetidine " type="Active ingredient"/>
		<entity charOffset="41-49" id="DBMI.pac84.s0.e1" origId="s0.e1" text="tacrine " type="Active ingredient"/>
		<pair e1="DBMI.pac84.s0.e0" e2="DBMI.pac84.s0.e1" id="DBMI.pac84.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrine " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac84.s0.e1" e2="DBMI.pac84.s0.e0" id="DBMI.pac84.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac84.sp0" origId="sp0" text="Cimetidine increased the Cmax and AUC of tacrine by approximately 54% and 64%, respectively.">
		<entity charOffset="0-11" id="DBMI.pac84.sp0.e0" origId="sp0.e0" text="Cimetidine " type="Active ingredient"/>
		<entity charOffset="41-49" id="DBMI.pac84.sp0.e1" origId="sp0.e1" text="tacrine " type="Active ingredient"/>
		<pair e1="DBMI.pac84.sp0.e0" e2="DBMI.pac84.sp0.e1" id="DBMI.pac84.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrine " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac84.sp0.e1" e2="DBMI.pac84.sp0.e0" id="DBMI.pac84.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac85" origId="pac85">
	<sentence id="DBMI.pac85.s0" origId="s0" text="In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.">
		<entity charOffset="83-95" id="DBMI.pac85.s0.e0" origId="s0.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="66-74" id="DBMI.pac85.s0.e1" origId="s0.e1" text="tacrine " type="Active ingredient"/>
		<pair e1="DBMI.pac85.s0.e0" e2="DBMI.pac85.s0.e1" id="DBMI.pac85.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac85.s0.e1" e2="DBMI.pac85.s0.e0" id="DBMI.pac85.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac85.s1" origId="s1" text="Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine."/>
	<sentencespan id="DBMI.pac85.sp0" origId="sp0" text="In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.">
		<entity charOffset="83-95" id="DBMI.pac85.sp0.e0" origId="sp0.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="66-74" id="DBMI.pac85.sp0.e1" origId="sp0.e1" text="tacrine " type="Active ingredient"/>
		<pair e1="DBMI.pac85.sp0.e0" e2="DBMI.pac85.sp0.e1" id="DBMI.pac85.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac85.sp0.e1" e2="DBMI.pac85.sp0.e0" id="DBMI.pac85.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac88" origId="pac88">
	<sentence id="DBMI.pac88.s0" origId="s0" text="SEPTRA may inhibit the hepatic metabolism of phenytoin.">
		<entity charOffset="0-7" id="DBMI.pac88.s0.e0" origId="s0.e0" text="SEPTRA " type="Drug product"/>
		<entity charOffset="45-55" id="DBMI.pac88.s0.e1" origId="s0.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac88.s0.e0" e2="DBMI.pac88.s0.e1" id="DBMI.pac88.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="phenytoin " precipitant="SEPTRA "/>
		<pair e1="DBMI.pac88.s0.e1" e2="DBMI.pac88.s0.e0" id="DBMI.pac88.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac88.s1" origId="s1" text="SEPTRA, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%.">
		<entity charOffset="56-63" id="DBMI.pac88.s1.e0" origId="s1.e0" text="SEPTRA " type="Drug product"/>
		<entity charOffset="113-123" id="DBMI.pac88.s1.e1" origId="s1.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac88.s1.e0" e2="DBMI.pac88.s1.e1" id="DBMI.pac88.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="SEPTRA "/>
		<pair e1="DBMI.pac88.s1.e1" e2="DBMI.pac88.s1.e0" id="DBMI.pac88.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac88.s2" origId="s2" text="When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect."/>
	<sentencespan id="DBMI.pac88.sp0" origId="sp0" text="SEPTRA may inhibit the hepatic metabolism of phenytoin. SEPTRA, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.">
		<entity charOffset="0-7" id="DBMI.pac88.sp0.e0" origId="sp0.e0" text="SEPTRA " type="Drug product"/>
		<entity charOffset="45-55" id="DBMI.pac88.sp0.e1" origId="sp0.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac88.sp0.e0" e2="DBMI.pac88.sp0.e1" id="DBMI.pac88.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="phenytoin " precipitant="SEPTRA "/>
		<pair e1="DBMI.pac88.sp0.e0" e2="DBMI.pac88.sp0.e1" id="DBMI.pac88.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin " precipitant="SEPTRA "/>
		<pair e1="DBMI.pac88.sp0.e1" e2="DBMI.pac88.sp0.e0" id="DBMI.pac88.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac9" origId="pac9">
	<sentence id="DBMI.pac9.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes\n\nMultiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds."/>
	<sentence id="DBMI.pac9.s1" origId="s1" text="The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available."/>
	<sentence id="DBMI.pac9.s2" origId="s2" text="Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole)."/>
	<sentence id="DBMI.pac9.s3" origId="s3" text="In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6."/>
	<sentence id="DBMI.pac9.s4" origId="s4" text="Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6."/>
	<sentence id="DBMI.pac9.s5" origId="s5" text="Such individuals have been referred to as &quot;poor metabolizers&quot; (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants."/>
	<sentence id="DBMI.pac9.s6" origId="s6" text="While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 &quot;extensive metabolizers&quot; (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group."/>
	<sentence id="DBMI.pac9.s7" origId="s7" text="This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6."/>
	<sentence id="DBMI.pac9.s8" origId="s8" text="Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine)."/>
	<sentence id="DBMI.pac9.s9" origId="s9" text="The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied."/>
	<sentence id="DBMI.pac9.s10" origId="s10" text="A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.">
		<entity charOffset="2392-2401" id="DBMI.pac9.s10.e0" origId="s10.e0" text="pimozide " type="Active ingredient"/>
		<entity charOffset="2303-2315" id="DBMI.pac9.s10.e1" origId="s10.e1" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="2402-2411" id="DBMI.pac9.s10.e2" origId="s10.e2" text="warfarin " type="Active ingredient"/>
		<entity charOffset="2412-2425" id="DBMI.pac9.s10.e3" origId="s10.e3" text="theophylline " type="Active ingredient"/>
		<entity charOffset="2451-2462" id="DBMI.pac9.s10.e4" origId="s10.e4" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="2466-2476" id="DBMI.pac9.s10.e5" origId="s10.e5" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac9.s10.e0" e2="DBMI.pac9.s10.e1" id="DBMI.pac9.s10.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="pimozide "/>
		<pair e1="DBMI.pac9.s10.e0" e2="DBMI.pac9.s10.e2" id="DBMI.pac9.s10.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e0" e2="DBMI.pac9.s10.e3" id="DBMI.pac9.s10.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e0" e2="DBMI.pac9.s10.e4" id="DBMI.pac9.s10.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e0" e2="DBMI.pac9.s10.e5" id="DBMI.pac9.s10.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e1" e2="DBMI.pac9.s10.e0" id="DBMI.pac9.s10.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e1" e2="DBMI.pac9.s10.e2" id="DBMI.pac9.s10.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e1" e2="DBMI.pac9.s10.e3" id="DBMI.pac9.s10.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e1" e2="DBMI.pac9.s10.e4" id="DBMI.pac9.s10.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e1" e2="DBMI.pac9.s10.e5" id="DBMI.pac9.s10.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e2" e2="DBMI.pac9.s10.e0" id="DBMI.pac9.s10.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e2" e2="DBMI.pac9.s10.e1" id="DBMI.pac9.s10.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="warfarin "/>
		<pair e1="DBMI.pac9.s10.e2" e2="DBMI.pac9.s10.e3" id="DBMI.pac9.s10.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e2" e2="DBMI.pac9.s10.e4" id="DBMI.pac9.s10.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e2" e2="DBMI.pac9.s10.e5" id="DBMI.pac9.s10.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e3" e2="DBMI.pac9.s10.e0" id="DBMI.pac9.s10.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e3" e2="DBMI.pac9.s10.e1" id="DBMI.pac9.s10.p16" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="theophylline "/>
		<pair e1="DBMI.pac9.s10.e3" e2="DBMI.pac9.s10.e2" id="DBMI.pac9.s10.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e3" e2="DBMI.pac9.s10.e4" id="DBMI.pac9.s10.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e3" e2="DBMI.pac9.s10.e5" id="DBMI.pac9.s10.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e4" e2="DBMI.pac9.s10.e0" id="DBMI.pac9.s10.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e4" e2="DBMI.pac9.s10.e1" id="DBMI.pac9.s10.p21" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="omeprazole "/>
		<pair e1="DBMI.pac9.s10.e4" e2="DBMI.pac9.s10.e2" id="DBMI.pac9.s10.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e4" e2="DBMI.pac9.s10.e3" id="DBMI.pac9.s10.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e4" e2="DBMI.pac9.s10.e5" id="DBMI.pac9.s10.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e5" e2="DBMI.pac9.s10.e0" id="DBMI.pac9.s10.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e5" e2="DBMI.pac9.s10.e1" id="DBMI.pac9.s10.p26" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac9.s10.e5" e2="DBMI.pac9.s10.e2" id="DBMI.pac9.s10.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e5" e2="DBMI.pac9.s10.e3" id="DBMI.pac9.s10.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s10.e5" e2="DBMI.pac9.s10.e4" id="DBMI.pac9.s10.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac9.s11" origId="s11" text="If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5])."/>
	<sentence id="DBMI.pac9.s12" origId="s12" text="7.2 CNS Active Drugs\n\nAntipsychotics: See WARNINGS AND PRECAUTIONS (5.3)."/>
	<sentence id="DBMI.pac9.s13" origId="s13" text="Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8)."/>
	<sentence id="DBMI.pac9.s14" origId="s14" text="Alprazolam: See WARNINGS AND PRECAUTIONS (5.8)."/>
	<sentence id="DBMI.pac9.s15" origId="s15" text="Diazepam: See WARNINGS AND PRECAUTIONS (5.8)."/>
	<sentence id="DBMI.pac9.s16" origId="s16" text="Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.)in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.">
		<entity charOffset="3105-3117" id="DBMI.pac9.s16.e0" origId="s16.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="3197-3207" id="DBMI.pac9.s16.e1" origId="s16.e1" text="lorazepam " type="Active ingredient"/>
		<pair e1="DBMI.pac9.s16.e0" e2="DBMI.pac9.s16.e1" id="DBMI.pac9.s16.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lorazepam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s16.e1" e2="DBMI.pac9.s16.e0" id="DBMI.pac9.s16.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvoxamine " precipitant="lorazepam "/>
	</sentence>
	<sentence id="DBMI.pac9.s17" origId="s17" text="On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone."/>
	<sentence id="DBMI.pac9.s18" origId="s18" text="Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.)revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.">
		<entity charOffset="3578-3586" id="DBMI.pac9.s18.e0" origId="s18.e0" text="ethanol " type="Active ingredient"/>
		<entity charOffset="3675-3687" id="DBMI.pac9.s18.e1" origId="s18.e1" text="fluvoxamine " type="Active ingredient"/>
		<pair e1="DBMI.pac9.s18.e0" e2="DBMI.pac9.s18.e1" id="DBMI.pac9.s18.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvoxamine " precipitant="ethanol "/>
		<pair e1="DBMI.pac9.s18.e1" e2="DBMI.pac9.s18.e0" id="DBMI.pac9.s18.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethanol " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s18.e1" e2="DBMI.pac9.s18.e0" id="DBMI.pac9.s18.p2" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="ethanol " precipitant="fluvoxamine "/>
	</sentence>
	<sentence id="DBMI.pac9.s19" origId="s19" text="As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets."/>
	<sentence id="DBMI.pac9.s20" origId="s20" text="Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.">
		<entity charOffset="4047-4059" id="DBMI.pac9.s20.e0" origId="s20.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="3953-3967" id="DBMI.pac9.s20.e1" origId="s20.e1" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac9.s20.e0" e2="DBMI.pac9.s20.e1" id="DBMI.pac9.s20.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s20.e1" e2="DBMI.pac9.s20.e0" id="DBMI.pac9.s20.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac9.s21" origId="s21" text="Clozapine: See WARNINGS AND PRECAUTIONS (5.8)."/>
	<sentence id="DBMI.pac9.s22" origId="s22" text="Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution."/>
	<sentence id="DBMI.pac9.s23" origId="s23" text="Seizures have been reported with the coadministration of fluvoxamine maleate and lithium."/>
	<sentence id="DBMI.pac9.s24" origId="s24" text="Methadone: See WARNINGS AND PRECAUTIONS (5.8)."/>
	<sentence id="DBMI.pac9.s25" origId="s25" text="Monoamine Oxidase Inhibitors: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.2)."/>
	<sentence id="DBMI.pac9.s26" origId="s26" text="Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6)."/>
	<sentence id="DBMI.pac9.s27" origId="s27" text="Ramelteon: See WARNINGS AND PRECAUTIONS (5.8)."/>
	<sentence id="DBMI.pac9.s28" origId="s28" text="Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3)."/>
	<sentence id="DBMI.pac9.s29" origId="s29" text="Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.">
		<entity charOffset="4801-4813" id="DBMI.pac9.s29.e0" origId="s29.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="4784-4792" id="DBMI.pac9.s29.e1" origId="s29.e1" text="tacrine " type="Active ingredient"/>
		<pair e1="DBMI.pac9.s29.e0" e2="DBMI.pac9.s29.e1" id="DBMI.pac9.s29.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s29.e1" e2="DBMI.pac9.s29.e0" id="DBMI.pac9.s29.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac9.s30" origId="s30" text="Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine."/>
	<sentence id="DBMI.pac9.s31" origId="s31" text="Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4)."/>
	<sentence id="DBMI.pac9.s32" origId="s32" text="Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5)."/>
	<sentence id="DBMI.pac9.s33" origId="s33" text="Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.">
		<entity charOffset="5416-5428" id="DBMI.pac9.s33.e0" origId="s33.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="5455-5468" id="DBMI.pac9.s33.e1" origId="s33.e1" text="clomipramine " type="Active ingredient"/>
		<entity charOffset="5440-5454" id="DBMI.pac9.s33.e2" origId="s33.e2" text="amitriptyline " type="Active ingredient"/>
		<entity charOffset="5471-5482" id="DBMI.pac9.s33.e3" origId="s33.e3" text="imipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac9.s33.e0" e2="DBMI.pac9.s33.e1" id="DBMI.pac9.s33.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="clomipramine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s33.e0" e2="DBMI.pac9.s33.e1" id="DBMI.pac9.s33.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="clomipramine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s33.e0" e2="DBMI.pac9.s33.e2" id="DBMI.pac9.s33.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="amitriptyline " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s33.e0" e2="DBMI.pac9.s33.e3" id="DBMI.pac9.s33.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="imipramine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s33.e1" e2="DBMI.pac9.s33.e0" id="DBMI.pac9.s33.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s33.e1" e2="DBMI.pac9.s33.e2" id="DBMI.pac9.s33.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s33.e1" e2="DBMI.pac9.s33.e3" id="DBMI.pac9.s33.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s33.e2" e2="DBMI.pac9.s33.e0" id="DBMI.pac9.s33.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s33.e2" e2="DBMI.pac9.s33.e1" id="DBMI.pac9.s33.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s33.e2" e2="DBMI.pac9.s33.e3" id="DBMI.pac9.s33.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s33.e3" e2="DBMI.pac9.s33.e0" id="DBMI.pac9.s33.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s33.e3" e2="DBMI.pac9.s33.e1" id="DBMI.pac9.s33.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.s33.e3" e2="DBMI.pac9.s33.e2" id="DBMI.pac9.s33.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac9.s34" origId="s34" text="Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced."/>
	<sentence id="DBMI.pac9.s35" origId="s35" text="Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan."/>
	<sentence id="DBMI.pac9.s36" origId="s36" text="If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3])."/>
	<sentence id="DBMI.pac9.s37" origId="s37" text="Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan."/>
	<sentence id="DBMI.pac9.s38" origId="s38" text="If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised."/>
	<sentence id="DBMI.pac9.s39" origId="s39" text="Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution."/>
	<sentence id="DBMI.pac9.s40" origId="s40" text="Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3])."/>
	<sentence id="DBMI.pac9.s41" origId="s41" text="7.3 Other Drugs\n\nAlosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert."/>
	<sentence id="DBMI.pac9.s42" origId="s42" text="Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.">
		<entity charOffset="6834-6846" id="DBMI.pac9.s42.e0" origId="s42.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="6977-6985" id="DBMI.pac9.s42.e1" origId="s42.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac9.s42.e0" e2="DBMI.pac9.s42.e1" id="DBMI.pac9.s42.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s42.e1" e2="DBMI.pac9.s42.e0" id="DBMI.pac9.s42.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac9.s43" origId="s43" text="Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem."/>
	<sentence id="DBMI.pac9.s44" origId="s44" text="Mexiletine: See WARNINGS AND PRECAUTIONS (5.8)."/>
	<sentence id="DBMI.pac9.s45" origId="s45" text="Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.">
		<entity charOffset="7199-7211" id="DBMI.pac9.s45.e0" origId="s45.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="7351-7363" id="DBMI.pac9.s45.e1" origId="s45.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac9.s45.e0" e2="DBMI.pac9.s45.e1" id="DBMI.pac9.s45.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s45.e1" e2="DBMI.pac9.s45.e0" id="DBMI.pac9.s45.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac9.s46" origId="s46" text="In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure."/>
	<sentence id="DBMI.pac9.s47" origId="s47" text="One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol."/>
	<sentence id="DBMI.pac9.s48" origId="s48" text="If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended."/>
	<sentence id="DBMI.pac9.s49" origId="s49" text="No dosage adjustment is required for fluvoxamine maleate tablets."/>
	<sentence id="DBMI.pac9.s50" origId="s50" text="Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.">
		<entity charOffset="7968-7980" id="DBMI.pac9.s50.e0" origId="s50.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="8084-8093" id="DBMI.pac9.s50.e1" origId="s50.e1" text="atenolol " type="Active ingredient"/>
		<pair e1="DBMI.pac9.s50.e0" e2="DBMI.pac9.s50.e1" id="DBMI.pac9.s50.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.s50.e1" e2="DBMI.pac9.s50.e0" id="DBMI.pac9.s50.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac9.s51" origId="s51" text="Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion."/>
	<sentence id="DBMI.pac9.s52" origId="s52" text="Theophylline: See WARNINGS AND PRECAUTIONS (5.8)."/>
	<sentence id="DBMI.pac9.s53" origId="s53" text="Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc."/>
	<sentence id="DBMI.pac9.s54" origId="s54" text="): See WARNINGS AND PRECAUTIONS [5.8 and 5.10]."/>
	<sentence id="DBMI.pac9.s55" origId="s55" text="7.4 Effects of Smoking on Fluvoxamine Metabolism\n\nSmokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers."/>
	<sentence id="DBMI.pac9.s56" origId="s56" text="7.5 Electroconvulsive Therapy (ECT)\n\nThere are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate."/>
	<sentencespan id="DBMI.pac9.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes\n\nMultiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole)."/>
	<sentencespan id="DBMI.pac9.sp1" origId="sp1" text="In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6. Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6. Such individuals have been referred to as &quot;poor metabolizers&quot; (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants."/>
	<sentencespan id="DBMI.pac9.sp2" origId="sp2" text="While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 &quot;extensive metabolizers&quot; (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6. Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine)."/>
	<sentencespan id="DBMI.pac9.sp3" origId="sp3" text="The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied. A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).">
		<entity charOffset="2392-2401" id="DBMI.pac9.sp3.e0" origId="sp3.e0" text="pimozide " type="Active ingredient"/>
		<entity charOffset="2303-2315" id="DBMI.pac9.sp3.e1" origId="sp3.e1" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="2402-2411" id="DBMI.pac9.sp3.e2" origId="sp3.e2" text="warfarin " type="Active ingredient"/>
		<entity charOffset="2412-2425" id="DBMI.pac9.sp3.e3" origId="sp3.e3" text="theophylline " type="Active ingredient"/>
		<entity charOffset="2451-2462" id="DBMI.pac9.sp3.e4" origId="sp3.e4" text="omeprazole " type="Active ingredient"/>
		<entity charOffset="2466-2476" id="DBMI.pac9.sp3.e5" origId="sp3.e5" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac9.sp3.e0" e2="DBMI.pac9.sp3.e1" id="DBMI.pac9.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="pimozide "/>
		<pair e1="DBMI.pac9.sp3.e0" e2="DBMI.pac9.sp3.e2" id="DBMI.pac9.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e0" e2="DBMI.pac9.sp3.e3" id="DBMI.pac9.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e0" e2="DBMI.pac9.sp3.e4" id="DBMI.pac9.sp3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e0" e2="DBMI.pac9.sp3.e5" id="DBMI.pac9.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e1" e2="DBMI.pac9.sp3.e0" id="DBMI.pac9.sp3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e1" e2="DBMI.pac9.sp3.e2" id="DBMI.pac9.sp3.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e1" e2="DBMI.pac9.sp3.e3" id="DBMI.pac9.sp3.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e1" e2="DBMI.pac9.sp3.e4" id="DBMI.pac9.sp3.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e1" e2="DBMI.pac9.sp3.e5" id="DBMI.pac9.sp3.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e2" e2="DBMI.pac9.sp3.e0" id="DBMI.pac9.sp3.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e2" e2="DBMI.pac9.sp3.e1" id="DBMI.pac9.sp3.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="warfarin "/>
		<pair e1="DBMI.pac9.sp3.e2" e2="DBMI.pac9.sp3.e3" id="DBMI.pac9.sp3.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e2" e2="DBMI.pac9.sp3.e4" id="DBMI.pac9.sp3.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e2" e2="DBMI.pac9.sp3.e5" id="DBMI.pac9.sp3.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e3" e2="DBMI.pac9.sp3.e0" id="DBMI.pac9.sp3.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e3" e2="DBMI.pac9.sp3.e1" id="DBMI.pac9.sp3.p16" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="theophylline "/>
		<pair e1="DBMI.pac9.sp3.e3" e2="DBMI.pac9.sp3.e2" id="DBMI.pac9.sp3.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e3" e2="DBMI.pac9.sp3.e4" id="DBMI.pac9.sp3.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e3" e2="DBMI.pac9.sp3.e5" id="DBMI.pac9.sp3.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e4" e2="DBMI.pac9.sp3.e0" id="DBMI.pac9.sp3.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e4" e2="DBMI.pac9.sp3.e1" id="DBMI.pac9.sp3.p21" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="omeprazole "/>
		<pair e1="DBMI.pac9.sp3.e4" e2="DBMI.pac9.sp3.e2" id="DBMI.pac9.sp3.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e4" e2="DBMI.pac9.sp3.e3" id="DBMI.pac9.sp3.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e4" e2="DBMI.pac9.sp3.e5" id="DBMI.pac9.sp3.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e5" e2="DBMI.pac9.sp3.e0" id="DBMI.pac9.sp3.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e5" e2="DBMI.pac9.sp3.e1" id="DBMI.pac9.sp3.p26" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fluvoxamine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac9.sp3.e5" e2="DBMI.pac9.sp3.e2" id="DBMI.pac9.sp3.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e5" e2="DBMI.pac9.sp3.e3" id="DBMI.pac9.sp3.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp3.e5" e2="DBMI.pac9.sp3.e4" id="DBMI.pac9.sp3.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac9.sp4" origId="sp4" text="7.2 CNS Active Drugs\n\nAntipsychotics: See WARNINGS AND PRECAUTIONS (5.3). Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8). Alprazolam: See WARNINGS AND PRECAUTIONS (5.8)."/>
	<sentencespan id="DBMI.pac9.sp5" origId="sp5" text="Diazepam: See WARNINGS AND PRECAUTIONS (5.8). Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.)in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.">
		<entity charOffset="3105-3117" id="DBMI.pac9.sp5.e0" origId="sp5.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="3197-3207" id="DBMI.pac9.sp5.e1" origId="sp5.e1" text="lorazepam " type="Active ingredient"/>
		<pair e1="DBMI.pac9.sp5.e0" e2="DBMI.pac9.sp5.e1" id="DBMI.pac9.sp5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lorazepam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp5.e1" e2="DBMI.pac9.sp5.e0" id="DBMI.pac9.sp5.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvoxamine " precipitant="lorazepam "/>
	</sentencespan>
	<sentencespan id="DBMI.pac9.sp6" origId="sp6" text="Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.)revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other. As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets. Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.">
		<entity charOffset="3578-3586" id="DBMI.pac9.sp6.e0" origId="sp6.e0" text="ethanol " type="Active ingredient"/>
		<entity charOffset="3675-3687" id="DBMI.pac9.sp6.e1" origId="sp6.e1" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="3953-3967" id="DBMI.pac9.sp6.e2" origId="sp6.e2" text="carbamazepine " type="Active ingredient"/>
		<pair e1="DBMI.pac9.sp6.e0" e2="DBMI.pac9.sp6.e1" id="DBMI.pac9.sp6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvoxamine " precipitant="ethanol "/>
		<pair e1="DBMI.pac9.sp6.e0" e2="DBMI.pac9.sp6.e2" id="DBMI.pac9.sp6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp6.e1" e2="DBMI.pac9.sp6.e0" id="DBMI.pac9.sp6.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethanol " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp6.e1" e2="DBMI.pac9.sp6.e0" id="DBMI.pac9.sp6.p3" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="ethanol " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp6.e1" e2="DBMI.pac9.sp6.e2" id="DBMI.pac9.sp6.p4" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp6.e2" e2="DBMI.pac9.sp6.e0" id="DBMI.pac9.sp6.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp6.e2" e2="DBMI.pac9.sp6.e1" id="DBMI.pac9.sp6.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac9.sp7" origId="sp7" text="Clozapine: See WARNINGS AND PRECAUTIONS (5.8). Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution. Seizures have been reported with the coadministration of fluvoxamine maleate and lithium."/>
	<sentencespan id="DBMI.pac9.sp8" origId="sp8" text="Methadone: See WARNINGS AND PRECAUTIONS (5.8). Monoamine Oxidase Inhibitors: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.2). Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6)."/>
	<sentencespan id="DBMI.pac9.sp9" origId="sp9" text="Ramelteon: See WARNINGS AND PRECAUTIONS (5.8). Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3). Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.">
		<entity charOffset="4801-4813" id="DBMI.pac9.sp9.e0" origId="sp9.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="4784-4792" id="DBMI.pac9.sp9.e1" origId="sp9.e1" text="tacrine " type="Active ingredient"/>
		<pair e1="DBMI.pac9.sp9.e0" e2="DBMI.pac9.sp9.e1" id="DBMI.pac9.sp9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp9.e1" e2="DBMI.pac9.sp9.e0" id="DBMI.pac9.sp9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac9.sp10" origId="sp10" text="Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine. Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4). Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5)."/>
	<sentencespan id="DBMI.pac9.sp11" origId="sp11" text="Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.">
		<entity charOffset="5416-5428" id="DBMI.pac9.sp11.e0" origId="sp11.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="5455-5468" id="DBMI.pac9.sp11.e1" origId="sp11.e1" text="clomipramine " type="Active ingredient"/>
		<entity charOffset="5440-5454" id="DBMI.pac9.sp11.e2" origId="sp11.e2" text="amitriptyline " type="Active ingredient"/>
		<entity charOffset="5471-5482" id="DBMI.pac9.sp11.e3" origId="sp11.e3" text="imipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac9.sp11.e0" e2="DBMI.pac9.sp11.e1" id="DBMI.pac9.sp11.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="clomipramine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp11.e0" e2="DBMI.pac9.sp11.e1" id="DBMI.pac9.sp11.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="clomipramine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp11.e0" e2="DBMI.pac9.sp11.e2" id="DBMI.pac9.sp11.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="amitriptyline " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp11.e0" e2="DBMI.pac9.sp11.e3" id="DBMI.pac9.sp11.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="imipramine " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp11.e1" e2="DBMI.pac9.sp11.e0" id="DBMI.pac9.sp11.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp11.e1" e2="DBMI.pac9.sp11.e2" id="DBMI.pac9.sp11.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp11.e1" e2="DBMI.pac9.sp11.e3" id="DBMI.pac9.sp11.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp11.e2" e2="DBMI.pac9.sp11.e0" id="DBMI.pac9.sp11.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp11.e2" e2="DBMI.pac9.sp11.e1" id="DBMI.pac9.sp11.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp11.e2" e2="DBMI.pac9.sp11.e3" id="DBMI.pac9.sp11.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp11.e3" e2="DBMI.pac9.sp11.e0" id="DBMI.pac9.sp11.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp11.e3" e2="DBMI.pac9.sp11.e1" id="DBMI.pac9.sp11.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac9.sp11.e3" e2="DBMI.pac9.sp11.e2" id="DBMI.pac9.sp11.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac9.sp12" origId="sp12" text="If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]). Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised."/>
	<sentencespan id="DBMI.pac9.sp13" origId="sp13" text="Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution. Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]). 7.3 Other Drugs\n\nAlosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert."/>
	<sentencespan id="DBMI.pac9.sp14" origId="sp14" text="Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin. Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem. Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).">
		<entity charOffset="6834-6846" id="DBMI.pac9.sp14.e0" origId="sp14.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="6977-6985" id="DBMI.pac9.sp14.e1" origId="sp14.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac9.sp14.e0" e2="DBMI.pac9.sp14.e1" id="DBMI.pac9.sp14.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp14.e1" e2="DBMI.pac9.sp14.e0" id="DBMI.pac9.sp14.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac9.sp15" origId="sp15" text="Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure. One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.">
		<entity charOffset="7199-7211" id="DBMI.pac9.sp15.e0" origId="sp15.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="7351-7363" id="DBMI.pac9.sp15.e1" origId="sp15.e1" text="propranolol " type="Active ingredient"/>
		<pair e1="DBMI.pac9.sp15.e0" e2="DBMI.pac9.sp15.e1" id="DBMI.pac9.sp15.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp15.e1" e2="DBMI.pac9.sp15.e0" id="DBMI.pac9.sp15.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac9.sp16" origId="sp16" text="If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended. No dosage adjustment is required for fluvoxamine maleate tablets. Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.">
		<entity charOffset="7968-7980" id="DBMI.pac9.sp16.e0" origId="sp16.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="8084-8093" id="DBMI.pac9.sp16.e1" origId="sp16.e1" text="atenolol " type="Active ingredient"/>
		<pair e1="DBMI.pac9.sp16.e0" e2="DBMI.pac9.sp16.e1" id="DBMI.pac9.sp16.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac9.sp16.e1" e2="DBMI.pac9.sp16.e0" id="DBMI.pac9.sp16.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac9.sp17" origId="sp17" text="Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion. Theophylline: See WARNINGS AND PRECAUTIONS (5.8). Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc."/>
	<sentencespan id="DBMI.pac9.sp18" origId="sp18" text="): See WARNINGS AND PRECAUTIONS [5.8 and 5.10]. 7.4 Effects of Smoking on Fluvoxamine Metabolism\n\nSmokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers. 7.5 Electroconvulsive Therapy (ECT)\n\nThere are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate."/>
</document>

<document id="DBMI.pac90" origId="pac90">
	<sentence id="DBMI.pac90.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Monoamine Oxidase Inhibitors\n\nWith other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) when taken in combination with an MAOI."/>
	<sentence id="DBMI.pac90.s1" origId="s1" text="Some cases presented with features resembling neuroleptic malignant syndrome."/>
	<sentence id="DBMI.pac90.s2" origId="s2" text="Such reactions may occur when these drugs are given concurrently or in close proximity [see Contraindications (4.2)]."/>
	<sentence id="DBMI.pac90.s3" origId="s3" text="7.2 Effect of CYP2D6 Inhibitors on Atomoxetine\n\nIn extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).">
		<entity charOffset="732-743" id="DBMI.pac90.s3.e0" origId="s3.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="780-792" id="DBMI.pac90.s3.e1" origId="s3.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="744-755" id="DBMI.pac90.s3.e2" origId="s3.e2" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="760-770" id="DBMI.pac90.s3.e3" origId="s3.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac90.s3.e0" e2="DBMI.pac90.s3.e1" id="DBMI.pac90.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac90.s3.e0" e2="DBMI.pac90.s3.e2" id="DBMI.pac90.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s3.e0" e2="DBMI.pac90.s3.e3" id="DBMI.pac90.s3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s3.e1" e2="DBMI.pac90.s3.e0" id="DBMI.pac90.s3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s3.e1" e2="DBMI.pac90.s3.e2" id="DBMI.pac90.s3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s3.e1" e2="DBMI.pac90.s3.e3" id="DBMI.pac90.s3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s3.e2" e2="DBMI.pac90.s3.e0" id="DBMI.pac90.s3.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s3.e2" e2="DBMI.pac90.s3.e1" id="DBMI.pac90.s3.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac90.s3.e2" e2="DBMI.pac90.s3.e3" id="DBMI.pac90.s3.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s3.e3" e2="DBMI.pac90.s3.e0" id="DBMI.pac90.s3.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s3.e3" e2="DBMI.pac90.s3.e1" id="DBMI.pac90.s3.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac90.s3.e3" e2="DBMI.pac90.s3.e2" id="DBMI.pac90.s3.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac90.s4" origId="s4" text="In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.">
		<entity charOffset="925-936" id="DBMI.pac90.s4.e0" origId="s4.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="962-974" id="DBMI.pac90.s4.e1" origId="s4.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="939-950" id="DBMI.pac90.s4.e2" origId="s4.e2" text="fluoxetine " type="Active ingredient"/>
		<pair e1="DBMI.pac90.s4.e0" e2="DBMI.pac90.s4.e1" id="DBMI.pac90.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac90.s4.e0" e2="DBMI.pac90.s4.e2" id="DBMI.pac90.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s4.e1" e2="DBMI.pac90.s4.e0" id="DBMI.pac90.s4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s4.e1" e2="DBMI.pac90.s4.e2" id="DBMI.pac90.s4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s4.e2" e2="DBMI.pac90.s4.e0" id="DBMI.pac90.s4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s4.e2" e2="DBMI.pac90.s4.e1" id="DBMI.pac90.s4.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
	</sentence>
	<sentence id="DBMI.pac90.s5" origId="s5" text="In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine."/>
	<sentence id="DBMI.pac90.s6" origId="s6" text="7.3 Pressor Agents\n\nBecause of possible effects on blood pressure, atomoxetine hydrochloride should be used cautiously with pressor agents (e.g., dopamine, dobutamine)."/>
	<sentence id="DBMI.pac90.s7" origId="s7" text="7.4 Albuterol\n\nAtomoxetine hydrochloride should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure."/>
	<sentence id="DBMI.pac90.s8" origId="s8" text="Albuterol (600 mcg iv over 2 hours) induced increases in heart rate and blood pressure."/>
	<sentence id="DBMI.pac90.s9" origId="s9" text="These effects were potentiated by atomoxetine (60 mg BID for 5 days) and were most marked after the initial coadministration of albuterol and atomoxetine."/>
	<sentence id="DBMI.pac90.s10" origId="s10" text="However, these effects on heart rate and blood pressure were not seen in another study after the coadministration with inhaled dose of albuterol (200 to 800 mcg) and atomoxetine (80 mg QD for 5 days) in 21 healthy Asian subjects who were excluded for poor metabolizer status."/>
	<sentence id="DBMI.pac90.s11" origId="s11" text="7.5 Effect of Atomoxetine on P450 Enzymes\n\nAtomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."/>
	<sentence id="DBMI.pac90.s12" origId="s12" text="CYP3A Substrate (e.g., Midazolam)  Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam.">
		<entity charOffset="2481-2493" id="DBMI.pac90.s12.e0" origId="s12.e0" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="2651-2661" id="DBMI.pac90.s12.e1" origId="s12.e1" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac90.s12.e0" e2="DBMI.pac90.s12.e1" id="DBMI.pac90.s12.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="atomoxetine "/>
		<pair e1="DBMI.pac90.s12.e1" e2="DBMI.pac90.s12.e0" id="DBMI.pac90.s12.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac90.s13" origId="s13" text="No dose adjustment is recommended for drugs metabolized by CYP3A."/>
	<sentence id="DBMI.pac90.s14" origId="s14" text="CYP2D6 Substrate (e.g., Desipramine)  Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine.">
		<entity charOffset="2788-2800" id="DBMI.pac90.s14.e0" origId="s14.e0" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="2970-2982" id="DBMI.pac90.s14.e1" origId="s14.e1" text="desipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac90.s14.e0" e2="DBMI.pac90.s14.e1" id="DBMI.pac90.s14.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="desipramine " precipitant="atomoxetine "/>
		<pair e1="DBMI.pac90.s14.e1" e2="DBMI.pac90.s14.e0" id="DBMI.pac90.s14.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac90.s15" origId="s15" text="No dose adjustment is recommended for drugs metabolized by CYP2D6."/>
	<sentence id="DBMI.pac90.s16" origId="s16" text="7.6 Alcohol\n\nConsumption of ethanol with atomoxetine hydrochloride did not change the intoxicating effects of ethanol."/>
	<sentence id="DBMI.pac90.s17" origId="s17" text="7.7 Methylphenidate\n\nCoadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone."/>
	<sentence id="DBMI.pac90.s18" origId="s18" text="7.8 Drugs Highly Bound to Plasma Protein\n\nIn vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations."/>
	<sentence id="DBMI.pac90.s19" origId="s19" text="Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin."/>
	<sentence id="DBMI.pac90.s20" origId="s20" text="Similarly, these compounds did not affect the binding of atomoxetine to human albumin."/>
	<sentence id="DBMI.pac90.s21" origId="s21" text="7.9 Drugs that Affect Gastric pH\n\nDrugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.">
		<entity charOffset="3783-3803" id="DBMI.pac90.s21.e0" origId="s21.e0" text="magnesium hydroxide " type="Active ingredient"/>
		<entity charOffset="3852-3864" id="DBMI.pac90.s21.e1" origId="s21.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="3803-3822" id="DBMI.pac90.s21.e2" origId="s21.e2" text="aluminum hydroxide " type="Active ingredient"/>
		<entity charOffset="3823-3834" id="DBMI.pac90.s21.e3" origId="s21.e3" text="omeprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac90.s21.e0" e2="DBMI.pac90.s21.e1" id="DBMI.pac90.s21.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atomoxetine " precipitant="magnesium hydroxide "/>
		<pair e1="DBMI.pac90.s21.e0" e2="DBMI.pac90.s21.e2" id="DBMI.pac90.s21.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s21.e0" e2="DBMI.pac90.s21.e3" id="DBMI.pac90.s21.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s21.e1" e2="DBMI.pac90.s21.e0" id="DBMI.pac90.s21.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s21.e1" e2="DBMI.pac90.s21.e2" id="DBMI.pac90.s21.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s21.e1" e2="DBMI.pac90.s21.e3" id="DBMI.pac90.s21.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s21.e2" e2="DBMI.pac90.s21.e0" id="DBMI.pac90.s21.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s21.e2" e2="DBMI.pac90.s21.e1" id="DBMI.pac90.s21.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atomoxetine " precipitant="aluminum hydroxide "/>
		<pair e1="DBMI.pac90.s21.e2" e2="DBMI.pac90.s21.e3" id="DBMI.pac90.s21.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s21.e3" e2="DBMI.pac90.s21.e0" id="DBMI.pac90.s21.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.s21.e3" e2="DBMI.pac90.s21.e1" id="DBMI.pac90.s21.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atomoxetine " precipitant="omeprazole "/>
		<pair e1="DBMI.pac90.s21.e3" e2="DBMI.pac90.s21.e2" id="DBMI.pac90.s21.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac90.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Monoamine Oxidase Inhibitors\n\nWith other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) when taken in combination with an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Such reactions may occur when these drugs are given concurrently or in close proximity [see Contraindications (4.2)]."/>
	<sentencespan id="DBMI.pac90.sp1" origId="sp1" text="7.2 Effect of CYP2D6 Inhibitors on Atomoxetine\n\nIn extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone. In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.">
		<entity charOffset="732-743" id="DBMI.pac90.sp1.e0" origId="sp1.e0" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="780-792" id="DBMI.pac90.sp1.e1" origId="sp1.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="744-755" id="DBMI.pac90.sp1.e2" origId="sp1.e2" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="760-770" id="DBMI.pac90.sp1.e3" origId="sp1.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac90.sp1.e0" e2="DBMI.pac90.sp1.e1" id="DBMI.pac90.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac90.sp1.e0" e2="DBMI.pac90.sp1.e1" id="DBMI.pac90.sp1.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac90.sp1.e0" e2="DBMI.pac90.sp1.e2" id="DBMI.pac90.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp1.e0" e2="DBMI.pac90.sp1.e3" id="DBMI.pac90.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp1.e1" e2="DBMI.pac90.sp1.e0" id="DBMI.pac90.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp1.e1" e2="DBMI.pac90.sp1.e2" id="DBMI.pac90.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp1.e1" e2="DBMI.pac90.sp1.e3" id="DBMI.pac90.sp1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp1.e2" e2="DBMI.pac90.sp1.e0" id="DBMI.pac90.sp1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp1.e2" e2="DBMI.pac90.sp1.e1" id="DBMI.pac90.sp1.p8" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac90.sp1.e2" e2="DBMI.pac90.sp1.e1" id="DBMI.pac90.sp1.p9" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac90.sp1.e2" e2="DBMI.pac90.sp1.e3" id="DBMI.pac90.sp1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp1.e3" e2="DBMI.pac90.sp1.e0" id="DBMI.pac90.sp1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp1.e3" e2="DBMI.pac90.sp1.e1" id="DBMI.pac90.sp1.p12" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac90.sp1.e3" e2="DBMI.pac90.sp1.e2" id="DBMI.pac90.sp1.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac90.sp2" origId="sp2" text="7.3 Pressor Agents\n\nBecause of possible effects on blood pressure, atomoxetine hydrochloride should be used cautiously with pressor agents (e.g., dopamine, dobutamine). 7.4 Albuterol\n\nAtomoxetine hydrochloride should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure. Albuterol (600 mcg iv over 2 hours) induced increases in heart rate and blood pressure."/>
	<sentencespan id="DBMI.pac90.sp3" origId="sp3" text="These effects were potentiated by atomoxetine (60 mg BID for 5 days) and were most marked after the initial coadministration of albuterol and atomoxetine. However, these effects on heart rate and blood pressure were not seen in another study after the coadministration with inhaled dose of albuterol (200 to 800 mcg) and atomoxetine (80 mg QD for 5 days) in 21 healthy Asian subjects who were excluded for poor metabolizer status. 7.5 Effect of Atomoxetine on P450 Enzymes\n\nAtomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."/>
	<sentencespan id="DBMI.pac90.sp4" origId="sp4" text="CYP3A Substrate (e.g., Midazolam)  Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam. No dose adjustment is recommended for drugs metabolized by CYP3A. CYP2D6 Substrate (e.g., Desipramine)  Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine.">
		<entity charOffset="2481-2493" id="DBMI.pac90.sp4.e0" origId="sp4.e0" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="2651-2661" id="DBMI.pac90.sp4.e1" origId="sp4.e1" text="midazolam " type="Active ingredient"/>
		<entity charOffset="2970-2982" id="DBMI.pac90.sp4.e2" origId="sp4.e2" text="desipramine " type="Active ingredient"/>
		<pair e1="DBMI.pac90.sp4.e0" e2="DBMI.pac90.sp4.e1" id="DBMI.pac90.sp4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam " precipitant="atomoxetine "/>
		<pair e1="DBMI.pac90.sp4.e0" e2="DBMI.pac90.sp4.e2" id="DBMI.pac90.sp4.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="desipramine " precipitant="atomoxetine "/>
		<pair e1="DBMI.pac90.sp4.e1" e2="DBMI.pac90.sp4.e0" id="DBMI.pac90.sp4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp4.e1" e2="DBMI.pac90.sp4.e2" id="DBMI.pac90.sp4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp4.e2" e2="DBMI.pac90.sp4.e0" id="DBMI.pac90.sp4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp4.e2" e2="DBMI.pac90.sp4.e1" id="DBMI.pac90.sp4.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac90.sp5" origId="sp5" text="No dose adjustment is recommended for drugs metabolized by CYP2D6. 7.6 Alcohol\n\nConsumption of ethanol with atomoxetine hydrochloride did not change the intoxicating effects of ethanol. 7.7 Methylphenidate\n\nCoadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone."/>
	<sentencespan id="DBMI.pac90.sp6" origId="sp6" text="7.8 Drugs Highly Bound to Plasma Protein\n\nIn vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations. Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin."/>
	<sentencespan id="DBMI.pac90.sp7" origId="sp7" text="7.9 Drugs that Affect Gastric pH\n\nDrugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.">
		<entity charOffset="3783-3803" id="DBMI.pac90.sp7.e0" origId="sp7.e0" text="magnesium hydroxide " type="Active ingredient"/>
		<entity charOffset="3852-3864" id="DBMI.pac90.sp7.e1" origId="sp7.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="3803-3822" id="DBMI.pac90.sp7.e2" origId="sp7.e2" text="aluminum hydroxide " type="Active ingredient"/>
		<entity charOffset="3823-3834" id="DBMI.pac90.sp7.e3" origId="sp7.e3" text="omeprazole " type="Active ingredient"/>
		<pair e1="DBMI.pac90.sp7.e0" e2="DBMI.pac90.sp7.e1" id="DBMI.pac90.sp7.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atomoxetine " precipitant="magnesium hydroxide "/>
		<pair e1="DBMI.pac90.sp7.e0" e2="DBMI.pac90.sp7.e2" id="DBMI.pac90.sp7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp7.e0" e2="DBMI.pac90.sp7.e3" id="DBMI.pac90.sp7.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp7.e1" e2="DBMI.pac90.sp7.e0" id="DBMI.pac90.sp7.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp7.e1" e2="DBMI.pac90.sp7.e2" id="DBMI.pac90.sp7.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp7.e1" e2="DBMI.pac90.sp7.e3" id="DBMI.pac90.sp7.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp7.e2" e2="DBMI.pac90.sp7.e0" id="DBMI.pac90.sp7.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp7.e2" e2="DBMI.pac90.sp7.e1" id="DBMI.pac90.sp7.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atomoxetine " precipitant="aluminum hydroxide "/>
		<pair e1="DBMI.pac90.sp7.e2" e2="DBMI.pac90.sp7.e3" id="DBMI.pac90.sp7.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp7.e3" e2="DBMI.pac90.sp7.e0" id="DBMI.pac90.sp7.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac90.sp7.e3" e2="DBMI.pac90.sp7.e1" id="DBMI.pac90.sp7.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atomoxetine " precipitant="omeprazole "/>
		<pair e1="DBMI.pac90.sp7.e3" e2="DBMI.pac90.sp7.e2" id="DBMI.pac90.sp7.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac91" origId="pac91">
	<sentence id="DBMI.pac91.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nThe precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies."/>
	<sentence id="DBMI.pac91.s1" origId="s1" text="12.2 Pharmacodynamics\n\nAn exposure-response analysis encompassing doses of atomoxetine (0.5, 1.2 or 1.8 mg/kg/day) or placebo demonstrated atomoxetine exposure correlates with efficacy as measured by the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator administered and scored."/>
	<sentence id="DBMI.pac91.s2" origId="s2" text="The exposure-efficacy relationship was similar to that observed between dose and efficacy with median exposures at the two highest doses resulting in near maximal changes from baseline [see Clinical Studies  (14.2)]."/>
	<sentence id="DBMI.pac91.s3" origId="s3" text="12.3 Pharmacokinetics\n\nAtomoxetine is well-absorbed after oral administration and is minimally affected by food."/>
	<sentence id="DBMI.pac91.s4" origId="s4" text="It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway and subsequent glucuronidation."/>
	<sentence id="DBMI.pac91.s5" origId="s5" text="Atomoxetine has a half-life of about 5 hours."/>
	<sentence id="DBMI.pac91.s6" origId="s6" text="A fraction of the population (about 7% of Caucasians and 2% of African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs."/>
	<sentence id="DBMI.pac91.s7" origId="s7" text="These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]."/>
	<sentence id="DBMI.pac91.s8" origId="s8" text="Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.">
		<entity charOffset="1654-1665" id="DBMI.pac91.s8.e0" origId="s8.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="1533-1545" id="DBMI.pac91.s8.e1" origId="s8.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="1666-1677" id="DBMI.pac91.s8.e2" origId="s8.e2" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="1682-1692" id="DBMI.pac91.s8.e3" origId="s8.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac91.s8.e0" e2="DBMI.pac91.s8.e1" id="DBMI.pac91.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac91.s8.e0" e2="DBMI.pac91.s8.e2" id="DBMI.pac91.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e0" e2="DBMI.pac91.s8.e3" id="DBMI.pac91.s8.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e1" e2="DBMI.pac91.s8.e0" id="DBMI.pac91.s8.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e1" e2="DBMI.pac91.s8.e2" id="DBMI.pac91.s8.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e1" e2="DBMI.pac91.s8.e3" id="DBMI.pac91.s8.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e2" e2="DBMI.pac91.s8.e0" id="DBMI.pac91.s8.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e2" e2="DBMI.pac91.s8.e1" id="DBMI.pac91.s8.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac91.s8.e2" e2="DBMI.pac91.s8.e3" id="DBMI.pac91.s8.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e3" e2="DBMI.pac91.s8.e0" id="DBMI.pac91.s8.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e3" e2="DBMI.pac91.s8.e1" id="DBMI.pac91.s8.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.s8.e3" e2="DBMI.pac91.s8.e2" id="DBMI.pac91.s8.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac91.s9" origId="s9" text="The pharmacokinetics of atomoxetine have been evaluated in more than 400 children and adolescents in selected clinical trials, primarily using population pharmacokinetic studies."/>
	<sentence id="DBMI.pac91.s10" origId="s10" text="Single-dose and steady-state individual pharmacokinetic data were also obtained in children, adolescents, and adults."/>
	<sentence id="DBMI.pac91.s11" origId="s11" text="When doses were normalized to a mg/kg basis, similar half-life, Cmax, and AUC values were observed in children, adolescents, and adults."/>
	<sentence id="DBMI.pac91.s12" origId="s12" text="Clearance and volume of distribution after adjustment for body weight were also similar."/>
	<sentence id="DBMI.pac91.s13" origId="s13" text="Absorption and distribution Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs."/>
	<sentence id="DBMI.pac91.s14" origId="s14" text="Maximal plasma concentrations (Cmax) are reached approximately 1 to 2 hours after dosing."/>
	<sentence id="DBMI.pac91.s15" origId="s15" text="Atomoxetine hydrochloride can be administered with or without food."/>
	<sentence id="DBMI.pac91.s16" origId="s16" text="Administration of atomoxetine hydrochloride with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC), but did decrease the rate of absorption, resulting in a 37% lower Cmax, and delayed Tmax by 3 hours."/>
	<sentence id="DBMI.pac91.s17" origId="s17" text="In clinical trials with children and adolescents, administration of atomoxetine hydrochloride with food resulted in a 9% lower Cmax."/>
	<sentence id="DBMI.pac91.s18" origId="s18" text="The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water."/>
	<sentence id="DBMI.pac91.s19" origId="s19" text="Volume of distribution is similar across the patient weight range after normalizing for body weight."/>
	<sentence id="DBMI.pac91.s20" origId="s20" text="At therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin."/>
	<sentence id="DBMI.pac91.s21" origId="s21" text="Metabolism and elimination  Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway."/>
	<sentence id="DBMI.pac91.s22" origId="s22" text="People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs)."/>
	<sentence id="DBMI.pac91.s23" origId="s23" text="For PMs, AUC of atomoxetine is approximately 10-fold and Css,max is about 5-fold greater than EMs ."/>
	<sentence id="DBMI.pac91.s24" origId="s24" text="Laboratory tests are available to identify CYP2D6 PMs."/>
	<sentence id="DBMI.pac91.s25" origId="s25" text="Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].">
		<entity charOffset="3818-3829" id="DBMI.pac91.s25.e0" origId="s25.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="3893-3905" id="DBMI.pac91.s25.e1" origId="s25.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="3830-3841" id="DBMI.pac91.s25.e2" origId="s25.e2" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="3845-3855" id="DBMI.pac91.s25.e3" origId="s25.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac91.s25.e0" e2="DBMI.pac91.s25.e1" id="DBMI.pac91.s25.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac91.s25.e0" e2="DBMI.pac91.s25.e2" id="DBMI.pac91.s25.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e0" e2="DBMI.pac91.s25.e3" id="DBMI.pac91.s25.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e1" e2="DBMI.pac91.s25.e0" id="DBMI.pac91.s25.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e1" e2="DBMI.pac91.s25.e2" id="DBMI.pac91.s25.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e1" e2="DBMI.pac91.s25.e3" id="DBMI.pac91.s25.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e2" e2="DBMI.pac91.s25.e0" id="DBMI.pac91.s25.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e2" e2="DBMI.pac91.s25.e1" id="DBMI.pac91.s25.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac91.s25.e2" e2="DBMI.pac91.s25.e3" id="DBMI.pac91.s25.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e3" e2="DBMI.pac91.s25.e0" id="DBMI.pac91.s25.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e3" e2="DBMI.pac91.s25.e1" id="DBMI.pac91.s25.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.s25.e3" e2="DBMI.pac91.s25.e1" id="DBMI.pac91.s25.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.s25.e3" e2="DBMI.pac91.s25.e2" id="DBMI.pac91.s25.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac91.s26" origId="s26" text="Atomoxetine did not inhibit or induce the CYP2D6 pathway."/>
	<sentence id="DBMI.pac91.s27" origId="s27" text="The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated."/>
	<sentence id="DBMI.pac91.s28" origId="s28" text="4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs)."/>
	<sentence id="DBMI.pac91.s29" origId="s29" text="4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes."/>
	<sentence id="DBMI.pac91.s30" origId="s30" text="N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs)."/>
	<sentence id="DBMI.pac91.s31" origId="s31" text="Mean apparent plasma clearance of atomoxetine after oral administration in adult EMs is 0.35 L/hr/kg and the mean half-life is 5.2 hours."/>
	<sentence id="DBMI.pac91.s32" origId="s32" text="Following oral administration of atomoxetine to PMs, mean apparent plasma clearance is 0.03 L/hr/kg and mean half-life is 21.6 hours."/>
	<sentence id="DBMI.pac91.s33" origId="s33" text="For PMs, AUC of atomoxetine is approximately 10-fold and Css,max is about 5-fold greater than EMs ."/>
	<sentence id="DBMI.pac91.s34" origId="s34" text="The elimination half-life of 4-hydroxyatomoxetine is similar to that of N-desmethylatomoxetine (6 to 8 hours) in EM subjects, while the half-life of N-desmethylatomoxetine is much longer in PM subjects (34 to 40 hours)."/>
	<sentence id="DBMI.pac91.s35" origId="s35" text="Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose)."/>
	<sentence id="DBMI.pac91.s36" origId="s36" text="Only a small fraction of the atomoxetine hydrochloride dose is excreted as unchanged atomoxetine (less than 3% of the dose), indicating extensive biotransformation."/>
	<sentence id="DBMI.pac91.s37" origId="s37" text="[See Use In Specific Populations (8.4, 8.5, 8.6, 8.7, 8.8, 8.9)]."/>
	<sentencespan id="DBMI.pac91.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nThe precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies. 12.2 Pharmacodynamics\n\nAn exposure-response analysis encompassing doses of atomoxetine (0.5, 1.2 or 1.8 mg/kg/day) or placebo demonstrated atomoxetine exposure correlates with efficacy as measured by the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator administered and scored. The exposure-efficacy relationship was similar to that observed between dose and efficacy with median exposures at the two highest doses resulting in near maximal changes from baseline [see Clinical Studies  (14.2)]."/>
	<sentencespan id="DBMI.pac91.sp1" origId="sp1" text="12.3 Pharmacokinetics\n\nAtomoxetine is well-absorbed after oral administration and is minimally affected by food. It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway and subsequent glucuronidation. Atomoxetine has a half-life of about 5 hours."/>
	<sentencespan id="DBMI.pac91.sp2" origId="sp2" text="A fraction of the population (about 7% of Caucasians and 2% of African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs. These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.">
		<entity charOffset="1654-1665" id="DBMI.pac91.sp2.e0" origId="sp2.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="1533-1545" id="DBMI.pac91.sp2.e1" origId="sp2.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="1666-1677" id="DBMI.pac91.sp2.e2" origId="sp2.e2" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="1682-1692" id="DBMI.pac91.sp2.e3" origId="sp2.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac91.sp2.e0" e2="DBMI.pac91.sp2.e1" id="DBMI.pac91.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac91.sp2.e0" e2="DBMI.pac91.sp2.e2" id="DBMI.pac91.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e0" e2="DBMI.pac91.sp2.e3" id="DBMI.pac91.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e1" e2="DBMI.pac91.sp2.e0" id="DBMI.pac91.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e1" e2="DBMI.pac91.sp2.e2" id="DBMI.pac91.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e1" e2="DBMI.pac91.sp2.e3" id="DBMI.pac91.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e2" e2="DBMI.pac91.sp2.e0" id="DBMI.pac91.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e2" e2="DBMI.pac91.sp2.e1" id="DBMI.pac91.sp2.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac91.sp2.e2" e2="DBMI.pac91.sp2.e3" id="DBMI.pac91.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e3" e2="DBMI.pac91.sp2.e0" id="DBMI.pac91.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e3" e2="DBMI.pac91.sp2.e1" id="DBMI.pac91.sp2.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.sp2.e3" e2="DBMI.pac91.sp2.e2" id="DBMI.pac91.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac91.sp3" origId="sp3" text="The pharmacokinetics of atomoxetine have been evaluated in more than 400 children and adolescents in selected clinical trials, primarily using population pharmacokinetic studies. Single-dose and steady-state individual pharmacokinetic data were also obtained in children, adolescents, and adults. When doses were normalized to a mg/kg basis, similar half-life, Cmax, and AUC values were observed in children, adolescents, and adults."/>
	<sentencespan id="DBMI.pac91.sp4" origId="sp4" text="Clearance and volume of distribution after adjustment for body weight were also similar. Absorption and distribution Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Maximal plasma concentrations (Cmax) are reached approximately 1 to 2 hours after dosing."/>
	<sentencespan id="DBMI.pac91.sp5" origId="sp5" text="Atomoxetine hydrochloride can be administered with or without food. Administration of atomoxetine hydrochloride with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC), but did decrease the rate of absorption, resulting in a 37% lower Cmax, and delayed Tmax by 3 hours. In clinical trials with children and adolescents, administration of atomoxetine hydrochloride with food resulted in a 9% lower Cmax."/>
	<sentencespan id="DBMI.pac91.sp6" origId="sp6" text="The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water. Volume of distribution is similar across the patient weight range after normalizing for body weight. At therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin."/>
	<sentencespan id="DBMI.pac91.sp7" origId="sp7" text="Metabolism and elimination  Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway. People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs). For PMs, AUC of atomoxetine is approximately 10-fold and Css,max is about 5-fold greater than EMs ."/>
	<sentencespan id="DBMI.pac91.sp8" origId="sp8" text="Laboratory tests are available to identify CYP2D6 PMs. Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)]. Atomoxetine did not inhibit or induce the CYP2D6 pathway.">
		<entity charOffset="3818-3829" id="DBMI.pac91.sp8.e0" origId="sp8.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="3893-3905" id="DBMI.pac91.sp8.e1" origId="sp8.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="3830-3841" id="DBMI.pac91.sp8.e2" origId="sp8.e2" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="3845-3855" id="DBMI.pac91.sp8.e3" origId="sp8.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac91.sp8.e0" e2="DBMI.pac91.sp8.e1" id="DBMI.pac91.sp8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac91.sp8.e0" e2="DBMI.pac91.sp8.e2" id="DBMI.pac91.sp8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e0" e2="DBMI.pac91.sp8.e3" id="DBMI.pac91.sp8.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e1" e2="DBMI.pac91.sp8.e0" id="DBMI.pac91.sp8.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e1" e2="DBMI.pac91.sp8.e2" id="DBMI.pac91.sp8.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e1" e2="DBMI.pac91.sp8.e3" id="DBMI.pac91.sp8.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e2" e2="DBMI.pac91.sp8.e0" id="DBMI.pac91.sp8.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e2" e2="DBMI.pac91.sp8.e1" id="DBMI.pac91.sp8.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac91.sp8.e2" e2="DBMI.pac91.sp8.e3" id="DBMI.pac91.sp8.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e3" e2="DBMI.pac91.sp8.e0" id="DBMI.pac91.sp8.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e3" e2="DBMI.pac91.sp8.e1" id="DBMI.pac91.sp8.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.sp8.e3" e2="DBMI.pac91.sp8.e1" id="DBMI.pac91.sp8.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.sp8.e3" e2="DBMI.pac91.sp8.e2" id="DBMI.pac91.sp8.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac91.sp9" origId="sp9" text="The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes."/>
	<sentencespan id="DBMI.pac91.sp10" origId="sp10" text="N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs). Mean apparent plasma clearance of atomoxetine after oral administration in adult EMs is 0.35 L/hr/kg and the mean half-life is 5.2 hours. Following oral administration of atomoxetine to PMs, mean apparent plasma clearance is 0.03 L/hr/kg and mean half-life is 21.6 hours."/>
	<sentencespan id="DBMI.pac91.sp11" origId="sp11" text="For PMs, AUC of atomoxetine is approximately 10-fold and Css,max is about 5-fold greater than EMs . The elimination half-life of 4-hydroxyatomoxetine is similar to that of N-desmethylatomoxetine (6 to 8 hours) in EM subjects, while the half-life of N-desmethylatomoxetine is much longer in PM subjects (34 to 40 hours). Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose)."/>
	<sentencespan id="DBMI.pac91.sp12" origId="sp12" text="Only a small fraction of the atomoxetine hydrochloride dose is excreted as unchanged atomoxetine (less than 3% of the dose), indicating extensive biotransformation. [See Use In Specific Populations (8.4, 8.5, 8.6, 8.7, 8.8, 8.9)]."/>
</document>

<document id="DBMI.pac92" origId="pac92">
	<sentence id="DBMI.pac92.s0" origId="s0" text="Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects.">
		<entity charOffset="65-78" id="DBMI.pac92.s0.e0" origId="s0.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="161-171" id="DBMI.pac92.s0.e1" origId="s0.e1" text="sirolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac92.s0.e0" e2="DBMI.pac92.s0.e1" id="DBMI.pac92.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sirolimus " precipitant="voriconazole "/>
		<pair e1="DBMI.pac92.s0.e1" e2="DBMI.pac92.s0.e0" id="DBMI.pac92.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac92.s1" origId="s1" text="Coadministration of voriconazole and sirolimus is contraindicated (see CONTRAINDICATIONS, PRECAUTIONS - Drug Interactions)."/>
	<sentencespan id="DBMI.pac92.sp0" origId="sp0" text="Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects. Coadministration of voriconazole and sirolimus is contraindicated (see CONTRAINDICATIONS, PRECAUTIONS - Drug Interactions).">
		<entity charOffset="65-78" id="DBMI.pac92.sp0.e0" origId="sp0.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="161-171" id="DBMI.pac92.sp0.e1" origId="sp0.e1" text="sirolimus " type="Active ingredient"/>
		<pair e1="DBMI.pac92.sp0.e0" e2="DBMI.pac92.sp0.e1" id="DBMI.pac92.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sirolimus " precipitant="voriconazole "/>
		<pair e1="DBMI.pac92.sp0.e1" e2="DBMI.pac92.sp0.e0" id="DBMI.pac92.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac94" origId="pac94">
	<sentence id="DBMI.pac94.s0" origId="s0" text="Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations."/>
	<sentence id="DBMI.pac94.s1" origId="s1" text="Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ">
		<entity charOffset="226-239" id="DBMI.pac94.s1.e0" origId="s1.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="194-205" id="DBMI.pac94.s1.e1" origId="s1.e1" text="alprazolam " type="Active ingredient"/>
		<entity charOffset="251-264" id="DBMI.pac94.s1.e2" origId="s1.e2" text="itraconazole " type="Active ingredient"/>
		<entity charOffset="276-287" id="DBMI.pac94.s1.e3" origId="s1.e3" text="nefazodone " type="Active ingredient"/>
		<entity charOffset="299-311" id="DBMI.pac94.s1.e4" origId="s1.e4" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="327-340" id="DBMI.pac94.s1.e5" origId="s1.e5" text="erythromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac94.s1.e0" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac94.s1.e0" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac94.s1.e0" e2="DBMI.pac94.s1.e2" id="DBMI.pac94.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e0" e2="DBMI.pac94.s1.e3" id="DBMI.pac94.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e0" e2="DBMI.pac94.s1.e4" id="DBMI.pac94.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e0" e2="DBMI.pac94.s1.e5" id="DBMI.pac94.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e1" e2="DBMI.pac94.s1.e0" id="DBMI.pac94.s1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e1" e2="DBMI.pac94.s1.e2" id="DBMI.pac94.s1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e1" e2="DBMI.pac94.s1.e3" id="DBMI.pac94.s1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e1" e2="DBMI.pac94.s1.e4" id="DBMI.pac94.s1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e1" e2="DBMI.pac94.s1.e5" id="DBMI.pac94.s1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e2" e2="DBMI.pac94.s1.e0" id="DBMI.pac94.s1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e2" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p12" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="itraconazole "/>
		<pair e1="DBMI.pac94.s1.e2" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p13" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="itraconazole "/>
		<pair e1="DBMI.pac94.s1.e2" e2="DBMI.pac94.s1.e3" id="DBMI.pac94.s1.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e2" e2="DBMI.pac94.s1.e4" id="DBMI.pac94.s1.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e2" e2="DBMI.pac94.s1.e5" id="DBMI.pac94.s1.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e3" e2="DBMI.pac94.s1.e0" id="DBMI.pac94.s1.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e3" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p18" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac94.s1.e3" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p19" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac94.s1.e3" e2="DBMI.pac94.s1.e2" id="DBMI.pac94.s1.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e3" e2="DBMI.pac94.s1.e4" id="DBMI.pac94.s1.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e3" e2="DBMI.pac94.s1.e5" id="DBMI.pac94.s1.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e4" e2="DBMI.pac94.s1.e0" id="DBMI.pac94.s1.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e4" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p24" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac94.s1.e4" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p25" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac94.s1.e4" e2="DBMI.pac94.s1.e2" id="DBMI.pac94.s1.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e4" e2="DBMI.pac94.s1.e3" id="DBMI.pac94.s1.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e4" e2="DBMI.pac94.s1.e5" id="DBMI.pac94.s1.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e5" e2="DBMI.pac94.s1.e0" id="DBMI.pac94.s1.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e5" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p30" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="erythromycin "/>
		<pair e1="DBMI.pac94.s1.e5" e2="DBMI.pac94.s1.e1" id="DBMI.pac94.s1.p31" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="erythromycin "/>
		<pair e1="DBMI.pac94.s1.e5" e2="DBMI.pac94.s1.e2" id="DBMI.pac94.s1.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e5" e2="DBMI.pac94.s1.e3" id="DBMI.pac94.s1.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.s1.e5" e2="DBMI.pac94.s1.e4" id="DBMI.pac94.s1.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac94.sp0" origId="sp0" text="Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ). ">
		<entity charOffset="226-239" id="DBMI.pac94.sp0.e0" origId="sp0.e0" text="ketoconazole " type="Active ingredient"/>
		<entity charOffset="194-205" id="DBMI.pac94.sp0.e1" origId="sp0.e1" text="alprazolam " type="Active ingredient"/>
		<entity charOffset="251-264" id="DBMI.pac94.sp0.e2" origId="sp0.e2" text="itraconazole " type="Active ingredient"/>
		<entity charOffset="276-287" id="DBMI.pac94.sp0.e3" origId="sp0.e3" text="nefazodone " type="Active ingredient"/>
		<entity charOffset="299-311" id="DBMI.pac94.sp0.e4" origId="sp0.e4" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="327-340" id="DBMI.pac94.sp0.e5" origId="sp0.e5" text="erythromycin " type="Active ingredient"/>
		<pair e1="DBMI.pac94.sp0.e0" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac94.sp0.e0" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="ketoconazole "/>
		<pair e1="DBMI.pac94.sp0.e0" e2="DBMI.pac94.sp0.e2" id="DBMI.pac94.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e0" e2="DBMI.pac94.sp0.e3" id="DBMI.pac94.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e0" e2="DBMI.pac94.sp0.e4" id="DBMI.pac94.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e0" e2="DBMI.pac94.sp0.e5" id="DBMI.pac94.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e1" e2="DBMI.pac94.sp0.e0" id="DBMI.pac94.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e1" e2="DBMI.pac94.sp0.e2" id="DBMI.pac94.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e1" e2="DBMI.pac94.sp0.e3" id="DBMI.pac94.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e1" e2="DBMI.pac94.sp0.e4" id="DBMI.pac94.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e1" e2="DBMI.pac94.sp0.e5" id="DBMI.pac94.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e2" e2="DBMI.pac94.sp0.e0" id="DBMI.pac94.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e2" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p12" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="itraconazole "/>
		<pair e1="DBMI.pac94.sp0.e2" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p13" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="itraconazole "/>
		<pair e1="DBMI.pac94.sp0.e2" e2="DBMI.pac94.sp0.e3" id="DBMI.pac94.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e2" e2="DBMI.pac94.sp0.e4" id="DBMI.pac94.sp0.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e2" e2="DBMI.pac94.sp0.e5" id="DBMI.pac94.sp0.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e3" e2="DBMI.pac94.sp0.e0" id="DBMI.pac94.sp0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e3" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p18" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac94.sp0.e3" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p19" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac94.sp0.e3" e2="DBMI.pac94.sp0.e2" id="DBMI.pac94.sp0.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e3" e2="DBMI.pac94.sp0.e4" id="DBMI.pac94.sp0.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e3" e2="DBMI.pac94.sp0.e5" id="DBMI.pac94.sp0.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e4" e2="DBMI.pac94.sp0.e0" id="DBMI.pac94.sp0.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e4" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p24" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac94.sp0.e4" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p25" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac94.sp0.e4" e2="DBMI.pac94.sp0.e2" id="DBMI.pac94.sp0.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e4" e2="DBMI.pac94.sp0.e3" id="DBMI.pac94.sp0.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e4" e2="DBMI.pac94.sp0.e5" id="DBMI.pac94.sp0.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e5" e2="DBMI.pac94.sp0.e0" id="DBMI.pac94.sp0.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e5" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p30" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="erythromycin "/>
		<pair e1="DBMI.pac94.sp0.e5" e2="DBMI.pac94.sp0.e1" id="DBMI.pac94.sp0.p31" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="erythromycin "/>
		<pair e1="DBMI.pac94.sp0.e5" e2="DBMI.pac94.sp0.e2" id="DBMI.pac94.sp0.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e5" e2="DBMI.pac94.sp0.e3" id="DBMI.pac94.sp0.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac94.sp0.e5" e2="DBMI.pac94.sp0.e4" id="DBMI.pac94.sp0.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac95" origId="pac95">
	<sentence id="DBMI.pac95.s0" origId="s0" text="Coadministration of nefazodone increased alprazolam concentration two-fold.">
		<entity charOffset="20-31" id="DBMI.pac95.s0.e0" origId="s0.e0" text="nefazodone " type="Active ingredient"/>
		<entity charOffset="41-52" id="DBMI.pac95.s0.e1" origId="s0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac95.s0.e0" e2="DBMI.pac95.s0.e1" id="DBMI.pac95.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac95.s0.e1" e2="DBMI.pac95.s0.e0" id="DBMI.pac95.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac95.sp0" origId="sp0" text="Coadministration of nefazodone increased alprazolam concentration two-fold.">
		<entity charOffset="20-31" id="DBMI.pac95.sp0.e0" origId="sp0.e0" text="nefazodone " type="Active ingredient"/>
		<entity charOffset="41-52" id="DBMI.pac95.sp0.e1" origId="sp0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac95.sp0.e0" e2="DBMI.pac95.sp0.e1" id="DBMI.pac95.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="nefazodone "/>
		<pair e1="DBMI.pac95.sp0.e1" e2="DBMI.pac95.sp0.e0" id="DBMI.pac95.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac96" origId="pac96">
	<sentence id="DBMI.pac96.s0" origId="s0" text="Coadministration of fluvoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71%, and decreased measured psychomotor performance.">
		<entity charOffset="20-32" id="DBMI.pac96.s0.e0" origId="s0.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="90-101" id="DBMI.pac96.s0.e1" origId="s0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac96.s0.e0" e2="DBMI.pac96.s0.e1" id="DBMI.pac96.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac96.s0.e1" e2="DBMI.pac96.s0.e0" id="DBMI.pac96.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac96.sp0" origId="sp0" text="Coadministration of fluvoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71%, and decreased measured psychomotor performance.">
		<entity charOffset="20-32" id="DBMI.pac96.sp0.e0" origId="sp0.e0" text="fluvoxamine " type="Active ingredient"/>
		<entity charOffset="90-101" id="DBMI.pac96.sp0.e1" origId="sp0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac96.sp0.e0" e2="DBMI.pac96.sp0.e1" id="DBMI.pac96.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="fluvoxamine "/>
		<pair e1="DBMI.pac96.sp0.e1" e2="DBMI.pac96.sp0.e0" id="DBMI.pac96.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac97" origId="pac97">
	<sentence id="DBMI.pac97.s0" origId="s0" text="Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%. ">
		<entity charOffset="20-31" id="DBMI.pac97.s0.e0" origId="s0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="77-88" id="DBMI.pac97.s0.e1" origId="s0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac97.s0.e0" e2="DBMI.pac97.s0.e1" id="DBMI.pac97.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="cimetidine "/>
		<pair e1="DBMI.pac97.s0.e1" e2="DBMI.pac97.s0.e0" id="DBMI.pac97.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac97.sp0" origId="sp0" text="Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%. ">
		<entity charOffset="20-31" id="DBMI.pac97.sp0.e0" origId="sp0.e0" text="cimetidine " type="Active ingredient"/>
		<entity charOffset="77-88" id="DBMI.pac97.sp0.e1" origId="sp0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac97.sp0.e0" e2="DBMI.pac97.sp0.e1" id="DBMI.pac97.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="cimetidine "/>
		<pair e1="DBMI.pac97.sp0.e1" e2="DBMI.pac97.sp0.e0" id="DBMI.pac97.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac98" origId="pac98">
	<sentence id="DBMI.pac98.s0" origId="s0" text=" The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.">
		<entity charOffset="183-194" id="DBMI.pac98.s0.e0" origId="s0.e0" text="alprazolam " type="Active ingredient"/>
		<entity charOffset="43-54" id="DBMI.pac98.s0.e1" origId="s0.e1" text="imipramine " type="Active ingredient"/>
		<entity charOffset="58-70" id="DBMI.pac98.s0.e2" origId="s0.e2" text="desipramine " type="Metabolite"/>
		<pair e1="DBMI.pac98.s0.e0" e2="DBMI.pac98.s0.e1" id="DBMI.pac98.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="imipramine " precipitant="alprazolam "/>
		<pair e1="DBMI.pac98.s0.e0" e2="DBMI.pac98.s0.e2" id="DBMI.pac98.s0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desipramine " precipitant="alprazolam "/>
		<pair e1="DBMI.pac98.s0.e1" e2="DBMI.pac98.s0.e0" id="DBMI.pac98.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac98.s0.e1" e2="DBMI.pac98.s0.e2" id="DBMI.pac98.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac98.s0.e2" e2="DBMI.pac98.s0.e0" id="DBMI.pac98.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac98.s0.e2" e2="DBMI.pac98.s0.e1" id="DBMI.pac98.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac98.s1" origId="s1" text="The clinical significance of these changes is unknown. "/>
	<sentencespan id="DBMI.pac98.sp0" origId="sp0" text=" The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day. The clinical significance of these changes is unknown. ">
		<entity charOffset="183-194" id="DBMI.pac98.sp0.e0" origId="sp0.e0" text="alprazolam " type="Active ingredient"/>
		<entity charOffset="43-54" id="DBMI.pac98.sp0.e1" origId="sp0.e1" text="imipramine " type="Active ingredient"/>
		<entity charOffset="58-70" id="DBMI.pac98.sp0.e2" origId="sp0.e2" text="desipramine " type="Metabolite"/>
		<pair e1="DBMI.pac98.sp0.e0" e2="DBMI.pac98.sp0.e1" id="DBMI.pac98.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="imipramine " precipitant="alprazolam "/>
		<pair e1="DBMI.pac98.sp0.e0" e2="DBMI.pac98.sp0.e2" id="DBMI.pac98.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desipramine " precipitant="alprazolam "/>
		<pair e1="DBMI.pac98.sp0.e1" e2="DBMI.pac98.sp0.e0" id="DBMI.pac98.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac98.sp0.e1" e2="DBMI.pac98.sp0.e2" id="DBMI.pac98.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac98.sp0.e2" e2="DBMI.pac98.sp0.e0" id="DBMI.pac98.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac98.sp0.e2" e2="DBMI.pac98.sp0.e1" id="DBMI.pac98.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac99" origId="pac99">
	<sentence id="DBMI.pac99.s0" origId="s0" text="Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%. ">
		<entity charOffset="20-33" id="DBMI.pac99.s0.e0" origId="s0.e0" text="propoxyphene " type="Active ingredient"/>
		<entity charOffset="79-90" id="DBMI.pac99.s0.e1" origId="s0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac99.s0.e0" e2="DBMI.pac99.s0.e1" id="DBMI.pac99.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="propoxyphene "/>
		<pair e1="DBMI.pac99.s0.e1" e2="DBMI.pac99.s0.e0" id="DBMI.pac99.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac99.sp0" origId="sp0" text="Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%. ">
		<entity charOffset="20-33" id="DBMI.pac99.sp0.e0" origId="sp0.e0" text="propoxyphene " type="Active ingredient"/>
		<entity charOffset="79-90" id="DBMI.pac99.sp0.e1" origId="sp0.e1" text="alprazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac99.sp0.e0" e2="DBMI.pac99.sp0.e1" id="DBMI.pac99.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="alprazolam " precipitant="propoxyphene "/>
		<pair e1="DBMI.pac99.sp0.e1" e2="DBMI.pac99.sp0.e0" id="DBMI.pac99.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>
</documents>
